data_1nz9_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1nz9 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.87 0.366 . . . . 0.0 110.97 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -58.23 147.8 29.29 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.952 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 79.54 6.52 88.96 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.967 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 12.9 m-20 -86.87 174.53 8.7 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.821 0.343 . . . . 0.0 110.99 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 36.3 mt-30 -113.96 132.61 55.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.836 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 31.0 m -131.9 136.2 57.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.081 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -80.03 166.26 21.73 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.703 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.458 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 8.0 t -79.86 167.34 2.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.973 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 3.3 p -79.31 -60.3 2.36 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 112.138 0.421 . . . . 0.0 112.138 -179.201 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -160.43 -164.18 1.21 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.822 0.344 . . . . 0.0 111.301 -179.542 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.37 -168.01 54.33 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.856 -0.687 . . . . 0.0 112.344 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.37 -19.02 56.44 Favored 'Trans proline' 0 C--N 1.343 0.277 0 C-N-CA 122.479 2.119 . . . . 0.0 111.95 179.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.458 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 3.9 m-85 -95.86 13.09 27.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.211 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -79.14 39.69 0.39 Allowed 'General case' 0 C--N 1.332 -0.179 0 N-CA-C 112.246 0.462 . . . . 0.0 112.246 -179.361 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . 0.409 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 1.0 OUTLIER -160.7 34.87 0.16 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.987 0.422 . . . . 0.0 110.675 179.336 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.409 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 47.2 m-85 -148.0 167.13 25.7 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.91 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 23.7 p -127.16 -173.98 3.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.672 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -150.43 164.81 29.86 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.657 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 5.6 m -103.99 108.47 19.83 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.779 0.323 . . . . 0.0 110.773 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 19.8 t -57.42 113.88 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.293 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 10.3 t -98.88 -33.92 10.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.778 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -153.48 158.48 41.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.894 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 2.7 mt -129.88 158.69 42.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.087 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -135.29 86.71 29.75 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.958 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -71.69 -34.13 9.47 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.56 2.174 . . . . 0.0 112.385 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -58.98 -33.55 70.81 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.993 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.23 -61.23 1.69 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.94 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 127.04 42.73 0.27 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.489 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 11.8 mttt -115.59 170.34 8.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.772 0.32 . . . . 0.0 110.982 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.1 m -155.37 137.08 5.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.077 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 38.7 tttt -114.69 128.25 56.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.788 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 29.7 m -139.88 142.51 32.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.231 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' MET . . . . . 0.4 ' CG ' ' O ' ' A' ' 164' ' ' MET . 0.4 OUTLIER -89.93 104.02 16.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.592 179.883 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 15.5 m -91.76 171.11 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.25 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -132.41 115.34 15.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.796 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 1.6 tp -120.23 133.82 65.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.162 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 1.2 t80 61.74 30.42 18.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.878 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 70.28 45.26 56.25 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.555 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 2.2 tpm_? -159.98 138.86 10.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.789 0.328 . . . . 0.0 110.908 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -60.8 151.94 28.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.778 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 66.1 m -160.02 91.17 1.77 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.989 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -68.37 117.45 4.97 Favored 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 122.475 2.117 . . . . 0.0 112.155 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 29.7 m -132.84 154.98 40.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.256 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -98.8 138.1 36.43 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.639 179.741 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -144.33 -162.2 1.43 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.263 0.554 . . . . 0.0 111.229 -179.796 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -153.11 156.71 39.18 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.079 178.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -45.86 -29.38 1.35 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.674 -179.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 7.3 m -76.01 -3.45 35.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.829 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -131.77 15.08 4.85 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.602 0.239 . . . . 0.0 111.437 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 15.7 m -142.0 170.03 12.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.865 0.364 . . . . 0.0 111.221 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 22.4 m -142.41 146.71 21.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.037 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.36 131.33 35.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.946 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.189 -0.91 . . . . 0.0 111.12 -179.997 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 21.5 mtp180 . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.724 0.297 . . . . 0.0 110.897 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -63.93 142.37 58.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.916 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 91.91 -14.05 65.27 Favored Glycine 0 CA--C 1.519 0.292 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.773 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 32.2 m-20 -54.54 165.01 0.63 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.766 0.317 . . . . 0.0 111.024 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -117.6 115.38 24.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.077 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 19.4 m -122.95 149.06 26.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.919 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.8 tpp180 -79.86 168.03 19.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.069 0.461 . . . . 0.0 110.854 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.45 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 3.8 t -80.21 167.95 2.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.028 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 1.5 p -79.66 -66.85 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.55 -179.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -160.44 -164.69 1.29 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.876 0.37 . . . . 0.0 111.097 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.94 -162.47 42.79 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.911 -0.661 . . . . 0.0 112.462 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -63.07 -18.42 65.06 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.458 2.106 . . . . 0.0 112.115 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.45 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 3.0 m-85 -102.14 29.24 5.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.957 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.38 35.67 0.45 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.775 0.321 . . . . 0.0 111.853 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -160.96 35.63 0.15 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.506 179.354 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -135.15 175.7 9.34 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.888 -179.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -119.99 178.65 4.53 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.752 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -147.11 115.6 0.79 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.568 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.1 m -82.0 113.02 19.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.755 0.312 . . . . 0.0 110.782 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 26.4 t -68.19 123.54 21.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.175 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -105.22 -60.47 1.61 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.846 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.58 165.83 15.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.91 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . 0.421 ' N ' ' CD1' ' A' ' 154' ' ' ILE . 0.1 OUTLIER -130.78 157.67 43.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.052 179.961 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 12.5 m-20 -121.58 89.27 47.28 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.902 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.25 -34.45 6.08 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.54 2.16 . . . . 0.0 112.298 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.33 27.67 1.62 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.386 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 5.1 mtm180 -160.08 -50.1 0.05 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.856 0.36 . . . . 0.0 110.784 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 103.27 63.56 0.7 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.461 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.8 mttt -145.88 165.9 27.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.891 0.376 . . . . 0.0 111.028 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 3.7 m -150.04 120.99 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.903 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -86.75 131.68 34.06 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.096 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 27.2 m -131.17 158.1 43.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.062 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 3.3 ptt? -116.27 126.58 53.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.029 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 2.5 t -106.99 153.88 8.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.847 179.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 2.1 p -122.98 103.32 8.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.063 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . 0.437 ' CG2' ' CZ ' ' A' ' 168' ' ' PHE . 39.4 mm -80.0 67.52 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.625 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . 0.437 ' CZ ' ' CG2' ' A' ' 167' ' ' ILE . 1.1 p90 43.52 79.43 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.405 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 83.15 34.49 20.68 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.673 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -160.13 109.21 1.75 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.786 0.327 . . . . 0.0 111.077 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 11.7 mt-10 -89.84 134.41 34.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.717 179.731 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -145.26 105.57 4.4 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.126 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.49 110.53 2.72 Favored 'Trans proline' 0 C--N 1.348 0.508 0 C-N-CA 122.46 2.107 . . . . 0.0 112.069 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 9.0 p -126.09 146.45 31.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.268 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -79.99 157.57 26.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.679 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 7.5 mt -159.99 -171.74 3.35 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-O 121.411 0.625 . . . . 0.0 111.408 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -146.55 153.61 40.57 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 115.021 -0.991 . . . . 0.0 110.205 178.074 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -46.06 -32.8 3.05 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.548 -179.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 6.2 m -81.74 11.47 4.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.709 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 7.4 mm-40 -125.46 3.19 7.68 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.596 0.236 . . . . 0.0 111.262 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 21.9 m -145.14 179.42 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 120.977 0.417 . . . . 0.0 111.113 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 15.7 m -150.64 148.14 15.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.145 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 7.1 tttt -63.89 131.94 49.27 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.94 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.146 0 CA-C-O 118.257 -0.878 . . . . 0.0 111.14 179.906 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 7.3 mtt-85 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.837 0.351 . . . . 0.0 110.887 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -63.24 152.92 36.26 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.693 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 65.71 11.75 54.73 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.982 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -89.57 165.42 14.27 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.799 0.3 . . . . 0.0 110.822 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -89.24 134.08 34.19 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.403 ' HB ' ' CG2' ' A' ' 181' ' ' VAL . 16.0 m -140.46 140.01 34.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.962 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.417 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.4 OUTLIER -80.79 164.83 22.43 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.999 0.428 . . . . 0.0 111.063 -179.912 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.48 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 5.2 t -81.9 167.3 2.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.042 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.3 p -79.47 -61.77 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.439 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 46.7 p -160.11 -165.14 1.41 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.87 0.367 . . . . 0.0 111.176 -179.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 80.15 -163.74 47.36 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.348 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -63.91 -14.76 45.12 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.394 2.062 . . . . 0.0 112.23 179.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.48 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 4.9 m-85 -102.52 14.64 31.44 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.253 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -77.48 36.87 0.2 Allowed 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 112.462 0.541 . . . . 0.0 112.462 -179.289 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . 0.408 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 2.2 t0 -161.05 34.41 0.14 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.932 0.396 . . . . 0.0 110.805 179.223 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.408 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 40.2 m-85 -146.1 165.98 27.49 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.745 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' THR . . . . . 0.417 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 0.7 OUTLIER -116.79 -176.18 2.92 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.792 179.939 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -153.26 -176.4 25.7 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.57 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 40.9 m -125.3 113.14 17.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.808 0.337 . . . . 0.0 110.853 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 32.9 t -63.91 106.24 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.101 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 5.8 p -83.99 -45.07 13.51 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.916 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 2.4 tp10 -152.68 171.69 17.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.812 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 17.5 pt -145.33 151.43 15.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.096 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 12.7 m-20 -117.68 86.76 24.5 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.915 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -62.04 -24.74 76.97 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.737 2.292 . . . . 0.0 112.326 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -90.21 29.12 1.28 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.407 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.07 -44.16 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.868 0.366 . . . . 0.0 111.015 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 104.55 39.5 2.38 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.291 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 4.5 mttt -127.87 161.4 29.13 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.921 0.391 . . . . 0.0 110.981 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 29.2 m -146.82 119.65 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.107 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 15.5 tttt -80.04 141.28 36.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.891 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 26.0 t -153.17 144.9 15.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.098 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -96.68 121.77 38.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.874 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 9.3 m -99.98 158.55 3.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.121 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 31.4 p -145.31 146.35 31.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.815 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.8 mp -131.17 94.82 2.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.165 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 57.3 m-85 60.06 37.74 20.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.949 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 91.74 27.85 15.81 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.493 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.26 89.0 3.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.794 0.331 . . . . 0.0 110.913 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -59.24 144.61 45.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -158.41 90.3 2.18 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.842 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_exo -60.49 125.78 18.27 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.573 2.182 . . . . 0.0 112.29 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 39.4 t -152.54 148.84 14.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.959 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -80.01 145.04 32.74 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.822 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.4 ' CD2' ' HB3' ' A' ' 180' ' ' GLN . 4.1 mt -125.63 -173.24 2.78 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.451 0.643 . . . . 0.0 111.324 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -152.91 153.76 33.67 Favored 'General case' 0 N--CA 1.446 -0.662 0 CA-C-N 115.023 -0.99 . . . . 0.0 109.99 178.147 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -42.79 -54.01 4.31 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.656 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 5.2 m -74.18 -9.61 58.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.418 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . 0.4 ' HB3' ' CD2' ' A' ' 176' ' ' LEU . 0.0 OUTLIER -99.55 -14.03 19.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.504 -179.806 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . 0.478 ' CG2' ' N ' ' A' ' 182' ' ' VAL . 1.3 p -132.59 160.32 42.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.033 0.444 . . . . 0.0 111.083 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . 0.478 ' N ' ' CG2' ' A' ' 181' ' ' VAL . 35.4 m -139.39 146.19 25.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.379 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.28 135.03 38.39 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.94 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.286 -0.864 . . . . 0.0 111.14 179.986 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.233 0.195 0 CA-C-O 120.747 0.308 . . . . 0.0 110.887 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -59.81 135.11 57.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.869 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 105.97 -27.69 16.58 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.485 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -63.36 178.4 0.54 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.748 0.309 . . . . 0.0 110.977 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -128.19 130.34 47.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.015 0.436 . . . . 0.0 111.116 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 148' ' ' THR . 25.9 m -130.16 142.91 42.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.705 179.775 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.403 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.1 OUTLIER -79.7 164.49 23.7 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.025 0.44 . . . . 0.0 111.048 -179.843 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.437 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 48.8 t -79.74 147.22 6.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.647 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 12.4 p -85.87 -22.22 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.422 -179.47 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 1.4 t -79.14 153.47 30.06 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.893 0.378 . . . . 0.0 111.429 -178.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . 0.41 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -66.89 -62.2 4.68 Favored Glycine 0 N--CA 1.452 -0.26 0 CA-C-N 115.893 -0.594 . . . . 0.0 112.733 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.41 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.2 Cg_endo -53.57 -23.2 24.51 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.583 2.189 . . . . 0.0 112.158 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.437 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 12.9 m-85 -109.81 0.61 18.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.387 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -69.63 50.71 0.1 Allowed 'General case' 0 N--CA 1.462 0.163 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -179.05 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -160.61 31.37 0.16 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.094 0.473 . . . . 0.0 110.527 179.029 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -155.4 146.41 22.5 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.389 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' THR . . . . . 0.403 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 9.0 p -104.56 169.05 8.69 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.952 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -129.01 133.41 7.57 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.59 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.8 m -86.55 110.47 19.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.823 0.344 . . . . 0.0 110.755 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 30.6 t -67.96 117.44 9.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.963 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.3 t -101.94 -30.37 11.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.899 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -147.21 165.78 29.02 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.83 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 2.0 pp -152.41 141.42 14.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.152 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -120.94 92.87 48.66 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.871 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.54 -22.63 32.83 Favored 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.555 2.17 . . . . 0.0 112.425 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -90.21 26.36 1.92 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.372 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 1.4 mtp85 -159.96 -45.25 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.827 0.346 . . . . 0.0 110.825 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 102.45 55.19 0.86 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.425 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.3 mttt -137.66 147.56 45.01 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.801 0.334 . . . . 0.0 111.152 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.421 HG11 ' CE1' ' A' ' 178' ' ' PHE . 31.1 m -139.05 116.48 11.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.973 179.799 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 70.1 tttt -89.69 118.56 29.4 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.89 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 28.0 m -130.37 149.42 33.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.137 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' MET . . . . . 0.425 ' O ' ' CG ' ' A' ' 164' ' ' MET . 3.7 ptt? -101.84 108.54 20.06 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.996 0.427 . . . . 0.0 110.81 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 27.1 m -98.31 143.08 13.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.126 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -91.9 90.55 7.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.938 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . 0.42 HG12 ' CD2' ' A' ' 168' ' ' PHE . 11.2 tt -89.55 129.67 40.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.82 179.849 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . 0.42 ' CD2' HG12 ' A' ' 167' ' ' ILE . 31.2 m-85 65.86 -72.49 0.08 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.915 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -169.61 36.0 0.19 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.635 -0.793 . . . . 0.0 112.657 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 8.9 ptp180 -160.03 164.19 33.39 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.793 0.33 . . . . 0.0 111.063 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -66.89 158.37 30.81 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.906 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -159.99 81.3 2.38 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.954 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -68.57 102.65 0.87 Allowed 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.682 2.255 . . . . 0.0 112.229 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.4 m -114.46 136.04 52.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.137 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -80.16 108.89 14.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.669 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -124.27 -158.96 0.84 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.322 0.582 . . . . 0.0 111.159 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -146.36 155.64 42.75 Favored 'General case' 0 N--CA 1.441 -0.875 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.167 178.161 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . 0.421 ' CE1' HG11 ' A' ' 161' ' ' VAL . 14.9 m-85 -42.97 -30.89 0.45 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.617 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.5 m -66.35 -30.14 70.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.313 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 33.5 mm-40 -102.39 21.59 14.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.55 -179.64 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 21.7 m -157.03 140.63 7.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.93 0.395 . . . . 0.0 111.13 179.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.1 m -117.03 146.27 21.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.146 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 3.4 tttm -83.3 128.2 34.3 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.869 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.247 -0.883 . . . . 0.0 111.113 179.97 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 48.4 mtt-85 . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.846 0.355 . . . . 0.0 110.854 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -57.51 155.42 9.54 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.742 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 77.1 0.52 70.58 Favored Glycine 0 CA--C 1.519 0.343 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.78 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -66.0 153.49 42.03 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.838 0.352 . . . . 0.0 110.938 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 16.6 mt-30 -95.49 123.5 39.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.912 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 18.7 m -139.66 139.33 38.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.055 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.442 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -80.29 165.91 21.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.946 0.403 . . . . 0.0 110.808 179.837 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.463 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 6.8 t -79.7 167.67 2.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.999 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.5 p -79.39 -63.18 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 N-CA-C 112.199 0.444 . . . . 0.0 112.199 -179.196 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -160.28 -174.46 4.52 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.918 0.39 . . . . 0.0 111.321 -179.579 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 87.12 -167.19 37.55 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.397 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -59.53 -19.28 51.41 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.345 2.03 . . . . 0.0 111.965 179.541 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.463 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 3.3 m-85 -98.49 13.97 29.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.42 39.22 0.45 Allowed 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.275 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . 0.45 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 0.2 OUTLIER -160.78 31.57 0.15 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.901 0.381 . . . . 0.0 110.893 179.32 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.45 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 22.4 m-85 -143.96 155.58 44.1 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.865 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' THR . . . . . 0.442 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 0.8 OUTLIER -110.7 159.56 17.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.224 179.423 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -128.21 179.15 16.71 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.287 -0.958 . . . . 0.0 113.145 -179.504 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' THR . . . . . 0.42 ' HB ' ' CG ' ' A' ' 164' ' ' MET . 2.4 m -121.63 116.88 25.41 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.768 0.318 . . . . 0.0 110.729 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 37.2 t -67.49 145.53 13.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.984 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 20.4 p -137.55 -55.54 0.69 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.976 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -115.91 159.68 21.24 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.912 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 1.9 pt -158.7 149.02 8.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.092 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 12.0 t30 -147.26 85.32 6.88 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.946 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.52 -22.34 27.54 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.523 2.149 . . . . 0.0 112.408 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -55.0 -69.48 0.13 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.124 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.87 -33.71 39.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.984 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 101.56 55.42 0.9 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.596 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 2.7 mtmp? -131.34 149.28 52.62 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.922 0.392 . . . . 0.0 110.807 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.421 HG13 ' CE2' ' A' ' 178' ' ' PHE . 27.9 m -142.58 136.76 27.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.128 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 17.8 tttp -100.31 141.33 33.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.94 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.406 HG11 ' N ' ' A' ' 150' ' ' THR . 12.0 t -152.08 137.06 10.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.986 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' MET . . . . . 0.423 ' CG ' ' O ' ' A' ' 164' ' ' MET . 0.1 OUTLIER -97.49 106.48 18.81 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.982 0.42 . . . . 0.0 111.022 -179.9 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 5.5 t -103.4 159.88 4.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.176 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 15.8 p -95.14 145.52 24.95 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.85 179.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . 0.483 HD11 HG22 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -114.6 -36.86 2.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.061 179.982 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -166.37 76.86 0.21 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 64.03 26.82 70.57 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.52 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.01 136.68 9.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.793 0.33 . . . . 0.0 110.879 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 7.2 pm0 -59.18 166.91 1.95 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.9 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 9.1 m -159.74 84.21 2.22 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.022 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.12 119.74 7.18 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.48 2.12 . . . . 0.0 112.138 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 15.6 m -142.13 151.2 18.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.255 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -83.63 142.51 30.75 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.575 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.405 ' CD1' ' N ' ' A' ' 176' ' ' LEU . 0.0 OUTLIER -152.56 -161.21 1.25 Allowed 'General case' 0 CA--C 1.518 -0.257 0 CA-C-O 121.301 0.572 . . . . 0.0 111.303 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -151.17 154.04 36.13 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.208 178.453 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . 0.421 ' CE2' HG13 ' A' ' 161' ' ' VAL . 12.3 m-85 -48.17 -27.73 2.56 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.522 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 7.5 t -78.17 -1.94 35.17 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.679 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -124.27 13.0 8.89 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.659 0.266 . . . . 0.0 111.391 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 15.6 m -144.31 160.97 15.16 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.807 0.337 . . . . 0.0 111.15 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 28.6 m -141.6 148.22 21.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.054 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -59.84 134.85 57.42 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.9 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.215 -0.898 . . . . 0.0 111.169 179.963 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.839 0.352 . . . . 0.0 110.966 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -62.44 129.79 42.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.879 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 121.51 -22.62 7.77 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.604 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -56.8 163.82 1.76 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.841 0.353 . . . . 0.0 111.046 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -104.54 135.43 45.97 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.91 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 11.9 m -138.1 130.0 38.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.064 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.4 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.98 165.37 22.66 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.898 -179.927 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.477 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 3.7 t -79.83 168.83 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.913 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -79.52 -66.01 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.876 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 52.1 p -160.22 -165.42 1.46 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.941 0.4 . . . . 0.0 110.954 -179.705 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.73 -159.07 37.76 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.451 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.71 -12.31 35.06 Favored 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.578 2.186 . . . . 0.0 112.385 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.477 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 3.2 m-85 -108.57 20.91 17.98 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.164 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.53 38.44 0.43 Allowed 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -179.401 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -161.03 36.98 0.15 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.791 0.329 . . . . 0.0 110.915 179.309 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 48.4 m-85 -147.91 161.06 42.07 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.951 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 1.9 p -120.42 -176.79 3.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.66 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -149.39 151.44 23.56 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.602 -0.809 . . . . 0.0 112.724 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.1 m -96.56 99.18 10.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.788 0.328 . . . . 0.0 110.74 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 48.7 t -56.98 105.95 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.303 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 30.4 p -83.85 -38.96 20.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.535 179.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -143.81 160.31 40.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.701 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.8 mp -132.52 139.67 49.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.162 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -131.38 84.74 55.41 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.789 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -68.19 -27.68 34.93 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.511 2.14 . . . . 0.0 112.363 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -59.69 -58.4 8.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.882 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -87.54 -30.06 20.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.949 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 94.96 37.32 5.23 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.493 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 8.7 mtmt -114.08 154.06 28.39 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.8 0.333 . . . . 0.0 110.968 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 17.8 m -147.23 141.35 19.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.08 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 18.2 ttpt -115.47 122.85 47.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.943 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 33.4 m -136.63 146.49 28.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.285 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -93.32 106.32 18.29 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.486 179.692 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 30.4 m -88.18 171.75 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.372 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 82.6 p -148.26 103.85 3.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.673 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 2.9 mp -79.94 85.56 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.222 -179.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 59.1 31.5 21.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.958 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 105.6 35.39 3.07 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.56 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 9.3 mtt-85 -135.38 91.84 2.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.795 0.331 . . . . 0.0 110.882 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -58.64 136.72 57.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.91 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 19.7 m -159.53 104.48 1.49 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.994 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -69.43 105.79 1.49 Allowed 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.342 2.028 . . . . 0.0 112.105 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 22.0 t -122.5 135.32 62.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.247 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -87.41 139.55 30.43 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.653 179.666 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -144.52 -162.5 1.5 Allowed 'General case' 0 CA--C 1.516 -0.333 0 CA-C-O 121.415 0.626 . . . . 0.0 111.263 -179.665 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -142.41 158.05 44.11 Favored 'General case' 0 N--CA 1.441 -0.896 0 CA-C-N 115.001 -1.0 . . . . 0.0 109.888 178.19 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -46.89 -33.47 4.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.424 -179.535 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -73.13 -8.75 57.14 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.534 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 16.5 mm-40 -110.8 -12.97 14.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.712 0.292 . . . . 0.0 111.559 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 8.2 m -128.5 174.34 12.05 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.134 0 CA-C-O 120.865 0.364 . . . . 0.0 111.317 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.02 146.97 20.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.025 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.19 123.9 28.32 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.261 -0.876 . . . . 0.0 111.085 179.993 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 30.8 mtp180 . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.723 0.297 . . . . 0.0 110.972 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.72 131.49 50.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.918 179.869 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.38 -23.39 20.57 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.69 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -57.91 -176.08 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.869 0.366 . . . . 0.0 110.974 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -121.73 139.98 52.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.956 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 17.1 m -139.98 142.75 31.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.011 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.438 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -80.01 165.18 22.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.038 0.447 . . . . 0.0 110.837 -179.954 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.466 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 4.6 t -79.86 168.03 2.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.92 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 3.2 p -79.37 -62.13 1.5 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.26 0 N-CA-C 112.011 0.375 . . . . 0.0 112.011 -179.263 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -160.5 -163.5 1.1 Allowed 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.876 0.369 . . . . 0.0 111.124 -179.515 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 78.17 -165.39 51.95 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.465 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_endo -62.17 -17.11 54.9 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.506 2.137 . . . . 0.0 112.022 179.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.466 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 3.9 m-85 -100.26 16.38 24.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.207 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -79.53 37.68 0.35 Allowed 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -179.366 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . 0.438 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 11.2 p30 -160.91 32.05 0.15 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.971 0.415 . . . . 0.0 110.818 179.277 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.438 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 24.8 m-85 -140.91 159.62 41.81 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.747 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' THR . . . . . 0.438 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 1.6 p -108.72 171.07 7.64 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.568 179.689 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -137.43 139.38 10.45 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.518 -0.849 . . . . 0.0 112.768 -179.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.9 m -91.2 105.66 17.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.751 0.31 . . . . 0.0 110.605 179.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 24.3 t -64.53 108.7 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.172 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 2.0 t -96.24 -30.54 13.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.955 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -140.63 164.98 28.71 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.979 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 9.5 tt -152.48 127.84 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.026 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 59.0 m-20 -103.22 93.87 5.09 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.951 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.67 -27.95 26.27 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.481 2.121 . . . . 0.0 112.293 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -90.35 26.8 1.83 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.394 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -159.86 -45.17 0.05 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.894 0.378 . . . . 0.0 110.901 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 101.56 36.55 3.75 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.486 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 19.4 mmmt -111.46 152.03 27.88 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.886 0.374 . . . . 0.0 110.849 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 12.3 m -140.27 125.99 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.032 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 22.4 tttt -103.88 119.66 39.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.844 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 33.7 m -132.15 152.65 37.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.116 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 11.9 ptp -100.55 121.07 40.98 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.045 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 7.1 t -101.93 158.29 4.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.016 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 7.3 m -115.12 110.16 19.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.961 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . 0.496 HD13 HG21 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -120.0 114.28 43.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.779 179.869 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 63.54 31.85 14.52 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.764 -179.617 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 72.4 36.4 59.36 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.478 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -142.96 109.03 5.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.799 0.333 . . . . 0.0 110.885 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -59.47 128.2 35.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.855 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 15.8 m -132.13 92.01 30.4 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.015 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -60.99 115.58 2.79 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.593 2.195 . . . . 0.0 112.046 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 11.3 p -121.74 147.56 25.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.295 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.3 pm0 -94.55 121.93 36.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.799 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -137.54 -159.18 0.93 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.306 0.574 . . . . 0.0 111.113 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -143.25 155.2 44.44 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.101 178.182 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -46.68 -29.09 1.71 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.578 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 6.4 p -70.67 -11.82 61.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.564 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -115.75 16.91 16.31 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.61 -0.268 . . . . 0.0 111.448 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 10.9 m -153.25 154.07 8.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-O 120.718 0.294 . . . . 0.0 111.234 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 28.9 m -127.21 146.41 33.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.177 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 17.7 tptm -71.31 139.54 49.95 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.205 -0.903 . . . . 0.0 111.121 -179.978 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 7.9 ttt85 . . . . . 0 C--O 1.233 0.192 0 CA-C-O 120.991 0.424 . . . . 0.0 110.912 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -56.01 155.84 5.96 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.776 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.99 9.36 59.75 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.869 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -80.78 162.18 24.18 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.775 0.321 . . . . 0.0 110.859 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 14.2 mt-30 -118.31 120.15 36.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.902 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 30.0 m -127.12 140.64 48.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.987 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.77 160.86 26.03 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.083 0.468 . . . . 0.0 110.883 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.479 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 43.4 t -79.92 150.56 4.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.644 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 35.5 m -91.97 -20.37 6.67 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 -179.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' SER . . . . . 0.437 ' O ' ' N ' ' A' ' 145' ' ' ALA . 0.4 OUTLIER -79.15 153.25 30.22 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.893 0.377 . . . . 0.0 111.187 -178.937 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . 0.402 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -64.43 -63.2 4.46 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.946 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.402 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.2 Cg_endo -52.65 -22.86 18.22 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.666 2.244 . . . . 0.0 112.341 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.479 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 15.2 m-85 -112.8 2.48 15.99 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.505 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.437 ' N ' ' O ' ' A' ' 141' ' ' SER . . . -69.82 46.93 0.08 Allowed 'General case' 0 CA--C 1.53 0.204 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -178.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . 0.406 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 11.4 p30 -160.71 32.19 0.15 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.023 0.44 . . . . 0.0 110.615 179.101 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.406 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 69.0 m-85 -154.63 145.08 22.15 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.604 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 68.7 p -102.03 172.81 6.7 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.709 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -128.14 132.67 7.45 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.47 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.8 m -95.93 104.45 16.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.745 0.307 . . . . 0.0 110.696 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 26.4 t -59.85 114.32 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.32 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -107.04 -40.13 5.54 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.64 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -135.2 153.48 51.93 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.685 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 2.0 mp -129.62 152.31 37.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.239 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 -130.16 79.09 73.48 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.762 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -69.07 -26.55 30.74 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.496 2.131 . . . . 0.0 112.427 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -61.93 -34.52 76.24 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.863 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 8.3 mtt180 -108.27 -43.69 4.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.921 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 112.82 48.45 0.62 Allowed Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.505 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -137.37 177.24 8.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.835 0.35 . . . . 0.0 110.996 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.472 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.3 p -152.06 159.73 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.125 0.488 . . . . 0.0 110.898 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . 0.472 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 7.1 tttm -119.43 124.35 46.31 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.867 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 29.7 m -136.4 146.33 29.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.252 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 8.5 ptm -92.71 130.38 38.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.878 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 27.7 m -131.5 144.49 37.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.184 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -108.28 139.46 42.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.922 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.8 mp -136.29 -66.83 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.182 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 16.3 m-85 -91.46 55.57 2.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.926 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 58.02 27.56 59.89 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.546 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -153.88 151.39 29.43 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.864 0.364 . . . . 0.0 110.938 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -69.38 161.05 30.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.811 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 16.4 m -153.52 96.49 2.81 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.876 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -66.77 83.37 0.31 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.389 2.059 . . . . 0.0 112.139 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 26.8 t -104.93 135.66 41.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.981 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -79.97 145.04 32.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.59 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 5.7 mt -146.17 -169.31 3.22 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 121.336 0.588 . . . . 0.0 111.41 -179.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -140.27 153.53 46.53 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 115.092 -0.958 . . . . 0.0 110.285 178.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 10.0 m-85 -50.18 -31.94 15.01 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.269 -179.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.9 p -79.76 -1.21 37.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.385 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 1.3 mm-40 -116.0 3.01 13.57 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.714 0.292 . . . . 0.0 111.491 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 5.2 m -140.56 167.02 18.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-O 120.923 0.392 . . . . 0.0 111.074 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.4 m -135.07 146.36 30.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.124 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.99 139.15 57.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.886 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.253 -0.88 . . . . 0.0 111.066 179.994 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 8.6 tpt180 . . . . . 0 C--O 1.23 0.068 0 CA-C-O 120.888 0.375 . . . . 0.0 110.86 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -66.07 132.24 48.08 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.795 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 106.45 -14.41 42.92 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.781 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -54.84 164.72 0.74 Allowed 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.912 0.387 . . . . 0.0 110.912 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -112.15 115.87 29.56 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.07 -179.869 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 31.5 m -116.6 139.27 44.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.852 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.4 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.4 OUTLIER -79.97 155.02 27.86 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.025 0.441 . . . . 0.0 110.975 -179.924 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.537 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 36.4 t -95.26 167.4 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.729 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.402 ' N ' ' CG1' ' A' ' 139' ' ' VAL . 14.1 m -133.9 -21.01 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.25 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -178.723 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' SER . . . . . 0.44 ' O ' ' CD2' ' A' ' 144' ' ' PHE . 2.7 m -79.49 149.65 31.45 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.112 0.482 . . . . 0.0 112.18 -178.249 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 39.64 -148.46 0.15 Allowed Glycine 0 C--N 1.334 0.424 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.678 179.46 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -73.62 4.43 4.03 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.774 2.316 . . . . 0.0 112.557 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.537 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 0.5 OUTLIER -79.55 -8.99 59.54 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.072 179.959 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.432 ' HA ' ' O ' ' A' ' 139' ' ' VAL . . . -67.82 39.49 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -178.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . 0.486 ' H ' ' C ' ' A' ' 144' ' ' PHE . 0.3 OUTLIER -160.89 31.23 0.15 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.103 0.478 . . . . 0.0 110.56 179.102 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.431 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 44.9 m-85 -148.88 154.51 39.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.772 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 67.6 p -108.69 134.88 50.82 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.872 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -94.2 160.75 24.02 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.579 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.0 m -102.34 103.74 14.2 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.772 0.32 . . . . 0.0 110.751 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 33.9 t -62.27 107.59 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.967 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -88.89 -49.34 6.86 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.843 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -135.48 171.06 14.99 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.698 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -137.64 158.82 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.168 -179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -140.95 83.47 14.07 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.819 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.58 -27.04 23.04 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.515 2.143 . . . . 0.0 112.351 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -59.13 -42.4 90.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.885 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 4.6 mpt_? -103.8 -60.16 1.61 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.884 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 130.21 49.55 0.12 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.494 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 13.0 mttm -130.62 161.34 31.8 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.826 0.346 . . . . 0.0 110.928 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 17.3 m -147.33 124.48 3.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.193 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 9.3 tttt -87.38 123.92 32.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.888 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 15.4 m -142.34 135.92 28.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.033 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -80.49 130.44 35.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.728 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 15.4 m -110.22 131.18 61.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.234 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -97.62 100.31 11.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.809 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 8.0 tt -95.59 111.07 25.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.105 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER 60.61 43.58 12.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.907 -179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 65.55 52.18 41.56 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.465 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -154.16 119.22 5.03 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.911 0.386 . . . . 0.0 110.833 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -58.94 134.11 56.66 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.932 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -147.75 96.73 4.05 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.867 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.69 118.06 5.16 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.452 2.102 . . . . 0.0 112.184 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 9.9 p -145.93 144.12 21.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.092 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -79.99 134.35 36.24 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.724 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -121.68 -172.0 2.34 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-O 121.375 0.607 . . . . 0.0 111.341 -179.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -150.28 151.95 33.76 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.466 178.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 3.7 m-85 -45.12 -46.5 11.83 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.623 -179.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.12 -20.88 63.15 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.143 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.93 -10.02 38.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.511 -179.786 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 27.7 m -138.98 -176.63 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.803 0.335 . . . . 0.0 111.399 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 14.4 m -150.32 157.37 6.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.032 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 10.9 tptt -71.69 138.07 48.3 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.888 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.038 0 CA-C-O 118.199 -0.905 . . . . 0.0 111.195 179.979 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 1.8 tpt180 . . . . . 0 C--O 1.23 0.077 0 CA-C-O 120.853 0.358 . . . . 0.0 110.922 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -60.46 118.56 6.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.896 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.99 19.75 14.24 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.597 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -76.4 158.49 31.34 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.784 0.326 . . . . 0.0 110.847 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 -109.81 126.74 54.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.108 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 12.7 m -141.02 141.03 31.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.863 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.416 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 1.7 ttp180 -79.64 161.72 25.7 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.066 0.46 . . . . 0.0 110.833 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.478 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 27.6 t -79.98 151.37 4.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.607 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.5 m -93.99 -19.44 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 -179.338 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' SER . . . . . 0.441 ' O ' ' N ' ' A' ' 145' ' ' ALA . 4.2 m -79.14 153.4 30.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.767 0.318 . . . . 0.0 111.026 -179.079 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . -64.31 -63.87 4.02 Favored Glycine 0 CA--C 1.519 0.31 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.964 -179.497 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -53.36 -22.76 21.73 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.753 2.302 . . . . 0.0 112.474 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.478 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 6.4 m-85 -111.12 1.05 17.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.516 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.441 ' N ' ' O ' ' A' ' 141' ' ' SER . . . -69.65 47.63 0.08 Allowed 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 112.61 0.596 . . . . 0.0 112.61 -178.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . 0.404 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 17.4 p-10 -160.79 32.34 0.15 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.157 0.503 . . . . 0.0 110.696 179.015 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.404 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 35.0 m-85 -154.56 145.53 22.64 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.507 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' THR . . . . . 0.416 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 75.5 p -99.86 175.91 5.62 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.849 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -136.86 151.59 21.01 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.652 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.2 m -114.12 112.36 23.08 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.726 0.298 . . . . 0.0 110.978 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 21.8 t -66.36 107.87 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.071 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.33 -50.42 6.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.845 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -135.62 164.36 28.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.009 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.8 mt -126.88 151.78 34.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.092 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -113.88 86.78 11.53 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.91 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.63 -27.13 22.72 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.591 2.194 . . . . 0.0 112.337 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -60.09 -51.1 71.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.949 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 2.6 ttt85 -97.37 -67.21 0.86 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.895 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 141.24 52.89 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.417 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 14.3 mttp -131.14 178.76 6.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.831 0.348 . . . . 0.0 110.82 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 28.1 m -145.87 123.07 4.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.071 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 62.6 tttt -79.88 116.43 20.02 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.625 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.1 t -124.55 150.2 29.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.042 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 4.5 ptt? -103.65 116.49 32.43 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.023 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 3.2 m -113.17 138.15 43.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.051 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -97.69 133.79 41.74 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.852 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . 0.473 HD13 HG21 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -133.47 117.88 29.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.999 179.971 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . 0.404 ' HB2' ' CD1' ' A' ' 167' ' ' ILE . 0.2 OUTLIER 62.99 30.28 16.39 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.958 -179.7 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 77.0 45.01 12.31 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.494 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -157.85 128.56 6.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.827 0.346 . . . . 0.0 110.869 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -59.74 144.36 48.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 22.3 m -144.18 83.07 10.36 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.943 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_exo -56.23 90.16 0.04 OUTLIER 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.566 2.178 . . . . 0.0 112.312 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 24.7 t -109.0 132.69 56.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.086 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -79.92 125.84 30.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.278 179.602 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -134.43 -160.81 1.08 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.405 0.621 . . . . 0.0 111.459 -179.317 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -151.44 156.53 40.84 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.936 178.299 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 14.5 m-85 -46.77 -28.07 1.41 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.599 -179.531 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -78.81 -0.26 29.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.708 -179.722 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 79.1 mt-30 -118.74 0.14 11.4 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-O 120.481 0.182 . . . . 0.0 111.405 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 5.7 m -144.98 156.02 13.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 120.86 0.362 . . . . 0.0 111.099 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 30.3 m -126.41 146.43 32.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.167 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.85 128.8 37.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.003 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.059 0 CA-C-O 118.309 -0.853 . . . . 0.0 111.143 179.992 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 3.3 mtt180 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.854 0.359 . . . . 0.0 110.936 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -60.34 120.69 10.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 108.67 11.3 23.38 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.674 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -90.04 169.4 11.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.756 0.313 . . . . 0.0 110.92 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.36 134.15 48.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.829 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 21.0 m -142.06 134.04 27.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.148 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -80.99 163.13 23.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.94 0.4 . . . . 0.0 110.627 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.501 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 11.7 t -79.83 166.99 2.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.912 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.1 m -79.31 -61.79 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -179.306 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 4.2 m -160.02 -166.4 1.7 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.811 0.338 . . . . 0.0 111.258 -179.466 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.59 -158.37 37.25 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.392 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -68.82 -10.96 30.6 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.586 2.191 . . . . 0.0 112.352 179.82 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.501 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 3.3 m-85 -107.31 14.18 26.33 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.468 -179.796 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -75.3 36.48 0.12 Allowed 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 112.403 0.519 . . . . 0.0 112.403 -179.342 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . 0.402 ' H ' ' C ' ' A' ' 144' ' ' PHE . 0.4 OUTLIER -161.16 34.13 0.14 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.913 0.387 . . . . 0.0 110.77 179.278 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -145.31 164.43 31.44 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.991 -179.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -121.66 -173.94 2.75 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.43 179.586 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -154.6 161.83 30.4 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.449 -0.881 . . . . 0.0 112.844 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 88.9 m -110.49 101.6 10.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.833 0.349 . . . . 0.0 110.841 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 31.6 t -59.45 114.63 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.178 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -83.25 -61.07 1.95 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.866 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -134.23 168.98 17.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.895 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.7 mt -126.96 135.51 63.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.069 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -107.12 84.48 1.67 Allowed Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.92 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.44 -28.12 22.36 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.607 2.204 . . . . 0.0 112.256 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -68.31 -34.15 75.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.968 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 25.0 mmt180 -101.53 -56.11 2.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.958 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 121.66 37.35 0.68 Allowed Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.495 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -126.98 175.09 8.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.758 0.314 . . . . 0.0 110.864 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.5 m -151.17 119.7 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.135 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 2.1 ttpm? -79.86 137.46 36.93 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.73 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 4.8 t -149.19 146.68 17.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.997 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.67 127.56 48.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.016 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 3.5 m -107.02 147.66 12.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.039 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 63.3 m -112.67 85.58 2.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.978 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 4.1 mp -98.09 126.81 51.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.031 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 61.57 31.33 18.84 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.902 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 69.5 38.38 79.32 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.554 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 72.5 mmt-85 -146.76 134.42 21.07 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.861 0.363 . . . . 0.0 110.924 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -72.29 147.99 45.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.882 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 1.8 m -157.14 88.41 2.62 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.804 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -50.8 115.54 2.06 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.608 2.205 . . . . 0.0 112.338 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 10.4 p -128.63 142.74 43.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.064 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -98.25 121.49 40.24 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.838 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.404 ' CD1' ' N ' ' A' ' 176' ' ' LEU . 0.0 OUTLIER -126.94 -160.41 1.0 Allowed 'General case' 0 CA--C 1.518 -0.286 0 CA-C-O 121.353 0.597 . . . . 0.0 110.894 -179.939 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -148.36 155.37 41.18 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.163 -0.926 . . . . 0.0 109.934 178.373 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 11.7 m-85 -48.31 -33.83 9.53 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.482 -179.47 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 90.9 p -78.21 -2.55 38.3 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.643 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -115.29 -2.81 12.58 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.545 0.212 . . . . 0.0 111.564 -179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 17.4 m -140.41 171.98 12.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-O 120.844 0.354 . . . . 0.0 111.393 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 27.5 m -136.72 146.43 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.219 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 5.2 mtmt -80.09 130.99 35.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.919 179.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.278 -0.867 . . . . 0.0 111.045 -179.972 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.23 0.065 0 CA-C-O 120.842 0.354 . . . . 0.0 110.921 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -59.62 123.73 17.84 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.48 5.72 27.76 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.834 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -67.61 162.57 23.23 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.739 0.304 . . . . 0.0 110.792 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -111.59 131.23 55.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.977 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 15.6 m -143.42 148.25 19.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.803 179.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -79.63 164.62 23.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.03 0.443 . . . . 0.0 111.033 -179.927 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.469 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 22.3 t -79.88 151.06 4.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.674 -179.636 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.408 HG13 ' CA ' ' A' ' 180' ' ' GLN . 11.4 p -90.83 -24.17 5.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-N 116.044 -0.526 . . . . 0.0 112.076 -179.655 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 6.2 m -79.33 154.67 28.9 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.999 0.428 . . . . 0.0 111.412 -178.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . 0.437 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -67.26 -61.19 5.32 Favored Glycine 0 N--CA 1.451 -0.308 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.69 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.437 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.2 Cg_endo -51.43 -24.55 16.64 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.663 2.242 . . . . 0.0 112.205 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.469 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 21.3 m-85 -112.98 4.36 16.7 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.419 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -70.06 46.58 0.08 Allowed 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -179.097 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . 0.427 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 17.5 p-10 -160.56 30.82 0.16 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.204 0.526 . . . . 0.0 110.498 179.037 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.427 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 24.2 m-85 -151.85 146.18 25.48 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.168 179.732 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 26.7 p -96.85 -177.36 3.86 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.737 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -144.63 159.34 27.78 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.608 -179.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 2.2 m -117.09 111.55 19.67 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.798 0.332 . . . . 0.0 110.862 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 21.6 t -69.37 131.92 33.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.047 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.74 -68.92 0.79 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.026 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -123.71 172.92 8.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.948 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 35.0 mt -139.35 128.93 30.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.074 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -100.81 99.51 10.48 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.897 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.41 -23.75 17.15 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.557 2.171 . . . . 0.0 112.417 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -90.27 23.2 2.99 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.301 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 16.4 mtp180 -158.6 -44.25 0.06 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.754 0.311 . . . . 0.0 110.765 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 97.4 57.39 1.06 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.472 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.55 162.95 34.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.765 0.317 . . . . 0.0 111.016 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.1 m -148.06 126.67 3.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.961 179.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 6.0 tttp -79.94 122.29 26.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.856 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 11.4 p -126.13 145.93 32.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.085 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.21 117.89 35.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.735 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 13.4 m -110.33 142.76 21.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.139 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 8.2 m -135.73 133.32 37.89 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.875 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 4.1 mp -102.69 53.47 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.937 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER 65.67 96.49 0.05 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.974 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 65.81 33.55 86.17 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.679 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -154.44 86.07 1.14 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.849 0.357 . . . . 0.0 111.019 -179.884 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -68.79 141.95 55.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.706 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 63.4 m -160.0 93.3 1.68 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.167 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_exo -62.06 124.81 15.11 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.651 2.234 . . . . 0.0 112.057 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 11.2 p -137.91 132.33 43.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.32 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -79.82 131.72 35.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.263 179.642 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 1.1 mp -133.07 -167.74 1.97 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.421 0.629 . . . . 0.0 111.608 -179.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . 0.427 ' O ' ' N ' ' A' ' 180' ' ' GLN . 0.6 OUTLIER -144.66 154.11 42.45 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 114.961 -1.018 . . . . 0.0 110.199 178.152 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -44.73 -33.68 1.96 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.612 -179.548 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -82.32 14.65 2.83 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.679 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . 0.427 ' N ' ' O ' ' A' ' 177' ' ' ASP . 21.6 mt-30 -127.85 4.91 6.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.576 0.227 . . . . 0.0 111.328 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 6.2 m -146.45 170.72 4.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.14 0 CA-C-O 120.874 0.369 . . . . 0.0 111.198 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 21.0 m -140.49 146.38 24.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.084 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 13.6 tttt -66.07 121.94 16.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.272 -0.871 . . . . 0.0 111.062 179.983 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 7.1 mmt180 . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.882 0.372 . . . . 0.0 111.059 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -64.22 122.83 17.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.792 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 96.23 18.26 31.8 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.617 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.49 176.51 9.33 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.798 0.333 . . . . 0.0 110.884 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 38.2 mt-30 -120.08 114.34 21.83 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.115 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 18.8 m -124.43 143.17 38.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.805 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -79.85 162.11 25.24 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.109 0.481 . . . . 0.0 111.054 -179.724 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.501 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 46.7 t -84.62 155.21 3.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.529 -179.423 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.413 HG23 ' HA ' ' A' ' 180' ' ' GLN . 35.6 m -96.89 -24.65 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 N-CA-C 112.675 0.62 . . . . 0.0 112.675 -179.165 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' SER . . . . . 0.522 ' O ' ' N ' ' A' ' 145' ' ' ALA . 0.2 OUTLIER -78.99 131.12 36.19 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.85 0.357 . . . . 0.0 111.32 -178.646 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . 0.465 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -44.19 -59.07 4.17 Favored Glycine 0 C--N 1.332 0.347 0 CA-C-N 115.823 -0.626 . . . . 0.0 113.597 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.465 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.7 Cg_endo -51.1 -22.74 11.3 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.669 2.246 . . . . 0.0 112.481 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.501 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 21.2 m-85 -120.13 4.83 10.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.466 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.522 ' N ' ' O ' ' A' ' 141' ' ' SER . . . -70.02 45.21 0.07 Allowed 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 112.55 0.574 . . . . 0.0 112.55 -178.653 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . 0.408 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 15.1 p-10 -160.69 31.74 0.15 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.13 0.491 . . . . 0.0 110.422 179.091 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.408 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 46.3 m-85 -155.66 145.98 21.78 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.439 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 1.4 p -101.76 168.89 9.16 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.789 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -132.49 132.45 6.64 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.515 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.7 m -87.35 109.05 19.27 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.723 0.297 . . . . 0.0 110.802 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 19.2 t -64.38 123.8 17.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.093 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.2 p -100.97 -43.66 5.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.957 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 6.6 mt-10 -136.77 151.25 48.98 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 7.8 mt -128.57 132.23 68.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.101 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -116.98 85.54 18.03 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.835 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -58.37 -30.05 90.06 Favored 'Trans proline' 0 C--N 1.343 0.278 0 C-N-CA 122.595 2.196 . . . . 0.0 112.321 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -60.38 -62.68 1.69 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.099 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 7.7 ttm180 -79.99 -30.89 39.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.029 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 93.53 27.15 13.54 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.58 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 2.9 mtmm -107.78 162.65 13.8 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.732 0.301 . . . . 0.0 110.754 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.423 HG13 ' CE1' ' A' ' 178' ' ' PHE . 15.7 m -153.71 123.19 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.163 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 29.4 tttt -85.66 146.97 26.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.816 179.806 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.422 ' CG2' ' CD1' ' A' ' 176' ' ' LEU . 25.0 m -144.96 170.1 7.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.276 -179.866 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -120.0 110.87 17.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.655 179.631 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 11.9 m -99.53 157.99 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.138 -179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 27.4 p -141.49 97.41 3.15 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.982 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.9 mp -79.87 83.53 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.962 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 24.7 m-85 62.29 70.39 0.57 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.902 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 60.26 47.06 92.97 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.566 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 1.5 mtm180 -146.38 91.48 2.05 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.905 0.383 . . . . 0.0 110.977 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -58.17 140.39 53.03 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.984 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 2.8 m -160.09 97.8 1.49 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.933 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.86 123.76 10.38 Favored 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.405 2.07 . . . . 0.0 112.12 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.9 t -139.74 145.26 26.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.134 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -88.92 142.47 27.62 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.859 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.422 ' CD1' ' CG2' ' A' ' 163' ' ' VAL . 0.1 OUTLIER -147.68 -161.29 1.3 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.337 0.589 . . . . 0.0 111.088 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -150.48 155.18 39.02 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.007 178.292 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . 0.423 ' CE1' HG13 ' A' ' 161' ' ' VAL . 25.6 m-85 -46.47 -30.4 2.18 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.536 -179.583 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 60.6 p -81.19 8.11 9.65 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.863 -179.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . 0.413 ' HA ' HG23 ' A' ' 140' ' ' VAL . 6.2 mt-30 -122.39 2.12 9.65 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-O 120.616 0.246 . . . . 0.0 111.286 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 4.8 m -143.24 172.31 7.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-O 120.88 0.371 . . . . 0.0 111.084 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 18.0 m -142.16 148.92 19.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.161 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.57 125.35 25.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.911 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.174 -0.917 . . . . 0.0 111.106 179.92 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.931 0.396 . . . . 0.0 110.88 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -62.6 135.47 57.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.912 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 105.31 -23.94 28.99 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.637 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.8 t0 -58.2 158.23 7.34 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.825 0.345 . . . . 0.0 110.947 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 13.9 mm-40 -110.41 138.42 46.82 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.002 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 18.4 m -140.01 134.11 36.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.911 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.439 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 2.6 ttm180 -79.95 166.03 22.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.995 0.426 . . . . 0.0 110.839 179.877 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.464 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 3.9 t -79.91 169.73 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.799 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -79.49 -65.53 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 111.835 0.309 . . . . 0.0 111.835 -179.5 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -160.18 -167.85 2.04 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.827 0.346 . . . . 0.0 111.059 -179.683 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 83.81 -162.27 39.09 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.417 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -64.28 -15.72 51.12 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.532 2.154 . . . . 0.0 112.241 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.464 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 2.8 m-85 -104.54 19.73 19.82 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.149 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.69 38.22 0.44 Allowed 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -179.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . 0.435 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 8.8 t70 -160.84 32.63 0.15 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.01 0.434 . . . . 0.0 110.977 179.234 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.435 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 17.0 m-85 -140.3 161.11 38.47 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.7 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' THR . . . . . 0.439 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 25.1 p -116.42 -178.45 3.42 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.741 179.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -145.43 137.42 7.04 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.664 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 14.5 m -92.83 108.64 20.15 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.78 0.324 . . . . 0.0 110.663 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 20.7 t -69.37 118.87 14.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.207 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -103.77 -34.82 8.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.854 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -151.25 159.72 44.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.859 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mp -139.83 140.52 35.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.136 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 24.3 m120 -103.71 92.2 4.05 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.863 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -69.4 -27.76 27.77 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.538 2.159 . . . . 0.0 112.25 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -70.25 -40.27 74.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.867 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 3.7 mmt180 -98.49 -62.42 1.24 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.855 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 125.47 55.42 0.16 Allowed Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.476 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -130.45 166.53 20.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.92 0.39 . . . . 0.0 110.921 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.416 HG12 ' CE1' ' A' ' 178' ' ' PHE . 3.4 m -147.94 116.93 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.059 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 26.1 ttpt -87.07 121.52 29.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.754 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 35.7 m -135.6 147.01 28.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.254 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 4.1 ptt? -102.17 118.73 37.51 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.043 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 7.4 t -106.2 158.45 6.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.12 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -110.18 94.65 5.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.946 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 1.4 tp -112.16 136.74 47.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.965 179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER 61.31 30.1 18.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.921 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 67.74 39.97 90.03 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.633 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -159.88 140.21 11.86 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.787 0.327 . . . . 0.0 110.967 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.57 150.92 45.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.77 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 14.8 p -153.3 93.47 3.12 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.042 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.88 87.18 0.29 Allowed 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.444 2.096 . . . . 0.0 112.039 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 34.6 t -101.62 135.3 38.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.338 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 10.9 pm0 -82.04 124.31 29.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.581 179.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -132.55 -160.9 1.09 Allowed 'General case' 0 CA--C 1.517 -0.308 0 CA-C-O 121.351 0.596 . . . . 0.0 111.254 -179.605 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -149.88 155.2 39.62 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.169 178.377 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . 0.416 ' CE1' HG12 ' A' ' 161' ' ' VAL . 42.6 m-85 -46.34 -29.02 1.49 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.732 -179.502 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 8.2 m -74.52 -5.7 44.21 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.738 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 11.9 mm-40 -120.76 -4.46 9.71 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 111.603 0.223 . . . . 0.0 111.603 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 6.6 m -122.76 178.03 3.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.86 0.362 . . . . 0.0 111.223 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 27.2 m -152.06 146.78 15.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.135 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 3.8 ttmm -67.51 125.2 25.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.927 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.17 -0.919 . . . . 0.0 111.105 -179.985 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.818 0.342 . . . . 0.0 110.907 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -67.6 140.26 56.9 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.011 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 93.95 -21.51 41.37 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.58 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.43 176.28 0.65 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.851 0.358 . . . . 0.0 110.94 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -112.36 143.35 43.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.04 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 18.0 m -139.42 133.13 38.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.907 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.418 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 1.6 ttt180 -79.85 165.14 23.02 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.017 0.437 . . . . 0.0 110.94 -179.819 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.465 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 4.4 t -80.03 169.08 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.904 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -79.63 -65.97 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.805 -179.5 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 51.8 p -160.13 -165.52 1.49 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.823 0.344 . . . . 0.0 111.017 -179.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.61 -160.56 39.64 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.414 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.65 -13.42 39.82 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.613 2.209 . . . . 0.0 112.295 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.465 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 3.6 m-85 -106.97 20.49 18.97 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.164 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.13 38.91 0.49 Allowed 'General case' 0 C--N 1.331 -0.239 0 N-CA-C 112.3 0.481 . . . . 0.0 112.3 -179.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -160.97 36.49 0.15 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.88 0.371 . . . . 0.0 110.951 179.358 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -147.84 158.48 44.05 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.815 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' THR . . . . . 0.418 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 58.2 p -118.93 169.2 10.08 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.792 179.869 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . 0.401 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -132.67 153.36 20.62 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.679 -179.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 2.7 m -101.81 107.72 18.99 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.819 0.343 . . . . 0.0 110.828 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 24.5 t -62.42 116.66 2.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.131 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 4.6 p -108.68 -57.2 2.17 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.859 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -113.23 155.99 24.08 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mp -142.31 141.72 28.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.172 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -123.65 101.29 36.88 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.812 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -69.23 -26.55 29.95 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.398 2.066 . . . . 0.0 112.438 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.57 -42.15 52.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.918 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 49.3 mtt-85 -87.43 -33.8 18.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.901 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 85.11 35.81 11.94 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.427 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 28.6 mttm -118.01 177.04 4.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.754 0.312 . . . . 0.0 110.857 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 6.1 m -158.94 121.49 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.166 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 80.5 tttt -84.87 132.75 34.35 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.822 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.401 ' HB ' ' HA3' ' A' ' 149' ' ' GLY . 33.8 m -139.67 138.67 39.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.144 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 12.6 ptm -90.67 113.84 26.0 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 27.4 m -115.46 156.91 16.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.171 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 16.7 p -105.98 142.52 35.54 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.719 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . 0.4 HG21 HD13 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -103.77 -38.96 5.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.997 179.927 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -171.18 86.15 0.09 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.866 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 58.16 30.24 63.79 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.559 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -158.13 134.46 9.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.807 0.337 . . . . 0.0 110.925 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -67.96 155.89 38.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 3.4 m -159.96 93.71 1.66 Allowed Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.756 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -67.84 125.84 13.75 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.502 2.135 . . . . 0.0 112.294 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 7.4 m -139.38 139.02 39.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.3 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -79.87 126.49 31.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.344 179.524 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 6.8 mt -133.88 -170.99 2.62 Favored 'General case' 0 CA--C 1.516 -0.359 0 CA-C-O 121.388 0.613 . . . . 0.0 111.698 -179.345 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -144.36 155.7 43.91 Favored 'General case' 0 N--CA 1.442 -0.832 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.286 178.196 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -45.62 -41.74 10.51 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.577 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 2.6 p -65.39 -15.88 63.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.373 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -103.78 -18.89 14.48 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.384 -179.689 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 11.0 m -120.75 173.05 6.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.922 0.392 . . . . 0.0 111.366 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 30.3 m -144.4 146.25 20.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.032 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.56 123.0 21.49 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.992 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.995 0 CA-C-O 118.324 -0.846 . . . . 0.0 111.061 179.977 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.769 0.318 . . . . 0.0 110.929 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -63.69 138.32 58.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.951 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 105.85 -22.4 31.9 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.613 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -57.41 156.16 8.26 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.818 0.342 . . . . 0.0 111.028 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 10.0 mt-30 -113.17 137.53 51.32 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.939 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 18.4 m -143.81 141.39 25.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.155 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.42 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 3.7 ttp180 -79.91 165.84 22.24 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.796 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.467 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 7.6 t -80.1 167.22 2.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.116 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.6 p -79.35 -61.41 1.73 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.92 -179.395 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 2.6 m -160.35 -165.13 1.38 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.912 0.386 . . . . 0.0 111.138 -179.464 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.56 -165.85 50.32 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.334 179.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -62.15 -17.11 54.82 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.474 2.116 . . . . 0.0 112.02 179.659 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.467 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 3.7 m-85 -99.57 14.6 29.4 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.119 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -78.75 38.06 0.31 Allowed 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -179.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -160.89 36.6 0.15 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.88 0.371 . . . . 0.0 110.774 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 16.2 m-85 -152.13 157.23 41.27 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.043 -179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 5.6 t -110.17 -176.02 2.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.636 179.823 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -154.89 140.41 7.38 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.539 -0.839 . . . . 0.0 112.779 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 12.2 m -94.16 110.19 21.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.754 0.311 . . . . 0.0 110.623 179.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 36.8 t -57.55 116.53 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.155 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -111.45 -29.57 7.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.0 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -135.72 167.01 21.94 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.943 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 23.3 pt -145.59 133.27 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.167 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -117.19 81.18 12.78 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.803 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.44 -32.45 12.36 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.656 2.237 . . . . 0.0 112.224 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -59.74 -35.49 74.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.919 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -102.17 -33.98 9.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.927 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 99.16 43.87 2.5 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.45 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -139.76 156.12 46.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.934 0.397 . . . . 0.0 110.867 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.467 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.2 p -123.52 159.79 27.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.924 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . 0.467 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 13.0 ttpt -128.65 140.22 51.87 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.184 -179.753 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 34.6 m -139.84 -179.73 2.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.233 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -120.08 111.9 18.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.702 179.565 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 31.0 m -98.25 167.92 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.263 -179.773 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.16 79.56 1.7 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.821 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 30.9 mm -80.54 108.37 13.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.173 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 59.15 55.27 4.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.064 0.459 . . . . 0.0 110.928 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 57.53 41.48 93.48 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.571 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 6.1 ttt180 -137.51 106.32 5.92 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.803 0.335 . . . . 0.0 110.924 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -73.21 127.02 31.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.874 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 52.3 m -147.17 131.44 8.6 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.79 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -74.79 106.71 2.31 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.516 2.144 . . . . 0.0 112.415 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 12.1 p -119.07 124.01 72.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.987 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 12.4 mt-10 -88.15 141.89 28.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.806 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -138.12 -162.55 1.32 Allowed 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 121.233 0.539 . . . . 0.0 111.151 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -146.04 152.2 38.96 Favored 'General case' 0 N--CA 1.444 -0.762 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.207 178.404 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 -48.74 -37.04 17.72 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.432 -179.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 17.3 p -75.74 -9.54 58.68 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.56 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 23.5 mt-30 -118.58 21.14 12.72 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-O 120.603 0.239 . . . . 0.0 111.417 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 17.6 m -152.92 146.5 14.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.891 0.377 . . . . 0.0 111.22 179.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 30.9 m -114.15 146.28 18.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.135 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 4.1 ttmt -80.92 137.28 36.13 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.955 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.065 0 CA-C-O 118.255 -0.879 . . . . 0.0 111.041 179.979 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.839 0.352 . . . . 0.0 110.843 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -69.21 141.25 54.54 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.835 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 89.29 -8.66 79.34 Favored Glycine 0 CA--C 1.519 0.339 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.724 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -56.87 164.14 1.67 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.826 0.346 . . . . 0.0 111.027 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -104.05 134.63 46.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.976 -179.867 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 21.0 m -141.66 131.54 24.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.886 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 3.4 ttp180 -79.78 164.28 23.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.013 0.435 . . . . 0.0 110.976 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.478 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 3.7 t -79.96 168.55 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.86 -179.884 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -79.6 -65.8 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.768 -179.518 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -160.11 -164.57 1.31 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.768 0.318 . . . . 0.0 110.903 -179.835 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.36 -157.34 36.5 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.529 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -69.53 -10.23 28.2 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.558 2.172 . . . . 0.0 112.519 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.478 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 2.6 m-85 -110.46 19.54 18.67 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.201 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -78.86 37.85 0.31 Allowed 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -179.352 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . 0.406 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 1.5 p30 -161.08 36.0 0.14 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.893 0.378 . . . . 0.0 110.896 179.281 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.406 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 44.0 m-85 -146.81 163.03 37.34 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.969 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 1.1 p -118.16 -177.07 3.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.771 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -147.47 142.95 10.68 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.526 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.7 m -99.7 103.71 15.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.779 0.324 . . . . 0.0 110.766 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 31.7 t -60.6 127.03 19.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.206 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.9 p -111.95 -33.98 6.12 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.858 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -136.01 157.7 46.21 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.874 179.883 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 25.9 pt -138.76 136.22 43.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.261 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -120.09 84.57 33.65 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.879 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -54.28 -26.44 43.19 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.535 2.157 . . . . 0.0 112.392 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -58.7 -73.3 0.08 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.907 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 7.2 mtt85 -80.01 -30.45 39.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.909 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 93.97 47.0 2.99 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.412 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -106.34 159.69 15.94 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.884 0.373 . . . . 0.0 110.872 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.2 m -143.16 116.94 3.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.15 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 19.1 tttp -90.78 111.23 22.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.826 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 33.8 m -119.24 148.71 22.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.163 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.5 ppp? -95.1 114.77 26.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.773 179.79 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 17.0 m -105.52 149.11 9.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.202 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 22.6 m -119.61 85.23 2.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.904 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 1.7 tp -82.21 118.11 29.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.092 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 60.57 33.62 20.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.873 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 75.18 30.09 59.42 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.505 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.12 108.65 8.96 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.753 0.311 . . . . 0.0 110.981 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -59.95 139.91 57.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.807 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 53.8 m -154.12 109.56 2.46 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.913 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -67.45 100.67 0.58 Allowed 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.341 2.027 . . . . 0.0 112.157 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 11.9 p -108.45 129.01 63.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.286 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -90.63 123.39 34.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.614 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -137.33 -159.52 0.96 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.43 0.633 . . . . 0.0 111.128 -179.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -145.56 157.33 44.0 Favored 'General case' 0 N--CA 1.441 -0.875 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.055 178.21 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -44.24 -30.42 0.8 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.656 -179.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 35.5 t -67.25 -23.55 65.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.435 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 22.6 mt-30 -101.83 -14.17 17.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.617 -179.617 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 10.7 m -123.39 172.15 11.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-O 120.858 0.361 . . . . 0.0 111.461 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 32.9 m -146.39 146.2 19.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.164 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 9.9 mttt -66.0 125.74 26.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.943 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.273 -0.87 . . . . 0.0 111.075 179.994 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 2.0 ttm180 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.745 0.307 . . . . 0.0 110.98 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -59.66 120.16 8.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.939 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 121.71 -19.9 8.34 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.64 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -55.48 -178.85 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.824 0.345 . . . . 0.0 110.994 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 2.0 mt-30 -132.02 136.14 47.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.148 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 31.0 m -139.45 147.93 23.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.789 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -79.84 164.75 23.36 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.962 0.411 . . . . 0.0 111.022 -179.771 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.461 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 39.7 t -79.8 149.35 5.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.433 -179.689 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 9.9 p -90.26 -20.36 6.99 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 115.991 -0.55 . . . . 0.0 112.181 -179.494 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' SER . . . . . 0.403 ' O ' ' N ' ' A' ' 145' ' ' ALA . 0.4 OUTLIER -79.23 152.65 30.5 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.908 0.385 . . . . 0.0 111.145 -179.032 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . 0.404 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -65.5 -63.37 4.14 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.892 -179.793 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.404 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.6 Cg_endo -53.76 -22.7 24.07 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.7 2.266 . . . . 0.0 112.32 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.461 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 17.5 m-85 -110.36 1.99 18.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.365 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.403 ' N ' ' O ' ' A' ' 141' ' ' SER . . . -70.31 49.68 0.11 Allowed 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -179.151 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -160.69 32.63 0.15 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.15 0.5 . . . . 0.0 110.465 179.093 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 46.5 m-85 -157.23 145.77 19.58 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.533 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 30.3 p -103.67 -179.26 3.9 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.865 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -144.71 141.98 10.52 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.619 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.4 m -93.38 107.41 19.24 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.714 0.293 . . . . 0.0 110.696 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 40.9 t -64.84 113.14 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.088 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 73.8 p -97.76 -46.4 5.98 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.763 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -124.69 167.48 14.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.848 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 12.6 pt -146.49 160.14 10.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.203 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 8.5 m-20 -132.24 89.71 36.55 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.923 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.15 -28.09 28.6 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.546 2.164 . . . . 0.0 112.289 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -62.49 -52.79 62.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.967 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.26 -49.43 5.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.905 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 115.44 52.23 0.41 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.574 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -125.88 170.15 11.94 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.864 0.364 . . . . 0.0 110.815 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.4 m -154.17 132.42 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.131 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 7.0 tttm -104.13 133.46 49.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.969 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 34.6 m -134.86 164.23 34.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.285 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 3.9 ptt? -106.7 120.55 42.27 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.808 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 16.9 m -117.51 157.56 18.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.13 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 23.6 m -142.37 105.81 4.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.974 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.1 mp -83.1 113.71 22.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.039 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 64.97 -77.71 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.971 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -154.47 44.23 0.57 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.448 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 5.2 ptt180 -148.24 115.27 6.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.883 0.373 . . . . 0.0 110.957 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -68.96 147.03 52.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.771 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 76.4 m -160.06 113.8 1.44 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.942 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -73.6 112.65 3.58 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.402 2.068 . . . . 0.0 112.141 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.5 t -119.41 124.4 72.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.225 -179.759 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -92.1 131.07 37.65 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.677 179.754 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -139.71 -161.65 1.22 Allowed 'General case' 0 CA--C 1.515 -0.385 0 CA-C-O 121.522 0.677 . . . . 0.0 111.259 -179.793 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -138.06 161.29 37.14 Favored 'General case' 0 N--CA 1.439 -1.004 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.172 177.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -43.45 -38.51 2.85 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.693 -0.685 . . . . 0.0 112.554 -179.006 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.38 5.36 12.79 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.135 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . 0.444 ' NE2' ' N ' ' A' ' 180' ' ' GLN . 1.2 mp0 -112.14 6.87 19.36 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.582 0.229 . . . . 0.0 111.407 -179.809 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 27.2 m -151.95 174.96 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 120.882 0.372 . . . . 0.0 111.289 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 12.9 m -143.14 146.68 21.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.084 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -60.82 123.27 17.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.926 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.253 -0.88 . . . . 0.0 111.045 -179.96 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.894 0.378 . . . . 0.0 110.915 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.4 pp20? -59.56 122.25 13.58 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.926 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.68 15.97 25.49 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.709 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -69.66 157.25 37.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.761 0.315 . . . . 0.0 110.91 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -93.16 132.19 37.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.981 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 14.9 m -140.79 133.25 31.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.927 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.41 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.8 OUTLIER -79.82 166.38 21.77 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.912 0.387 . . . . 0.0 110.967 -179.907 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.442 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 7.3 t -79.74 167.9 2.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.969 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 3.0 p -79.41 -61.47 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 -179.291 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 39.6 p -160.45 -164.1 1.19 Allowed 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.766 0.317 . . . . 0.0 111.246 -179.675 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.86 -168.58 54.26 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.325 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -59.93 -18.56 50.54 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.541 2.161 . . . . 0.0 112.087 179.671 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.442 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 4.1 m-85 -97.04 16.8 18.55 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.094 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.58 39.44 0.47 Allowed 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 112.146 0.425 . . . . 0.0 112.146 -179.425 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . 0.416 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 8.3 t0 -160.74 34.69 0.15 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.979 0.419 . . . . 0.0 110.71 179.43 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.416 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 24.3 m-85 -146.13 160.68 41.59 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.711 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' THR . . . . . 0.41 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 3.2 p -120.22 172.99 7.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.989 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -138.62 159.92 25.48 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.563 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' THR . . . . . 0.415 ' HB ' ' CG ' ' A' ' 164' ' ' MET . 3.4 m -109.38 110.02 21.05 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.765 0.317 . . . . 0.0 110.796 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 31.6 t -60.2 99.84 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.113 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -90.95 -39.23 12.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.74 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -132.7 154.0 50.59 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.708 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 32.9 pt -148.56 136.5 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.095 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -114.32 89.18 16.95 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.892 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.06 -26.26 37.14 Favored 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.545 2.164 . . . . 0.0 112.406 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -59.79 -32.31 70.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.851 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 27.4 mtt85 -113.87 -46.33 3.03 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.905 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 118.76 44.54 0.5 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.494 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 2.0 mmtt -119.26 166.13 13.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.769 0.318 . . . . 0.0 110.883 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.9 m -156.0 129.5 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.043 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -99.83 123.02 43.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.956 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 30.6 m -123.54 138.89 51.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.126 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 164' ' ' MET . . . . . 0.415 ' CG ' ' HB ' ' A' ' 150' ' ' THR . 0.3 OUTLIER -91.85 106.47 18.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.965 0.412 . . . . 0.0 110.796 -179.969 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 13.5 m -90.14 167.0 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.096 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 3.4 m -130.16 92.76 3.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.911 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 4.1 mp -98.77 114.83 37.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.924 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 62.2 29.93 17.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 75.85 55.03 5.08 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.536 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -157.48 117.95 3.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.744 0.307 . . . . 0.0 111.0 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -65.94 121.18 14.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.819 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 23.5 m -130.64 89.78 42.56 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.962 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -68.17 101.35 0.7 Allowed 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.432 2.088 . . . . 0.0 112.231 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 28.3 m -110.32 138.74 36.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.155 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -80.02 117.96 21.32 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.559 179.615 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -137.16 -159.76 0.99 Allowed 'General case' 0 CA--C 1.517 -0.323 0 CA-C-O 121.292 0.567 . . . . 0.0 111.15 -179.622 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -150.71 154.88 38.22 Favored 'General case' 0 N--CA 1.442 -0.848 0 CA-C-N 115.232 -0.894 . . . . 0.0 110.151 178.399 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -46.61 -28.88 1.59 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.546 -179.731 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.9 p -67.6 -14.44 62.94 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.339 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 5.3 mt-30 -116.88 10.15 14.04 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.515 -179.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 31.4 m -156.99 150.39 9.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.807 0.337 . . . . 0.0 111.224 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -121.29 173.72 6.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.898 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.85 150.3 37.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.956 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.995 0 CA-C-O 118.224 -0.893 . . . . 0.0 111.115 -179.998 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.063 0 CA-C-O 120.89 0.376 . . . . 0.0 110.824 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -65.07 135.42 55.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.846 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.82 -26.03 13.47 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.58 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -60.17 166.49 2.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.752 0.31 . . . . 0.0 110.912 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -112.7 130.38 56.08 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.989 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 19.5 m -134.27 141.94 42.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.946 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.9 166.19 21.9 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.967 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.449 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 4.2 t -79.77 169.18 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.014 -179.861 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.1 p -79.18 -64.76 0.86 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 CA-C-N 116.566 -0.288 . . . . 0.0 111.773 -179.451 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -160.42 -163.55 1.11 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.811 0.339 . . . . 0.0 111.096 -179.642 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.37 -164.71 49.63 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.518 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -62.83 -16.39 53.29 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.495 2.13 . . . . 0.0 112.173 179.725 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.449 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 3.5 m-85 -102.59 20.17 17.65 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.083 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.49 39.85 0.62 Allowed 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 111.98 0.363 . . . . 0.0 111.98 -179.509 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -160.81 35.97 0.15 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.927 0.394 . . . . 0.0 110.781 179.447 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 19.2 m-85 -146.16 172.3 13.64 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.793 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 33.8 p -122.55 -172.12 2.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.877 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -156.64 144.02 10.31 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.626 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.6 m -93.04 105.82 17.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.841 0.353 . . . . 0.0 110.845 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 25.1 t -61.9 137.74 23.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.403 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 65.4 p -119.88 -49.06 2.33 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.69 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -128.72 159.64 35.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.871 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mp -142.43 132.18 22.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.13 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -104.61 108.96 62.17 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.75 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -74.2 -44.05 0.48 Allowed 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.432 2.088 . . . . 0.0 112.409 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -65.4 -44.64 86.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.017 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 1.5 mtt180 -83.97 -41.08 17.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.894 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 89.49 36.72 7.31 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.336 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 24.6 mtpt -117.62 177.6 4.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.759 0.314 . . . . 0.0 110.941 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.469 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.3 p -159.91 159.57 2.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.09 0.471 . . . . 0.0 111.054 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . 0.469 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 20.3 tttm -127.53 133.3 49.83 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.799 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.402 ' CG2' HD11 ' A' ' 176' ' ' LEU . 18.3 m -139.17 160.16 29.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.177 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 12.5 ptp -102.29 116.22 32.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.603 179.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 15.5 m -107.62 160.26 6.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.362 -179.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 6.9 t -152.1 135.26 15.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.722 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.1 mp -91.8 -67.0 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.131 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -148.52 87.13 1.56 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.832 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 70.24 25.69 75.28 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.455 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 4.4 ttm180 -148.76 112.51 5.09 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.872 0.368 . . . . 0.0 110.889 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -89.46 157.39 18.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.836 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 65.1 m -160.11 112.39 1.42 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.969 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -71.72 121.18 7.43 Favored 'Trans proline' 0 C--N 1.347 0.46 0 C-N-CA 122.438 2.092 . . . . 0.0 112.117 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 27.4 m -128.08 142.79 42.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.362 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -93.28 127.85 39.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.672 179.791 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.402 HD11 ' CG2' ' A' ' 163' ' ' VAL . 0.0 OUTLIER -137.45 -159.87 1.0 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.324 0.583 . . . . 0.0 111.203 -179.769 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . 0.408 ' O ' ' N ' ' A' ' 180' ' ' GLN . 0.1 OUTLIER -149.47 154.11 38.31 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 115.103 -0.953 . . . . 0.0 110.269 178.447 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 31.0 m-85 -43.99 -28.57 0.48 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.862 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.09 8.12 7.81 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 111.865 0.32 . . . . 0.0 111.865 -179.791 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . 0.408 ' N ' ' O ' ' A' ' 177' ' ' ASP . 9.9 mt-30 -131.05 9.25 4.84 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.601 0.238 . . . . 0.0 111.27 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 5.6 m -141.85 174.69 6.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 120.751 0.31 . . . . 0.0 111.089 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 17.3 m -147.55 154.49 11.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.132 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.25 134.02 44.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.899 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.267 -0.873 . . . . 0.0 111.092 -179.937 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.778 0.323 . . . . 0.0 110.872 . . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -62.48 139.42 58.58 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.833 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 97.34 -24.61 30.69 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.567 -179.987 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -58.0 -168.59 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.737 0.304 . . . . 0.0 111.009 -179.947 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 5.1 mm-40 -135.27 138.64 43.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.084 -179.907 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.502 ' HB ' ' O ' ' A' ' 182' ' ' VAL . 27.1 m -136.93 157.5 35.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.913 179.911 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.431 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 1.0 OUTLIER -90.49 165.93 13.52 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.944 0.402 . . . . 0.0 110.883 179.904 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.472 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 5.2 t -79.95 168.31 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.046 -179.914 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 1.7 p -79.25 -65.41 0.78 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.778 -179.544 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 4.0 m -160.24 -164.43 1.27 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.849 0.357 . . . . 0.0 111.082 -179.552 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.53 -160.53 41.75 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.446 179.989 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -67.46 -11.6 32.73 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.421 2.08 . . . . 0.0 112.406 179.689 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.472 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 4.2 m-85 -107.92 19.67 19.74 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.105 -179.997 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.53 37.51 0.41 Allowed 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 112.197 0.443 . . . . 0.0 112.197 -179.467 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -161.08 35.6 0.14 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.996 0.427 . . . . 0.0 110.836 179.423 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -146.55 153.86 40.86 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.646 -179.892 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 148' ' ' THR . . . . . 0.431 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 44.4 p -103.01 -179.91 4.09 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.816 -179.957 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -143.12 149.37 21.3 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.541 -0.838 . . . . 0.0 112.661 -179.818 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 16.2 m -95.73 102.69 14.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.831 0.348 . . . . 0.0 110.654 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 46.4 t -59.98 116.67 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.059 -179.917 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 3.3 p -97.02 -47.12 5.92 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.828 179.973 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -138.84 158.51 44.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.86 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 32.0 mt -131.08 141.57 45.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.198 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.4 m-20 -121.86 100.79 43.05 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.67 179.969 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -63.58 -55.62 0.67 Allowed 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.613 2.209 . . . . 0.0 112.43 -179.765 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -57.54 -43.75 84.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.414 -179.662 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 1.9 tpm_? -79.97 -26.2 40.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.154 -179.728 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 69.69 31.07 70.4 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.313 -179.902 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 20.0 mttt -111.7 165.17 12.27 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.78 0.324 . . . . 0.0 111.0 -179.902 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 6.9 m -147.3 126.34 4.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.006 179.907 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 3.5 ttmt -101.2 127.86 47.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.021 -179.899 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.401 ' CG2' ' CD1' ' A' ' 176' ' ' LEU . 18.8 m -141.74 149.47 19.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.218 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 164' ' ' MET . . . . . 0.445 ' O ' ' HG3' ' A' ' 164' ' ' MET . 0.0 OUTLIER -98.52 120.66 39.33 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.843 179.687 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 31.2 m -107.05 153.99 8.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.347 -179.685 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -122.14 147.92 45.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.773 179.888 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 2.0 mp -102.85 -62.73 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.08 -179.973 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.3 59.51 1.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.881 -179.915 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 98.21 -20.76 49.22 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.575 -179.972 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 4.0 ttt180 -97.79 127.73 43.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.788 0.328 . . . . 0.0 110.975 -179.924 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -84.24 155.13 22.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.856 179.968 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 42.1 m -157.79 101.11 1.81 Allowed Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.88 179.888 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -67.36 113.64 2.96 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.453 2.102 . . . . 0.0 112.192 -179.997 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.4 t -128.9 150.94 35.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.151 -179.931 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.99 157.34 26.84 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.754 179.949 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.42 ' CD2' ' HB3' ' A' ' 180' ' ' GLN . 1.0 OUTLIER -154.78 -171.06 3.71 Favored 'General case' 0 CA--C 1.516 -0.348 0 CA-C-O 121.26 0.552 . . . . 0.0 111.164 -179.963 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -150.14 152.97 35.55 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.462 178.421 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -46.86 -45.19 20.14 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.388 -179.815 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 9.2 t -79.52 -1.53 38.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.531 -179.85 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . 0.42 ' HB3' ' CD2' ' A' ' 176' ' ' LEU . 1.2 mt-30 -112.41 7.41 19.13 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.581 -0.281 . . . . 0.0 111.392 -179.84 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 23.2 m -136.23 178.58 4.86 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.927 0.394 . . . . 0.0 111.274 179.933 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . 0.502 ' O ' ' HB ' ' A' ' 137' ' ' VAL . 0.4 OUTLIER -133.34 -150.58 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.346 -179.965 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -122.52 138.86 54.43 Favored 'General case' 0 C--N 1.331 -0.197 0 O-C-N 122.176 -0.327 . . . . 0.0 111.0 -179.918 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.044 0 CA-C-O 118.166 -0.921 . . . . 0.0 111.098 179.864 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 44.4 mtm180 . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.934 0.397 . . . . 0.0 110.923 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -56.67 155.92 6.99 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.803 -179.939 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.55 8.21 59.49 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.86 -179.856 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.34 179.1 0.23 Allowed 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.801 0.334 . . . . 0.0 110.789 179.893 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 10.7 mt-30 -139.92 133.32 30.01 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.116 -179.859 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 148' ' ' THR . 23.1 m -142.49 146.18 22.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.774 179.88 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.447 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.5 OUTLIER -79.72 167.12 21.07 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 121.039 0.447 . . . . 0.0 111.172 -179.829 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.458 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 20.3 t -79.75 152.27 4.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.366 -179.571 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 14.7 p -92.47 -24.42 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 CA-C-N 116.082 -0.508 . . . . 0.0 112.148 -179.326 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 141' ' ' SER . . . . . 0.409 ' O ' ' N ' ' A' ' 145' ' ' ALA . 9.8 m -79.4 153.89 29.39 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.888 0.375 . . . . 0.0 111.274 -178.952 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . 0.428 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -66.13 -61.48 5.44 Favored Glycine 0 CA--C 1.519 0.312 0 C-N-CA 121.046 -0.597 . . . . 0.0 112.777 -179.86 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.428 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.6 Cg_endo -52.82 -23.85 21.99 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.581 2.188 . . . . 0.0 112.278 179.885 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.458 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 17.4 m-85 -111.6 2.64 17.43 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.281 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.409 ' N ' ' O ' ' A' ' 141' ' ' SER . . . -70.22 50.02 0.11 Allowed 'General case' 0 C--O 1.233 0.218 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -179.163 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . 0.402 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 5.7 t70 -160.68 32.21 0.15 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.045 0.45 . . . . 0.0 110.399 179.134 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.402 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 65.8 m-85 -155.24 146.2 22.52 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.376 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 148' ' ' THR . . . . . 0.447 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 19.3 p -103.38 170.63 7.83 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.372 -0.377 . . . . 0.0 111.004 -179.853 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -126.77 130.12 6.84 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.593 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.3 m -92.22 106.21 18.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.759 0.314 . . . . 0.0 110.892 -179.99 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 20.2 t -63.79 106.79 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.936 179.928 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.6 t -88.12 -30.67 19.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.878 -179.933 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -158.71 162.79 37.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.898 179.947 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.8 mt -126.12 130.46 72.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.126 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 70.6 m-20 -102.7 95.33 6.12 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.834 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.34 -34.93 11.78 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.409 2.073 . . . . 0.0 112.328 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -66.73 -31.44 72.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.942 -180.0 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -96.39 -43.6 7.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.898 -179.921 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 96.73 38.71 4.34 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.401 -179.889 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.4 mttm -135.1 175.61 9.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.888 0.375 . . . . 0.0 110.996 -179.974 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.2 m -136.59 127.78 42.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.002 179.943 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 18.0 tttt -87.3 111.75 21.37 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.847 -179.958 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 31.4 m -124.13 148.58 28.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.296 -179.999 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 12.5 ptm -102.01 120.09 39.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.833 179.97 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 18.5 m -124.2 136.6 59.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.896 0.379 . . . . 0.0 111.213 -179.984 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 2.7 m -95.55 142.49 27.83 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.778 179.85 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . 0.441 ' O ' HG13 ' A' ' 167' ' ' ILE . 3.8 tp -117.17 42.08 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.1 0.476 . . . . 0.0 110.95 -179.942 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER 63.99 99.18 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.847 179.877 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 125.8 -48.79 0.94 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.434 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 8.6 ptt180 -160.07 160.03 32.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.844 0.354 . . . . 0.0 110.894 179.948 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -66.67 166.23 13.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.82 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -154.65 90.03 3.15 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.967 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -68.42 102.54 0.84 Allowed 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.502 2.134 . . . . 0.0 112.255 179.938 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 34.8 m -119.1 137.97 51.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.114 -179.966 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -79.84 120.88 24.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.494 179.57 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 7.6 mt -124.31 -170.55 2.16 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.341 0.591 . . . . 0.0 111.504 -179.395 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -143.08 155.5 44.62 Favored 'General case' 0 N--CA 1.442 -0.848 0 CA-C-N 114.996 -1.002 . . . . 0.0 110.197 178.129 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -48.54 -30.86 5.71 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.509 -179.606 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -79.86 -0.32 34.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.463 179.955 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 30.7 mt-30 -119.59 5.51 11.06 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.609 -0.268 . . . . 0.0 111.316 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 5.3 m -143.46 179.69 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.879 0.371 . . . . 0.0 111.212 179.97 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 23.9 m -152.68 146.61 15.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.016 179.958 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.42 125.93 25.78 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.908 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.001 0 CA-C-O 118.201 -0.904 . . . . 0.0 111.002 -179.952 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 51.1 ttt-85 . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.732 0.301 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -59.85 117.82 5.47 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.923 179.978 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 107.19 16.36 13.66 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.831 -0.7 . . . . 0.0 112.756 179.998 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -76.41 158.63 31.2 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.86 0.362 . . . . 0.0 110.81 179.948 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -101.17 128.26 47.36 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.957 -179.992 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 11.3 m -141.61 135.87 30.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.814 179.965 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.418 ' CZ ' ' HB2' ' A' ' 138' ' ' ARG . 0.7 OUTLIER -79.79 162.95 24.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.943 0.402 . . . . 0.0 110.873 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.489 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 4.9 t -79.88 167.85 2.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.947 -179.84 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.4 p -79.35 -61.95 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.276 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.898 -179.264 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -160.23 -164.57 1.29 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.734 0.302 . . . . 0.0 111.216 -179.581 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.46 -164.15 49.0 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.368 179.972 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -63.27 -16.08 52.26 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.383 2.056 . . . . 0.0 112.146 179.666 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.489 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 2.6 m-85 -101.31 15.73 27.85 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.185 179.956 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -78.48 37.26 0.27 Allowed 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 112.411 0.523 . . . . 0.0 112.411 -179.345 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . 0.414 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 1.9 t0 -161.11 32.8 0.14 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.033 0.444 . . . . 0.0 110.78 179.146 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.42 ' CE2' HG23 ' A' ' 167' ' ' ILE . 22.8 m-85 -140.77 170.06 16.47 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.616 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 3.1 p -118.05 -179.38 3.74 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.799 179.934 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -150.36 138.67 6.83 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.592 -179.978 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.3 m -97.82 107.49 20.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.777 0.322 . . . . 0.0 110.851 179.833 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 23.5 t -55.52 115.7 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.236 -179.822 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.87 -33.19 8.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.877 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -144.56 157.82 44.04 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.839 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mp -141.1 129.45 23.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.15 179.993 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -100.5 98.58 8.25 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.779 -179.943 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.4 -43.26 2.22 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.527 2.152 . . . . 0.0 112.347 -179.984 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -78.39 -38.65 41.23 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.881 -179.901 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.0 -34.88 38.15 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.859 -179.901 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 80.59 67.31 1.56 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.48 -179.992 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 30.7 mttm -152.05 173.39 14.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.798 0.333 . . . . 0.0 110.933 -179.978 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 4.1 m -149.34 122.3 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.02 179.943 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 36.0 ttmt -104.61 135.31 46.25 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.997 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.404 ' CG2' ' CD1' ' A' ' 176' ' ' LEU . 33.9 m -138.76 163.47 27.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.104 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -103.12 111.43 23.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.611 179.722 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 28.5 m -101.86 167.65 2.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.173 -179.803 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 1.5 m -131.11 125.11 32.25 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.872 -179.959 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . 0.42 HG23 ' CE2' ' A' ' 147' ' ' PHE . 1.5 pp -149.09 138.76 15.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.124 179.879 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 62.41 30.29 17.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.774 -179.947 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 64.78 42.57 97.04 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.532 -179.926 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 66.4 mtp180 -157.17 137.96 13.28 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.809 0.338 . . . . 0.0 110.894 -179.984 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 15.5 mp0 -81.51 127.05 32.42 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.735 179.864 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.17 115.21 11.84 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.041 -179.866 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.37 113.19 3.53 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.483 2.122 . . . . 0.0 112.075 179.889 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 10.7 p -123.69 136.55 59.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.259 -179.834 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -80.49 146.86 31.15 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.68 179.742 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.404 ' CD1' ' CG2' ' A' ' 163' ' ' VAL . 0.0 OUTLIER -137.78 -165.05 1.71 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.385 0.612 . . . . 0.0 111.313 -179.721 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -152.84 155.31 36.86 Favored 'General case' 0 N--CA 1.446 -0.643 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.923 178.392 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -47.63 -40.89 20.74 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.517 -179.668 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 18.2 p -78.82 -2.32 39.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.734 -179.799 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 79.5 mt-30 -120.23 9.25 11.02 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.574 0.226 . . . . 0.0 111.519 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 22.7 m -146.02 165.01 9.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.85 0.357 . . . . 0.0 111.196 179.943 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.0 m -143.8 146.46 20.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.048 179.911 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 4.9 tttt -65.85 137.36 57.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.022 179.949 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.204 -0.903 . . . . 0.0 111.139 -179.981 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.927 0.394 . . . . 0.0 110.794 . . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -69.33 135.95 51.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.892 179.929 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 67.18 21.26 71.83 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.609 179.933 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -78.69 163.47 25.4 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.776 0.322 . . . . 0.0 110.801 179.979 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 35.1 mt-30 -103.16 125.21 49.75 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.052 -179.907 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 31.5 m -134.73 144.13 35.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.968 179.974 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.41 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.82 167.3 20.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.936 0.398 . . . . 0.0 110.887 179.978 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.434 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 7.6 t -79.82 168.0 2.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.92 -179.932 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.7 p -79.54 -62.82 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 112.001 0.371 . . . . 0.0 112.001 -179.193 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -160.4 -164.15 1.21 Allowed 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.87 0.367 . . . . 0.0 111.105 -179.622 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 78.7 -167.1 52.66 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.94 -0.647 . . . . 0.0 112.456 179.89 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -61.93 -17.25 54.66 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.422 2.082 . . . . 0.0 112.094 179.699 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.434 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 4.3 m-85 -98.6 20.28 13.15 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.141 179.886 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.6 39.87 0.63 Allowed 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.496 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -160.77 36.22 0.15 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.998 0.428 . . . . 0.0 110.605 179.406 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.424 ' CZ ' HG22 ' A' ' 167' ' ' ILE . 26.4 m-85 -148.18 160.22 43.15 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.682 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 148' ' ' THR . . . . . 0.41 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 7.3 p -109.47 -178.12 3.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.852 179.894 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . 0.4 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -147.85 140.07 8.19 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.609 -179.848 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.9 m -97.0 109.19 22.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.737 0.304 . . . . 0.0 110.957 179.99 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 17.5 t -64.47 101.96 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.259 -179.989 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.36 -33.74 15.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.799 179.854 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -139.83 150.12 44.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.979 179.965 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 16.5 mt -130.99 136.77 57.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.067 -179.969 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -127.83 86.16 58.94 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.759 179.963 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.61 -37.49 7.08 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.515 2.144 . . . . 0.0 112.374 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -59.84 -42.87 94.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.859 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.3 -38.52 16.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.824 179.947 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 97.32 43.37 3.0 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.621 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -139.1 159.12 42.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.859 0.362 . . . . 0.0 110.865 -179.961 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.447 ' CG2' ' CE1' ' A' ' 178' ' ' PHE . 6.1 t -131.05 157.62 43.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.001 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 22.2 tttm -122.07 108.29 13.19 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.943 -179.992 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.4 ' HB ' ' HA3' ' A' ' 149' ' ' GLY . 31.0 m -123.38 146.55 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.263 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 15.0 ptp -99.39 123.49 43.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.687 179.9 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 17.0 m -115.25 158.11 15.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.318 -179.893 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 1.2 m -137.61 125.45 22.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.758 179.973 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . 0.424 HG22 ' CZ ' ' A' ' 147' ' ' PHE . 1.8 pp -130.15 147.07 33.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.128 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 62.82 -79.91 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.973 -179.996 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -167.73 36.21 0.22 Allowed Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.446 -179.926 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 6.4 mmt85 -153.19 133.29 13.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.748 0.309 . . . . 0.0 110.936 179.972 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -81.05 137.82 36.01 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.758 179.968 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 9.3 m -141.86 103.44 5.78 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.061 -179.88 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -72.09 114.44 3.98 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.475 2.117 . . . . 0.0 112.167 179.785 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.3 t -125.38 144.97 33.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.37 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -80.02 136.63 36.64 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.671 179.936 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 5.6 mt -133.05 -168.04 2.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.063 0.459 . . . . 0.0 111.329 -179.843 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -142.33 151.83 42.34 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.603 178.382 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . 0.447 ' CE1' ' CG2' ' A' ' 161' ' ' VAL . 20.7 m-85 -47.8 -38.2 15.25 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.502 -179.608 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.4 m -82.05 11.46 5.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.558 179.978 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -120.74 3.49 10.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.668 -0.242 . . . . 0.0 111.28 179.922 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 2.9 m -144.08 177.69 2.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-O 120.858 0.361 . . . . 0.0 111.301 -179.957 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 27.8 m -143.32 146.42 21.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.116 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -71.4 128.62 36.46 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.95 179.954 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.139 -0.934 . . . . 0.0 111.055 -179.991 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 8.2 mtt180 . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.775 0.322 . . . . 0.0 110.904 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -59.49 141.05 55.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.87 -179.976 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 90.96 -14.3 63.78 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.759 -179.852 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -61.34 174.0 0.79 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.825 0.345 . . . . 0.0 110.966 -179.962 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -112.76 143.09 44.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.895 -179.854 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 15.6 m -140.18 138.66 37.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.991 179.93 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.415 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.94 166.45 21.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.826 0.346 . . . . 0.0 110.945 179.973 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.454 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 3.4 t -79.78 169.19 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.892 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.1 p -79.48 -65.35 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.814 -179.413 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -160.44 -163.48 1.1 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.859 0.361 . . . . 0.0 111.102 -179.65 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.27 -165.28 50.28 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.419 179.908 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -61.7 -17.74 56.39 Favored 'Trans proline' 0 C--N 1.343 0.248 0 C-N-CA 122.481 2.12 . . . . 0.0 112.124 179.74 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.454 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 2.0 m-85 -102.15 22.04 13.88 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.978 179.947 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.29 38.95 0.63 Allowed 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.133 0.42 . . . . 0.0 112.133 -179.436 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -160.8 36.5 0.15 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.914 0.388 . . . . 0.0 110.771 179.4 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 22.0 m-85 -141.35 172.99 11.93 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.645 -179.975 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 148' ' ' THR . . . . . 0.415 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 0.2 OUTLIER -125.0 171.01 10.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.99 179.986 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -137.12 136.2 8.15 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.504 -179.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 2.8 m -89.31 100.87 13.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.846 0.355 . . . . 0.0 110.81 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 21.5 t -58.9 115.04 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.267 -179.92 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 73.7 p -102.1 -32.28 10.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.842 179.954 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -151.91 160.2 43.59 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.942 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 6.5 pt -133.19 145.6 33.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.052 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -130.15 72.23 81.98 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.967 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -59.3 -29.04 89.23 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.614 2.209 . . . . 0.0 112.323 -179.939 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -57.98 -52.25 66.28 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.947 -179.928 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 3.2 tpm_? -90.82 -39.11 12.53 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.89 -179.966 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 105.9 41.81 1.77 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.432 179.975 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 30.7 mttp -131.29 158.71 39.92 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.768 0.318 . . . . 0.0 110.79 179.946 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.481 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.3 p -141.48 159.76 21.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 121.116 0.484 . . . . 0.0 110.91 -179.902 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . 0.481 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 25.6 ttmt -123.7 129.18 50.71 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.969 179.825 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 18.4 m -145.18 140.44 22.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.115 -179.933 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.09 133.68 33.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.795 179.857 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 15.5 m -124.91 167.85 18.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.174 -179.998 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -117.43 151.06 37.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.963 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . 0.417 HG22 HD12 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -157.18 119.16 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.947 -179.953 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER 61.01 30.39 19.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.728 -179.867 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 77.6 31.68 49.26 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.47 179.961 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 17.9 mtm180 -142.25 144.39 33.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.895 0.378 . . . . 0.0 110.841 -179.897 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -80.9 148.95 29.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.831 179.867 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 68.5 m -154.82 91.9 2.93 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.064 179.973 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -58.74 104.27 0.18 Allowed 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.529 2.153 . . . . 0.0 112.157 179.998 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.5 t -122.18 142.23 39.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.162 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -79.91 159.56 26.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.866 179.849 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 4.9 mt -147.5 -171.38 3.78 Favored 'General case' 0 CA--C 1.516 -0.347 0 CA-C-O 121.266 0.555 . . . . 0.0 111.223 -179.636 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -145.11 153.29 41.25 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.415 178.102 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 30.2 m-85 -48.38 -41.64 29.44 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.333 -179.708 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.7 m -78.51 -2.14 37.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.343 -179.959 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 4.8 mt-30 -116.84 6.58 13.16 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.594 -0.276 . . . . 0.0 111.345 -179.787 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 27.4 m -142.75 -179.44 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.959 0.409 . . . . 0.0 111.271 -179.91 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 12.6 m -155.34 146.5 12.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.977 179.956 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 4.0 tmtt? -72.38 138.26 47.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.968 -179.955 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.086 0 CA-C-O 118.256 -0.878 . . . . 0.0 111.151 179.997 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.877 0.37 . . . . 0.0 110.854 . . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -60.13 128.6 37.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.981 179.906 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 121.97 -24.92 6.93 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.529 -179.962 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -59.31 169.81 1.1 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.816 0.341 . . . . 0.0 110.882 -179.887 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -124.94 136.21 53.54 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.059 -179.921 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 12.6 m -140.52 145.21 26.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.723 179.924 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.81 163.76 24.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.034 0.445 . . . . 0.0 111.125 -179.801 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.448 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 46.7 t -79.77 147.44 6.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.548 -179.672 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.413 HG13 ' CA ' ' A' ' 180' ' ' GLN . 12.5 p -86.27 -21.83 7.39 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 CA-C-N 116.02 -0.536 . . . . 0.0 112.35 -179.555 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 141' ' ' SER . . . . . 0.408 ' O ' ' N ' ' A' ' 145' ' ' ALA . 1.7 m -79.18 152.83 30.47 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.939 0.4 . . . . 0.0 111.475 -178.783 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . 0.426 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -66.74 -61.79 5.03 Favored Glycine 0 C--N 1.332 0.34 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.699 -179.811 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.426 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.2 Cg_endo -53.41 -23.56 24.78 Favored 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.548 2.166 . . . . 0.0 112.083 179.853 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.448 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 9.2 m-85 -110.73 2.66 18.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.375 179.751 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 141' ' ' SER . . . -70.36 48.99 0.11 Allowed 'General case' 0 C--N 1.332 -0.193 0 N-CA-C 112.448 0.536 . . . . 0.0 112.448 -179.074 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . 0.464 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 16.4 p-10 -160.44 29.91 0.16 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.172 0.511 . . . . 0.0 110.49 179.116 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.464 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 15.2 m-85 -150.44 147.97 28.18 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.183 179.741 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 69.6 p -102.25 168.58 9.26 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.798 0.333 . . . . 0.0 110.708 179.888 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -128.86 129.05 6.03 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.634 -0.793 . . . . 0.0 112.539 -179.865 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.7 m -86.76 105.83 17.25 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.739 0.305 . . . . 0.0 110.73 179.886 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 30.2 t -62.76 117.78 4.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.083 -179.862 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -93.04 -46.35 7.5 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.925 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -144.89 152.68 40.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.864 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mt -112.58 148.37 15.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.128 -179.951 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -119.24 84.01 26.77 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.85 -179.974 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -72.93 -37.88 3.31 Favored 'Trans proline' 0 C--N 1.343 0.27 0 C-N-CA 122.571 2.181 . . . . 0.0 112.303 179.969 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -60.13 -55.1 38.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.835 -179.93 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 12.6 ttt-85 -79.9 -67.11 0.79 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.004 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 129.92 59.49 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.498 -179.953 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 5.5 mtmm -155.64 -179.09 7.78 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.801 0.334 . . . . 0.0 110.84 -179.953 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.48 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.2 p -154.44 159.81 2.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.896 179.915 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . 0.48 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 10.8 tttt -124.15 127.75 48.24 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.932 -179.9 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 16.7 m -136.16 156.65 36.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.183 -179.991 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 16.4 ptm -106.54 120.02 40.83 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.004 179.93 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . 0.418 ' CG1' ' HB2' ' A' ' 147' ' ' PHE . 2.6 t -117.62 153.83 19.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.102 -179.956 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 2.3 m -100.8 142.82 31.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.935 179.918 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -159.78 -46.29 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.147 179.972 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . 0.403 ' CE2' ' HB ' ' A' ' 172' ' ' THR . 5.0 p90 -97.58 35.25 1.69 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.973 179.965 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 96.48 -30.98 7.94 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.448 -179.912 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.63 177.34 7.46 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.894 0.378 . . . . 0.0 110.691 179.953 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -69.51 168.26 15.0 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.881 -179.939 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 172' ' ' THR . . . . . 0.403 ' HB ' ' CE2' ' A' ' 168' ' ' PHE . 11.5 t -148.05 124.73 5.49 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.829 -179.914 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -71.77 97.36 0.81 Allowed 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.427 2.084 . . . . 0.0 112.331 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 10.5 t -121.67 132.86 69.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.164 -179.987 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -79.91 124.41 28.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.124 179.436 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -127.41 -170.08 2.16 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.322 0.582 . . . . 0.0 111.639 -179.164 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -142.38 152.98 43.39 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.394 178.342 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -42.5 -58.42 2.26 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.607 -179.596 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 6.0 t -56.28 -23.0 33.64 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.241 179.998 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . 0.413 ' CA ' HG13 ' A' ' 140' ' ' VAL . 5.4 mp0 -89.57 3.88 51.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.638 -179.837 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 16.5 m -147.44 167.95 4.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.811 0.339 . . . . 0.0 111.166 179.967 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.4 m -145.08 146.19 20.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.1 179.872 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 1.5 tttp -61.68 136.68 58.09 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.825 -179.822 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.246 -0.883 . . . . 0.0 111.036 179.986 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 12.7 tpp180 . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.82 0.343 . . . . 0.0 110.876 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -61.54 144.76 53.79 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.861 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 96.71 -23.6 34.6 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.573 -179.988 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -57.34 163.79 2.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.906 0.384 . . . . 0.0 111.017 -179.994 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 33.0 mm-40 -121.06 139.14 53.72 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.969 -179.918 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 20.9 m -137.01 140.76 42.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.82 179.989 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . 0.459 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.7 162.85 24.95 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.027 0.441 . . . . 0.0 111.002 -179.934 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.467 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 37.6 t -79.88 151.46 4.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.409 -179.627 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.3 m -93.1 -21.29 6.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 112.4 0.518 . . . . 0.0 112.4 -179.216 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 141' ' ' SER . . . . . 0.429 ' O ' ' N ' ' A' ' 145' ' ' ALA . 4.5 m -79.18 153.87 29.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.792 0.33 . . . . 0.0 111.315 -179.013 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . 0.415 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -65.12 -62.56 4.82 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 121.058 -0.591 . . . . 0.0 113.006 -179.664 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.415 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.4 Cg_endo -52.81 -23.17 19.84 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.685 2.257 . . . . 0.0 112.379 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.467 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 10.2 m-85 -112.62 2.65 16.27 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.471 179.982 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.429 ' N ' ' O ' ' A' ' 141' ' ' SER . . . -70.11 48.39 0.1 Allowed 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -179.117 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -160.72 32.39 0.15 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.13 0.49 . . . . 0.0 110.631 179.109 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.404 ' CD2' ' O ' ' A' ' 166' ' ' THR . 42.5 m-85 -154.87 145.59 22.38 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.469 179.946 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 148' ' ' THR . . . . . 0.459 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 67.8 p -99.88 -177.58 3.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.908 -179.879 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -139.85 129.12 4.16 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.596 -179.838 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.0 m -90.05 113.83 25.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.742 0.306 . . . . 0.0 110.68 179.754 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 21.7 t -70.71 120.83 19.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.305 -179.726 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -108.84 -31.75 7.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.713 179.643 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -153.95 161.35 42.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.705 179.824 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.6 mp -134.21 152.43 34.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.331 -179.966 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 -123.17 90.89 50.21 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.806 179.932 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.15 -34.04 13.99 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.613 2.209 . . . . 0.0 112.357 -179.893 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -90.14 18.14 6.25 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.338 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 31.2 ttt85 -138.07 -46.01 0.52 Allowed 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.808 0.337 . . . . 0.0 110.791 179.936 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 99.19 39.82 3.42 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.392 179.962 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 16.3 mtmt -146.18 170.5 16.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.815 0.34 . . . . 0.0 111.086 -179.979 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.475 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.0 OUTLIER -149.43 159.59 5.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.118 0.485 . . . . 0.0 110.795 179.918 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . 0.475 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 59.6 tttp -105.21 121.61 44.2 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.967 179.993 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 5.6 m -134.95 134.76 53.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.176 -179.982 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 7.6 ptm -93.55 135.43 34.82 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.841 179.954 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 27.6 m -134.25 149.76 30.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.217 179.915 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 166' ' ' THR . . . . . 0.404 ' O ' ' CD2' ' A' ' 147' ' ' PHE . 3.8 m -113.26 110.57 20.59 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.809 -180.0 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . 0.445 HD12 HG22 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -97.32 113.83 32.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.075 179.985 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . 0.404 ' HB2' ' CD1' ' A' ' 167' ' ' ILE . 0.7 OUTLIER 59.52 43.26 16.33 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.894 -179.782 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 66.41 30.68 77.01 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.459 -179.922 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -129.86 124.55 33.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.743 0.306 . . . . 0.0 110.899 -179.905 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.85 126.08 26.18 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.725 179.957 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 2.0 m -150.66 89.68 4.37 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.127 -179.8 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -72.76 125.57 10.64 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.517 2.145 . . . . 0.0 112.104 179.81 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 5.3 m -134.24 136.58 53.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.317 -179.866 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 3.3 pm0 -79.88 126.64 31.26 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.964 179.209 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 7.0 mt -127.62 -170.08 2.17 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.395 0.617 . . . . 0.0 111.772 -179.131 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -141.33 154.59 45.77 Favored 'General case' 0 N--CA 1.442 -0.868 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.357 178.162 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -48.49 -31.14 5.97 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.366 -179.551 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.2 m -79.47 1.2 26.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.574 179.998 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -122.12 10.7 10.08 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.652 0.263 . . . . 0.0 111.401 -179.798 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 14.4 m -149.35 159.14 5.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.944 0.402 . . . . 0.0 111.272 -179.989 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.0 m -123.27 146.48 28.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.048 179.985 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.79 120.46 17.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.864 -179.931 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.267 -0.873 . . . . 0.0 111.082 -179.942 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.789 0.328 . . . . 0.0 110.942 . . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -65.67 134.35 53.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.846 179.872 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 98.36 -2.83 59.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.845 -179.958 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -58.54 167.68 1.38 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.912 0.387 . . . . 0.0 110.897 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.27 116.93 29.78 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.028 179.999 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 30.1 m -123.17 138.76 52.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.833 179.932 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.99 161.9 25.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.956 0.408 . . . . 0.0 111.142 -179.899 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.486 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 39.8 t -104.21 167.05 2.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.559 179.702 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 16.2 m -138.04 -9.88 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 N-CA-C 113.001 0.741 . . . . 0.0 113.001 -178.874 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 141' ' ' SER . . . . . 0.461 ' O ' ' CD2' ' A' ' 144' ' ' PHE . 1.1 m -79.5 142.61 35.66 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.996 0.427 . . . . 0.0 111.761 -178.946 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 35.78 -139.83 0.24 Allowed Glycine 0 C--N 1.335 0.511 0 CA-C-N 115.67 -0.695 . . . . 0.0 113.656 179.523 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -74.3 3.86 4.87 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.691 2.261 . . . . 0.0 112.682 179.761 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.486 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 0.1 OUTLIER -79.57 -10.03 59.73 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.635 -0.257 . . . . 0.0 111.055 179.831 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.447 ' HA ' ' O ' ' A' ' 139' ' ' VAL . . . -68.52 41.84 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -178.996 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . 0.436 ' H ' ' C ' ' A' ' 144' ' ' PHE . 0.8 OUTLIER -160.95 32.78 0.15 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.056 0.455 . . . . 0.0 110.654 179.167 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.431 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 55.8 m-85 -151.7 164.41 37.01 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.582 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 80.6 p -118.73 162.86 17.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.734 179.849 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -130.79 163.48 23.35 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.693 -179.847 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.6 m -103.24 103.35 13.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.766 0.317 . . . . 0.0 110.661 179.964 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 46.4 t -60.31 112.61 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.975 -179.935 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -101.81 -42.62 6.09 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.79 179.906 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -120.1 150.97 39.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.794 179.841 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 12.5 pt -143.31 124.14 10.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.154 179.984 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -117.3 86.61 21.99 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.896 -179.993 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -72.52 -20.22 23.89 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.555 2.17 . . . . 0.0 112.516 -179.938 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.38 25.65 2.18 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.389 -179.94 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 2.2 tpm_? -160.0 -45.06 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.772 0.32 . . . . 0.0 110.838 179.979 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 104.04 61.69 0.68 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.459 179.896 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 17.2 mtpt -154.18 149.6 27.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.813 0.34 . . . . 0.0 110.998 179.963 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 26.9 m -147.21 154.04 11.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.18 179.933 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 12.6 ttpt -127.13 129.61 48.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.907 -179.952 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 34.9 m -136.6 145.68 29.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.23 179.928 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -89.43 113.32 24.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.459 179.824 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 20.9 m -123.19 159.76 26.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.359 -179.696 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 17.2 p -111.55 139.25 47.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.785 179.869 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . 0.429 HG21 HD11 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -93.32 -36.38 7.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.04 -179.874 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 10.5 t80 -172.82 78.54 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.982 179.996 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 68.44 28.22 73.35 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.425 -179.93 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -156.72 124.28 5.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.728 0.299 . . . . 0.0 110.88 -179.995 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 67.8 mt-10 -61.08 154.61 22.44 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.788 179.905 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 25.4 m -160.08 89.84 1.82 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.146 -179.925 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -66.13 105.02 0.78 Allowed 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.615 2.21 . . . . 0.0 111.82 179.766 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 31.0 m -118.5 149.39 20.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.349 -179.716 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -89.14 135.91 33.31 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.731 179.759 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.404 HD12 ' N ' ' A' ' 176' ' ' LEU . 0.0 OUTLIER -146.98 -161.12 1.26 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.397 0.617 . . . . 0.0 110.936 -179.709 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -151.85 153.2 33.73 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.379 178.474 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -42.36 -30.58 0.34 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.677 -179.654 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.4 m -69.57 -39.31 77.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.115 -179.963 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 -88.93 8.76 27.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.499 -179.724 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 5.4 m -145.72 179.53 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.791 0.329 . . . . 0.0 111.165 179.903 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.6 m -145.09 147.07 19.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.167 179.975 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.3 130.83 36.67 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.887 179.937 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.169 -0.919 . . . . 0.0 111.08 179.977 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.839 0.352 . . . . 0.0 111.028 . . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -71.53 120.73 17.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.851 179.909 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 115.59 -14.96 17.49 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.671 -179.919 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -56.26 174.07 0.15 Allowed 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.795 0.331 . . . . 0.0 110.979 -179.921 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.73 140.67 51.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.95 -179.992 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 19.9 m -144.58 139.79 23.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.021 -179.959 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.97 163.1 24.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.955 0.407 . . . . 0.0 110.945 179.865 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.484 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 21.7 t -79.83 156.08 4.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 115.848 -0.615 . . . . 0.0 111.576 -179.659 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.7 m -96.64 -26.19 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 N-CA-C 112.424 0.528 . . . . 0.0 112.424 -179.135 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 141' ' ' SER . . . . . 0.432 ' O ' ' N ' ' A' ' 145' ' ' ALA . 91.1 p -79.13 155.18 28.83 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.833 0.349 . . . . 0.0 111.401 -178.706 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . 0.448 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -64.82 -60.77 6.52 Favored Glycine 0 CA--C 1.52 0.346 0 CA-C-N 115.957 -0.565 . . . . 0.0 113.063 -179.581 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . 0.448 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 7.8 Cg_endo -50.11 -24.84 11.79 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.671 2.248 . . . . 0.0 112.507 -179.793 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.484 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 7.4 m-85 -115.77 4.52 14.0 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.468 -179.974 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.432 ' N ' ' O ' ' A' ' 141' ' ' SER . . . -69.81 45.21 0.07 Allowed 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -178.809 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . 0.412 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 11.8 p-10 -160.69 32.19 0.15 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.032 0.444 . . . . 0.0 110.53 178.929 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.412 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 64.6 m-85 -153.67 145.3 23.31 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.648 179.891 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 1.8 p -102.39 175.73 5.42 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.744 179.863 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . 0.405 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -138.47 141.32 11.89 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.685 -179.9 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 4.6 m -93.56 109.84 21.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.837 0.351 . . . . 0.0 110.747 -179.999 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 16.4 t -68.65 96.84 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.054 179.902 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -81.39 -30.83 33.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.799 179.988 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -154.33 157.29 38.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.817 179.942 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.6 pt -128.62 172.98 14.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.196 179.987 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 -147.59 87.62 5.91 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.847 179.994 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.97 -33.63 15.43 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.584 2.19 . . . . 0.0 112.258 -179.974 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -68.92 -42.75 76.37 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.95 179.878 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 23.4 mmt180 -89.38 -61.87 1.6 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.913 179.982 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 120.54 57.12 0.24 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.488 179.954 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -145.0 173.01 12.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.804 0.335 . . . . 0.0 110.803 -179.973 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.426 HG11 ' CE1' ' A' ' 178' ' ' PHE . 31.1 m -153.98 118.36 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.056 179.892 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -79.85 113.87 18.34 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.712 -179.95 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.405 ' HB ' ' HA3' ' A' ' 149' ' ' GLY . 32.1 m -126.1 141.22 46.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.32 -179.756 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 5.1 ptm -101.68 117.16 34.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.925 179.934 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 15.8 m -108.56 -179.62 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.008 179.902 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.66 116.9 10.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.943 -179.837 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 2.4 mp -120.94 128.39 76.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.93 179.832 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 61.3 34.46 18.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.966 179.887 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 65.7 51.44 46.99 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.598 179.947 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 2.5 ttt85 -160.06 128.09 4.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.837 0.351 . . . . 0.0 110.952 179.96 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -58.69 129.11 40.52 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.926 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.83 85.85 40.11 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.996 -179.932 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -68.67 109.42 2.08 Favored 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.488 2.125 . . . . 0.0 112.028 179.723 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.6 t -126.39 141.11 46.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.344 -179.741 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.93 118.67 21.9 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.181 179.434 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 1.2 mp -119.94 -170.39 1.95 Allowed 'General case' 0 CA--C 1.515 -0.376 0 CA-C-O 121.406 0.622 . . . . 0.0 111.63 -179.178 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -142.89 155.37 44.73 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 114.911 -1.04 . . . . 0.0 110.004 178.016 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . 0.426 ' CE1' HG11 ' A' ' 161' ' ' VAL . 15.6 m-85 -47.14 -30.22 2.73 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.457 -179.533 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 83.6 p -80.08 2.65 23.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.686 -179.89 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 3.7 mt-30 -122.38 3.21 9.72 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-O 120.642 0.258 . . . . 0.0 111.361 180.0 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 11.3 m -139.97 169.63 16.09 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 120.765 0.317 . . . . 0.0 111.384 179.913 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 18.5 m -148.51 146.69 17.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.05 179.942 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 75.2 tttt -57.68 122.53 13.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.093 179.993 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.373 -0.822 . . . . 0.0 110.987 -179.962 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 6.2 ttt85 . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.843 0.354 . . . . 0.0 110.844 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -61.54 138.59 58.29 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.885 -179.951 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 108.74 -22.75 25.44 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.68 -179.9 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -57.08 165.03 1.42 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.827 0.346 . . . . 0.0 110.951 -179.974 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -107.85 143.69 36.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.877 -179.935 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 25.4 m -139.92 143.09 30.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.165 179.994 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.47 165.63 13.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.052 0.453 . . . . 0.0 110.955 179.939 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.539 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 4.2 t -80.18 169.47 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.968 -179.921 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -80.02 -71.49 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 116.525 -0.307 . . . . 0.0 111.393 -179.945 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -160.5 -163.52 1.1 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.96 -179.699 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.91 -160.54 41.01 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.457 179.842 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -57.94 -20.85 46.65 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.507 2.138 . . . . 0.0 111.976 179.786 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.539 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 1.5 m-85 -110.77 41.6 1.76 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.666 179.859 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -90.15 31.52 0.99 Allowed 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -179.424 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -161.26 38.69 0.14 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.284 179.492 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -134.72 154.18 51.68 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.002 0.429 . . . . 0.0 111.183 -179.758 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 31.4 p -118.23 171.86 7.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.446 179.722 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -144.66 155.89 26.6 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.362 -0.923 . . . . 0.0 112.905 -179.785 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 14.0 m -103.31 105.45 15.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.782 0.325 . . . . 0.0 110.781 179.743 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 48.8 t -58.48 118.13 2.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.108 -179.925 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 35.1 p -102.21 -46.67 4.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.852 179.977 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -125.98 157.87 36.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.912 179.985 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.9 mp -139.99 139.13 37.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.123 179.879 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -121.62 85.12 43.5 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.91 179.996 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.99 -28.35 13.13 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.531 2.154 . . . . 0.0 112.383 -179.917 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -69.84 -32.56 71.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.94 -179.953 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.75 -59.57 1.75 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.949 179.942 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 123.06 66.86 0.22 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.532 -179.994 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 43.7 mttp -148.46 163.48 37.03 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.804 0.335 . . . . 0.0 110.878 179.978 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.6 m -151.04 138.53 13.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.112 179.896 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 16.4 tttp -118.12 126.23 51.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.868 -179.985 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 33.5 m -135.94 149.01 27.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.275 -179.96 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 164' ' ' MET . . . . . 0.4 ' O ' ' CG ' ' A' ' 164' ' ' MET . 10.5 ptt? -90.04 111.53 22.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.598 179.791 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 31.1 m -114.69 137.43 48.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.359 -179.851 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 5.5 t -92.22 136.94 32.78 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.575 179.774 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 18.5 tt -83.82 -29.26 7.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.069 -179.909 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -178.23 38.92 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.85 -179.976 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 124.13 -25.88 5.96 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.48 -179.973 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.14 122.68 45.82 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.865 0.364 . . . . 0.0 110.821 -179.967 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -63.1 121.01 12.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.99 179.933 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 53.9 m -117.57 100.4 52.59 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.824 -179.9 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -66.54 111.1 2.01 Favored 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 122.344 2.029 . . . . 0.0 112.215 -179.958 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 38.3 t -127.17 141.7 45.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.105 -179.773 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -86.63 138.11 31.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.626 179.736 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -148.15 -162.27 1.52 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.282 0.563 . . . . 0.0 111.298 -179.65 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -146.15 157.02 43.82 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 115.067 -0.97 . . . . 0.0 109.896 178.213 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 19.6 m-85 -47.0 -28.54 1.68 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.694 -179.503 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 40.7 t -75.76 -5.97 48.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.592 -179.902 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 3.1 mm-40 -114.97 -6.95 12.57 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.599 -0.273 . . . . 0.0 111.449 -179.907 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 30.2 m -142.7 158.66 18.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 120.829 0.347 . . . . 0.0 111.331 -179.98 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 22.6 m -117.79 146.57 22.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.076 -179.984 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.19 129.58 34.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.921 -179.962 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.175 -0.917 . . . . 0.0 111.194 -179.991 . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 19.3 mtp180 . . . . . 0 C--O 1.232 0.163 0 CA-C-O 120.776 0.322 . . . . 5.3499999999999996 110.931 . . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -59.53 118.69 6.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.302 -0.408 . . . . 2.4900000000000002 110.818 179.926 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 128.57 -21.2 5.41 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.823 -0.703 . . . . 0.93000000000000005 112.627 -179.921 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -55.37 164.74 0.9 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.821 0.343 . . . . 1.6899999999999999 110.929 -179.995 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 64.7 mt-30 -117.26 114.82 24.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.457 . . . . 3.1099999999999999 111.06 -179.977 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 16.9 m -118.61 141.95 35.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 1.24 110.822 179.894 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -79.68 166.69 21.57 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.994 0.426 . . . . 3.2200000000000002 111.028 -179.773 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 139' ' ' VAL . . . . . 0.443 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 8.7 t -79.52 167.39 2.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.935 -0.575 . . . . 1.28 110.995 -179.901 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.8 p -78.87 -61.46 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.296 0 N-CA-C 112.052 0.39 . . . . 2.2999999999999998 112.052 -179.289 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -160.83 -163.98 1.14 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.807 0.337 . . . . 3.21 111.29 -179.652 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.53 -169.35 54.75 Favored Glycine 0 C--N 1.331 0.284 0 C-N-CA 120.875 -0.679 . . . . 2.3599999999999999 112.357 179.958 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -59.14 -19.34 48.83 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.507 2.138 . . . . 1.8400000000000001 111.998 179.672 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.443 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 4.1 m-85 -95.98 18.37 13.5 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.16 -0.473 . . . . 2.5 111.065 179.939 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.05 40.4 0.62 Allowed 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 112.058 0.392 . . . . 1.6699999999999999 112.058 -179.453 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . 0.403 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 0.5 OUTLIER -161.4 35.6 0.14 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.98 0.419 . . . . 2.4199999999999999 110.692 179.493 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 147' ' ' PHE . . . . . 0.403 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 36.6 m-85 -146.82 169.76 18.44 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.929 -0.578 . . . . 2.4199999999999999 110.783 179.994 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 12.7 p -122.31 -178.43 3.88 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.264 -0.425 . . . . 1.55 110.874 179.943 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -145.49 134.74 5.62 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.648 -0.787 . . . . 0.62 112.549 -179.927 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.8 m -87.96 104.8 16.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.751 0.31 . . . . 1.3300000000000001 110.817 179.893 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 43.6 t -64.21 121.18 12.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.239 -0.437 . . . . 1.21 111.059 -179.967 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 14.9 p -107.37 -39.88 5.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.162 -0.472 . . . . 1.75 110.907 179.91 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -130.72 159.33 37.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.189 -0.459 . . . . 2.3199999999999998 110.855 179.922 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 26.9 mt -136.36 135.44 49.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.266 -0.425 . . . . 2.27 111.125 -179.968 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -115.83 86.31 15.98 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.108 -0.496 . . . . 2.1699999999999999 110.907 179.997 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.61 -30.43 18.35 Favored 'Trans proline' 0 C--N 1.345 0.343 0 C-N-CA 122.53 2.153 . . . . 2.0600000000000001 112.327 179.994 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -63.1 -42.67 99.63 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.191 -0.459 . . . . 3.6299999999999999 110.889 -179.996 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 3.6 mtt85 -96.09 -52.29 4.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.17 -0.468 . . . . 4.46 110.845 -179.954 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 116.71 39.2 0.85 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.768 -0.729 . . . . 1.3400000000000001 112.469 -179.948 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 15.0 mttt -120.65 168.98 10.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.818 0.342 . . . . 2.4900000000000002 110.959 179.97 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.415 HG13 ' CE1' ' A' ' 178' ' ' PHE . 19.4 m -150.72 125.47 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 1.9199999999999999 111.065 179.983 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 68.6 tttt -94.83 130.07 41.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.126 -0.488 . . . . 2.4700000000000002 110.922 -179.989 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.401 ' CG2' ' CD1' ' A' ' 176' ' ' LEU . 17.2 m -140.48 163.23 23.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.457 . . . . 1.5700000000000001 111.087 -179.97 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 3.2 ptt? -109.51 116.93 32.69 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 2.4199999999999999 110.954 179.914 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 6.9 m -96.45 163.95 2.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 1.6899999999999999 111.025 -179.997 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.13 106.25 9.13 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 2.0699999999999998 110.99 -179.964 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 5.2 mt -110.0 109.19 27.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.137 -0.483 . . . . 2.7599999999999998 110.97 179.94 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 62.38 47.28 5.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.194 -0.457 . . . . 5.0599999999999996 110.935 -179.958 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 61.01 50.8 63.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.727 -0.749 . . . . 1.6899999999999999 112.551 179.986 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 12.2 ttt180 -153.72 129.34 10.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.819 0.343 . . . . 5.6100000000000003 110.957 179.965 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 -71.15 145.62 49.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 2.5899999999999999 110.865 -179.924 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 4.1 m -159.96 92.44 1.72 Allowed Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.116 -0.493 . . . . 1.8700000000000001 110.828 179.951 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -67.42 119.62 6.64 Favored 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.451 2.101 . . . . 1.26 112.326 -179.952 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.5 t -132.21 139.11 50.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 2.2400000000000002 111.047 179.969 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -80.76 119.88 23.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.446 . . . . 2.46 110.869 -179.976 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 176' ' ' LEU . . . . . 0.401 ' CD1' ' CG2' ' A' ' 163' ' ' VAL . 0.2 OUTLIER -125.02 -162.46 1.1 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.368 0.604 . . . . 2.2599999999999998 110.916 -179.979 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -152.73 152.75 32.03 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 115.168 -0.923 . . . . 1.49 110.221 178.405 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 178' ' ' PHE . . . . . 0.415 ' CE1' HG13 ' A' ' 161' ' ' VAL . 17.1 m-85 -44.99 -29.53 0.85 Allowed 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.925 -0.58 . . . . 2.6400000000000001 111.56 -179.726 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 60.1 m -72.25 -33.21 67.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.327 -0.397 . . . . 2.1099999999999999 111.096 -179.826 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 38.1 mt-30 -97.2 18.2 15.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.354 -0.384 . . . . 2.7400000000000002 111.337 -179.895 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 32.4 m -151.79 164.51 2.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.843 0.354 . . . . 1.3400000000000001 111.113 179.891 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 23.1 m -139.83 149.96 22.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 1.4399999999999999 111.123 179.907 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 8.2 tttt -73.41 129.97 39.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 3.4199999999999999 110.867 179.973 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.111 0 CA-C-O 118.292 -0.861 . . . . 1.6899999999999999 111.046 179.978 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.4 0 CA-C-O 120.796 0.332 . . . . 0.0 111.026 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 22.6 mm-40 -134.6 155.74 49.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.893 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 11.2 p -143.77 148.82 18.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.085 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -86.18 -44.45 12.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.127 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . 0.401 ' CZ ' HG21 ' A' ' 151' ' ' VAL . 5.3 t80 -151.43 157.48 42.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.943 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -150.51 134.1 16.53 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.97 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -58.23 147.8 29.29 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.952 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 79.54 6.52 88.96 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.967 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 12.9 m-20 -86.87 174.53 8.7 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.821 0.343 . . . . 0.0 110.99 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 36.3 mt-30 -113.96 132.61 55.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.836 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 31.0 m -131.9 136.2 57.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.081 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -80.03 166.26 21.73 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.703 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.458 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 8.0 t -79.86 167.34 2.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.973 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 3.3 p -79.31 -60.3 2.36 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 112.138 0.421 . . . . 0.0 112.138 -179.201 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -160.43 -164.18 1.21 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.822 0.344 . . . . 0.0 111.301 -179.542 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.37 -168.01 54.33 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.856 -0.687 . . . . 0.0 112.344 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.37 -19.02 56.44 Favored 'Trans proline' 0 C--N 1.343 0.277 0 C-N-CA 122.479 2.119 . . . . 0.0 111.95 179.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.458 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 3.9 m-85 -95.86 13.09 27.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.211 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -79.14 39.69 0.39 Allowed 'General case' 0 C--N 1.332 -0.179 0 N-CA-C 112.246 0.462 . . . . 0.0 112.246 -179.361 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . 0.409 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 1.0 OUTLIER -160.7 34.87 0.16 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.987 0.422 . . . . 0.0 110.675 179.336 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.409 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 47.2 m-85 -148.0 167.13 25.7 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.91 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 23.7 p -127.16 -173.98 3.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.672 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -150.43 164.81 29.86 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.657 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 5.6 m -103.99 108.47 19.83 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.779 0.323 . . . . 0.0 110.773 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.401 HG21 ' CZ ' ' A' ' 131' ' ' PHE . 19.8 t -57.42 113.88 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.293 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 10.3 t -98.88 -33.92 10.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.778 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -153.48 158.48 41.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.894 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 2.7 mt -129.88 158.69 42.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.087 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -135.29 86.71 29.75 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.958 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -71.69 -34.13 9.47 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.56 2.174 . . . . 0.0 112.385 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -58.98 -33.55 70.81 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.993 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.23 -61.23 1.69 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.94 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 127.04 42.73 0.27 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.489 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 11.8 mttt -115.59 170.34 8.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.772 0.32 . . . . 0.0 110.982 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.1 m -155.37 137.08 5.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.077 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 38.7 tttt -114.69 128.25 56.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.788 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 29.7 m -139.88 142.51 32.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.231 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' MET . . . . . 0.4 ' CG ' ' O ' ' A' ' 164' ' ' MET . 0.4 OUTLIER -89.93 104.02 16.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.592 179.883 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 15.5 m -91.76 171.11 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.25 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -132.41 115.34 15.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.796 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 1.6 tp -120.23 133.82 65.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.162 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 1.2 t80 61.74 30.42 18.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.878 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 70.28 45.26 56.25 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.555 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 2.2 tpm_? -159.98 138.86 10.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.789 0.328 . . . . 0.0 110.908 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -60.8 151.94 28.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.778 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 66.1 m -160.02 91.17 1.77 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.989 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -68.37 117.45 4.97 Favored 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 122.475 2.117 . . . . 0.0 112.155 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 29.7 m -132.84 154.98 40.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.256 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -98.8 138.1 36.43 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.639 179.741 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -144.33 -162.2 1.43 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.263 0.554 . . . . 0.0 111.229 -179.796 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -153.11 156.71 39.18 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.079 178.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -45.86 -29.38 1.35 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.674 -179.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 7.3 m -76.01 -3.45 35.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.829 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -131.77 15.08 4.85 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.602 0.239 . . . . 0.0 111.437 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 15.7 m -142.0 170.03 12.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.865 0.364 . . . . 0.0 111.221 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 22.4 m -142.41 146.71 21.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.037 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -83.36 131.33 35.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.946 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.189 -0.91 . . . . 0.0 111.12 -179.997 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.309 0 CA-C-O 120.749 0.309 . . . . 0.0 111.022 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 60.51 158.81 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.909 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 11.3 m -138.05 35.27 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.024 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -77.78 138.04 38.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.141 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -92.67 150.29 20.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.913 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 21.5 mtp180 -145.24 146.26 31.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.897 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -63.93 142.37 58.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.916 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 91.91 -14.05 65.27 Favored Glycine 0 CA--C 1.519 0.292 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.773 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 32.2 m-20 -54.54 165.01 0.63 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.766 0.317 . . . . 0.0 111.024 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -117.6 115.38 24.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.077 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 19.4 m -122.95 149.06 26.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.919 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.8 tpp180 -79.86 168.03 19.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.069 0.461 . . . . 0.0 110.854 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.45 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 3.8 t -80.21 167.95 2.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.028 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 1.5 p -79.66 -66.85 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.55 -179.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -160.44 -164.69 1.29 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.876 0.37 . . . . 0.0 111.097 -179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.94 -162.47 42.79 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.911 -0.661 . . . . 0.0 112.462 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -63.07 -18.42 65.06 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.458 2.106 . . . . 0.0 112.115 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.45 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 3.0 m-85 -102.14 29.24 5.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.957 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.38 35.67 0.45 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.775 0.321 . . . . 0.0 111.853 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -160.96 35.63 0.15 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.506 179.354 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -135.15 175.7 9.34 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.888 -179.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -119.99 178.65 4.53 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.752 179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -147.11 115.6 0.79 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.568 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.1 m -82.0 113.02 19.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.755 0.312 . . . . 0.0 110.782 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 26.4 t -68.19 123.54 21.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.175 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -105.22 -60.47 1.61 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.846 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.58 165.83 15.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.91 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . 0.421 ' N ' ' CD1' ' A' ' 154' ' ' ILE . 0.1 OUTLIER -130.78 157.67 43.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.052 179.961 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 12.5 m-20 -121.58 89.27 47.28 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.902 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.25 -34.45 6.08 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.54 2.16 . . . . 0.0 112.298 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.33 27.67 1.62 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.386 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 5.1 mtm180 -160.08 -50.1 0.05 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.856 0.36 . . . . 0.0 110.784 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 103.27 63.56 0.7 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.461 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.8 mttt -145.88 165.9 27.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.891 0.376 . . . . 0.0 111.028 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 3.7 m -150.04 120.99 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.903 179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -86.75 131.68 34.06 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.096 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 27.2 m -131.17 158.1 43.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.062 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 3.3 ptt? -116.27 126.58 53.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.029 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 2.5 t -106.99 153.88 8.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.847 179.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 2.1 p -122.98 103.32 8.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.063 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . 0.437 ' CG2' ' CZ ' ' A' ' 168' ' ' PHE . 39.4 mm -80.0 67.52 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.625 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . 0.437 ' CZ ' ' CG2' ' A' ' 167' ' ' ILE . 1.1 p90 43.52 79.43 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.405 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 83.15 34.49 20.68 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.673 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -160.13 109.21 1.75 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.786 0.327 . . . . 0.0 111.077 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 11.7 mt-10 -89.84 134.41 34.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.717 179.731 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -145.26 105.57 4.4 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.126 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.49 110.53 2.72 Favored 'Trans proline' 0 C--N 1.348 0.508 0 C-N-CA 122.46 2.107 . . . . 0.0 112.069 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 9.0 p -126.09 146.45 31.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.268 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -79.99 157.57 26.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.679 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 7.5 mt -159.99 -171.74 3.35 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-O 121.411 0.625 . . . . 0.0 111.408 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -146.55 153.61 40.57 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 115.021 -0.991 . . . . 0.0 110.205 178.074 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -46.06 -32.8 3.05 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.548 -179.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 6.2 m -81.74 11.47 4.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.709 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 7.4 mm-40 -125.46 3.19 7.68 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.596 0.236 . . . . 0.0 111.262 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 21.9 m -145.14 179.42 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 120.977 0.417 . . . . 0.0 111.113 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 15.7 m -150.64 148.14 15.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.145 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 7.1 tttt -63.89 131.94 49.27 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.94 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.146 0 CA-C-O 118.257 -0.878 . . . . 0.0 111.14 179.906 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.336 0 CA-C-O 120.846 0.355 . . . . 0.0 111.002 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 2.4 mt-30 -83.45 -40.32 19.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.902 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 11.3 p -119.09 -39.18 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.189 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -64.94 -31.17 72.28 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.21 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -111.86 143.44 42.81 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.926 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 7.3 mtt-85 -133.38 135.35 44.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.887 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -63.24 152.92 36.26 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.693 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 65.71 11.75 54.73 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.982 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -89.57 165.42 14.27 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.799 0.3 . . . . 0.0 110.822 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -89.24 134.08 34.19 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.403 ' HB ' ' CG2' ' A' ' 181' ' ' VAL . 16.0 m -140.46 140.01 34.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.962 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.417 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.4 OUTLIER -80.79 164.83 22.43 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.999 0.428 . . . . 0.0 111.063 -179.912 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.48 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 5.2 t -81.9 167.3 2.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.042 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.3 p -79.47 -61.77 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.439 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 46.7 p -160.11 -165.14 1.41 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.87 0.367 . . . . 0.0 111.176 -179.47 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 80.15 -163.74 47.36 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.348 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -63.91 -14.76 45.12 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.394 2.062 . . . . 0.0 112.23 179.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.48 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 4.9 m-85 -102.52 14.64 31.44 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.253 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -77.48 36.87 0.2 Allowed 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 112.462 0.541 . . . . 0.0 112.462 -179.289 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . 0.408 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 2.2 t0 -161.05 34.41 0.14 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.932 0.396 . . . . 0.0 110.805 179.223 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.408 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 40.2 m-85 -146.1 165.98 27.49 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.745 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' THR . . . . . 0.417 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 0.7 OUTLIER -116.79 -176.18 2.92 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.792 179.939 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -153.26 -176.4 25.7 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.57 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 40.9 m -125.3 113.14 17.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.808 0.337 . . . . 0.0 110.853 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 32.9 t -63.91 106.24 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.101 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 5.8 p -83.99 -45.07 13.51 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.916 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 2.4 tp10 -152.68 171.69 17.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.812 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 17.5 pt -145.33 151.43 15.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.096 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 12.7 m-20 -117.68 86.76 24.5 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.915 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -62.04 -24.74 76.97 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.737 2.292 . . . . 0.0 112.326 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -90.21 29.12 1.28 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.407 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.07 -44.16 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.868 0.366 . . . . 0.0 111.015 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 104.55 39.5 2.38 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.291 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 4.5 mttt -127.87 161.4 29.13 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.921 0.391 . . . . 0.0 110.981 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 29.2 m -146.82 119.65 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.107 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 15.5 tttt -80.04 141.28 36.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.891 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 26.0 t -153.17 144.9 15.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.098 -179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -96.68 121.77 38.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.874 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 9.3 m -99.98 158.55 3.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.121 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 31.4 p -145.31 146.35 31.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.815 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.8 mp -131.17 94.82 2.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.165 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 57.3 m-85 60.06 37.74 20.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.949 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 91.74 27.85 15.81 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.493 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.26 89.0 3.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.794 0.331 . . . . 0.0 110.913 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -59.24 144.61 45.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -158.41 90.3 2.18 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.842 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_exo -60.49 125.78 18.27 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.573 2.182 . . . . 0.0 112.29 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 39.4 t -152.54 148.84 14.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.959 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -80.01 145.04 32.74 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.822 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.4 ' CD2' ' HB3' ' A' ' 180' ' ' GLN . 4.1 mt -125.63 -173.24 2.78 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.451 0.643 . . . . 0.0 111.324 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -152.91 153.76 33.67 Favored 'General case' 0 N--CA 1.446 -0.662 0 CA-C-N 115.023 -0.99 . . . . 0.0 109.99 178.147 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -42.79 -54.01 4.31 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.656 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 5.2 m -74.18 -9.61 58.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.418 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . 0.4 ' HB3' ' CD2' ' A' ' 176' ' ' LEU . 0.0 OUTLIER -99.55 -14.03 19.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.504 -179.806 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . 0.478 ' CG2' ' N ' ' A' ' 182' ' ' VAL . 1.3 p -132.59 160.32 42.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.033 0.444 . . . . 0.0 111.083 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . 0.478 ' N ' ' CG2' ' A' ' 181' ' ' VAL . 35.4 m -139.39 146.19 25.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.379 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -77.28 135.03 38.39 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.94 179.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.286 -0.864 . . . . 0.0 111.14 179.986 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.377 0 CA-C-O 120.807 0.337 . . . . 0.0 111.029 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 13.3 tt0 60.07 74.57 0.44 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.864 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 12.0 p -114.84 152.58 16.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.098 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -66.54 -48.55 69.33 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.095 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . 0.41 ' CE2' HG23 ' A' ' 151' ' ' VAL . 6.2 t80 -125.21 149.04 48.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.959 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.01 145.07 15.06 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -59.81 135.11 57.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.869 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 105.97 -27.69 16.58 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.485 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -63.36 178.4 0.54 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.748 0.309 . . . . 0.0 110.977 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -128.19 130.34 47.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.015 0.436 . . . . 0.0 111.116 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 148' ' ' THR . 25.9 m -130.16 142.91 42.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.705 179.775 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.403 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.1 OUTLIER -79.7 164.49 23.7 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.025 0.44 . . . . 0.0 111.048 -179.843 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.437 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 48.8 t -79.74 147.22 6.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.647 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 12.4 p -85.87 -22.22 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.422 -179.47 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 1.4 t -79.14 153.47 30.06 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.893 0.378 . . . . 0.0 111.429 -178.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . 0.41 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -66.89 -62.2 4.68 Favored Glycine 0 N--CA 1.452 -0.26 0 CA-C-N 115.893 -0.594 . . . . 0.0 112.733 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.41 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.2 Cg_endo -53.57 -23.2 24.51 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.583 2.189 . . . . 0.0 112.158 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.437 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 12.9 m-85 -109.81 0.61 18.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.387 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -69.63 50.71 0.1 Allowed 'General case' 0 N--CA 1.462 0.163 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -179.05 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -160.61 31.37 0.16 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.094 0.473 . . . . 0.0 110.527 179.029 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -155.4 146.41 22.5 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.389 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' THR . . . . . 0.403 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 9.0 p -104.56 169.05 8.69 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.952 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -129.01 133.41 7.57 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.59 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.8 m -86.55 110.47 19.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.823 0.344 . . . . 0.0 110.755 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . 0.41 HG23 ' CE2' ' A' ' 131' ' ' PHE . 30.6 t -67.96 117.44 9.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.963 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.3 t -101.94 -30.37 11.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.899 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -147.21 165.78 29.02 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.83 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 2.0 pp -152.41 141.42 14.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.152 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -120.94 92.87 48.66 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.871 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.54 -22.63 32.83 Favored 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.555 2.17 . . . . 0.0 112.425 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -90.21 26.36 1.92 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.372 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 1.4 mtp85 -159.96 -45.25 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.827 0.346 . . . . 0.0 110.825 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 102.45 55.19 0.86 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.425 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.3 mttt -137.66 147.56 45.01 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.801 0.334 . . . . 0.0 111.152 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.421 HG11 ' CE1' ' A' ' 178' ' ' PHE . 31.1 m -139.05 116.48 11.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.973 179.799 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 70.1 tttt -89.69 118.56 29.4 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.89 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 28.0 m -130.37 149.42 33.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.137 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' MET . . . . . 0.425 ' O ' ' CG ' ' A' ' 164' ' ' MET . 3.7 ptt? -101.84 108.54 20.06 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.996 0.427 . . . . 0.0 110.81 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 27.1 m -98.31 143.08 13.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.126 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -91.9 90.55 7.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.938 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . 0.42 HG12 ' CD2' ' A' ' 168' ' ' PHE . 11.2 tt -89.55 129.67 40.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.82 179.849 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . 0.42 ' CD2' HG12 ' A' ' 167' ' ' ILE . 31.2 m-85 65.86 -72.49 0.08 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.915 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -169.61 36.0 0.19 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.635 -0.793 . . . . 0.0 112.657 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 8.9 ptp180 -160.03 164.19 33.39 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.793 0.33 . . . . 0.0 111.063 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -66.89 158.37 30.81 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.906 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -159.99 81.3 2.38 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.954 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -68.57 102.65 0.87 Allowed 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.682 2.255 . . . . 0.0 112.229 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.4 m -114.46 136.04 52.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.137 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -80.16 108.89 14.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.669 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -124.27 -158.96 0.84 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.322 0.582 . . . . 0.0 111.159 -179.605 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -146.36 155.64 42.75 Favored 'General case' 0 N--CA 1.441 -0.875 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.167 178.161 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . 0.421 ' CE1' HG11 ' A' ' 161' ' ' VAL . 14.9 m-85 -42.97 -30.89 0.45 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.617 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.5 m -66.35 -30.14 70.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.313 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 33.5 mm-40 -102.39 21.59 14.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.55 -179.64 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 21.7 m -157.03 140.63 7.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.93 0.395 . . . . 0.0 111.13 179.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.1 m -117.03 146.27 21.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.146 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 3.4 tttm -83.3 128.2 34.3 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.869 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.247 -0.883 . . . . 0.0 111.113 179.97 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.362 0 CA-C-O 120.834 0.35 . . . . 0.0 111.001 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 10.6 mp0 -131.53 31.62 4.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.931 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.5 t -145.18 94.6 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.187 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -75.44 75.53 2.51 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.994 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -96.94 145.14 26.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.959 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 48.4 mtt-85 -153.51 155.86 37.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.854 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -57.51 155.42 9.54 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.742 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 77.1 0.52 70.58 Favored Glycine 0 CA--C 1.519 0.343 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.78 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -66.0 153.49 42.03 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.838 0.352 . . . . 0.0 110.938 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 16.6 mt-30 -95.49 123.5 39.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.912 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 18.7 m -139.66 139.33 38.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.055 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.442 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -80.29 165.91 21.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.946 0.403 . . . . 0.0 110.808 179.837 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.463 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 6.8 t -79.7 167.67 2.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.999 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.5 p -79.39 -63.18 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 N-CA-C 112.199 0.444 . . . . 0.0 112.199 -179.196 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -160.28 -174.46 4.52 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.918 0.39 . . . . 0.0 111.321 -179.579 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 87.12 -167.19 37.55 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.397 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -59.53 -19.28 51.41 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.345 2.03 . . . . 0.0 111.965 179.541 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.463 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 3.3 m-85 -98.49 13.97 29.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.42 39.22 0.45 Allowed 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.275 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . 0.45 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 0.2 OUTLIER -160.78 31.57 0.15 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.901 0.381 . . . . 0.0 110.893 179.32 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.45 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 22.4 m-85 -143.96 155.58 44.1 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.865 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' THR . . . . . 0.442 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 0.8 OUTLIER -110.7 159.56 17.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.224 179.423 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -128.21 179.15 16.71 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.287 -0.958 . . . . 0.0 113.145 -179.504 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' THR . . . . . 0.42 ' HB ' ' CG ' ' A' ' 164' ' ' MET . 2.4 m -121.63 116.88 25.41 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.768 0.318 . . . . 0.0 110.729 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 37.2 t -67.49 145.53 13.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.984 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 20.4 p -137.55 -55.54 0.69 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.976 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -115.91 159.68 21.24 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.912 -179.869 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 1.9 pt -158.7 149.02 8.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.092 179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 12.0 t30 -147.26 85.32 6.88 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.946 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.52 -22.34 27.54 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.523 2.149 . . . . 0.0 112.408 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -55.0 -69.48 0.13 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.124 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.87 -33.71 39.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.984 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 101.56 55.42 0.9 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.596 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 2.7 mtmp? -131.34 149.28 52.62 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.922 0.392 . . . . 0.0 110.807 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.421 HG13 ' CE2' ' A' ' 178' ' ' PHE . 27.9 m -142.58 136.76 27.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.128 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 17.8 tttp -100.31 141.33 33.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.94 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.406 HG11 ' N ' ' A' ' 150' ' ' THR . 12.0 t -152.08 137.06 10.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.986 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' MET . . . . . 0.423 ' CG ' ' O ' ' A' ' 164' ' ' MET . 0.1 OUTLIER -97.49 106.48 18.81 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.982 0.42 . . . . 0.0 111.022 -179.9 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 5.5 t -103.4 159.88 4.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.176 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 15.8 p -95.14 145.52 24.95 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.85 179.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . 0.483 HD11 HG22 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -114.6 -36.86 2.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.061 179.982 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -166.37 76.86 0.21 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 64.03 26.82 70.57 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.52 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.01 136.68 9.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.793 0.33 . . . . 0.0 110.879 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 7.2 pm0 -59.18 166.91 1.95 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.9 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 9.1 m -159.74 84.21 2.22 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.022 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.12 119.74 7.18 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.48 2.12 . . . . 0.0 112.138 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 15.6 m -142.13 151.2 18.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.255 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -83.63 142.51 30.75 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.575 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.405 ' CD1' ' N ' ' A' ' 176' ' ' LEU . 0.0 OUTLIER -152.56 -161.21 1.25 Allowed 'General case' 0 CA--C 1.518 -0.257 0 CA-C-O 121.301 0.572 . . . . 0.0 111.303 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -151.17 154.04 36.13 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.208 178.453 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . 0.421 ' CE2' HG13 ' A' ' 161' ' ' VAL . 12.3 m-85 -48.17 -27.73 2.56 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.522 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 7.5 t -78.17 -1.94 35.17 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.679 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -124.27 13.0 8.89 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.659 0.266 . . . . 0.0 111.391 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 15.6 m -144.31 160.97 15.16 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.807 0.337 . . . . 0.0 111.15 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 28.6 m -141.6 148.22 21.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.054 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -59.84 134.85 57.42 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.9 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.215 -0.898 . . . . 0.0 111.169 179.963 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.332 0 CA-C-O 120.845 0.355 . . . . 0.0 111.037 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER 63.44 140.86 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.87 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 20.8 t -130.78 159.58 42.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.164 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -57.23 128.14 35.49 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.128 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 6.2 t80 -143.57 148.68 36.29 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.938 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -159.83 145.5 15.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.966 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -62.44 129.79 42.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.879 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 121.51 -22.62 7.77 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.604 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -56.8 163.82 1.76 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.841 0.353 . . . . 0.0 111.046 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -104.54 135.43 45.97 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.91 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 11.9 m -138.1 130.0 38.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.064 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.4 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.98 165.37 22.66 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.898 -179.927 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.477 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 3.7 t -79.83 168.83 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.913 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -79.52 -66.01 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.876 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 52.1 p -160.22 -165.42 1.46 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.941 0.4 . . . . 0.0 110.954 -179.705 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.73 -159.07 37.76 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.451 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.71 -12.31 35.06 Favored 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.578 2.186 . . . . 0.0 112.385 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.477 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 3.2 m-85 -108.57 20.91 17.98 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.164 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.53 38.44 0.43 Allowed 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -179.401 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -161.03 36.98 0.15 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.791 0.329 . . . . 0.0 110.915 179.309 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 48.4 m-85 -147.91 161.06 42.07 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.951 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 1.9 p -120.42 -176.79 3.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.66 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -149.39 151.44 23.56 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.602 -0.809 . . . . 0.0 112.724 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.1 m -96.56 99.18 10.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.788 0.328 . . . . 0.0 110.74 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 48.7 t -56.98 105.95 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.303 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 30.4 p -83.85 -38.96 20.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.535 179.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -143.81 160.31 40.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.701 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.8 mp -132.52 139.67 49.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.162 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -131.38 84.74 55.41 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.789 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -68.19 -27.68 34.93 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.511 2.14 . . . . 0.0 112.363 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -59.69 -58.4 8.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.882 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -87.54 -30.06 20.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.949 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 94.96 37.32 5.23 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.493 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 8.7 mtmt -114.08 154.06 28.39 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.8 0.333 . . . . 0.0 110.968 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 17.8 m -147.23 141.35 19.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.08 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 18.2 ttpt -115.47 122.85 47.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.943 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 33.4 m -136.63 146.49 28.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.285 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -93.32 106.32 18.29 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.486 179.692 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 30.4 m -88.18 171.75 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.372 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 82.6 p -148.26 103.85 3.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.673 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 2.9 mp -79.94 85.56 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.222 -179.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 59.1 31.5 21.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.958 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 105.6 35.39 3.07 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.56 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 9.3 mtt-85 -135.38 91.84 2.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.795 0.331 . . . . 0.0 110.882 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -58.64 136.72 57.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.91 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 19.7 m -159.53 104.48 1.49 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.994 -179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -69.43 105.79 1.49 Allowed 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.342 2.028 . . . . 0.0 112.105 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 22.0 t -122.5 135.32 62.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.247 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -87.41 139.55 30.43 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.653 179.666 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -144.52 -162.5 1.5 Allowed 'General case' 0 CA--C 1.516 -0.333 0 CA-C-O 121.415 0.626 . . . . 0.0 111.263 -179.665 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -142.41 158.05 44.11 Favored 'General case' 0 N--CA 1.441 -0.896 0 CA-C-N 115.001 -1.0 . . . . 0.0 109.888 178.19 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -46.89 -33.47 4.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.424 -179.535 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -73.13 -8.75 57.14 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.534 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 16.5 mm-40 -110.8 -12.97 14.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.712 0.292 . . . . 0.0 111.559 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 8.2 m -128.5 174.34 12.05 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.134 0 CA-C-O 120.865 0.364 . . . . 0.0 111.317 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.02 146.97 20.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.025 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.19 123.9 28.32 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.261 -0.876 . . . . 0.0 111.085 179.993 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.379 0 CA-C-O 120.784 0.326 . . . . 0.0 111.033 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.11 125.47 26.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.918 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 16.0 t -98.64 31.12 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.062 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -85.71 74.53 10.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.99 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 42.5 t80 -131.98 150.47 52.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.859 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 30.8 mtp180 -142.33 134.87 28.05 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.972 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.72 131.49 50.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.918 179.869 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.38 -23.39 20.57 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.69 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -57.91 -176.08 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.869 0.366 . . . . 0.0 110.974 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -121.73 139.98 52.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.956 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 17.1 m -139.98 142.75 31.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.011 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.438 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -80.01 165.18 22.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.038 0.447 . . . . 0.0 110.837 -179.954 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.466 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 4.6 t -79.86 168.03 2.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.92 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 3.2 p -79.37 -62.13 1.5 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.26 0 N-CA-C 112.011 0.375 . . . . 0.0 112.011 -179.263 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -160.5 -163.5 1.1 Allowed 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.876 0.369 . . . . 0.0 111.124 -179.515 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 78.17 -165.39 51.95 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.465 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_endo -62.17 -17.11 54.9 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.506 2.137 . . . . 0.0 112.022 179.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.466 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 3.9 m-85 -100.26 16.38 24.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.207 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -79.53 37.68 0.35 Allowed 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -179.366 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . 0.438 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 11.2 p30 -160.91 32.05 0.15 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.971 0.415 . . . . 0.0 110.818 179.277 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.438 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 24.8 m-85 -140.91 159.62 41.81 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.747 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' THR . . . . . 0.438 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 1.6 p -108.72 171.07 7.64 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.568 179.689 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -137.43 139.38 10.45 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.518 -0.849 . . . . 0.0 112.768 -179.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.9 m -91.2 105.66 17.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.751 0.31 . . . . 0.0 110.605 179.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 24.3 t -64.53 108.7 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.172 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 2.0 t -96.24 -30.54 13.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.955 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -140.63 164.98 28.71 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.979 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 9.5 tt -152.48 127.84 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.026 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 59.0 m-20 -103.22 93.87 5.09 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.951 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.67 -27.95 26.27 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.481 2.121 . . . . 0.0 112.293 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -90.35 26.8 1.83 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.394 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -159.86 -45.17 0.05 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.894 0.378 . . . . 0.0 110.901 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 101.56 36.55 3.75 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.486 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 19.4 mmmt -111.46 152.03 27.88 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.886 0.374 . . . . 0.0 110.849 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 12.3 m -140.27 125.99 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.032 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 22.4 tttt -103.88 119.66 39.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.844 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 33.7 m -132.15 152.65 37.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.116 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 11.9 ptp -100.55 121.07 40.98 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.045 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 7.1 t -101.93 158.29 4.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.016 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 7.3 m -115.12 110.16 19.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.961 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . 0.496 HD13 HG21 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -120.0 114.28 43.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.779 179.869 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER 63.54 31.85 14.52 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.764 -179.617 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 72.4 36.4 59.36 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.478 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -142.96 109.03 5.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.799 0.333 . . . . 0.0 110.885 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -59.47 128.2 35.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.855 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 15.8 m -132.13 92.01 30.4 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.015 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -60.99 115.58 2.79 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.593 2.195 . . . . 0.0 112.046 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 11.3 p -121.74 147.56 25.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.295 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.3 pm0 -94.55 121.93 36.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.799 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -137.54 -159.18 0.93 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.306 0.574 . . . . 0.0 111.113 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -143.25 155.2 44.44 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.101 178.182 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -46.68 -29.09 1.71 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.578 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 6.4 p -70.67 -11.82 61.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.564 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -115.75 16.91 16.31 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.61 -0.268 . . . . 0.0 111.448 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 10.9 m -153.25 154.07 8.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-O 120.718 0.294 . . . . 0.0 111.234 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 28.9 m -127.21 146.41 33.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.177 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 17.7 tptm -71.31 139.54 49.95 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.205 -0.903 . . . . 0.0 111.121 -179.978 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.357 0 CA-C-O 120.894 0.378 . . . . 0.0 111.053 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -88.93 132.99 34.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.869 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.74 82.61 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.147 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.15 142.96 53.46 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.098 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 18.6 t80 -153.63 158.33 40.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.832 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 7.9 ttt85 -159.23 146.4 17.13 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.991 0.424 . . . . 0.0 110.912 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -56.01 155.84 5.96 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.776 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.99 9.36 59.75 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.869 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -80.78 162.18 24.18 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.775 0.321 . . . . 0.0 110.859 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 14.2 mt-30 -118.31 120.15 36.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.902 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 30.0 m -127.12 140.64 48.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.987 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.77 160.86 26.03 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.083 0.468 . . . . 0.0 110.883 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.479 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 43.4 t -79.92 150.56 4.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.644 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 35.5 m -91.97 -20.37 6.67 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 -179.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' SER . . . . . 0.437 ' O ' ' N ' ' A' ' 145' ' ' ALA . 0.4 OUTLIER -79.15 153.25 30.22 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.893 0.377 . . . . 0.0 111.187 -178.937 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . 0.402 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -64.43 -63.2 4.46 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.946 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.402 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.2 Cg_endo -52.65 -22.86 18.22 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.666 2.244 . . . . 0.0 112.341 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.479 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 15.2 m-85 -112.8 2.48 15.99 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.505 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.437 ' N ' ' O ' ' A' ' 141' ' ' SER . . . -69.82 46.93 0.08 Allowed 'General case' 0 CA--C 1.53 0.204 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -178.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . 0.406 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 11.4 p30 -160.71 32.19 0.15 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.023 0.44 . . . . 0.0 110.615 179.101 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.406 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 69.0 m-85 -154.63 145.08 22.15 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.604 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 68.7 p -102.03 172.81 6.7 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.709 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -128.14 132.67 7.45 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.47 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.8 m -95.93 104.45 16.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.745 0.307 . . . . 0.0 110.696 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 26.4 t -59.85 114.32 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.32 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -107.04 -40.13 5.54 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.64 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -135.2 153.48 51.93 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.685 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 2.0 mp -129.62 152.31 37.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.239 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 -130.16 79.09 73.48 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.762 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -69.07 -26.55 30.74 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.496 2.131 . . . . 0.0 112.427 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -61.93 -34.52 76.24 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.863 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 8.3 mtt180 -108.27 -43.69 4.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.921 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 112.82 48.45 0.62 Allowed Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.505 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -137.37 177.24 8.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.835 0.35 . . . . 0.0 110.996 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.472 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.3 p -152.06 159.73 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.125 0.488 . . . . 0.0 110.898 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . 0.472 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 7.1 tttm -119.43 124.35 46.31 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.867 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 29.7 m -136.4 146.33 29.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.252 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 8.5 ptm -92.71 130.38 38.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.878 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 27.7 m -131.5 144.49 37.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.184 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -108.28 139.46 42.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.922 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.8 mp -136.29 -66.83 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.182 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 16.3 m-85 -91.46 55.57 2.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.926 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 58.02 27.56 59.89 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.546 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -153.88 151.39 29.43 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.864 0.364 . . . . 0.0 110.938 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -69.38 161.05 30.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.811 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 16.4 m -153.52 96.49 2.81 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.876 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -66.77 83.37 0.31 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.389 2.059 . . . . 0.0 112.139 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 26.8 t -104.93 135.66 41.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.981 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -79.97 145.04 32.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.59 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 5.7 mt -146.17 -169.31 3.22 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 121.336 0.588 . . . . 0.0 111.41 -179.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -140.27 153.53 46.53 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 115.092 -0.958 . . . . 0.0 110.285 178.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 10.0 m-85 -50.18 -31.94 15.01 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.269 -179.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.9 p -79.76 -1.21 37.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.385 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 1.3 mm-40 -116.0 3.01 13.57 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.714 0.292 . . . . 0.0 111.491 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 5.2 m -140.56 167.02 18.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-O 120.923 0.392 . . . . 0.0 111.074 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.4 m -135.07 146.36 30.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.124 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.99 139.15 57.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.886 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.253 -0.88 . . . . 0.0 111.066 179.994 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 120.82 0.343 . . . . 0.0 111.024 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.42 -44.77 15.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.938 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 14.7 m -96.58 179.55 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.104 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.87 133.42 48.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.113 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 21.2 t80 -83.19 161.91 21.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.913 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 8.6 tpt180 -154.62 146.78 23.73 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.86 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -66.07 132.24 48.08 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.795 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 106.45 -14.41 42.92 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.781 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -54.84 164.72 0.74 Allowed 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.912 0.387 . . . . 0.0 110.912 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -112.15 115.87 29.56 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.07 -179.869 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 31.5 m -116.6 139.27 44.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.852 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.4 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.4 OUTLIER -79.97 155.02 27.86 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.025 0.441 . . . . 0.0 110.975 -179.924 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.537 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 36.4 t -95.26 167.4 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.729 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.402 ' N ' ' CG1' ' A' ' 139' ' ' VAL . 14.1 m -133.9 -21.01 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.25 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -178.723 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' SER . . . . . 0.44 ' O ' ' CD2' ' A' ' 144' ' ' PHE . 2.7 m -79.49 149.65 31.45 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.112 0.482 . . . . 0.0 112.18 -178.249 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 39.64 -148.46 0.15 Allowed Glycine 0 C--N 1.334 0.424 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.678 179.46 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -73.62 4.43 4.03 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.774 2.316 . . . . 0.0 112.557 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.537 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 0.5 OUTLIER -79.55 -8.99 59.54 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.072 179.959 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.432 ' HA ' ' O ' ' A' ' 139' ' ' VAL . . . -67.82 39.49 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -178.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . 0.486 ' H ' ' C ' ' A' ' 144' ' ' PHE . 0.3 OUTLIER -160.89 31.23 0.15 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.103 0.478 . . . . 0.0 110.56 179.102 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.431 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 44.9 m-85 -148.88 154.51 39.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.772 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' THR . . . . . 0.4 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 67.6 p -108.69 134.88 50.82 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.872 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -94.2 160.75 24.02 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.579 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.0 m -102.34 103.74 14.2 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.772 0.32 . . . . 0.0 110.751 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 33.9 t -62.27 107.59 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.967 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -88.89 -49.34 6.86 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.843 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -135.48 171.06 14.99 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.698 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -137.64 158.82 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.168 -179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -140.95 83.47 14.07 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.819 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.58 -27.04 23.04 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.515 2.143 . . . . 0.0 112.351 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -59.13 -42.4 90.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.885 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 4.6 mpt_? -103.8 -60.16 1.61 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.884 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 130.21 49.55 0.12 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.494 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 13.0 mttm -130.62 161.34 31.8 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.826 0.346 . . . . 0.0 110.928 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 17.3 m -147.33 124.48 3.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.193 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 9.3 tttt -87.38 123.92 32.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.888 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 15.4 m -142.34 135.92 28.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.033 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -80.49 130.44 35.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.728 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 15.4 m -110.22 131.18 61.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.234 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -97.62 100.31 11.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.809 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 8.0 tt -95.59 111.07 25.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.105 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER 60.61 43.58 12.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.907 -179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 65.55 52.18 41.56 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.465 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -154.16 119.22 5.03 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.911 0.386 . . . . 0.0 110.833 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -58.94 134.11 56.66 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.932 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -147.75 96.73 4.05 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.867 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.69 118.06 5.16 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.452 2.102 . . . . 0.0 112.184 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 9.9 p -145.93 144.12 21.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.092 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -79.99 134.35 36.24 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.724 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 2.1 mm? -121.68 -172.0 2.34 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-O 121.375 0.607 . . . . 0.0 111.341 -179.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -150.28 151.95 33.76 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.466 178.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 3.7 m-85 -45.12 -46.5 11.83 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.623 -179.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.12 -20.88 63.15 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.143 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.93 -10.02 38.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.511 -179.786 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 27.7 m -138.98 -176.63 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.803 0.335 . . . . 0.0 111.399 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 14.4 m -150.32 157.37 6.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.032 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 10.9 tptt -71.69 138.07 48.3 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.888 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.038 0 CA-C-O 118.199 -0.905 . . . . 0.0 111.195 179.979 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.337 0 CA-C-O 120.844 0.354 . . . . 0.0 110.954 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -166.32 97.81 0.6 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.87 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.4 t -120.85 118.62 56.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.186 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -70.64 157.23 38.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.166 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 2.7 t80 -98.02 155.47 17.09 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.906 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 1.8 tpt180 -156.62 146.53 21.01 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.922 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -60.46 118.56 6.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.896 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.99 19.75 14.24 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.597 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -76.4 158.49 31.34 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.784 0.326 . . . . 0.0 110.847 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 -109.81 126.74 54.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.108 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 12.7 m -141.02 141.03 31.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.863 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.416 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 1.7 ttp180 -79.64 161.72 25.7 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.066 0.46 . . . . 0.0 110.833 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.478 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 27.6 t -79.98 151.37 4.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.607 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.5 m -93.99 -19.44 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 -179.338 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' SER . . . . . 0.441 ' O ' ' N ' ' A' ' 145' ' ' ALA . 4.2 m -79.14 153.4 30.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.767 0.318 . . . . 0.0 111.026 -179.079 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . -64.31 -63.87 4.02 Favored Glycine 0 CA--C 1.519 0.31 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.964 -179.497 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -53.36 -22.76 21.73 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.753 2.302 . . . . 0.0 112.474 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.478 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 6.4 m-85 -111.12 1.05 17.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.516 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.441 ' N ' ' O ' ' A' ' 141' ' ' SER . . . -69.65 47.63 0.08 Allowed 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 112.61 0.596 . . . . 0.0 112.61 -178.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . 0.404 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 17.4 p-10 -160.79 32.34 0.15 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.157 0.503 . . . . 0.0 110.696 179.015 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.404 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 35.0 m-85 -154.56 145.53 22.64 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.507 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' THR . . . . . 0.416 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 75.5 p -99.86 175.91 5.62 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.849 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -136.86 151.59 21.01 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.652 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.2 m -114.12 112.36 23.08 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.726 0.298 . . . . 0.0 110.978 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 21.8 t -66.36 107.87 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.071 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.33 -50.42 6.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.845 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -135.62 164.36 28.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.009 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.8 mt -126.88 151.78 34.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.092 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -113.88 86.78 11.53 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.91 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.63 -27.13 22.72 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.591 2.194 . . . . 0.0 112.337 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -60.09 -51.1 71.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.949 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 2.6 ttt85 -97.37 -67.21 0.86 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.895 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 141.24 52.89 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.417 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 14.3 mttp -131.14 178.76 6.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.831 0.348 . . . . 0.0 110.82 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 28.1 m -145.87 123.07 4.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.071 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 62.6 tttt -79.88 116.43 20.02 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.625 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.1 t -124.55 150.2 29.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.042 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 4.5 ptt? -103.65 116.49 32.43 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.023 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 3.2 m -113.17 138.15 43.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.051 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -97.69 133.79 41.74 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.852 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . 0.473 HD13 HG21 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -133.47 117.88 29.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.999 179.971 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . 0.404 ' HB2' ' CD1' ' A' ' 167' ' ' ILE . 0.2 OUTLIER 62.99 30.28 16.39 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.958 -179.7 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 77.0 45.01 12.31 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.494 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -157.85 128.56 6.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.827 0.346 . . . . 0.0 110.869 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -59.74 144.36 48.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 22.3 m -144.18 83.07 10.36 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.943 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_exo -56.23 90.16 0.04 OUTLIER 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.566 2.178 . . . . 0.0 112.312 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 24.7 t -109.0 132.69 56.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.086 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -79.92 125.84 30.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.278 179.602 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -134.43 -160.81 1.08 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.405 0.621 . . . . 0.0 111.459 -179.317 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -151.44 156.53 40.84 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.936 178.299 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 14.5 m-85 -46.77 -28.07 1.41 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.599 -179.531 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -78.81 -0.26 29.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.708 -179.722 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 79.1 mt-30 -118.74 0.14 11.4 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-O 120.481 0.182 . . . . 0.0 111.405 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 5.7 m -144.98 156.02 13.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 120.86 0.362 . . . . 0.0 111.099 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 30.3 m -126.41 146.43 32.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.167 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.85 128.8 37.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.003 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.059 0 CA-C-O 118.309 -0.853 . . . . 0.0 111.143 179.992 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.312 0 CA-C-O 120.928 0.394 . . . . 0.0 111.102 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 -69.2 137.71 53.46 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.949 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 5.1 m -119.85 113.2 39.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.177 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -89.88 -60.34 1.96 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.142 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -83.96 151.83 24.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.942 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 3.3 mtt180 -147.36 131.74 17.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.936 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -60.34 120.69 10.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 108.67 11.3 23.38 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.674 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -90.04 169.4 11.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.756 0.313 . . . . 0.0 110.92 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.36 134.15 48.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.829 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 21.0 m -142.06 134.04 27.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.148 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -80.99 163.13 23.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.94 0.4 . . . . 0.0 110.627 179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.501 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 11.7 t -79.83 166.99 2.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.912 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.1 m -79.31 -61.79 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -179.306 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 4.2 m -160.02 -166.4 1.7 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.811 0.338 . . . . 0.0 111.258 -179.466 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.59 -158.37 37.25 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.392 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -68.82 -10.96 30.6 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.586 2.191 . . . . 0.0 112.352 179.82 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.501 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 3.3 m-85 -107.31 14.18 26.33 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.468 -179.796 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -75.3 36.48 0.12 Allowed 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 112.403 0.519 . . . . 0.0 112.403 -179.342 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . 0.402 ' H ' ' C ' ' A' ' 144' ' ' PHE . 0.4 OUTLIER -161.16 34.13 0.14 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.913 0.387 . . . . 0.0 110.77 179.278 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -145.31 164.43 31.44 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.991 -179.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -121.66 -173.94 2.75 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.43 179.586 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -154.6 161.83 30.4 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.449 -0.881 . . . . 0.0 112.844 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 88.9 m -110.49 101.6 10.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.833 0.349 . . . . 0.0 110.841 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 31.6 t -59.45 114.63 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.178 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -83.25 -61.07 1.95 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.866 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -134.23 168.98 17.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.895 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.7 mt -126.96 135.51 63.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.069 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -107.12 84.48 1.67 Allowed Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.92 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.44 -28.12 22.36 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.607 2.204 . . . . 0.0 112.256 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -68.31 -34.15 75.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.968 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 25.0 mmt180 -101.53 -56.11 2.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.958 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 121.66 37.35 0.68 Allowed Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.495 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -126.98 175.09 8.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.758 0.314 . . . . 0.0 110.864 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.5 m -151.17 119.7 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.135 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 2.1 ttpm? -79.86 137.46 36.93 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.73 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 4.8 t -149.19 146.68 17.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.997 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.67 127.56 48.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.016 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 3.5 m -107.02 147.66 12.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.039 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 63.3 m -112.67 85.58 2.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.978 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 4.1 mp -98.09 126.81 51.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.031 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 61.57 31.33 18.84 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.902 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 69.5 38.38 79.32 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.554 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 72.5 mmt-85 -146.76 134.42 21.07 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.861 0.363 . . . . 0.0 110.924 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -72.29 147.99 45.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.882 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 1.8 m -157.14 88.41 2.62 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.804 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -50.8 115.54 2.06 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.608 2.205 . . . . 0.0 112.338 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 10.4 p -128.63 142.74 43.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.064 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -98.25 121.49 40.24 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.838 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.404 ' CD1' ' N ' ' A' ' 176' ' ' LEU . 0.0 OUTLIER -126.94 -160.41 1.0 Allowed 'General case' 0 CA--C 1.518 -0.286 0 CA-C-O 121.353 0.597 . . . . 0.0 110.894 -179.939 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -148.36 155.37 41.18 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.163 -0.926 . . . . 0.0 109.934 178.373 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 11.7 m-85 -48.31 -33.83 9.53 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.482 -179.47 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 90.9 p -78.21 -2.55 38.3 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.643 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -115.29 -2.81 12.58 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.545 0.212 . . . . 0.0 111.564 -179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 17.4 m -140.41 171.98 12.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-O 120.844 0.354 . . . . 0.0 111.393 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 27.5 m -136.72 146.43 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.219 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 5.2 mtmt -80.09 130.99 35.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.919 179.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.278 -0.867 . . . . 0.0 111.045 -179.972 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.331 0 CA-C-O 120.876 0.369 . . . . 0.0 110.976 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 30.2 tt0 60.49 162.59 0.06 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.811 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 9.5 p -145.68 147.32 18.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.049 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -76.49 122.23 24.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.059 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -118.72 155.38 31.17 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.827 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -143.06 132.91 24.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.921 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -59.62 123.73 17.84 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.48 5.72 27.76 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.834 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -67.61 162.57 23.23 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.739 0.304 . . . . 0.0 110.792 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -111.59 131.23 55.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.977 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 15.6 m -143.42 148.25 19.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.803 179.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -79.63 164.62 23.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.03 0.443 . . . . 0.0 111.033 -179.927 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.469 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 22.3 t -79.88 151.06 4.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.674 -179.636 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.408 HG13 ' CA ' ' A' ' 180' ' ' GLN . 11.4 p -90.83 -24.17 5.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-N 116.044 -0.526 . . . . 0.0 112.076 -179.655 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 6.2 m -79.33 154.67 28.9 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.999 0.428 . . . . 0.0 111.412 -178.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . 0.437 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -67.26 -61.19 5.32 Favored Glycine 0 N--CA 1.451 -0.308 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.69 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.437 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.2 Cg_endo -51.43 -24.55 16.64 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.663 2.242 . . . . 0.0 112.205 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.469 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 21.3 m-85 -112.98 4.36 16.7 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.419 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -70.06 46.58 0.08 Allowed 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -179.097 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . 0.427 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 17.5 p-10 -160.56 30.82 0.16 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.204 0.526 . . . . 0.0 110.498 179.037 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.427 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 24.2 m-85 -151.85 146.18 25.48 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.168 179.732 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 26.7 p -96.85 -177.36 3.86 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.737 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -144.63 159.34 27.78 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.608 -179.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 2.2 m -117.09 111.55 19.67 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.798 0.332 . . . . 0.0 110.862 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 21.6 t -69.37 131.92 33.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.047 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.74 -68.92 0.79 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.026 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -123.71 172.92 8.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.948 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 35.0 mt -139.35 128.93 30.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.074 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -100.81 99.51 10.48 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.897 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.41 -23.75 17.15 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.557 2.171 . . . . 0.0 112.417 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -90.27 23.2 2.99 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.301 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 16.4 mtp180 -158.6 -44.25 0.06 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.754 0.311 . . . . 0.0 110.765 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 97.4 57.39 1.06 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.472 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.55 162.95 34.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.765 0.317 . . . . 0.0 111.016 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.1 m -148.06 126.67 3.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.961 179.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 6.0 tttp -79.94 122.29 26.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.856 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 11.4 p -126.13 145.93 32.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.085 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.21 117.89 35.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.735 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 13.4 m -110.33 142.76 21.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.139 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 8.2 m -135.73 133.32 37.89 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.875 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 4.1 mp -102.69 53.47 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.937 179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER 65.67 96.49 0.05 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.974 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 65.81 33.55 86.17 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.679 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -154.44 86.07 1.14 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.849 0.357 . . . . 0.0 111.019 -179.884 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -68.79 141.95 55.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.706 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 63.4 m -160.0 93.3 1.68 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.167 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_exo -62.06 124.81 15.11 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.651 2.234 . . . . 0.0 112.057 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 11.2 p -137.91 132.33 43.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.32 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -79.82 131.72 35.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.263 179.642 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 1.1 mp -133.07 -167.74 1.97 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.421 0.629 . . . . 0.0 111.608 -179.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . 0.427 ' O ' ' N ' ' A' ' 180' ' ' GLN . 0.6 OUTLIER -144.66 154.11 42.45 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 114.961 -1.018 . . . . 0.0 110.199 178.152 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 8.9 m-85 -44.73 -33.68 1.96 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.612 -179.548 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -82.32 14.65 2.83 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.679 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . 0.427 ' N ' ' O ' ' A' ' 177' ' ' ASP . 21.6 mt-30 -127.85 4.91 6.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.576 0.227 . . . . 0.0 111.328 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 6.2 m -146.45 170.72 4.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.14 0 CA-C-O 120.874 0.369 . . . . 0.0 111.198 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 21.0 m -140.49 146.38 24.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.084 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 13.6 tttt -66.07 121.94 16.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.272 -0.871 . . . . 0.0 111.062 179.983 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.294 0 CA-C-O 120.7 0.286 . . . . 0.0 111.05 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 25.0 mt-30 -131.88 77.55 1.77 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.926 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 6.5 m -112.31 -32.69 2.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.15 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -82.56 113.89 20.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.116 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 16.5 t80 -97.13 157.91 15.7 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.787 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 7.1 mmt180 -142.02 148.14 38.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.059 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -64.22 122.83 17.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.792 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 96.23 18.26 31.8 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.617 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.49 176.51 9.33 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.798 0.333 . . . . 0.0 110.884 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 38.2 mt-30 -120.08 114.34 21.83 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.115 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 18.8 m -124.43 143.17 38.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.805 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -79.85 162.11 25.24 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.109 0.481 . . . . 0.0 111.054 -179.724 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.501 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 46.7 t -84.62 155.21 3.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.529 -179.423 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.413 HG23 ' HA ' ' A' ' 180' ' ' GLN . 35.6 m -96.89 -24.65 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 N-CA-C 112.675 0.62 . . . . 0.0 112.675 -179.165 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' SER . . . . . 0.522 ' O ' ' N ' ' A' ' 145' ' ' ALA . 0.2 OUTLIER -78.99 131.12 36.19 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.85 0.357 . . . . 0.0 111.32 -178.646 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . 0.465 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -44.19 -59.07 4.17 Favored Glycine 0 C--N 1.332 0.347 0 CA-C-N 115.823 -0.626 . . . . 0.0 113.597 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.465 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.7 Cg_endo -51.1 -22.74 11.3 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.669 2.246 . . . . 0.0 112.481 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.501 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 21.2 m-85 -120.13 4.83 10.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.466 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.522 ' N ' ' O ' ' A' ' 141' ' ' SER . . . -70.02 45.21 0.07 Allowed 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 112.55 0.574 . . . . 0.0 112.55 -178.653 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . 0.408 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 15.1 p-10 -160.69 31.74 0.15 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.13 0.491 . . . . 0.0 110.422 179.091 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.408 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 46.3 m-85 -155.66 145.98 21.78 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.439 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 1.4 p -101.76 168.89 9.16 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.789 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -132.49 132.45 6.64 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.515 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.7 m -87.35 109.05 19.27 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.723 0.297 . . . . 0.0 110.802 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 19.2 t -64.38 123.8 17.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.093 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.2 p -100.97 -43.66 5.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.957 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 6.6 mt-10 -136.77 151.25 48.98 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 7.8 mt -128.57 132.23 68.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.101 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -116.98 85.54 18.03 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.835 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -58.37 -30.05 90.06 Favored 'Trans proline' 0 C--N 1.343 0.278 0 C-N-CA 122.595 2.196 . . . . 0.0 112.321 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -60.38 -62.68 1.69 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.099 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 7.7 ttm180 -79.99 -30.89 39.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.029 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 93.53 27.15 13.54 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.58 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 2.9 mtmm -107.78 162.65 13.8 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.732 0.301 . . . . 0.0 110.754 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.423 HG13 ' CE1' ' A' ' 178' ' ' PHE . 15.7 m -153.71 123.19 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.163 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 29.4 tttt -85.66 146.97 26.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.816 179.806 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.422 ' CG2' ' CD1' ' A' ' 176' ' ' LEU . 25.0 m -144.96 170.1 7.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.276 -179.866 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -120.0 110.87 17.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.655 179.631 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 11.9 m -99.53 157.99 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.138 -179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 27.4 p -141.49 97.41 3.15 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.982 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.9 mp -79.87 83.53 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.962 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 24.7 m-85 62.29 70.39 0.57 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.902 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 60.26 47.06 92.97 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.566 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 1.5 mtm180 -146.38 91.48 2.05 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.905 0.383 . . . . 0.0 110.977 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -58.17 140.39 53.03 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.984 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 2.8 m -160.09 97.8 1.49 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.933 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.86 123.76 10.38 Favored 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.405 2.07 . . . . 0.0 112.12 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.9 t -139.74 145.26 26.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.134 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -88.92 142.47 27.62 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.859 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.422 ' CD1' ' CG2' ' A' ' 163' ' ' VAL . 0.1 OUTLIER -147.68 -161.29 1.3 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.337 0.589 . . . . 0.0 111.088 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -150.48 155.18 39.02 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.007 178.292 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . 0.423 ' CE1' HG13 ' A' ' 161' ' ' VAL . 25.6 m-85 -46.47 -30.4 2.18 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.536 -179.583 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 60.6 p -81.19 8.11 9.65 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.863 -179.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . 0.413 ' HA ' HG23 ' A' ' 140' ' ' VAL . 6.2 mt-30 -122.39 2.12 9.65 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-O 120.616 0.246 . . . . 0.0 111.286 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 4.8 m -143.24 172.31 7.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-O 120.88 0.371 . . . . 0.0 111.084 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 18.0 m -142.16 148.92 19.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.161 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.57 125.35 25.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.911 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.174 -0.917 . . . . 0.0 111.106 179.92 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.308 0 CA-C-O 120.774 0.321 . . . . 0.0 111.006 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 1.5 mt-30 -98.91 30.71 3.25 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.919 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.4 t -136.63 148.16 27.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.197 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -59.96 -63.82 1.16 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.121 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 6.0 t80 -90.57 154.67 19.43 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.855 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -158.09 157.5 32.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.88 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -62.6 135.47 57.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.912 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 105.31 -23.94 28.99 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.637 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.8 t0 -58.2 158.23 7.34 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.825 0.345 . . . . 0.0 110.947 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 13.9 mm-40 -110.41 138.42 46.82 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.002 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 18.4 m -140.01 134.11 36.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.911 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.439 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 2.6 ttm180 -79.95 166.03 22.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.995 0.426 . . . . 0.0 110.839 179.877 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.464 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 3.9 t -79.91 169.73 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.799 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -79.49 -65.53 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 111.835 0.309 . . . . 0.0 111.835 -179.5 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -160.18 -167.85 2.04 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.827 0.346 . . . . 0.0 111.059 -179.683 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 83.81 -162.27 39.09 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.417 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -64.28 -15.72 51.12 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.532 2.154 . . . . 0.0 112.241 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.464 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 2.8 m-85 -104.54 19.73 19.82 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.149 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.69 38.22 0.44 Allowed 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -179.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . 0.435 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 8.8 t70 -160.84 32.63 0.15 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.01 0.434 . . . . 0.0 110.977 179.234 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.435 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 17.0 m-85 -140.3 161.11 38.47 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.7 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' THR . . . . . 0.439 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 25.1 p -116.42 -178.45 3.42 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.741 179.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -145.43 137.42 7.04 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.664 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 14.5 m -92.83 108.64 20.15 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.78 0.324 . . . . 0.0 110.663 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 20.7 t -69.37 118.87 14.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.207 -179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -103.77 -34.82 8.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.854 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -151.25 159.72 44.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.859 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mp -139.83 140.52 35.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.136 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 24.3 m120 -103.71 92.2 4.05 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.863 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -69.4 -27.76 27.77 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.538 2.159 . . . . 0.0 112.25 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -70.25 -40.27 74.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.867 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 3.7 mmt180 -98.49 -62.42 1.24 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.855 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 125.47 55.42 0.16 Allowed Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.476 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -130.45 166.53 20.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.92 0.39 . . . . 0.0 110.921 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.416 HG12 ' CE1' ' A' ' 178' ' ' PHE . 3.4 m -147.94 116.93 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.059 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 26.1 ttpt -87.07 121.52 29.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.754 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 35.7 m -135.6 147.01 28.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.254 -179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 4.1 ptt? -102.17 118.73 37.51 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.043 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 7.4 t -106.2 158.45 6.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.12 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -110.18 94.65 5.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.946 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 1.4 tp -112.16 136.74 47.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.965 179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER 61.31 30.1 18.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.921 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 67.74 39.97 90.03 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.633 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -159.88 140.21 11.86 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.787 0.327 . . . . 0.0 110.967 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.57 150.92 45.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.77 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 14.8 p -153.3 93.47 3.12 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.042 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.88 87.18 0.29 Allowed 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.444 2.096 . . . . 0.0 112.039 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 34.6 t -101.62 135.3 38.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.338 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 10.9 pm0 -82.04 124.31 29.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.581 179.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -132.55 -160.9 1.09 Allowed 'General case' 0 CA--C 1.517 -0.308 0 CA-C-O 121.351 0.596 . . . . 0.0 111.254 -179.605 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -149.88 155.2 39.62 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.169 178.377 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . 0.416 ' CE1' HG12 ' A' ' 161' ' ' VAL . 42.6 m-85 -46.34 -29.02 1.49 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.732 -179.502 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 8.2 m -74.52 -5.7 44.21 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.738 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 11.9 mm-40 -120.76 -4.46 9.71 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 111.603 0.223 . . . . 0.0 111.603 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 6.6 m -122.76 178.03 3.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.86 0.362 . . . . 0.0 111.223 -179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 27.2 m -152.06 146.78 15.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.135 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 3.8 ttmm -67.51 125.2 25.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.927 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.17 -0.919 . . . . 0.0 111.105 -179.985 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.377 0 CA-C-O 120.81 0.338 . . . . 0.0 111.067 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -140.33 143.97 36.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.861 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 11.2 p -133.4 137.47 53.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.077 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -74.61 -44.52 50.22 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.155 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 6.7 t80 -145.06 145.83 31.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.859 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -149.94 152.03 34.34 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.907 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -67.6 140.26 56.9 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.011 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 93.95 -21.51 41.37 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.58 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.43 176.28 0.65 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.851 0.358 . . . . 0.0 110.94 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -112.36 143.35 43.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.04 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 18.0 m -139.42 133.13 38.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.907 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.418 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 1.6 ttt180 -79.85 165.14 23.02 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.017 0.437 . . . . 0.0 110.94 -179.819 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.465 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 4.4 t -80.03 169.08 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.904 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -79.63 -65.97 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.805 -179.5 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 51.8 p -160.13 -165.52 1.49 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.823 0.344 . . . . 0.0 111.017 -179.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.61 -160.56 39.64 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.414 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.65 -13.42 39.82 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.613 2.209 . . . . 0.0 112.295 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.465 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 3.6 m-85 -106.97 20.49 18.97 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.164 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -81.13 38.91 0.49 Allowed 'General case' 0 C--N 1.331 -0.239 0 N-CA-C 112.3 0.481 . . . . 0.0 112.3 -179.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -160.97 36.49 0.15 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.88 0.371 . . . . 0.0 110.951 179.358 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -147.84 158.48 44.05 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.815 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' THR . . . . . 0.418 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 58.2 p -118.93 169.2 10.08 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.792 179.869 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . 0.401 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -132.67 153.36 20.62 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.679 -179.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 2.7 m -101.81 107.72 18.99 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.819 0.343 . . . . 0.0 110.828 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 24.5 t -62.42 116.66 2.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.131 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 4.6 p -108.68 -57.2 2.17 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.859 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -113.23 155.99 24.08 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mp -142.31 141.72 28.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.172 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -123.65 101.29 36.88 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.812 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -69.23 -26.55 29.95 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.398 2.066 . . . . 0.0 112.438 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.57 -42.15 52.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.918 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 49.3 mtt-85 -87.43 -33.8 18.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.901 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 85.11 35.81 11.94 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.427 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 28.6 mttm -118.01 177.04 4.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.754 0.312 . . . . 0.0 110.857 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 6.1 m -158.94 121.49 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.166 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 80.5 tttt -84.87 132.75 34.35 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.822 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.401 ' HB ' ' HA3' ' A' ' 149' ' ' GLY . 33.8 m -139.67 138.67 39.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.144 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 12.6 ptm -90.67 113.84 26.0 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 27.4 m -115.46 156.91 16.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.171 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 16.7 p -105.98 142.52 35.54 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.719 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . 0.4 HG21 HD13 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -103.77 -38.96 5.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.997 179.927 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -171.18 86.15 0.09 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.866 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 58.16 30.24 63.79 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.559 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -158.13 134.46 9.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.807 0.337 . . . . 0.0 110.925 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -67.96 155.89 38.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 3.4 m -159.96 93.71 1.66 Allowed Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.756 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -67.84 125.84 13.75 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.502 2.135 . . . . 0.0 112.294 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 7.4 m -139.38 139.02 39.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.3 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -79.87 126.49 31.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.344 179.524 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 6.8 mt -133.88 -170.99 2.62 Favored 'General case' 0 CA--C 1.516 -0.359 0 CA-C-O 121.388 0.613 . . . . 0.0 111.698 -179.345 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -144.36 155.7 43.91 Favored 'General case' 0 N--CA 1.442 -0.832 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.286 178.196 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -45.62 -41.74 10.51 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.577 -179.567 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 2.6 p -65.39 -15.88 63.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.373 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -103.78 -18.89 14.48 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.384 -179.689 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 11.0 m -120.75 173.05 6.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.922 0.392 . . . . 0.0 111.366 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 30.3 m -144.4 146.25 20.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.032 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.56 123.0 21.49 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.992 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.995 0 CA-C-O 118.324 -0.846 . . . . 0.0 111.061 179.977 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.372 0 CA-C-O 120.868 0.366 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 1.8 mm-40 -159.34 -57.92 0.06 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.829 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 12.8 m -158.09 -43.58 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.287 -179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -55.93 -172.26 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.142 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 7.4 t80 -95.21 147.53 23.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.877 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -147.43 142.31 26.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.929 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -63.69 138.32 58.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.951 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 105.85 -22.4 31.9 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.613 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -57.41 156.16 8.26 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.818 0.342 . . . . 0.0 111.028 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 10.0 mt-30 -113.17 137.53 51.32 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.939 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 18.4 m -143.81 141.39 25.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.155 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.42 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 3.7 ttp180 -79.91 165.84 22.24 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.796 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.467 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 7.6 t -80.1 167.22 2.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.116 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.6 p -79.35 -61.41 1.73 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.92 -179.395 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 2.6 m -160.35 -165.13 1.38 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.912 0.386 . . . . 0.0 111.138 -179.464 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.56 -165.85 50.32 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.334 179.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -62.15 -17.11 54.82 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.474 2.116 . . . . 0.0 112.02 179.659 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.467 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 3.7 m-85 -99.57 14.6 29.4 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.119 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -78.75 38.06 0.31 Allowed 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -179.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -160.89 36.6 0.15 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.88 0.371 . . . . 0.0 110.774 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 16.2 m-85 -152.13 157.23 41.27 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.043 -179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 5.6 t -110.17 -176.02 2.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.636 179.823 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -154.89 140.41 7.38 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.539 -0.839 . . . . 0.0 112.779 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 12.2 m -94.16 110.19 21.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.754 0.311 . . . . 0.0 110.623 179.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 36.8 t -57.55 116.53 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.155 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -111.45 -29.57 7.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.0 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -135.72 167.01 21.94 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.943 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 23.3 pt -145.59 133.27 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.167 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -117.19 81.18 12.78 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.803 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.44 -32.45 12.36 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.656 2.237 . . . . 0.0 112.224 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -59.74 -35.49 74.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.919 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -102.17 -33.98 9.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.927 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 99.16 43.87 2.5 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.45 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -139.76 156.12 46.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.934 0.397 . . . . 0.0 110.867 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.467 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.2 p -123.52 159.79 27.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.924 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . 0.467 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 13.0 ttpt -128.65 140.22 51.87 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.184 -179.753 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 34.6 m -139.84 -179.73 2.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.233 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -120.08 111.9 18.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.702 179.565 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 31.0 m -98.25 167.92 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.263 -179.773 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.16 79.56 1.7 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.821 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 30.9 mm -80.54 108.37 13.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.173 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 59.15 55.27 4.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.064 0.459 . . . . 0.0 110.928 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 57.53 41.48 93.48 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.571 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 6.1 ttt180 -137.51 106.32 5.92 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.803 0.335 . . . . 0.0 110.924 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -73.21 127.02 31.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.874 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 52.3 m -147.17 131.44 8.6 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.79 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -74.79 106.71 2.31 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.516 2.144 . . . . 0.0 112.415 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 12.1 p -119.07 124.01 72.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.987 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 12.4 mt-10 -88.15 141.89 28.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.806 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -138.12 -162.55 1.32 Allowed 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 121.233 0.539 . . . . 0.0 111.151 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -146.04 152.2 38.96 Favored 'General case' 0 N--CA 1.444 -0.762 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.207 178.404 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 -48.74 -37.04 17.72 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.432 -179.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 17.3 p -75.74 -9.54 58.68 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.56 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 23.5 mt-30 -118.58 21.14 12.72 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-O 120.603 0.239 . . . . 0.0 111.417 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 17.6 m -152.92 146.5 14.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.891 0.377 . . . . 0.0 111.22 179.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 30.9 m -114.15 146.28 18.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.135 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 4.1 ttmt -80.92 137.28 36.13 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.955 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.065 0 CA-C-O 118.255 -0.879 . . . . 0.0 111.041 179.979 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.868 0.366 . . . . 0.0 110.95 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -97.98 51.84 1.05 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.955 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 19.1 t -132.19 132.5 60.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.195 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -90.3 25.52 2.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.536 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 16.3 t80 -156.5 163.33 39.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.806 0.336 . . . . 0.0 110.991 -179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.24 136.63 50.35 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.843 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -69.21 141.25 54.54 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.835 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 89.29 -8.66 79.34 Favored Glycine 0 CA--C 1.519 0.339 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.724 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -56.87 164.14 1.67 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.826 0.346 . . . . 0.0 111.027 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -104.05 134.63 46.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.976 -179.867 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 21.0 m -141.66 131.54 24.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.886 179.839 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 3.4 ttp180 -79.78 164.28 23.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.013 0.435 . . . . 0.0 110.976 -180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.478 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 3.7 t -79.96 168.55 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.86 -179.884 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -79.6 -65.8 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.768 -179.518 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -160.11 -164.57 1.31 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.768 0.318 . . . . 0.0 110.903 -179.835 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.36 -157.34 36.5 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.529 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -69.53 -10.23 28.2 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.558 2.172 . . . . 0.0 112.519 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.478 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 2.6 m-85 -110.46 19.54 18.67 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.201 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -78.86 37.85 0.31 Allowed 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -179.352 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . 0.406 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 1.5 p30 -161.08 36.0 0.14 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.893 0.378 . . . . 0.0 110.896 179.281 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.406 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 44.0 m-85 -146.81 163.03 37.34 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.969 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 1.1 p -118.16 -177.07 3.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.771 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -147.47 142.95 10.68 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.526 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.7 m -99.7 103.71 15.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.779 0.324 . . . . 0.0 110.766 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 31.7 t -60.6 127.03 19.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.206 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.9 p -111.95 -33.98 6.12 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.858 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -136.01 157.7 46.21 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.874 179.883 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 25.9 pt -138.76 136.22 43.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.261 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -120.09 84.57 33.65 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.879 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -54.28 -26.44 43.19 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.535 2.157 . . . . 0.0 112.392 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -58.7 -73.3 0.08 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.907 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 7.2 mtt85 -80.01 -30.45 39.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.909 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 93.97 47.0 2.99 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.412 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -106.34 159.69 15.94 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.884 0.373 . . . . 0.0 110.872 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.2 m -143.16 116.94 3.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.15 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 19.1 tttp -90.78 111.23 22.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.826 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 33.8 m -119.24 148.71 22.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.163 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.5 ppp? -95.1 114.77 26.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.773 179.79 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 17.0 m -105.52 149.11 9.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.202 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 22.6 m -119.61 85.23 2.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.904 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 1.7 tp -82.21 118.11 29.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.092 -179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 60.57 33.62 20.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.873 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 75.18 30.09 59.42 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.505 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.12 108.65 8.96 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.753 0.311 . . . . 0.0 110.981 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -59.95 139.91 57.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.807 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 53.8 m -154.12 109.56 2.46 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.913 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -67.45 100.67 0.58 Allowed 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.341 2.027 . . . . 0.0 112.157 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 11.9 p -108.45 129.01 63.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.286 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -90.63 123.39 34.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.614 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -137.33 -159.52 0.96 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.43 0.633 . . . . 0.0 111.128 -179.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -145.56 157.33 44.0 Favored 'General case' 0 N--CA 1.441 -0.875 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.055 178.21 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 6.4 m-85 -44.24 -30.42 0.8 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.656 -179.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 35.5 t -67.25 -23.55 65.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.435 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 22.6 mt-30 -101.83 -14.17 17.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.617 -179.617 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 10.7 m -123.39 172.15 11.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-O 120.858 0.361 . . . . 0.0 111.461 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 32.9 m -146.39 146.2 19.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.164 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 9.9 mttt -66.0 125.74 26.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.943 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.273 -0.87 . . . . 0.0 111.075 179.994 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.353 0 CA-C-O 120.788 0.328 . . . . 0.0 111.028 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 60.65 172.23 0.1 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.85 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 15.3 m -111.16 -32.29 2.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.137 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -87.8 -176.57 5.55 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.103 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 11.0 p90 -93.36 179.23 5.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.827 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 2.0 ttm180 -112.69 167.22 10.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.98 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -59.66 120.16 8.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.939 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 121.71 -19.9 8.34 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.64 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -55.48 -178.85 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.824 0.345 . . . . 0.0 110.994 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 2.0 mt-30 -132.02 136.14 47.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.148 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 31.0 m -139.45 147.93 23.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.789 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -79.84 164.75 23.36 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.962 0.411 . . . . 0.0 111.022 -179.771 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.461 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 39.7 t -79.8 149.35 5.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.433 -179.689 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 9.9 p -90.26 -20.36 6.99 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 115.991 -0.55 . . . . 0.0 112.181 -179.494 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' SER . . . . . 0.403 ' O ' ' N ' ' A' ' 145' ' ' ALA . 0.4 OUTLIER -79.23 152.65 30.5 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.908 0.385 . . . . 0.0 111.145 -179.032 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . 0.404 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -65.5 -63.37 4.14 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.892 -179.793 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.404 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.6 Cg_endo -53.76 -22.7 24.07 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.7 2.266 . . . . 0.0 112.32 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.461 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 17.5 m-85 -110.36 1.99 18.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.365 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.403 ' N ' ' O ' ' A' ' 141' ' ' SER . . . -70.31 49.68 0.11 Allowed 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -179.151 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -160.69 32.63 0.15 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.15 0.5 . . . . 0.0 110.465 179.093 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 46.5 m-85 -157.23 145.77 19.58 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.533 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 30.3 p -103.67 -179.26 3.9 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.865 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -144.71 141.98 10.52 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.619 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.4 m -93.38 107.41 19.24 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.714 0.293 . . . . 0.0 110.696 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 40.9 t -64.84 113.14 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.088 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 73.8 p -97.76 -46.4 5.98 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.763 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -124.69 167.48 14.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.848 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 12.6 pt -146.49 160.14 10.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.203 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 8.5 m-20 -132.24 89.71 36.55 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.923 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.15 -28.09 28.6 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.546 2.164 . . . . 0.0 112.289 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -62.49 -52.79 62.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.967 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.26 -49.43 5.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.905 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 115.44 52.23 0.41 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.574 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -125.88 170.15 11.94 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.864 0.364 . . . . 0.0 110.815 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.4 m -154.17 132.42 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.131 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 7.0 tttm -104.13 133.46 49.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.969 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 34.6 m -134.86 164.23 34.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.285 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 3.9 ptt? -106.7 120.55 42.27 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.808 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 16.9 m -117.51 157.56 18.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.13 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 23.6 m -142.37 105.81 4.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.974 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.1 mp -83.1 113.71 22.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.039 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 64.97 -77.71 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.971 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -154.47 44.23 0.57 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.448 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 5.2 ptt180 -148.24 115.27 6.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.883 0.373 . . . . 0.0 110.957 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -68.96 147.03 52.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.771 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 76.4 m -160.06 113.8 1.44 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.942 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -73.6 112.65 3.58 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.402 2.068 . . . . 0.0 112.141 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.5 t -119.41 124.4 72.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.225 -179.759 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -92.1 131.07 37.65 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.677 179.754 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -139.71 -161.65 1.22 Allowed 'General case' 0 CA--C 1.515 -0.385 0 CA-C-O 121.522 0.677 . . . . 0.0 111.259 -179.793 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -138.06 161.29 37.14 Favored 'General case' 0 N--CA 1.439 -1.004 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.172 177.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -43.45 -38.51 2.85 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.693 -0.685 . . . . 0.0 112.554 -179.006 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.38 5.36 12.79 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.135 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . 0.444 ' NE2' ' N ' ' A' ' 180' ' ' GLN . 1.2 mp0 -112.14 6.87 19.36 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.582 0.229 . . . . 0.0 111.407 -179.809 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 27.2 m -151.95 174.96 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 120.882 0.372 . . . . 0.0 111.289 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 12.9 m -143.14 146.68 21.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.084 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -60.82 123.27 17.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.926 -179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.253 -0.88 . . . . 0.0 111.045 -179.96 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.335 0 CA-C-O 120.808 0.337 . . . . 0.0 111.034 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 7.0 mm-40 -119.27 -176.04 3.05 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.747 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 8.7 m -79.92 122.08 34.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.051 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.39 179.21 0.16 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.278 -179.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 67.9 t80 -157.66 155.22 29.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.806 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -148.23 150.61 34.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.915 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.4 pp20? -59.56 122.25 13.58 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.926 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.68 15.97 25.49 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.709 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -69.66 157.25 37.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.761 0.315 . . . . 0.0 110.91 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -93.16 132.19 37.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.981 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 14.9 m -140.79 133.25 31.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.927 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.41 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.8 OUTLIER -79.82 166.38 21.77 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.912 0.387 . . . . 0.0 110.967 -179.907 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.442 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 7.3 t -79.74 167.9 2.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.969 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 3.0 p -79.41 -61.47 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 -179.291 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 39.6 p -160.45 -164.1 1.19 Allowed 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.766 0.317 . . . . 0.0 111.246 -179.675 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.86 -168.58 54.26 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.325 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -59.93 -18.56 50.54 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.541 2.161 . . . . 0.0 112.087 179.671 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.442 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 4.1 m-85 -97.04 16.8 18.55 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.094 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.58 39.44 0.47 Allowed 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 112.146 0.425 . . . . 0.0 112.146 -179.425 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . 0.416 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 8.3 t0 -160.74 34.69 0.15 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.979 0.419 . . . . 0.0 110.71 179.43 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.416 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 24.3 m-85 -146.13 160.68 41.59 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.711 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' THR . . . . . 0.41 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 3.2 p -120.22 172.99 7.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.989 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -138.62 159.92 25.48 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.563 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' THR . . . . . 0.415 ' HB ' ' CG ' ' A' ' 164' ' ' MET . 3.4 m -109.38 110.02 21.05 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.765 0.317 . . . . 0.0 110.796 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 31.6 t -60.2 99.84 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.113 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -90.95 -39.23 12.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.74 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -132.7 154.0 50.59 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.708 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 32.9 pt -148.56 136.5 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.095 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -114.32 89.18 16.95 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.892 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.06 -26.26 37.14 Favored 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.545 2.164 . . . . 0.0 112.406 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -59.79 -32.31 70.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.851 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 27.4 mtt85 -113.87 -46.33 3.03 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.905 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 118.76 44.54 0.5 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.494 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 2.0 mmtt -119.26 166.13 13.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.769 0.318 . . . . 0.0 110.883 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.9 m -156.0 129.5 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.043 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -99.83 123.02 43.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.956 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 30.6 m -123.54 138.89 51.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.126 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' MET . . . . . 0.415 ' CG ' ' HB ' ' A' ' 150' ' ' THR . 0.3 OUTLIER -91.85 106.47 18.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.965 0.412 . . . . 0.0 110.796 -179.969 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 13.5 m -90.14 167.0 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.096 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 3.4 m -130.16 92.76 3.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.911 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 4.1 mp -98.77 114.83 37.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.924 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 62.2 29.93 17.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 75.85 55.03 5.08 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.536 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -157.48 117.95 3.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.744 0.307 . . . . 0.0 111.0 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -65.94 121.18 14.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.819 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 23.5 m -130.64 89.78 42.56 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.962 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -68.17 101.35 0.7 Allowed 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.432 2.088 . . . . 0.0 112.231 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 28.3 m -110.32 138.74 36.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.155 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -80.02 117.96 21.32 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.559 179.615 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -137.16 -159.76 0.99 Allowed 'General case' 0 CA--C 1.517 -0.323 0 CA-C-O 121.292 0.567 . . . . 0.0 111.15 -179.622 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -150.71 154.88 38.22 Favored 'General case' 0 N--CA 1.442 -0.848 0 CA-C-N 115.232 -0.894 . . . . 0.0 110.151 178.399 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -46.61 -28.88 1.59 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.546 -179.731 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.9 p -67.6 -14.44 62.94 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.339 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 5.3 mt-30 -116.88 10.15 14.04 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.515 -179.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 31.4 m -156.99 150.39 9.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.807 0.337 . . . . 0.0 111.224 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -121.29 173.72 6.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.898 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -75.85 150.3 37.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.956 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.995 0 CA-C-O 118.224 -0.893 . . . . 0.0 111.115 -179.998 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.279 0 CA-C-O 120.806 0.336 . . . . 0.0 110.995 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -169.54 95.18 0.3 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.926 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 31.5 m -113.92 31.12 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.077 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -82.4 164.09 21.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.132 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 11.1 t80 -109.67 162.38 14.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.924 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -159.36 145.44 16.31 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.824 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -65.07 135.42 55.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.846 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.82 -26.03 13.47 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.58 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -60.17 166.49 2.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.752 0.31 . . . . 0.0 110.912 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -112.7 130.38 56.08 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.989 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 19.5 m -134.27 141.94 42.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.946 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.9 166.19 21.9 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.967 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.449 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 4.2 t -79.77 169.18 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.014 -179.861 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.1 p -79.18 -64.76 0.86 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 CA-C-N 116.566 -0.288 . . . . 0.0 111.773 -179.451 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -160.42 -163.55 1.11 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.811 0.339 . . . . 0.0 111.096 -179.642 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.37 -164.71 49.63 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.518 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -62.83 -16.39 53.29 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.495 2.13 . . . . 0.0 112.173 179.725 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.449 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 3.5 m-85 -102.59 20.17 17.65 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.083 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.49 39.85 0.62 Allowed 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 111.98 0.363 . . . . 0.0 111.98 -179.509 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -160.81 35.97 0.15 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.927 0.394 . . . . 0.0 110.781 179.447 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 19.2 m-85 -146.16 172.3 13.64 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.793 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 33.8 p -122.55 -172.12 2.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.877 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -156.64 144.02 10.31 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.626 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.6 m -93.04 105.82 17.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.841 0.353 . . . . 0.0 110.845 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 25.1 t -61.9 137.74 23.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.403 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 65.4 p -119.88 -49.06 2.33 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.69 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -128.72 159.64 35.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.871 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mp -142.43 132.18 22.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.13 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -104.61 108.96 62.17 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.75 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -74.2 -44.05 0.48 Allowed 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.432 2.088 . . . . 0.0 112.409 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -65.4 -44.64 86.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.017 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 1.5 mtt180 -83.97 -41.08 17.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.894 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 89.49 36.72 7.31 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.336 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 24.6 mtpt -117.62 177.6 4.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.759 0.314 . . . . 0.0 110.941 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.469 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.3 p -159.91 159.57 2.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.09 0.471 . . . . 0.0 111.054 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . 0.469 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 20.3 tttm -127.53 133.3 49.83 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.799 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.402 ' CG2' HD11 ' A' ' 176' ' ' LEU . 18.3 m -139.17 160.16 29.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.177 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 12.5 ptp -102.29 116.22 32.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.603 179.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 15.5 m -107.62 160.26 6.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.362 -179.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 6.9 t -152.1 135.26 15.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.722 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.1 mp -91.8 -67.0 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.131 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -148.52 87.13 1.56 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.832 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 70.24 25.69 75.28 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.455 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 4.4 ttm180 -148.76 112.51 5.09 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.872 0.368 . . . . 0.0 110.889 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -89.46 157.39 18.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.836 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 65.1 m -160.11 112.39 1.42 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.969 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -71.72 121.18 7.43 Favored 'Trans proline' 0 C--N 1.347 0.46 0 C-N-CA 122.438 2.092 . . . . 0.0 112.117 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 27.4 m -128.08 142.79 42.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.362 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -93.28 127.85 39.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.672 179.791 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.402 HD11 ' CG2' ' A' ' 163' ' ' VAL . 0.0 OUTLIER -137.45 -159.87 1.0 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.324 0.583 . . . . 0.0 111.203 -179.769 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . 0.408 ' O ' ' N ' ' A' ' 180' ' ' GLN . 0.1 OUTLIER -149.47 154.11 38.31 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 115.103 -0.953 . . . . 0.0 110.269 178.447 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 31.0 m-85 -43.99 -28.57 0.48 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.862 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.09 8.12 7.81 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 111.865 0.32 . . . . 0.0 111.865 -179.791 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . 0.408 ' N ' ' O ' ' A' ' 177' ' ' ASP . 9.9 mt-30 -131.05 9.25 4.84 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.601 0.238 . . . . 0.0 111.27 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 5.6 m -141.85 174.69 6.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 120.751 0.31 . . . . 0.0 111.089 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 17.3 m -147.55 154.49 11.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.132 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.25 134.02 44.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.899 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.267 -0.873 . . . . 0.0 111.092 -179.937 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 120.79 0.329 . . . . 0.0 111.096 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 -107.41 149.63 27.67 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.945 179.899 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.5 t -89.13 108.77 19.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.168 -179.963 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -74.78 -30.77 61.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.007 179.996 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 30.8 t80 -80.01 155.83 27.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.905 -179.975 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.04 146.57 15.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.872 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -62.48 139.42 58.58 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.833 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 97.34 -24.61 30.69 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.567 -179.987 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -58.0 -168.59 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.737 0.304 . . . . 0.0 111.009 -179.947 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 5.1 mm-40 -135.27 138.64 43.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.084 -179.907 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.502 ' HB ' ' O ' ' A' ' 182' ' ' VAL . 27.1 m -136.93 157.5 35.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.913 179.911 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.431 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 1.0 OUTLIER -90.49 165.93 13.52 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.944 0.402 . . . . 0.0 110.883 179.904 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.472 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 5.2 t -79.95 168.31 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.046 -179.914 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 1.7 p -79.25 -65.41 0.78 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.778 -179.544 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 4.0 m -160.24 -164.43 1.27 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.849 0.357 . . . . 0.0 111.082 -179.552 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.53 -160.53 41.75 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.446 179.989 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -67.46 -11.6 32.73 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.421 2.08 . . . . 0.0 112.406 179.689 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.472 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 4.2 m-85 -107.92 19.67 19.74 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.105 -179.997 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -80.53 37.51 0.41 Allowed 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 112.197 0.443 . . . . 0.0 112.197 -179.467 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -161.08 35.6 0.14 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.996 0.427 . . . . 0.0 110.836 179.423 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -146.55 153.86 40.86 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.646 -179.892 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 148' ' ' THR . . . . . 0.431 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 44.4 p -103.01 -179.91 4.09 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.816 -179.957 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -143.12 149.37 21.3 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.541 -0.838 . . . . 0.0 112.661 -179.818 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 16.2 m -95.73 102.69 14.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.831 0.348 . . . . 0.0 110.654 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 46.4 t -59.98 116.67 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.059 -179.917 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 3.3 p -97.02 -47.12 5.92 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.828 179.973 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -138.84 158.51 44.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.86 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 32.0 mt -131.08 141.57 45.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.198 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.4 m-20 -121.86 100.79 43.05 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.67 179.969 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -63.58 -55.62 0.67 Allowed 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.613 2.209 . . . . 0.0 112.43 -179.765 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -57.54 -43.75 84.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.414 -179.662 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 1.9 tpm_? -79.97 -26.2 40.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.154 -179.728 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 69.69 31.07 70.4 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.313 -179.902 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 20.0 mttt -111.7 165.17 12.27 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.78 0.324 . . . . 0.0 111.0 -179.902 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 6.9 m -147.3 126.34 4.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.006 179.907 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 3.5 ttmt -101.2 127.86 47.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.021 -179.899 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.401 ' CG2' ' CD1' ' A' ' 176' ' ' LEU . 18.8 m -141.74 149.47 19.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.218 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 164' ' ' MET . . . . . 0.445 ' O ' ' HG3' ' A' ' 164' ' ' MET . 0.0 OUTLIER -98.52 120.66 39.33 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.843 179.687 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 31.2 m -107.05 153.99 8.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.347 -179.685 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -122.14 147.92 45.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.773 179.888 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 2.0 mp -102.85 -62.73 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.08 -179.973 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.3 59.51 1.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.881 -179.915 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 98.21 -20.76 49.22 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.575 -179.972 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 4.0 ttt180 -97.79 127.73 43.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.788 0.328 . . . . 0.0 110.975 -179.924 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -84.24 155.13 22.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.856 179.968 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 42.1 m -157.79 101.11 1.81 Allowed Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.88 179.888 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -67.36 113.64 2.96 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.453 2.102 . . . . 0.0 112.192 -179.997 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.4 t -128.9 150.94 35.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.151 -179.931 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.99 157.34 26.84 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.754 179.949 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.42 ' CD2' ' HB3' ' A' ' 180' ' ' GLN . 1.0 OUTLIER -154.78 -171.06 3.71 Favored 'General case' 0 CA--C 1.516 -0.348 0 CA-C-O 121.26 0.552 . . . . 0.0 111.164 -179.963 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -150.14 152.97 35.55 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.462 178.421 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -46.86 -45.19 20.14 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.388 -179.815 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 9.2 t -79.52 -1.53 38.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.531 -179.85 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . 0.42 ' HB3' ' CD2' ' A' ' 176' ' ' LEU . 1.2 mt-30 -112.41 7.41 19.13 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.581 -0.281 . . . . 0.0 111.392 -179.84 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 23.2 m -136.23 178.58 4.86 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.927 0.394 . . . . 0.0 111.274 179.933 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . 0.502 ' O ' ' HB ' ' A' ' 137' ' ' VAL . 0.4 OUTLIER -133.34 -150.58 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.346 -179.965 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -122.52 138.86 54.43 Favored 'General case' 0 C--N 1.331 -0.197 0 O-C-N 122.176 -0.327 . . . . 0.0 111.0 -179.918 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.044 0 CA-C-O 118.166 -0.921 . . . . 0.0 111.098 179.864 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 120.728 0.299 . . . . 0.0 110.991 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -59.43 163.75 3.83 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.861 -179.979 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 11.0 p -108.82 143.73 18.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.139 179.997 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -89.53 104.42 16.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.115 179.923 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 16.9 t80 -95.18 163.94 13.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.873 -179.906 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 44.4 mtm180 -154.49 139.91 17.74 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.923 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -56.67 155.92 6.99 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.803 -179.939 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.55 8.21 59.49 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.86 -179.856 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.34 179.1 0.23 Allowed 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.801 0.334 . . . . 0.0 110.789 179.893 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 10.7 mt-30 -139.92 133.32 30.01 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.116 -179.859 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 148' ' ' THR . 23.1 m -142.49 146.18 22.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.774 179.88 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.447 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.5 OUTLIER -79.72 167.12 21.07 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 121.039 0.447 . . . . 0.0 111.172 -179.829 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.458 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 20.3 t -79.75 152.27 4.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.366 -179.571 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 14.7 p -92.47 -24.42 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 CA-C-N 116.082 -0.508 . . . . 0.0 112.148 -179.326 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 141' ' ' SER . . . . . 0.409 ' O ' ' N ' ' A' ' 145' ' ' ALA . 9.8 m -79.4 153.89 29.39 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.888 0.375 . . . . 0.0 111.274 -178.952 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . 0.428 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -66.13 -61.48 5.44 Favored Glycine 0 CA--C 1.519 0.312 0 C-N-CA 121.046 -0.597 . . . . 0.0 112.777 -179.86 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.428 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.6 Cg_endo -52.82 -23.85 21.99 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.581 2.188 . . . . 0.0 112.278 179.885 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.458 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 17.4 m-85 -111.6 2.64 17.43 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.281 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.409 ' N ' ' O ' ' A' ' 141' ' ' SER . . . -70.22 50.02 0.11 Allowed 'General case' 0 C--O 1.233 0.218 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -179.163 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . 0.402 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 5.7 t70 -160.68 32.21 0.15 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.045 0.45 . . . . 0.0 110.399 179.134 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.402 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 65.8 m-85 -155.24 146.2 22.52 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.376 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 148' ' ' THR . . . . . 0.447 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 19.3 p -103.38 170.63 7.83 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.372 -0.377 . . . . 0.0 111.004 -179.853 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -126.77 130.12 6.84 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.593 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.3 m -92.22 106.21 18.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.759 0.314 . . . . 0.0 110.892 -179.99 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 20.2 t -63.79 106.79 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.936 179.928 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.6 t -88.12 -30.67 19.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.878 -179.933 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -158.71 162.79 37.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.898 179.947 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.8 mt -126.12 130.46 72.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.126 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 70.6 m-20 -102.7 95.33 6.12 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.834 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.34 -34.93 11.78 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.409 2.073 . . . . 0.0 112.328 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -66.73 -31.44 72.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.942 -180.0 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -96.39 -43.6 7.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.898 -179.921 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 96.73 38.71 4.34 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.401 -179.889 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.4 mttm -135.1 175.61 9.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.888 0.375 . . . . 0.0 110.996 -179.974 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 5.2 m -136.59 127.78 42.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.002 179.943 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 18.0 tttt -87.3 111.75 21.37 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.847 -179.958 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 31.4 m -124.13 148.58 28.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.296 -179.999 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 12.5 ptm -102.01 120.09 39.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.833 179.97 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 18.5 m -124.2 136.6 59.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.896 0.379 . . . . 0.0 111.213 -179.984 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 2.7 m -95.55 142.49 27.83 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.778 179.85 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . 0.441 ' O ' HG13 ' A' ' 167' ' ' ILE . 3.8 tp -117.17 42.08 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.1 0.476 . . . . 0.0 110.95 -179.942 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER 63.99 99.18 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.847 179.877 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 125.8 -48.79 0.94 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.434 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 8.6 ptt180 -160.07 160.03 32.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.844 0.354 . . . . 0.0 110.894 179.948 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -66.67 166.23 13.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.82 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -154.65 90.03 3.15 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.967 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -68.42 102.54 0.84 Allowed 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.502 2.134 . . . . 0.0 112.255 179.938 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 34.8 m -119.1 137.97 51.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.114 -179.966 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -79.84 120.88 24.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.494 179.57 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 7.6 mt -124.31 -170.55 2.16 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.341 0.591 . . . . 0.0 111.504 -179.395 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -143.08 155.5 44.62 Favored 'General case' 0 N--CA 1.442 -0.848 0 CA-C-N 114.996 -1.002 . . . . 0.0 110.197 178.129 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -48.54 -30.86 5.71 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.509 -179.606 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -79.86 -0.32 34.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.463 179.955 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 30.7 mt-30 -119.59 5.51 11.06 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.609 -0.268 . . . . 0.0 111.316 -179.964 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 5.3 m -143.46 179.69 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.879 0.371 . . . . 0.0 111.212 179.97 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 23.9 m -152.68 146.61 15.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.016 179.958 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.42 125.93 25.78 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.908 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.001 0 CA-C-O 118.201 -0.904 . . . . 0.0 111.002 -179.952 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.35 0 CA-C-O 120.837 0.351 . . . . 0.0 111.025 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -162.57 37.13 0.11 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.793 179.907 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 12.4 p -106.31 133.22 51.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.131 -179.953 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -67.33 -54.79 17.49 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.114 179.954 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -96.16 138.89 33.13 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.89 179.975 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 51.1 ttt-85 -147.47 143.85 28.17 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.906 -179.961 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -59.85 117.82 5.47 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.923 179.978 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 107.19 16.36 13.66 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.831 -0.7 . . . . 0.0 112.756 179.998 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -76.41 158.63 31.2 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.86 0.362 . . . . 0.0 110.81 179.948 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -101.17 128.26 47.36 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.957 -179.992 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 11.3 m -141.61 135.87 30.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.814 179.965 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.418 ' CZ ' ' HB2' ' A' ' 138' ' ' ARG . 0.7 OUTLIER -79.79 162.95 24.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.943 0.402 . . . . 0.0 110.873 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.489 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 4.9 t -79.88 167.85 2.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.947 -179.84 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.4 p -79.35 -61.95 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.276 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.898 -179.264 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -160.23 -164.57 1.29 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.734 0.302 . . . . 0.0 111.216 -179.581 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.46 -164.15 49.0 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.368 179.972 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -63.27 -16.08 52.26 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.383 2.056 . . . . 0.0 112.146 179.666 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.489 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 2.6 m-85 -101.31 15.73 27.85 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.185 179.956 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -78.48 37.26 0.27 Allowed 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 112.411 0.523 . . . . 0.0 112.411 -179.345 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . 0.414 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 1.9 t0 -161.11 32.8 0.14 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.033 0.444 . . . . 0.0 110.78 179.146 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.42 ' CE2' HG23 ' A' ' 167' ' ' ILE . 22.8 m-85 -140.77 170.06 16.47 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.616 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 3.1 p -118.05 -179.38 3.74 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.799 179.934 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -150.36 138.67 6.83 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.592 -179.978 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.3 m -97.82 107.49 20.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.777 0.322 . . . . 0.0 110.851 179.833 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 23.5 t -55.52 115.7 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.236 -179.822 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.87 -33.19 8.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.877 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -144.56 157.82 44.04 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.839 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mp -141.1 129.45 23.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.15 179.993 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -100.5 98.58 8.25 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.779 -179.943 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.4 -43.26 2.22 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.527 2.152 . . . . 0.0 112.347 -179.984 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -78.39 -38.65 41.23 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.881 -179.901 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.0 -34.88 38.15 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.859 -179.901 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 80.59 67.31 1.56 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.48 -179.992 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 30.7 mttm -152.05 173.39 14.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.798 0.333 . . . . 0.0 110.933 -179.978 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 4.1 m -149.34 122.3 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.02 179.943 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 36.0 ttmt -104.61 135.31 46.25 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.997 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.404 ' CG2' ' CD1' ' A' ' 176' ' ' LEU . 33.9 m -138.76 163.47 27.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.104 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -103.12 111.43 23.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.611 179.722 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 28.5 m -101.86 167.65 2.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.173 -179.803 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 1.5 m -131.11 125.11 32.25 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.872 -179.959 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . 0.42 HG23 ' CE2' ' A' ' 147' ' ' PHE . 1.5 pp -149.09 138.76 15.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.124 179.879 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 62.41 30.29 17.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.774 -179.947 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 64.78 42.57 97.04 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.532 -179.926 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 66.4 mtp180 -157.17 137.96 13.28 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.809 0.338 . . . . 0.0 110.894 -179.984 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 15.5 mp0 -81.51 127.05 32.42 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.735 179.864 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.17 115.21 11.84 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.041 -179.866 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.37 113.19 3.53 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.483 2.122 . . . . 0.0 112.075 179.889 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 10.7 p -123.69 136.55 59.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.259 -179.834 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -80.49 146.86 31.15 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.68 179.742 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.404 ' CD1' ' CG2' ' A' ' 163' ' ' VAL . 0.0 OUTLIER -137.78 -165.05 1.71 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.385 0.612 . . . . 0.0 111.313 -179.721 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -152.84 155.31 36.86 Favored 'General case' 0 N--CA 1.446 -0.643 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.923 178.392 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -47.63 -40.89 20.74 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.517 -179.668 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 18.2 p -78.82 -2.32 39.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.734 -179.799 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 79.5 mt-30 -120.23 9.25 11.02 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.574 0.226 . . . . 0.0 111.519 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 22.7 m -146.02 165.01 9.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.85 0.357 . . . . 0.0 111.196 179.943 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.0 m -143.8 146.46 20.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.048 179.911 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 4.9 tttt -65.85 137.36 57.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.022 179.949 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.204 -0.903 . . . . 0.0 111.139 -179.981 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.338 0 CA-C-O 120.851 0.358 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 -111.34 -30.77 7.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.061 -179.997 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 11.4 p -93.72 -29.27 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.137 -179.932 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.04 -70.65 0.18 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.117 -179.949 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 21.0 t80 -115.81 166.81 11.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.984 179.981 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.68 140.29 51.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.794 179.969 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -69.33 135.95 51.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.892 179.929 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 67.18 21.26 71.83 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.609 179.933 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -78.69 163.47 25.4 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.776 0.322 . . . . 0.0 110.801 179.979 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 35.1 mt-30 -103.16 125.21 49.75 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.052 -179.907 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 31.5 m -134.73 144.13 35.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.968 179.974 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.41 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.82 167.3 20.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.936 0.398 . . . . 0.0 110.887 179.978 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.434 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 7.6 t -79.82 168.0 2.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.92 -179.932 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.7 p -79.54 -62.82 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 112.001 0.371 . . . . 0.0 112.001 -179.193 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -160.4 -164.15 1.21 Allowed 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.87 0.367 . . . . 0.0 111.105 -179.622 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 78.7 -167.1 52.66 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.94 -0.647 . . . . 0.0 112.456 179.89 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -61.93 -17.25 54.66 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.422 2.082 . . . . 0.0 112.094 179.699 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.434 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 4.3 m-85 -98.6 20.28 13.15 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.141 179.886 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.6 39.87 0.63 Allowed 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.496 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -160.77 36.22 0.15 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.998 0.428 . . . . 0.0 110.605 179.406 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.424 ' CZ ' HG22 ' A' ' 167' ' ' ILE . 26.4 m-85 -148.18 160.22 43.15 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.682 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 148' ' ' THR . . . . . 0.41 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 7.3 p -109.47 -178.12 3.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.852 179.894 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . 0.4 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -147.85 140.07 8.19 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.609 -179.848 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.9 m -97.0 109.19 22.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.737 0.304 . . . . 0.0 110.957 179.99 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 17.5 t -64.47 101.96 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.259 -179.989 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.36 -33.74 15.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.799 179.854 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -139.83 150.12 44.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.979 179.965 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 16.5 mt -130.99 136.77 57.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.067 -179.969 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -127.83 86.16 58.94 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.759 179.963 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.61 -37.49 7.08 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.515 2.144 . . . . 0.0 112.374 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -59.84 -42.87 94.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.859 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.3 -38.52 16.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.824 179.947 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 97.32 43.37 3.0 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.621 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -139.1 159.12 42.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.859 0.362 . . . . 0.0 110.865 -179.961 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.447 ' CG2' ' CE1' ' A' ' 178' ' ' PHE . 6.1 t -131.05 157.62 43.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.001 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 22.2 tttm -122.07 108.29 13.19 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.943 -179.992 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.4 ' HB ' ' HA3' ' A' ' 149' ' ' GLY . 31.0 m -123.38 146.55 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.263 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 15.0 ptp -99.39 123.49 43.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.687 179.9 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 17.0 m -115.25 158.11 15.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.318 -179.893 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 1.2 m -137.61 125.45 22.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.758 179.973 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . 0.424 HG22 ' CZ ' ' A' ' 147' ' ' PHE . 1.8 pp -130.15 147.07 33.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.128 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 62.82 -79.91 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.973 -179.996 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -167.73 36.21 0.22 Allowed Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.446 -179.926 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 6.4 mmt85 -153.19 133.29 13.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.748 0.309 . . . . 0.0 110.936 179.972 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -81.05 137.82 36.01 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.758 179.968 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 9.3 m -141.86 103.44 5.78 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.061 -179.88 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -72.09 114.44 3.98 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.475 2.117 . . . . 0.0 112.167 179.785 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.3 t -125.38 144.97 33.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.37 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -80.02 136.63 36.64 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.671 179.936 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 5.6 mt -133.05 -168.04 2.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.063 0.459 . . . . 0.0 111.329 -179.843 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -142.33 151.83 42.34 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.603 178.382 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . 0.447 ' CE1' ' CG2' ' A' ' 161' ' ' VAL . 20.7 m-85 -47.8 -38.2 15.25 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.502 -179.608 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.4 m -82.05 11.46 5.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.558 179.978 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -120.74 3.49 10.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.668 -0.242 . . . . 0.0 111.28 179.922 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 2.9 m -144.08 177.69 2.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-O 120.858 0.361 . . . . 0.0 111.301 -179.957 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 27.8 m -143.32 146.42 21.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.116 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -71.4 128.62 36.46 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.95 179.954 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.139 -0.934 . . . . 0.0 111.055 -179.991 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.355 0 CA-C-O 120.76 0.314 . . . . 0.0 111.001 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 39.1 mt-30 -145.51 157.07 44.06 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.894 179.968 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 6.4 m -133.52 23.81 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.266 -179.948 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -89.92 -54.24 4.13 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.912 0.387 . . . . 0.0 111.098 179.873 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -151.1 -178.51 6.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.891 -179.892 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 8.2 mtt180 -110.91 146.34 36.72 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.904 -179.984 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -59.49 141.05 55.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.87 -179.976 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 90.96 -14.3 63.78 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.759 -179.852 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -61.34 174.0 0.79 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.825 0.345 . . . . 0.0 110.966 -179.962 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -112.76 143.09 44.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.895 -179.854 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 15.6 m -140.18 138.66 37.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.991 179.93 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.415 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.94 166.45 21.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.826 0.346 . . . . 0.0 110.945 179.973 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.454 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 3.4 t -79.78 169.19 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.892 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.1 p -79.48 -65.35 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.814 -179.413 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -160.44 -163.48 1.1 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.859 0.361 . . . . 0.0 111.102 -179.65 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.27 -165.28 50.28 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.419 179.908 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -61.7 -17.74 56.39 Favored 'Trans proline' 0 C--N 1.343 0.248 0 C-N-CA 122.481 2.12 . . . . 0.0 112.124 179.74 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.454 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 2.0 m-85 -102.15 22.04 13.88 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.978 179.947 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -83.29 38.95 0.63 Allowed 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.133 0.42 . . . . 0.0 112.133 -179.436 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -160.8 36.5 0.15 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.914 0.388 . . . . 0.0 110.771 179.4 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 22.0 m-85 -141.35 172.99 11.93 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.645 -179.975 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 148' ' ' THR . . . . . 0.415 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 0.2 OUTLIER -125.0 171.01 10.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.99 179.986 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -137.12 136.2 8.15 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.504 -179.988 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 2.8 m -89.31 100.87 13.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.846 0.355 . . . . 0.0 110.81 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 21.5 t -58.9 115.04 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.267 -179.92 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 73.7 p -102.1 -32.28 10.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.842 179.954 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -151.91 160.2 43.59 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.942 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 6.5 pt -133.19 145.6 33.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.052 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -130.15 72.23 81.98 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.967 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -59.3 -29.04 89.23 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.614 2.209 . . . . 0.0 112.323 -179.939 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -57.98 -52.25 66.28 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.947 -179.928 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 3.2 tpm_? -90.82 -39.11 12.53 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.89 -179.966 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 105.9 41.81 1.77 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.432 179.975 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 30.7 mttp -131.29 158.71 39.92 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.768 0.318 . . . . 0.0 110.79 179.946 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.481 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.3 p -141.48 159.76 21.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 121.116 0.484 . . . . 0.0 110.91 -179.902 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . 0.481 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 25.6 ttmt -123.7 129.18 50.71 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.969 179.825 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 18.4 m -145.18 140.44 22.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.115 -179.933 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.09 133.68 33.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.795 179.857 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 15.5 m -124.91 167.85 18.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.174 -179.998 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -117.43 151.06 37.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.963 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . 0.417 HG22 HD12 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -157.18 119.16 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.947 -179.953 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER 61.01 30.39 19.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.728 -179.867 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 77.6 31.68 49.26 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.47 179.961 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 17.9 mtm180 -142.25 144.39 33.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.895 0.378 . . . . 0.0 110.841 -179.897 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -80.9 148.95 29.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.831 179.867 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 68.5 m -154.82 91.9 2.93 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.064 179.973 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -58.74 104.27 0.18 Allowed 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.529 2.153 . . . . 0.0 112.157 179.998 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.5 t -122.18 142.23 39.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.162 -179.94 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -79.91 159.56 26.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.866 179.849 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 4.9 mt -147.5 -171.38 3.78 Favored 'General case' 0 CA--C 1.516 -0.347 0 CA-C-O 121.266 0.555 . . . . 0.0 111.223 -179.636 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -145.11 153.29 41.25 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.415 178.102 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 30.2 m-85 -48.38 -41.64 29.44 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.333 -179.708 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.7 m -78.51 -2.14 37.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.343 -179.959 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 4.8 mt-30 -116.84 6.58 13.16 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.594 -0.276 . . . . 0.0 111.345 -179.787 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 27.4 m -142.75 -179.44 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.959 0.409 . . . . 0.0 111.271 -179.91 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 12.6 m -155.34 146.5 12.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.977 179.956 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 4.0 tmtt? -72.38 138.26 47.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.968 -179.955 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.086 0 CA-C-O 118.256 -0.878 . . . . 0.0 111.151 179.997 . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.318 0 CA-C-O 120.888 0.375 . . . . 0.0 111.045 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 2.8 mm-40 60.04 31.16 20.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.031 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 9.7 p -102.67 146.26 10.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.122 -179.993 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -86.78 166.62 15.1 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.109 -179.926 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 6.0 p90 -124.48 -178.67 4.2 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.82 -179.91 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -107.99 159.46 16.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.854 179.95 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -60.13 128.6 37.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.981 179.906 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 121.97 -24.92 6.93 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.529 -179.962 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -59.31 169.81 1.1 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.816 0.341 . . . . 0.0 110.882 -179.887 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -124.94 136.21 53.54 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.059 -179.921 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 12.6 m -140.52 145.21 26.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.723 179.924 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.81 163.76 24.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.034 0.445 . . . . 0.0 111.125 -179.801 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.448 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 46.7 t -79.77 147.44 6.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.548 -179.672 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.413 HG13 ' CA ' ' A' ' 180' ' ' GLN . 12.5 p -86.27 -21.83 7.39 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 CA-C-N 116.02 -0.536 . . . . 0.0 112.35 -179.555 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 141' ' ' SER . . . . . 0.408 ' O ' ' N ' ' A' ' 145' ' ' ALA . 1.7 m -79.18 152.83 30.47 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.939 0.4 . . . . 0.0 111.475 -178.783 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . 0.426 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -66.74 -61.79 5.03 Favored Glycine 0 C--N 1.332 0.34 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.699 -179.811 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.426 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.2 Cg_endo -53.41 -23.56 24.78 Favored 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.548 2.166 . . . . 0.0 112.083 179.853 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.448 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 9.2 m-85 -110.73 2.66 18.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.375 179.751 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.408 ' N ' ' O ' ' A' ' 141' ' ' SER . . . -70.36 48.99 0.11 Allowed 'General case' 0 C--N 1.332 -0.193 0 N-CA-C 112.448 0.536 . . . . 0.0 112.448 -179.074 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . 0.464 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 16.4 p-10 -160.44 29.91 0.16 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.172 0.511 . . . . 0.0 110.49 179.116 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.464 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 15.2 m-85 -150.44 147.97 28.18 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.183 179.741 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 69.6 p -102.25 168.58 9.26 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.798 0.333 . . . . 0.0 110.708 179.888 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -128.86 129.05 6.03 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.634 -0.793 . . . . 0.0 112.539 -179.865 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.7 m -86.76 105.83 17.25 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.739 0.305 . . . . 0.0 110.73 179.886 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 30.2 t -62.76 117.78 4.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.083 -179.862 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -93.04 -46.35 7.5 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.925 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -144.89 152.68 40.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.864 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mt -112.58 148.37 15.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.128 -179.951 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -119.24 84.01 26.77 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.85 -179.974 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -72.93 -37.88 3.31 Favored 'Trans proline' 0 C--N 1.343 0.27 0 C-N-CA 122.571 2.181 . . . . 0.0 112.303 179.969 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -60.13 -55.1 38.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.835 -179.93 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 12.6 ttt-85 -79.9 -67.11 0.79 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.004 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 129.92 59.49 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.498 -179.953 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 5.5 mtmm -155.64 -179.09 7.78 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.801 0.334 . . . . 0.0 110.84 -179.953 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.48 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.2 p -154.44 159.81 2.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.896 179.915 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . 0.48 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 10.8 tttt -124.15 127.75 48.24 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.932 -179.9 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 16.7 m -136.16 156.65 36.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.183 -179.991 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 16.4 ptm -106.54 120.02 40.83 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.004 179.93 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . 0.418 ' CG1' ' HB2' ' A' ' 147' ' ' PHE . 2.6 t -117.62 153.83 19.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.102 -179.956 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 2.3 m -100.8 142.82 31.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.935 179.918 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -159.78 -46.29 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.147 179.972 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . 0.403 ' CE2' ' HB ' ' A' ' 172' ' ' THR . 5.0 p90 -97.58 35.25 1.69 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.973 179.965 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 96.48 -30.98 7.94 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.448 -179.912 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.63 177.34 7.46 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.894 0.378 . . . . 0.0 110.691 179.953 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -69.51 168.26 15.0 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.881 -179.939 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 172' ' ' THR . . . . . 0.403 ' HB ' ' CE2' ' A' ' 168' ' ' PHE . 11.5 t -148.05 124.73 5.49 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.829 -179.914 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -71.77 97.36 0.81 Allowed 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.427 2.084 . . . . 0.0 112.331 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 10.5 t -121.67 132.86 69.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.164 -179.987 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -79.91 124.41 28.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.124 179.436 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -127.41 -170.08 2.16 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.322 0.582 . . . . 0.0 111.639 -179.164 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -142.38 152.98 43.39 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.394 178.342 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -42.5 -58.42 2.26 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.607 -179.596 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 6.0 t -56.28 -23.0 33.64 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.241 179.998 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . 0.413 ' CA ' HG13 ' A' ' 140' ' ' VAL . 5.4 mp0 -89.57 3.88 51.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.638 -179.837 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 16.5 m -147.44 167.95 4.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.811 0.339 . . . . 0.0 111.166 179.967 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.4 m -145.08 146.19 20.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.1 179.872 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 1.5 tttp -61.68 136.68 58.09 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.825 -179.822 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.246 -0.883 . . . . 0.0 111.036 179.986 . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.41 0 CA-C-O 120.894 0.378 . . . . 0.0 111.062 . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -60.26 125.51 23.96 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.941 -179.949 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 17.8 m -134.5 86.04 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.135 179.991 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -89.68 150.44 22.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.062 -179.959 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -118.43 150.09 40.15 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.906 179.961 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 12.7 tpp180 -153.52 147.56 25.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.876 179.966 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -61.54 144.76 53.79 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.861 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 96.71 -23.6 34.6 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.573 -179.988 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -57.34 163.79 2.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.906 0.384 . . . . 0.0 111.017 -179.994 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 33.0 mm-40 -121.06 139.14 53.72 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.969 -179.918 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 20.9 m -137.01 140.76 42.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.82 179.989 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.459 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.7 162.85 24.95 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.027 0.441 . . . . 0.0 111.002 -179.934 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.467 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 37.6 t -79.88 151.46 4.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.409 -179.627 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 34.3 m -93.1 -21.29 6.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 112.4 0.518 . . . . 0.0 112.4 -179.216 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 141' ' ' SER . . . . . 0.429 ' O ' ' N ' ' A' ' 145' ' ' ALA . 4.5 m -79.18 153.87 29.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.792 0.33 . . . . 0.0 111.315 -179.013 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . 0.415 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -65.12 -62.56 4.82 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 121.058 -0.591 . . . . 0.0 113.006 -179.664 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.415 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.4 Cg_endo -52.81 -23.17 19.84 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.685 2.257 . . . . 0.0 112.379 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.467 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 10.2 m-85 -112.62 2.65 16.27 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.471 179.982 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.429 ' N ' ' O ' ' A' ' 141' ' ' SER . . . -70.11 48.39 0.1 Allowed 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -179.117 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -160.72 32.39 0.15 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.13 0.49 . . . . 0.0 110.631 179.109 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.404 ' CD2' ' O ' ' A' ' 166' ' ' THR . 42.5 m-85 -154.87 145.59 22.38 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.469 179.946 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 148' ' ' THR . . . . . 0.459 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 67.8 p -99.88 -177.58 3.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.908 -179.879 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -139.85 129.12 4.16 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.596 -179.838 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.0 m -90.05 113.83 25.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.742 0.306 . . . . 0.0 110.68 179.754 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 21.7 t -70.71 120.83 19.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.305 -179.726 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -108.84 -31.75 7.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.713 179.643 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -153.95 161.35 42.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.705 179.824 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.6 mp -134.21 152.43 34.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.331 -179.966 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 -123.17 90.89 50.21 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.806 179.932 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.15 -34.04 13.99 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.613 2.209 . . . . 0.0 112.357 -179.893 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -90.14 18.14 6.25 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.338 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 31.2 ttt85 -138.07 -46.01 0.52 Allowed 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.808 0.337 . . . . 0.0 110.791 179.936 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 99.19 39.82 3.42 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.392 179.962 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 16.3 mtmt -146.18 170.5 16.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.815 0.34 . . . . 0.0 111.086 -179.979 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.475 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.0 OUTLIER -149.43 159.59 5.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.118 0.485 . . . . 0.0 110.795 179.918 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . 0.475 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 59.6 tttp -105.21 121.61 44.2 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.967 179.993 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 5.6 m -134.95 134.76 53.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.176 -179.982 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 7.6 ptm -93.55 135.43 34.82 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.841 179.954 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 27.6 m -134.25 149.76 30.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.217 179.915 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 166' ' ' THR . . . . . 0.404 ' O ' ' CD2' ' A' ' 147' ' ' PHE . 3.8 m -113.26 110.57 20.59 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.809 -180.0 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . 0.445 HD12 HG22 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -97.32 113.83 32.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.075 179.985 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . 0.404 ' HB2' ' CD1' ' A' ' 167' ' ' ILE . 0.7 OUTLIER 59.52 43.26 16.33 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.894 -179.782 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 66.41 30.68 77.01 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.459 -179.922 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -129.86 124.55 33.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.743 0.306 . . . . 0.0 110.899 -179.905 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.85 126.08 26.18 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.725 179.957 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 2.0 m -150.66 89.68 4.37 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.127 -179.8 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -72.76 125.57 10.64 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.517 2.145 . . . . 0.0 112.104 179.81 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 5.3 m -134.24 136.58 53.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.317 -179.866 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 3.3 pm0 -79.88 126.64 31.26 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.964 179.209 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 7.0 mt -127.62 -170.08 2.17 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.395 0.617 . . . . 0.0 111.772 -179.131 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -141.33 154.59 45.77 Favored 'General case' 0 N--CA 1.442 -0.868 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.357 178.162 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -48.49 -31.14 5.97 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.366 -179.551 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.2 m -79.47 1.2 26.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.574 179.998 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -122.12 10.7 10.08 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.652 0.263 . . . . 0.0 111.401 -179.798 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 14.4 m -149.35 159.14 5.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.944 0.402 . . . . 0.0 111.272 -179.989 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.0 m -123.27 146.48 28.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.048 179.985 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.79 120.46 17.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.864 -179.931 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.267 -0.873 . . . . 0.0 111.082 -179.942 . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.317 0 CA-C-O 120.833 0.349 . . . . 0.0 111.015 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 23.6 mt-30 -147.41 170.32 17.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.841 -179.995 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 5.0 m -132.33 103.63 6.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.116 179.992 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -61.96 -172.55 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.04 179.919 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 77.1 t80 -143.5 162.39 35.95 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.751 179.976 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -153.73 149.55 27.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.942 -179.951 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -65.67 134.35 53.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.846 179.872 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 98.36 -2.83 59.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.845 -179.958 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -58.54 167.68 1.38 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.912 0.387 . . . . 0.0 110.897 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.27 116.93 29.78 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.028 179.999 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 30.1 m -123.17 138.76 52.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.833 179.932 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.99 161.9 25.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.956 0.408 . . . . 0.0 111.142 -179.899 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.486 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 39.8 t -104.21 167.05 2.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.559 179.702 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 16.2 m -138.04 -9.88 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 N-CA-C 113.001 0.741 . . . . 0.0 113.001 -178.874 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 141' ' ' SER . . . . . 0.461 ' O ' ' CD2' ' A' ' 144' ' ' PHE . 1.1 m -79.5 142.61 35.66 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.996 0.427 . . . . 0.0 111.761 -178.946 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 35.78 -139.83 0.24 Allowed Glycine 0 C--N 1.335 0.511 0 CA-C-N 115.67 -0.695 . . . . 0.0 113.656 179.523 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -74.3 3.86 4.87 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.691 2.261 . . . . 0.0 112.682 179.761 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.486 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 0.1 OUTLIER -79.57 -10.03 59.73 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.635 -0.257 . . . . 0.0 111.055 179.831 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.447 ' HA ' ' O ' ' A' ' 139' ' ' VAL . . . -68.52 41.84 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -178.996 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . 0.436 ' H ' ' C ' ' A' ' 144' ' ' PHE . 0.8 OUTLIER -160.95 32.78 0.15 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.056 0.455 . . . . 0.0 110.654 179.167 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.431 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 55.8 m-85 -151.7 164.41 37.01 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.582 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 80.6 p -118.73 162.86 17.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.734 179.849 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -130.79 163.48 23.35 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.693 -179.847 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.6 m -103.24 103.35 13.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.766 0.317 . . . . 0.0 110.661 179.964 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 46.4 t -60.31 112.61 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.975 -179.935 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -101.81 -42.62 6.09 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.79 179.906 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -120.1 150.97 39.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.794 179.841 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 12.5 pt -143.31 124.14 10.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.154 179.984 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -117.3 86.61 21.99 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.896 -179.993 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -72.52 -20.22 23.89 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.555 2.17 . . . . 0.0 112.516 -179.938 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.38 25.65 2.18 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.389 -179.94 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 2.2 tpm_? -160.0 -45.06 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.772 0.32 . . . . 0.0 110.838 179.979 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 104.04 61.69 0.68 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.459 179.896 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 17.2 mtpt -154.18 149.6 27.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.813 0.34 . . . . 0.0 110.998 179.963 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 26.9 m -147.21 154.04 11.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.18 179.933 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 12.6 ttpt -127.13 129.61 48.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.907 -179.952 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 34.9 m -136.6 145.68 29.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.23 179.928 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -89.43 113.32 24.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.459 179.824 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 20.9 m -123.19 159.76 26.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.359 -179.696 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 17.2 p -111.55 139.25 47.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.785 179.869 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . 0.429 HG21 HD11 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -93.32 -36.38 7.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.04 -179.874 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 10.5 t80 -172.82 78.54 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.982 179.996 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 68.44 28.22 73.35 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.425 -179.93 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -156.72 124.28 5.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.728 0.299 . . . . 0.0 110.88 -179.995 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 67.8 mt-10 -61.08 154.61 22.44 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.788 179.905 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 25.4 m -160.08 89.84 1.82 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.146 -179.925 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -66.13 105.02 0.78 Allowed 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.615 2.21 . . . . 0.0 111.82 179.766 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 31.0 m -118.5 149.39 20.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.349 -179.716 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -89.14 135.91 33.31 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.731 179.759 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.404 HD12 ' N ' ' A' ' 176' ' ' LEU . 0.0 OUTLIER -146.98 -161.12 1.26 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.397 0.617 . . . . 0.0 110.936 -179.709 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -151.85 153.2 33.73 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.379 178.474 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -42.36 -30.58 0.34 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.677 -179.654 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.4 m -69.57 -39.31 77.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.115 -179.963 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 -88.93 8.76 27.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.499 -179.724 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 5.4 m -145.72 179.53 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.791 0.329 . . . . 0.0 111.165 179.903 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.6 m -145.09 147.07 19.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.167 179.975 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -78.3 130.83 36.67 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.887 179.937 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.169 -0.919 . . . . 0.0 111.08 179.977 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.403 0 CA-C-O 120.935 0.398 . . . . 0.0 111.015 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -94.22 166.78 11.94 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.916 179.975 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.76 105.79 19.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.103 179.91 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -76.26 -32.28 58.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.175 -179.958 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 9.8 t80 -146.99 150.47 35.2 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.912 180.0 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -134.87 154.36 51.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.028 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -71.53 120.73 17.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.851 179.909 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 115.59 -14.96 17.49 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.671 -179.919 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -56.26 174.07 0.15 Allowed 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.795 0.331 . . . . 0.0 110.979 -179.921 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.73 140.67 51.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.95 -179.992 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 19.9 m -144.58 139.79 23.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.021 -179.959 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.97 163.1 24.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.955 0.407 . . . . 0.0 110.945 179.865 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.484 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 21.7 t -79.83 156.08 4.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 115.848 -0.615 . . . . 0.0 111.576 -179.659 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 33.7 m -96.64 -26.19 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 N-CA-C 112.424 0.528 . . . . 0.0 112.424 -179.135 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 141' ' ' SER . . . . . 0.432 ' O ' ' N ' ' A' ' 145' ' ' ALA . 91.1 p -79.13 155.18 28.83 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.833 0.349 . . . . 0.0 111.401 -178.706 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . 0.448 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -64.82 -60.77 6.52 Favored Glycine 0 CA--C 1.52 0.346 0 CA-C-N 115.957 -0.565 . . . . 0.0 113.063 -179.581 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . 0.448 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 7.8 Cg_endo -50.11 -24.84 11.79 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.671 2.248 . . . . 0.0 112.507 -179.793 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.484 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 7.4 m-85 -115.77 4.52 14.0 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.468 -179.974 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.432 ' N ' ' O ' ' A' ' 141' ' ' SER . . . -69.81 45.21 0.07 Allowed 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -178.809 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . 0.412 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 11.8 p-10 -160.69 32.19 0.15 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.032 0.444 . . . . 0.0 110.53 178.929 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.412 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 64.6 m-85 -153.67 145.3 23.31 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.648 179.891 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 1.8 p -102.39 175.73 5.42 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.744 179.863 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . 0.405 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -138.47 141.32 11.89 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.685 -179.9 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 4.6 m -93.56 109.84 21.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.837 0.351 . . . . 0.0 110.747 -179.999 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 16.4 t -68.65 96.84 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.054 179.902 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -81.39 -30.83 33.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.799 179.988 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -154.33 157.29 38.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.817 179.942 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.6 pt -128.62 172.98 14.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.196 179.987 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 -147.59 87.62 5.91 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.847 179.994 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.97 -33.63 15.43 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.584 2.19 . . . . 0.0 112.258 -179.974 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -68.92 -42.75 76.37 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.95 179.878 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 23.4 mmt180 -89.38 -61.87 1.6 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.913 179.982 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 120.54 57.12 0.24 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.488 179.954 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -145.0 173.01 12.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.804 0.335 . . . . 0.0 110.803 -179.973 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.426 HG11 ' CE1' ' A' ' 178' ' ' PHE . 31.1 m -153.98 118.36 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.056 179.892 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -79.85 113.87 18.34 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.712 -179.95 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.405 ' HB ' ' HA3' ' A' ' 149' ' ' GLY . 32.1 m -126.1 141.22 46.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.32 -179.756 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 5.1 ptm -101.68 117.16 34.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.925 179.934 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 15.8 m -108.56 -179.62 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.008 179.902 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.66 116.9 10.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.943 -179.837 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 2.4 mp -120.94 128.39 76.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.93 179.832 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 61.3 34.46 18.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.966 179.887 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 65.7 51.44 46.99 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.598 179.947 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 2.5 ttt85 -160.06 128.09 4.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.837 0.351 . . . . 0.0 110.952 179.96 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -58.69 129.11 40.52 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.926 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.83 85.85 40.11 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.996 -179.932 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -68.67 109.42 2.08 Favored 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.488 2.125 . . . . 0.0 112.028 179.723 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.6 t -126.39 141.11 46.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.344 -179.741 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.93 118.67 21.9 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.181 179.434 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 1.2 mp -119.94 -170.39 1.95 Allowed 'General case' 0 CA--C 1.515 -0.376 0 CA-C-O 121.406 0.622 . . . . 0.0 111.63 -179.178 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -142.89 155.37 44.73 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 114.911 -1.04 . . . . 0.0 110.004 178.016 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . 0.426 ' CE1' HG11 ' A' ' 161' ' ' VAL . 15.6 m-85 -47.14 -30.22 2.73 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.457 -179.533 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 83.6 p -80.08 2.65 23.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.686 -179.89 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 3.7 mt-30 -122.38 3.21 9.72 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-O 120.642 0.258 . . . . 0.0 111.361 180.0 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 11.3 m -139.97 169.63 16.09 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 120.765 0.317 . . . . 0.0 111.384 179.913 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 18.5 m -148.51 146.69 17.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.05 179.942 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 75.2 tttt -57.68 122.53 13.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.093 179.993 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.373 -0.822 . . . . 0.0 110.987 -179.962 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 120.797 0.332 . . . . 0.0 111.02 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 60.99 101.26 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.792 179.87 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 10.5 m -79.93 91.39 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.196 179.922 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -61.61 -42.23 98.58 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.133 179.914 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -124.19 155.3 38.77 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.908 -179.966 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 6.2 ttt85 -155.34 148.93 25.2 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.844 179.988 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -61.54 138.59 58.29 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.885 -179.951 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 108.74 -22.75 25.44 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.68 -179.9 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -57.08 165.03 1.42 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.827 0.346 . . . . 0.0 110.951 -179.974 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -107.85 143.69 36.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.877 -179.935 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 25.4 m -139.92 143.09 30.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.165 179.994 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.47 165.63 13.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.052 0.453 . . . . 0.0 110.955 179.939 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.539 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 4.2 t -80.18 169.47 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.968 -179.921 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -80.02 -71.49 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 116.525 -0.307 . . . . 0.0 111.393 -179.945 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -160.5 -163.52 1.1 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.96 -179.699 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.91 -160.54 41.01 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.457 179.842 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -57.94 -20.85 46.65 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.507 2.138 . . . . 0.0 111.976 179.786 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.539 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 1.5 m-85 -110.77 41.6 1.76 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.666 179.859 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -90.15 31.52 0.99 Allowed 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -179.424 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -161.26 38.69 0.14 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.284 179.492 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -134.72 154.18 51.68 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.002 0.429 . . . . 0.0 111.183 -179.758 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 31.4 p -118.23 171.86 7.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.446 179.722 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -144.66 155.89 26.6 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.362 -0.923 . . . . 0.0 112.905 -179.785 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 14.0 m -103.31 105.45 15.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.782 0.325 . . . . 0.0 110.781 179.743 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 48.8 t -58.48 118.13 2.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.108 -179.925 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 35.1 p -102.21 -46.67 4.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.852 179.977 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -125.98 157.87 36.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.912 179.985 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.9 mp -139.99 139.13 37.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.123 179.879 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -121.62 85.12 43.5 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.91 179.996 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.99 -28.35 13.13 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.531 2.154 . . . . 0.0 112.383 -179.917 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -69.84 -32.56 71.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.94 -179.953 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.75 -59.57 1.75 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.949 179.942 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 123.06 66.86 0.22 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.532 -179.994 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 43.7 mttp -148.46 163.48 37.03 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.804 0.335 . . . . 0.0 110.878 179.978 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 15.6 m -151.04 138.53 13.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.112 179.896 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 16.4 tttp -118.12 126.23 51.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.868 -179.985 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 33.5 m -135.94 149.01 27.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.275 -179.96 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 164' ' ' MET . . . . . 0.4 ' O ' ' CG ' ' A' ' 164' ' ' MET . 10.5 ptt? -90.04 111.53 22.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.598 179.791 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 31.1 m -114.69 137.43 48.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.359 -179.851 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 5.5 t -92.22 136.94 32.78 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.575 179.774 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 18.5 tt -83.82 -29.26 7.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.069 -179.909 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -178.23 38.92 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.85 -179.976 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 124.13 -25.88 5.96 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.48 -179.973 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.14 122.68 45.82 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.865 0.364 . . . . 0.0 110.821 -179.967 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -63.1 121.01 12.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.99 179.933 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 53.9 m -117.57 100.4 52.59 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.824 -179.9 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -66.54 111.1 2.01 Favored 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 122.344 2.029 . . . . 0.0 112.215 -179.958 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 38.3 t -127.17 141.7 45.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.105 -179.773 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -86.63 138.11 31.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.626 179.736 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -148.15 -162.27 1.52 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.282 0.563 . . . . 0.0 111.298 -179.65 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -146.15 157.02 43.82 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 115.067 -0.97 . . . . 0.0 109.896 178.213 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 19.6 m-85 -47.0 -28.54 1.68 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.694 -179.503 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 40.7 t -75.76 -5.97 48.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.592 -179.902 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 3.1 mm-40 -114.97 -6.95 12.57 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.599 -0.273 . . . . 0.0 111.449 -179.907 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 30.2 m -142.7 158.66 18.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 120.829 0.347 . . . . 0.0 111.331 -179.98 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 22.6 m -117.79 146.57 22.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.076 -179.984 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.19 129.58 34.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.921 -179.962 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.175 -0.917 . . . . 0.0 111.194 -179.991 . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.309 0 CA-C-O 120.801 0.334 . . . . 8.8300000000000001 111.087 . . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 8.7 mt-30 61.62 116.95 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.194 -0.457 . . . . 8.3399999999999999 111.021 -179.929 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.5 t -79.96 78.61 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.272 -0.422 . . . . 5.4800000000000004 111.131 179.926 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -61.15 121.77 13.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.111 -0.495 . . . . 3.2799999999999998 111.171 179.99 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -97.17 139.98 32.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.188 -0.46 . . . . 2.46 110.888 179.972 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 19.3 mtp180 -132.87 135.23 45.48 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.219 -0.446 . . . . 5.3499999999999996 110.931 179.975 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -59.53 118.69 6.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.302 -0.408 . . . . 2.4900000000000002 110.818 179.926 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 128.57 -21.2 5.41 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.823 -0.703 . . . . 0.93000000000000005 112.627 -179.921 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -55.37 164.74 0.9 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.821 0.343 . . . . 1.6899999999999999 110.929 -179.995 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 64.7 mt-30 -117.26 114.82 24.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.457 . . . . 3.1099999999999999 111.06 -179.977 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 16.9 m -118.61 141.95 35.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 1.24 110.822 179.894 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -79.68 166.69 21.57 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.994 0.426 . . . . 3.2200000000000002 111.028 -179.773 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 139' ' ' VAL . . . . . 0.443 ' HB ' ' O ' ' A' ' 144' ' ' PHE . 8.7 t -79.52 167.39 2.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.935 -0.575 . . . . 1.28 110.995 -179.901 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 2.8 p -78.87 -61.46 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.296 0 N-CA-C 112.052 0.39 . . . . 2.2999999999999998 112.052 -179.289 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 141' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -160.83 -163.98 1.14 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.807 0.337 . . . . 3.21 111.29 -179.652 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.53 -169.35 54.75 Favored Glycine 0 C--N 1.331 0.284 0 C-N-CA 120.875 -0.679 . . . . 2.3599999999999999 112.357 179.958 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -59.14 -19.34 48.83 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.507 2.138 . . . . 1.8400000000000001 111.998 179.672 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.443 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 4.1 m-85 -95.98 18.37 13.5 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.16 -0.473 . . . . 2.5 111.065 179.939 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.05 40.4 0.62 Allowed 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 112.058 0.392 . . . . 1.6699999999999999 112.058 -179.453 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . 0.403 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 0.5 OUTLIER -161.4 35.6 0.14 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.98 0.419 . . . . 2.4199999999999999 110.692 179.493 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 147' ' ' PHE . . . . . 0.403 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 36.6 m-85 -146.82 169.76 18.44 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.929 -0.578 . . . . 2.4199999999999999 110.783 179.994 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 12.7 p -122.31 -178.43 3.88 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.264 -0.425 . . . . 1.55 110.874 179.943 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -145.49 134.74 5.62 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.648 -0.787 . . . . 0.62 112.549 -179.927 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.8 m -87.96 104.8 16.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.751 0.31 . . . . 1.3300000000000001 110.817 179.893 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 43.6 t -64.21 121.18 12.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.239 -0.437 . . . . 1.21 111.059 -179.967 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 14.9 p -107.37 -39.88 5.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.162 -0.472 . . . . 1.75 110.907 179.91 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -130.72 159.33 37.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.189 -0.459 . . . . 2.3199999999999998 110.855 179.922 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 26.9 mt -136.36 135.44 49.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.266 -0.425 . . . . 2.27 111.125 -179.968 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -115.83 86.31 15.98 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.108 -0.496 . . . . 2.1699999999999999 110.907 179.997 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.61 -30.43 18.35 Favored 'Trans proline' 0 C--N 1.345 0.343 0 C-N-CA 122.53 2.153 . . . . 2.0600000000000001 112.327 179.994 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -63.1 -42.67 99.63 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.191 -0.459 . . . . 3.6299999999999999 110.889 -179.996 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 3.6 mtt85 -96.09 -52.29 4.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.17 -0.468 . . . . 4.46 110.845 -179.954 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 116.71 39.2 0.85 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.768 -0.729 . . . . 1.3400000000000001 112.469 -179.948 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 15.0 mttt -120.65 168.98 10.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.818 0.342 . . . . 2.4900000000000002 110.959 179.97 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.415 HG13 ' CE1' ' A' ' 178' ' ' PHE . 19.4 m -150.72 125.47 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 1.9199999999999999 111.065 179.983 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 68.6 tttt -94.83 130.07 41.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.126 -0.488 . . . . 2.4700000000000002 110.922 -179.989 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.401 ' CG2' ' CD1' ' A' ' 176' ' ' LEU . 17.2 m -140.48 163.23 23.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.457 . . . . 1.5700000000000001 111.087 -179.97 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 3.2 ptt? -109.51 116.93 32.69 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 2.4199999999999999 110.954 179.914 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 6.9 m -96.45 163.95 2.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 1.6899999999999999 111.025 -179.997 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.13 106.25 9.13 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 2.0699999999999998 110.99 -179.964 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 5.2 mt -110.0 109.19 27.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.137 -0.483 . . . . 2.7599999999999998 110.97 179.94 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 62.38 47.28 5.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.194 -0.457 . . . . 5.0599999999999996 110.935 -179.958 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 61.01 50.8 63.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.727 -0.749 . . . . 1.6899999999999999 112.551 179.986 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 12.2 ttt180 -153.72 129.34 10.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.819 0.343 . . . . 5.6100000000000003 110.957 179.965 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 -71.15 145.62 49.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 2.5899999999999999 110.865 -179.924 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 4.1 m -159.96 92.44 1.72 Allowed Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.116 -0.493 . . . . 1.8700000000000001 110.828 179.951 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -67.42 119.62 6.64 Favored 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.451 2.101 . . . . 1.26 112.326 -179.952 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.5 t -132.21 139.11 50.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 2.2400000000000002 111.047 179.969 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -80.76 119.88 23.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.446 . . . . 2.46 110.869 -179.976 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 176' ' ' LEU . . . . . 0.401 ' CD1' ' CG2' ' A' ' 163' ' ' VAL . 0.2 OUTLIER -125.02 -162.46 1.1 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.368 0.604 . . . . 2.2599999999999998 110.916 -179.979 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -152.73 152.75 32.03 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 115.168 -0.923 . . . . 1.49 110.221 178.405 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 178' ' ' PHE . . . . . 0.415 ' CE1' HG13 ' A' ' 161' ' ' VAL . 17.1 m-85 -44.99 -29.53 0.85 Allowed 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.925 -0.58 . . . . 2.6400000000000001 111.56 -179.726 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 60.1 m -72.25 -33.21 67.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.327 -0.397 . . . . 2.1099999999999999 111.096 -179.826 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 38.1 mt-30 -97.2 18.2 15.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.354 -0.384 . . . . 2.7400000000000002 111.337 -179.895 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 32.4 m -151.79 164.51 2.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.843 0.354 . . . . 1.3400000000000001 111.113 179.891 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 23.1 m -139.83 149.96 22.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 1.4399999999999999 111.123 179.907 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 8.2 tttt -73.41 129.97 39.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 3.4199999999999999 110.867 179.973 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.111 0 CA-C-O 118.292 -0.861 . . . . 1.6899999999999999 111.046 179.978 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.87 0.366 . . . . 0.0 110.97 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -58.23 147.8 29.29 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.952 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 79.54 6.52 88.96 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.967 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 12.9 m-20 -86.87 174.53 8.7 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.821 0.343 . . . . 0.0 110.99 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 36.3 mt-30 -113.96 132.61 55.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.836 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.438 HG12 ' HA ' ' A' ' 183' ' ' LYS . 31.0 m -131.9 136.2 57.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.081 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -80.03 166.26 21.73 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.703 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.582 HG11 ' HB2' ' A' ' 144' ' ' PHE . 8.0 t -79.86 167.34 2.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.973 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.6 HG13 ' H ' ' A' ' 141' ' ' SER . 3.3 p -79.31 -60.3 2.36 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 112.138 0.421 . . . . 0.0 112.138 -179.201 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.657 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.1 OUTLIER -160.43 -164.18 1.21 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.822 0.344 . . . . 0.0 111.301 -179.542 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.37 -168.01 54.33 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.856 -0.687 . . . . 0.0 112.344 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.37 -19.02 56.44 Favored 'Trans proline' 0 C--N 1.343 0.277 0 C-N-CA 122.479 2.119 . . . . 0.0 111.95 179.593 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.582 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.9 m-85 -95.86 13.09 27.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.211 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.657 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -79.14 39.69 0.39 Allowed 'General case' 0 C--N 1.332 -0.179 0 N-CA-C 112.246 0.462 . . . . 0.0 112.246 -179.361 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 146' ' ' ASP . . . . . 0.409 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 1.0 OUTLIER -160.7 34.87 0.16 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.987 0.422 . . . . 0.0 110.675 179.336 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.494 ' O ' HG23 ' A' ' 139' ' ' VAL . 47.2 m-85 -148.0 167.13 25.7 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.91 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.669 ' O ' HG12 ' A' ' 165' ' ' VAL . 23.7 p -127.16 -173.98 3.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.672 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -150.43 164.81 29.86 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.657 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 5.6 m -103.99 108.47 19.83 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.779 0.323 . . . . 0.0 110.773 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.476 ' HA ' HG12 ' A' ' 163' ' ' VAL . 19.8 t -57.42 113.88 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.293 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 10.3 t -98.88 -33.92 10.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.778 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -153.48 158.48 41.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.894 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 154' ' ' ILE . . . . . 0.485 HG22 ' N ' ' A' ' 155' ' ' ASN . 2.7 mt -129.88 158.69 42.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.087 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.485 ' N ' HG22 ' A' ' 154' ' ' ILE . 0.8 OUTLIER -135.29 86.71 29.75 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.958 -179.997 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -71.69 -34.13 9.47 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.56 2.174 . . . . 0.0 112.385 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -58.98 -33.55 70.81 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.993 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.23 -61.23 1.69 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.94 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 127.04 42.73 0.27 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.489 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 160' ' ' LYS . . . . . 0.412 ' O ' HG13 ' A' ' 161' ' ' VAL . 11.8 mttt -115.59 170.34 8.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.772 0.32 . . . . 0.0 110.982 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.72 HG22 ' HA ' ' A' ' 177' ' ' ASP . 5.1 m -155.37 137.08 5.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.077 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 38.7 tttt -114.69 128.25 56.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.788 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.865 HG22 HD11 ' A' ' 176' ' ' LEU . 29.7 m -139.88 142.51 32.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.231 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 164' ' ' MET . . . . . 0.4 ' CG ' ' O ' ' A' ' 164' ' ' MET . 0.4 OUTLIER -89.93 104.02 16.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.592 179.883 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.669 HG12 ' O ' ' A' ' 148' ' ' THR . 15.5 m -91.76 171.11 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.25 -179.791 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -132.41 115.34 15.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.796 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.406 HD12 ' CE2' ' A' ' 147' ' ' PHE . 1.6 tp -120.23 133.82 65.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.162 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 1.2 t80 61.74 30.42 18.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.878 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 70.28 45.26 56.25 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.555 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 2.2 tpm_? -159.98 138.86 10.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.789 0.328 . . . . 0.0 110.908 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -60.8 151.94 28.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.778 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 66.1 m -160.02 91.17 1.77 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.989 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -68.37 117.45 4.97 Favored 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 122.475 2.117 . . . . 0.0 112.155 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 29.7 m -132.84 154.98 40.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.256 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -98.8 138.1 36.43 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.639 179.741 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.865 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -144.33 -162.2 1.43 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.263 0.554 . . . . 0.0 111.229 -179.796 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.72 ' HA ' HG22 ' A' ' 161' ' ' VAL . 7.3 m-20 -153.11 156.71 39.18 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.079 178.424 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -45.86 -29.38 1.35 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.674 -179.714 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 7.3 m -76.01 -3.45 35.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.829 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -131.77 15.08 4.85 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.602 0.239 . . . . 0.0 111.437 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.474 HG22 ' O ' ' A' ' 177' ' ' ASP . 15.7 m -142.0 170.03 12.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.865 0.364 . . . . 0.0 111.221 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 22.4 m -142.41 146.71 21.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.037 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.438 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -83.36 131.33 35.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.946 -179.953 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.189 -0.91 . . . . 0.0 111.12 -179.997 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 21.5 mtp180 . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.724 0.297 . . . . 0.0 110.897 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -63.93 142.37 58.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.916 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 91.91 -14.05 65.27 Favored Glycine 0 CA--C 1.519 0.292 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.773 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 32.2 m-20 -54.54 165.01 0.63 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.766 0.317 . . . . 0.0 111.024 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -117.6 115.38 24.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.077 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.614 HG12 ' HA ' ' A' ' 183' ' ' LYS . 19.4 m -122.95 149.06 26.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.919 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.8 tpp180 -79.86 168.03 19.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.069 0.461 . . . . 0.0 110.854 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.574 HG23 ' O ' ' A' ' 147' ' ' PHE . 3.8 t -80.21 167.95 2.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.028 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.666 HG13 ' H ' ' A' ' 141' ' ' SER . 1.5 p -79.66 -66.85 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.55 -179.759 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.666 ' H ' HG13 ' A' ' 140' ' ' VAL . 0.2 OUTLIER -160.44 -164.69 1.29 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.876 0.37 . . . . 0.0 111.097 -179.91 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.94 -162.47 42.79 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.911 -0.661 . . . . 0.0 112.462 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -63.07 -18.42 65.06 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.458 2.106 . . . . 0.0 112.115 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.507 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.0 m-85 -102.14 29.24 5.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.957 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.38 35.67 0.45 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.775 0.321 . . . . 0.0 111.853 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -160.96 35.63 0.15 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.506 179.354 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.574 ' O ' HG23 ' A' ' 139' ' ' VAL . 48.3 m-85 -135.15 175.7 9.34 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.888 -179.753 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.435 HG22 ' O ' ' A' ' 137' ' ' VAL . 0.3 OUTLIER -119.99 178.65 4.53 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.752 179.942 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -147.11 115.6 0.79 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.568 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.1 m -82.0 113.02 19.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.755 0.312 . . . . 0.0 110.782 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 26.4 t -68.19 123.54 21.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.175 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -105.22 -60.47 1.61 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.846 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.58 165.83 15.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.91 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 154' ' ' ILE . . . . . 0.669 ' N ' HD13 ' A' ' 154' ' ' ILE . 0.1 OUTLIER -130.78 157.67 43.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.052 179.961 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 12.5 m-20 -121.58 89.27 47.28 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.902 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.25 -34.45 6.08 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.54 2.16 . . . . 0.0 112.298 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.33 27.67 1.62 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.386 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 5.1 mtm180 -160.08 -50.1 0.05 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.856 0.36 . . . . 0.0 110.784 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 103.27 63.56 0.7 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.461 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.8 mttt -145.88 165.9 27.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.891 0.376 . . . . 0.0 111.028 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.535 HG11 ' CE1' ' A' ' 178' ' ' PHE . 3.7 m -150.04 120.99 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.903 179.797 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -86.75 131.68 34.06 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.096 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.613 HG21 HD12 ' A' ' 176' ' ' LEU . 27.2 m -131.17 158.1 43.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.062 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 3.3 ptt? -116.27 126.58 53.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.029 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 2.5 t -106.99 153.88 8.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.847 179.735 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 2.1 p -122.98 103.32 8.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.063 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.512 HG22 ' CZ ' ' A' ' 168' ' ' PHE . 39.4 mm -80.0 67.52 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.625 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 168' ' ' PHE . . . . . 0.512 ' CZ ' HG22 ' A' ' 167' ' ' ILE . 1.1 p90 43.52 79.43 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.405 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 83.15 34.49 20.68 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.673 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -160.13 109.21 1.75 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.786 0.327 . . . . 0.0 111.077 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 11.7 mt-10 -89.84 134.41 34.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.717 179.731 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -145.26 105.57 4.4 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.126 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.49 110.53 2.72 Favored 'Trans proline' 0 C--N 1.348 0.508 0 C-N-CA 122.46 2.107 . . . . 0.0 112.069 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 9.0 p -126.09 146.45 31.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.268 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -79.99 157.57 26.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.679 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.753 HD22 ' HB3' ' A' ' 180' ' ' GLN . 7.5 mt -159.99 -171.74 3.35 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-O 121.411 0.625 . . . . 0.0 111.408 -179.81 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.401 ' HA ' HG22 ' A' ' 161' ' ' VAL . 1.9 m-20 -146.55 153.61 40.57 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 115.021 -0.991 . . . . 0.0 110.205 178.074 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 178' ' ' PHE . . . . . 0.535 ' CE1' HG11 ' A' ' 161' ' ' VAL . 27.3 m-85 -46.06 -32.8 3.05 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.548 -179.573 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 6.2 m -81.74 11.47 4.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.709 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.753 ' HB3' HD22 ' A' ' 176' ' ' LEU . 7.4 mm-40 -125.46 3.19 7.68 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.596 0.236 . . . . 0.0 111.262 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.751 HG13 HD13 ' A' ' 176' ' ' LEU . 21.9 m -145.14 179.42 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 120.977 0.417 . . . . 0.0 111.113 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 15.7 m -150.64 148.14 15.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.145 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.614 ' HA ' HG12 ' A' ' 137' ' ' VAL . 7.1 tttt -63.89 131.94 49.27 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.94 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.146 0 CA-C-O 118.257 -0.878 . . . . 0.0 111.14 179.906 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 7.3 mtt-85 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.837 0.351 . . . . 0.0 110.887 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -63.24 152.92 36.26 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.693 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 65.71 11.75 54.73 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.982 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -89.57 165.42 14.27 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.799 0.3 . . . . 0.0 110.822 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -89.24 134.08 34.19 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.705 HG12 ' HA ' ' A' ' 183' ' ' LYS . 16.0 m -140.46 140.01 34.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.962 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.431 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.4 OUTLIER -80.79 164.83 22.43 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.999 0.428 . . . . 0.0 111.063 -179.912 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.625 HG11 ' HB2' ' A' ' 144' ' ' PHE . 5.2 t -81.9 167.3 2.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.042 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.608 HG13 ' H ' ' A' ' 141' ' ' SER . 2.3 p -79.47 -61.77 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.439 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.705 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 46.7 p -160.11 -165.14 1.41 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.87 0.367 . . . . 0.0 111.176 -179.47 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 80.15 -163.74 47.36 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.348 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -63.91 -14.76 45.12 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.394 2.062 . . . . 0.0 112.23 179.676 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.625 ' HB2' HG11 ' A' ' 139' ' ' VAL . 4.9 m-85 -102.52 14.64 31.44 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.253 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.705 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -77.48 36.87 0.2 Allowed 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 112.462 0.541 . . . . 0.0 112.462 -179.289 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 146' ' ' ASP . . . . . 0.408 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 2.2 t0 -161.05 34.41 0.14 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.932 0.396 . . . . 0.0 110.805 179.223 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.573 ' O ' HG23 ' A' ' 139' ' ' VAL . 40.2 m-85 -146.1 165.98 27.49 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.745 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.431 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 0.7 OUTLIER -116.79 -176.18 2.92 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.792 179.939 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 149' ' ' GLY . . . . . 0.413 ' HA3' HG12 ' A' ' 163' ' ' VAL . . . -153.26 -176.4 25.7 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.57 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 150' ' ' THR . . . . . 0.419 ' N ' HG13 ' A' ' 163' ' ' VAL . 40.9 m -125.3 113.14 17.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.808 0.337 . . . . 0.0 110.853 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 32.9 t -63.91 106.24 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.101 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 5.8 p -83.99 -45.07 13.51 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.916 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 2.4 tp10 -152.68 171.69 17.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.812 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 154' ' ' ILE . . . . . 0.825 HG22 HG12 ' A' ' 161' ' ' VAL . 17.5 pt -145.33 151.43 15.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.096 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 12.7 m-20 -117.68 86.76 24.5 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.915 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -62.04 -24.74 76.97 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.737 2.292 . . . . 0.0 112.326 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -90.21 29.12 1.28 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.407 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.07 -44.16 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.868 0.366 . . . . 0.0 111.015 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 104.55 39.5 2.38 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.291 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 4.5 mttt -127.87 161.4 29.13 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.921 0.391 . . . . 0.0 110.981 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.825 HG12 HG22 ' A' ' 154' ' ' ILE . 29.2 m -146.82 119.65 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.107 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 15.5 tttt -80.04 141.28 36.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.891 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.869 ' HB ' HD12 ' A' ' 176' ' ' LEU . 26.0 t -153.17 144.9 15.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.098 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -96.68 121.77 38.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.874 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.456 HG22 ' O ' ' A' ' 172' ' ' THR . 9.3 m -99.98 158.55 3.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.121 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 166' ' ' THR . . . . . 0.668 HG22 ' HA ' ' A' ' 171' ' ' GLU . 31.4 p -145.31 146.35 31.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.815 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.8 mp -131.17 94.82 2.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.165 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 57.3 m-85 60.06 37.74 20.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.949 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 91.74 27.85 15.81 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.493 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.26 89.0 3.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.794 0.331 . . . . 0.0 110.913 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 171' ' ' GLU . . . . . 0.668 ' HA ' HG22 ' A' ' 166' ' ' THR . 1.8 mt-10 -59.24 144.61 45.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 172' ' ' THR . . . . . 0.456 ' O ' HG22 ' A' ' 165' ' ' VAL . 0.2 OUTLIER -158.41 90.3 2.18 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.842 179.94 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_exo -60.49 125.78 18.27 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.573 2.182 . . . . 0.0 112.29 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 39.4 t -152.54 148.84 14.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.959 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -80.01 145.04 32.74 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.822 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.869 HD12 ' HB ' ' A' ' 163' ' ' VAL . 4.1 mt -125.63 -173.24 2.78 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.451 0.643 . . . . 0.0 111.324 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.813 ' O ' HG12 ' A' ' 181' ' ' VAL . 3.1 m-20 -152.91 153.76 33.67 Favored 'General case' 0 N--CA 1.446 -0.662 0 CA-C-N 115.023 -0.99 . . . . 0.0 109.99 178.147 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -42.79 -54.01 4.31 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.656 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 5.2 m -74.18 -9.61 58.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.418 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.55 ' HB3' HD23 ' A' ' 176' ' ' LEU . 0.0 OUTLIER -99.55 -14.03 19.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.504 -179.806 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.813 HG12 ' O ' ' A' ' 177' ' ' ASP . 1.3 p -132.59 160.32 42.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.033 0.444 . . . . 0.0 111.083 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 182' ' ' VAL . . . . . 0.478 ' N ' ' CG2' ' A' ' 181' ' ' VAL . 35.4 m -139.39 146.19 25.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.379 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.705 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -77.28 135.03 38.39 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.94 179.847 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.286 -0.864 . . . . 0.0 111.14 179.986 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.233 0.195 0 CA-C-O 120.747 0.308 . . . . 0.0 110.887 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -59.81 135.11 57.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.869 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 105.97 -27.69 16.58 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.485 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -63.36 178.4 0.54 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.748 0.309 . . . . 0.0 110.977 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -128.19 130.34 47.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.015 0.436 . . . . 0.0 111.116 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.647 HG12 ' HA ' ' A' ' 183' ' ' LYS . 25.9 m -130.16 142.91 42.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.705 179.775 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.42 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.1 OUTLIER -79.7 164.49 23.7 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.025 0.44 . . . . 0.0 111.048 -179.843 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.817 HG11 ' HB2' ' A' ' 144' ' ' PHE . 48.8 t -79.74 147.22 6.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.647 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.549 HG11 ' HA ' ' A' ' 180' ' ' GLN . 12.4 p -85.87 -22.22 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.422 -179.47 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.747 ' H ' HG12 ' A' ' 139' ' ' VAL . 1.4 t -79.14 153.47 30.06 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.893 0.378 . . . . 0.0 111.429 -178.817 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 142' ' ' GLY . . . . . 0.415 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -66.89 -62.2 4.68 Favored Glycine 0 N--CA 1.452 -0.26 0 CA-C-N 115.893 -0.594 . . . . 0.0 112.733 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.415 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.2 Cg_endo -53.57 -23.2 24.51 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.583 2.189 . . . . 0.0 112.158 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.817 ' HB2' HG11 ' A' ' 139' ' ' VAL . 12.9 m-85 -109.81 0.61 18.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.387 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.658 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -69.63 50.71 0.1 Allowed 'General case' 0 N--CA 1.462 0.163 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -179.05 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -160.61 31.37 0.16 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.094 0.473 . . . . 0.0 110.527 179.029 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.696 ' O ' HG23 ' A' ' 139' ' ' VAL . 19.0 m-85 -155.4 146.41 22.5 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.389 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 9.0 p -104.56 169.05 8.69 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.952 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -129.01 133.41 7.57 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.59 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.8 m -86.55 110.47 19.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.823 0.344 . . . . 0.0 110.755 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.607 HG22 HG12 ' A' ' 163' ' ' VAL . 30.6 t -67.96 117.44 9.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.963 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.3 t -101.94 -30.37 11.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.899 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -147.21 165.78 29.02 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.83 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 154' ' ' ILE . . . . . 0.638 HD12 ' HD3' ' A' ' 156' ' ' PRO . 2.0 pp -152.41 141.42 14.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.152 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -120.94 92.87 48.66 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.871 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 156' ' ' PRO . . . . . 0.638 ' HD3' HD12 ' A' ' 154' ' ' ILE . 54.4 Cg_endo -69.54 -22.63 32.83 Favored 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.555 2.17 . . . . 0.0 112.425 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -90.21 26.36 1.92 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.372 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 1.4 mtp85 -159.96 -45.25 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.827 0.346 . . . . 0.0 110.825 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 102.45 55.19 0.86 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.425 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.3 mttt -137.66 147.56 45.01 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.801 0.334 . . . . 0.0 111.152 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.707 HG22 ' HA ' ' A' ' 177' ' ' ASP . 31.1 m -139.05 116.48 11.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.973 179.799 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 70.1 tttt -89.69 118.56 29.4 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.89 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.607 HG12 HG22 ' A' ' 151' ' ' VAL . 28.0 m -130.37 149.42 33.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.137 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 164' ' ' MET . . . . . 0.425 ' O ' ' CG ' ' A' ' 164' ' ' MET . 3.7 ptt? -101.84 108.54 20.06 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.996 0.427 . . . . 0.0 110.81 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 27.1 m -98.31 143.08 13.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.126 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -91.9 90.55 7.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.938 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.794 HG22 ' OG1' ' A' ' 172' ' ' THR . 11.2 tt -89.55 129.67 40.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.82 179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 168' ' ' PHE . . . . . 0.418 ' CD2' HG12 ' A' ' 167' ' ' ILE . 31.2 m-85 65.86 -72.49 0.08 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.915 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -169.61 36.0 0.19 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.635 -0.793 . . . . 0.0 112.657 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 8.9 ptp180 -160.03 164.19 33.39 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.793 0.33 . . . . 0.0 111.063 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -66.89 158.37 30.81 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.906 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 172' ' ' THR . . . . . 0.794 ' OG1' HG22 ' A' ' 167' ' ' ILE . 0.3 OUTLIER -159.99 81.3 2.38 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.954 -179.985 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -68.57 102.65 0.87 Allowed 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.682 2.255 . . . . 0.0 112.229 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.823 ' CG2' HD21 ' A' ' 176' ' ' LEU . 21.4 m -114.46 136.04 52.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.137 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -80.16 108.89 14.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.669 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.823 HD21 ' CG2' ' A' ' 174' ' ' VAL . 0.3 OUTLIER -124.27 -158.96 0.84 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.322 0.582 . . . . 0.0 111.159 -179.605 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.707 ' HA ' HG22 ' A' ' 161' ' ' VAL . 4.7 m-20 -146.36 155.64 42.75 Favored 'General case' 0 N--CA 1.441 -0.875 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.167 178.161 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 178' ' ' PHE . . . . . 0.531 ' CE1' HG11 ' A' ' 161' ' ' VAL . 14.9 m-85 -42.97 -30.89 0.45 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.617 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.5 m -66.35 -30.14 70.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.313 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.549 ' HA ' HG11 ' A' ' 140' ' ' VAL . 33.5 mm-40 -102.39 21.59 14.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.55 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.422 HG13 ' O ' ' A' ' 180' ' ' GLN . 21.7 m -157.03 140.63 7.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.93 0.395 . . . . 0.0 111.13 179.698 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.1 m -117.03 146.27 21.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.146 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.647 ' HA ' HG12 ' A' ' 137' ' ' VAL . 3.4 tttm -83.3 128.2 34.3 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.869 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.247 -0.883 . . . . 0.0 111.113 179.97 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 48.4 mtt-85 . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.846 0.355 . . . . 0.0 110.854 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -57.51 155.42 9.54 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.742 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.42 ' HA2' HG22 ' A' ' 150' ' ' THR . . . 77.1 0.52 70.58 Favored Glycine 0 CA--C 1.519 0.343 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.78 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -66.0 153.49 42.03 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.838 0.352 . . . . 0.0 110.938 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 16.6 mt-30 -95.49 123.5 39.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.912 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.671 HG12 ' HA ' ' A' ' 183' ' ' LYS . 18.7 m -139.66 139.33 38.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.055 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.46 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -80.29 165.91 21.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.946 0.403 . . . . 0.0 110.808 179.837 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 147' ' ' PHE . 6.8 t -79.7 167.67 2.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.999 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.644 HG13 ' H ' ' A' ' 141' ' ' SER . 2.5 p -79.39 -63.18 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 N-CA-C 112.199 0.444 . . . . 0.0 112.199 -179.196 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.677 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.9 OUTLIER -160.28 -174.46 4.52 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.918 0.39 . . . . 0.0 111.321 -179.579 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 87.12 -167.19 37.55 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.397 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -59.53 -19.28 51.41 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.345 2.03 . . . . 0.0 111.965 179.541 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.539 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.3 m-85 -98.49 13.97 29.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.677 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -80.42 39.22 0.45 Allowed 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.275 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 146' ' ' ASP . . . . . 0.45 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 0.2 OUTLIER -160.78 31.57 0.15 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.901 0.381 . . . . 0.0 110.893 179.32 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.719 ' O ' HG23 ' A' ' 139' ' ' VAL . 22.4 m-85 -143.96 155.58 44.1 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.865 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.46 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 0.8 OUTLIER -110.7 159.56 17.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.224 179.423 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 149' ' ' GLY . . . . . 0.621 ' HA3' HG12 ' A' ' 163' ' ' VAL . . . -128.21 179.15 16.71 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.287 -0.958 . . . . 0.0 113.145 -179.504 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 150' ' ' THR . . . . . 0.42 HG22 ' HA2' ' A' ' 134' ' ' GLY . 2.4 m -121.63 116.88 25.41 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.768 0.318 . . . . 0.0 110.729 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 37.2 t -67.49 145.53 13.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.984 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 20.4 p -137.55 -55.54 0.69 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.976 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 153' ' ' GLU . . . . . 0.529 ' O ' HG23 ' A' ' 154' ' ' ILE . 0.5 OUTLIER -115.91 159.68 21.24 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.912 -179.869 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 154' ' ' ILE . . . . . 0.563 HG22 HG12 ' A' ' 161' ' ' VAL . 1.9 pt -158.7 149.02 8.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.092 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 12.0 t30 -147.26 85.32 6.88 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.946 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.52 -22.34 27.54 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.523 2.149 . . . . 0.0 112.408 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -55.0 -69.48 0.13 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.124 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.87 -33.71 39.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.984 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 101.56 55.42 0.9 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.596 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 2.7 mtmp? -131.34 149.28 52.62 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.922 0.392 . . . . 0.0 110.807 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.906 HG22 ' HA ' ' A' ' 177' ' ' ASP . 27.9 m -142.58 136.76 27.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.128 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 17.8 tttp -100.31 141.33 33.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.94 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.624 HG23 HD13 ' A' ' 176' ' ' LEU . 12.0 t -152.08 137.06 10.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.986 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 164' ' ' MET . . . . . 0.423 ' CG ' ' O ' ' A' ' 164' ' ' MET . 0.1 OUTLIER -97.49 106.48 18.81 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.982 0.42 . . . . 0.0 111.022 -179.9 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.448 HG12 ' N ' ' A' ' 166' ' ' THR . 5.5 t -103.4 159.88 4.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.176 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 166' ' ' THR . . . . . 0.448 ' N ' HG12 ' A' ' 165' ' ' VAL . 15.8 p -95.14 145.52 24.95 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.85 179.902 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.816 ' O ' HD13 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -114.6 -36.86 2.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.061 179.982 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -166.37 76.86 0.21 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 64.03 26.82 70.57 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.52 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.01 136.68 9.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.793 0.33 . . . . 0.0 110.879 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 7.2 pm0 -59.18 166.91 1.95 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.9 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 9.1 m -159.74 84.21 2.22 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.022 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.12 119.74 7.18 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.48 2.12 . . . . 0.0 112.138 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 15.6 m -142.13 151.2 18.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.255 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -83.63 142.51 30.75 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.575 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.624 HD13 HG23 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -152.56 -161.21 1.25 Allowed 'General case' 0 CA--C 1.518 -0.257 0 CA-C-O 121.301 0.572 . . . . 0.0 111.303 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.906 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.7 OUTLIER -151.17 154.04 36.13 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.208 178.453 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 178' ' ' PHE . . . . . 0.458 ' CE2' HG11 ' A' ' 161' ' ' VAL . 12.3 m-85 -48.17 -27.73 2.56 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.522 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 7.5 t -78.17 -1.94 35.17 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.679 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -124.27 13.0 8.89 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.659 0.266 . . . . 0.0 111.391 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 15.6 m -144.31 160.97 15.16 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.807 0.337 . . . . 0.0 111.15 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 28.6 m -141.6 148.22 21.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.054 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.671 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.1 OUTLIER -59.84 134.85 57.42 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.9 -179.938 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.215 -0.898 . . . . 0.0 111.169 179.963 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.839 0.352 . . . . 0.0 110.966 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -62.44 129.79 42.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.879 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 121.51 -22.62 7.77 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.604 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -56.8 163.82 1.76 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.841 0.353 . . . . 0.0 111.046 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -104.54 135.43 45.97 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.91 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.795 HG12 ' HA ' ' A' ' 183' ' ' LYS . 11.9 m -138.1 130.0 38.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.064 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.416 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.98 165.37 22.66 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.898 -179.927 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.694 HG23 ' O ' ' A' ' 147' ' ' PHE . 3.7 t -79.83 168.83 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.913 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.636 HG23 ' H ' ' A' ' 141' ' ' SER . 1.0 OUTLIER -79.52 -66.01 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.876 -179.55 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.684 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 52.1 p -160.22 -165.42 1.46 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.941 0.4 . . . . 0.0 110.954 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.73 -159.07 37.76 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.451 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.71 -12.31 35.06 Favored 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.578 2.186 . . . . 0.0 112.385 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.545 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.2 m-85 -108.57 20.91 17.98 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.164 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.684 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -80.53 38.44 0.43 Allowed 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -179.401 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -161.03 36.98 0.15 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.791 0.329 . . . . 0.0 110.915 179.309 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.694 ' O ' HG23 ' A' ' 139' ' ' VAL . 48.4 m-85 -147.91 161.06 42.07 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.951 -179.828 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.416 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 1.9 p -120.42 -176.79 3.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.66 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -149.39 151.44 23.56 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.602 -0.809 . . . . 0.0 112.724 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.1 m -96.56 99.18 10.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.788 0.328 . . . . 0.0 110.74 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.753 ' HA ' HG12 ' A' ' 163' ' ' VAL . 48.7 t -56.98 105.95 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.303 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 30.4 p -83.85 -38.96 20.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.535 179.683 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -143.81 160.31 40.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.701 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.8 mp -132.52 139.67 49.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.162 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -131.38 84.74 55.41 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.789 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -68.19 -27.68 34.93 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.511 2.14 . . . . 0.0 112.363 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -59.69 -58.4 8.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.882 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -87.54 -30.06 20.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.949 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 94.96 37.32 5.23 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.493 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 8.7 mtmt -114.08 154.06 28.39 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.8 0.333 . . . . 0.0 110.968 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.405 HG22 ' HA ' ' A' ' 177' ' ' ASP . 17.8 m -147.23 141.35 19.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.08 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 18.2 ttpt -115.47 122.85 47.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.943 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 1.038 HG22 HD11 ' A' ' 176' ' ' LEU . 33.4 m -136.63 146.49 28.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.285 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -93.32 106.32 18.29 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.486 179.692 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.523 HG22 ' O ' ' A' ' 172' ' ' THR . 30.4 m -88.18 171.75 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.372 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 82.6 p -148.26 103.85 3.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.673 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 2.9 mp -79.94 85.56 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.222 -179.849 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 59.1 31.5 21.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.958 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 105.6 35.39 3.07 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.56 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 9.3 mtt-85 -135.38 91.84 2.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.795 0.331 . . . . 0.0 110.882 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -58.64 136.72 57.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.91 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 172' ' ' THR . . . . . 0.523 ' O ' HG22 ' A' ' 165' ' ' VAL . 19.7 m -159.53 104.48 1.49 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.994 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -69.43 105.79 1.49 Allowed 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.342 2.028 . . . . 0.0 112.105 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 22.0 t -122.5 135.32 62.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.247 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -87.41 139.55 30.43 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.653 179.666 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 1.038 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -144.52 -162.5 1.5 Allowed 'General case' 0 CA--C 1.516 -0.333 0 CA-C-O 121.415 0.626 . . . . 0.0 111.263 -179.665 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.405 ' HA ' HG22 ' A' ' 161' ' ' VAL . 10.0 m-20 -142.41 158.05 44.11 Favored 'General case' 0 N--CA 1.441 -0.896 0 CA-C-N 115.001 -1.0 . . . . 0.0 109.888 178.19 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -46.89 -33.47 4.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.424 -179.535 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -73.13 -8.75 57.14 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.534 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.58 ' C ' HG13 ' A' ' 140' ' ' VAL . 16.5 mm-40 -110.8 -12.97 14.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.712 0.292 . . . . 0.0 111.559 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.474 ' CG1' HD22 ' A' ' 176' ' ' LEU . 8.2 m -128.5 174.34 12.05 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.134 0 CA-C-O 120.865 0.364 . . . . 0.0 111.317 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.02 146.97 20.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.025 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.795 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -80.19 123.9 28.32 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.94 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.261 -0.876 . . . . 0.0 111.085 179.993 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 30.8 mtp180 . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.723 0.297 . . . . 0.0 110.972 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.72 131.49 50.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.918 179.869 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.38 -23.39 20.57 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.69 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -57.91 -176.08 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.869 0.366 . . . . 0.0 110.974 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -121.73 139.98 52.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.956 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.894 HG12 ' HA ' ' A' ' 183' ' ' LYS . 17.1 m -139.98 142.75 31.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.011 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.453 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -80.01 165.18 22.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.038 0.447 . . . . 0.0 110.837 -179.954 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.709 HG23 ' O ' ' A' ' 147' ' ' PHE . 4.6 t -79.86 168.03 2.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.92 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.654 HG13 ' H ' ' A' ' 141' ' ' SER . 3.2 p -79.37 -62.13 1.5 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.26 0 N-CA-C 112.011 0.375 . . . . 0.0 112.011 -179.263 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.658 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.7 OUTLIER -160.5 -163.5 1.1 Allowed 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.876 0.369 . . . . 0.0 111.124 -179.515 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 78.17 -165.39 51.95 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.465 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_endo -62.17 -17.11 54.9 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.506 2.137 . . . . 0.0 112.022 179.66 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.553 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.9 m-85 -100.26 16.38 24.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.207 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.658 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -79.53 37.68 0.35 Allowed 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -179.366 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 146' ' ' ASP . . . . . 0.438 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 11.2 p30 -160.91 32.05 0.15 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.971 0.415 . . . . 0.0 110.818 179.277 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.709 ' O ' HG23 ' A' ' 139' ' ' VAL . 24.8 m-85 -140.91 159.62 41.81 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.747 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 1.6 p -108.72 171.07 7.64 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.568 179.689 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -137.43 139.38 10.45 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.518 -0.849 . . . . 0.0 112.768 -179.787 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.9 m -91.2 105.66 17.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.751 0.31 . . . . 0.0 110.605 179.72 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.451 ' HA ' HG12 ' A' ' 163' ' ' VAL . 24.3 t -64.53 108.7 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.172 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 2.0 t -96.24 -30.54 13.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.955 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -140.63 164.98 28.71 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.979 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 9.5 tt -152.48 127.84 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.026 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 59.0 m-20 -103.22 93.87 5.09 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.951 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.67 -27.95 26.27 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.481 2.121 . . . . 0.0 112.293 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -90.35 26.8 1.83 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.394 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -159.86 -45.17 0.05 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.894 0.378 . . . . 0.0 110.901 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 101.56 36.55 3.75 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.486 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 19.4 mmmt -111.46 152.03 27.88 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.886 0.374 . . . . 0.0 110.849 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.758 HG22 ' HA ' ' A' ' 177' ' ' ASP . 12.3 m -140.27 125.99 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.032 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 22.4 tttt -103.88 119.66 39.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.844 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.736 HG22 ' CD1' ' A' ' 176' ' ' LEU . 33.7 m -132.15 152.65 37.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.116 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 11.9 ptp -100.55 121.07 40.98 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.045 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.423 HG12 ' N ' ' A' ' 166' ' ' THR . 7.1 t -101.93 158.29 4.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.016 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 166' ' ' THR . . . . . 0.423 ' N ' HG12 ' A' ' 165' ' ' VAL . 7.3 m -115.12 110.16 19.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.961 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.751 HD13 ' HB2' ' A' ' 168' ' ' PHE . 0.0 OUTLIER -120.0 114.28 43.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.779 179.869 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 168' ' ' PHE . . . . . 0.751 ' HB2' HD13 ' A' ' 167' ' ' ILE . 0.1 OUTLIER 63.54 31.85 14.52 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.764 -179.617 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 72.4 36.4 59.36 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.478 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -142.96 109.03 5.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.799 0.333 . . . . 0.0 110.885 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -59.47 128.2 35.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.855 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 15.8 m -132.13 92.01 30.4 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.015 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -60.99 115.58 2.79 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.593 2.195 . . . . 0.0 112.046 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 11.3 p -121.74 147.56 25.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.295 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.3 pm0 -94.55 121.93 36.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.799 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.736 ' CD1' HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -137.54 -159.18 0.93 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.306 0.574 . . . . 0.0 111.113 -179.773 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.758 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.6 OUTLIER -143.25 155.2 44.44 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.101 178.182 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 178' ' ' PHE . . . . . 0.478 ' CE2' HG11 ' A' ' 161' ' ' VAL . 8.2 m-85 -46.68 -29.09 1.71 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.578 -179.627 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 6.4 p -70.67 -11.82 61.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.564 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -115.75 16.91 16.31 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.61 -0.268 . . . . 0.0 111.448 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 10.9 m -153.25 154.07 8.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-O 120.718 0.294 . . . . 0.0 111.234 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 28.9 m -127.21 146.41 33.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.177 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.894 ' HA ' HG12 ' A' ' 137' ' ' VAL . 17.7 tptm -71.31 139.54 49.95 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.205 -0.903 . . . . 0.0 111.121 -179.978 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 7.9 ttt85 . . . . . 0 C--O 1.233 0.192 0 CA-C-O 120.991 0.424 . . . . 0.0 110.912 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -56.01 155.84 5.96 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.776 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.99 9.36 59.75 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.869 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -80.78 162.18 24.18 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.775 0.321 . . . . 0.0 110.859 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 14.2 mt-30 -118.31 120.15 36.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.902 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.618 HG12 ' HA ' ' A' ' 183' ' ' LYS . 30.0 m -127.12 140.64 48.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.987 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.411 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.77 160.86 26.03 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.083 0.468 . . . . 0.0 110.883 -179.853 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.859 HG11 ' HB2' ' A' ' 144' ' ' PHE . 43.4 t -79.92 150.56 4.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.644 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.528 HG22 ' O ' ' A' ' 180' ' ' GLN . 35.5 m -91.97 -20.37 6.67 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 -179.418 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.733 ' H ' HG12 ' A' ' 139' ' ' VAL . 0.4 OUTLIER -79.15 153.25 30.22 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.893 0.377 . . . . 0.0 111.187 -178.937 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 142' ' ' GLY . . . . . 0.409 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -64.43 -63.2 4.46 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.946 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.409 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.2 Cg_endo -52.65 -22.86 18.22 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.666 2.244 . . . . 0.0 112.341 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.859 ' HB2' HG11 ' A' ' 139' ' ' VAL . 15.2 m-85 -112.8 2.48 15.99 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.505 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.674 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -69.82 46.93 0.08 Allowed 'General case' 0 CA--C 1.53 0.204 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -178.927 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 146' ' ' ASP . . . . . 0.406 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 11.4 p30 -160.71 32.19 0.15 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.023 0.44 . . . . 0.0 110.615 179.101 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.666 ' O ' HG23 ' A' ' 139' ' ' VAL . 69.0 m-85 -154.63 145.08 22.15 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.604 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.51 ' O ' HG12 ' A' ' 165' ' ' VAL . 68.7 p -102.03 172.81 6.7 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.709 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -128.14 132.67 7.45 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.47 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.8 m -95.93 104.45 16.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.745 0.307 . . . . 0.0 110.696 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.473 HG13 HG23 ' A' ' 161' ' ' VAL . 26.4 t -59.85 114.32 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.32 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -107.04 -40.13 5.54 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.64 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -135.2 153.48 51.93 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.685 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 2.0 mp -129.62 152.31 37.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.239 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 -130.16 79.09 73.48 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.762 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -69.07 -26.55 30.74 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.496 2.131 . . . . 0.0 112.427 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -61.93 -34.52 76.24 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.863 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 8.3 mtt180 -108.27 -43.69 4.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.921 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 112.82 48.45 0.62 Allowed Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.505 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -137.37 177.24 8.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.835 0.35 . . . . 0.0 110.996 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.473 HG23 HG13 ' A' ' 151' ' ' VAL . 1.3 p -152.06 159.73 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.125 0.488 . . . . 0.0 110.898 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 162' ' ' LYS . . . . . 0.472 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 7.1 tttm -119.43 124.35 46.31 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.867 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.419 HG12 ' HA ' ' A' ' 151' ' ' VAL . 29.7 m -136.4 146.33 29.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.252 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 8.5 ptm -92.71 130.38 38.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.878 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.51 HG12 ' O ' ' A' ' 148' ' ' THR . 27.7 m -131.5 144.49 37.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.184 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 166' ' ' THR . . . . . 0.533 HG23 ' C ' ' A' ' 170' ' ' ARG . 0.6 OUTLIER -108.28 139.46 42.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.922 -179.952 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.8 mp -136.29 -66.83 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.182 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 16.3 m-85 -91.46 55.57 2.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.926 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 58.02 27.56 59.89 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.546 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 170' ' ' ARG . . . . . 0.533 ' C ' HG23 ' A' ' 166' ' ' THR . 0.5 OUTLIER -153.88 151.39 29.43 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.864 0.364 . . . . 0.0 110.938 -179.913 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -69.38 161.05 30.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.811 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 172' ' ' THR . . . . . 0.553 HG22 ' CG2' ' A' ' 174' ' ' VAL . 16.4 m -153.52 96.49 2.81 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.876 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -66.77 83.37 0.31 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.389 2.059 . . . . 0.0 112.139 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.553 ' CG2' HG22 ' A' ' 172' ' ' THR . 26.8 t -104.93 135.66 41.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.981 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -79.97 145.04 32.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.59 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.905 HD13 HG13 ' A' ' 181' ' ' VAL . 5.7 mt -146.17 -169.31 3.22 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 121.336 0.588 . . . . 0.0 111.41 -179.55 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -140.27 153.53 46.53 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 115.092 -0.958 . . . . 0.0 110.285 178.175 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 10.0 m-85 -50.18 -31.94 15.01 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.269 -179.589 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.9 p -79.76 -1.21 37.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.385 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.72 ' HB3' HD22 ' A' ' 176' ' ' LEU . 1.3 mm-40 -116.0 3.01 13.57 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.714 0.292 . . . . 0.0 111.491 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.905 HG13 HD13 ' A' ' 176' ' ' LEU . 5.2 m -140.56 167.02 18.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-O 120.923 0.392 . . . . 0.0 111.074 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.4 m -135.07 146.36 30.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.124 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.618 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -59.99 139.15 57.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.886 -179.998 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.253 -0.88 . . . . 0.0 111.066 179.994 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 8.6 tpt180 . . . . . 0 C--O 1.23 0.068 0 CA-C-O 120.888 0.375 . . . . 0.0 110.86 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -66.07 132.24 48.08 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.795 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 106.45 -14.41 42.92 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.781 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -54.84 164.72 0.74 Allowed 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.912 0.387 . . . . 0.0 110.912 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' GLN . . . . . 0.456 ' O ' ' HB3' ' A' ' 184' ' ' ALA . 0.3 OUTLIER -112.15 115.87 29.56 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.07 -179.869 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 31.5 m -116.6 139.27 44.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.852 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.417 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.4 OUTLIER -79.97 155.02 27.86 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.025 0.441 . . . . 0.0 110.975 -179.924 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.588 HG12 ' N ' ' A' ' 140' ' ' VAL . 36.4 t -95.26 167.4 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.729 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.877 HG22 ' O ' ' A' ' 180' ' ' GLN . 14.1 m -133.9 -21.01 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.25 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -178.723 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.44 ' O ' ' CD2' ' A' ' 144' ' ' PHE . 2.7 m -79.49 149.65 31.45 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.112 0.482 . . . . 0.0 112.18 -178.249 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 39.64 -148.46 0.15 Allowed Glycine 0 C--N 1.334 0.424 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.678 179.46 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -73.62 4.43 4.03 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.774 2.316 . . . . 0.0 112.557 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.551 ' HB2' HG11 ' A' ' 139' ' ' VAL . 0.5 OUTLIER -79.55 -8.99 59.54 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.072 179.959 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.44 ' HA ' ' O ' ' A' ' 139' ' ' VAL . . . -67.82 39.49 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -178.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 146' ' ' ASP . . . . . 0.453 ' H ' ' C ' ' A' ' 144' ' ' PHE . 0.3 OUTLIER -160.89 31.23 0.15 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.103 0.478 . . . . 0.0 110.56 179.102 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.431 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 44.9 m-85 -148.88 154.51 39.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.772 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.417 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 67.6 p -108.69 134.88 50.82 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.872 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -94.2 160.75 24.02 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.579 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.0 m -102.34 103.74 14.2 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.772 0.32 . . . . 0.0 110.751 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.704 ' HA ' HG12 ' A' ' 163' ' ' VAL . 33.9 t -62.27 107.59 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.967 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -88.89 -49.34 6.86 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.843 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -135.48 171.06 14.99 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.698 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 154' ' ' ILE . . . . . 0.596 HD12 ' HD3' ' A' ' 156' ' ' PRO . 1.0 OUTLIER -137.64 158.82 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.168 -179.907 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -140.95 83.47 14.07 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.819 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 156' ' ' PRO . . . . . 0.596 ' HD3' HD12 ' A' ' 154' ' ' ILE . 56.5 Cg_endo -70.58 -27.04 23.04 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.515 2.143 . . . . 0.0 112.351 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -59.13 -42.4 90.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.885 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 4.6 mpt_? -103.8 -60.16 1.61 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.884 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 130.21 49.55 0.12 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.494 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 13.0 mttm -130.62 161.34 31.8 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.826 0.346 . . . . 0.0 110.928 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 17.3 m -147.33 124.48 3.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.193 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 9.3 tttt -87.38 123.92 32.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.888 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.704 HG12 ' HA ' ' A' ' 151' ' ' VAL . 15.4 m -142.34 135.92 28.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.033 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 164' ' ' MET . . . . . 0.404 ' HE3' ' C ' ' A' ' 164' ' ' MET . 0.0 OUTLIER -80.49 130.44 35.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.728 -179.992 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.632 HG22 HG12 ' A' ' 174' ' ' VAL . 15.4 m -110.22 131.18 61.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.234 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -97.62 100.31 11.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.809 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.586 HG23 ' O ' ' A' ' 167' ' ' ILE . 8.0 tt -95.59 111.07 25.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.105 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER 60.61 43.58 12.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.907 -179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 65.55 52.18 41.56 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.465 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -154.16 119.22 5.03 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.911 0.386 . . . . 0.0 110.833 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -58.94 134.11 56.66 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.932 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -147.75 96.73 4.05 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.867 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.69 118.06 5.16 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.452 2.102 . . . . 0.0 112.184 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.632 HG12 HG22 ' A' ' 165' ' ' VAL . 9.9 p -145.93 144.12 21.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.092 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -79.99 134.35 36.24 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.724 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.814 HD12 ' HB3' ' A' ' 180' ' ' GLN . 2.1 mm? -121.68 -172.0 2.34 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-O 121.375 0.607 . . . . 0.0 111.341 -179.715 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.577 ' O ' HG22 ' A' ' 181' ' ' VAL . 2.5 m-20 -150.28 151.95 33.76 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.466 178.366 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 3.7 m-85 -45.12 -46.5 11.83 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.623 -179.759 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.12 -20.88 63.15 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.143 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.877 ' O ' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -92.93 -10.02 38.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.511 -179.786 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 177' ' ' ASP . 27.7 m -138.98 -176.63 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.803 0.335 . . . . 0.0 111.399 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 182' ' ' VAL . . . . . 0.4 HG23 ' HB2' ' A' ' 138' ' ' ARG . 14.4 m -150.32 157.37 6.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.032 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 10.9 tptt -71.69 138.07 48.3 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.888 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 184' ' ' ALA . . . . . 0.456 ' HB3' ' O ' ' A' ' 136' ' ' GLN . . . . . . . . 0 C--O 1.249 1.038 0 CA-C-O 118.199 -0.905 . . . . 0.0 111.195 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 1.8 tpt180 . . . . . 0 C--O 1.23 0.077 0 CA-C-O 120.853 0.358 . . . . 0.0 110.922 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -60.46 118.56 6.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.896 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.99 19.75 14.24 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.597 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -76.4 158.49 31.34 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.784 0.326 . . . . 0.0 110.847 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 -109.81 126.74 54.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.108 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.879 HG12 ' HA ' ' A' ' 183' ' ' LYS . 12.7 m -141.02 141.03 31.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.863 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.431 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 1.7 ttp180 -79.64 161.72 25.7 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.066 0.46 . . . . 0.0 110.833 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.855 HG11 ' HB2' ' A' ' 144' ' ' PHE . 27.6 t -79.98 151.37 4.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.607 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.552 HG13 ' O ' ' A' ' 180' ' ' GLN . 33.5 m -93.99 -19.44 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 -179.338 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.72 ' H ' HG12 ' A' ' 139' ' ' VAL . 4.2 m -79.14 153.4 30.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.767 0.318 . . . . 0.0 111.026 -179.079 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . -64.31 -63.87 4.02 Favored Glycine 0 CA--C 1.519 0.31 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.964 -179.497 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -53.36 -22.76 21.73 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.753 2.302 . . . . 0.0 112.474 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.855 ' HB2' HG11 ' A' ' 139' ' ' VAL . 6.4 m-85 -111.12 1.05 17.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.516 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.691 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -69.65 47.63 0.08 Allowed 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 112.61 0.596 . . . . 0.0 112.61 -178.848 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 146' ' ' ASP . . . . . 0.404 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 17.4 p-10 -160.79 32.34 0.15 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.157 0.503 . . . . 0.0 110.696 179.015 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.757 ' O ' HG23 ' A' ' 139' ' ' VAL . 35.0 m-85 -154.56 145.53 22.64 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.507 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.431 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 75.5 p -99.86 175.91 5.62 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.849 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -136.86 151.59 21.01 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.652 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.2 m -114.12 112.36 23.08 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.726 0.298 . . . . 0.0 110.978 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 21.8 t -66.36 107.87 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.071 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.33 -50.42 6.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.845 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -135.62 164.36 28.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.009 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.8 mt -126.88 151.78 34.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.092 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -113.88 86.78 11.53 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.91 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.63 -27.13 22.72 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.591 2.194 . . . . 0.0 112.337 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -60.09 -51.1 71.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.949 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 2.6 ttt85 -97.37 -67.21 0.86 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.895 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 141.24 52.89 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.417 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 14.3 mttp -131.14 178.76 6.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.831 0.348 . . . . 0.0 110.82 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.701 HG11 ' CE1' ' A' ' 178' ' ' PHE . 28.1 m -145.87 123.07 4.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.071 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 62.6 tttt -79.88 116.43 20.02 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.625 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.1 t -124.55 150.2 29.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.042 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 4.5 ptt? -103.65 116.49 32.43 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.023 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 3.2 m -113.17 138.15 43.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.051 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -97.69 133.79 41.74 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.852 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.612 HD13 ' HB2' ' A' ' 168' ' ' PHE . 0.0 OUTLIER -133.47 117.88 29.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.999 179.971 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 168' ' ' PHE . . . . . 0.612 ' HB2' HD13 ' A' ' 167' ' ' ILE . 0.2 OUTLIER 62.99 30.28 16.39 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.958 -179.7 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 77.0 45.01 12.31 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.494 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -157.85 128.56 6.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.827 0.346 . . . . 0.0 110.869 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -59.74 144.36 48.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 172' ' ' THR . . . . . 0.701 ' O ' HG23 ' A' ' 174' ' ' VAL . 22.3 m -144.18 83.07 10.36 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.943 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_exo -56.23 90.16 0.04 OUTLIER 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.566 2.178 . . . . 0.0 112.312 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.701 HG23 ' O ' ' A' ' 172' ' ' THR . 24.7 t -109.0 132.69 56.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.086 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -79.92 125.84 30.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.278 179.602 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -134.43 -160.81 1.08 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.405 0.621 . . . . 0.0 111.459 -179.317 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.683 ' HA ' HG22 ' A' ' 161' ' ' VAL . 1.5 m-20 -151.44 156.53 40.84 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.936 178.299 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 178' ' ' PHE . . . . . 0.701 ' CE1' HG11 ' A' ' 161' ' ' VAL . 14.5 m-85 -46.77 -28.07 1.41 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.599 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -78.81 -0.26 29.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.708 -179.722 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.552 ' O ' HG13 ' A' ' 140' ' ' VAL . 79.1 mt-30 -118.74 0.14 11.4 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-O 120.481 0.182 . . . . 0.0 111.405 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 5.7 m -144.98 156.02 13.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 120.86 0.362 . . . . 0.0 111.099 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 30.3 m -126.41 146.43 32.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.167 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.879 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -64.85 128.8 37.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.003 179.97 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.059 0 CA-C-O 118.309 -0.853 . . . . 0.0 111.143 179.992 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 3.3 mtt180 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.854 0.359 . . . . 0.0 110.936 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -60.34 120.69 10.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 108.67 11.3 23.38 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.674 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -90.04 169.4 11.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.756 0.313 . . . . 0.0 110.92 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.36 134.15 48.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.829 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.743 HG12 ' HA ' ' A' ' 183' ' ' LYS . 21.0 m -142.06 134.04 27.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.148 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.406 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.1 OUTLIER -80.99 163.13 23.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.94 0.4 . . . . 0.0 110.627 179.913 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.634 HG11 ' HB2' ' A' ' 144' ' ' PHE . 11.7 t -79.83 166.99 2.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.912 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.624 HG13 ' C ' ' A' ' 180' ' ' GLN . 2.1 m -79.31 -61.79 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -179.306 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.738 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 4.2 m -160.02 -166.4 1.7 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.811 0.338 . . . . 0.0 111.258 -179.466 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.59 -158.37 37.25 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.392 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -68.82 -10.96 30.6 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.586 2.191 . . . . 0.0 112.352 179.82 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.634 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.3 m-85 -107.31 14.18 26.33 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.468 -179.796 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.738 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -75.3 36.48 0.12 Allowed 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 112.403 0.519 . . . . 0.0 112.403 -179.342 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -161.16 34.13 0.14 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.913 0.387 . . . . 0.0 110.77 179.278 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.4 ' O ' HG23 ' A' ' 139' ' ' VAL . 23.1 m-85 -145.31 164.43 31.44 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.991 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.514 HG22 ' C ' ' A' ' 137' ' ' VAL . 0.6 OUTLIER -121.66 -173.94 2.75 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.43 179.586 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -154.6 161.83 30.4 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.449 -0.881 . . . . 0.0 112.844 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 150' ' ' THR . . . . . 0.46 ' C ' HG13 ' A' ' 163' ' ' VAL . 88.9 m -110.49 101.6 10.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.833 0.349 . . . . 0.0 110.841 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 31.6 t -59.45 114.63 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.178 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -83.25 -61.07 1.95 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.866 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -134.23 168.98 17.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.895 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 154' ' ' ILE . . . . . 0.465 HG23 HG12 ' A' ' 161' ' ' VAL . 3.7 mt -126.96 135.51 63.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.069 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -107.12 84.48 1.67 Allowed Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.92 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.44 -28.12 22.36 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.607 2.204 . . . . 0.0 112.256 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -68.31 -34.15 75.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.968 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 25.0 mmt180 -101.53 -56.11 2.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.958 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 121.66 37.35 0.68 Allowed Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.495 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -126.98 175.09 8.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.758 0.314 . . . . 0.0 110.864 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.697 HG11 ' CE1' ' A' ' 178' ' ' PHE . 15.5 m -151.17 119.7 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.135 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 2.1 ttpm? -79.86 137.46 36.93 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.73 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.633 ' HB ' HD21 ' A' ' 176' ' ' LEU . 4.8 t -149.19 146.68 17.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.997 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.67 127.56 48.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.016 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.618 ' CG2' HD11 ' A' ' 167' ' ' ILE . 3.5 m -107.02 147.66 12.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.039 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 63.3 m -112.67 85.58 2.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.978 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.618 HD11 ' CG2' ' A' ' 165' ' ' VAL . 4.1 mp -98.09 126.81 51.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.031 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 61.57 31.33 18.84 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.902 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 69.5 38.38 79.32 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.554 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 72.5 mmt-85 -146.76 134.42 21.07 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.861 0.363 . . . . 0.0 110.924 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -72.29 147.99 45.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.882 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 1.8 m -157.14 88.41 2.62 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.804 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -50.8 115.54 2.06 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.608 2.205 . . . . 0.0 112.338 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.882 HG13 HD11 ' A' ' 176' ' ' LEU . 10.4 p -128.63 142.74 43.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.064 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 175' ' ' GLU . . . . . 0.872 ' C ' HD13 ' A' ' 176' ' ' LEU . 6.8 pt-20 -98.25 121.49 40.24 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.838 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.882 HD11 HG13 ' A' ' 174' ' ' VAL . 0.0 OUTLIER -126.94 -160.41 1.0 Allowed 'General case' 0 CA--C 1.518 -0.286 0 CA-C-O 121.353 0.597 . . . . 0.0 110.894 -179.939 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.427 ' HA ' HG22 ' A' ' 161' ' ' VAL . 4.8 m-20 -148.36 155.37 41.18 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.163 -0.926 . . . . 0.0 109.934 178.373 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 178' ' ' PHE . . . . . 0.697 ' CE1' HG11 ' A' ' 161' ' ' VAL . 11.7 m-85 -48.31 -33.83 9.53 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.482 -179.47 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 90.9 p -78.21 -2.55 38.3 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.643 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.624 ' C ' HG13 ' A' ' 140' ' ' VAL . 4.3 mt-30 -115.29 -2.81 12.58 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.545 0.212 . . . . 0.0 111.564 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 17.4 m -140.41 171.98 12.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-O 120.844 0.354 . . . . 0.0 111.393 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 27.5 m -136.72 146.43 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.219 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.743 ' HA ' HG12 ' A' ' 137' ' ' VAL . 5.2 mtmt -80.09 130.99 35.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.919 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.278 -0.867 . . . . 0.0 111.045 -179.972 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.23 0.065 0 CA-C-O 120.842 0.354 . . . . 0.0 110.921 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -59.62 123.73 17.84 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.48 5.72 27.76 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.834 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -67.61 162.57 23.23 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.739 0.304 . . . . 0.0 110.792 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -111.59 131.23 55.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.977 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.654 HG12 ' HA ' ' A' ' 183' ' ' LYS . 15.6 m -143.42 148.25 19.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.803 179.837 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.767 ' HD3' HG22 ' A' ' 148' ' ' THR . 0.2 OUTLIER -79.63 164.62 23.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.03 0.443 . . . . 0.0 111.033 -179.927 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.901 HG23 ' O ' ' A' ' 147' ' ' PHE . 22.3 t -79.88 151.06 4.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.674 -179.636 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 11.4 p -90.83 -24.17 5.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-N 116.044 -0.526 . . . . 0.0 112.076 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.684 ' H ' HG12 ' A' ' 139' ' ' VAL . 6.2 m -79.33 154.67 28.9 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.999 0.428 . . . . 0.0 111.412 -178.891 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 142' ' ' GLY . . . . . 0.439 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -67.26 -61.19 5.32 Favored Glycine 0 N--CA 1.451 -0.308 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.69 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.439 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.2 Cg_endo -51.43 -24.55 16.64 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.663 2.242 . . . . 0.0 112.205 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.865 ' HB2' HG11 ' A' ' 139' ' ' VAL . 21.3 m-85 -112.98 4.36 16.7 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.419 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.681 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -70.06 46.58 0.08 Allowed 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -179.097 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 146' ' ' ASP . . . . . 0.427 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 17.5 p-10 -160.56 30.82 0.16 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.204 0.526 . . . . 0.0 110.498 179.037 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.901 ' O ' HG23 ' A' ' 139' ' ' VAL . 24.2 m-85 -151.85 146.18 25.48 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.168 179.732 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.767 HG22 ' HD3' ' A' ' 138' ' ' ARG . 26.7 p -96.85 -177.36 3.86 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.737 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 149' ' ' GLY . . . . . 0.4 ' HA3' ' CG2' ' A' ' 163' ' ' VAL . . . -144.63 159.34 27.78 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.608 -179.875 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 2.2 m -117.09 111.55 19.67 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.798 0.332 . . . . 0.0 110.862 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 21.6 t -69.37 131.92 33.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.047 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.74 -68.92 0.79 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.026 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -123.71 172.92 8.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.948 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 154' ' ' ILE . . . . . 0.443 HG23 HG12 ' A' ' 161' ' ' VAL . 35.0 mt -139.35 128.93 30.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.074 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -100.81 99.51 10.48 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.897 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.41 -23.75 17.15 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.557 2.171 . . . . 0.0 112.417 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -90.27 23.2 2.99 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.301 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 16.4 mtp180 -158.6 -44.25 0.06 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.754 0.311 . . . . 0.0 110.765 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 97.4 57.39 1.06 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.472 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.55 162.95 34.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.765 0.317 . . . . 0.0 111.016 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.641 HG11 ' CE1' ' A' ' 178' ' ' PHE . 24.1 m -148.06 126.67 3.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.961 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 6.0 tttp -79.94 122.29 26.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.856 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.4 ' CG2' ' HA3' ' A' ' 149' ' ' GLY . 11.4 p -126.13 145.93 32.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.085 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.21 117.89 35.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.735 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.683 HG22 HG12 ' A' ' 174' ' ' VAL . 13.4 m -110.33 142.76 21.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.139 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 166' ' ' THR . . . . . 0.484 HG23 ' C ' ' A' ' 170' ' ' ARG . 8.2 m -135.73 133.32 37.89 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.875 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.482 HG22 ' O ' ' A' ' 167' ' ' ILE . 4.1 mp -102.69 53.47 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.937 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER 65.67 96.49 0.05 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.974 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 65.81 33.55 86.17 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.679 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 170' ' ' ARG . . . . . 0.484 ' C ' HG23 ' A' ' 166' ' ' THR . 0.0 OUTLIER -154.44 86.07 1.14 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.849 0.357 . . . . 0.0 111.019 -179.884 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -68.79 141.95 55.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.706 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 63.4 m -160.0 93.3 1.68 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.167 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_exo -62.06 124.81 15.11 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.651 2.234 . . . . 0.0 112.057 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.683 HG12 HG22 ' A' ' 165' ' ' VAL . 11.2 p -137.91 132.33 43.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.32 -179.828 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -79.82 131.72 35.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.263 179.642 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.806 HD23 HG13 ' A' ' 181' ' ' VAL . 1.1 mp -133.07 -167.74 1.97 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.421 0.629 . . . . 0.0 111.608 -179.319 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.442 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.6 OUTLIER -144.66 154.11 42.45 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 114.961 -1.018 . . . . 0.0 110.199 178.152 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 178' ' ' PHE . . . . . 0.641 ' CE1' HG11 ' A' ' 161' ' ' VAL . 8.9 m-85 -44.73 -33.68 1.96 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.612 -179.548 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -82.32 14.65 2.83 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.679 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.427 ' N ' ' O ' ' A' ' 177' ' ' ASP . 21.6 mt-30 -127.85 4.91 6.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.576 0.227 . . . . 0.0 111.328 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.806 HG13 HD23 ' A' ' 176' ' ' LEU . 6.2 m -146.45 170.72 4.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.14 0 CA-C-O 120.874 0.369 . . . . 0.0 111.198 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 21.0 m -140.49 146.38 24.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.084 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.654 ' HA ' HG12 ' A' ' 137' ' ' VAL . 13.6 tttt -66.07 121.94 16.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.272 -0.871 . . . . 0.0 111.062 179.983 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 7.1 mmt180 . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.882 0.372 . . . . 0.0 111.059 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -64.22 122.83 17.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.792 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 96.23 18.26 31.8 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.617 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.49 176.51 9.33 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.798 0.333 . . . . 0.0 110.884 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 38.2 mt-30 -120.08 114.34 21.83 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.115 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.609 HG12 ' HA ' ' A' ' 183' ' ' LYS . 18.8 m -124.43 143.17 38.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.805 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -79.85 162.11 25.24 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.109 0.481 . . . . 0.0 111.054 -179.724 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.856 HG11 ' HB2' ' A' ' 144' ' ' PHE . 46.7 t -84.62 155.21 3.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.529 -179.423 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.553 HG13 ' O ' ' A' ' 180' ' ' GLN . 35.6 m -96.89 -24.65 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 N-CA-C 112.675 0.62 . . . . 0.0 112.675 -179.165 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.617 ' H ' HG12 ' A' ' 139' ' ' VAL . 0.2 OUTLIER -78.99 131.12 36.19 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.85 0.357 . . . . 0.0 111.32 -178.646 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 142' ' ' GLY . . . . . 0.476 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -44.19 -59.07 4.17 Favored Glycine 0 C--N 1.332 0.347 0 CA-C-N 115.823 -0.626 . . . . 0.0 113.597 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.476 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.7 Cg_endo -51.1 -22.74 11.3 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.669 2.246 . . . . 0.0 112.481 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.856 ' HB2' HG11 ' A' ' 139' ' ' VAL . 21.2 m-85 -120.13 4.83 10.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.466 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.522 ' N ' ' O ' ' A' ' 141' ' ' SER . . . -70.02 45.21 0.07 Allowed 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 112.55 0.574 . . . . 0.0 112.55 -178.653 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 146' ' ' ASP . . . . . 0.408 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 15.1 p-10 -160.69 31.74 0.15 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.13 0.491 . . . . 0.0 110.422 179.091 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.659 ' O ' HG23 ' A' ' 139' ' ' VAL . 46.3 m-85 -155.66 145.98 21.78 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.439 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 1.4 p -101.76 168.89 9.16 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.789 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -132.49 132.45 6.64 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.515 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.7 m -87.35 109.05 19.27 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.723 0.297 . . . . 0.0 110.802 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 19.2 t -64.38 123.8 17.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.093 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.2 p -100.97 -43.66 5.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.957 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 6.6 mt-10 -136.77 151.25 48.98 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 154' ' ' ILE . . . . . 0.488 HG23 HG12 ' A' ' 161' ' ' VAL . 7.8 mt -128.57 132.23 68.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.101 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -116.98 85.54 18.03 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.835 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -58.37 -30.05 90.06 Favored 'Trans proline' 0 C--N 1.343 0.278 0 C-N-CA 122.595 2.196 . . . . 0.0 112.321 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -60.38 -62.68 1.69 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.099 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 7.7 ttm180 -79.99 -30.89 39.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.029 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 93.53 27.15 13.54 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.58 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 2.9 mtmm -107.78 162.65 13.8 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.732 0.301 . . . . 0.0 110.754 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.759 HG11 ' CE1' ' A' ' 178' ' ' PHE . 15.7 m -153.71 123.19 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.163 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 29.4 tttt -85.66 146.97 26.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.816 179.806 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.781 HG21 HD11 ' A' ' 176' ' ' LEU . 25.0 m -144.96 170.1 7.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.276 -179.866 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -120.0 110.87 17.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.655 179.631 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.51 HG22 ' O ' ' A' ' 172' ' ' THR . 11.9 m -99.53 157.99 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.138 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 27.4 p -141.49 97.41 3.15 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.982 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.495 ' H ' HD12 ' A' ' 167' ' ' ILE . 3.9 mp -79.87 83.53 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.962 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 24.7 m-85 62.29 70.39 0.57 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.902 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 60.26 47.06 92.97 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.566 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 1.5 mtm180 -146.38 91.48 2.05 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.905 0.383 . . . . 0.0 110.977 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -58.17 140.39 53.03 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.984 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 172' ' ' THR . . . . . 0.51 ' O ' HG22 ' A' ' 165' ' ' VAL . 2.8 m -160.09 97.8 1.49 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.933 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.86 123.76 10.38 Favored 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.405 2.07 . . . . 0.0 112.12 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.9 t -139.74 145.26 26.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.134 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 175' ' ' GLU . . . . . 0.89 ' O ' HD23 ' A' ' 176' ' ' LEU . 0.4 OUTLIER -88.92 142.47 27.62 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.859 179.997 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.89 HD23 ' O ' ' A' ' 175' ' ' GLU . 0.1 OUTLIER -147.68 -161.29 1.3 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.337 0.589 . . . . 0.0 111.088 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.583 ' HA ' HG22 ' A' ' 161' ' ' VAL . 1.0 OUTLIER -150.48 155.18 39.02 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.007 178.292 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 178' ' ' PHE . . . . . 0.759 ' CE1' HG11 ' A' ' 161' ' ' VAL . 25.6 m-85 -46.47 -30.4 2.18 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.536 -179.583 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 60.6 p -81.19 8.11 9.65 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.863 -179.799 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.553 ' O ' HG13 ' A' ' 140' ' ' VAL . 6.2 mt-30 -122.39 2.12 9.65 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-O 120.616 0.246 . . . . 0.0 111.286 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 4.8 m -143.24 172.31 7.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-O 120.88 0.371 . . . . 0.0 111.084 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 18.0 m -142.16 148.92 19.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.161 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.609 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -67.57 125.35 25.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.911 -179.968 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.174 -0.917 . . . . 0.0 111.106 179.92 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.931 0.396 . . . . 0.0 110.88 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -62.6 135.47 57.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.912 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 105.31 -23.94 28.99 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.637 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.8 t0 -58.2 158.23 7.34 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.825 0.345 . . . . 0.0 110.947 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 13.9 mm-40 -110.41 138.42 46.82 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.002 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.489 HG12 ' HA ' ' A' ' 183' ' ' LYS . 18.4 m -140.01 134.11 36.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.911 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.457 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 2.6 ttm180 -79.95 166.03 22.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.995 0.426 . . . . 0.0 110.839 179.877 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.673 HG23 ' O ' ' A' ' 147' ' ' PHE . 3.9 t -79.91 169.73 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.799 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.6 HG23 ' H ' ' A' ' 141' ' ' SER . 0.7 OUTLIER -79.49 -65.53 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 111.835 0.309 . . . . 0.0 111.835 -179.5 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.67 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.0 OUTLIER -160.18 -167.85 2.04 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.827 0.346 . . . . 0.0 111.059 -179.683 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 83.81 -162.27 39.09 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.417 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -64.28 -15.72 51.12 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.532 2.154 . . . . 0.0 112.241 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.655 ' HD1' HD13 ' A' ' 167' ' ' ILE . 2.8 m-85 -104.54 19.73 19.82 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.149 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.67 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -80.69 38.22 0.44 Allowed 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -179.259 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 146' ' ' ASP . . . . . 0.435 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 8.8 t70 -160.84 32.63 0.15 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.01 0.434 . . . . 0.0 110.977 179.234 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.673 ' O ' HG23 ' A' ' 139' ' ' VAL . 17.0 m-85 -140.3 161.11 38.47 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.7 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.457 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 25.1 p -116.42 -178.45 3.42 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.741 179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -145.43 137.42 7.04 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.664 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 14.5 m -92.83 108.64 20.15 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.78 0.324 . . . . 0.0 110.663 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.416 HG22 HG12 ' A' ' 163' ' ' VAL . 20.7 t -69.37 118.87 14.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.207 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -103.77 -34.82 8.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.854 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -151.25 159.72 44.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.859 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mp -139.83 140.52 35.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.136 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 24.3 m120 -103.71 92.2 4.05 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.863 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -69.4 -27.76 27.77 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.538 2.159 . . . . 0.0 112.25 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -70.25 -40.27 74.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.867 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 3.7 mmt180 -98.49 -62.42 1.24 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.855 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 125.47 55.42 0.16 Allowed Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.476 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -130.45 166.53 20.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.92 0.39 . . . . 0.0 110.921 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.659 HG22 ' HA ' ' A' ' 177' ' ' ASP . 3.4 m -147.94 116.93 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.059 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 26.1 ttpt -87.07 121.52 29.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.754 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.416 HG12 HG22 ' A' ' 151' ' ' VAL . 35.7 m -135.6 147.01 28.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.254 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 4.1 ptt? -102.17 118.73 37.51 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.043 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.432 HG12 ' N ' ' A' ' 166' ' ' THR . 7.4 t -106.2 158.45 6.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.12 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 166' ' ' THR . . . . . 0.432 ' N ' HG12 ' A' ' 165' ' ' VAL . 0.6 OUTLIER -110.18 94.65 5.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.946 179.977 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.655 HD13 ' HD1' ' A' ' 144' ' ' PHE . 1.4 tp -112.16 136.74 47.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.965 179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER 61.31 30.1 18.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.921 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 67.74 39.97 90.03 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.633 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -159.88 140.21 11.86 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.787 0.327 . . . . 0.0 110.967 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.57 150.92 45.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.77 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 172' ' ' THR . . . . . 0.403 ' O ' HG23 ' A' ' 174' ' ' VAL . 14.8 p -153.3 93.47 3.12 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.042 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.88 87.18 0.29 Allowed 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.444 2.096 . . . . 0.0 112.039 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 172' ' ' THR . 34.6 t -101.62 135.3 38.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.338 -179.746 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 175' ' ' GLU . . . . . 0.417 ' C ' HD23 ' A' ' 176' ' ' LEU . 10.9 pm0 -82.04 124.31 29.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.581 179.687 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.417 HD23 ' C ' ' A' ' 175' ' ' GLU . 0.2 OUTLIER -132.55 -160.9 1.09 Allowed 'General case' 0 CA--C 1.517 -0.308 0 CA-C-O 121.351 0.596 . . . . 0.0 111.254 -179.605 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.659 ' HA ' HG22 ' A' ' 161' ' ' VAL . 4.6 m-20 -149.88 155.2 39.62 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.169 178.377 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 178' ' ' PHE . . . . . 0.565 ' CE1' HG11 ' A' ' 161' ' ' VAL . 42.6 m-85 -46.34 -29.02 1.49 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.732 -179.502 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 8.2 m -74.52 -5.7 44.21 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.738 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.535 ' C ' HG13 ' A' ' 140' ' ' VAL . 11.9 mm-40 -120.76 -4.46 9.71 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 111.603 0.223 . . . . 0.0 111.603 -179.833 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.414 ' CG2' ' HA ' ' A' ' 178' ' ' PHE . 6.6 m -122.76 178.03 3.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.86 0.362 . . . . 0.0 111.223 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 182' ' ' VAL . . . . . 0.446 HG22 ' O ' ' A' ' 138' ' ' ARG . 27.2 m -152.06 146.78 15.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.135 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.489 ' HA ' HG12 ' A' ' 137' ' ' VAL . 3.8 ttmm -67.51 125.2 25.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.927 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.17 -0.919 . . . . 0.0 111.105 -179.985 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.818 0.342 . . . . 0.0 110.907 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -67.6 140.26 56.9 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.011 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 93.95 -21.51 41.37 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.58 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.43 176.28 0.65 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.851 0.358 . . . . 0.0 110.94 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -112.36 143.35 43.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.04 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.639 HG12 ' HA ' ' A' ' 183' ' ' LYS . 18.0 m -139.42 133.13 38.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.907 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.435 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 1.6 ttt180 -79.85 165.14 23.02 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.017 0.437 . . . . 0.0 110.94 -179.819 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 147' ' ' PHE . 4.4 t -80.03 169.08 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.904 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.619 HG23 ' H ' ' A' ' 141' ' ' SER . 0.8 OUTLIER -79.63 -65.97 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.805 -179.5 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.687 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 51.8 p -160.13 -165.52 1.49 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.823 0.344 . . . . 0.0 111.017 -179.78 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.61 -160.56 39.64 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.414 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.65 -13.42 39.82 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.613 2.209 . . . . 0.0 112.295 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.526 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.6 m-85 -106.97 20.49 18.97 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.164 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.687 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -81.13 38.91 0.49 Allowed 'General case' 0 C--N 1.331 -0.239 0 N-CA-C 112.3 0.481 . . . . 0.0 112.3 -179.377 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -160.97 36.49 0.15 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.88 0.371 . . . . 0.0 110.951 179.358 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.719 ' O ' HG23 ' A' ' 139' ' ' VAL . 48.0 m-85 -147.84 158.48 44.05 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.815 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.669 ' O ' HG12 ' A' ' 165' ' ' VAL . 58.2 p -118.93 169.2 10.08 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.792 179.869 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 149' ' ' GLY . . . . . 0.413 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -132.67 153.36 20.62 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.679 -179.832 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 2.7 m -101.81 107.72 18.99 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.819 0.343 . . . . 0.0 110.828 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 24.5 t -62.42 116.66 2.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.131 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 4.6 p -108.68 -57.2 2.17 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.859 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -113.23 155.99 24.08 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 154' ' ' ILE . . . . . 0.472 HG23 HG12 ' A' ' 161' ' ' VAL . 4.0 mp -142.31 141.72 28.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.172 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -123.65 101.29 36.88 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.812 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -69.23 -26.55 29.95 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.398 2.066 . . . . 0.0 112.438 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.57 -42.15 52.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.918 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 49.3 mtt-85 -87.43 -33.8 18.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.901 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 85.11 35.81 11.94 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.427 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 160' ' ' LYS . . . . . 0.533 ' O ' HG13 ' A' ' 161' ' ' VAL . 28.6 mttm -118.01 177.04 4.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.754 0.312 . . . . 0.0 110.857 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.576 HG11 ' CE1' ' A' ' 178' ' ' PHE . 6.1 m -158.94 121.49 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.166 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 80.5 tttt -84.87 132.75 34.35 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.822 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.413 ' HB ' ' HA3' ' A' ' 149' ' ' GLY . 33.8 m -139.67 138.67 39.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.144 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 12.6 ptm -90.67 113.84 26.0 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.669 HG12 ' O ' ' A' ' 148' ' ' THR . 27.4 m -115.46 156.91 16.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.171 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 16.7 p -105.98 142.52 35.54 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.719 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.811 ' O ' HD13 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -103.77 -38.96 5.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.997 179.927 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -171.18 86.15 0.09 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.866 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 58.16 30.24 63.79 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.559 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -158.13 134.46 9.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.807 0.337 . . . . 0.0 110.925 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -67.96 155.89 38.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 3.4 m -159.96 93.71 1.66 Allowed Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.756 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -67.84 125.84 13.75 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.502 2.135 . . . . 0.0 112.294 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 7.4 m -139.38 139.02 39.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.3 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -79.87 126.49 31.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.344 179.524 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.904 HD13 HG13 ' A' ' 181' ' ' VAL . 6.8 mt -133.88 -170.99 2.62 Favored 'General case' 0 CA--C 1.516 -0.359 0 CA-C-O 121.388 0.613 . . . . 0.0 111.698 -179.345 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.453 ' O ' HG22 ' A' ' 181' ' ' VAL . 5.2 m-20 -144.36 155.7 43.91 Favored 'General case' 0 N--CA 1.442 -0.832 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.286 178.196 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 178' ' ' PHE . . . . . 0.576 ' CE1' HG11 ' A' ' 161' ' ' VAL . 10.7 m-85 -45.62 -41.74 10.51 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.577 -179.567 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 2.6 p -65.39 -15.88 63.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.373 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.779 ' CB ' HD22 ' A' ' 176' ' ' LEU . 4.0 mt-30 -103.78 -18.89 14.48 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.384 -179.689 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.904 HG13 HD13 ' A' ' 176' ' ' LEU . 11.0 m -120.75 173.05 6.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.922 0.392 . . . . 0.0 111.366 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 30.3 m -144.4 146.25 20.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.032 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.639 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -71.56 123.0 21.49 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.992 179.973 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.995 0 CA-C-O 118.324 -0.846 . . . . 0.0 111.061 179.977 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.769 0.318 . . . . 0.0 110.929 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -63.69 138.32 58.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.951 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 105.85 -22.4 31.9 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.613 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -57.41 156.16 8.26 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.818 0.342 . . . . 0.0 111.028 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 10.0 mt-30 -113.17 137.53 51.32 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.939 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.804 HG12 ' HA ' ' A' ' 183' ' ' LYS . 18.4 m -143.81 141.39 25.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.155 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.435 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 3.7 ttp180 -79.91 165.84 22.24 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.796 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.748 HG23 ' O ' ' A' ' 147' ' ' PHE . 7.6 t -80.1 167.22 2.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.116 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.624 HG13 ' H ' ' A' ' 141' ' ' SER . 2.6 p -79.35 -61.41 1.73 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.92 -179.395 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.677 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 2.6 m -160.35 -165.13 1.38 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.912 0.386 . . . . 0.0 111.138 -179.464 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.56 -165.85 50.32 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.334 179.864 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -62.15 -17.11 54.82 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.474 2.116 . . . . 0.0 112.02 179.659 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.587 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.7 m-85 -99.57 14.6 29.4 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.119 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.677 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -78.75 38.06 0.31 Allowed 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -179.234 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -160.89 36.6 0.15 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.88 0.371 . . . . 0.0 110.774 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.748 ' O ' HG23 ' A' ' 139' ' ' VAL . 16.2 m-85 -152.13 157.23 41.27 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.043 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.435 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 5.6 t -110.17 -176.02 2.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.636 179.823 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -154.89 140.41 7.38 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.539 -0.839 . . . . 0.0 112.779 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 12.2 m -94.16 110.19 21.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.754 0.311 . . . . 0.0 110.623 179.692 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.653 ' HA ' HG12 ' A' ' 163' ' ' VAL . 36.8 t -57.55 116.53 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.155 -179.842 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -111.45 -29.57 7.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.0 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -135.72 167.01 21.94 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.943 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 23.3 pt -145.59 133.27 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.167 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -117.19 81.18 12.78 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.803 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.44 -32.45 12.36 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.656 2.237 . . . . 0.0 112.224 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -59.74 -35.49 74.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.919 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -102.17 -33.98 9.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.927 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 99.16 43.87 2.5 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.45 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -139.76 156.12 46.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.934 0.397 . . . . 0.0 110.867 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.467 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.2 p -123.52 159.79 27.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.924 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 162' ' ' LYS . . . . . 0.467 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 13.0 ttpt -128.65 140.22 51.87 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.184 -179.753 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.928 HG22 HD11 ' A' ' 176' ' ' LEU . 34.6 m -139.84 -179.73 2.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.233 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -120.08 111.9 18.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.702 179.565 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.403 HG22 ' O ' ' A' ' 172' ' ' THR . 31.0 m -98.25 167.92 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.263 -179.773 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.16 79.56 1.7 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.821 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 30.9 mm -80.54 108.37 13.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.173 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 59.15 55.27 4.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.064 0.459 . . . . 0.0 110.928 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 57.53 41.48 93.48 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.571 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 6.1 ttt180 -137.51 106.32 5.92 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.803 0.335 . . . . 0.0 110.924 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -73.21 127.02 31.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.874 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 172' ' ' THR . . . . . 0.403 ' O ' HG22 ' A' ' 165' ' ' VAL . 52.3 m -147.17 131.44 8.6 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.79 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -74.79 106.71 2.31 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.516 2.144 . . . . 0.0 112.415 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.443 ' O ' HG13 ' A' ' 174' ' ' VAL . 12.1 p -119.07 124.01 72.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.987 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 12.4 mt-10 -88.15 141.89 28.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.806 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.928 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -138.12 -162.55 1.32 Allowed 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 121.233 0.539 . . . . 0.0 111.151 -179.644 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.694 ' O ' HG22 ' A' ' 181' ' ' VAL . 0.3 OUTLIER -146.04 152.2 38.96 Favored 'General case' 0 N--CA 1.444 -0.762 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.207 178.404 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 -48.74 -37.04 17.72 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.432 -179.663 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 17.3 p -75.74 -9.54 58.68 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.56 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 23.5 mt-30 -118.58 21.14 12.72 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-O 120.603 0.239 . . . . 0.0 111.417 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.694 HG22 ' O ' ' A' ' 177' ' ' ASP . 17.6 m -152.92 146.5 14.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.891 0.377 . . . . 0.0 111.22 179.786 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 30.9 m -114.15 146.28 18.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.135 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.804 ' HA ' HG12 ' A' ' 137' ' ' VAL . 4.1 ttmt -80.92 137.28 36.13 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.955 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.065 0 CA-C-O 118.255 -0.879 . . . . 0.0 111.041 179.979 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.839 0.352 . . . . 0.0 110.843 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -69.21 141.25 54.54 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.835 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 89.29 -8.66 79.34 Favored Glycine 0 CA--C 1.519 0.339 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.724 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -56.87 164.14 1.67 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.826 0.346 . . . . 0.0 111.027 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -104.05 134.63 46.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.976 -179.867 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.735 HG12 ' HA ' ' A' ' 183' ' ' LYS . 21.0 m -141.66 131.54 24.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.886 179.839 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.414 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 3.4 ttp180 -79.78 164.28 23.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.013 0.435 . . . . 0.0 110.976 -180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.635 HG23 ' O ' ' A' ' 147' ' ' PHE . 3.7 t -79.96 168.55 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.86 -179.884 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.617 HG23 ' H ' ' A' ' 141' ' ' SER . 0.7 OUTLIER -79.6 -65.8 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.768 -179.518 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.716 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.3 OUTLIER -160.11 -164.57 1.31 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.768 0.318 . . . . 0.0 110.903 -179.835 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.36 -157.34 36.5 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.529 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -69.53 -10.23 28.2 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.558 2.172 . . . . 0.0 112.519 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.604 ' HB2' HG11 ' A' ' 139' ' ' VAL . 2.6 m-85 -110.46 19.54 18.67 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.201 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.716 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -78.86 37.85 0.31 Allowed 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -179.352 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 146' ' ' ASP . . . . . 0.406 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 1.5 p30 -161.08 36.0 0.14 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.893 0.378 . . . . 0.0 110.896 179.281 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.635 ' O ' HG23 ' A' ' 139' ' ' VAL . 44.0 m-85 -146.81 163.03 37.34 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.969 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.414 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 1.1 p -118.16 -177.07 3.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.771 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -147.47 142.95 10.68 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.526 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.7 m -99.7 103.71 15.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.779 0.324 . . . . 0.0 110.766 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.519 HG22 HG12 ' A' ' 163' ' ' VAL . 31.7 t -60.6 127.03 19.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.206 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.9 p -111.95 -33.98 6.12 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.858 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -136.01 157.7 46.21 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.874 179.883 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 25.9 pt -138.76 136.22 43.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.261 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -120.09 84.57 33.65 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.879 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -54.28 -26.44 43.19 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.535 2.157 . . . . 0.0 112.392 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -58.7 -73.3 0.08 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.907 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 7.2 mtt85 -80.01 -30.45 39.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.909 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 93.97 47.0 2.99 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.412 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -106.34 159.69 15.94 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.884 0.373 . . . . 0.0 110.872 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.504 HG11 ' HE1' ' A' ' 178' ' ' PHE . 5.2 m -143.16 116.94 3.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.15 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 19.1 tttp -90.78 111.23 22.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.826 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.614 HG22 ' CD1' ' A' ' 176' ' ' LEU . 33.8 m -119.24 148.71 22.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.163 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.5 ppp? -95.1 114.77 26.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.773 179.79 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.478 HG22 ' O ' ' A' ' 172' ' ' THR . 17.0 m -105.52 149.11 9.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.202 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 22.6 m -119.61 85.23 2.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.904 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.523 HG23 ' O ' ' A' ' 167' ' ' ILE . 1.7 tp -82.21 118.11 29.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.092 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 60.57 33.62 20.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.873 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 75.18 30.09 59.42 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.505 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.12 108.65 8.96 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.753 0.311 . . . . 0.0 110.981 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -59.95 139.91 57.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.807 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 172' ' ' THR . . . . . 0.478 ' O ' HG22 ' A' ' 165' ' ' VAL . 53.8 m -154.12 109.56 2.46 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.913 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -67.45 100.67 0.58 Allowed 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.341 2.027 . . . . 0.0 112.157 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 11.9 p -108.45 129.01 63.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.286 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -90.63 123.39 34.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.614 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.614 ' CD1' HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -137.33 -159.52 0.96 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.43 0.633 . . . . 0.0 111.128 -179.712 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.456 ' HA ' HG22 ' A' ' 161' ' ' VAL . 7.5 m-20 -145.56 157.33 44.0 Favored 'General case' 0 N--CA 1.441 -0.875 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.055 178.21 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 178' ' ' PHE . . . . . 0.504 ' HE1' HG11 ' A' ' 161' ' ' VAL . 6.4 m-85 -44.24 -30.42 0.8 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.656 -179.631 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 35.5 t -67.25 -23.55 65.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.435 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.539 ' O ' HG13 ' A' ' 140' ' ' VAL . 22.6 mt-30 -101.83 -14.17 17.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.617 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 10.7 m -123.39 172.15 11.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-O 120.858 0.361 . . . . 0.0 111.461 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 32.9 m -146.39 146.2 19.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.164 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.735 ' HA ' HG12 ' A' ' 137' ' ' VAL . 9.9 mttt -66.0 125.74 26.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.943 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.273 -0.87 . . . . 0.0 111.075 179.994 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 2.0 ttm180 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.745 0.307 . . . . 0.0 110.98 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -59.66 120.16 8.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.939 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 121.71 -19.9 8.34 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.64 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -55.48 -178.85 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.824 0.345 . . . . 0.0 110.994 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 2.0 mt-30 -132.02 136.14 47.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.148 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.893 HG21 HG21 ' A' ' 181' ' ' VAL . 31.0 m -139.45 147.93 23.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.789 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -79.84 164.75 23.36 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.962 0.411 . . . . 0.0 111.022 -179.771 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.856 HG23 ' O ' ' A' ' 147' ' ' PHE . 39.7 t -79.8 149.35 5.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.433 -179.689 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 9.9 p -90.26 -20.36 6.99 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 115.991 -0.55 . . . . 0.0 112.181 -179.494 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.75 ' H ' HG12 ' A' ' 139' ' ' VAL . 0.4 OUTLIER -79.23 152.65 30.5 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.908 0.385 . . . . 0.0 111.145 -179.032 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 142' ' ' GLY . . . . . 0.407 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -65.5 -63.37 4.14 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.892 -179.793 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.407 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.6 Cg_endo -53.76 -22.7 24.07 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.7 2.266 . . . . 0.0 112.32 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.804 ' HB2' HG11 ' A' ' 139' ' ' VAL . 17.5 m-85 -110.36 1.99 18.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.365 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.651 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -70.31 49.68 0.11 Allowed 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -179.151 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -160.69 32.63 0.15 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.15 0.5 . . . . 0.0 110.465 179.093 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.856 ' O ' HG23 ' A' ' 139' ' ' VAL . 46.5 m-85 -157.23 145.77 19.58 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.533 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.444 ' O ' HG12 ' A' ' 165' ' ' VAL . 30.3 p -103.67 -179.26 3.9 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.865 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -144.71 141.98 10.52 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.619 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.4 m -93.38 107.41 19.24 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.714 0.293 . . . . 0.0 110.696 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.577 ' HA ' HG12 ' A' ' 163' ' ' VAL . 40.9 t -64.84 113.14 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.088 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 73.8 p -97.76 -46.4 5.98 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.763 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -124.69 167.48 14.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.848 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 154' ' ' ILE . . . . . 0.728 HG22 HG12 ' A' ' 161' ' ' VAL . 12.6 pt -146.49 160.14 10.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.203 -179.937 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 8.5 m-20 -132.24 89.71 36.55 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.923 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.15 -28.09 28.6 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.546 2.164 . . . . 0.0 112.289 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -62.49 -52.79 62.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.967 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.26 -49.43 5.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.905 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 115.44 52.23 0.41 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.574 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -125.88 170.15 11.94 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.864 0.364 . . . . 0.0 110.815 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.728 HG12 HG22 ' A' ' 154' ' ' ILE . 5.4 m -154.17 132.42 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.131 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 7.0 tttm -104.13 133.46 49.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.969 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.743 HG22 HD11 ' A' ' 176' ' ' LEU . 34.6 m -134.86 164.23 34.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.285 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 3.9 ptt? -106.7 120.55 42.27 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.808 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.444 HG12 ' O ' ' A' ' 148' ' ' THR . 16.9 m -117.51 157.56 18.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.13 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 23.6 m -142.37 105.81 4.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.974 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.1 mp -83.1 113.71 22.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.039 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 64.97 -77.71 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.971 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -154.47 44.23 0.57 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.448 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 5.2 ptt180 -148.24 115.27 6.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.883 0.373 . . . . 0.0 110.957 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -68.96 147.03 52.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.771 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 76.4 m -160.06 113.8 1.44 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.942 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -73.6 112.65 3.58 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.402 2.068 . . . . 0.0 112.141 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.5 t -119.41 124.4 72.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.225 -179.759 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -92.1 131.07 37.65 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.677 179.754 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.743 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -139.71 -161.65 1.22 Allowed 'General case' 0 CA--C 1.515 -0.385 0 CA-C-O 121.522 0.677 . . . . 0.0 111.259 -179.793 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.589 ' HA ' HG22 ' A' ' 161' ' ' VAL . 1.2 m-20 -138.06 161.29 37.14 Favored 'General case' 0 N--CA 1.439 -1.004 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.172 177.992 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 178' ' ' PHE . . . . . 0.48 ' HE1' HG11 ' A' ' 161' ' ' VAL . 3.4 m-85 -43.45 -38.51 2.85 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.693 -0.685 . . . . 0.0 112.554 -179.006 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.38 5.36 12.79 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.135 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -112.14 6.87 19.36 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.582 0.229 . . . . 0.0 111.407 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.893 HG21 HG21 ' A' ' 137' ' ' VAL . 27.2 m -151.95 174.96 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 120.882 0.372 . . . . 0.0 111.289 -179.848 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 12.9 m -143.14 146.68 21.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.084 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.424 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.9 OUTLIER -60.82 123.27 17.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.926 -179.933 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.253 -0.88 . . . . 0.0 111.045 -179.96 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.894 0.378 . . . . 0.0 110.915 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.4 pp20? -59.56 122.25 13.58 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.926 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.68 15.97 25.49 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.709 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -69.66 157.25 37.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.761 0.315 . . . . 0.0 110.91 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -93.16 132.19 37.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.981 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.413 HG12 ' HA ' ' A' ' 183' ' ' LYS . 14.9 m -140.79 133.25 31.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.927 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.423 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.8 OUTLIER -79.82 166.38 21.77 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.912 0.387 . . . . 0.0 110.967 -179.907 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.655 HG23 ' O ' ' A' ' 147' ' ' PHE . 7.3 t -79.74 167.9 2.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.969 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.632 HG13 ' H ' ' A' ' 141' ' ' SER . 3.0 p -79.41 -61.47 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 -179.291 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.632 ' H ' HG13 ' A' ' 140' ' ' VAL . 39.6 p -160.45 -164.1 1.19 Allowed 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.766 0.317 . . . . 0.0 111.246 -179.675 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.86 -168.58 54.26 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.325 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -59.93 -18.56 50.54 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.541 2.161 . . . . 0.0 112.087 179.671 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.538 ' HB2' HG11 ' A' ' 139' ' ' VAL . 4.1 m-85 -97.04 16.8 18.55 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.094 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.539 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -80.58 39.44 0.47 Allowed 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 112.146 0.425 . . . . 0.0 112.146 -179.425 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 146' ' ' ASP . . . . . 0.416 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 8.3 t0 -160.74 34.69 0.15 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.979 0.419 . . . . 0.0 110.71 179.43 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.655 ' O ' HG23 ' A' ' 139' ' ' VAL . 24.3 m-85 -146.13 160.68 41.59 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.711 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.423 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 3.2 p -120.22 172.99 7.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.989 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -138.62 159.92 25.48 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.563 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.4 m -109.38 110.02 21.05 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.765 0.317 . . . . 0.0 110.796 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 31.6 t -60.2 99.84 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.113 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -90.95 -39.23 12.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.74 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -132.7 154.0 50.59 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.708 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 154' ' ' ILE . . . . . 0.995 HG22 HG12 ' A' ' 161' ' ' VAL . 32.9 pt -148.56 136.5 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.095 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -114.32 89.18 16.95 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.892 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.06 -26.26 37.14 Favored 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.545 2.164 . . . . 0.0 112.406 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -59.79 -32.31 70.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.851 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 27.4 mtt85 -113.87 -46.33 3.03 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.905 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 118.76 44.54 0.5 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.494 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 160' ' ' LYS . . . . . 0.436 ' O ' HG13 ' A' ' 161' ' ' VAL . 2.0 mmtt -119.26 166.13 13.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.769 0.318 . . . . 0.0 110.883 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.995 HG12 HG22 ' A' ' 154' ' ' ILE . 5.9 m -156.0 129.5 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.043 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -99.83 123.02 43.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.956 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 30.6 m -123.54 138.89 51.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.126 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -91.85 106.47 18.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.965 0.412 . . . . 0.0 110.796 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.505 ' CG2' HD11 ' A' ' 167' ' ' ILE . 13.5 m -90.14 167.0 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.096 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 3.4 m -130.16 92.76 3.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.911 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.505 HD11 ' CG2' ' A' ' 165' ' ' VAL . 4.1 mp -98.77 114.83 37.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.924 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 62.2 29.93 17.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 75.85 55.03 5.08 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.536 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -157.48 117.95 3.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.744 0.307 . . . . 0.0 111.0 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -65.94 121.18 14.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.819 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 172' ' ' THR . . . . . 0.482 ' O ' HG22 ' A' ' 165' ' ' VAL . 23.5 m -130.64 89.78 42.56 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.962 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -68.17 101.35 0.7 Allowed 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.432 2.088 . . . . 0.0 112.231 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.738 ' CG2' HD21 ' A' ' 176' ' ' LEU . 28.3 m -110.32 138.74 36.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.155 -179.815 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 175' ' ' GLU . . . . . 0.433 ' O ' HD23 ' A' ' 176' ' ' LEU . 0.4 OUTLIER -80.02 117.96 21.32 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.559 179.615 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.738 HD21 ' CG2' ' A' ' 174' ' ' VAL . 0.3 OUTLIER -137.16 -159.76 0.99 Allowed 'General case' 0 CA--C 1.517 -0.323 0 CA-C-O 121.292 0.567 . . . . 0.0 111.15 -179.622 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.501 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.9 OUTLIER -150.71 154.88 38.22 Favored 'General case' 0 N--CA 1.442 -0.848 0 CA-C-N 115.232 -0.894 . . . . 0.0 110.151 178.399 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -46.61 -28.88 1.59 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.546 -179.731 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.9 p -67.6 -14.44 62.94 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.339 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.404 ' O ' HG13 ' A' ' 181' ' ' VAL . 5.3 mt-30 -116.88 10.15 14.04 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.515 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.438 HG12 ' HA ' ' A' ' 139' ' ' VAL . 31.4 m -156.99 150.39 9.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.807 0.337 . . . . 0.0 111.224 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 182' ' ' VAL . . . . . 0.489 HG12 ' H ' ' A' ' 183' ' ' LYS . 0.3 OUTLIER -121.29 173.72 6.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.898 179.958 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.489 ' H ' HG12 ' A' ' 182' ' ' VAL . 0.1 OUTLIER -75.85 150.3 37.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.956 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.995 0 CA-C-O 118.224 -0.893 . . . . 0.0 111.115 -179.998 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.063 0 CA-C-O 120.89 0.376 . . . . 0.0 110.824 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -65.07 135.42 55.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.846 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.82 -26.03 13.47 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.58 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -60.17 166.49 2.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.752 0.31 . . . . 0.0 110.912 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -112.7 130.38 56.08 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.989 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 19.5 m -134.27 141.94 42.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.946 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.9 166.19 21.9 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.967 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.563 HG12 ' H ' ' A' ' 140' ' ' VAL . 4.2 t -79.77 169.18 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.014 -179.861 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.665 HG13 ' H ' ' A' ' 141' ' ' SER . 2.1 p -79.18 -64.76 0.86 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 CA-C-N 116.566 -0.288 . . . . 0.0 111.773 -179.451 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.665 ' H ' HG13 ' A' ' 140' ' ' VAL . 0.2 OUTLIER -160.42 -163.55 1.11 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.811 0.339 . . . . 0.0 111.096 -179.642 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.37 -164.71 49.63 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.518 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -62.83 -16.39 53.29 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.495 2.13 . . . . 0.0 112.173 179.725 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.474 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.5 m-85 -102.59 20.17 17.65 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.083 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.649 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -82.49 39.85 0.62 Allowed 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 111.98 0.363 . . . . 0.0 111.98 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -160.81 35.97 0.15 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.927 0.394 . . . . 0.0 110.781 179.447 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.494 ' O ' HG23 ' A' ' 139' ' ' VAL . 19.2 m-85 -146.16 172.3 13.64 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.793 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.449 ' O ' HG12 ' A' ' 165' ' ' VAL . 33.8 p -122.55 -172.12 2.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.877 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -156.64 144.02 10.31 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.626 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.6 m -93.04 105.82 17.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.841 0.353 . . . . 0.0 110.845 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.586 ' HA ' HG12 ' A' ' 163' ' ' VAL . 25.1 t -61.9 137.74 23.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.403 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 65.4 p -119.88 -49.06 2.33 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.69 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -128.72 159.64 35.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.871 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mp -142.43 132.18 22.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.13 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -104.61 108.96 62.17 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.75 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -74.2 -44.05 0.48 Allowed 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.432 2.088 . . . . 0.0 112.409 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -65.4 -44.64 86.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.017 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 1.5 mtt180 -83.97 -41.08 17.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.894 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 89.49 36.72 7.31 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.336 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 24.6 mtpt -117.62 177.6 4.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.759 0.314 . . . . 0.0 110.941 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.554 HG23 HG13 ' A' ' 151' ' ' VAL . 1.3 p -159.91 159.57 2.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.09 0.471 . . . . 0.0 111.054 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 162' ' ' LYS . . . . . 0.469 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 20.3 tttm -127.53 133.3 49.83 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.799 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.825 HG22 HD11 ' A' ' 176' ' ' LEU . 18.3 m -139.17 160.16 29.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.177 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 12.5 ptp -102.29 116.22 32.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.603 179.706 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.449 HG12 ' O ' ' A' ' 148' ' ' THR . 15.5 m -107.62 160.26 6.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.362 -179.667 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 6.9 t -152.1 135.26 15.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.722 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.1 mp -91.8 -67.0 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.131 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -148.52 87.13 1.56 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.832 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 70.24 25.69 75.28 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.455 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 4.4 ttm180 -148.76 112.51 5.09 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.872 0.368 . . . . 0.0 110.889 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -89.46 157.39 18.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.836 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 65.1 m -160.11 112.39 1.42 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.969 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -71.72 121.18 7.43 Favored 'Trans proline' 0 C--N 1.347 0.46 0 C-N-CA 122.438 2.092 . . . . 0.0 112.117 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 27.4 m -128.08 142.79 42.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.362 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -93.28 127.85 39.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.672 179.791 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.825 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -137.45 -159.87 1.0 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.324 0.583 . . . . 0.0 111.203 -179.769 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.406 ' O ' ' N ' ' A' ' 180' ' ' GLN . 0.1 OUTLIER -149.47 154.11 38.31 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 115.103 -0.953 . . . . 0.0 110.269 178.447 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 31.0 m-85 -43.99 -28.57 0.48 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.862 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.09 8.12 7.81 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 111.865 0.32 . . . . 0.0 111.865 -179.791 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.406 ' N ' ' O ' ' A' ' 177' ' ' ASP . 8.6 mt-30 -131.05 9.25 4.84 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.601 0.238 . . . . 0.0 111.27 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 5.6 m -141.85 174.69 6.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 120.751 0.31 . . . . 0.0 111.089 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 17.3 m -147.55 154.49 11.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.132 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.25 134.02 44.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.899 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.267 -0.873 . . . . 0.0 111.092 -179.937 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.778 0.323 . . . . 0.0 110.872 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -62.48 139.42 58.58 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.833 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 97.34 -24.61 30.69 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.567 -179.987 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -58.0 -168.59 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.737 0.304 . . . . 0.0 111.009 -179.947 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 5.1 mm-40 -135.27 138.64 43.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.084 -179.907 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.513 ' HB ' ' O ' ' A' ' 182' ' ' VAL . 27.1 m -136.93 157.5 35.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.913 179.911 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.451 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 1.0 OUTLIER -90.49 165.93 13.52 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.944 0.402 . . . . 0.0 110.883 179.904 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.814 HG23 ' O ' ' A' ' 147' ' ' PHE . 5.2 t -79.95 168.31 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.046 -179.914 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.67 HG13 ' H ' ' A' ' 141' ' ' SER . 1.7 p -79.25 -65.41 0.78 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.778 -179.544 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.71 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 4.0 m -160.24 -164.43 1.27 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.849 0.357 . . . . 0.0 111.082 -179.552 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.53 -160.53 41.75 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.446 179.989 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -67.46 -11.6 32.73 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.421 2.08 . . . . 0.0 112.406 179.689 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.534 ' HB2' HG11 ' A' ' 139' ' ' VAL . 4.2 m-85 -107.92 19.67 19.74 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.105 -179.997 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.71 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -80.53 37.51 0.41 Allowed 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 112.197 0.443 . . . . 0.0 112.197 -179.467 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -161.08 35.6 0.14 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.996 0.427 . . . . 0.0 110.836 179.423 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.814 ' O ' HG23 ' A' ' 139' ' ' VAL . 8.6 m-85 -146.55 153.86 40.86 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.646 -179.892 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.624 ' O ' HG12 ' A' ' 165' ' ' VAL . 44.4 p -103.01 -179.91 4.09 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.816 -179.957 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -143.12 149.37 21.3 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.541 -0.838 . . . . 0.0 112.661 -179.818 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 16.2 m -95.73 102.69 14.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.831 0.348 . . . . 0.0 110.654 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.708 ' HA ' HG12 ' A' ' 163' ' ' VAL . 46.4 t -59.98 116.67 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.059 -179.917 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 3.3 p -97.02 -47.12 5.92 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.828 179.973 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -138.84 158.51 44.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.86 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 32.0 mt -131.08 141.57 45.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.198 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.4 m-20 -121.86 100.79 43.05 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.67 179.969 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -63.58 -55.62 0.67 Allowed 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.613 2.209 . . . . 0.0 112.43 -179.765 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -57.54 -43.75 84.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.414 -179.662 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 1.9 tpm_? -79.97 -26.2 40.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.154 -179.728 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 69.69 31.07 70.4 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.313 -179.902 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 20.0 mttt -111.7 165.17 12.27 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.78 0.324 . . . . 0.0 111.0 -179.902 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.627 HG22 ' HA ' ' A' ' 177' ' ' ASP . 6.9 m -147.3 126.34 4.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.006 179.907 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 3.5 ttmt -101.2 127.86 47.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.021 -179.899 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.708 HG12 ' HA ' ' A' ' 151' ' ' VAL . 18.8 m -141.74 149.47 19.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.218 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 164' ' ' MET . . . . . 0.443 ' O ' ' HG3' ' A' ' 164' ' ' MET . 0.0 OUTLIER -98.52 120.66 39.33 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.843 179.687 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.624 HG12 ' O ' ' A' ' 148' ' ' THR . 31.2 m -107.05 153.99 8.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.347 -179.685 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 166' ' ' THR . . . . . 0.411 HG22 ' HA ' ' A' ' 171' ' ' GLU . 0.7 OUTLIER -122.14 147.92 45.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.773 179.888 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 2.0 mp -102.85 -62.73 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.08 -179.973 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.3 59.51 1.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.881 -179.915 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 98.21 -20.76 49.22 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.575 -179.972 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 4.0 ttt180 -97.79 127.73 43.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.788 0.328 . . . . 0.0 110.975 -179.924 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 171' ' ' GLU . . . . . 0.411 ' HA ' HG22 ' A' ' 166' ' ' THR . 0.1 OUTLIER -84.24 155.13 22.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.856 179.968 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 42.1 m -157.79 101.11 1.81 Allowed Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.88 179.888 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -67.36 113.64 2.96 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.453 2.102 . . . . 0.0 112.192 -179.997 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.4 t -128.9 150.94 35.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.151 -179.931 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.99 157.34 26.84 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.754 179.949 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.849 HD22 HG13 ' A' ' 181' ' ' VAL . 1.0 OUTLIER -154.78 -171.06 3.71 Favored 'General case' 0 CA--C 1.516 -0.348 0 CA-C-O 121.26 0.552 . . . . 0.0 111.164 -179.963 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.627 ' HA ' HG22 ' A' ' 161' ' ' VAL . 3.5 m-20 -150.14 152.97 35.55 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.462 178.421 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -46.86 -45.19 20.14 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.388 -179.815 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 9.2 t -79.52 -1.53 38.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.531 -179.85 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.626 ' HB3' HD23 ' A' ' 176' ' ' LEU . 1.2 mt-30 -112.41 7.41 19.13 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.581 -0.281 . . . . 0.0 111.392 -179.84 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.849 HG13 HD22 ' A' ' 176' ' ' LEU . 23.2 m -136.23 178.58 4.86 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.927 0.394 . . . . 0.0 111.274 179.933 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 182' ' ' VAL . . . . . 0.513 ' O ' ' HB ' ' A' ' 137' ' ' VAL . 0.4 OUTLIER -133.34 -150.58 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.346 -179.965 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -122.52 138.86 54.43 Favored 'General case' 0 C--N 1.331 -0.197 0 O-C-N 122.176 -0.327 . . . . 0.0 111.0 -179.918 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.044 0 CA-C-O 118.166 -0.921 . . . . 0.0 111.098 179.864 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 44.4 mtm180 . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.934 0.397 . . . . 0.0 110.923 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -56.67 155.92 6.99 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.803 -179.939 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.55 8.21 59.49 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.86 -179.856 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.34 179.1 0.23 Allowed 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.801 0.334 . . . . 0.0 110.789 179.893 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 10.7 mt-30 -139.92 133.32 30.01 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.116 -179.859 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.587 HG12 ' HA ' ' A' ' 183' ' ' LYS . 23.1 m -142.49 146.18 22.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.774 179.88 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.464 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.5 OUTLIER -79.72 167.12 21.07 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 121.039 0.447 . . . . 0.0 111.172 -179.829 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.894 HG23 ' O ' ' A' ' 147' ' ' PHE . 20.3 t -79.75 152.27 4.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.366 -179.571 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 14.7 p -92.47 -24.42 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 CA-C-N 116.082 -0.508 . . . . 0.0 112.148 -179.326 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.669 ' O ' ' HB2' ' A' ' 145' ' ' ALA . 9.8 m -79.4 153.89 29.39 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.888 0.375 . . . . 0.0 111.274 -178.952 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 142' ' ' GLY . . . . . 0.435 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -66.13 -61.48 5.44 Favored Glycine 0 CA--C 1.519 0.312 0 C-N-CA 121.046 -0.597 . . . . 0.0 112.777 -179.86 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.435 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.6 Cg_endo -52.82 -23.85 21.99 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.581 2.188 . . . . 0.0 112.278 179.885 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.828 ' HB2' HG11 ' A' ' 139' ' ' VAL . 17.4 m-85 -111.6 2.64 17.43 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.281 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.669 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -70.22 50.02 0.11 Allowed 'General case' 0 C--O 1.233 0.218 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -179.163 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 146' ' ' ASP . . . . . 0.402 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 5.7 t70 -160.68 32.21 0.15 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.045 0.45 . . . . 0.0 110.399 179.134 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.894 ' O ' HG23 ' A' ' 139' ' ' VAL . 65.8 m-85 -155.24 146.2 22.52 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.376 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.765 ' O ' HG12 ' A' ' 165' ' ' VAL . 19.3 p -103.38 170.63 7.83 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.372 -0.377 . . . . 0.0 111.004 -179.853 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 149' ' ' GLY . . . . . 0.404 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -126.77 130.12 6.84 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.593 -179.969 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.3 m -92.22 106.21 18.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.759 0.314 . . . . 0.0 110.892 -179.99 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.452 HG22 HG12 ' A' ' 163' ' ' VAL . 20.2 t -63.79 106.79 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.936 179.928 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 152' ' ' THR . . . . . 0.433 HG21 ' HE2' ' A' ' 162' ' ' LYS . 1.6 t -88.12 -30.67 19.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.878 -179.933 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -158.71 162.79 37.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.898 179.947 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.8 mt -126.12 130.46 72.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.126 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 70.6 m-20 -102.7 95.33 6.12 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.834 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.34 -34.93 11.78 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.409 2.073 . . . . 0.0 112.328 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -66.73 -31.44 72.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.942 -180.0 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -96.39 -43.6 7.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.898 -179.921 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 96.73 38.71 4.34 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.401 -179.889 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.4 mttm -135.1 175.61 9.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.888 0.375 . . . . 0.0 110.996 -179.974 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.665 HG11 ' CE1' ' A' ' 178' ' ' PHE . 5.2 m -136.59 127.78 42.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.002 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 162' ' ' LYS . . . . . 0.433 ' HE2' HG21 ' A' ' 152' ' ' THR . 18.0 tttt -87.3 111.75 21.37 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.847 -179.958 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.452 HG12 HG22 ' A' ' 151' ' ' VAL . 31.4 m -124.13 148.58 28.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.296 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 12.5 ptm -102.01 120.09 39.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.833 179.97 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.765 HG12 ' O ' ' A' ' 148' ' ' THR . 18.5 m -124.2 136.6 59.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.896 0.379 . . . . 0.0 111.213 -179.984 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 2.7 m -95.55 142.49 27.83 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.778 179.85 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.457 ' O ' HG13 ' A' ' 167' ' ' ILE . 3.8 tp -117.17 42.08 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.1 0.476 . . . . 0.0 110.95 -179.942 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER 63.99 99.18 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.847 179.877 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 125.8 -48.79 0.94 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.434 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 8.6 ptt180 -160.07 160.03 32.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.844 0.354 . . . . 0.0 110.894 179.948 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -66.67 166.23 13.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.82 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -154.65 90.03 3.15 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.967 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -68.42 102.54 0.84 Allowed 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.502 2.134 . . . . 0.0 112.255 179.938 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.502 HG22 HG22 ' A' ' 165' ' ' VAL . 34.8 m -119.1 137.97 51.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.114 -179.966 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -79.84 120.88 24.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.494 179.57 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.82 HD13 HG13 ' A' ' 181' ' ' VAL . 7.6 mt -124.31 -170.55 2.16 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.341 0.591 . . . . 0.0 111.504 -179.395 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.476 ' HA ' HG22 ' A' ' 161' ' ' VAL . 5.0 m-20 -143.08 155.5 44.62 Favored 'General case' 0 N--CA 1.442 -0.848 0 CA-C-N 114.996 -1.002 . . . . 0.0 110.197 178.129 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 178' ' ' PHE . . . . . 0.665 ' CE1' HG11 ' A' ' 161' ' ' VAL . 9.6 m-85 -48.54 -30.86 5.71 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.509 -179.606 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -79.86 -0.32 34.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.463 179.955 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.765 ' CB ' HD22 ' A' ' 176' ' ' LEU . 30.7 mt-30 -119.59 5.51 11.06 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.609 -0.268 . . . . 0.0 111.316 -179.964 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.82 HG13 HD13 ' A' ' 176' ' ' LEU . 5.3 m -143.46 179.69 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.879 0.371 . . . . 0.0 111.212 179.97 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 23.9 m -152.68 146.61 15.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.016 179.958 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.587 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.1 OUTLIER -63.42 125.93 25.78 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.908 -179.977 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.001 0 CA-C-O 118.201 -0.904 . . . . 0.0 111.002 -179.952 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 51.1 ttt-85 . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.732 0.301 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -59.85 117.82 5.47 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.923 179.978 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.615 ' HA2' HG22 ' A' ' 150' ' ' THR . . . 107.19 16.36 13.66 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.831 -0.7 . . . . 0.0 112.756 179.998 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -76.41 158.63 31.2 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.86 0.362 . . . . 0.0 110.81 179.948 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.1 tt0 -101.17 128.26 47.36 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.957 -179.992 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.934 HG12 ' HA ' ' A' ' 183' ' ' LYS . 11.3 m -141.61 135.87 30.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.814 179.965 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.426 ' CZ ' ' HB2' ' A' ' 138' ' ' ARG . 0.7 OUTLIER -79.79 162.95 24.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.943 0.402 . . . . 0.0 110.873 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.58 HG11 ' HB2' ' A' ' 144' ' ' PHE . 4.9 t -79.88 167.85 2.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.947 -179.84 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.638 HG13 ' H ' ' A' ' 141' ' ' SER . 2.4 p -79.35 -61.95 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.276 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.898 -179.264 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.686 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.1 OUTLIER -160.23 -164.57 1.29 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.734 0.302 . . . . 0.0 111.216 -179.581 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.46 -164.15 49.0 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.368 179.972 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -63.27 -16.08 52.26 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.383 2.056 . . . . 0.0 112.146 179.666 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.58 ' HB2' HG11 ' A' ' 139' ' ' VAL . 2.6 m-85 -101.31 15.73 27.85 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.185 179.956 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.686 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -78.48 37.26 0.27 Allowed 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 112.411 0.523 . . . . 0.0 112.411 -179.345 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 146' ' ' ASP . . . . . 0.414 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 1.9 t0 -161.11 32.8 0.14 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.033 0.444 . . . . 0.0 110.78 179.146 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.518 ' CE2' HG22 ' A' ' 167' ' ' ILE . 22.8 m-85 -140.77 170.06 16.47 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.616 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.407 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 3.1 p -118.05 -179.38 3.74 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.799 179.934 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -150.36 138.67 6.83 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.592 -179.978 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 150' ' ' THR . . . . . 0.615 HG22 ' HA2' ' A' ' 134' ' ' GLY . 3.3 m -97.82 107.49 20.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.777 0.322 . . . . 0.0 110.851 179.833 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.624 ' HA ' HG12 ' A' ' 163' ' ' VAL . 23.5 t -55.52 115.7 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.236 -179.822 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.87 -33.19 8.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.877 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -144.56 157.82 44.04 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.839 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mp -141.1 129.45 23.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.15 179.993 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -100.5 98.58 8.25 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.779 -179.943 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.4 -43.26 2.22 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.527 2.152 . . . . 0.0 112.347 -179.984 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -78.39 -38.65 41.23 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.881 -179.901 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.0 -34.88 38.15 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.859 -179.901 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 80.59 67.31 1.56 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.48 -179.992 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 30.7 mttm -152.05 173.39 14.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.798 0.333 . . . . 0.0 110.933 -179.978 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.806 ' O ' HD12 ' A' ' 176' ' ' LEU . 4.1 m -149.34 122.3 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.02 179.943 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 36.0 ttmt -104.61 135.31 46.25 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.997 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 1.029 HG22 HD11 ' A' ' 176' ' ' LEU . 33.9 m -138.76 163.47 27.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.104 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -103.12 111.43 23.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.611 179.722 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.438 HG22 HG12 ' A' ' 174' ' ' VAL . 28.5 m -101.86 167.65 2.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.173 -179.803 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 1.5 m -131.11 125.11 32.25 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.872 -179.959 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.518 HG22 ' CE2' ' A' ' 147' ' ' PHE . 1.5 pp -149.09 138.76 15.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.124 179.879 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 62.41 30.29 17.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.774 -179.947 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 64.78 42.57 97.04 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.532 -179.926 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 66.4 mtp180 -157.17 137.96 13.28 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.809 0.338 . . . . 0.0 110.894 -179.984 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 15.5 mp0 -81.51 127.05 32.42 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.735 179.864 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.17 115.21 11.84 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.041 -179.866 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.37 113.19 3.53 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.483 2.122 . . . . 0.0 112.075 179.889 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.438 HG12 HG22 ' A' ' 165' ' ' VAL . 10.7 p -123.69 136.55 59.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.259 -179.834 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -80.49 146.86 31.15 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.68 179.742 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 1.029 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -137.78 -165.05 1.71 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.385 0.612 . . . . 0.0 111.313 -179.721 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.7 ' O ' HG22 ' A' ' 181' ' ' VAL . 5.4 m-20 -152.84 155.31 36.86 Favored 'General case' 0 N--CA 1.446 -0.643 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.923 178.392 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -47.63 -40.89 20.74 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.517 -179.668 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 18.2 p -78.82 -2.32 39.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.734 -179.799 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 79.5 mt-30 -120.23 9.25 11.02 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.574 0.226 . . . . 0.0 111.519 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.7 HG22 ' O ' ' A' ' 177' ' ' ASP . 22.7 m -146.02 165.01 9.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.85 0.357 . . . . 0.0 111.196 179.943 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.0 m -143.8 146.46 20.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.048 179.911 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.934 ' HA ' HG12 ' A' ' 137' ' ' VAL . 4.9 tttt -65.85 137.36 57.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.022 179.949 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.204 -0.903 . . . . 0.0 111.139 -179.981 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.927 0.394 . . . . 0.0 110.794 . . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -69.33 135.95 51.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.892 179.929 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 67.18 21.26 71.83 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.609 179.933 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -78.69 163.47 25.4 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.776 0.322 . . . . 0.0 110.801 179.979 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 35.1 mt-30 -103.16 125.21 49.75 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.052 -179.907 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.666 HG12 ' HA ' ' A' ' 183' ' ' LYS . 31.5 m -134.73 144.13 35.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.968 179.974 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.427 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.82 167.3 20.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.936 0.398 . . . . 0.0 110.887 179.978 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.781 HG23 ' O ' ' A' ' 147' ' ' PHE . 7.6 t -79.82 168.0 2.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.92 -179.932 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.659 HG13 ' H ' ' A' ' 141' ' ' SER . 2.7 p -79.54 -62.82 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 112.001 0.371 . . . . 0.0 112.001 -179.193 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.659 ' H ' HG13 ' A' ' 140' ' ' VAL . 0.3 OUTLIER -160.4 -164.15 1.21 Allowed 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.87 0.367 . . . . 0.0 111.105 -179.622 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 78.7 -167.1 52.66 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.94 -0.647 . . . . 0.0 112.456 179.89 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -61.93 -17.25 54.66 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.422 2.082 . . . . 0.0 112.094 179.699 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.49 ' HB2' HG11 ' A' ' 139' ' ' VAL . 4.3 m-85 -98.6 20.28 13.15 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.141 179.886 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.475 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -82.6 39.87 0.63 Allowed 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.496 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -160.77 36.22 0.15 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.998 0.428 . . . . 0.0 110.605 179.406 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.868 ' CZ ' HG22 ' A' ' 167' ' ' ILE . 26.4 m-85 -148.18 160.22 43.15 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.682 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.481 ' O ' HG12 ' A' ' 165' ' ' VAL . 7.3 p -109.47 -178.12 3.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.852 179.894 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 149' ' ' GLY . . . . . 0.422 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -147.85 140.07 8.19 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.609 -179.848 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.9 m -97.0 109.19 22.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.737 0.304 . . . . 0.0 110.957 179.99 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 17.5 t -64.47 101.96 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.259 -179.989 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.36 -33.74 15.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.799 179.854 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -139.83 150.12 44.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.979 179.965 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 16.5 mt -130.99 136.77 57.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.067 -179.969 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -127.83 86.16 58.94 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.759 179.963 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.61 -37.49 7.08 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.515 2.144 . . . . 0.0 112.374 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -59.84 -42.87 94.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.859 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.3 -38.52 16.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.824 179.947 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 97.32 43.37 3.0 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.621 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -139.1 159.12 42.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.859 0.362 . . . . 0.0 110.865 -179.961 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.447 ' CG2' ' CE1' ' A' ' 178' ' ' PHE . 6.1 t -131.05 157.62 43.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.001 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 162' ' ' LYS . . . . . 0.411 ' N ' HG12 ' A' ' 161' ' ' VAL . 22.2 tttm -122.07 108.29 13.19 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.943 -179.992 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.422 ' HB ' ' HA3' ' A' ' 149' ' ' GLY . 31.0 m -123.38 146.55 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.263 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 15.0 ptp -99.39 123.49 43.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.687 179.9 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.481 HG12 ' O ' ' A' ' 148' ' ' THR . 17.0 m -115.25 158.11 15.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.318 -179.893 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 166' ' ' THR . . . . . 0.407 HG23 ' HA ' ' A' ' 171' ' ' GLU . 1.2 m -137.61 125.45 22.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.758 179.973 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.868 HG22 ' CZ ' ' A' ' 147' ' ' PHE . 1.8 pp -130.15 147.07 33.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.128 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 62.82 -79.91 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.973 -179.996 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -167.73 36.21 0.22 Allowed Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.446 -179.926 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 6.4 mmt85 -153.19 133.29 13.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.748 0.309 . . . . 0.0 110.936 179.972 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 171' ' ' GLU . . . . . 0.407 ' HA ' HG23 ' A' ' 166' ' ' THR . 1.1 tt0 -81.05 137.82 36.01 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.758 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 9.3 m -141.86 103.44 5.78 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.061 -179.88 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -72.09 114.44 3.98 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.475 2.117 . . . . 0.0 112.167 179.785 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.3 t -125.38 144.97 33.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.37 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -80.02 136.63 36.64 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.671 179.936 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.916 HD13 HG13 ' A' ' 181' ' ' VAL . 5.6 mt -133.05 -168.04 2.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.063 0.459 . . . . 0.0 111.329 -179.843 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -142.33 151.83 42.34 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.603 178.382 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 178' ' ' PHE . . . . . 0.447 ' CE1' ' CG2' ' A' ' 161' ' ' VAL . 20.7 m-85 -47.8 -38.2 15.25 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.502 -179.608 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.4 m -82.05 11.46 5.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.558 179.978 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.813 ' HB3' HD22 ' A' ' 176' ' ' LEU . 4.3 mp0 -120.74 3.49 10.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.668 -0.242 . . . . 0.0 111.28 179.922 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.916 HG13 HD13 ' A' ' 176' ' ' LEU . 2.9 m -144.08 177.69 2.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-O 120.858 0.361 . . . . 0.0 111.301 -179.957 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 27.8 m -143.32 146.42 21.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.116 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.666 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.6 OUTLIER -71.4 128.62 36.46 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.95 179.954 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.139 -0.934 . . . . 0.0 111.055 -179.991 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 8.2 mtt180 . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.775 0.322 . . . . 0.0 110.904 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -59.49 141.05 55.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.87 -179.976 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 90.96 -14.3 63.78 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.759 -179.852 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -61.34 174.0 0.79 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.825 0.345 . . . . 0.0 110.966 -179.962 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -112.76 143.09 44.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.895 -179.854 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.706 HG12 ' HA ' ' A' ' 183' ' ' LYS . 15.6 m -140.18 138.66 37.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.991 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.427 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.94 166.45 21.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.826 0.346 . . . . 0.0 110.945 179.973 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.568 HG12 ' H ' ' A' ' 140' ' ' VAL . 3.4 t -79.78 169.19 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.892 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.739 HG22 ' OG ' ' A' ' 141' ' ' SER . 2.1 p -79.48 -65.35 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.814 -179.413 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.739 ' OG ' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -160.44 -163.48 1.1 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.859 0.361 . . . . 0.0 111.102 -179.65 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.27 -165.28 50.28 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.419 179.908 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -61.7 -17.74 56.39 Favored 'Trans proline' 0 C--N 1.343 0.248 0 C-N-CA 122.481 2.12 . . . . 0.0 112.124 179.74 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.457 ' HB2' HG11 ' A' ' 139' ' ' VAL . 2.0 m-85 -102.15 22.04 13.88 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.978 179.947 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.625 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -83.29 38.95 0.63 Allowed 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.133 0.42 . . . . 0.0 112.133 -179.436 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -160.8 36.5 0.15 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.914 0.388 . . . . 0.0 110.771 179.4 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.418 ' O ' HG23 ' A' ' 139' ' ' VAL . 22.0 m-85 -141.35 172.99 11.93 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.645 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.429 ' O ' HG12 ' A' ' 165' ' ' VAL . 0.2 OUTLIER -125.0 171.01 10.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.99 179.986 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -137.12 136.2 8.15 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.504 -179.988 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 2.8 m -89.31 100.87 13.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.846 0.355 . . . . 0.0 110.81 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.619 ' HA ' HG12 ' A' ' 163' ' ' VAL . 21.5 t -58.9 115.04 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.267 -179.92 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 73.7 p -102.1 -32.28 10.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.842 179.954 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -151.91 160.2 43.59 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.942 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 6.5 pt -133.19 145.6 33.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.052 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -130.15 72.23 81.98 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.967 -179.985 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -59.3 -29.04 89.23 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.614 2.209 . . . . 0.0 112.323 -179.939 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -57.98 -52.25 66.28 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.947 -179.928 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 3.2 tpm_? -90.82 -39.11 12.53 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.89 -179.966 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 105.9 41.81 1.77 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.432 179.975 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 30.7 mttp -131.29 158.71 39.92 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.768 0.318 . . . . 0.0 110.79 179.946 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.481 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.3 p -141.48 159.76 21.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 121.116 0.484 . . . . 0.0 110.91 -179.902 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 162' ' ' LYS . . . . . 0.481 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 25.6 ttmt -123.7 129.18 50.71 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.969 179.825 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.837 ' CG2' HD12 ' A' ' 176' ' ' LEU . 18.4 m -145.18 140.44 22.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.115 -179.933 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.09 133.68 33.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.795 179.857 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.429 HG12 ' O ' ' A' ' 148' ' ' THR . 15.5 m -124.91 167.85 18.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.174 -179.998 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -117.43 151.06 37.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.963 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.564 HD13 ' HB2' ' A' ' 168' ' ' PHE . 0.0 OUTLIER -157.18 119.16 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.947 -179.953 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 168' ' ' PHE . . . . . 0.564 ' HB2' HD13 ' A' ' 167' ' ' ILE . 0.3 OUTLIER 61.01 30.39 19.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.728 -179.867 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 77.6 31.68 49.26 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.47 179.961 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 17.9 mtm180 -142.25 144.39 33.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.895 0.378 . . . . 0.0 110.841 -179.897 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -80.9 148.95 29.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.831 179.867 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 172' ' ' THR . . . . . 0.653 ' O ' HG23 ' A' ' 174' ' ' VAL . 68.5 m -154.82 91.9 2.93 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.064 179.973 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -58.74 104.27 0.18 Allowed 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.529 2.153 . . . . 0.0 112.157 179.998 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.653 HG23 ' O ' ' A' ' 172' ' ' THR . 21.5 t -122.18 142.23 39.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.162 -179.94 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -79.91 159.56 26.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.866 179.849 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.852 HD13 ' CG1' ' A' ' 181' ' ' VAL . 4.9 mt -147.5 -171.38 3.78 Favored 'General case' 0 CA--C 1.516 -0.347 0 CA-C-O 121.266 0.555 . . . . 0.0 111.223 -179.636 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.542 ' O ' HG22 ' A' ' 181' ' ' VAL . 1.5 m-20 -145.11 153.29 41.25 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.415 178.102 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 30.2 m-85 -48.38 -41.64 29.44 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.333 -179.708 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.7 m -78.51 -2.14 37.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.343 -179.959 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.404 ' HB3' ' CD2' ' A' ' 176' ' ' LEU . 4.8 mt-30 -116.84 6.58 13.16 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.594 -0.276 . . . . 0.0 111.345 -179.787 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.852 ' CG1' HD13 ' A' ' 176' ' ' LEU . 27.4 m -142.75 -179.44 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.959 0.409 . . . . 0.0 111.271 -179.91 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 12.6 m -155.34 146.5 12.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.977 179.956 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.706 ' HA ' HG12 ' A' ' 137' ' ' VAL . 4.0 tmtt? -72.38 138.26 47.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.968 -179.955 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.086 0 CA-C-O 118.256 -0.878 . . . . 0.0 111.151 179.997 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.877 0.37 . . . . 0.0 110.854 . . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -60.13 128.6 37.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.981 179.906 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 121.97 -24.92 6.93 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.529 -179.962 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -59.31 169.81 1.1 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.816 0.341 . . . . 0.0 110.882 -179.887 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -124.94 136.21 53.54 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.059 -179.921 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.784 HG12 ' HA ' ' A' ' 183' ' ' LYS . 12.6 m -140.52 145.21 26.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.723 179.924 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.401 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.81 163.76 24.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.034 0.445 . . . . 0.0 111.125 -179.801 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.832 HG11 ' HB2' ' A' ' 144' ' ' PHE . 46.7 t -79.77 147.44 6.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.548 -179.672 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 12.5 p -86.27 -21.83 7.39 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 CA-C-N 116.02 -0.536 . . . . 0.0 112.35 -179.555 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.756 ' H ' HG12 ' A' ' 139' ' ' VAL . 1.7 m -79.18 152.83 30.47 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.939 0.4 . . . . 0.0 111.475 -178.783 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 142' ' ' GLY . . . . . 0.427 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -66.74 -61.79 5.03 Favored Glycine 0 C--N 1.332 0.34 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.699 -179.811 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.427 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.2 Cg_endo -53.41 -23.56 24.78 Favored 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.548 2.166 . . . . 0.0 112.083 179.853 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.832 ' HB2' HG11 ' A' ' 139' ' ' VAL . 9.2 m-85 -110.73 2.66 18.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.375 179.751 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.66 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -70.36 48.99 0.11 Allowed 'General case' 0 C--N 1.332 -0.193 0 N-CA-C 112.448 0.536 . . . . 0.0 112.448 -179.074 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 146' ' ' ASP . . . . . 0.464 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 16.4 p-10 -160.44 29.91 0.16 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.172 0.511 . . . . 0.0 110.49 179.116 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.682 ' O ' HG23 ' A' ' 139' ' ' VAL . 15.2 m-85 -150.44 147.97 28.18 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.183 179.741 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.401 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 69.6 p -102.25 168.58 9.26 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.798 0.333 . . . . 0.0 110.708 179.888 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -128.86 129.05 6.03 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.634 -0.793 . . . . 0.0 112.539 -179.865 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.7 m -86.76 105.83 17.25 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.739 0.305 . . . . 0.0 110.73 179.886 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.474 HG13 HG23 ' A' ' 161' ' ' VAL . 30.2 t -62.76 117.78 4.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.083 -179.862 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -93.04 -46.35 7.5 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.925 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -144.89 152.68 40.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.864 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mt -112.58 148.37 15.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.128 -179.951 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -119.24 84.01 26.77 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.85 -179.974 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -72.93 -37.88 3.31 Favored 'Trans proline' 0 C--N 1.343 0.27 0 C-N-CA 122.571 2.181 . . . . 0.0 112.303 179.969 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -60.13 -55.1 38.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.835 -179.93 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 12.6 ttt-85 -79.9 -67.11 0.79 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.004 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 129.92 59.49 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.498 -179.953 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 5.5 mtmm -155.64 -179.09 7.78 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.801 0.334 . . . . 0.0 110.84 -179.953 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.48 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.2 p -154.44 159.81 2.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.896 179.915 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 162' ' ' LYS . . . . . 0.48 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 10.8 tttt -124.15 127.75 48.24 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.932 -179.9 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.449 HG12 ' HA ' ' A' ' 151' ' ' VAL . 16.7 m -136.16 156.65 36.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.183 -179.991 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 16.4 ptm -106.54 120.02 40.83 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.004 179.93 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.752 ' O ' HG22 ' A' ' 172' ' ' THR . 2.6 t -117.62 153.83 19.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.102 -179.956 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 166' ' ' THR . . . . . 0.408 HG23 ' C ' ' A' ' 170' ' ' ARG . 2.3 m -100.8 142.82 31.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.935 179.918 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.561 HD13 ' C ' ' A' ' 167' ' ' ILE . 0.0 OUTLIER -159.78 -46.29 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.147 179.972 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 168' ' ' PHE . . . . . 0.5 ' N ' HG23 ' A' ' 167' ' ' ILE . 5.0 p90 -97.58 35.25 1.69 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.973 179.965 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 96.48 -30.98 7.94 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.448 -179.912 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 170' ' ' ARG . . . . . 0.408 ' C ' HG23 ' A' ' 166' ' ' THR . 0.0 OUTLIER -130.63 177.34 7.46 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.894 0.378 . . . . 0.0 110.691 179.953 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -69.51 168.26 15.0 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.881 -179.939 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 172' ' ' THR . . . . . 0.752 HG22 ' O ' ' A' ' 165' ' ' VAL . 11.5 t -148.05 124.73 5.49 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.829 -179.914 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -71.77 97.36 0.81 Allowed 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.427 2.084 . . . . 0.0 112.331 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.522 HG23 HG23 ' A' ' 172' ' ' THR . 10.5 t -121.67 132.86 69.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.164 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -79.91 124.41 28.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.124 179.436 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.821 HD12 ' HB3' ' A' ' 180' ' ' GLN . 1.8 mm? -127.41 -170.08 2.16 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.322 0.582 . . . . 0.0 111.639 -179.164 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.428 ' HA ' HG12 ' A' ' 161' ' ' VAL . 0.4 OUTLIER -142.38 152.98 43.39 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.394 178.342 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -42.5 -58.42 2.26 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.607 -179.596 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 6.0 t -56.28 -23.0 33.64 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.241 179.998 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.821 ' HB3' HD12 ' A' ' 176' ' ' LEU . 5.4 mp0 -89.57 3.88 51.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.638 -179.837 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.42 HG22 ' O ' ' A' ' 177' ' ' ASP . 16.5 m -147.44 167.95 4.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.811 0.339 . . . . 0.0 111.166 179.967 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.4 m -145.08 146.19 20.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.1 179.872 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.784 ' HA ' HG12 ' A' ' 137' ' ' VAL . 1.5 tttp -61.68 136.68 58.09 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.825 -179.822 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.246 -0.883 . . . . 0.0 111.036 179.986 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 12.7 tpp180 . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.82 0.343 . . . . 0.0 110.876 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -61.54 144.76 53.79 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.861 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 96.71 -23.6 34.6 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.573 -179.988 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -57.34 163.79 2.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.906 0.384 . . . . 0.0 111.017 -179.994 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 136' ' ' GLN . . . . . 0.444 ' NE2' HG23 ' A' ' 150' ' ' THR . 33.0 mm-40 -121.06 139.14 53.72 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.969 -179.918 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.7 HG12 ' HA ' ' A' ' 183' ' ' LYS . 20.9 m -137.01 140.76 42.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.82 179.989 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.477 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.7 162.85 24.95 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.027 0.441 . . . . 0.0 111.002 -179.934 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.867 HG11 ' HB2' ' A' ' 144' ' ' PHE . 37.6 t -79.88 151.46 4.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.409 -179.627 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.512 HG13 ' C ' ' A' ' 180' ' ' GLN . 34.3 m -93.1 -21.29 6.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 112.4 0.518 . . . . 0.0 112.4 -179.216 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.697 ' H ' HG12 ' A' ' 139' ' ' VAL . 4.5 m -79.18 153.87 29.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.792 0.33 . . . . 0.0 111.315 -179.013 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 142' ' ' GLY . . . . . 0.423 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -65.12 -62.56 4.82 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 121.058 -0.591 . . . . 0.0 113.006 -179.664 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.423 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.4 Cg_endo -52.81 -23.17 19.84 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.685 2.257 . . . . 0.0 112.379 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.867 ' HB2' HG11 ' A' ' 139' ' ' VAL . 10.2 m-85 -112.62 2.65 16.27 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.471 179.982 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.689 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -70.11 48.39 0.1 Allowed 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -179.117 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -160.72 32.39 0.15 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.13 0.49 . . . . 0.0 110.631 179.109 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.733 ' O ' HG23 ' A' ' 139' ' ' VAL . 42.5 m-85 -154.87 145.59 22.38 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.469 179.946 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.718 ' O ' HG12 ' A' ' 165' ' ' VAL . 67.8 p -99.88 -177.58 3.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.908 -179.879 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -139.85 129.12 4.16 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.596 -179.838 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 150' ' ' THR . . . . . 0.444 HG23 ' NE2' ' A' ' 136' ' ' GLN . 3.0 m -90.05 113.83 25.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.742 0.306 . . . . 0.0 110.68 179.754 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 21.7 t -70.71 120.83 19.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.305 -179.726 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -108.84 -31.75 7.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.713 179.643 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -153.95 161.35 42.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.705 179.824 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.6 mp -134.21 152.43 34.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.331 -179.966 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 -123.17 90.89 50.21 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.806 179.932 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.15 -34.04 13.99 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.613 2.209 . . . . 0.0 112.357 -179.893 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -90.14 18.14 6.25 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.338 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 31.2 ttt85 -138.07 -46.01 0.52 Allowed 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.808 0.337 . . . . 0.0 110.791 179.936 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 99.19 39.82 3.42 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.392 179.962 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 16.3 mtmt -146.18 170.5 16.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.815 0.34 . . . . 0.0 111.086 -179.979 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.475 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.0 OUTLIER -149.43 159.59 5.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.118 0.485 . . . . 0.0 110.795 179.918 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 162' ' ' LYS . . . . . 0.475 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 59.6 tttp -105.21 121.61 44.2 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.967 179.993 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 5.6 m -134.95 134.76 53.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.176 -179.982 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 7.6 ptm -93.55 135.43 34.82 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.841 179.954 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.718 HG12 ' O ' ' A' ' 148' ' ' THR . 27.6 m -134.25 149.76 30.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.217 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 166' ' ' THR . . . . . 0.404 ' O ' ' CD2' ' A' ' 147' ' ' PHE . 3.8 m -113.26 110.57 20.59 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.809 -180.0 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.711 HD13 ' HB2' ' A' ' 168' ' ' PHE . 0.0 OUTLIER -97.32 113.83 32.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.075 179.985 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 168' ' ' PHE . . . . . 0.711 ' HB2' HD13 ' A' ' 167' ' ' ILE . 0.7 OUTLIER 59.52 43.26 16.33 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.894 -179.782 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 66.41 30.68 77.01 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.459 -179.922 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -129.86 124.55 33.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.743 0.306 . . . . 0.0 110.899 -179.905 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.85 126.08 26.18 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.725 179.957 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 2.0 m -150.66 89.68 4.37 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.127 -179.8 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -72.76 125.57 10.64 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.517 2.145 . . . . 0.0 112.104 179.81 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 174' ' ' VAL . . . . . 0.532 HG22 HG22 ' A' ' 165' ' ' VAL . 5.3 m -134.24 136.58 53.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.317 -179.866 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 3.3 pm0 -79.88 126.64 31.26 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.964 179.209 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.783 HD13 HG13 ' A' ' 181' ' ' VAL . 7.0 mt -127.62 -170.08 2.17 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.395 0.617 . . . . 0.0 111.772 -179.131 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.434 ' HA ' HG12 ' A' ' 161' ' ' VAL . 0.5 OUTLIER -141.33 154.59 45.77 Favored 'General case' 0 N--CA 1.442 -0.868 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.357 178.162 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -48.49 -31.14 5.97 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.366 -179.551 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.2 m -79.47 1.2 26.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.574 179.998 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.751 ' CB ' HD22 ' A' ' 176' ' ' LEU . 0.0 OUTLIER -122.12 10.7 10.08 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.652 0.263 . . . . 0.0 111.401 -179.798 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.783 HG13 HD13 ' A' ' 176' ' ' LEU . 14.4 m -149.35 159.14 5.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.944 0.402 . . . . 0.0 111.272 -179.989 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.0 m -123.27 146.48 28.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.048 179.985 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.7 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -71.79 120.46 17.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.864 -179.931 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.267 -0.873 . . . . 0.0 111.082 -179.942 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.789 0.328 . . . . 0.0 110.942 . . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -65.67 134.35 53.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.846 179.872 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 98.36 -2.83 59.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.845 -179.958 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -58.54 167.68 1.38 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.912 0.387 . . . . 0.0 110.897 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.27 116.93 29.78 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.028 179.999 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.714 HG12 ' HA ' ' A' ' 183' ' ' LYS . 30.1 m -123.17 138.76 52.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.833 179.932 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.4 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.99 161.9 25.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.956 0.408 . . . . 0.0 111.142 -179.899 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.579 HG12 ' N ' ' A' ' 140' ' ' VAL . 39.8 t -104.21 167.05 2.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.559 179.702 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.822 HG22 ' O ' ' A' ' 180' ' ' GLN . 16.2 m -138.04 -9.88 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 N-CA-C 113.001 0.741 . . . . 0.0 113.001 -178.874 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.461 ' O ' ' CD2' ' A' ' 144' ' ' PHE . 1.1 m -79.5 142.61 35.66 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.996 0.427 . . . . 0.0 111.761 -178.946 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 35.78 -139.83 0.24 Allowed Glycine 0 C--N 1.335 0.511 0 CA-C-N 115.67 -0.695 . . . . 0.0 113.656 179.523 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -74.3 3.86 4.87 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.691 2.261 . . . . 0.0 112.682 179.761 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.496 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 0.1 OUTLIER -79.57 -10.03 59.73 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.635 -0.257 . . . . 0.0 111.055 179.831 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.455 ' HA ' ' O ' ' A' ' 139' ' ' VAL . . . -68.52 41.84 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -178.996 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 146' ' ' ASP . . . . . 0.431 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 0.8 OUTLIER -160.95 32.78 0.15 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.056 0.455 . . . . 0.0 110.654 179.167 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.431 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 55.8 m-85 -151.7 164.41 37.01 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.582 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.609 ' O ' HG12 ' A' ' 165' ' ' VAL . 80.6 p -118.73 162.86 17.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.734 179.849 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -130.79 163.48 23.35 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.693 -179.847 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.6 m -103.24 103.35 13.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.766 0.317 . . . . 0.0 110.661 179.964 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.672 ' HA ' HG12 ' A' ' 163' ' ' VAL . 46.4 t -60.31 112.61 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.975 -179.935 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -101.81 -42.62 6.09 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.79 179.906 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -120.1 150.97 39.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.794 179.841 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 12.5 pt -143.31 124.14 10.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.154 179.984 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -117.3 86.61 21.99 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.896 -179.993 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -72.52 -20.22 23.89 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.555 2.17 . . . . 0.0 112.516 -179.938 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.38 25.65 2.18 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.389 -179.94 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 2.2 tpm_? -160.0 -45.06 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.772 0.32 . . . . 0.0 110.838 179.979 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 104.04 61.69 0.68 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.459 179.896 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 17.2 mtpt -154.18 149.6 27.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.813 0.34 . . . . 0.0 110.998 179.963 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.671 HG22 ' HA ' ' A' ' 177' ' ' ASP . 26.9 m -147.21 154.04 11.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.18 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 12.6 ttpt -127.13 129.61 48.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.907 -179.952 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.72 HG22 ' CD1' ' A' ' 176' ' ' LEU . 34.9 m -136.6 145.68 29.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.23 179.928 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -89.43 113.32 24.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.459 179.824 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.609 HG12 ' O ' ' A' ' 148' ' ' THR . 20.9 m -123.19 159.76 26.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.359 -179.696 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 166' ' ' THR . . . . . 0.546 HG22 ' HA ' ' A' ' 171' ' ' GLU . 17.2 p -111.55 139.25 47.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.785 179.869 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.805 ' O ' HD13 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -93.32 -36.38 7.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.04 -179.874 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 10.5 t80 -172.82 78.54 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.982 179.996 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 68.44 28.22 73.35 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.425 -179.93 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -156.72 124.28 5.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.728 0.299 . . . . 0.0 110.88 -179.995 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 171' ' ' GLU . . . . . 0.546 ' HA ' HG22 ' A' ' 166' ' ' THR . 67.8 mt-10 -61.08 154.61 22.44 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.788 179.905 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 25.4 m -160.08 89.84 1.82 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.146 -179.925 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -66.13 105.02 0.78 Allowed 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.615 2.21 . . . . 0.0 111.82 179.766 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 31.0 m -118.5 149.39 20.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.349 -179.716 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -89.14 135.91 33.31 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.731 179.759 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.72 ' CD1' HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -146.98 -161.12 1.26 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.397 0.617 . . . . 0.0 110.936 -179.709 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.686 ' O ' HG22 ' A' ' 181' ' ' VAL . 0.8 OUTLIER -151.85 153.2 33.73 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.379 178.474 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 178' ' ' PHE . . . . . 0.634 ' CE1' HG11 ' A' ' 161' ' ' VAL . 23.1 m-85 -42.36 -30.58 0.34 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.677 -179.654 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.4 m -69.57 -39.31 77.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.115 -179.963 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.822 ' O ' HG22 ' A' ' 140' ' ' VAL . 33.3 mt-30 -88.93 8.76 27.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.499 -179.724 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.686 HG22 ' O ' ' A' ' 177' ' ' ASP . 5.4 m -145.72 179.53 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.791 0.329 . . . . 0.0 111.165 179.903 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.6 m -145.09 147.07 19.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.167 179.975 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.714 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.1 OUTLIER -78.3 130.83 36.67 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.887 179.937 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.169 -0.919 . . . . 0.0 111.08 179.977 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.839 0.352 . . . . 0.0 111.028 . . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -71.53 120.73 17.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.851 179.909 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 115.59 -14.96 17.49 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.671 -179.919 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -56.26 174.07 0.15 Allowed 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.795 0.331 . . . . 0.0 110.979 -179.921 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.73 140.67 51.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.95 -179.992 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.594 HG12 ' HA ' ' A' ' 183' ' ' LYS . 19.9 m -144.58 139.79 23.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.021 -179.959 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 138' ' ' ARG . . . . . 0.405 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.97 163.1 24.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.955 0.407 . . . . 0.0 110.945 179.865 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.918 HG11 ' HB2' ' A' ' 144' ' ' PHE . 21.7 t -79.83 156.08 4.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 115.848 -0.615 . . . . 0.0 111.576 -179.659 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.511 HG13 ' C ' ' A' ' 180' ' ' GLN . 33.7 m -96.64 -26.19 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 N-CA-C 112.424 0.528 . . . . 0.0 112.424 -179.135 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.688 ' O ' ' HB2' ' A' ' 145' ' ' ALA . 91.1 p -79.13 155.18 28.83 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.833 0.349 . . . . 0.0 111.401 -178.706 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 142' ' ' GLY . . . . . 0.454 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -64.82 -60.77 6.52 Favored Glycine 0 CA--C 1.52 0.346 0 CA-C-N 115.957 -0.565 . . . . 0.0 113.063 -179.581 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 143' ' ' PRO . . . . . 0.454 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 7.8 Cg_endo -50.11 -24.84 11.79 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.671 2.248 . . . . 0.0 112.507 -179.793 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.918 ' HB2' HG11 ' A' ' 139' ' ' VAL . 7.4 m-85 -115.77 4.52 14.0 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.468 -179.974 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.688 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -69.81 45.21 0.07 Allowed 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -178.809 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 146' ' ' ASP . . . . . 0.412 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 11.8 p-10 -160.69 32.19 0.15 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.032 0.444 . . . . 0.0 110.53 178.929 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.815 ' O ' HG23 ' A' ' 139' ' ' VAL . 64.6 m-85 -153.67 145.3 23.31 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.648 179.891 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.479 ' O ' HG12 ' A' ' 165' ' ' VAL . 1.8 p -102.39 175.73 5.42 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.744 179.863 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 149' ' ' GLY . . . . . 0.427 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -138.47 141.32 11.89 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.685 -179.9 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 4.6 m -93.56 109.84 21.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.837 0.351 . . . . 0.0 110.747 -179.999 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 16.4 t -68.65 96.84 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.054 179.902 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -81.39 -30.83 33.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.799 179.988 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -154.33 157.29 38.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.817 179.942 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.6 pt -128.62 172.98 14.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.196 179.987 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 -147.59 87.62 5.91 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.847 179.994 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.97 -33.63 15.43 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.584 2.19 . . . . 0.0 112.258 -179.974 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -68.92 -42.75 76.37 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.95 179.878 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 23.4 mmt180 -89.38 -61.87 1.6 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.913 179.982 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 120.54 57.12 0.24 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.488 179.954 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -145.0 173.01 12.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.804 0.335 . . . . 0.0 110.803 -179.973 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.614 HG22 ' HA ' ' A' ' 177' ' ' ASP . 31.1 m -153.98 118.36 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.056 179.892 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -79.85 113.87 18.34 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.712 -179.95 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.427 ' HB ' ' HA3' ' A' ' 149' ' ' GLY . 32.1 m -126.1 141.22 46.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.32 -179.756 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 5.1 ptm -101.68 117.16 34.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.925 179.934 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.479 HG12 ' O ' ' A' ' 148' ' ' THR . 15.8 m -108.56 -179.62 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.008 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.66 116.9 10.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.943 -179.837 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 167' ' ' ILE . . . . . 0.857 HD12 ' OG1' ' A' ' 172' ' ' THR . 2.4 mp -120.94 128.39 76.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.93 179.832 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 168' ' ' PHE . . . . . 0.442 ' CD1' HG22 ' A' ' 167' ' ' ILE . 4.6 m-85 61.3 34.46 18.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.966 179.887 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 65.7 51.44 46.99 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.598 179.947 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 2.5 ttt85 -160.06 128.09 4.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.837 0.351 . . . . 0.0 110.952 179.96 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -58.69 129.11 40.52 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.926 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 172' ' ' THR . . . . . 0.857 ' OG1' HD12 ' A' ' 167' ' ' ILE . 0.2 OUTLIER -133.83 85.85 40.11 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.996 -179.932 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -68.67 109.42 2.08 Favored 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.488 2.125 . . . . 0.0 112.028 179.723 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.6 t -126.39 141.11 46.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.344 -179.741 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.93 118.67 21.9 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.181 179.434 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.598 HD23 ' HB3' ' A' ' 180' ' ' GLN . 1.2 mp -119.94 -170.39 1.95 Allowed 'General case' 0 CA--C 1.515 -0.376 0 CA-C-O 121.406 0.622 . . . . 0.0 111.63 -179.178 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.614 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.6 OUTLIER -142.89 155.37 44.73 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 114.911 -1.04 . . . . 0.0 110.004 178.016 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 178' ' ' PHE . . . . . 0.437 ' CE1' HG11 ' A' ' 161' ' ' VAL . 15.6 m-85 -47.14 -30.22 2.73 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.457 -179.533 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 83.6 p -80.08 2.65 23.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.686 -179.89 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.598 ' HB3' HD23 ' A' ' 176' ' ' LEU . 3.7 mt-30 -122.38 3.21 9.72 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-O 120.642 0.258 . . . . 0.0 111.361 180.0 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.528 HG13 ' CD2' ' A' ' 176' ' ' LEU . 11.3 m -139.97 169.63 16.09 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 120.765 0.317 . . . . 0.0 111.384 179.913 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 18.5 m -148.51 146.69 17.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.05 179.942 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.594 ' HA ' HG12 ' A' ' 137' ' ' VAL . 75.2 tttt -57.68 122.53 13.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.093 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.373 -0.822 . . . . 0.0 110.987 -179.962 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 6.2 ttt85 . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.843 0.354 . . . . 0.0 110.844 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -61.54 138.59 58.29 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.885 -179.951 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 108.74 -22.75 25.44 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.68 -179.9 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -57.08 165.03 1.42 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.827 0.346 . . . . 0.0 110.951 -179.974 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -107.85 143.69 36.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.877 -179.935 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.78 HG12 ' HA ' ' A' ' 183' ' ' LYS . 25.4 m -139.92 143.09 30.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.165 179.994 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.47 165.63 13.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.052 0.453 . . . . 0.0 110.955 179.939 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.898 HG23 ' O ' ' A' ' 147' ' ' PHE . 4.2 t -80.18 169.47 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.968 -179.921 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.603 HG23 ' H ' ' A' ' 141' ' ' SER . 0.1 OUTLIER -80.02 -71.49 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 116.525 -0.307 . . . . 0.0 111.393 -179.945 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.603 ' H ' HG23 ' A' ' 140' ' ' VAL . 0.1 OUTLIER -160.5 -163.52 1.1 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.96 -179.699 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.91 -160.54 41.01 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.457 179.842 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -57.94 -20.85 46.65 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.507 2.138 . . . . 0.0 111.976 179.786 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.545 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 1.5 m-85 -110.77 41.6 1.76 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.666 179.859 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.514 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -90.15 31.52 0.99 Allowed 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -179.424 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -161.26 38.69 0.14 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.284 179.492 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.898 ' O ' HG23 ' A' ' 139' ' ' VAL . 23.2 m-85 -134.72 154.18 51.68 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.002 0.429 . . . . 0.0 111.183 -179.758 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 148' ' ' THR . . . . . 0.628 ' O ' HG12 ' A' ' 165' ' ' VAL . 31.4 p -118.23 171.86 7.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.446 179.722 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -144.66 155.89 26.6 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.362 -0.923 . . . . 0.0 112.905 -179.785 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 14.0 m -103.31 105.45 15.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.782 0.325 . . . . 0.0 110.781 179.743 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.734 ' HA ' HG12 ' A' ' 163' ' ' VAL . 48.8 t -58.48 118.13 2.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.108 -179.925 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 35.1 p -102.21 -46.67 4.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.852 179.977 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -125.98 157.87 36.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.912 179.985 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.9 mp -139.99 139.13 37.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.123 179.879 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -121.62 85.12 43.5 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.91 179.996 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.99 -28.35 13.13 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.531 2.154 . . . . 0.0 112.383 -179.917 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -69.84 -32.56 71.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.94 -179.953 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.75 -59.57 1.75 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.949 179.942 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 123.06 66.86 0.22 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.532 -179.994 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 43.7 mttp -148.46 163.48 37.03 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.804 0.335 . . . . 0.0 110.878 179.978 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.646 HG22 ' HA ' ' A' ' 177' ' ' ASP . 15.6 m -151.04 138.53 13.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.112 179.896 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 16.4 tttp -118.12 126.23 51.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.868 -179.985 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.842 HG22 HD11 ' A' ' 176' ' ' LEU . 33.5 m -135.94 149.01 27.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.275 -179.96 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 164' ' ' MET . . . . . 0.4 ' O ' ' CG ' ' A' ' 164' ' ' MET . 10.5 ptt? -90.04 111.53 22.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.598 179.791 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.628 HG12 ' O ' ' A' ' 148' ' ' THR . 31.1 m -114.69 137.43 48.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.359 -179.851 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 5.5 t -92.22 136.94 32.78 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.575 179.774 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 18.5 tt -83.82 -29.26 7.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.069 -179.909 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -178.23 38.92 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.85 -179.976 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 124.13 -25.88 5.96 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.48 -179.973 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.14 122.68 45.82 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.865 0.364 . . . . 0.0 110.821 -179.967 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -63.1 121.01 12.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.99 179.933 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 53.9 m -117.57 100.4 52.59 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.824 -179.9 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -66.54 111.1 2.01 Favored 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 122.344 2.029 . . . . 0.0 112.215 -179.958 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 38.3 t -127.17 141.7 45.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.105 -179.773 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -86.63 138.11 31.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.626 179.736 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.842 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -148.15 -162.27 1.52 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.282 0.563 . . . . 0.0 111.298 -179.65 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.646 ' HA ' HG22 ' A' ' 161' ' ' VAL . 1.4 m-20 -146.15 157.02 43.82 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 115.067 -0.97 . . . . 0.0 109.896 178.213 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 178' ' ' PHE . . . . . 0.47 ' CE1' HG11 ' A' ' 161' ' ' VAL . 19.6 m-85 -47.0 -28.54 1.68 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.694 -179.503 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 40.7 t -75.76 -5.97 48.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.592 -179.902 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.513 ' O ' HG22 ' A' ' 140' ' ' VAL . 3.1 mm-40 -114.97 -6.95 12.57 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.599 -0.273 . . . . 0.0 111.449 -179.907 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.459 ' CG1' HD22 ' A' ' 176' ' ' LEU . 30.2 m -142.7 158.66 18.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 120.829 0.347 . . . . 0.0 111.331 -179.98 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 22.6 m -117.79 146.57 22.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.076 -179.984 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.78 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -86.19 129.58 34.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.921 -179.962 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.175 -0.917 . . . . 0.0 111.194 -179.991 . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 19.3 mtp180 . . . . . 0 C--O 1.232 0.163 0 CA-C-O 120.776 0.322 . . . . 4.75 110.931 . . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -59.53 118.69 6.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.302 -0.408 . . . . 2.49 110.818 179.926 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 128.57 -21.2 5.41 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.823 -0.703 . . . . 0.85 112.627 -179.921 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -55.37 164.74 0.9 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.821 0.343 . . . . 1.69 110.929 -179.995 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 64.7 mt-30 -117.26 114.82 24.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.457 . . . . 2.56 111.06 -179.977 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.647 HG12 ' HA ' ' A' ' 183' ' ' LYS . 16.9 m -118.61 141.95 35.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.58 110.822 179.894 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -79.68 166.69 21.57 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.994 0.426 . . . . 2.7 111.028 -179.773 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 139' ' ' VAL . . . . . 0.524 HG12 ' N ' ' A' ' 140' ' ' VAL . 8.7 t -79.52 167.39 2.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.935 -0.575 . . . . 0.79 110.995 -179.901 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.636 HG13 ' H ' ' A' ' 141' ' ' SER . 2.8 p -78.87 -61.46 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.296 0 N-CA-C 112.052 0.39 . . . . 1.7 112.052 -179.289 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 141' ' ' SER . . . . . 0.636 ' H ' HG13 ' A' ' 140' ' ' VAL . 0.9 OUTLIER -160.83 -163.98 1.14 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.807 0.337 . . . . 3.04 111.29 -179.652 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.53 -169.35 54.75 Favored Glycine 0 C--N 1.331 0.284 0 C-N-CA 120.875 -0.679 . . . . 1.83 112.357 179.958 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -59.14 -19.34 48.83 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.507 2.138 . . . . 1.63 111.998 179.672 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.512 ' HB2' HG11 ' A' ' 139' ' ' VAL . 4.1 m-85 -95.98 18.37 13.5 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.16 -0.473 . . . . 1.67 111.065 179.939 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.488 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -82.05 40.4 0.62 Allowed 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 112.058 0.392 . . . . 1.09 112.058 -179.453 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 146' ' ' ASP . . . . . 0.403 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 0.5 OUTLIER -161.4 35.6 0.14 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.98 0.419 . . . . 2.42 110.692 179.493 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 147' ' ' PHE . . . . . 0.518 ' O ' HG23 ' A' ' 139' ' ' VAL . 36.6 m-85 -146.82 169.76 18.44 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.929 -0.578 . . . . 1.59 110.783 179.994 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 12.7 p -122.31 -178.43 3.88 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.264 -0.425 . . . . 0.88 110.874 179.943 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -145.49 134.74 5.62 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.648 -0.787 . . . . 0.62 112.549 -179.927 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.8 m -87.96 104.8 16.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.751 0.31 . . . . 0.75 110.817 179.893 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.695 ' HA ' HG12 ' A' ' 163' ' ' VAL . 43.6 t -64.21 121.18 12.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.239 -0.437 . . . . 0.66 111.059 -179.967 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 14.9 p -107.37 -39.88 5.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.162 -0.472 . . . . 1.22 110.907 179.91 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -130.72 159.33 37.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.189 -0.459 . . . . 2.32 110.855 179.922 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 26.9 mt -136.36 135.44 49.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.266 -0.425 . . . . 1.78 111.125 -179.968 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -115.83 86.31 15.98 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.108 -0.496 . . . . 1.88 110.907 179.997 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.61 -30.43 18.35 Favored 'Trans proline' 0 C--N 1.345 0.343 0 C-N-CA 122.53 2.153 . . . . 1.83 112.327 179.994 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -63.1 -42.67 99.63 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.191 -0.459 . . . . 3.63 110.889 -179.996 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 3.6 mtt85 -96.09 -52.29 4.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.17 -0.468 . . . . 3.92 110.845 -179.954 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 116.71 39.2 0.85 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.768 -0.729 . . . . 1.28 112.469 -179.948 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 15.0 mttt -120.65 168.98 10.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.818 0.342 . . . . 2.03 110.959 179.97 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.71 HG11 ' CE1' ' A' ' 178' ' ' PHE . 19.4 m -150.72 125.47 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 1.28 111.065 179.983 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 68.6 tttt -94.83 130.07 41.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.126 -0.488 . . . . 1.89 110.922 -179.989 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.695 HG12 ' HA ' ' A' ' 151' ' ' VAL . 17.2 m -140.48 163.23 23.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.457 . . . . 0.93 111.087 -179.97 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 3.2 ptt? -109.51 116.93 32.69 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 1.89 110.954 179.914 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 165' ' ' VAL . . . . . 0.567 HG22 ' O ' ' A' ' 172' ' ' THR . 6.9 m -96.45 163.95 2.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 1.13 111.025 -179.997 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.13 106.25 9.13 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 1.6 110.99 -179.964 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 5.2 mt -110.0 109.19 27.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.137 -0.483 . . . . 2.24 110.97 179.94 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 62.38 47.28 5.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.194 -0.457 . . . . 4.37 110.935 -179.958 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 61.01 50.8 63.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.727 -0.749 . . . . 1.51 112.551 179.986 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 12.2 ttt180 -153.72 129.34 10.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.819 0.343 . . . . 5.0 110.957 179.965 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 -71.15 145.62 49.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 2.59 110.865 -179.924 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 172' ' ' THR . . . . . 0.567 ' O ' HG22 ' A' ' 165' ' ' VAL . 4.1 m -159.96 92.44 1.72 Allowed Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.116 -0.493 . . . . 1.28 110.828 179.951 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -67.42 119.62 6.64 Favored 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.451 2.101 . . . . 0.95 112.326 -179.952 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.5 t -132.21 139.11 50.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 1.63 111.047 179.969 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 175' ' ' GLU . . . . . 0.515 ' C ' HD23 ' A' ' 176' ' ' LEU . 4.6 pt-20 -80.76 119.88 23.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.446 . . . . 2.46 110.869 -179.976 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 176' ' ' LEU . . . . . 0.523 HD12 HG11 ' A' ' 181' ' ' VAL . 0.2 OUTLIER -125.02 -162.46 1.1 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.368 0.604 . . . . 1.64 110.916 -179.979 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 177' ' ' ASP . . . . . 0.624 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.6 OUTLIER -152.73 152.75 32.03 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 115.168 -0.923 . . . . 1.49 110.221 178.405 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 178' ' ' PHE . . . . . 0.71 ' CE1' HG11 ' A' ' 161' ' ' VAL . 17.1 m-85 -44.99 -29.53 0.85 Allowed 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.925 -0.58 . . . . 1.86 111.56 -179.726 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 60.1 m -72.25 -33.21 67.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.327 -0.397 . . . . 1.68 111.096 -179.826 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 38.1 mt-30 -97.2 18.2 15.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.354 -0.384 . . . . 2.16 111.337 -179.895 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 177' ' ' ASP . 32.4 m -151.79 164.51 2.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.843 0.354 . . . . 0.77 111.113 179.891 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 23.1 m -139.83 149.96 22.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 0.88 111.123 179.907 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 183' ' ' LYS . . . . . 0.647 ' HA ' HG12 ' A' ' 137' ' ' VAL . 8.2 tttt -73.41 129.97 39.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 2.98 110.867 179.973 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.111 0 CA-C-O 118.292 -0.861 . . . . 1.69 111.046 179.978 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.4 0 CA-C-O 120.796 0.332 . . . . 0.0 111.026 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 22.6 mm-40 -134.6 155.74 49.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.893 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.489 HG21 ' HG2' ' A' ' 132' ' ' ARG . 11.2 p -143.77 148.82 18.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.085 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -86.18 -44.45 12.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.127 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -151.43 157.48 42.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.943 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' ARG . . . . . 0.489 ' HG2' HG21 ' A' ' 129' ' ' VAL . 0.1 OUTLIER -150.51 134.1 16.53 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.97 179.946 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -58.23 147.8 29.29 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.952 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 79.54 6.52 88.96 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.967 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 12.9 m-20 -86.87 174.53 8.7 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.821 0.343 . . . . 0.0 110.99 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 36.3 mt-30 -113.96 132.61 55.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.836 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.438 HG12 ' HA ' ' A' ' 183' ' ' LYS . 31.0 m -131.9 136.2 57.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.081 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -80.03 166.26 21.73 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.703 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.582 HG11 ' HB2' ' A' ' 144' ' ' PHE . 8.0 t -79.86 167.34 2.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.973 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.6 HG13 ' H ' ' A' ' 141' ' ' SER . 3.3 p -79.31 -60.3 2.36 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 112.138 0.421 . . . . 0.0 112.138 -179.201 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.657 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.1 OUTLIER -160.43 -164.18 1.21 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.822 0.344 . . . . 0.0 111.301 -179.542 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.37 -168.01 54.33 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.856 -0.687 . . . . 0.0 112.344 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.37 -19.02 56.44 Favored 'Trans proline' 0 C--N 1.343 0.277 0 C-N-CA 122.479 2.119 . . . . 0.0 111.95 179.593 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.582 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.9 m-85 -95.86 13.09 27.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.211 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.657 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -79.14 39.69 0.39 Allowed 'General case' 0 C--N 1.332 -0.179 0 N-CA-C 112.246 0.462 . . . . 0.0 112.246 -179.361 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' ASP . . . . . 0.409 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 1.0 OUTLIER -160.7 34.87 0.16 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.987 0.422 . . . . 0.0 110.675 179.336 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.494 ' O ' HG23 ' A' ' 139' ' ' VAL . 47.2 m-85 -148.0 167.13 25.7 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.91 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.669 ' O ' HG12 ' A' ' 165' ' ' VAL . 23.7 p -127.16 -173.98 3.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.672 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -150.43 164.81 29.86 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.657 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 5.6 m -103.99 108.47 19.83 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.779 0.323 . . . . 0.0 110.773 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.476 ' HA ' HG12 ' A' ' 163' ' ' VAL . 19.8 t -57.42 113.88 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.293 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 10.3 t -98.88 -33.92 10.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.778 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -153.48 158.48 41.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.894 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' ILE . . . . . 0.485 HG22 ' N ' ' A' ' 155' ' ' ASN . 2.7 mt -129.88 158.69 42.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.087 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.485 ' N ' HG22 ' A' ' 154' ' ' ILE . 0.8 OUTLIER -135.29 86.71 29.75 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.958 -179.997 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -71.69 -34.13 9.47 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.56 2.174 . . . . 0.0 112.385 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -58.98 -33.55 70.81 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.993 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.23 -61.23 1.69 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.94 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 127.04 42.73 0.27 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.489 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' LYS . . . . . 0.412 ' O ' HG13 ' A' ' 161' ' ' VAL . 11.8 mttt -115.59 170.34 8.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.772 0.32 . . . . 0.0 110.982 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.72 HG22 ' HA ' ' A' ' 177' ' ' ASP . 5.1 m -155.37 137.08 5.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.077 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 38.7 tttt -114.69 128.25 56.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.788 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.865 HG22 HD11 ' A' ' 176' ' ' LEU . 29.7 m -139.88 142.51 32.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.231 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 164' ' ' MET . . . . . 0.4 ' CG ' ' O ' ' A' ' 164' ' ' MET . 0.4 OUTLIER -89.93 104.02 16.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.592 179.883 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.669 HG12 ' O ' ' A' ' 148' ' ' THR . 15.5 m -91.76 171.11 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.25 -179.791 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -132.41 115.34 15.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.796 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.406 HD12 ' CE2' ' A' ' 147' ' ' PHE . 1.6 tp -120.23 133.82 65.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.162 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 1.2 t80 61.74 30.42 18.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.878 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 70.28 45.26 56.25 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.555 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 2.2 tpm_? -159.98 138.86 10.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.789 0.328 . . . . 0.0 110.908 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -60.8 151.94 28.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.778 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 66.1 m -160.02 91.17 1.77 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.989 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -68.37 117.45 4.97 Favored 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 122.475 2.117 . . . . 0.0 112.155 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 29.7 m -132.84 154.98 40.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.256 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -98.8 138.1 36.43 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.639 179.741 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.865 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -144.33 -162.2 1.43 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.263 0.554 . . . . 0.0 111.229 -179.796 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.72 ' HA ' HG22 ' A' ' 161' ' ' VAL . 7.3 m-20 -153.11 156.71 39.18 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.079 178.424 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -45.86 -29.38 1.35 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.674 -179.714 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 7.3 m -76.01 -3.45 35.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.829 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -131.77 15.08 4.85 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.602 0.239 . . . . 0.0 111.437 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.474 HG22 ' O ' ' A' ' 177' ' ' ASP . 15.7 m -142.0 170.03 12.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.865 0.364 . . . . 0.0 111.221 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 22.4 m -142.41 146.71 21.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.037 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.438 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -83.36 131.33 35.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.946 -179.953 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.189 -0.91 . . . . 0.0 111.12 -179.997 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.309 0 CA-C-O 120.749 0.309 . . . . 0.0 111.022 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 60.51 158.81 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.909 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 11.3 m -138.05 35.27 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.024 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -77.78 138.04 38.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.141 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.605 ' CZ ' HG21 ' A' ' 151' ' ' VAL . 10.4 t80 -92.67 150.29 20.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.913 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 21.5 mtp180 -145.24 146.26 31.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.897 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -63.93 142.37 58.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.916 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 91.91 -14.05 65.27 Favored Glycine 0 CA--C 1.519 0.292 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.773 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 32.2 m-20 -54.54 165.01 0.63 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.766 0.317 . . . . 0.0 111.024 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -117.6 115.38 24.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.077 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.614 HG12 ' HA ' ' A' ' 183' ' ' LYS . 19.4 m -122.95 149.06 26.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.919 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.8 tpp180 -79.86 168.03 19.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.069 0.461 . . . . 0.0 110.854 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.574 HG23 ' O ' ' A' ' 147' ' ' PHE . 3.8 t -80.21 167.95 2.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.028 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.666 HG13 ' H ' ' A' ' 141' ' ' SER . 1.5 p -79.66 -66.85 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.55 -179.759 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.666 ' H ' HG13 ' A' ' 140' ' ' VAL . 0.2 OUTLIER -160.44 -164.69 1.29 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.876 0.37 . . . . 0.0 111.097 -179.91 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.94 -162.47 42.79 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.911 -0.661 . . . . 0.0 112.462 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -63.07 -18.42 65.06 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.458 2.106 . . . . 0.0 112.115 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.507 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.0 m-85 -102.14 29.24 5.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.957 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.38 35.67 0.45 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.775 0.321 . . . . 0.0 111.853 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -160.96 35.63 0.15 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.506 179.354 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.574 ' O ' HG23 ' A' ' 139' ' ' VAL . 48.3 m-85 -135.15 175.7 9.34 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.888 -179.753 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.435 HG22 ' O ' ' A' ' 137' ' ' VAL . 0.3 OUTLIER -119.99 178.65 4.53 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.752 179.942 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -147.11 115.6 0.79 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.568 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.1 m -82.0 113.02 19.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.755 0.312 . . . . 0.0 110.782 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.605 HG21 ' CZ ' ' A' ' 131' ' ' PHE . 26.4 t -68.19 123.54 21.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.175 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -105.22 -60.47 1.61 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.846 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.58 165.83 15.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.91 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 154' ' ' ILE . . . . . 0.669 ' N ' HD13 ' A' ' 154' ' ' ILE . 0.1 OUTLIER -130.78 157.67 43.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.052 179.961 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 12.5 m-20 -121.58 89.27 47.28 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.902 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.25 -34.45 6.08 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.54 2.16 . . . . 0.0 112.298 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.33 27.67 1.62 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.386 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 5.1 mtm180 -160.08 -50.1 0.05 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.856 0.36 . . . . 0.0 110.784 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 103.27 63.56 0.7 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.461 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.8 mttt -145.88 165.9 27.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.891 0.376 . . . . 0.0 111.028 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.535 HG11 ' CE1' ' A' ' 178' ' ' PHE . 3.7 m -150.04 120.99 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.903 179.797 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -86.75 131.68 34.06 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.096 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.613 HG21 HD12 ' A' ' 176' ' ' LEU . 27.2 m -131.17 158.1 43.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.062 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 3.3 ptt? -116.27 126.58 53.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.029 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 2.5 t -106.99 153.88 8.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.847 179.735 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 2.1 p -122.98 103.32 8.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.063 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.512 HG22 ' CZ ' ' A' ' 168' ' ' PHE . 39.4 mm -80.0 67.52 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.625 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 168' ' ' PHE . . . . . 0.512 ' CZ ' HG22 ' A' ' 167' ' ' ILE . 1.1 p90 43.52 79.43 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.405 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 83.15 34.49 20.68 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.673 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -160.13 109.21 1.75 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.786 0.327 . . . . 0.0 111.077 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 11.7 mt-10 -89.84 134.41 34.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.717 179.731 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -145.26 105.57 4.4 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.126 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.49 110.53 2.72 Favored 'Trans proline' 0 C--N 1.348 0.508 0 C-N-CA 122.46 2.107 . . . . 0.0 112.069 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 9.0 p -126.09 146.45 31.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.268 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -79.99 157.57 26.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.679 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.753 HD22 ' HB3' ' A' ' 180' ' ' GLN . 7.5 mt -159.99 -171.74 3.35 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-O 121.411 0.625 . . . . 0.0 111.408 -179.81 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.401 ' HA ' HG22 ' A' ' 161' ' ' VAL . 1.9 m-20 -146.55 153.61 40.57 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 115.021 -0.991 . . . . 0.0 110.205 178.074 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 178' ' ' PHE . . . . . 0.535 ' CE1' HG11 ' A' ' 161' ' ' VAL . 27.3 m-85 -46.06 -32.8 3.05 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.548 -179.573 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 6.2 m -81.74 11.47 4.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.709 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.753 ' HB3' HD22 ' A' ' 176' ' ' LEU . 7.4 mm-40 -125.46 3.19 7.68 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.596 0.236 . . . . 0.0 111.262 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.751 HG13 HD13 ' A' ' 176' ' ' LEU . 21.9 m -145.14 179.42 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 120.977 0.417 . . . . 0.0 111.113 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 15.7 m -150.64 148.14 15.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.145 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.614 ' HA ' HG12 ' A' ' 137' ' ' VAL . 7.1 tttt -63.89 131.94 49.27 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.94 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.146 0 CA-C-O 118.257 -0.878 . . . . 0.0 111.14 179.906 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.336 0 CA-C-O 120.846 0.355 . . . . 0.0 111.002 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 2.4 mt-30 -83.45 -40.32 19.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.902 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 11.3 p -119.09 -39.18 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.189 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -64.94 -31.17 72.28 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.21 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.492 ' CZ ' HG21 ' A' ' 151' ' ' VAL . 11.5 t80 -111.86 143.44 42.81 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.926 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 7.3 mtt-85 -133.38 135.35 44.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.887 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -63.24 152.92 36.26 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.693 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 65.71 11.75 54.73 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.982 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -89.57 165.42 14.27 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.799 0.3 . . . . 0.0 110.822 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -89.24 134.08 34.19 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.705 HG12 ' HA ' ' A' ' 183' ' ' LYS . 16.0 m -140.46 140.01 34.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.962 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.431 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.4 OUTLIER -80.79 164.83 22.43 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.999 0.428 . . . . 0.0 111.063 -179.912 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.625 HG11 ' HB2' ' A' ' 144' ' ' PHE . 5.2 t -81.9 167.3 2.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.042 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.608 HG13 ' H ' ' A' ' 141' ' ' SER . 2.3 p -79.47 -61.77 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.439 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.705 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 46.7 p -160.11 -165.14 1.41 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.87 0.367 . . . . 0.0 111.176 -179.47 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 80.15 -163.74 47.36 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.348 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -63.91 -14.76 45.12 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.394 2.062 . . . . 0.0 112.23 179.676 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.625 ' HB2' HG11 ' A' ' 139' ' ' VAL . 4.9 m-85 -102.52 14.64 31.44 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.253 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.705 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -77.48 36.87 0.2 Allowed 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 112.462 0.541 . . . . 0.0 112.462 -179.289 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 146' ' ' ASP . . . . . 0.408 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 2.2 t0 -161.05 34.41 0.14 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.932 0.396 . . . . 0.0 110.805 179.223 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.573 ' O ' HG23 ' A' ' 139' ' ' VAL . 40.2 m-85 -146.1 165.98 27.49 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.745 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.431 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 0.7 OUTLIER -116.79 -176.18 2.92 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.792 179.939 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 149' ' ' GLY . . . . . 0.413 ' HA3' HG12 ' A' ' 163' ' ' VAL . . . -153.26 -176.4 25.7 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.57 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' THR . . . . . 0.419 ' N ' HG13 ' A' ' 163' ' ' VAL . 40.9 m -125.3 113.14 17.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.808 0.337 . . . . 0.0 110.853 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.492 HG21 ' CZ ' ' A' ' 131' ' ' PHE . 32.9 t -63.91 106.24 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.101 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 5.8 p -83.99 -45.07 13.51 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.916 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 2.4 tp10 -152.68 171.69 17.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.812 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 154' ' ' ILE . . . . . 0.825 HG22 HG12 ' A' ' 161' ' ' VAL . 17.5 pt -145.33 151.43 15.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.096 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 12.7 m-20 -117.68 86.76 24.5 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.915 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -62.04 -24.74 76.97 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.737 2.292 . . . . 0.0 112.326 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -90.21 29.12 1.28 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.407 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.07 -44.16 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.868 0.366 . . . . 0.0 111.015 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 104.55 39.5 2.38 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.291 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 4.5 mttt -127.87 161.4 29.13 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.921 0.391 . . . . 0.0 110.981 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.825 HG12 HG22 ' A' ' 154' ' ' ILE . 29.2 m -146.82 119.65 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.107 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 15.5 tttt -80.04 141.28 36.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.891 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.869 ' HB ' HD12 ' A' ' 176' ' ' LEU . 26.0 t -153.17 144.9 15.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.098 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -96.68 121.77 38.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.874 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.456 HG22 ' O ' ' A' ' 172' ' ' THR . 9.3 m -99.98 158.55 3.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.121 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 166' ' ' THR . . . . . 0.668 HG22 ' HA ' ' A' ' 171' ' ' GLU . 31.4 p -145.31 146.35 31.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.815 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.8 mp -131.17 94.82 2.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.165 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 57.3 m-85 60.06 37.74 20.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.949 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 91.74 27.85 15.81 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.493 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.26 89.0 3.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.794 0.331 . . . . 0.0 110.913 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 171' ' ' GLU . . . . . 0.668 ' HA ' HG22 ' A' ' 166' ' ' THR . 1.8 mt-10 -59.24 144.61 45.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 172' ' ' THR . . . . . 0.456 ' O ' HG22 ' A' ' 165' ' ' VAL . 0.2 OUTLIER -158.41 90.3 2.18 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.842 179.94 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_exo -60.49 125.78 18.27 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.573 2.182 . . . . 0.0 112.29 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 39.4 t -152.54 148.84 14.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.959 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -80.01 145.04 32.74 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.822 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.869 HD12 ' HB ' ' A' ' 163' ' ' VAL . 4.1 mt -125.63 -173.24 2.78 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.451 0.643 . . . . 0.0 111.324 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.813 ' O ' HG12 ' A' ' 181' ' ' VAL . 3.1 m-20 -152.91 153.76 33.67 Favored 'General case' 0 N--CA 1.446 -0.662 0 CA-C-N 115.023 -0.99 . . . . 0.0 109.99 178.147 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -42.79 -54.01 4.31 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.656 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 5.2 m -74.18 -9.61 58.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.418 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.55 ' HB3' HD23 ' A' ' 176' ' ' LEU . 0.0 OUTLIER -99.55 -14.03 19.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.504 -179.806 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.813 HG12 ' O ' ' A' ' 177' ' ' ASP . 1.3 p -132.59 160.32 42.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.033 0.444 . . . . 0.0 111.083 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 182' ' ' VAL . . . . . 0.478 ' N ' ' CG2' ' A' ' 181' ' ' VAL . 35.4 m -139.39 146.19 25.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.379 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.705 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -77.28 135.03 38.39 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.94 179.847 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.286 -0.864 . . . . 0.0 111.14 179.986 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.377 0 CA-C-O 120.807 0.337 . . . . 0.0 111.029 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 13.3 tt0 60.07 74.57 0.44 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.864 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 12.0 p -114.84 152.58 16.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.098 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -66.54 -48.55 69.33 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.095 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.752 ' CE2' HG21 ' A' ' 151' ' ' VAL . 6.2 t80 -125.21 149.04 48.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.959 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.01 145.07 15.06 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -59.81 135.11 57.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.869 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 105.97 -27.69 16.58 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.485 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -63.36 178.4 0.54 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.748 0.309 . . . . 0.0 110.977 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -128.19 130.34 47.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.015 0.436 . . . . 0.0 111.116 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.684 HG11 ' HE1' ' A' ' 131' ' ' PHE . 25.9 m -130.16 142.91 42.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.705 179.775 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.42 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.1 OUTLIER -79.7 164.49 23.7 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.025 0.44 . . . . 0.0 111.048 -179.843 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.817 HG11 ' HB2' ' A' ' 144' ' ' PHE . 48.8 t -79.74 147.22 6.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.647 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.549 HG11 ' HA ' ' A' ' 180' ' ' GLN . 12.4 p -85.87 -22.22 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.422 -179.47 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.747 ' H ' HG12 ' A' ' 139' ' ' VAL . 1.4 t -79.14 153.47 30.06 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.893 0.378 . . . . 0.0 111.429 -178.817 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' GLY . . . . . 0.415 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -66.89 -62.2 4.68 Favored Glycine 0 N--CA 1.452 -0.26 0 CA-C-N 115.893 -0.594 . . . . 0.0 112.733 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.415 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.2 Cg_endo -53.57 -23.2 24.51 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.583 2.189 . . . . 0.0 112.158 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.817 ' HB2' HG11 ' A' ' 139' ' ' VAL . 12.9 m-85 -109.81 0.61 18.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.387 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.658 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -69.63 50.71 0.1 Allowed 'General case' 0 N--CA 1.462 0.163 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -179.05 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -160.61 31.37 0.16 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.094 0.473 . . . . 0.0 110.527 179.029 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.696 ' O ' HG23 ' A' ' 139' ' ' VAL . 19.0 m-85 -155.4 146.41 22.5 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.389 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 9.0 p -104.56 169.05 8.69 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.952 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -129.01 133.41 7.57 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.59 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.8 m -86.55 110.47 19.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.823 0.344 . . . . 0.0 110.755 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.752 HG21 ' CE2' ' A' ' 131' ' ' PHE . 30.6 t -67.96 117.44 9.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.963 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.3 t -101.94 -30.37 11.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.899 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -147.21 165.78 29.02 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.83 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 154' ' ' ILE . . . . . 0.638 HD12 ' HD3' ' A' ' 156' ' ' PRO . 2.0 pp -152.41 141.42 14.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.152 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -120.94 92.87 48.66 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.871 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 156' ' ' PRO . . . . . 0.638 ' HD3' HD12 ' A' ' 154' ' ' ILE . 54.4 Cg_endo -69.54 -22.63 32.83 Favored 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.555 2.17 . . . . 0.0 112.425 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -90.21 26.36 1.92 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.372 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 1.4 mtp85 -159.96 -45.25 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.827 0.346 . . . . 0.0 110.825 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 102.45 55.19 0.86 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.425 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.3 mttt -137.66 147.56 45.01 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.801 0.334 . . . . 0.0 111.152 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.707 HG22 ' HA ' ' A' ' 177' ' ' ASP . 31.1 m -139.05 116.48 11.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.973 179.799 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 70.1 tttt -89.69 118.56 29.4 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.89 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.607 HG12 HG22 ' A' ' 151' ' ' VAL . 28.0 m -130.37 149.42 33.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.137 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 164' ' ' MET . . . . . 0.425 ' O ' ' CG ' ' A' ' 164' ' ' MET . 3.7 ptt? -101.84 108.54 20.06 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.996 0.427 . . . . 0.0 110.81 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 27.1 m -98.31 143.08 13.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.126 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -91.9 90.55 7.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.938 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.794 HG22 ' OG1' ' A' ' 172' ' ' THR . 11.2 tt -89.55 129.67 40.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.82 179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 168' ' ' PHE . . . . . 0.418 ' CD2' HG12 ' A' ' 167' ' ' ILE . 31.2 m-85 65.86 -72.49 0.08 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.915 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -169.61 36.0 0.19 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.635 -0.793 . . . . 0.0 112.657 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 8.9 ptp180 -160.03 164.19 33.39 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.793 0.33 . . . . 0.0 111.063 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -66.89 158.37 30.81 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.906 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 172' ' ' THR . . . . . 0.794 ' OG1' HG22 ' A' ' 167' ' ' ILE . 0.3 OUTLIER -159.99 81.3 2.38 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.954 -179.985 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -68.57 102.65 0.87 Allowed 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.682 2.255 . . . . 0.0 112.229 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.823 ' CG2' HD21 ' A' ' 176' ' ' LEU . 21.4 m -114.46 136.04 52.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.137 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -80.16 108.89 14.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.669 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.823 HD21 ' CG2' ' A' ' 174' ' ' VAL . 0.3 OUTLIER -124.27 -158.96 0.84 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.322 0.582 . . . . 0.0 111.159 -179.605 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.707 ' HA ' HG22 ' A' ' 161' ' ' VAL . 4.7 m-20 -146.36 155.64 42.75 Favored 'General case' 0 N--CA 1.441 -0.875 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.167 178.161 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 178' ' ' PHE . . . . . 0.531 ' CE1' HG11 ' A' ' 161' ' ' VAL . 14.9 m-85 -42.97 -30.89 0.45 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.617 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.5 m -66.35 -30.14 70.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.313 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.549 ' HA ' HG11 ' A' ' 140' ' ' VAL . 33.5 mm-40 -102.39 21.59 14.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.55 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.422 HG13 ' O ' ' A' ' 180' ' ' GLN . 21.7 m -157.03 140.63 7.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.93 0.395 . . . . 0.0 111.13 179.698 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.1 m -117.03 146.27 21.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.146 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.647 ' HA ' HG12 ' A' ' 137' ' ' VAL . 3.4 tttm -83.3 128.2 34.3 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.869 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.247 -0.883 . . . . 0.0 111.113 179.97 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 127' ' ' ALA . . . . . 0.439 ' HB3' ' OE1' ' A' ' 128' ' ' GLN . . . . . . . . 0 N--CA 1.486 1.362 0 CA-C-O 120.834 0.35 . . . . 0.0 111.001 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' GLN . . . . . 0.439 ' OE1' ' HB3' ' A' ' 127' ' ' ALA . 10.6 mp0 -131.53 31.62 4.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.931 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.5 t -145.18 94.6 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.187 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -75.44 75.53 2.51 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.994 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.456 ' HZ ' HG21 ' A' ' 151' ' ' VAL . 22.3 t80 -96.94 145.14 26.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.959 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 48.4 mtt-85 -153.51 155.86 37.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.854 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -57.51 155.42 9.54 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.742 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.42 ' HA2' HG22 ' A' ' 150' ' ' THR . . . 77.1 0.52 70.58 Favored Glycine 0 CA--C 1.519 0.343 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.78 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -66.0 153.49 42.03 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.838 0.352 . . . . 0.0 110.938 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 16.6 mt-30 -95.49 123.5 39.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.912 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.671 HG12 ' HA ' ' A' ' 183' ' ' LYS . 18.7 m -139.66 139.33 38.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.055 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.46 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -80.29 165.91 21.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.946 0.403 . . . . 0.0 110.808 179.837 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 147' ' ' PHE . 6.8 t -79.7 167.67 2.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.999 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.644 HG13 ' H ' ' A' ' 141' ' ' SER . 2.5 p -79.39 -63.18 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 N-CA-C 112.199 0.444 . . . . 0.0 112.199 -179.196 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.677 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.9 OUTLIER -160.28 -174.46 4.52 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.918 0.39 . . . . 0.0 111.321 -179.579 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 87.12 -167.19 37.55 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.397 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -59.53 -19.28 51.41 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.345 2.03 . . . . 0.0 111.965 179.541 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.539 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.3 m-85 -98.49 13.97 29.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.677 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -80.42 39.22 0.45 Allowed 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.275 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 146' ' ' ASP . . . . . 0.45 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 0.2 OUTLIER -160.78 31.57 0.15 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.901 0.381 . . . . 0.0 110.893 179.32 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.719 ' O ' HG23 ' A' ' 139' ' ' VAL . 22.4 m-85 -143.96 155.58 44.1 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.865 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.46 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 0.8 OUTLIER -110.7 159.56 17.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.224 179.423 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 149' ' ' GLY . . . . . 0.621 ' HA3' HG12 ' A' ' 163' ' ' VAL . . . -128.21 179.15 16.71 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.287 -0.958 . . . . 0.0 113.145 -179.504 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 150' ' ' THR . . . . . 0.42 HG22 ' HA2' ' A' ' 134' ' ' GLY . 2.4 m -121.63 116.88 25.41 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.768 0.318 . . . . 0.0 110.729 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.456 HG21 ' HZ ' ' A' ' 131' ' ' PHE . 37.2 t -67.49 145.53 13.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.984 179.823 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 20.4 p -137.55 -55.54 0.69 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.976 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 153' ' ' GLU . . . . . 0.529 ' O ' HG23 ' A' ' 154' ' ' ILE . 0.5 OUTLIER -115.91 159.68 21.24 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.912 -179.869 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 154' ' ' ILE . . . . . 0.563 HG22 HG12 ' A' ' 161' ' ' VAL . 1.9 pt -158.7 149.02 8.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.092 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 12.0 t30 -147.26 85.32 6.88 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.946 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.52 -22.34 27.54 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.523 2.149 . . . . 0.0 112.408 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -55.0 -69.48 0.13 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.124 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.87 -33.71 39.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.984 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 101.56 55.42 0.9 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.596 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 2.7 mtmp? -131.34 149.28 52.62 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.922 0.392 . . . . 0.0 110.807 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.906 HG22 ' HA ' ' A' ' 177' ' ' ASP . 27.9 m -142.58 136.76 27.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.128 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 17.8 tttp -100.31 141.33 33.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.94 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.624 HG23 HD13 ' A' ' 176' ' ' LEU . 12.0 t -152.08 137.06 10.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.986 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 164' ' ' MET . . . . . 0.423 ' CG ' ' O ' ' A' ' 164' ' ' MET . 0.1 OUTLIER -97.49 106.48 18.81 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.982 0.42 . . . . 0.0 111.022 -179.9 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.448 HG12 ' N ' ' A' ' 166' ' ' THR . 5.5 t -103.4 159.88 4.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.176 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 166' ' ' THR . . . . . 0.448 ' N ' HG12 ' A' ' 165' ' ' VAL . 15.8 p -95.14 145.52 24.95 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.85 179.902 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.816 ' O ' HD13 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -114.6 -36.86 2.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.061 179.982 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -166.37 76.86 0.21 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 64.03 26.82 70.57 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.52 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.01 136.68 9.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.793 0.33 . . . . 0.0 110.879 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 7.2 pm0 -59.18 166.91 1.95 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.9 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 9.1 m -159.74 84.21 2.22 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.022 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.12 119.74 7.18 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.48 2.12 . . . . 0.0 112.138 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 15.6 m -142.13 151.2 18.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.255 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -83.63 142.51 30.75 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.575 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.624 HD13 HG23 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -152.56 -161.21 1.25 Allowed 'General case' 0 CA--C 1.518 -0.257 0 CA-C-O 121.301 0.572 . . . . 0.0 111.303 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.906 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.7 OUTLIER -151.17 154.04 36.13 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.208 178.453 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 178' ' ' PHE . . . . . 0.458 ' CE2' HG11 ' A' ' 161' ' ' VAL . 12.3 m-85 -48.17 -27.73 2.56 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.522 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 7.5 t -78.17 -1.94 35.17 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.679 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -124.27 13.0 8.89 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.659 0.266 . . . . 0.0 111.391 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 15.6 m -144.31 160.97 15.16 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.807 0.337 . . . . 0.0 111.15 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 28.6 m -141.6 148.22 21.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.054 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.671 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.1 OUTLIER -59.84 134.85 57.42 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.9 -179.938 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.215 -0.898 . . . . 0.0 111.169 179.963 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.332 0 CA-C-O 120.845 0.355 . . . . 0.0 111.037 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER 63.44 140.86 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.87 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.485 HG12 ' N ' ' A' ' 130' ' ' ALA . 20.8 t -130.78 159.58 42.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.164 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.485 ' N ' HG12 ' A' ' 129' ' ' VAL . . . -57.23 128.14 35.49 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.128 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 6.2 t80 -143.57 148.68 36.29 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.938 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -159.83 145.5 15.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.966 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -62.44 129.79 42.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.879 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 121.51 -22.62 7.77 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.604 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -56.8 163.82 1.76 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.841 0.353 . . . . 0.0 111.046 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -104.54 135.43 45.97 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.91 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.795 HG12 ' HA ' ' A' ' 183' ' ' LYS . 11.9 m -138.1 130.0 38.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.064 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.416 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.98 165.37 22.66 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.898 -179.927 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.694 HG23 ' O ' ' A' ' 147' ' ' PHE . 3.7 t -79.83 168.83 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.913 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.636 HG23 ' H ' ' A' ' 141' ' ' SER . 1.0 OUTLIER -79.52 -66.01 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.876 -179.55 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.684 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 52.1 p -160.22 -165.42 1.46 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.941 0.4 . . . . 0.0 110.954 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.73 -159.07 37.76 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.451 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.71 -12.31 35.06 Favored 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.578 2.186 . . . . 0.0 112.385 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.545 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.2 m-85 -108.57 20.91 17.98 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.164 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.684 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -80.53 38.44 0.43 Allowed 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -179.401 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -161.03 36.98 0.15 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.791 0.329 . . . . 0.0 110.915 179.309 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.694 ' O ' HG23 ' A' ' 139' ' ' VAL . 48.4 m-85 -147.91 161.06 42.07 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.951 -179.828 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.416 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 1.9 p -120.42 -176.79 3.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.66 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -149.39 151.44 23.56 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.602 -0.809 . . . . 0.0 112.724 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.1 m -96.56 99.18 10.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.788 0.328 . . . . 0.0 110.74 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.753 ' HA ' HG12 ' A' ' 163' ' ' VAL . 48.7 t -56.98 105.95 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.303 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 30.4 p -83.85 -38.96 20.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.535 179.683 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -143.81 160.31 40.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.701 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.8 mp -132.52 139.67 49.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.162 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -131.38 84.74 55.41 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.789 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -68.19 -27.68 34.93 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.511 2.14 . . . . 0.0 112.363 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -59.69 -58.4 8.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.882 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -87.54 -30.06 20.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.949 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 94.96 37.32 5.23 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.493 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 8.7 mtmt -114.08 154.06 28.39 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.8 0.333 . . . . 0.0 110.968 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.405 HG22 ' HA ' ' A' ' 177' ' ' ASP . 17.8 m -147.23 141.35 19.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.08 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 18.2 ttpt -115.47 122.85 47.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.943 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 1.038 HG22 HD11 ' A' ' 176' ' ' LEU . 33.4 m -136.63 146.49 28.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.285 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -93.32 106.32 18.29 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.486 179.692 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.523 HG22 ' O ' ' A' ' 172' ' ' THR . 30.4 m -88.18 171.75 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.372 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 82.6 p -148.26 103.85 3.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.673 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 2.9 mp -79.94 85.56 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.222 -179.849 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 59.1 31.5 21.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.958 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 105.6 35.39 3.07 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.56 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 9.3 mtt-85 -135.38 91.84 2.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.795 0.331 . . . . 0.0 110.882 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -58.64 136.72 57.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.91 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 172' ' ' THR . . . . . 0.523 ' O ' HG22 ' A' ' 165' ' ' VAL . 19.7 m -159.53 104.48 1.49 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.994 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -69.43 105.79 1.49 Allowed 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.342 2.028 . . . . 0.0 112.105 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 22.0 t -122.5 135.32 62.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.247 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -87.41 139.55 30.43 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.653 179.666 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 1.038 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -144.52 -162.5 1.5 Allowed 'General case' 0 CA--C 1.516 -0.333 0 CA-C-O 121.415 0.626 . . . . 0.0 111.263 -179.665 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.405 ' HA ' HG22 ' A' ' 161' ' ' VAL . 10.0 m-20 -142.41 158.05 44.11 Favored 'General case' 0 N--CA 1.441 -0.896 0 CA-C-N 115.001 -1.0 . . . . 0.0 109.888 178.19 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -46.89 -33.47 4.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.424 -179.535 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -73.13 -8.75 57.14 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.534 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.58 ' C ' HG13 ' A' ' 140' ' ' VAL . 16.5 mm-40 -110.8 -12.97 14.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.712 0.292 . . . . 0.0 111.559 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.474 ' CG1' HD22 ' A' ' 176' ' ' LEU . 8.2 m -128.5 174.34 12.05 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.134 0 CA-C-O 120.865 0.364 . . . . 0.0 111.317 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.02 146.97 20.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.025 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.795 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -80.19 123.9 28.32 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.94 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.261 -0.876 . . . . 0.0 111.085 179.993 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.379 0 CA-C-O 120.784 0.326 . . . . 0.0 111.033 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.11 125.47 26.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.918 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.593 HG12 ' O ' ' A' ' 129' ' ' VAL . 16.0 t -98.64 31.12 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.062 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -85.71 74.53 10.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.99 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.582 ' HZ ' HG21 ' A' ' 151' ' ' VAL . 42.5 t80 -131.98 150.47 52.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.859 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 30.8 mtp180 -142.33 134.87 28.05 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.972 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.72 131.49 50.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.918 179.869 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.38 -23.39 20.57 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.69 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -57.91 -176.08 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.869 0.366 . . . . 0.0 110.974 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -121.73 139.98 52.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.956 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.894 HG12 ' HA ' ' A' ' 183' ' ' LYS . 17.1 m -139.98 142.75 31.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.011 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.453 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -80.01 165.18 22.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.038 0.447 . . . . 0.0 110.837 -179.954 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.709 HG23 ' O ' ' A' ' 147' ' ' PHE . 4.6 t -79.86 168.03 2.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.92 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.654 HG13 ' H ' ' A' ' 141' ' ' SER . 3.2 p -79.37 -62.13 1.5 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.26 0 N-CA-C 112.011 0.375 . . . . 0.0 112.011 -179.263 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.658 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.7 OUTLIER -160.5 -163.5 1.1 Allowed 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.876 0.369 . . . . 0.0 111.124 -179.515 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 78.17 -165.39 51.95 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.465 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_endo -62.17 -17.11 54.9 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.506 2.137 . . . . 0.0 112.022 179.66 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.553 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.9 m-85 -100.26 16.38 24.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.207 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.658 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -79.53 37.68 0.35 Allowed 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -179.366 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' ASP . . . . . 0.438 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 11.2 p30 -160.91 32.05 0.15 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.971 0.415 . . . . 0.0 110.818 179.277 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.709 ' O ' HG23 ' A' ' 139' ' ' VAL . 24.8 m-85 -140.91 159.62 41.81 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.747 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 1.6 p -108.72 171.07 7.64 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.568 179.689 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -137.43 139.38 10.45 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.518 -0.849 . . . . 0.0 112.768 -179.787 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.9 m -91.2 105.66 17.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.751 0.31 . . . . 0.0 110.605 179.72 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.582 HG21 ' HZ ' ' A' ' 131' ' ' PHE . 24.3 t -64.53 108.7 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.172 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 2.0 t -96.24 -30.54 13.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.955 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -140.63 164.98 28.71 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.979 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 9.5 tt -152.48 127.84 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.026 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 59.0 m-20 -103.22 93.87 5.09 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.951 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.67 -27.95 26.27 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.481 2.121 . . . . 0.0 112.293 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -90.35 26.8 1.83 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.394 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -159.86 -45.17 0.05 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.894 0.378 . . . . 0.0 110.901 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 101.56 36.55 3.75 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.486 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 19.4 mmmt -111.46 152.03 27.88 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.886 0.374 . . . . 0.0 110.849 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.758 HG22 ' HA ' ' A' ' 177' ' ' ASP . 12.3 m -140.27 125.99 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.032 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 22.4 tttt -103.88 119.66 39.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.844 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.736 HG22 ' CD1' ' A' ' 176' ' ' LEU . 33.7 m -132.15 152.65 37.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.116 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 11.9 ptp -100.55 121.07 40.98 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.045 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.423 HG12 ' N ' ' A' ' 166' ' ' THR . 7.1 t -101.93 158.29 4.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.016 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 166' ' ' THR . . . . . 0.423 ' N ' HG12 ' A' ' 165' ' ' VAL . 7.3 m -115.12 110.16 19.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.961 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.751 HD13 ' HB2' ' A' ' 168' ' ' PHE . 0.0 OUTLIER -120.0 114.28 43.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.779 179.869 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 168' ' ' PHE . . . . . 0.751 ' HB2' HD13 ' A' ' 167' ' ' ILE . 0.1 OUTLIER 63.54 31.85 14.52 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.764 -179.617 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 72.4 36.4 59.36 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.478 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -142.96 109.03 5.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.799 0.333 . . . . 0.0 110.885 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -59.47 128.2 35.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.855 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 15.8 m -132.13 92.01 30.4 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.015 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -60.99 115.58 2.79 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.593 2.195 . . . . 0.0 112.046 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 11.3 p -121.74 147.56 25.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.295 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.3 pm0 -94.55 121.93 36.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.799 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.736 ' CD1' HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -137.54 -159.18 0.93 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.306 0.574 . . . . 0.0 111.113 -179.773 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.758 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.6 OUTLIER -143.25 155.2 44.44 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.101 178.182 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 178' ' ' PHE . . . . . 0.478 ' CE2' HG11 ' A' ' 161' ' ' VAL . 8.2 m-85 -46.68 -29.09 1.71 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.578 -179.627 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 6.4 p -70.67 -11.82 61.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.564 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -115.75 16.91 16.31 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.61 -0.268 . . . . 0.0 111.448 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 10.9 m -153.25 154.07 8.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-O 120.718 0.294 . . . . 0.0 111.234 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 28.9 m -127.21 146.41 33.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.177 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.894 ' HA ' HG12 ' A' ' 137' ' ' VAL . 17.7 tptm -71.31 139.54 49.95 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.205 -0.903 . . . . 0.0 111.121 -179.978 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.357 0 CA-C-O 120.894 0.378 . . . . 0.0 111.053 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -88.93 132.99 34.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.869 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.74 82.61 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.147 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.15 142.96 53.46 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.098 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.53 ' CZ ' HG21 ' A' ' 151' ' ' VAL . 18.6 t80 -153.63 158.33 40.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.832 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 7.9 ttt85 -159.23 146.4 17.13 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.991 0.424 . . . . 0.0 110.912 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -56.01 155.84 5.96 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.776 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.99 9.36 59.75 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.869 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -80.78 162.18 24.18 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.775 0.321 . . . . 0.0 110.859 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 14.2 mt-30 -118.31 120.15 36.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.902 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.618 HG12 ' HA ' ' A' ' 183' ' ' LYS . 30.0 m -127.12 140.64 48.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.987 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.411 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.77 160.86 26.03 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.083 0.468 . . . . 0.0 110.883 -179.853 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.859 HG11 ' HB2' ' A' ' 144' ' ' PHE . 43.4 t -79.92 150.56 4.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.644 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.528 HG22 ' O ' ' A' ' 180' ' ' GLN . 35.5 m -91.97 -20.37 6.67 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 -179.418 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.733 ' H ' HG12 ' A' ' 139' ' ' VAL . 0.4 OUTLIER -79.15 153.25 30.22 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.893 0.377 . . . . 0.0 111.187 -178.937 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 142' ' ' GLY . . . . . 0.409 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -64.43 -63.2 4.46 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.946 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.409 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.2 Cg_endo -52.65 -22.86 18.22 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.666 2.244 . . . . 0.0 112.341 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.859 ' HB2' HG11 ' A' ' 139' ' ' VAL . 15.2 m-85 -112.8 2.48 15.99 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.505 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.674 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -69.82 46.93 0.08 Allowed 'General case' 0 CA--C 1.53 0.204 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -178.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 146' ' ' ASP . . . . . 0.406 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 11.4 p30 -160.71 32.19 0.15 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.023 0.44 . . . . 0.0 110.615 179.101 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.666 ' O ' HG23 ' A' ' 139' ' ' VAL . 69.0 m-85 -154.63 145.08 22.15 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.604 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.51 ' O ' HG12 ' A' ' 165' ' ' VAL . 68.7 p -102.03 172.81 6.7 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.709 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -128.14 132.67 7.45 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.47 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.8 m -95.93 104.45 16.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.745 0.307 . . . . 0.0 110.696 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.53 HG21 ' CZ ' ' A' ' 131' ' ' PHE . 26.4 t -59.85 114.32 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.32 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -107.04 -40.13 5.54 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.64 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -135.2 153.48 51.93 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.685 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 2.0 mp -129.62 152.31 37.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.239 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 -130.16 79.09 73.48 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.762 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -69.07 -26.55 30.74 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.496 2.131 . . . . 0.0 112.427 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -61.93 -34.52 76.24 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.863 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 8.3 mtt180 -108.27 -43.69 4.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.921 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 112.82 48.45 0.62 Allowed Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.505 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -137.37 177.24 8.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.835 0.35 . . . . 0.0 110.996 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.473 HG23 HG13 ' A' ' 151' ' ' VAL . 1.3 p -152.06 159.73 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.125 0.488 . . . . 0.0 110.898 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.472 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 7.1 tttm -119.43 124.35 46.31 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.867 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.419 HG12 ' HA ' ' A' ' 151' ' ' VAL . 29.7 m -136.4 146.33 29.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.252 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 8.5 ptm -92.71 130.38 38.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.878 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.51 HG12 ' O ' ' A' ' 148' ' ' THR . 27.7 m -131.5 144.49 37.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.184 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 166' ' ' THR . . . . . 0.533 HG23 ' C ' ' A' ' 170' ' ' ARG . 0.6 OUTLIER -108.28 139.46 42.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.922 -179.952 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.8 mp -136.29 -66.83 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.182 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 16.3 m-85 -91.46 55.57 2.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.926 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 58.02 27.56 59.89 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.546 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 170' ' ' ARG . . . . . 0.533 ' C ' HG23 ' A' ' 166' ' ' THR . 0.5 OUTLIER -153.88 151.39 29.43 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.864 0.364 . . . . 0.0 110.938 -179.913 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -69.38 161.05 30.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.811 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 172' ' ' THR . . . . . 0.553 HG22 ' CG2' ' A' ' 174' ' ' VAL . 16.4 m -153.52 96.49 2.81 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.876 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -66.77 83.37 0.31 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.389 2.059 . . . . 0.0 112.139 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.553 ' CG2' HG22 ' A' ' 172' ' ' THR . 26.8 t -104.93 135.66 41.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.981 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -79.97 145.04 32.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.59 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.905 HD13 HG13 ' A' ' 181' ' ' VAL . 5.7 mt -146.17 -169.31 3.22 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 121.336 0.588 . . . . 0.0 111.41 -179.55 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -140.27 153.53 46.53 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 115.092 -0.958 . . . . 0.0 110.285 178.175 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 10.0 m-85 -50.18 -31.94 15.01 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.269 -179.589 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.9 p -79.76 -1.21 37.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.385 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.72 ' HB3' HD22 ' A' ' 176' ' ' LEU . 1.3 mm-40 -116.0 3.01 13.57 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.714 0.292 . . . . 0.0 111.491 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.905 HG13 HD13 ' A' ' 176' ' ' LEU . 5.2 m -140.56 167.02 18.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-O 120.923 0.392 . . . . 0.0 111.074 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.4 m -135.07 146.36 30.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.124 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.618 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -59.99 139.15 57.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.886 -179.998 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.253 -0.88 . . . . 0.0 111.066 179.994 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 120.82 0.343 . . . . 0.0 111.024 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.42 -44.77 15.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.938 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 14.7 m -96.58 179.55 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.104 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.87 133.42 48.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.113 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 21.2 t80 -83.19 161.91 21.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.913 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 8.6 tpt180 -154.62 146.78 23.73 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.86 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -66.07 132.24 48.08 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.795 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 106.45 -14.41 42.92 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.781 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -54.84 164.72 0.74 Allowed 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.912 0.387 . . . . 0.0 110.912 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' GLN . . . . . 0.456 ' O ' ' HB3' ' A' ' 184' ' ' ALA . 0.3 OUTLIER -112.15 115.87 29.56 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.07 -179.869 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 31.5 m -116.6 139.27 44.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.852 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.417 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.4 OUTLIER -79.97 155.02 27.86 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.025 0.441 . . . . 0.0 110.975 -179.924 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.588 HG12 ' N ' ' A' ' 140' ' ' VAL . 36.4 t -95.26 167.4 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.729 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.877 HG22 ' O ' ' A' ' 180' ' ' GLN . 14.1 m -133.9 -21.01 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.25 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -178.723 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.44 ' O ' ' CD2' ' A' ' 144' ' ' PHE . 2.7 m -79.49 149.65 31.45 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.112 0.482 . . . . 0.0 112.18 -178.249 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 39.64 -148.46 0.15 Allowed Glycine 0 C--N 1.334 0.424 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.678 179.46 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -73.62 4.43 4.03 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.774 2.316 . . . . 0.0 112.557 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.551 ' HB2' HG11 ' A' ' 139' ' ' VAL . 0.5 OUTLIER -79.55 -8.99 59.54 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.072 179.959 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.44 ' HA ' ' O ' ' A' ' 139' ' ' VAL . . . -67.82 39.49 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -178.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' ASP . . . . . 0.453 ' H ' ' C ' ' A' ' 144' ' ' PHE . 0.3 OUTLIER -160.89 31.23 0.15 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.103 0.478 . . . . 0.0 110.56 179.102 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.431 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 44.9 m-85 -148.88 154.51 39.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.772 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.417 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 67.6 p -108.69 134.88 50.82 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.872 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -94.2 160.75 24.02 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.579 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.0 m -102.34 103.74 14.2 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.772 0.32 . . . . 0.0 110.751 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.704 ' HA ' HG12 ' A' ' 163' ' ' VAL . 33.9 t -62.27 107.59 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.967 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -88.89 -49.34 6.86 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.843 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -135.48 171.06 14.99 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.698 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 154' ' ' ILE . . . . . 0.596 HD12 ' HD3' ' A' ' 156' ' ' PRO . 1.0 OUTLIER -137.64 158.82 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.168 -179.907 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -140.95 83.47 14.07 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.819 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 156' ' ' PRO . . . . . 0.596 ' HD3' HD12 ' A' ' 154' ' ' ILE . 56.5 Cg_endo -70.58 -27.04 23.04 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.515 2.143 . . . . 0.0 112.351 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -59.13 -42.4 90.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.885 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 4.6 mpt_? -103.8 -60.16 1.61 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.884 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 130.21 49.55 0.12 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.494 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 13.0 mttm -130.62 161.34 31.8 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.826 0.346 . . . . 0.0 110.928 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 17.3 m -147.33 124.48 3.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.193 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 9.3 tttt -87.38 123.92 32.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.888 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.704 HG12 ' HA ' ' A' ' 151' ' ' VAL . 15.4 m -142.34 135.92 28.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.033 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 164' ' ' MET . . . . . 0.404 ' HE3' ' C ' ' A' ' 164' ' ' MET . 0.0 OUTLIER -80.49 130.44 35.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.728 -179.992 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.632 HG22 HG12 ' A' ' 174' ' ' VAL . 15.4 m -110.22 131.18 61.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.234 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -97.62 100.31 11.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.809 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.586 HG23 ' O ' ' A' ' 167' ' ' ILE . 8.0 tt -95.59 111.07 25.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.105 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER 60.61 43.58 12.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.907 -179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 65.55 52.18 41.56 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.465 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -154.16 119.22 5.03 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.911 0.386 . . . . 0.0 110.833 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -58.94 134.11 56.66 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.932 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -147.75 96.73 4.05 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.867 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.69 118.06 5.16 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.452 2.102 . . . . 0.0 112.184 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.632 HG12 HG22 ' A' ' 165' ' ' VAL . 9.9 p -145.93 144.12 21.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.092 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -79.99 134.35 36.24 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.724 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.814 HD12 ' HB3' ' A' ' 180' ' ' GLN . 2.1 mm? -121.68 -172.0 2.34 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-O 121.375 0.607 . . . . 0.0 111.341 -179.715 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.577 ' O ' HG22 ' A' ' 181' ' ' VAL . 2.5 m-20 -150.28 151.95 33.76 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.466 178.366 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 3.7 m-85 -45.12 -46.5 11.83 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.623 -179.759 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.12 -20.88 63.15 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.143 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.877 ' O ' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -92.93 -10.02 38.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.511 -179.786 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 177' ' ' ASP . 27.7 m -138.98 -176.63 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.803 0.335 . . . . 0.0 111.399 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 182' ' ' VAL . . . . . 0.4 HG23 ' HB2' ' A' ' 138' ' ' ARG . 14.4 m -150.32 157.37 6.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.032 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 10.9 tptt -71.69 138.07 48.3 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.888 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 184' ' ' ALA . . . . . 0.456 ' HB3' ' O ' ' A' ' 136' ' ' GLN . . . . . . . . 0 C--O 1.249 1.038 0 CA-C-O 118.199 -0.905 . . . . 0.0 111.195 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.337 0 CA-C-O 120.844 0.354 . . . . 0.0 110.954 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -166.32 97.81 0.6 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.87 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.402 HG11 ' HD2' ' A' ' 183' ' ' LYS . 21.4 t -120.85 118.62 56.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.186 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -70.64 157.23 38.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.166 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.475 ' CZ ' HG21 ' A' ' 151' ' ' VAL . 2.7 t80 -98.02 155.47 17.09 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.906 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 1.8 tpt180 -156.62 146.53 21.01 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.922 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -60.46 118.56 6.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.896 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.99 19.75 14.24 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.597 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -76.4 158.49 31.34 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.784 0.326 . . . . 0.0 110.847 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 -109.81 126.74 54.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.108 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.879 HG12 ' HA ' ' A' ' 183' ' ' LYS . 12.7 m -141.02 141.03 31.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.863 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.431 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 1.7 ttp180 -79.64 161.72 25.7 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.066 0.46 . . . . 0.0 110.833 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.855 HG11 ' HB2' ' A' ' 144' ' ' PHE . 27.6 t -79.98 151.37 4.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.607 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.552 HG13 ' O ' ' A' ' 180' ' ' GLN . 33.5 m -93.99 -19.44 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 -179.338 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.72 ' H ' HG12 ' A' ' 139' ' ' VAL . 4.2 m -79.14 153.4 30.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.767 0.318 . . . . 0.0 111.026 -179.079 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . -64.31 -63.87 4.02 Favored Glycine 0 CA--C 1.519 0.31 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.964 -179.497 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -53.36 -22.76 21.73 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.753 2.302 . . . . 0.0 112.474 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.855 ' HB2' HG11 ' A' ' 139' ' ' VAL . 6.4 m-85 -111.12 1.05 17.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.516 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.691 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -69.65 47.63 0.08 Allowed 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 112.61 0.596 . . . . 0.0 112.61 -178.848 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 146' ' ' ASP . . . . . 0.404 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 17.4 p-10 -160.79 32.34 0.15 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.157 0.503 . . . . 0.0 110.696 179.015 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.757 ' O ' HG23 ' A' ' 139' ' ' VAL . 35.0 m-85 -154.56 145.53 22.64 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.507 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.431 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 75.5 p -99.86 175.91 5.62 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.849 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -136.86 151.59 21.01 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.652 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.2 m -114.12 112.36 23.08 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.726 0.298 . . . . 0.0 110.978 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.475 HG21 ' CZ ' ' A' ' 131' ' ' PHE . 21.8 t -66.36 107.87 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.071 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.33 -50.42 6.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.845 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -135.62 164.36 28.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.009 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.8 mt -126.88 151.78 34.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.092 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -113.88 86.78 11.53 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.91 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.63 -27.13 22.72 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.591 2.194 . . . . 0.0 112.337 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -60.09 -51.1 71.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.949 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 2.6 ttt85 -97.37 -67.21 0.86 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.895 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 141.24 52.89 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.417 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 14.3 mttp -131.14 178.76 6.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.831 0.348 . . . . 0.0 110.82 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.701 HG11 ' CE1' ' A' ' 178' ' ' PHE . 28.1 m -145.87 123.07 4.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.071 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 62.6 tttt -79.88 116.43 20.02 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.625 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.1 t -124.55 150.2 29.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.042 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 4.5 ptt? -103.65 116.49 32.43 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.023 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 3.2 m -113.17 138.15 43.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.051 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -97.69 133.79 41.74 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.852 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.612 HD13 ' HB2' ' A' ' 168' ' ' PHE . 0.0 OUTLIER -133.47 117.88 29.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.999 179.971 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 168' ' ' PHE . . . . . 0.612 ' HB2' HD13 ' A' ' 167' ' ' ILE . 0.2 OUTLIER 62.99 30.28 16.39 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.958 -179.7 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 77.0 45.01 12.31 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.494 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -157.85 128.56 6.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.827 0.346 . . . . 0.0 110.869 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -59.74 144.36 48.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 172' ' ' THR . . . . . 0.701 ' O ' HG23 ' A' ' 174' ' ' VAL . 22.3 m -144.18 83.07 10.36 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.943 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_exo -56.23 90.16 0.04 OUTLIER 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.566 2.178 . . . . 0.0 112.312 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.701 HG23 ' O ' ' A' ' 172' ' ' THR . 24.7 t -109.0 132.69 56.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.086 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -79.92 125.84 30.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.278 179.602 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -134.43 -160.81 1.08 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.405 0.621 . . . . 0.0 111.459 -179.317 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.683 ' HA ' HG22 ' A' ' 161' ' ' VAL . 1.5 m-20 -151.44 156.53 40.84 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.936 178.299 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 178' ' ' PHE . . . . . 0.701 ' CE1' HG11 ' A' ' 161' ' ' VAL . 14.5 m-85 -46.77 -28.07 1.41 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.599 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -78.81 -0.26 29.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.708 -179.722 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.552 ' O ' HG13 ' A' ' 140' ' ' VAL . 79.1 mt-30 -118.74 0.14 11.4 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-O 120.481 0.182 . . . . 0.0 111.405 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 5.7 m -144.98 156.02 13.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 120.86 0.362 . . . . 0.0 111.099 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 30.3 m -126.41 146.43 32.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.167 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.879 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -64.85 128.8 37.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.003 179.97 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.059 0 CA-C-O 118.309 -0.853 . . . . 0.0 111.143 179.992 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.312 0 CA-C-O 120.928 0.394 . . . . 0.0 111.102 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 -69.2 137.71 53.46 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.949 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 5.1 m -119.85 113.2 39.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.177 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -89.88 -60.34 1.96 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.142 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.582 ' CZ ' HG21 ' A' ' 151' ' ' VAL . 3.2 t80 -83.96 151.83 24.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.942 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 3.3 mtt180 -147.36 131.74 17.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.936 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -60.34 120.69 10.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 108.67 11.3 23.38 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.674 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -90.04 169.4 11.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.756 0.313 . . . . 0.0 110.92 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.36 134.15 48.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.829 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.743 HG12 ' HA ' ' A' ' 183' ' ' LYS . 21.0 m -142.06 134.04 27.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.148 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.406 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.1 OUTLIER -80.99 163.13 23.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.94 0.4 . . . . 0.0 110.627 179.913 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.634 HG11 ' HB2' ' A' ' 144' ' ' PHE . 11.7 t -79.83 166.99 2.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.912 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.624 HG13 ' C ' ' A' ' 180' ' ' GLN . 2.1 m -79.31 -61.79 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -179.306 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.738 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 4.2 m -160.02 -166.4 1.7 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.811 0.338 . . . . 0.0 111.258 -179.466 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.59 -158.37 37.25 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.392 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -68.82 -10.96 30.6 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.586 2.191 . . . . 0.0 112.352 179.82 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.634 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.3 m-85 -107.31 14.18 26.33 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.468 -179.796 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.738 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -75.3 36.48 0.12 Allowed 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 112.403 0.519 . . . . 0.0 112.403 -179.342 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -161.16 34.13 0.14 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.913 0.387 . . . . 0.0 110.77 179.278 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.4 ' O ' HG23 ' A' ' 139' ' ' VAL . 23.1 m-85 -145.31 164.43 31.44 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.991 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.514 HG22 ' C ' ' A' ' 137' ' ' VAL . 0.6 OUTLIER -121.66 -173.94 2.75 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.43 179.586 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -154.6 161.83 30.4 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.449 -0.881 . . . . 0.0 112.844 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 150' ' ' THR . . . . . 0.46 ' C ' HG13 ' A' ' 163' ' ' VAL . 88.9 m -110.49 101.6 10.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.833 0.349 . . . . 0.0 110.841 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.582 HG21 ' CZ ' ' A' ' 131' ' ' PHE . 31.6 t -59.45 114.63 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.178 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -83.25 -61.07 1.95 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.866 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -134.23 168.98 17.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.895 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 154' ' ' ILE . . . . . 0.465 HG23 HG12 ' A' ' 161' ' ' VAL . 3.7 mt -126.96 135.51 63.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.069 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -107.12 84.48 1.67 Allowed Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.92 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.44 -28.12 22.36 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.607 2.204 . . . . 0.0 112.256 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -68.31 -34.15 75.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.968 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 25.0 mmt180 -101.53 -56.11 2.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.958 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 121.66 37.35 0.68 Allowed Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.495 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -126.98 175.09 8.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.758 0.314 . . . . 0.0 110.864 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.697 HG11 ' CE1' ' A' ' 178' ' ' PHE . 15.5 m -151.17 119.7 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.135 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 2.1 ttpm? -79.86 137.46 36.93 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.73 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.633 ' HB ' HD21 ' A' ' 176' ' ' LEU . 4.8 t -149.19 146.68 17.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.997 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.67 127.56 48.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.016 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.618 ' CG2' HD11 ' A' ' 167' ' ' ILE . 3.5 m -107.02 147.66 12.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.039 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 63.3 m -112.67 85.58 2.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.978 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.618 HD11 ' CG2' ' A' ' 165' ' ' VAL . 4.1 mp -98.09 126.81 51.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.031 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 61.57 31.33 18.84 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.902 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 69.5 38.38 79.32 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.554 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 72.5 mmt-85 -146.76 134.42 21.07 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.861 0.363 . . . . 0.0 110.924 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -72.29 147.99 45.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.882 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 1.8 m -157.14 88.41 2.62 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.804 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -50.8 115.54 2.06 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.608 2.205 . . . . 0.0 112.338 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.882 HG13 HD11 ' A' ' 176' ' ' LEU . 10.4 p -128.63 142.74 43.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.064 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 175' ' ' GLU . . . . . 0.872 ' C ' HD13 ' A' ' 176' ' ' LEU . 6.8 pt-20 -98.25 121.49 40.24 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.838 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.882 HD11 HG13 ' A' ' 174' ' ' VAL . 0.0 OUTLIER -126.94 -160.41 1.0 Allowed 'General case' 0 CA--C 1.518 -0.286 0 CA-C-O 121.353 0.597 . . . . 0.0 110.894 -179.939 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.427 ' HA ' HG22 ' A' ' 161' ' ' VAL . 4.8 m-20 -148.36 155.37 41.18 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.163 -0.926 . . . . 0.0 109.934 178.373 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 178' ' ' PHE . . . . . 0.697 ' CE1' HG11 ' A' ' 161' ' ' VAL . 11.7 m-85 -48.31 -33.83 9.53 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.482 -179.47 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 90.9 p -78.21 -2.55 38.3 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.643 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.624 ' C ' HG13 ' A' ' 140' ' ' VAL . 4.3 mt-30 -115.29 -2.81 12.58 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.545 0.212 . . . . 0.0 111.564 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 17.4 m -140.41 171.98 12.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-O 120.844 0.354 . . . . 0.0 111.393 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 27.5 m -136.72 146.43 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.219 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.743 ' HA ' HG12 ' A' ' 137' ' ' VAL . 5.2 mtmt -80.09 130.99 35.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.919 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.278 -0.867 . . . . 0.0 111.045 -179.972 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.331 0 CA-C-O 120.876 0.369 . . . . 0.0 110.976 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 30.2 tt0 60.49 162.59 0.06 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.811 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 9.5 p -145.68 147.32 18.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.049 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -76.49 122.23 24.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.059 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -118.72 155.38 31.17 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.827 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -143.06 132.91 24.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.921 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -59.62 123.73 17.84 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.48 5.72 27.76 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.834 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -67.61 162.57 23.23 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.739 0.304 . . . . 0.0 110.792 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -111.59 131.23 55.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.977 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.654 HG12 ' HA ' ' A' ' 183' ' ' LYS . 15.6 m -143.42 148.25 19.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.803 179.837 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.767 ' HD3' HG22 ' A' ' 148' ' ' THR . 0.2 OUTLIER -79.63 164.62 23.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.03 0.443 . . . . 0.0 111.033 -179.927 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.901 HG23 ' O ' ' A' ' 147' ' ' PHE . 22.3 t -79.88 151.06 4.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.674 -179.636 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 11.4 p -90.83 -24.17 5.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-N 116.044 -0.526 . . . . 0.0 112.076 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.684 ' H ' HG12 ' A' ' 139' ' ' VAL . 6.2 m -79.33 154.67 28.9 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.999 0.428 . . . . 0.0 111.412 -178.891 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 142' ' ' GLY . . . . . 0.439 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -67.26 -61.19 5.32 Favored Glycine 0 N--CA 1.451 -0.308 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.69 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.439 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.2 Cg_endo -51.43 -24.55 16.64 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.663 2.242 . . . . 0.0 112.205 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.865 ' HB2' HG11 ' A' ' 139' ' ' VAL . 21.3 m-85 -112.98 4.36 16.7 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.419 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.681 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -70.06 46.58 0.08 Allowed 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -179.097 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 146' ' ' ASP . . . . . 0.427 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 17.5 p-10 -160.56 30.82 0.16 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.204 0.526 . . . . 0.0 110.498 179.037 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.901 ' O ' HG23 ' A' ' 139' ' ' VAL . 24.2 m-85 -151.85 146.18 25.48 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.168 179.732 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.767 HG22 ' HD3' ' A' ' 138' ' ' ARG . 26.7 p -96.85 -177.36 3.86 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.737 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 149' ' ' GLY . . . . . 0.4 ' HA3' ' CG2' ' A' ' 163' ' ' VAL . . . -144.63 159.34 27.78 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.608 -179.875 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 2.2 m -117.09 111.55 19.67 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.798 0.332 . . . . 0.0 110.862 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 21.6 t -69.37 131.92 33.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.047 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.74 -68.92 0.79 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.026 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -123.71 172.92 8.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.948 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' ILE . . . . . 0.443 HG23 HG12 ' A' ' 161' ' ' VAL . 35.0 mt -139.35 128.93 30.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.074 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -100.81 99.51 10.48 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.897 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.41 -23.75 17.15 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.557 2.171 . . . . 0.0 112.417 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -90.27 23.2 2.99 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.301 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 16.4 mtp180 -158.6 -44.25 0.06 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.754 0.311 . . . . 0.0 110.765 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 97.4 57.39 1.06 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.472 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.55 162.95 34.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.765 0.317 . . . . 0.0 111.016 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.641 HG11 ' CE1' ' A' ' 178' ' ' PHE . 24.1 m -148.06 126.67 3.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.961 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 6.0 tttp -79.94 122.29 26.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.856 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.4 ' CG2' ' HA3' ' A' ' 149' ' ' GLY . 11.4 p -126.13 145.93 32.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.085 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.21 117.89 35.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.735 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.683 HG22 HG12 ' A' ' 174' ' ' VAL . 13.4 m -110.33 142.76 21.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.139 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 166' ' ' THR . . . . . 0.484 HG23 ' C ' ' A' ' 170' ' ' ARG . 8.2 m -135.73 133.32 37.89 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.875 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.482 HG22 ' O ' ' A' ' 167' ' ' ILE . 4.1 mp -102.69 53.47 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.937 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER 65.67 96.49 0.05 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.974 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 65.81 33.55 86.17 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.679 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 170' ' ' ARG . . . . . 0.484 ' C ' HG23 ' A' ' 166' ' ' THR . 0.0 OUTLIER -154.44 86.07 1.14 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.849 0.357 . . . . 0.0 111.019 -179.884 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -68.79 141.95 55.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.706 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 63.4 m -160.0 93.3 1.68 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.167 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_exo -62.06 124.81 15.11 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.651 2.234 . . . . 0.0 112.057 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.683 HG12 HG22 ' A' ' 165' ' ' VAL . 11.2 p -137.91 132.33 43.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.32 -179.828 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -79.82 131.72 35.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.263 179.642 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.806 HD23 HG13 ' A' ' 181' ' ' VAL . 1.1 mp -133.07 -167.74 1.97 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.421 0.629 . . . . 0.0 111.608 -179.319 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.442 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.6 OUTLIER -144.66 154.11 42.45 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 114.961 -1.018 . . . . 0.0 110.199 178.152 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 178' ' ' PHE . . . . . 0.641 ' CE1' HG11 ' A' ' 161' ' ' VAL . 8.9 m-85 -44.73 -33.68 1.96 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.612 -179.548 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -82.32 14.65 2.83 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.679 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.427 ' N ' ' O ' ' A' ' 177' ' ' ASP . 21.6 mt-30 -127.85 4.91 6.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.576 0.227 . . . . 0.0 111.328 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.806 HG13 HD23 ' A' ' 176' ' ' LEU . 6.2 m -146.45 170.72 4.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.14 0 CA-C-O 120.874 0.369 . . . . 0.0 111.198 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 21.0 m -140.49 146.38 24.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.084 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.654 ' HA ' HG12 ' A' ' 137' ' ' VAL . 13.6 tttt -66.07 121.94 16.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.272 -0.871 . . . . 0.0 111.062 179.983 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.294 0 CA-C-O 120.7 0.286 . . . . 0.0 111.05 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 25.0 mt-30 -131.88 77.55 1.77 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.926 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 6.5 m -112.31 -32.69 2.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.15 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -82.56 113.89 20.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.116 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.535 ' CZ ' HG21 ' A' ' 151' ' ' VAL . 16.5 t80 -97.13 157.91 15.7 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.787 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 7.1 mmt180 -142.02 148.14 38.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.059 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -64.22 122.83 17.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.792 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 96.23 18.26 31.8 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.617 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.49 176.51 9.33 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.798 0.333 . . . . 0.0 110.884 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 38.2 mt-30 -120.08 114.34 21.83 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.115 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.609 HG12 ' HA ' ' A' ' 183' ' ' LYS . 18.8 m -124.43 143.17 38.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.805 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -79.85 162.11 25.24 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.109 0.481 . . . . 0.0 111.054 -179.724 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.856 HG11 ' HB2' ' A' ' 144' ' ' PHE . 46.7 t -84.62 155.21 3.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.529 -179.423 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.553 HG13 ' O ' ' A' ' 180' ' ' GLN . 35.6 m -96.89 -24.65 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 N-CA-C 112.675 0.62 . . . . 0.0 112.675 -179.165 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.617 ' H ' HG12 ' A' ' 139' ' ' VAL . 0.2 OUTLIER -78.99 131.12 36.19 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.85 0.357 . . . . 0.0 111.32 -178.646 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 142' ' ' GLY . . . . . 0.476 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -44.19 -59.07 4.17 Favored Glycine 0 C--N 1.332 0.347 0 CA-C-N 115.823 -0.626 . . . . 0.0 113.597 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.476 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.7 Cg_endo -51.1 -22.74 11.3 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.669 2.246 . . . . 0.0 112.481 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.856 ' HB2' HG11 ' A' ' 139' ' ' VAL . 21.2 m-85 -120.13 4.83 10.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.466 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.522 ' N ' ' O ' ' A' ' 141' ' ' SER . . . -70.02 45.21 0.07 Allowed 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 112.55 0.574 . . . . 0.0 112.55 -178.653 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 146' ' ' ASP . . . . . 0.408 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 15.1 p-10 -160.69 31.74 0.15 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.13 0.491 . . . . 0.0 110.422 179.091 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.659 ' O ' HG23 ' A' ' 139' ' ' VAL . 46.3 m-85 -155.66 145.98 21.78 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.439 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 1.4 p -101.76 168.89 9.16 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.789 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -132.49 132.45 6.64 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.515 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.7 m -87.35 109.05 19.27 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.723 0.297 . . . . 0.0 110.802 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.535 HG21 ' CZ ' ' A' ' 131' ' ' PHE . 19.2 t -64.38 123.8 17.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.093 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.2 p -100.97 -43.66 5.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.957 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 6.6 mt-10 -136.77 151.25 48.98 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' ILE . . . . . 0.488 HG23 HG12 ' A' ' 161' ' ' VAL . 7.8 mt -128.57 132.23 68.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.101 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -116.98 85.54 18.03 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.835 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -58.37 -30.05 90.06 Favored 'Trans proline' 0 C--N 1.343 0.278 0 C-N-CA 122.595 2.196 . . . . 0.0 112.321 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -60.38 -62.68 1.69 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.099 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 7.7 ttm180 -79.99 -30.89 39.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.029 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 93.53 27.15 13.54 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.58 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 2.9 mtmm -107.78 162.65 13.8 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.732 0.301 . . . . 0.0 110.754 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.759 HG11 ' CE1' ' A' ' 178' ' ' PHE . 15.7 m -153.71 123.19 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.163 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 29.4 tttt -85.66 146.97 26.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.816 179.806 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.781 HG21 HD11 ' A' ' 176' ' ' LEU . 25.0 m -144.96 170.1 7.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.276 -179.866 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -120.0 110.87 17.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.655 179.631 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.51 HG22 ' O ' ' A' ' 172' ' ' THR . 11.9 m -99.53 157.99 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.138 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 27.4 p -141.49 97.41 3.15 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.982 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.495 ' H ' HD12 ' A' ' 167' ' ' ILE . 3.9 mp -79.87 83.53 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.962 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 24.7 m-85 62.29 70.39 0.57 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.902 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 60.26 47.06 92.97 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.566 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 1.5 mtm180 -146.38 91.48 2.05 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.905 0.383 . . . . 0.0 110.977 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -58.17 140.39 53.03 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.984 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 172' ' ' THR . . . . . 0.51 ' O ' HG22 ' A' ' 165' ' ' VAL . 2.8 m -160.09 97.8 1.49 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.933 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.86 123.76 10.38 Favored 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.405 2.07 . . . . 0.0 112.12 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.9 t -139.74 145.26 26.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.134 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 175' ' ' GLU . . . . . 0.89 ' O ' HD23 ' A' ' 176' ' ' LEU . 0.4 OUTLIER -88.92 142.47 27.62 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.859 179.997 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.89 HD23 ' O ' ' A' ' 175' ' ' GLU . 0.1 OUTLIER -147.68 -161.29 1.3 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.337 0.589 . . . . 0.0 111.088 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.583 ' HA ' HG22 ' A' ' 161' ' ' VAL . 1.0 OUTLIER -150.48 155.18 39.02 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.007 178.292 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 178' ' ' PHE . . . . . 0.759 ' CE1' HG11 ' A' ' 161' ' ' VAL . 25.6 m-85 -46.47 -30.4 2.18 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.536 -179.583 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 60.6 p -81.19 8.11 9.65 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.863 -179.799 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.553 ' O ' HG13 ' A' ' 140' ' ' VAL . 6.2 mt-30 -122.39 2.12 9.65 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-O 120.616 0.246 . . . . 0.0 111.286 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 4.8 m -143.24 172.31 7.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-O 120.88 0.371 . . . . 0.0 111.084 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 18.0 m -142.16 148.92 19.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.161 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.609 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -67.57 125.35 25.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.911 -179.968 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.174 -0.917 . . . . 0.0 111.106 179.92 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.308 0 CA-C-O 120.774 0.321 . . . . 0.0 111.006 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 1.5 mt-30 -98.91 30.71 3.25 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.919 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.4 t -136.63 148.16 27.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.197 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -59.96 -63.82 1.16 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.121 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.64 ' CE2' HG21 ' A' ' 151' ' ' VAL . 6.0 t80 -90.57 154.67 19.43 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.855 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -158.09 157.5 32.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.88 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -62.6 135.47 57.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.912 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 105.31 -23.94 28.99 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.637 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.8 t0 -58.2 158.23 7.34 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.825 0.345 . . . . 0.0 110.947 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 13.9 mm-40 -110.41 138.42 46.82 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.002 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.489 HG12 ' HA ' ' A' ' 183' ' ' LYS . 18.4 m -140.01 134.11 36.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.911 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.457 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 2.6 ttm180 -79.95 166.03 22.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.995 0.426 . . . . 0.0 110.839 179.877 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.673 HG23 ' O ' ' A' ' 147' ' ' PHE . 3.9 t -79.91 169.73 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.799 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.6 HG23 ' H ' ' A' ' 141' ' ' SER . 0.7 OUTLIER -79.49 -65.53 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 111.835 0.309 . . . . 0.0 111.835 -179.5 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.67 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.0 OUTLIER -160.18 -167.85 2.04 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.827 0.346 . . . . 0.0 111.059 -179.683 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 83.81 -162.27 39.09 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.417 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -64.28 -15.72 51.12 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.532 2.154 . . . . 0.0 112.241 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.655 ' HD1' HD13 ' A' ' 167' ' ' ILE . 2.8 m-85 -104.54 19.73 19.82 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.149 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.67 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -80.69 38.22 0.44 Allowed 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -179.259 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 146' ' ' ASP . . . . . 0.435 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 8.8 t70 -160.84 32.63 0.15 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.01 0.434 . . . . 0.0 110.977 179.234 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.673 ' O ' HG23 ' A' ' 139' ' ' VAL . 17.0 m-85 -140.3 161.11 38.47 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.7 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.457 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 25.1 p -116.42 -178.45 3.42 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.741 179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -145.43 137.42 7.04 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.664 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 14.5 m -92.83 108.64 20.15 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.78 0.324 . . . . 0.0 110.663 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.64 HG21 ' CE2' ' A' ' 131' ' ' PHE . 20.7 t -69.37 118.87 14.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.207 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -103.77 -34.82 8.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.854 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -151.25 159.72 44.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.859 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mp -139.83 140.52 35.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.136 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 24.3 m120 -103.71 92.2 4.05 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.863 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -69.4 -27.76 27.77 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.538 2.159 . . . . 0.0 112.25 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -70.25 -40.27 74.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.867 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 3.7 mmt180 -98.49 -62.42 1.24 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.855 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 125.47 55.42 0.16 Allowed Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.476 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -130.45 166.53 20.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.92 0.39 . . . . 0.0 110.921 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.659 HG22 ' HA ' ' A' ' 177' ' ' ASP . 3.4 m -147.94 116.93 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.059 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 26.1 ttpt -87.07 121.52 29.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.754 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.416 HG12 HG22 ' A' ' 151' ' ' VAL . 35.7 m -135.6 147.01 28.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.254 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 4.1 ptt? -102.17 118.73 37.51 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.043 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.432 HG12 ' N ' ' A' ' 166' ' ' THR . 7.4 t -106.2 158.45 6.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.12 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 166' ' ' THR . . . . . 0.432 ' N ' HG12 ' A' ' 165' ' ' VAL . 0.6 OUTLIER -110.18 94.65 5.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.946 179.977 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.655 HD13 ' HD1' ' A' ' 144' ' ' PHE . 1.4 tp -112.16 136.74 47.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.965 179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER 61.31 30.1 18.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.921 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 67.74 39.97 90.03 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.633 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -159.88 140.21 11.86 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.787 0.327 . . . . 0.0 110.967 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.57 150.92 45.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.77 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 172' ' ' THR . . . . . 0.403 ' O ' HG23 ' A' ' 174' ' ' VAL . 14.8 p -153.3 93.47 3.12 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.042 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.88 87.18 0.29 Allowed 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.444 2.096 . . . . 0.0 112.039 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 172' ' ' THR . 34.6 t -101.62 135.3 38.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.338 -179.746 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 175' ' ' GLU . . . . . 0.417 ' C ' HD23 ' A' ' 176' ' ' LEU . 10.9 pm0 -82.04 124.31 29.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.581 179.687 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.417 HD23 ' C ' ' A' ' 175' ' ' GLU . 0.2 OUTLIER -132.55 -160.9 1.09 Allowed 'General case' 0 CA--C 1.517 -0.308 0 CA-C-O 121.351 0.596 . . . . 0.0 111.254 -179.605 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.659 ' HA ' HG22 ' A' ' 161' ' ' VAL . 4.6 m-20 -149.88 155.2 39.62 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.169 178.377 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 178' ' ' PHE . . . . . 0.565 ' CE1' HG11 ' A' ' 161' ' ' VAL . 42.6 m-85 -46.34 -29.02 1.49 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.732 -179.502 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 8.2 m -74.52 -5.7 44.21 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.738 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.535 ' C ' HG13 ' A' ' 140' ' ' VAL . 11.9 mm-40 -120.76 -4.46 9.71 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 111.603 0.223 . . . . 0.0 111.603 -179.833 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.414 ' CG2' ' HA ' ' A' ' 178' ' ' PHE . 6.6 m -122.76 178.03 3.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.86 0.362 . . . . 0.0 111.223 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 182' ' ' VAL . . . . . 0.446 HG22 ' O ' ' A' ' 138' ' ' ARG . 27.2 m -152.06 146.78 15.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.135 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.489 ' HA ' HG12 ' A' ' 137' ' ' VAL . 3.8 ttmm -67.51 125.2 25.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.927 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.17 -0.919 . . . . 0.0 111.105 -179.985 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.377 0 CA-C-O 120.81 0.338 . . . . 0.0 111.067 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -140.33 143.97 36.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.861 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.45 HG21 ' HG3' ' A' ' 132' ' ' ARG . 11.2 p -133.4 137.47 53.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.077 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -74.61 -44.52 50.22 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.155 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 6.7 t80 -145.06 145.83 31.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.859 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' ARG . . . . . 0.45 ' HG3' HG21 ' A' ' 129' ' ' VAL . 0.0 OUTLIER -149.94 152.03 34.34 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.907 180.0 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -67.6 140.26 56.9 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.011 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 93.95 -21.51 41.37 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.58 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.43 176.28 0.65 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.851 0.358 . . . . 0.0 110.94 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -112.36 143.35 43.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.04 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.639 HG12 ' HA ' ' A' ' 183' ' ' LYS . 18.0 m -139.42 133.13 38.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.907 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.435 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 1.6 ttt180 -79.85 165.14 23.02 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.017 0.437 . . . . 0.0 110.94 -179.819 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 147' ' ' PHE . 4.4 t -80.03 169.08 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.904 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.619 HG23 ' H ' ' A' ' 141' ' ' SER . 0.8 OUTLIER -79.63 -65.97 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.805 -179.5 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.687 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 51.8 p -160.13 -165.52 1.49 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.823 0.344 . . . . 0.0 111.017 -179.78 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.61 -160.56 39.64 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.414 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.65 -13.42 39.82 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.613 2.209 . . . . 0.0 112.295 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.526 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.6 m-85 -106.97 20.49 18.97 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.164 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.687 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -81.13 38.91 0.49 Allowed 'General case' 0 C--N 1.331 -0.239 0 N-CA-C 112.3 0.481 . . . . 0.0 112.3 -179.377 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -160.97 36.49 0.15 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.88 0.371 . . . . 0.0 110.951 179.358 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.719 ' O ' HG23 ' A' ' 139' ' ' VAL . 48.0 m-85 -147.84 158.48 44.05 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.815 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.669 ' O ' HG12 ' A' ' 165' ' ' VAL . 58.2 p -118.93 169.2 10.08 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.792 179.869 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 149' ' ' GLY . . . . . 0.413 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -132.67 153.36 20.62 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.679 -179.832 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 2.7 m -101.81 107.72 18.99 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.819 0.343 . . . . 0.0 110.828 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 24.5 t -62.42 116.66 2.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.131 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 4.6 p -108.68 -57.2 2.17 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.859 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -113.23 155.99 24.08 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 154' ' ' ILE . . . . . 0.472 HG23 HG12 ' A' ' 161' ' ' VAL . 4.0 mp -142.31 141.72 28.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.172 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -123.65 101.29 36.88 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.812 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -69.23 -26.55 29.95 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.398 2.066 . . . . 0.0 112.438 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.57 -42.15 52.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.918 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 49.3 mtt-85 -87.43 -33.8 18.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.901 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 85.11 35.81 11.94 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.427 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 160' ' ' LYS . . . . . 0.533 ' O ' HG13 ' A' ' 161' ' ' VAL . 28.6 mttm -118.01 177.04 4.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.754 0.312 . . . . 0.0 110.857 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.576 HG11 ' CE1' ' A' ' 178' ' ' PHE . 6.1 m -158.94 121.49 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.166 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 80.5 tttt -84.87 132.75 34.35 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.822 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.413 ' HB ' ' HA3' ' A' ' 149' ' ' GLY . 33.8 m -139.67 138.67 39.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.144 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 12.6 ptm -90.67 113.84 26.0 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.669 HG12 ' O ' ' A' ' 148' ' ' THR . 27.4 m -115.46 156.91 16.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.171 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 16.7 p -105.98 142.52 35.54 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.719 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.811 ' O ' HD13 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -103.77 -38.96 5.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.997 179.927 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -171.18 86.15 0.09 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.866 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 58.16 30.24 63.79 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.559 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -158.13 134.46 9.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.807 0.337 . . . . 0.0 110.925 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -67.96 155.89 38.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 3.4 m -159.96 93.71 1.66 Allowed Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.756 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -67.84 125.84 13.75 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.502 2.135 . . . . 0.0 112.294 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 7.4 m -139.38 139.02 39.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.3 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -79.87 126.49 31.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.344 179.524 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.904 HD13 HG13 ' A' ' 181' ' ' VAL . 6.8 mt -133.88 -170.99 2.62 Favored 'General case' 0 CA--C 1.516 -0.359 0 CA-C-O 121.388 0.613 . . . . 0.0 111.698 -179.345 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.453 ' O ' HG22 ' A' ' 181' ' ' VAL . 5.2 m-20 -144.36 155.7 43.91 Favored 'General case' 0 N--CA 1.442 -0.832 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.286 178.196 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 178' ' ' PHE . . . . . 0.576 ' CE1' HG11 ' A' ' 161' ' ' VAL . 10.7 m-85 -45.62 -41.74 10.51 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.577 -179.567 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 2.6 p -65.39 -15.88 63.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.373 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.779 ' CB ' HD22 ' A' ' 176' ' ' LEU . 4.0 mt-30 -103.78 -18.89 14.48 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.384 -179.689 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.904 HG13 HD13 ' A' ' 176' ' ' LEU . 11.0 m -120.75 173.05 6.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.922 0.392 . . . . 0.0 111.366 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 30.3 m -144.4 146.25 20.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.032 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.639 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -71.56 123.0 21.49 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.992 179.973 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.995 0 CA-C-O 118.324 -0.846 . . . . 0.0 111.061 179.977 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.372 0 CA-C-O 120.868 0.366 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 128' ' ' GLN . . . . . 0.49 ' O ' HG13 ' A' ' 129' ' ' VAL . 1.8 mm-40 -159.34 -57.92 0.06 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.829 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.49 HG13 ' O ' ' A' ' 128' ' ' GLN . 12.8 m -158.09 -43.58 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.287 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -55.93 -172.26 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.142 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.617 ' CZ ' HG21 ' A' ' 151' ' ' VAL . 7.4 t80 -95.21 147.53 23.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.877 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -147.43 142.31 26.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.929 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -63.69 138.32 58.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.951 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 105.85 -22.4 31.9 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.613 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -57.41 156.16 8.26 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.818 0.342 . . . . 0.0 111.028 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 10.0 mt-30 -113.17 137.53 51.32 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.939 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.804 HG12 ' HA ' ' A' ' 183' ' ' LYS . 18.4 m -143.81 141.39 25.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.155 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.435 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 3.7 ttp180 -79.91 165.84 22.24 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.796 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.748 HG23 ' O ' ' A' ' 147' ' ' PHE . 7.6 t -80.1 167.22 2.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.116 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.624 HG13 ' H ' ' A' ' 141' ' ' SER . 2.6 p -79.35 -61.41 1.73 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.92 -179.395 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.677 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 2.6 m -160.35 -165.13 1.38 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.912 0.386 . . . . 0.0 111.138 -179.464 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.56 -165.85 50.32 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.334 179.864 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -62.15 -17.11 54.82 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.474 2.116 . . . . 0.0 112.02 179.659 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.587 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.7 m-85 -99.57 14.6 29.4 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.119 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.677 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -78.75 38.06 0.31 Allowed 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -179.234 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -160.89 36.6 0.15 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.88 0.371 . . . . 0.0 110.774 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.748 ' O ' HG23 ' A' ' 139' ' ' VAL . 16.2 m-85 -152.13 157.23 41.27 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.043 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.435 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 5.6 t -110.17 -176.02 2.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.636 179.823 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -154.89 140.41 7.38 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.539 -0.839 . . . . 0.0 112.779 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 12.2 m -94.16 110.19 21.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.754 0.311 . . . . 0.0 110.623 179.692 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.653 ' HA ' HG12 ' A' ' 163' ' ' VAL . 36.8 t -57.55 116.53 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.155 -179.842 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -111.45 -29.57 7.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.0 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -135.72 167.01 21.94 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.943 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 23.3 pt -145.59 133.27 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.167 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -117.19 81.18 12.78 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.803 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.44 -32.45 12.36 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.656 2.237 . . . . 0.0 112.224 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -59.74 -35.49 74.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.919 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -102.17 -33.98 9.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.927 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 99.16 43.87 2.5 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.45 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -139.76 156.12 46.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.934 0.397 . . . . 0.0 110.867 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.467 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.2 p -123.52 159.79 27.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.924 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.467 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 13.0 ttpt -128.65 140.22 51.87 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.184 -179.753 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.928 HG22 HD11 ' A' ' 176' ' ' LEU . 34.6 m -139.84 -179.73 2.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.233 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -120.08 111.9 18.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.702 179.565 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.403 HG22 ' O ' ' A' ' 172' ' ' THR . 31.0 m -98.25 167.92 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.263 -179.773 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.16 79.56 1.7 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.821 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 30.9 mm -80.54 108.37 13.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.173 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 59.15 55.27 4.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.064 0.459 . . . . 0.0 110.928 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 57.53 41.48 93.48 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.571 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 6.1 ttt180 -137.51 106.32 5.92 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.803 0.335 . . . . 0.0 110.924 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -73.21 127.02 31.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.874 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 172' ' ' THR . . . . . 0.403 ' O ' HG22 ' A' ' 165' ' ' VAL . 52.3 m -147.17 131.44 8.6 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.79 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -74.79 106.71 2.31 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.516 2.144 . . . . 0.0 112.415 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.443 ' O ' HG13 ' A' ' 174' ' ' VAL . 12.1 p -119.07 124.01 72.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.987 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 12.4 mt-10 -88.15 141.89 28.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.806 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.928 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -138.12 -162.55 1.32 Allowed 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 121.233 0.539 . . . . 0.0 111.151 -179.644 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.694 ' O ' HG22 ' A' ' 181' ' ' VAL . 0.3 OUTLIER -146.04 152.2 38.96 Favored 'General case' 0 N--CA 1.444 -0.762 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.207 178.404 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 -48.74 -37.04 17.72 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.432 -179.663 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 17.3 p -75.74 -9.54 58.68 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.56 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 23.5 mt-30 -118.58 21.14 12.72 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-O 120.603 0.239 . . . . 0.0 111.417 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.694 HG22 ' O ' ' A' ' 177' ' ' ASP . 17.6 m -152.92 146.5 14.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.891 0.377 . . . . 0.0 111.22 179.786 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 30.9 m -114.15 146.28 18.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.135 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.804 ' HA ' HG12 ' A' ' 137' ' ' VAL . 4.1 ttmt -80.92 137.28 36.13 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.955 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.065 0 CA-C-O 118.255 -0.879 . . . . 0.0 111.041 179.979 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.868 0.366 . . . . 0.0 110.95 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -97.98 51.84 1.05 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.955 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.521 HG12 ' H ' ' A' ' 131' ' ' PHE . 19.1 t -132.19 132.5 60.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.195 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -90.3 25.52 2.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.536 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.521 ' H ' HG12 ' A' ' 129' ' ' VAL . 16.3 t80 -156.5 163.33 39.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.806 0.336 . . . . 0.0 110.991 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.24 136.63 50.35 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.843 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -69.21 141.25 54.54 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.835 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 89.29 -8.66 79.34 Favored Glycine 0 CA--C 1.519 0.339 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.724 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -56.87 164.14 1.67 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.826 0.346 . . . . 0.0 111.027 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -104.05 134.63 46.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.976 -179.867 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.735 HG12 ' HA ' ' A' ' 183' ' ' LYS . 21.0 m -141.66 131.54 24.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.886 179.839 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.414 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 3.4 ttp180 -79.78 164.28 23.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.013 0.435 . . . . 0.0 110.976 -180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.635 HG23 ' O ' ' A' ' 147' ' ' PHE . 3.7 t -79.96 168.55 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.86 -179.884 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.617 HG23 ' H ' ' A' ' 141' ' ' SER . 0.7 OUTLIER -79.6 -65.8 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.768 -179.518 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.716 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.3 OUTLIER -160.11 -164.57 1.31 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.768 0.318 . . . . 0.0 110.903 -179.835 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.36 -157.34 36.5 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.529 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -69.53 -10.23 28.2 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.558 2.172 . . . . 0.0 112.519 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.604 ' HB2' HG11 ' A' ' 139' ' ' VAL . 2.6 m-85 -110.46 19.54 18.67 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.201 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.716 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -78.86 37.85 0.31 Allowed 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -179.352 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 146' ' ' ASP . . . . . 0.406 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 1.5 p30 -161.08 36.0 0.14 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.893 0.378 . . . . 0.0 110.896 179.281 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.635 ' O ' HG23 ' A' ' 139' ' ' VAL . 44.0 m-85 -146.81 163.03 37.34 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.969 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.414 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 1.1 p -118.16 -177.07 3.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.771 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -147.47 142.95 10.68 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.526 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.7 m -99.7 103.71 15.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.779 0.324 . . . . 0.0 110.766 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.519 HG22 HG12 ' A' ' 163' ' ' VAL . 31.7 t -60.6 127.03 19.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.206 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.9 p -111.95 -33.98 6.12 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.858 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -136.01 157.7 46.21 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.874 179.883 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 25.9 pt -138.76 136.22 43.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.261 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -120.09 84.57 33.65 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.879 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -54.28 -26.44 43.19 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.535 2.157 . . . . 0.0 112.392 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -58.7 -73.3 0.08 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.907 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 7.2 mtt85 -80.01 -30.45 39.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.909 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 93.97 47.0 2.99 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.412 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -106.34 159.69 15.94 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.884 0.373 . . . . 0.0 110.872 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.504 HG11 ' HE1' ' A' ' 178' ' ' PHE . 5.2 m -143.16 116.94 3.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.15 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 19.1 tttp -90.78 111.23 22.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.826 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.614 HG22 ' CD1' ' A' ' 176' ' ' LEU . 33.8 m -119.24 148.71 22.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.163 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.5 ppp? -95.1 114.77 26.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.773 179.79 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.478 HG22 ' O ' ' A' ' 172' ' ' THR . 17.0 m -105.52 149.11 9.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.202 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 22.6 m -119.61 85.23 2.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.904 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.523 HG23 ' O ' ' A' ' 167' ' ' ILE . 1.7 tp -82.21 118.11 29.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.092 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 60.57 33.62 20.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.873 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 75.18 30.09 59.42 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.505 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.12 108.65 8.96 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.753 0.311 . . . . 0.0 110.981 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -59.95 139.91 57.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.807 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 172' ' ' THR . . . . . 0.478 ' O ' HG22 ' A' ' 165' ' ' VAL . 53.8 m -154.12 109.56 2.46 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.913 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -67.45 100.67 0.58 Allowed 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.341 2.027 . . . . 0.0 112.157 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 11.9 p -108.45 129.01 63.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.286 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -90.63 123.39 34.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.614 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.614 ' CD1' HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -137.33 -159.52 0.96 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.43 0.633 . . . . 0.0 111.128 -179.712 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.456 ' HA ' HG22 ' A' ' 161' ' ' VAL . 7.5 m-20 -145.56 157.33 44.0 Favored 'General case' 0 N--CA 1.441 -0.875 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.055 178.21 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 178' ' ' PHE . . . . . 0.504 ' HE1' HG11 ' A' ' 161' ' ' VAL . 6.4 m-85 -44.24 -30.42 0.8 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.656 -179.631 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 35.5 t -67.25 -23.55 65.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.435 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.539 ' O ' HG13 ' A' ' 140' ' ' VAL . 22.6 mt-30 -101.83 -14.17 17.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.617 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 10.7 m -123.39 172.15 11.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-O 120.858 0.361 . . . . 0.0 111.461 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 32.9 m -146.39 146.2 19.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.164 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.735 ' HA ' HG12 ' A' ' 137' ' ' VAL . 9.9 mttt -66.0 125.74 26.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.943 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.273 -0.87 . . . . 0.0 111.075 179.994 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.353 0 CA-C-O 120.788 0.328 . . . . 0.0 111.028 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 128' ' ' GLN . . . . . 0.521 ' OE1' ' HB3' ' A' ' 130' ' ' ALA . 0.0 OUTLIER 60.65 172.23 0.1 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.85 179.94 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 15.3 m -111.16 -32.29 2.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.137 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' ALA . . . . . 0.521 ' HB3' ' OE1' ' A' ' 128' ' ' GLN . . . -87.8 -176.57 5.55 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.103 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 11.0 p90 -93.36 179.23 5.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.827 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 2.0 ttm180 -112.69 167.22 10.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.98 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -59.66 120.16 8.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.939 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 121.71 -19.9 8.34 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.64 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -55.48 -178.85 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.824 0.345 . . . . 0.0 110.994 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 2.0 mt-30 -132.02 136.14 47.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.148 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.893 HG21 HG21 ' A' ' 181' ' ' VAL . 31.0 m -139.45 147.93 23.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.789 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -79.84 164.75 23.36 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.962 0.411 . . . . 0.0 111.022 -179.771 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.856 HG23 ' O ' ' A' ' 147' ' ' PHE . 39.7 t -79.8 149.35 5.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.433 -179.689 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 9.9 p -90.26 -20.36 6.99 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 115.991 -0.55 . . . . 0.0 112.181 -179.494 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.75 ' H ' HG12 ' A' ' 139' ' ' VAL . 0.4 OUTLIER -79.23 152.65 30.5 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.908 0.385 . . . . 0.0 111.145 -179.032 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 142' ' ' GLY . . . . . 0.407 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -65.5 -63.37 4.14 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.892 -179.793 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.407 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.6 Cg_endo -53.76 -22.7 24.07 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.7 2.266 . . . . 0.0 112.32 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.804 ' HB2' HG11 ' A' ' 139' ' ' VAL . 17.5 m-85 -110.36 1.99 18.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.365 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.651 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -70.31 49.68 0.11 Allowed 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -179.151 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -160.69 32.63 0.15 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.15 0.5 . . . . 0.0 110.465 179.093 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.856 ' O ' HG23 ' A' ' 139' ' ' VAL . 46.5 m-85 -157.23 145.77 19.58 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.533 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.444 ' O ' HG12 ' A' ' 165' ' ' VAL . 30.3 p -103.67 -179.26 3.9 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.865 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -144.71 141.98 10.52 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.619 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.4 m -93.38 107.41 19.24 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.714 0.293 . . . . 0.0 110.696 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.577 ' HA ' HG12 ' A' ' 163' ' ' VAL . 40.9 t -64.84 113.14 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.088 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 73.8 p -97.76 -46.4 5.98 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.763 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -124.69 167.48 14.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.848 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 154' ' ' ILE . . . . . 0.728 HG22 HG12 ' A' ' 161' ' ' VAL . 12.6 pt -146.49 160.14 10.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.203 -179.937 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 8.5 m-20 -132.24 89.71 36.55 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.923 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.15 -28.09 28.6 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.546 2.164 . . . . 0.0 112.289 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -62.49 -52.79 62.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.967 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.26 -49.43 5.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.905 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 115.44 52.23 0.41 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.574 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -125.88 170.15 11.94 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.864 0.364 . . . . 0.0 110.815 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.728 HG12 HG22 ' A' ' 154' ' ' ILE . 5.4 m -154.17 132.42 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.131 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 7.0 tttm -104.13 133.46 49.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.969 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.743 HG22 HD11 ' A' ' 176' ' ' LEU . 34.6 m -134.86 164.23 34.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.285 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 3.9 ptt? -106.7 120.55 42.27 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.808 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.444 HG12 ' O ' ' A' ' 148' ' ' THR . 16.9 m -117.51 157.56 18.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.13 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 23.6 m -142.37 105.81 4.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.974 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.1 mp -83.1 113.71 22.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.039 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 64.97 -77.71 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.971 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -154.47 44.23 0.57 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.448 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 5.2 ptt180 -148.24 115.27 6.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.883 0.373 . . . . 0.0 110.957 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -68.96 147.03 52.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.771 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 76.4 m -160.06 113.8 1.44 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.942 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -73.6 112.65 3.58 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.402 2.068 . . . . 0.0 112.141 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.5 t -119.41 124.4 72.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.225 -179.759 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -92.1 131.07 37.65 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.677 179.754 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.743 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -139.71 -161.65 1.22 Allowed 'General case' 0 CA--C 1.515 -0.385 0 CA-C-O 121.522 0.677 . . . . 0.0 111.259 -179.793 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.589 ' HA ' HG22 ' A' ' 161' ' ' VAL . 1.2 m-20 -138.06 161.29 37.14 Favored 'General case' 0 N--CA 1.439 -1.004 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.172 177.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 178' ' ' PHE . . . . . 0.48 ' HE1' HG11 ' A' ' 161' ' ' VAL . 3.4 m-85 -43.45 -38.51 2.85 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.693 -0.685 . . . . 0.0 112.554 -179.006 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.38 5.36 12.79 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.135 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -112.14 6.87 19.36 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.582 0.229 . . . . 0.0 111.407 -179.809 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.893 HG21 HG21 ' A' ' 137' ' ' VAL . 27.2 m -151.95 174.96 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 120.882 0.372 . . . . 0.0 111.289 -179.848 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 12.9 m -143.14 146.68 21.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.084 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.424 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.9 OUTLIER -60.82 123.27 17.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.926 -179.933 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.253 -0.88 . . . . 0.0 111.045 -179.96 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.335 0 CA-C-O 120.808 0.337 . . . . 0.0 111.034 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 7.0 mm-40 -119.27 -176.04 3.05 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.747 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.403 HG22 ' H ' ' A' ' 129' ' ' VAL . 8.7 m -79.92 122.08 34.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.051 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.39 179.21 0.16 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.278 -179.831 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 67.9 t80 -157.66 155.22 29.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.806 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -148.23 150.61 34.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.915 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.4 pp20? -59.56 122.25 13.58 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.926 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.68 15.97 25.49 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.709 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -69.66 157.25 37.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.761 0.315 . . . . 0.0 110.91 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -93.16 132.19 37.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.981 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.413 HG12 ' HA ' ' A' ' 183' ' ' LYS . 14.9 m -140.79 133.25 31.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.927 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.423 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.8 OUTLIER -79.82 166.38 21.77 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.912 0.387 . . . . 0.0 110.967 -179.907 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.655 HG23 ' O ' ' A' ' 147' ' ' PHE . 7.3 t -79.74 167.9 2.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.969 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.632 HG13 ' H ' ' A' ' 141' ' ' SER . 3.0 p -79.41 -61.47 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 -179.291 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.632 ' H ' HG13 ' A' ' 140' ' ' VAL . 39.6 p -160.45 -164.1 1.19 Allowed 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.766 0.317 . . . . 0.0 111.246 -179.675 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.86 -168.58 54.26 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.325 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -59.93 -18.56 50.54 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.541 2.161 . . . . 0.0 112.087 179.671 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.538 ' HB2' HG11 ' A' ' 139' ' ' VAL . 4.1 m-85 -97.04 16.8 18.55 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.094 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.539 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -80.58 39.44 0.47 Allowed 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 112.146 0.425 . . . . 0.0 112.146 -179.425 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 146' ' ' ASP . . . . . 0.416 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 8.3 t0 -160.74 34.69 0.15 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.979 0.419 . . . . 0.0 110.71 179.43 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.655 ' O ' HG23 ' A' ' 139' ' ' VAL . 24.3 m-85 -146.13 160.68 41.59 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.711 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.423 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 3.2 p -120.22 172.99 7.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.989 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -138.62 159.92 25.48 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.563 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.4 m -109.38 110.02 21.05 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.765 0.317 . . . . 0.0 110.796 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 31.6 t -60.2 99.84 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.113 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -90.95 -39.23 12.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.74 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -132.7 154.0 50.59 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.708 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 154' ' ' ILE . . . . . 0.995 HG22 HG12 ' A' ' 161' ' ' VAL . 32.9 pt -148.56 136.5 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.095 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -114.32 89.18 16.95 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.892 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.06 -26.26 37.14 Favored 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.545 2.164 . . . . 0.0 112.406 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -59.79 -32.31 70.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.851 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 27.4 mtt85 -113.87 -46.33 3.03 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.905 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 118.76 44.54 0.5 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.494 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 160' ' ' LYS . . . . . 0.436 ' O ' HG13 ' A' ' 161' ' ' VAL . 2.0 mmtt -119.26 166.13 13.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.769 0.318 . . . . 0.0 110.883 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.995 HG12 HG22 ' A' ' 154' ' ' ILE . 5.9 m -156.0 129.5 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.043 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -99.83 123.02 43.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.956 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 30.6 m -123.54 138.89 51.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.126 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -91.85 106.47 18.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.965 0.412 . . . . 0.0 110.796 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.505 ' CG2' HD11 ' A' ' 167' ' ' ILE . 13.5 m -90.14 167.0 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.096 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 3.4 m -130.16 92.76 3.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.911 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.505 HD11 ' CG2' ' A' ' 165' ' ' VAL . 4.1 mp -98.77 114.83 37.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.924 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 62.2 29.93 17.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 75.85 55.03 5.08 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.536 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -157.48 117.95 3.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.744 0.307 . . . . 0.0 111.0 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -65.94 121.18 14.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.819 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 172' ' ' THR . . . . . 0.482 ' O ' HG22 ' A' ' 165' ' ' VAL . 23.5 m -130.64 89.78 42.56 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.962 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -68.17 101.35 0.7 Allowed 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.432 2.088 . . . . 0.0 112.231 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.738 ' CG2' HD21 ' A' ' 176' ' ' LEU . 28.3 m -110.32 138.74 36.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.155 -179.815 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 175' ' ' GLU . . . . . 0.433 ' O ' HD23 ' A' ' 176' ' ' LEU . 0.4 OUTLIER -80.02 117.96 21.32 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.559 179.615 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.738 HD21 ' CG2' ' A' ' 174' ' ' VAL . 0.3 OUTLIER -137.16 -159.76 0.99 Allowed 'General case' 0 CA--C 1.517 -0.323 0 CA-C-O 121.292 0.567 . . . . 0.0 111.15 -179.622 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.501 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.9 OUTLIER -150.71 154.88 38.22 Favored 'General case' 0 N--CA 1.442 -0.848 0 CA-C-N 115.232 -0.894 . . . . 0.0 110.151 178.399 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -46.61 -28.88 1.59 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.546 -179.731 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.9 p -67.6 -14.44 62.94 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.339 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.404 ' O ' HG13 ' A' ' 181' ' ' VAL . 5.3 mt-30 -116.88 10.15 14.04 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.515 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.438 HG12 ' HA ' ' A' ' 139' ' ' VAL . 31.4 m -156.99 150.39 9.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.807 0.337 . . . . 0.0 111.224 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 182' ' ' VAL . . . . . 0.489 HG12 ' H ' ' A' ' 183' ' ' LYS . 0.3 OUTLIER -121.29 173.72 6.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.898 179.958 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.489 ' H ' HG12 ' A' ' 182' ' ' VAL . 0.1 OUTLIER -75.85 150.3 37.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.956 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.995 0 CA-C-O 118.224 -0.893 . . . . 0.0 111.115 -179.998 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.279 0 CA-C-O 120.806 0.336 . . . . 0.0 110.995 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -169.54 95.18 0.3 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.926 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 31.5 m -113.92 31.12 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.077 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -82.4 164.09 21.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.132 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.581 ' CZ ' HG21 ' A' ' 151' ' ' VAL . 11.1 t80 -109.67 162.38 14.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.924 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -159.36 145.44 16.31 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.824 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -65.07 135.42 55.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.846 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.82 -26.03 13.47 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.58 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -60.17 166.49 2.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.752 0.31 . . . . 0.0 110.912 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -112.7 130.38 56.08 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.989 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 19.5 m -134.27 141.94 42.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.946 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.9 166.19 21.9 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.967 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.563 HG12 ' H ' ' A' ' 140' ' ' VAL . 4.2 t -79.77 169.18 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.014 -179.861 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.665 HG13 ' H ' ' A' ' 141' ' ' SER . 2.1 p -79.18 -64.76 0.86 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 CA-C-N 116.566 -0.288 . . . . 0.0 111.773 -179.451 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.665 ' H ' HG13 ' A' ' 140' ' ' VAL . 0.2 OUTLIER -160.42 -163.55 1.11 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.811 0.339 . . . . 0.0 111.096 -179.642 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.37 -164.71 49.63 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.518 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -62.83 -16.39 53.29 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.495 2.13 . . . . 0.0 112.173 179.725 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.474 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.5 m-85 -102.59 20.17 17.65 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.083 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.649 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -82.49 39.85 0.62 Allowed 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 111.98 0.363 . . . . 0.0 111.98 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -160.81 35.97 0.15 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.927 0.394 . . . . 0.0 110.781 179.447 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.494 ' O ' HG23 ' A' ' 139' ' ' VAL . 19.2 m-85 -146.16 172.3 13.64 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.793 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.449 ' O ' HG12 ' A' ' 165' ' ' VAL . 33.8 p -122.55 -172.12 2.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.877 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -156.64 144.02 10.31 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.626 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.6 m -93.04 105.82 17.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.841 0.353 . . . . 0.0 110.845 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.586 ' HA ' HG12 ' A' ' 163' ' ' VAL . 25.1 t -61.9 137.74 23.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.403 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 65.4 p -119.88 -49.06 2.33 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.69 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -128.72 159.64 35.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.871 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mp -142.43 132.18 22.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.13 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -104.61 108.96 62.17 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.75 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -74.2 -44.05 0.48 Allowed 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.432 2.088 . . . . 0.0 112.409 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -65.4 -44.64 86.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.017 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 1.5 mtt180 -83.97 -41.08 17.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.894 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 89.49 36.72 7.31 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.336 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 24.6 mtpt -117.62 177.6 4.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.759 0.314 . . . . 0.0 110.941 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.554 HG23 HG13 ' A' ' 151' ' ' VAL . 1.3 p -159.91 159.57 2.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.09 0.471 . . . . 0.0 111.054 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.469 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 20.3 tttm -127.53 133.3 49.83 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.799 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.825 HG22 HD11 ' A' ' 176' ' ' LEU . 18.3 m -139.17 160.16 29.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.177 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 12.5 ptp -102.29 116.22 32.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.603 179.706 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.449 HG12 ' O ' ' A' ' 148' ' ' THR . 15.5 m -107.62 160.26 6.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.362 -179.667 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 6.9 t -152.1 135.26 15.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.722 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.1 mp -91.8 -67.0 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.131 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -148.52 87.13 1.56 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.832 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 70.24 25.69 75.28 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.455 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 4.4 ttm180 -148.76 112.51 5.09 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.872 0.368 . . . . 0.0 110.889 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -89.46 157.39 18.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.836 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 65.1 m -160.11 112.39 1.42 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.969 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -71.72 121.18 7.43 Favored 'Trans proline' 0 C--N 1.347 0.46 0 C-N-CA 122.438 2.092 . . . . 0.0 112.117 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 27.4 m -128.08 142.79 42.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.362 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -93.28 127.85 39.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.672 179.791 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.825 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -137.45 -159.87 1.0 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.324 0.583 . . . . 0.0 111.203 -179.769 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.406 ' O ' ' N ' ' A' ' 180' ' ' GLN . 0.1 OUTLIER -149.47 154.11 38.31 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 115.103 -0.953 . . . . 0.0 110.269 178.447 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 31.0 m-85 -43.99 -28.57 0.48 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.862 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.09 8.12 7.81 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 111.865 0.32 . . . . 0.0 111.865 -179.791 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.406 ' N ' ' O ' ' A' ' 177' ' ' ASP . 8.6 mt-30 -131.05 9.25 4.84 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.601 0.238 . . . . 0.0 111.27 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 5.6 m -141.85 174.69 6.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 120.751 0.31 . . . . 0.0 111.089 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 17.3 m -147.55 154.49 11.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.132 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.25 134.02 44.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.899 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.267 -0.873 . . . . 0.0 111.092 -179.937 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 120.79 0.329 . . . . 0.0 111.096 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 -107.41 149.63 27.67 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.945 179.899 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.5 t -89.13 108.77 19.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.168 -179.963 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -74.78 -30.77 61.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.007 179.996 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.497 ' CZ ' HG21 ' A' ' 151' ' ' VAL . 30.8 t80 -80.01 155.83 27.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.905 -179.975 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.04 146.57 15.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.872 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -62.48 139.42 58.58 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.833 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 97.34 -24.61 30.69 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.567 -179.987 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -58.0 -168.59 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.737 0.304 . . . . 0.0 111.009 -179.947 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 5.1 mm-40 -135.27 138.64 43.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.084 -179.907 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.513 ' HB ' ' O ' ' A' ' 182' ' ' VAL . 27.1 m -136.93 157.5 35.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.913 179.911 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.451 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 1.0 OUTLIER -90.49 165.93 13.52 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.944 0.402 . . . . 0.0 110.883 179.904 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.814 HG23 ' O ' ' A' ' 147' ' ' PHE . 5.2 t -79.95 168.31 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.046 -179.914 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.67 HG13 ' H ' ' A' ' 141' ' ' SER . 1.7 p -79.25 -65.41 0.78 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.778 -179.544 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.71 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 4.0 m -160.24 -164.43 1.27 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.849 0.357 . . . . 0.0 111.082 -179.552 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.53 -160.53 41.75 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.446 179.989 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -67.46 -11.6 32.73 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.421 2.08 . . . . 0.0 112.406 179.689 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.534 ' HB2' HG11 ' A' ' 139' ' ' VAL . 4.2 m-85 -107.92 19.67 19.74 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.105 -179.997 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.71 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -80.53 37.51 0.41 Allowed 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 112.197 0.443 . . . . 0.0 112.197 -179.467 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -161.08 35.6 0.14 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.996 0.427 . . . . 0.0 110.836 179.423 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.814 ' O ' HG23 ' A' ' 139' ' ' VAL . 8.6 m-85 -146.55 153.86 40.86 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.646 -179.892 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.624 ' O ' HG12 ' A' ' 165' ' ' VAL . 44.4 p -103.01 -179.91 4.09 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.816 -179.957 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -143.12 149.37 21.3 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.541 -0.838 . . . . 0.0 112.661 -179.818 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 16.2 m -95.73 102.69 14.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.831 0.348 . . . . 0.0 110.654 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.708 ' HA ' HG12 ' A' ' 163' ' ' VAL . 46.4 t -59.98 116.67 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.059 -179.917 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 3.3 p -97.02 -47.12 5.92 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.828 179.973 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -138.84 158.51 44.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.86 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 32.0 mt -131.08 141.57 45.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.198 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.4 m-20 -121.86 100.79 43.05 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.67 179.969 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -63.58 -55.62 0.67 Allowed 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.613 2.209 . . . . 0.0 112.43 -179.765 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -57.54 -43.75 84.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.414 -179.662 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 1.9 tpm_? -79.97 -26.2 40.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.154 -179.728 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 69.69 31.07 70.4 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.313 -179.902 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 20.0 mttt -111.7 165.17 12.27 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.78 0.324 . . . . 0.0 111.0 -179.902 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.627 HG22 ' HA ' ' A' ' 177' ' ' ASP . 6.9 m -147.3 126.34 4.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.006 179.907 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 3.5 ttmt -101.2 127.86 47.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.021 -179.899 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.708 HG12 ' HA ' ' A' ' 151' ' ' VAL . 18.8 m -141.74 149.47 19.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.218 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 164' ' ' MET . . . . . 0.443 ' O ' ' HG3' ' A' ' 164' ' ' MET . 0.0 OUTLIER -98.52 120.66 39.33 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.843 179.687 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.624 HG12 ' O ' ' A' ' 148' ' ' THR . 31.2 m -107.05 153.99 8.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.347 -179.685 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 166' ' ' THR . . . . . 0.411 HG22 ' HA ' ' A' ' 171' ' ' GLU . 0.7 OUTLIER -122.14 147.92 45.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.773 179.888 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 2.0 mp -102.85 -62.73 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.08 -179.973 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.3 59.51 1.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.881 -179.915 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 98.21 -20.76 49.22 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.575 -179.972 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 4.0 ttt180 -97.79 127.73 43.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.788 0.328 . . . . 0.0 110.975 -179.924 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 171' ' ' GLU . . . . . 0.411 ' HA ' HG22 ' A' ' 166' ' ' THR . 0.1 OUTLIER -84.24 155.13 22.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.856 179.968 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 42.1 m -157.79 101.11 1.81 Allowed Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.88 179.888 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -67.36 113.64 2.96 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.453 2.102 . . . . 0.0 112.192 -179.997 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.4 t -128.9 150.94 35.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.151 -179.931 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.99 157.34 26.84 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.754 179.949 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.849 HD22 HG13 ' A' ' 181' ' ' VAL . 1.0 OUTLIER -154.78 -171.06 3.71 Favored 'General case' 0 CA--C 1.516 -0.348 0 CA-C-O 121.26 0.552 . . . . 0.0 111.164 -179.963 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.627 ' HA ' HG22 ' A' ' 161' ' ' VAL . 3.5 m-20 -150.14 152.97 35.55 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.462 178.421 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -46.86 -45.19 20.14 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.388 -179.815 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 9.2 t -79.52 -1.53 38.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.531 -179.85 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.626 ' HB3' HD23 ' A' ' 176' ' ' LEU . 1.2 mt-30 -112.41 7.41 19.13 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.581 -0.281 . . . . 0.0 111.392 -179.84 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.849 HG13 HD22 ' A' ' 176' ' ' LEU . 23.2 m -136.23 178.58 4.86 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.927 0.394 . . . . 0.0 111.274 179.933 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 182' ' ' VAL . . . . . 0.513 ' O ' ' HB ' ' A' ' 137' ' ' VAL . 0.4 OUTLIER -133.34 -150.58 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.346 -179.965 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -122.52 138.86 54.43 Favored 'General case' 0 C--N 1.331 -0.197 0 O-C-N 122.176 -0.327 . . . . 0.0 111.0 -179.918 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.044 0 CA-C-O 118.166 -0.921 . . . . 0.0 111.098 179.864 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 120.728 0.299 . . . . 0.0 110.991 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -59.43 163.75 3.83 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.861 -179.979 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 11.0 p -108.82 143.73 18.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.139 179.997 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -89.53 104.42 16.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.115 179.923 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.702 ' HZ ' HG21 ' A' ' 151' ' ' VAL . 16.9 t80 -95.18 163.94 13.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.873 -179.906 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 44.4 mtm180 -154.49 139.91 17.74 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.923 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -56.67 155.92 6.99 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.803 -179.939 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.55 8.21 59.49 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.86 -179.856 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.34 179.1 0.23 Allowed 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.801 0.334 . . . . 0.0 110.789 179.893 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 10.7 mt-30 -139.92 133.32 30.01 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.116 -179.859 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.587 HG12 ' HA ' ' A' ' 183' ' ' LYS . 23.1 m -142.49 146.18 22.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.774 179.88 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.464 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.5 OUTLIER -79.72 167.12 21.07 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 121.039 0.447 . . . . 0.0 111.172 -179.829 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.894 HG23 ' O ' ' A' ' 147' ' ' PHE . 20.3 t -79.75 152.27 4.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.366 -179.571 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 14.7 p -92.47 -24.42 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 CA-C-N 116.082 -0.508 . . . . 0.0 112.148 -179.326 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.669 ' O ' ' HB2' ' A' ' 145' ' ' ALA . 9.8 m -79.4 153.89 29.39 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.888 0.375 . . . . 0.0 111.274 -178.952 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 142' ' ' GLY . . . . . 0.435 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -66.13 -61.48 5.44 Favored Glycine 0 CA--C 1.519 0.312 0 C-N-CA 121.046 -0.597 . . . . 0.0 112.777 -179.86 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.435 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.6 Cg_endo -52.82 -23.85 21.99 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.581 2.188 . . . . 0.0 112.278 179.885 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.828 ' HB2' HG11 ' A' ' 139' ' ' VAL . 17.4 m-85 -111.6 2.64 17.43 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.281 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.669 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -70.22 50.02 0.11 Allowed 'General case' 0 C--O 1.233 0.218 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -179.163 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 146' ' ' ASP . . . . . 0.402 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 5.7 t70 -160.68 32.21 0.15 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.045 0.45 . . . . 0.0 110.399 179.134 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.894 ' O ' HG23 ' A' ' 139' ' ' VAL . 65.8 m-85 -155.24 146.2 22.52 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.376 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.765 ' O ' HG12 ' A' ' 165' ' ' VAL . 19.3 p -103.38 170.63 7.83 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.372 -0.377 . . . . 0.0 111.004 -179.853 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 149' ' ' GLY . . . . . 0.404 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -126.77 130.12 6.84 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.593 -179.969 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.3 m -92.22 106.21 18.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.759 0.314 . . . . 0.0 110.892 -179.99 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.702 HG21 ' HZ ' ' A' ' 131' ' ' PHE . 20.2 t -63.79 106.79 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.936 179.928 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 152' ' ' THR . . . . . 0.433 HG21 ' HE2' ' A' ' 162' ' ' LYS . 1.6 t -88.12 -30.67 19.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.878 -179.933 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -158.71 162.79 37.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.898 179.947 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.8 mt -126.12 130.46 72.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.126 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 70.6 m-20 -102.7 95.33 6.12 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.834 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.34 -34.93 11.78 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.409 2.073 . . . . 0.0 112.328 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -66.73 -31.44 72.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.942 -180.0 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -96.39 -43.6 7.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.898 -179.921 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 96.73 38.71 4.34 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.401 -179.889 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.4 mttm -135.1 175.61 9.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.888 0.375 . . . . 0.0 110.996 -179.974 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.665 HG11 ' CE1' ' A' ' 178' ' ' PHE . 5.2 m -136.59 127.78 42.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.002 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.433 ' HE2' HG21 ' A' ' 152' ' ' THR . 18.0 tttt -87.3 111.75 21.37 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.847 -179.958 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.452 HG12 HG22 ' A' ' 151' ' ' VAL . 31.4 m -124.13 148.58 28.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.296 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 12.5 ptm -102.01 120.09 39.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.833 179.97 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.765 HG12 ' O ' ' A' ' 148' ' ' THR . 18.5 m -124.2 136.6 59.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.896 0.379 . . . . 0.0 111.213 -179.984 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 2.7 m -95.55 142.49 27.83 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.778 179.85 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.457 ' O ' HG13 ' A' ' 167' ' ' ILE . 3.8 tp -117.17 42.08 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.1 0.476 . . . . 0.0 110.95 -179.942 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER 63.99 99.18 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.847 179.877 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 125.8 -48.79 0.94 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.434 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 8.6 ptt180 -160.07 160.03 32.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.844 0.354 . . . . 0.0 110.894 179.948 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -66.67 166.23 13.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.82 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -154.65 90.03 3.15 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.967 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -68.42 102.54 0.84 Allowed 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.502 2.134 . . . . 0.0 112.255 179.938 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.502 HG22 HG22 ' A' ' 165' ' ' VAL . 34.8 m -119.1 137.97 51.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.114 -179.966 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -79.84 120.88 24.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.494 179.57 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.82 HD13 HG13 ' A' ' 181' ' ' VAL . 7.6 mt -124.31 -170.55 2.16 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.341 0.591 . . . . 0.0 111.504 -179.395 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.476 ' HA ' HG22 ' A' ' 161' ' ' VAL . 5.0 m-20 -143.08 155.5 44.62 Favored 'General case' 0 N--CA 1.442 -0.848 0 CA-C-N 114.996 -1.002 . . . . 0.0 110.197 178.129 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 178' ' ' PHE . . . . . 0.665 ' CE1' HG11 ' A' ' 161' ' ' VAL . 9.6 m-85 -48.54 -30.86 5.71 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.509 -179.606 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -79.86 -0.32 34.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.463 179.955 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.765 ' CB ' HD22 ' A' ' 176' ' ' LEU . 30.7 mt-30 -119.59 5.51 11.06 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.609 -0.268 . . . . 0.0 111.316 -179.964 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.82 HG13 HD13 ' A' ' 176' ' ' LEU . 5.3 m -143.46 179.69 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.879 0.371 . . . . 0.0 111.212 179.97 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 23.9 m -152.68 146.61 15.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.016 179.958 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.587 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.1 OUTLIER -63.42 125.93 25.78 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.908 -179.977 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.001 0 CA-C-O 118.201 -0.904 . . . . 0.0 111.002 -179.952 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.35 0 CA-C-O 120.837 0.351 . . . . 0.0 111.025 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -162.57 37.13 0.11 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.793 179.907 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 12.4 p -106.31 133.22 51.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.131 -179.953 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -67.33 -54.79 17.49 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.114 179.954 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -96.16 138.89 33.13 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.89 179.975 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 51.1 ttt-85 -147.47 143.85 28.17 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.906 -179.961 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -59.85 117.82 5.47 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.923 179.978 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.615 ' HA2' HG22 ' A' ' 150' ' ' THR . . . 107.19 16.36 13.66 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.831 -0.7 . . . . 0.0 112.756 179.998 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -76.41 158.63 31.2 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.86 0.362 . . . . 0.0 110.81 179.948 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.1 tt0 -101.17 128.26 47.36 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.957 -179.992 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.934 HG12 ' HA ' ' A' ' 183' ' ' LYS . 11.3 m -141.61 135.87 30.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.814 179.965 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.426 ' CZ ' ' HB2' ' A' ' 138' ' ' ARG . 0.7 OUTLIER -79.79 162.95 24.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.943 0.402 . . . . 0.0 110.873 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.58 HG11 ' HB2' ' A' ' 144' ' ' PHE . 4.9 t -79.88 167.85 2.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.947 -179.84 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.638 HG13 ' H ' ' A' ' 141' ' ' SER . 2.4 p -79.35 -61.95 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.276 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.898 -179.264 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.686 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.1 OUTLIER -160.23 -164.57 1.29 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.734 0.302 . . . . 0.0 111.216 -179.581 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.46 -164.15 49.0 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.368 179.972 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -63.27 -16.08 52.26 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.383 2.056 . . . . 0.0 112.146 179.666 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.58 ' HB2' HG11 ' A' ' 139' ' ' VAL . 2.6 m-85 -101.31 15.73 27.85 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.185 179.956 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.686 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -78.48 37.26 0.27 Allowed 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 112.411 0.523 . . . . 0.0 112.411 -179.345 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 146' ' ' ASP . . . . . 0.414 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 1.9 t0 -161.11 32.8 0.14 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.033 0.444 . . . . 0.0 110.78 179.146 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.518 ' CE2' HG22 ' A' ' 167' ' ' ILE . 22.8 m-85 -140.77 170.06 16.47 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.616 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.407 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 3.1 p -118.05 -179.38 3.74 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.799 179.934 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -150.36 138.67 6.83 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.592 -179.978 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 150' ' ' THR . . . . . 0.615 HG22 ' HA2' ' A' ' 134' ' ' GLY . 3.3 m -97.82 107.49 20.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.777 0.322 . . . . 0.0 110.851 179.833 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.624 ' HA ' HG12 ' A' ' 163' ' ' VAL . 23.5 t -55.52 115.7 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.236 -179.822 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.87 -33.19 8.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.877 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -144.56 157.82 44.04 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.839 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mp -141.1 129.45 23.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.15 179.993 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -100.5 98.58 8.25 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.779 -179.943 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.4 -43.26 2.22 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.527 2.152 . . . . 0.0 112.347 -179.984 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -78.39 -38.65 41.23 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.881 -179.901 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.0 -34.88 38.15 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.859 -179.901 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 80.59 67.31 1.56 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.48 -179.992 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 30.7 mttm -152.05 173.39 14.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.798 0.333 . . . . 0.0 110.933 -179.978 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.806 ' O ' HD12 ' A' ' 176' ' ' LEU . 4.1 m -149.34 122.3 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.02 179.943 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 36.0 ttmt -104.61 135.31 46.25 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.997 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 1.029 HG22 HD11 ' A' ' 176' ' ' LEU . 33.9 m -138.76 163.47 27.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.104 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -103.12 111.43 23.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.611 179.722 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.438 HG22 HG12 ' A' ' 174' ' ' VAL . 28.5 m -101.86 167.65 2.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.173 -179.803 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 1.5 m -131.11 125.11 32.25 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.872 -179.959 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.518 HG22 ' CE2' ' A' ' 147' ' ' PHE . 1.5 pp -149.09 138.76 15.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.124 179.879 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 62.41 30.29 17.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.774 -179.947 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 64.78 42.57 97.04 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.532 -179.926 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 66.4 mtp180 -157.17 137.96 13.28 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.809 0.338 . . . . 0.0 110.894 -179.984 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 15.5 mp0 -81.51 127.05 32.42 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.735 179.864 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.17 115.21 11.84 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.041 -179.866 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.37 113.19 3.53 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.483 2.122 . . . . 0.0 112.075 179.889 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.438 HG12 HG22 ' A' ' 165' ' ' VAL . 10.7 p -123.69 136.55 59.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.259 -179.834 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -80.49 146.86 31.15 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.68 179.742 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 1.029 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -137.78 -165.05 1.71 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.385 0.612 . . . . 0.0 111.313 -179.721 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.7 ' O ' HG22 ' A' ' 181' ' ' VAL . 5.4 m-20 -152.84 155.31 36.86 Favored 'General case' 0 N--CA 1.446 -0.643 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.923 178.392 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -47.63 -40.89 20.74 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.517 -179.668 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 18.2 p -78.82 -2.32 39.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.734 -179.799 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 79.5 mt-30 -120.23 9.25 11.02 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.574 0.226 . . . . 0.0 111.519 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.7 HG22 ' O ' ' A' ' 177' ' ' ASP . 22.7 m -146.02 165.01 9.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.85 0.357 . . . . 0.0 111.196 179.943 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.0 m -143.8 146.46 20.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.048 179.911 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.934 ' HA ' HG12 ' A' ' 137' ' ' VAL . 4.9 tttt -65.85 137.36 57.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.022 179.949 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.204 -0.903 . . . . 0.0 111.139 -179.981 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.338 0 CA-C-O 120.851 0.358 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 -111.34 -30.77 7.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.061 -179.997 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 11.4 p -93.72 -29.27 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.137 -179.932 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.04 -70.65 0.18 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.117 -179.949 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.577 ' CZ ' HG21 ' A' ' 151' ' ' VAL . 21.0 t80 -115.81 166.81 11.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.984 179.981 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.68 140.29 51.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.794 179.969 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -69.33 135.95 51.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.892 179.929 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 67.18 21.26 71.83 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.609 179.933 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -78.69 163.47 25.4 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.776 0.322 . . . . 0.0 110.801 179.979 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 35.1 mt-30 -103.16 125.21 49.75 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.052 -179.907 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.666 HG12 ' HA ' ' A' ' 183' ' ' LYS . 31.5 m -134.73 144.13 35.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.968 179.974 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.427 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.82 167.3 20.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.936 0.398 . . . . 0.0 110.887 179.978 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.781 HG23 ' O ' ' A' ' 147' ' ' PHE . 7.6 t -79.82 168.0 2.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.92 -179.932 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.659 HG13 ' H ' ' A' ' 141' ' ' SER . 2.7 p -79.54 -62.82 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 112.001 0.371 . . . . 0.0 112.001 -179.193 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.659 ' H ' HG13 ' A' ' 140' ' ' VAL . 0.3 OUTLIER -160.4 -164.15 1.21 Allowed 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.87 0.367 . . . . 0.0 111.105 -179.622 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 78.7 -167.1 52.66 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.94 -0.647 . . . . 0.0 112.456 179.89 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -61.93 -17.25 54.66 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.422 2.082 . . . . 0.0 112.094 179.699 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.49 ' HB2' HG11 ' A' ' 139' ' ' VAL . 4.3 m-85 -98.6 20.28 13.15 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.141 179.886 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.475 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -82.6 39.87 0.63 Allowed 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.496 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -160.77 36.22 0.15 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.998 0.428 . . . . 0.0 110.605 179.406 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.868 ' CZ ' HG22 ' A' ' 167' ' ' ILE . 26.4 m-85 -148.18 160.22 43.15 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.682 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.481 ' O ' HG12 ' A' ' 165' ' ' VAL . 7.3 p -109.47 -178.12 3.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.852 179.894 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 149' ' ' GLY . . . . . 0.422 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -147.85 140.07 8.19 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.609 -179.848 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.9 m -97.0 109.19 22.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.737 0.304 . . . . 0.0 110.957 179.99 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.577 HG21 ' CZ ' ' A' ' 131' ' ' PHE . 17.5 t -64.47 101.96 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.259 -179.989 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.36 -33.74 15.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.799 179.854 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -139.83 150.12 44.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.979 179.965 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 16.5 mt -130.99 136.77 57.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.067 -179.969 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -127.83 86.16 58.94 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.759 179.963 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.61 -37.49 7.08 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.515 2.144 . . . . 0.0 112.374 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -59.84 -42.87 94.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.859 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.3 -38.52 16.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.824 179.947 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 97.32 43.37 3.0 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.621 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -139.1 159.12 42.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.859 0.362 . . . . 0.0 110.865 -179.961 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.447 ' CG2' ' CE1' ' A' ' 178' ' ' PHE . 6.1 t -131.05 157.62 43.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.001 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.411 ' N ' HG12 ' A' ' 161' ' ' VAL . 22.2 tttm -122.07 108.29 13.19 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.943 -179.992 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.422 ' HB ' ' HA3' ' A' ' 149' ' ' GLY . 31.0 m -123.38 146.55 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.263 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 15.0 ptp -99.39 123.49 43.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.687 179.9 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.481 HG12 ' O ' ' A' ' 148' ' ' THR . 17.0 m -115.25 158.11 15.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.318 -179.893 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 166' ' ' THR . . . . . 0.407 HG23 ' HA ' ' A' ' 171' ' ' GLU . 1.2 m -137.61 125.45 22.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.758 179.973 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.868 HG22 ' CZ ' ' A' ' 147' ' ' PHE . 1.8 pp -130.15 147.07 33.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.128 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 62.82 -79.91 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.973 -179.996 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -167.73 36.21 0.22 Allowed Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.446 -179.926 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 6.4 mmt85 -153.19 133.29 13.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.748 0.309 . . . . 0.0 110.936 179.972 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 171' ' ' GLU . . . . . 0.407 ' HA ' HG23 ' A' ' 166' ' ' THR . 1.1 tt0 -81.05 137.82 36.01 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.758 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 9.3 m -141.86 103.44 5.78 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.061 -179.88 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -72.09 114.44 3.98 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.475 2.117 . . . . 0.0 112.167 179.785 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.3 t -125.38 144.97 33.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.37 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -80.02 136.63 36.64 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.671 179.936 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.916 HD13 HG13 ' A' ' 181' ' ' VAL . 5.6 mt -133.05 -168.04 2.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.063 0.459 . . . . 0.0 111.329 -179.843 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -142.33 151.83 42.34 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.603 178.382 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 178' ' ' PHE . . . . . 0.447 ' CE1' ' CG2' ' A' ' 161' ' ' VAL . 20.7 m-85 -47.8 -38.2 15.25 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.502 -179.608 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.4 m -82.05 11.46 5.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.558 179.978 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.813 ' HB3' HD22 ' A' ' 176' ' ' LEU . 4.3 mp0 -120.74 3.49 10.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.668 -0.242 . . . . 0.0 111.28 179.922 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.916 HG13 HD13 ' A' ' 176' ' ' LEU . 2.9 m -144.08 177.69 2.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-O 120.858 0.361 . . . . 0.0 111.301 -179.957 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 27.8 m -143.32 146.42 21.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.116 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.666 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.6 OUTLIER -71.4 128.62 36.46 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.95 179.954 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.139 -0.934 . . . . 0.0 111.055 -179.991 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.355 0 CA-C-O 120.76 0.314 . . . . 0.0 111.001 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 39.1 mt-30 -145.51 157.07 44.06 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.894 179.968 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 6.4 m -133.52 23.81 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.266 -179.948 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -89.92 -54.24 4.13 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.912 0.387 . . . . 0.0 111.098 179.873 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -151.1 -178.51 6.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.891 -179.892 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 8.2 mtt180 -110.91 146.34 36.72 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.904 -179.984 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -59.49 141.05 55.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.87 -179.976 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 90.96 -14.3 63.78 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.759 -179.852 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -61.34 174.0 0.79 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.825 0.345 . . . . 0.0 110.966 -179.962 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -112.76 143.09 44.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.895 -179.854 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.706 HG12 ' HA ' ' A' ' 183' ' ' LYS . 15.6 m -140.18 138.66 37.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.991 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.427 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.94 166.45 21.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.826 0.346 . . . . 0.0 110.945 179.973 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.568 HG12 ' H ' ' A' ' 140' ' ' VAL . 3.4 t -79.78 169.19 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.892 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.739 HG22 ' OG ' ' A' ' 141' ' ' SER . 2.1 p -79.48 -65.35 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.814 -179.413 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.739 ' OG ' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -160.44 -163.48 1.1 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.859 0.361 . . . . 0.0 111.102 -179.65 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.27 -165.28 50.28 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.419 179.908 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -61.7 -17.74 56.39 Favored 'Trans proline' 0 C--N 1.343 0.248 0 C-N-CA 122.481 2.12 . . . . 0.0 112.124 179.74 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.457 ' HB2' HG11 ' A' ' 139' ' ' VAL . 2.0 m-85 -102.15 22.04 13.88 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.978 179.947 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.625 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -83.29 38.95 0.63 Allowed 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.133 0.42 . . . . 0.0 112.133 -179.436 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -160.8 36.5 0.15 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.914 0.388 . . . . 0.0 110.771 179.4 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.418 ' O ' HG23 ' A' ' 139' ' ' VAL . 22.0 m-85 -141.35 172.99 11.93 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.645 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.429 ' O ' HG12 ' A' ' 165' ' ' VAL . 0.2 OUTLIER -125.0 171.01 10.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.99 179.986 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -137.12 136.2 8.15 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.504 -179.988 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 2.8 m -89.31 100.87 13.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.846 0.355 . . . . 0.0 110.81 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.619 ' HA ' HG12 ' A' ' 163' ' ' VAL . 21.5 t -58.9 115.04 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.267 -179.92 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 73.7 p -102.1 -32.28 10.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.842 179.954 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -151.91 160.2 43.59 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.942 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 6.5 pt -133.19 145.6 33.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.052 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -130.15 72.23 81.98 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.967 -179.985 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -59.3 -29.04 89.23 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.614 2.209 . . . . 0.0 112.323 -179.939 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -57.98 -52.25 66.28 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.947 -179.928 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 3.2 tpm_? -90.82 -39.11 12.53 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.89 -179.966 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 105.9 41.81 1.77 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.432 179.975 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 30.7 mttp -131.29 158.71 39.92 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.768 0.318 . . . . 0.0 110.79 179.946 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.481 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.3 p -141.48 159.76 21.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 121.116 0.484 . . . . 0.0 110.91 -179.902 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.481 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 25.6 ttmt -123.7 129.18 50.71 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.969 179.825 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.837 ' CG2' HD12 ' A' ' 176' ' ' LEU . 18.4 m -145.18 140.44 22.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.115 -179.933 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.09 133.68 33.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.795 179.857 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.429 HG12 ' O ' ' A' ' 148' ' ' THR . 15.5 m -124.91 167.85 18.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.174 -179.998 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -117.43 151.06 37.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.963 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.564 HD13 ' HB2' ' A' ' 168' ' ' PHE . 0.0 OUTLIER -157.18 119.16 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.947 -179.953 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 168' ' ' PHE . . . . . 0.564 ' HB2' HD13 ' A' ' 167' ' ' ILE . 0.3 OUTLIER 61.01 30.39 19.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.728 -179.867 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 77.6 31.68 49.26 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.47 179.961 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 17.9 mtm180 -142.25 144.39 33.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.895 0.378 . . . . 0.0 110.841 -179.897 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -80.9 148.95 29.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.831 179.867 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 172' ' ' THR . . . . . 0.653 ' O ' HG23 ' A' ' 174' ' ' VAL . 68.5 m -154.82 91.9 2.93 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.064 179.973 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -58.74 104.27 0.18 Allowed 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.529 2.153 . . . . 0.0 112.157 179.998 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.653 HG23 ' O ' ' A' ' 172' ' ' THR . 21.5 t -122.18 142.23 39.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.162 -179.94 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -79.91 159.56 26.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.866 179.849 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.852 HD13 ' CG1' ' A' ' 181' ' ' VAL . 4.9 mt -147.5 -171.38 3.78 Favored 'General case' 0 CA--C 1.516 -0.347 0 CA-C-O 121.266 0.555 . . . . 0.0 111.223 -179.636 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.542 ' O ' HG22 ' A' ' 181' ' ' VAL . 1.5 m-20 -145.11 153.29 41.25 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.415 178.102 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 30.2 m-85 -48.38 -41.64 29.44 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.333 -179.708 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.7 m -78.51 -2.14 37.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.343 -179.959 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.404 ' HB3' ' CD2' ' A' ' 176' ' ' LEU . 4.8 mt-30 -116.84 6.58 13.16 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.594 -0.276 . . . . 0.0 111.345 -179.787 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.852 ' CG1' HD13 ' A' ' 176' ' ' LEU . 27.4 m -142.75 -179.44 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.959 0.409 . . . . 0.0 111.271 -179.91 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 12.6 m -155.34 146.5 12.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.977 179.956 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.706 ' HA ' HG12 ' A' ' 137' ' ' VAL . 4.0 tmtt? -72.38 138.26 47.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.968 -179.955 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.086 0 CA-C-O 118.256 -0.878 . . . . 0.0 111.151 179.997 . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.318 0 CA-C-O 120.888 0.375 . . . . 0.0 111.045 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 2.8 mm-40 60.04 31.16 20.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.031 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 9.7 p -102.67 146.26 10.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.122 -179.993 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -86.78 166.62 15.1 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.109 -179.926 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.486 ' CE1' HG21 ' A' ' 151' ' ' VAL . 6.0 p90 -124.48 -178.67 4.2 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.82 -179.91 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -107.99 159.46 16.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.854 179.95 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -60.13 128.6 37.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.981 179.906 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 121.97 -24.92 6.93 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.529 -179.962 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -59.31 169.81 1.1 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.816 0.341 . . . . 0.0 110.882 -179.887 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -124.94 136.21 53.54 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.059 -179.921 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.784 HG12 ' HA ' ' A' ' 183' ' ' LYS . 12.6 m -140.52 145.21 26.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.723 179.924 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.401 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.81 163.76 24.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.034 0.445 . . . . 0.0 111.125 -179.801 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.832 HG11 ' HB2' ' A' ' 144' ' ' PHE . 46.7 t -79.77 147.44 6.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.548 -179.672 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 12.5 p -86.27 -21.83 7.39 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 CA-C-N 116.02 -0.536 . . . . 0.0 112.35 -179.555 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.756 ' H ' HG12 ' A' ' 139' ' ' VAL . 1.7 m -79.18 152.83 30.47 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.939 0.4 . . . . 0.0 111.475 -178.783 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 142' ' ' GLY . . . . . 0.427 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -66.74 -61.79 5.03 Favored Glycine 0 C--N 1.332 0.34 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.699 -179.811 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.427 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.2 Cg_endo -53.41 -23.56 24.78 Favored 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.548 2.166 . . . . 0.0 112.083 179.853 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.832 ' HB2' HG11 ' A' ' 139' ' ' VAL . 9.2 m-85 -110.73 2.66 18.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.375 179.751 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.66 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -70.36 48.99 0.11 Allowed 'General case' 0 C--N 1.332 -0.193 0 N-CA-C 112.448 0.536 . . . . 0.0 112.448 -179.074 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 146' ' ' ASP . . . . . 0.464 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 16.4 p-10 -160.44 29.91 0.16 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.172 0.511 . . . . 0.0 110.49 179.116 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.682 ' O ' HG23 ' A' ' 139' ' ' VAL . 15.2 m-85 -150.44 147.97 28.18 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.183 179.741 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.401 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 69.6 p -102.25 168.58 9.26 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.798 0.333 . . . . 0.0 110.708 179.888 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -128.86 129.05 6.03 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.634 -0.793 . . . . 0.0 112.539 -179.865 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.7 m -86.76 105.83 17.25 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.739 0.305 . . . . 0.0 110.73 179.886 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.486 HG21 ' CE1' ' A' ' 131' ' ' PHE . 30.2 t -62.76 117.78 4.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.083 -179.862 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -93.04 -46.35 7.5 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.925 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -144.89 152.68 40.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.864 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mt -112.58 148.37 15.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.128 -179.951 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -119.24 84.01 26.77 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.85 -179.974 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -72.93 -37.88 3.31 Favored 'Trans proline' 0 C--N 1.343 0.27 0 C-N-CA 122.571 2.181 . . . . 0.0 112.303 179.969 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -60.13 -55.1 38.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.835 -179.93 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 12.6 ttt-85 -79.9 -67.11 0.79 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.004 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 129.92 59.49 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.498 -179.953 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 5.5 mtmm -155.64 -179.09 7.78 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.801 0.334 . . . . 0.0 110.84 -179.953 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.48 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.2 p -154.44 159.81 2.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.896 179.915 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.48 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 10.8 tttt -124.15 127.75 48.24 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.932 -179.9 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.449 HG12 ' HA ' ' A' ' 151' ' ' VAL . 16.7 m -136.16 156.65 36.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.183 -179.991 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 16.4 ptm -106.54 120.02 40.83 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.004 179.93 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.752 ' O ' HG22 ' A' ' 172' ' ' THR . 2.6 t -117.62 153.83 19.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.102 -179.956 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 166' ' ' THR . . . . . 0.408 HG23 ' C ' ' A' ' 170' ' ' ARG . 2.3 m -100.8 142.82 31.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.935 179.918 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.561 HD13 ' C ' ' A' ' 167' ' ' ILE . 0.0 OUTLIER -159.78 -46.29 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.147 179.972 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 168' ' ' PHE . . . . . 0.5 ' N ' HG23 ' A' ' 167' ' ' ILE . 5.0 p90 -97.58 35.25 1.69 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.973 179.965 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 96.48 -30.98 7.94 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.448 -179.912 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 170' ' ' ARG . . . . . 0.408 ' C ' HG23 ' A' ' 166' ' ' THR . 0.0 OUTLIER -130.63 177.34 7.46 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.894 0.378 . . . . 0.0 110.691 179.953 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -69.51 168.26 15.0 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.881 -179.939 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 172' ' ' THR . . . . . 0.752 HG22 ' O ' ' A' ' 165' ' ' VAL . 11.5 t -148.05 124.73 5.49 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.829 -179.914 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -71.77 97.36 0.81 Allowed 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.427 2.084 . . . . 0.0 112.331 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.522 HG23 HG23 ' A' ' 172' ' ' THR . 10.5 t -121.67 132.86 69.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.164 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -79.91 124.41 28.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.124 179.436 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.821 HD12 ' HB3' ' A' ' 180' ' ' GLN . 1.8 mm? -127.41 -170.08 2.16 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.322 0.582 . . . . 0.0 111.639 -179.164 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.428 ' HA ' HG12 ' A' ' 161' ' ' VAL . 0.4 OUTLIER -142.38 152.98 43.39 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.394 178.342 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -42.5 -58.42 2.26 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.607 -179.596 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 6.0 t -56.28 -23.0 33.64 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.241 179.998 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.821 ' HB3' HD12 ' A' ' 176' ' ' LEU . 5.4 mp0 -89.57 3.88 51.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.638 -179.837 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.42 HG22 ' O ' ' A' ' 177' ' ' ASP . 16.5 m -147.44 167.95 4.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.811 0.339 . . . . 0.0 111.166 179.967 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.4 m -145.08 146.19 20.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.1 179.872 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.784 ' HA ' HG12 ' A' ' 137' ' ' VAL . 1.5 tttp -61.68 136.68 58.09 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.825 -179.822 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.246 -0.883 . . . . 0.0 111.036 179.986 . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.41 0 CA-C-O 120.894 0.378 . . . . 0.0 111.062 . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -60.26 125.51 23.96 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.941 -179.949 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.573 HG23 ' O ' ' A' ' 129' ' ' VAL . 17.8 m -134.5 86.04 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.135 179.991 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -89.68 150.44 22.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.062 -179.959 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -118.43 150.09 40.15 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.906 179.961 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 12.7 tpp180 -153.52 147.56 25.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.876 179.966 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -61.54 144.76 53.79 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.861 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 96.71 -23.6 34.6 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.573 -179.988 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -57.34 163.79 2.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.906 0.384 . . . . 0.0 111.017 -179.994 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 136' ' ' GLN . . . . . 0.444 ' NE2' HG23 ' A' ' 150' ' ' THR . 33.0 mm-40 -121.06 139.14 53.72 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.969 -179.918 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.7 HG12 ' HA ' ' A' ' 183' ' ' LYS . 20.9 m -137.01 140.76 42.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.82 179.989 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.477 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.7 162.85 24.95 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.027 0.441 . . . . 0.0 111.002 -179.934 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.867 HG11 ' HB2' ' A' ' 144' ' ' PHE . 37.6 t -79.88 151.46 4.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.409 -179.627 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.512 HG13 ' C ' ' A' ' 180' ' ' GLN . 34.3 m -93.1 -21.29 6.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 112.4 0.518 . . . . 0.0 112.4 -179.216 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.697 ' H ' HG12 ' A' ' 139' ' ' VAL . 4.5 m -79.18 153.87 29.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.792 0.33 . . . . 0.0 111.315 -179.013 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 142' ' ' GLY . . . . . 0.423 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -65.12 -62.56 4.82 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 121.058 -0.591 . . . . 0.0 113.006 -179.664 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.423 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.4 Cg_endo -52.81 -23.17 19.84 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.685 2.257 . . . . 0.0 112.379 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.867 ' HB2' HG11 ' A' ' 139' ' ' VAL . 10.2 m-85 -112.62 2.65 16.27 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.471 179.982 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.689 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -70.11 48.39 0.1 Allowed 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -179.117 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -160.72 32.39 0.15 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.13 0.49 . . . . 0.0 110.631 179.109 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.733 ' O ' HG23 ' A' ' 139' ' ' VAL . 42.5 m-85 -154.87 145.59 22.38 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.469 179.946 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.718 ' O ' HG12 ' A' ' 165' ' ' VAL . 67.8 p -99.88 -177.58 3.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.908 -179.879 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -139.85 129.12 4.16 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.596 -179.838 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 150' ' ' THR . . . . . 0.444 HG23 ' NE2' ' A' ' 136' ' ' GLN . 3.0 m -90.05 113.83 25.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.742 0.306 . . . . 0.0 110.68 179.754 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 21.7 t -70.71 120.83 19.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.305 -179.726 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -108.84 -31.75 7.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.713 179.643 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -153.95 161.35 42.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.705 179.824 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.6 mp -134.21 152.43 34.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.331 -179.966 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 -123.17 90.89 50.21 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.806 179.932 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.15 -34.04 13.99 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.613 2.209 . . . . 0.0 112.357 -179.893 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -90.14 18.14 6.25 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.338 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 31.2 ttt85 -138.07 -46.01 0.52 Allowed 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.808 0.337 . . . . 0.0 110.791 179.936 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 99.19 39.82 3.42 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.392 179.962 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 16.3 mtmt -146.18 170.5 16.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.815 0.34 . . . . 0.0 111.086 -179.979 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.475 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.0 OUTLIER -149.43 159.59 5.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.118 0.485 . . . . 0.0 110.795 179.918 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.475 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 59.6 tttp -105.21 121.61 44.2 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.967 179.993 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 5.6 m -134.95 134.76 53.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.176 -179.982 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 7.6 ptm -93.55 135.43 34.82 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.841 179.954 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.718 HG12 ' O ' ' A' ' 148' ' ' THR . 27.6 m -134.25 149.76 30.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.217 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 166' ' ' THR . . . . . 0.404 ' O ' ' CD2' ' A' ' 147' ' ' PHE . 3.8 m -113.26 110.57 20.59 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.809 -180.0 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.711 HD13 ' HB2' ' A' ' 168' ' ' PHE . 0.0 OUTLIER -97.32 113.83 32.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.075 179.985 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 168' ' ' PHE . . . . . 0.711 ' HB2' HD13 ' A' ' 167' ' ' ILE . 0.7 OUTLIER 59.52 43.26 16.33 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.894 -179.782 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 66.41 30.68 77.01 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.459 -179.922 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -129.86 124.55 33.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.743 0.306 . . . . 0.0 110.899 -179.905 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.85 126.08 26.18 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.725 179.957 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 2.0 m -150.66 89.68 4.37 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.127 -179.8 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -72.76 125.57 10.64 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.517 2.145 . . . . 0.0 112.104 179.81 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 174' ' ' VAL . . . . . 0.532 HG22 HG22 ' A' ' 165' ' ' VAL . 5.3 m -134.24 136.58 53.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.317 -179.866 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 3.3 pm0 -79.88 126.64 31.26 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.964 179.209 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.783 HD13 HG13 ' A' ' 181' ' ' VAL . 7.0 mt -127.62 -170.08 2.17 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.395 0.617 . . . . 0.0 111.772 -179.131 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.434 ' HA ' HG12 ' A' ' 161' ' ' VAL . 0.5 OUTLIER -141.33 154.59 45.77 Favored 'General case' 0 N--CA 1.442 -0.868 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.357 178.162 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -48.49 -31.14 5.97 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.366 -179.551 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.2 m -79.47 1.2 26.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.574 179.998 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.751 ' CB ' HD22 ' A' ' 176' ' ' LEU . 0.0 OUTLIER -122.12 10.7 10.08 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.652 0.263 . . . . 0.0 111.401 -179.798 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.783 HG13 HD13 ' A' ' 176' ' ' LEU . 14.4 m -149.35 159.14 5.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.944 0.402 . . . . 0.0 111.272 -179.989 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.0 m -123.27 146.48 28.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.048 179.985 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.7 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -71.79 120.46 17.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.864 -179.931 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.267 -0.873 . . . . 0.0 111.082 -179.942 . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.317 0 CA-C-O 120.833 0.349 . . . . 0.0 111.015 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 23.6 mt-30 -147.41 170.32 17.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.841 -179.995 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 129' ' ' VAL . 5.0 m -132.33 103.63 6.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.116 179.992 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -61.96 -172.55 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.04 179.919 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 131' ' ' PHE . . . . . 0.439 ' HZ ' HG11 ' A' ' 151' ' ' VAL . 77.1 t80 -143.5 162.39 35.95 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.751 179.976 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -153.73 149.55 27.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.942 -179.951 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -65.67 134.35 53.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.846 179.872 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 98.36 -2.83 59.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.845 -179.958 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -58.54 167.68 1.38 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.912 0.387 . . . . 0.0 110.897 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.27 116.93 29.78 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.028 179.999 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.714 HG12 ' HA ' ' A' ' 183' ' ' LYS . 30.1 m -123.17 138.76 52.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.833 179.932 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.4 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.99 161.9 25.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.956 0.408 . . . . 0.0 111.142 -179.899 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.579 HG12 ' N ' ' A' ' 140' ' ' VAL . 39.8 t -104.21 167.05 2.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.559 179.702 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.822 HG22 ' O ' ' A' ' 180' ' ' GLN . 16.2 m -138.04 -9.88 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 N-CA-C 113.001 0.741 . . . . 0.0 113.001 -178.874 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.461 ' O ' ' CD2' ' A' ' 144' ' ' PHE . 1.1 m -79.5 142.61 35.66 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.996 0.427 . . . . 0.0 111.761 -178.946 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 35.78 -139.83 0.24 Allowed Glycine 0 C--N 1.335 0.511 0 CA-C-N 115.67 -0.695 . . . . 0.0 113.656 179.523 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -74.3 3.86 4.87 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.691 2.261 . . . . 0.0 112.682 179.761 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.496 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 0.1 OUTLIER -79.57 -10.03 59.73 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.635 -0.257 . . . . 0.0 111.055 179.831 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.455 ' HA ' ' O ' ' A' ' 139' ' ' VAL . . . -68.52 41.84 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -178.996 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 146' ' ' ASP . . . . . 0.431 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 0.8 OUTLIER -160.95 32.78 0.15 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.056 0.455 . . . . 0.0 110.654 179.167 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.431 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 55.8 m-85 -151.7 164.41 37.01 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.582 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.609 ' O ' HG12 ' A' ' 165' ' ' VAL . 80.6 p -118.73 162.86 17.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.734 179.849 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -130.79 163.48 23.35 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.693 -179.847 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.6 m -103.24 103.35 13.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.766 0.317 . . . . 0.0 110.661 179.964 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.672 ' HA ' HG12 ' A' ' 163' ' ' VAL . 46.4 t -60.31 112.61 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.975 -179.935 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -101.81 -42.62 6.09 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.79 179.906 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -120.1 150.97 39.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.794 179.841 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 12.5 pt -143.31 124.14 10.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.154 179.984 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -117.3 86.61 21.99 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.896 -179.993 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -72.52 -20.22 23.89 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.555 2.17 . . . . 0.0 112.516 -179.938 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.38 25.65 2.18 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.389 -179.94 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 2.2 tpm_? -160.0 -45.06 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.772 0.32 . . . . 0.0 110.838 179.979 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 104.04 61.69 0.68 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.459 179.896 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 17.2 mtpt -154.18 149.6 27.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.813 0.34 . . . . 0.0 110.998 179.963 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.671 HG22 ' HA ' ' A' ' 177' ' ' ASP . 26.9 m -147.21 154.04 11.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.18 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 12.6 ttpt -127.13 129.61 48.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.907 -179.952 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.72 HG22 ' CD1' ' A' ' 176' ' ' LEU . 34.9 m -136.6 145.68 29.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.23 179.928 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -89.43 113.32 24.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.459 179.824 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.609 HG12 ' O ' ' A' ' 148' ' ' THR . 20.9 m -123.19 159.76 26.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.359 -179.696 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 166' ' ' THR . . . . . 0.546 HG22 ' HA ' ' A' ' 171' ' ' GLU . 17.2 p -111.55 139.25 47.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.785 179.869 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.805 ' O ' HD13 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -93.32 -36.38 7.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.04 -179.874 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 10.5 t80 -172.82 78.54 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.982 179.996 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 68.44 28.22 73.35 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.425 -179.93 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -156.72 124.28 5.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.728 0.299 . . . . 0.0 110.88 -179.995 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 171' ' ' GLU . . . . . 0.546 ' HA ' HG22 ' A' ' 166' ' ' THR . 67.8 mt-10 -61.08 154.61 22.44 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.788 179.905 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 25.4 m -160.08 89.84 1.82 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.146 -179.925 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -66.13 105.02 0.78 Allowed 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.615 2.21 . . . . 0.0 111.82 179.766 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 31.0 m -118.5 149.39 20.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.349 -179.716 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -89.14 135.91 33.31 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.731 179.759 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.72 ' CD1' HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -146.98 -161.12 1.26 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.397 0.617 . . . . 0.0 110.936 -179.709 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.686 ' O ' HG22 ' A' ' 181' ' ' VAL . 0.8 OUTLIER -151.85 153.2 33.73 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.379 178.474 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 178' ' ' PHE . . . . . 0.634 ' CE1' HG11 ' A' ' 161' ' ' VAL . 23.1 m-85 -42.36 -30.58 0.34 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.677 -179.654 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.4 m -69.57 -39.31 77.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.115 -179.963 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.822 ' O ' HG22 ' A' ' 140' ' ' VAL . 33.3 mt-30 -88.93 8.76 27.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.499 -179.724 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.686 HG22 ' O ' ' A' ' 177' ' ' ASP . 5.4 m -145.72 179.53 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.791 0.329 . . . . 0.0 111.165 179.903 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.6 m -145.09 147.07 19.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.167 179.975 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.714 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.1 OUTLIER -78.3 130.83 36.67 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.887 179.937 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.169 -0.919 . . . . 0.0 111.08 179.977 . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.403 0 CA-C-O 120.935 0.398 . . . . 0.0 111.015 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -94.22 166.78 11.94 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.916 179.975 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.76 105.79 19.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.103 179.91 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -76.26 -32.28 58.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.175 -179.958 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 9.8 t80 -146.99 150.47 35.2 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.912 180.0 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -134.87 154.36 51.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.028 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -71.53 120.73 17.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.851 179.909 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 115.59 -14.96 17.49 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.671 -179.919 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -56.26 174.07 0.15 Allowed 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.795 0.331 . . . . 0.0 110.979 -179.921 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.73 140.67 51.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.95 -179.992 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.594 HG12 ' HA ' ' A' ' 183' ' ' LYS . 19.9 m -144.58 139.79 23.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.021 -179.959 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.405 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.97 163.1 24.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.955 0.407 . . . . 0.0 110.945 179.865 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.918 HG11 ' HB2' ' A' ' 144' ' ' PHE . 21.7 t -79.83 156.08 4.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 115.848 -0.615 . . . . 0.0 111.576 -179.659 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.511 HG13 ' C ' ' A' ' 180' ' ' GLN . 33.7 m -96.64 -26.19 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 N-CA-C 112.424 0.528 . . . . 0.0 112.424 -179.135 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.688 ' O ' ' HB2' ' A' ' 145' ' ' ALA . 91.1 p -79.13 155.18 28.83 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.833 0.349 . . . . 0.0 111.401 -178.706 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 142' ' ' GLY . . . . . 0.454 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -64.82 -60.77 6.52 Favored Glycine 0 CA--C 1.52 0.346 0 CA-C-N 115.957 -0.565 . . . . 0.0 113.063 -179.581 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 143' ' ' PRO . . . . . 0.454 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 7.8 Cg_endo -50.11 -24.84 11.79 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.671 2.248 . . . . 0.0 112.507 -179.793 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.918 ' HB2' HG11 ' A' ' 139' ' ' VAL . 7.4 m-85 -115.77 4.52 14.0 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.468 -179.974 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.688 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -69.81 45.21 0.07 Allowed 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -178.809 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 146' ' ' ASP . . . . . 0.412 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 11.8 p-10 -160.69 32.19 0.15 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.032 0.444 . . . . 0.0 110.53 178.929 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.815 ' O ' HG23 ' A' ' 139' ' ' VAL . 64.6 m-85 -153.67 145.3 23.31 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.648 179.891 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.479 ' O ' HG12 ' A' ' 165' ' ' VAL . 1.8 p -102.39 175.73 5.42 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.744 179.863 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 149' ' ' GLY . . . . . 0.427 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -138.47 141.32 11.89 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.685 -179.9 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 4.6 m -93.56 109.84 21.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.837 0.351 . . . . 0.0 110.747 -179.999 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 16.4 t -68.65 96.84 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.054 179.902 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -81.39 -30.83 33.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.799 179.988 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -154.33 157.29 38.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.817 179.942 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.6 pt -128.62 172.98 14.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.196 179.987 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 -147.59 87.62 5.91 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.847 179.994 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.97 -33.63 15.43 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.584 2.19 . . . . 0.0 112.258 -179.974 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -68.92 -42.75 76.37 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.95 179.878 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 23.4 mmt180 -89.38 -61.87 1.6 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.913 179.982 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 120.54 57.12 0.24 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.488 179.954 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -145.0 173.01 12.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.804 0.335 . . . . 0.0 110.803 -179.973 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.614 HG22 ' HA ' ' A' ' 177' ' ' ASP . 31.1 m -153.98 118.36 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.056 179.892 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -79.85 113.87 18.34 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.712 -179.95 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.427 ' HB ' ' HA3' ' A' ' 149' ' ' GLY . 32.1 m -126.1 141.22 46.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.32 -179.756 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 5.1 ptm -101.68 117.16 34.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.925 179.934 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.479 HG12 ' O ' ' A' ' 148' ' ' THR . 15.8 m -108.56 -179.62 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.008 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.66 116.9 10.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.943 -179.837 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 167' ' ' ILE . . . . . 0.857 HD12 ' OG1' ' A' ' 172' ' ' THR . 2.4 mp -120.94 128.39 76.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.93 179.832 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 168' ' ' PHE . . . . . 0.442 ' CD1' HG22 ' A' ' 167' ' ' ILE . 4.6 m-85 61.3 34.46 18.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.966 179.887 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 65.7 51.44 46.99 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.598 179.947 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 2.5 ttt85 -160.06 128.09 4.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.837 0.351 . . . . 0.0 110.952 179.96 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -58.69 129.11 40.52 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.926 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 172' ' ' THR . . . . . 0.857 ' OG1' HD12 ' A' ' 167' ' ' ILE . 0.2 OUTLIER -133.83 85.85 40.11 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.996 -179.932 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -68.67 109.42 2.08 Favored 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.488 2.125 . . . . 0.0 112.028 179.723 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.6 t -126.39 141.11 46.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.344 -179.741 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.93 118.67 21.9 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.181 179.434 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.598 HD23 ' HB3' ' A' ' 180' ' ' GLN . 1.2 mp -119.94 -170.39 1.95 Allowed 'General case' 0 CA--C 1.515 -0.376 0 CA-C-O 121.406 0.622 . . . . 0.0 111.63 -179.178 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.614 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.6 OUTLIER -142.89 155.37 44.73 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 114.911 -1.04 . . . . 0.0 110.004 178.016 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 178' ' ' PHE . . . . . 0.437 ' CE1' HG11 ' A' ' 161' ' ' VAL . 15.6 m-85 -47.14 -30.22 2.73 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.457 -179.533 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 83.6 p -80.08 2.65 23.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.686 -179.89 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.598 ' HB3' HD23 ' A' ' 176' ' ' LEU . 3.7 mt-30 -122.38 3.21 9.72 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-O 120.642 0.258 . . . . 0.0 111.361 180.0 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.528 HG13 ' CD2' ' A' ' 176' ' ' LEU . 11.3 m -139.97 169.63 16.09 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 120.765 0.317 . . . . 0.0 111.384 179.913 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 18.5 m -148.51 146.69 17.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.05 179.942 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.594 ' HA ' HG12 ' A' ' 137' ' ' VAL . 75.2 tttt -57.68 122.53 13.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.093 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.373 -0.822 . . . . 0.0 110.987 -179.962 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 120.797 0.332 . . . . 0.0 111.02 . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 60.99 101.26 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.792 179.87 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 129' ' ' VAL . 10.5 m -79.93 91.39 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.196 179.922 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -61.61 -42.23 98.58 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.133 179.914 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -124.19 155.3 38.77 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.908 -179.966 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 6.2 ttt85 -155.34 148.93 25.2 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.844 179.988 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -61.54 138.59 58.29 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.885 -179.951 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 108.74 -22.75 25.44 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.68 -179.9 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -57.08 165.03 1.42 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.827 0.346 . . . . 0.0 110.951 -179.974 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -107.85 143.69 36.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.877 -179.935 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.78 HG12 ' HA ' ' A' ' 183' ' ' LYS . 25.4 m -139.92 143.09 30.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.165 179.994 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.47 165.63 13.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.052 0.453 . . . . 0.0 110.955 179.939 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.898 HG23 ' O ' ' A' ' 147' ' ' PHE . 4.2 t -80.18 169.47 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.968 -179.921 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.603 HG23 ' H ' ' A' ' 141' ' ' SER . 0.1 OUTLIER -80.02 -71.49 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 116.525 -0.307 . . . . 0.0 111.393 -179.945 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.603 ' H ' HG23 ' A' ' 140' ' ' VAL . 0.1 OUTLIER -160.5 -163.52 1.1 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.96 -179.699 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.91 -160.54 41.01 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.457 179.842 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -57.94 -20.85 46.65 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.507 2.138 . . . . 0.0 111.976 179.786 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.545 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 1.5 m-85 -110.77 41.6 1.76 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.666 179.859 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.514 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -90.15 31.52 0.99 Allowed 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -179.424 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -161.26 38.69 0.14 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.284 179.492 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.898 ' O ' HG23 ' A' ' 139' ' ' VAL . 23.2 m-85 -134.72 154.18 51.68 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.002 0.429 . . . . 0.0 111.183 -179.758 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 148' ' ' THR . . . . . 0.628 ' O ' HG12 ' A' ' 165' ' ' VAL . 31.4 p -118.23 171.86 7.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.446 179.722 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -144.66 155.89 26.6 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.362 -0.923 . . . . 0.0 112.905 -179.785 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 14.0 m -103.31 105.45 15.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.782 0.325 . . . . 0.0 110.781 179.743 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.734 ' HA ' HG12 ' A' ' 163' ' ' VAL . 48.8 t -58.48 118.13 2.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.108 -179.925 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 35.1 p -102.21 -46.67 4.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.852 179.977 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -125.98 157.87 36.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.912 179.985 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.9 mp -139.99 139.13 37.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.123 179.879 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -121.62 85.12 43.5 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.91 179.996 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.99 -28.35 13.13 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.531 2.154 . . . . 0.0 112.383 -179.917 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -69.84 -32.56 71.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.94 -179.953 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.75 -59.57 1.75 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.949 179.942 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 123.06 66.86 0.22 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.532 -179.994 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 43.7 mttp -148.46 163.48 37.03 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.804 0.335 . . . . 0.0 110.878 179.978 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.646 HG22 ' HA ' ' A' ' 177' ' ' ASP . 15.6 m -151.04 138.53 13.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.112 179.896 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 16.4 tttp -118.12 126.23 51.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.868 -179.985 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.842 HG22 HD11 ' A' ' 176' ' ' LEU . 33.5 m -135.94 149.01 27.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.275 -179.96 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 164' ' ' MET . . . . . 0.4 ' O ' ' CG ' ' A' ' 164' ' ' MET . 10.5 ptt? -90.04 111.53 22.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.598 179.791 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.628 HG12 ' O ' ' A' ' 148' ' ' THR . 31.1 m -114.69 137.43 48.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.359 -179.851 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 5.5 t -92.22 136.94 32.78 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.575 179.774 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 18.5 tt -83.82 -29.26 7.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.069 -179.909 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -178.23 38.92 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.85 -179.976 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 124.13 -25.88 5.96 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.48 -179.973 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.14 122.68 45.82 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.865 0.364 . . . . 0.0 110.821 -179.967 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -63.1 121.01 12.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.99 179.933 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 53.9 m -117.57 100.4 52.59 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.824 -179.9 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -66.54 111.1 2.01 Favored 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 122.344 2.029 . . . . 0.0 112.215 -179.958 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 38.3 t -127.17 141.7 45.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.105 -179.773 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -86.63 138.11 31.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.626 179.736 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.842 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -148.15 -162.27 1.52 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.282 0.563 . . . . 0.0 111.298 -179.65 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.646 ' HA ' HG22 ' A' ' 161' ' ' VAL . 1.4 m-20 -146.15 157.02 43.82 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 115.067 -0.97 . . . . 0.0 109.896 178.213 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 178' ' ' PHE . . . . . 0.47 ' CE1' HG11 ' A' ' 161' ' ' VAL . 19.6 m-85 -47.0 -28.54 1.68 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.694 -179.503 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 40.7 t -75.76 -5.97 48.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.592 -179.902 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.513 ' O ' HG22 ' A' ' 140' ' ' VAL . 3.1 mm-40 -114.97 -6.95 12.57 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.599 -0.273 . . . . 0.0 111.449 -179.907 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.459 ' CG1' HD22 ' A' ' 176' ' ' LEU . 30.2 m -142.7 158.66 18.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 120.829 0.347 . . . . 0.0 111.331 -179.98 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 22.6 m -117.79 146.57 22.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.076 -179.984 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.78 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -86.19 129.58 34.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.921 -179.962 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.175 -0.917 . . . . 0.0 111.194 -179.991 . . . . . . . . 0 0 . 1 . 031 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.309 0 CA-C-O 120.801 0.334 . . . . 8.49 111.087 . . . . . . . . . 0 0 . 1 . 031 nuclear build full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 8.7 mt-30 61.62 116.95 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.194 -0.457 . . . . 7.73 111.021 -179.929 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.5 t -79.96 78.61 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.272 -0.422 . . . . 5.13 111.131 179.926 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -61.15 121.77 13.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.111 -0.495 . . . . 2.79 111.171 179.99 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -97.17 139.98 32.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.188 -0.46 . . . . 1.63 110.888 179.972 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 19.3 mtp180 -132.87 135.23 45.48 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.219 -0.446 . . . . 4.75 110.931 179.975 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -59.53 118.69 6.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.302 -0.408 . . . . 2.49 110.818 179.926 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 128.57 -21.2 5.41 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.823 -0.703 . . . . 0.85 112.627 -179.921 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -55.37 164.74 0.9 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.821 0.343 . . . . 1.69 110.929 -179.995 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 64.7 mt-30 -117.26 114.82 24.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.457 . . . . 2.56 111.06 -179.977 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.647 HG12 ' HA ' ' A' ' 183' ' ' LYS . 16.9 m -118.61 141.95 35.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.58 110.822 179.894 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -79.68 166.69 21.57 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.994 0.426 . . . . 2.7 111.028 -179.773 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 139' ' ' VAL . . . . . 0.524 HG12 ' N ' ' A' ' 140' ' ' VAL . 8.7 t -79.52 167.39 2.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.935 -0.575 . . . . 0.79 110.995 -179.901 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.636 HG13 ' H ' ' A' ' 141' ' ' SER . 2.8 p -78.87 -61.46 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.296 0 N-CA-C 112.052 0.39 . . . . 1.7 112.052 -179.289 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 141' ' ' SER . . . . . 0.636 ' H ' HG13 ' A' ' 140' ' ' VAL . 0.9 OUTLIER -160.83 -163.98 1.14 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.807 0.337 . . . . 3.04 111.29 -179.652 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.53 -169.35 54.75 Favored Glycine 0 C--N 1.331 0.284 0 C-N-CA 120.875 -0.679 . . . . 1.83 112.357 179.958 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -59.14 -19.34 48.83 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.507 2.138 . . . . 1.63 111.998 179.672 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.512 ' HB2' HG11 ' A' ' 139' ' ' VAL . 4.1 m-85 -95.98 18.37 13.5 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.16 -0.473 . . . . 1.67 111.065 179.939 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.488 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -82.05 40.4 0.62 Allowed 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 112.058 0.392 . . . . 1.09 112.058 -179.453 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 146' ' ' ASP . . . . . 0.403 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 0.5 OUTLIER -161.4 35.6 0.14 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.98 0.419 . . . . 2.42 110.692 179.493 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 147' ' ' PHE . . . . . 0.518 ' O ' HG23 ' A' ' 139' ' ' VAL . 36.6 m-85 -146.82 169.76 18.44 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.929 -0.578 . . . . 1.59 110.783 179.994 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 12.7 p -122.31 -178.43 3.88 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.264 -0.425 . . . . 0.88 110.874 179.943 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -145.49 134.74 5.62 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.648 -0.787 . . . . 0.62 112.549 -179.927 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.8 m -87.96 104.8 16.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.751 0.31 . . . . 0.75 110.817 179.893 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.695 ' HA ' HG12 ' A' ' 163' ' ' VAL . 43.6 t -64.21 121.18 12.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.239 -0.437 . . . . 0.66 111.059 -179.967 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 14.9 p -107.37 -39.88 5.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.162 -0.472 . . . . 1.22 110.907 179.91 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -130.72 159.33 37.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.189 -0.459 . . . . 2.32 110.855 179.922 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 26.9 mt -136.36 135.44 49.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.266 -0.425 . . . . 1.78 111.125 -179.968 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -115.83 86.31 15.98 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.108 -0.496 . . . . 1.88 110.907 179.997 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.61 -30.43 18.35 Favored 'Trans proline' 0 C--N 1.345 0.343 0 C-N-CA 122.53 2.153 . . . . 1.83 112.327 179.994 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -63.1 -42.67 99.63 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.191 -0.459 . . . . 3.63 110.889 -179.996 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 3.6 mtt85 -96.09 -52.29 4.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.17 -0.468 . . . . 3.92 110.845 -179.954 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 116.71 39.2 0.85 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.768 -0.729 . . . . 1.28 112.469 -179.948 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 15.0 mttt -120.65 168.98 10.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.818 0.342 . . . . 2.03 110.959 179.97 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.71 HG11 ' CE1' ' A' ' 178' ' ' PHE . 19.4 m -150.72 125.47 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 1.28 111.065 179.983 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 68.6 tttt -94.83 130.07 41.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.126 -0.488 . . . . 1.89 110.922 -179.989 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.695 HG12 ' HA ' ' A' ' 151' ' ' VAL . 17.2 m -140.48 163.23 23.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.457 . . . . 0.93 111.087 -179.97 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 3.2 ptt? -109.51 116.93 32.69 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 1.89 110.954 179.914 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 165' ' ' VAL . . . . . 0.567 HG22 ' O ' ' A' ' 172' ' ' THR . 6.9 m -96.45 163.95 2.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 1.13 111.025 -179.997 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.13 106.25 9.13 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 1.6 110.99 -179.964 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 5.2 mt -110.0 109.19 27.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.137 -0.483 . . . . 2.24 110.97 179.94 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 62.38 47.28 5.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.194 -0.457 . . . . 4.37 110.935 -179.958 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 61.01 50.8 63.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.727 -0.749 . . . . 1.51 112.551 179.986 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 12.2 ttt180 -153.72 129.34 10.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.819 0.343 . . . . 5.0 110.957 179.965 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 -71.15 145.62 49.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 2.59 110.865 -179.924 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 172' ' ' THR . . . . . 0.567 ' O ' HG22 ' A' ' 165' ' ' VAL . 4.1 m -159.96 92.44 1.72 Allowed Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.116 -0.493 . . . . 1.28 110.828 179.951 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -67.42 119.62 6.64 Favored 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.451 2.101 . . . . 0.95 112.326 -179.952 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.5 t -132.21 139.11 50.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 1.63 111.047 179.969 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 175' ' ' GLU . . . . . 0.515 ' C ' HD23 ' A' ' 176' ' ' LEU . 4.6 pt-20 -80.76 119.88 23.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.446 . . . . 2.46 110.869 -179.976 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 176' ' ' LEU . . . . . 0.523 HD12 HG11 ' A' ' 181' ' ' VAL . 0.2 OUTLIER -125.02 -162.46 1.1 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.368 0.604 . . . . 1.64 110.916 -179.979 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 177' ' ' ASP . . . . . 0.624 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.6 OUTLIER -152.73 152.75 32.03 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 115.168 -0.923 . . . . 1.49 110.221 178.405 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 178' ' ' PHE . . . . . 0.71 ' CE1' HG11 ' A' ' 161' ' ' VAL . 17.1 m-85 -44.99 -29.53 0.85 Allowed 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.925 -0.58 . . . . 1.86 111.56 -179.726 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 60.1 m -72.25 -33.21 67.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.327 -0.397 . . . . 1.68 111.096 -179.826 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 38.1 mt-30 -97.2 18.2 15.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.354 -0.384 . . . . 2.16 111.337 -179.895 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 177' ' ' ASP . 32.4 m -151.79 164.51 2.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.843 0.354 . . . . 0.77 111.113 179.891 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 23.1 m -139.83 149.96 22.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 0.88 111.123 179.907 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.647 ' HA ' HG12 ' A' ' 137' ' ' VAL . 8.2 tttt -73.41 129.97 39.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 2.98 110.867 179.973 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.111 0 CA-C-O 118.292 -0.861 . . . . 1.69 111.046 179.978 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.87 0.366 . . . . 0.0 110.97 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -58.23 147.8 29.29 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.952 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 79.54 6.52 88.96 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.967 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 12.9 m-20 -86.87 174.53 8.7 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.821 0.343 . . . . 0.0 110.99 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 36.3 mt-30 -113.96 132.61 55.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.836 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.438 HG12 ' HA ' ' A' ' 183' ' ' LYS . 31.0 m -131.9 136.2 57.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.081 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -80.03 166.26 21.73 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.703 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.582 HG11 ' HB2' ' A' ' 144' ' ' PHE . 8.0 t -79.86 167.34 2.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.973 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.6 HG13 ' H ' ' A' ' 141' ' ' SER . 3.3 p -79.31 -60.3 2.36 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 112.138 0.421 . . . . 0.0 112.138 -179.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.657 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.1 OUTLIER -160.43 -164.18 1.21 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.822 0.344 . . . . 0.0 111.301 -179.542 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.37 -168.01 54.33 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.856 -0.687 . . . . 0.0 112.344 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.37 -19.02 56.44 Favored 'Trans proline' 0 C--N 1.343 0.277 0 C-N-CA 122.479 2.119 . . . . 0.0 111.95 179.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.582 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.9 m-85 -95.86 13.09 27.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.211 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.657 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -79.14 39.69 0.39 Allowed 'General case' 0 C--N 1.332 -0.179 0 N-CA-C 112.246 0.462 . . . . 0.0 112.246 -179.361 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . 0.409 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 1.0 OUTLIER -160.7 34.87 0.16 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.987 0.422 . . . . 0.0 110.675 179.336 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.494 ' O ' HG23 ' A' ' 139' ' ' VAL . 47.2 m-85 -148.0 167.13 25.7 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.91 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.669 ' O ' HG12 ' A' ' 165' ' ' VAL . 23.7 p -127.16 -173.98 3.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.672 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -150.43 164.81 29.86 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.657 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 5.6 m -103.99 108.47 19.83 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.779 0.323 . . . . 0.0 110.773 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.476 ' HA ' HG12 ' A' ' 163' ' ' VAL . 19.8 t -57.42 113.88 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.293 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 10.3 t -98.88 -33.92 10.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.778 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -153.48 158.48 41.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.894 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . 0.485 HG22 ' N ' ' A' ' 155' ' ' ASN . 2.7 mt -129.88 158.69 42.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.087 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.485 ' N ' HG22 ' A' ' 154' ' ' ILE . 0.8 OUTLIER -135.29 86.71 29.75 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.958 -179.997 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -71.69 -34.13 9.47 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.56 2.174 . . . . 0.0 112.385 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -58.98 -33.55 70.81 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.993 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.23 -61.23 1.69 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.94 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 127.04 42.73 0.27 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.489 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . 0.412 ' O ' HG13 ' A' ' 161' ' ' VAL . 11.8 mttt -115.59 170.34 8.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.772 0.32 . . . . 0.0 110.982 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.72 HG22 ' HA ' ' A' ' 177' ' ' ASP . 5.1 m -155.37 137.08 5.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.077 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 38.7 tttt -114.69 128.25 56.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.788 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.865 HG22 HD11 ' A' ' 176' ' ' LEU . 29.7 m -139.88 142.51 32.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.231 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . 0.4 ' CG ' ' O ' ' A' ' 164' ' ' MET . 0.4 OUTLIER -89.93 104.02 16.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.592 179.883 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.669 HG12 ' O ' ' A' ' 148' ' ' THR . 15.5 m -91.76 171.11 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.25 -179.791 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -132.41 115.34 15.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.796 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.406 HD12 ' CE2' ' A' ' 147' ' ' PHE . 1.6 tp -120.23 133.82 65.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.162 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 1.2 t80 61.74 30.42 18.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.878 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 70.28 45.26 56.25 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.555 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 2.2 tpm_? -159.98 138.86 10.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.789 0.328 . . . . 0.0 110.908 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -60.8 151.94 28.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.778 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 66.1 m -160.02 91.17 1.77 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.989 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -68.37 117.45 4.97 Favored 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 122.475 2.117 . . . . 0.0 112.155 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 29.7 m -132.84 154.98 40.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.256 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -98.8 138.1 36.43 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.639 179.741 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.865 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -144.33 -162.2 1.43 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.263 0.554 . . . . 0.0 111.229 -179.796 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.72 ' HA ' HG22 ' A' ' 161' ' ' VAL . 7.3 m-20 -153.11 156.71 39.18 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.079 178.424 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -45.86 -29.38 1.35 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.674 -179.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 7.3 m -76.01 -3.45 35.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.829 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -131.77 15.08 4.85 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.602 0.239 . . . . 0.0 111.437 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.474 HG22 ' O ' ' A' ' 177' ' ' ASP . 15.7 m -142.0 170.03 12.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.865 0.364 . . . . 0.0 111.221 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 22.4 m -142.41 146.71 21.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.037 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.438 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -83.36 131.33 35.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.946 -179.953 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.189 -0.91 . . . . 0.0 111.12 -179.997 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 21.5 mtp180 . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.724 0.297 . . . . 0.0 110.897 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -63.93 142.37 58.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.916 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 91.91 -14.05 65.27 Favored Glycine 0 CA--C 1.519 0.292 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.773 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 32.2 m-20 -54.54 165.01 0.63 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.766 0.317 . . . . 0.0 111.024 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -117.6 115.38 24.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.077 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.614 HG12 ' HA ' ' A' ' 183' ' ' LYS . 19.4 m -122.95 149.06 26.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.919 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.8 tpp180 -79.86 168.03 19.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.069 0.461 . . . . 0.0 110.854 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.574 HG23 ' O ' ' A' ' 147' ' ' PHE . 3.8 t -80.21 167.95 2.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.028 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.666 HG13 ' H ' ' A' ' 141' ' ' SER . 1.5 p -79.66 -66.85 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.55 -179.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.666 ' H ' HG13 ' A' ' 140' ' ' VAL . 0.2 OUTLIER -160.44 -164.69 1.29 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.876 0.37 . . . . 0.0 111.097 -179.91 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.94 -162.47 42.79 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.911 -0.661 . . . . 0.0 112.462 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -63.07 -18.42 65.06 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.458 2.106 . . . . 0.0 112.115 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.507 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.0 m-85 -102.14 29.24 5.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.957 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.38 35.67 0.45 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.775 0.321 . . . . 0.0 111.853 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -160.96 35.63 0.15 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.506 179.354 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.574 ' O ' HG23 ' A' ' 139' ' ' VAL . 48.3 m-85 -135.15 175.7 9.34 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.888 -179.753 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.435 HG22 ' O ' ' A' ' 137' ' ' VAL . 0.3 OUTLIER -119.99 178.65 4.53 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.752 179.942 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -147.11 115.6 0.79 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.568 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.1 m -82.0 113.02 19.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.755 0.312 . . . . 0.0 110.782 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 26.4 t -68.19 123.54 21.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.175 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -105.22 -60.47 1.61 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.846 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.58 165.83 15.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.91 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . 0.669 ' N ' HD13 ' A' ' 154' ' ' ILE . 0.1 OUTLIER -130.78 157.67 43.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.052 179.961 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 12.5 m-20 -121.58 89.27 47.28 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.902 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.25 -34.45 6.08 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.54 2.16 . . . . 0.0 112.298 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.33 27.67 1.62 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.386 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 5.1 mtm180 -160.08 -50.1 0.05 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.856 0.36 . . . . 0.0 110.784 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 103.27 63.56 0.7 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.461 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.8 mttt -145.88 165.9 27.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.891 0.376 . . . . 0.0 111.028 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.535 HG11 ' CE1' ' A' ' 178' ' ' PHE . 3.7 m -150.04 120.99 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.903 179.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -86.75 131.68 34.06 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.096 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.613 HG21 HD12 ' A' ' 176' ' ' LEU . 27.2 m -131.17 158.1 43.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.062 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 3.3 ptt? -116.27 126.58 53.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.029 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 2.5 t -106.99 153.88 8.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.847 179.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 2.1 p -122.98 103.32 8.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.063 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.512 HG22 ' CZ ' ' A' ' 168' ' ' PHE . 39.4 mm -80.0 67.52 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.625 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . 0.512 ' CZ ' HG22 ' A' ' 167' ' ' ILE . 1.1 p90 43.52 79.43 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.405 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 83.15 34.49 20.68 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.673 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -160.13 109.21 1.75 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.786 0.327 . . . . 0.0 111.077 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 11.7 mt-10 -89.84 134.41 34.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.717 179.731 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -145.26 105.57 4.4 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.126 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.49 110.53 2.72 Favored 'Trans proline' 0 C--N 1.348 0.508 0 C-N-CA 122.46 2.107 . . . . 0.0 112.069 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 9.0 p -126.09 146.45 31.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.268 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -79.99 157.57 26.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.679 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.753 HD22 ' HB3' ' A' ' 180' ' ' GLN . 7.5 mt -159.99 -171.74 3.35 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-O 121.411 0.625 . . . . 0.0 111.408 -179.81 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.401 ' HA ' HG22 ' A' ' 161' ' ' VAL . 1.9 m-20 -146.55 153.61 40.57 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 115.021 -0.991 . . . . 0.0 110.205 178.074 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . 0.535 ' CE1' HG11 ' A' ' 161' ' ' VAL . 27.3 m-85 -46.06 -32.8 3.05 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.548 -179.573 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 6.2 m -81.74 11.47 4.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.709 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.753 ' HB3' HD22 ' A' ' 176' ' ' LEU . 7.4 mm-40 -125.46 3.19 7.68 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.596 0.236 . . . . 0.0 111.262 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.751 HG13 HD13 ' A' ' 176' ' ' LEU . 21.9 m -145.14 179.42 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 120.977 0.417 . . . . 0.0 111.113 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 15.7 m -150.64 148.14 15.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.145 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.614 ' HA ' HG12 ' A' ' 137' ' ' VAL . 7.1 tttt -63.89 131.94 49.27 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.94 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.146 0 CA-C-O 118.257 -0.878 . . . . 0.0 111.14 179.906 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 7.3 mtt-85 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.837 0.351 . . . . 0.0 110.887 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -63.24 152.92 36.26 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.693 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 65.71 11.75 54.73 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.982 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -89.57 165.42 14.27 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.799 0.3 . . . . 0.0 110.822 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -89.24 134.08 34.19 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.705 HG12 ' HA ' ' A' ' 183' ' ' LYS . 16.0 m -140.46 140.01 34.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.962 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.431 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.4 OUTLIER -80.79 164.83 22.43 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.999 0.428 . . . . 0.0 111.063 -179.912 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.625 HG11 ' HB2' ' A' ' 144' ' ' PHE . 5.2 t -81.9 167.3 2.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.042 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.608 HG13 ' H ' ' A' ' 141' ' ' SER . 2.3 p -79.47 -61.77 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.439 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.705 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 46.7 p -160.11 -165.14 1.41 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.87 0.367 . . . . 0.0 111.176 -179.47 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 80.15 -163.74 47.36 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.348 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -63.91 -14.76 45.12 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.394 2.062 . . . . 0.0 112.23 179.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.625 ' HB2' HG11 ' A' ' 139' ' ' VAL . 4.9 m-85 -102.52 14.64 31.44 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.253 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.705 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -77.48 36.87 0.2 Allowed 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 112.462 0.541 . . . . 0.0 112.462 -179.289 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . 0.408 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 2.2 t0 -161.05 34.41 0.14 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.932 0.396 . . . . 0.0 110.805 179.223 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.573 ' O ' HG23 ' A' ' 139' ' ' VAL . 40.2 m-85 -146.1 165.98 27.49 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.745 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.431 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 0.7 OUTLIER -116.79 -176.18 2.92 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.792 179.939 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . 0.413 ' HA3' HG12 ' A' ' 163' ' ' VAL . . . -153.26 -176.4 25.7 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.57 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . 0.419 ' N ' HG13 ' A' ' 163' ' ' VAL . 40.9 m -125.3 113.14 17.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.808 0.337 . . . . 0.0 110.853 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 32.9 t -63.91 106.24 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.101 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 5.8 p -83.99 -45.07 13.51 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.916 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 2.4 tp10 -152.68 171.69 17.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.812 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . 0.825 HG22 HG12 ' A' ' 161' ' ' VAL . 17.5 pt -145.33 151.43 15.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.096 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 12.7 m-20 -117.68 86.76 24.5 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.915 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -62.04 -24.74 76.97 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.737 2.292 . . . . 0.0 112.326 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -90.21 29.12 1.28 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.407 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.07 -44.16 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.868 0.366 . . . . 0.0 111.015 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 104.55 39.5 2.38 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.291 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 4.5 mttt -127.87 161.4 29.13 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.921 0.391 . . . . 0.0 110.981 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.825 HG12 HG22 ' A' ' 154' ' ' ILE . 29.2 m -146.82 119.65 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.107 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 15.5 tttt -80.04 141.28 36.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.891 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.869 ' HB ' HD12 ' A' ' 176' ' ' LEU . 26.0 t -153.17 144.9 15.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.098 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -96.68 121.77 38.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.874 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.456 HG22 ' O ' ' A' ' 172' ' ' THR . 9.3 m -99.98 158.55 3.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.121 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . 0.668 HG22 ' HA ' ' A' ' 171' ' ' GLU . 31.4 p -145.31 146.35 31.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.815 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.8 mp -131.17 94.82 2.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.165 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 57.3 m-85 60.06 37.74 20.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.949 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 91.74 27.85 15.81 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.493 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.26 89.0 3.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.794 0.331 . . . . 0.0 110.913 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . 0.668 ' HA ' HG22 ' A' ' 166' ' ' THR . 1.8 mt-10 -59.24 144.61 45.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . 0.456 ' O ' HG22 ' A' ' 165' ' ' VAL . 0.2 OUTLIER -158.41 90.3 2.18 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.842 179.94 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_exo -60.49 125.78 18.27 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.573 2.182 . . . . 0.0 112.29 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 39.4 t -152.54 148.84 14.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.959 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -80.01 145.04 32.74 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.822 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.869 HD12 ' HB ' ' A' ' 163' ' ' VAL . 4.1 mt -125.63 -173.24 2.78 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.451 0.643 . . . . 0.0 111.324 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.813 ' O ' HG12 ' A' ' 181' ' ' VAL . 3.1 m-20 -152.91 153.76 33.67 Favored 'General case' 0 N--CA 1.446 -0.662 0 CA-C-N 115.023 -0.99 . . . . 0.0 109.99 178.147 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -42.79 -54.01 4.31 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.656 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 5.2 m -74.18 -9.61 58.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.418 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.55 ' HB3' HD23 ' A' ' 176' ' ' LEU . 0.0 OUTLIER -99.55 -14.03 19.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.504 -179.806 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.813 HG12 ' O ' ' A' ' 177' ' ' ASP . 1.3 p -132.59 160.32 42.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.033 0.444 . . . . 0.0 111.083 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . 0.478 ' N ' ' CG2' ' A' ' 181' ' ' VAL . 35.4 m -139.39 146.19 25.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.379 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.705 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -77.28 135.03 38.39 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.94 179.847 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.286 -0.864 . . . . 0.0 111.14 179.986 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.233 0.195 0 CA-C-O 120.747 0.308 . . . . 0.0 110.887 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -59.81 135.11 57.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.869 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 105.97 -27.69 16.58 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.485 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -63.36 178.4 0.54 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.748 0.309 . . . . 0.0 110.977 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -128.19 130.34 47.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.015 0.436 . . . . 0.0 111.116 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.647 HG12 ' HA ' ' A' ' 183' ' ' LYS . 25.9 m -130.16 142.91 42.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.705 179.775 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.42 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.1 OUTLIER -79.7 164.49 23.7 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.025 0.44 . . . . 0.0 111.048 -179.843 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.817 HG11 ' HB2' ' A' ' 144' ' ' PHE . 48.8 t -79.74 147.22 6.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.647 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.549 HG11 ' HA ' ' A' ' 180' ' ' GLN . 12.4 p -85.87 -22.22 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.422 -179.47 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.747 ' H ' HG12 ' A' ' 139' ' ' VAL . 1.4 t -79.14 153.47 30.06 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.893 0.378 . . . . 0.0 111.429 -178.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . 0.415 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -66.89 -62.2 4.68 Favored Glycine 0 N--CA 1.452 -0.26 0 CA-C-N 115.893 -0.594 . . . . 0.0 112.733 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.415 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.2 Cg_endo -53.57 -23.2 24.51 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.583 2.189 . . . . 0.0 112.158 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.817 ' HB2' HG11 ' A' ' 139' ' ' VAL . 12.9 m-85 -109.81 0.61 18.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.387 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.658 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -69.63 50.71 0.1 Allowed 'General case' 0 N--CA 1.462 0.163 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -179.05 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -160.61 31.37 0.16 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.094 0.473 . . . . 0.0 110.527 179.029 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.696 ' O ' HG23 ' A' ' 139' ' ' VAL . 19.0 m-85 -155.4 146.41 22.5 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.389 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 9.0 p -104.56 169.05 8.69 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.952 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -129.01 133.41 7.57 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.59 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.8 m -86.55 110.47 19.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.823 0.344 . . . . 0.0 110.755 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.607 HG22 HG12 ' A' ' 163' ' ' VAL . 30.6 t -67.96 117.44 9.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.963 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.3 t -101.94 -30.37 11.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.899 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -147.21 165.78 29.02 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.83 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . 0.638 HD12 ' HD3' ' A' ' 156' ' ' PRO . 2.0 pp -152.41 141.42 14.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.152 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -120.94 92.87 48.66 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.871 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . 0.638 ' HD3' HD12 ' A' ' 154' ' ' ILE . 54.4 Cg_endo -69.54 -22.63 32.83 Favored 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.555 2.17 . . . . 0.0 112.425 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -90.21 26.36 1.92 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.372 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 1.4 mtp85 -159.96 -45.25 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.827 0.346 . . . . 0.0 110.825 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 102.45 55.19 0.86 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.425 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.3 mttt -137.66 147.56 45.01 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.801 0.334 . . . . 0.0 111.152 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.707 HG22 ' HA ' ' A' ' 177' ' ' ASP . 31.1 m -139.05 116.48 11.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.973 179.799 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 70.1 tttt -89.69 118.56 29.4 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.89 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.607 HG12 HG22 ' A' ' 151' ' ' VAL . 28.0 m -130.37 149.42 33.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.137 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . 0.425 ' O ' ' CG ' ' A' ' 164' ' ' MET . 3.7 ptt? -101.84 108.54 20.06 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.996 0.427 . . . . 0.0 110.81 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 27.1 m -98.31 143.08 13.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.126 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -91.9 90.55 7.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.938 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.794 HG22 ' OG1' ' A' ' 172' ' ' THR . 11.2 tt -89.55 129.67 40.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.82 179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . 0.418 ' CD2' HG12 ' A' ' 167' ' ' ILE . 31.2 m-85 65.86 -72.49 0.08 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.915 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -169.61 36.0 0.19 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.635 -0.793 . . . . 0.0 112.657 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 8.9 ptp180 -160.03 164.19 33.39 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.793 0.33 . . . . 0.0 111.063 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -66.89 158.37 30.81 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.906 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . 0.794 ' OG1' HG22 ' A' ' 167' ' ' ILE . 0.3 OUTLIER -159.99 81.3 2.38 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.954 -179.985 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -68.57 102.65 0.87 Allowed 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.682 2.255 . . . . 0.0 112.229 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.823 ' CG2' HD21 ' A' ' 176' ' ' LEU . 21.4 m -114.46 136.04 52.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.137 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -80.16 108.89 14.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.669 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.823 HD21 ' CG2' ' A' ' 174' ' ' VAL . 0.3 OUTLIER -124.27 -158.96 0.84 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.322 0.582 . . . . 0.0 111.159 -179.605 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.707 ' HA ' HG22 ' A' ' 161' ' ' VAL . 4.7 m-20 -146.36 155.64 42.75 Favored 'General case' 0 N--CA 1.441 -0.875 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.167 178.161 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . 0.531 ' CE1' HG11 ' A' ' 161' ' ' VAL . 14.9 m-85 -42.97 -30.89 0.45 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.617 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.5 m -66.35 -30.14 70.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.313 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.549 ' HA ' HG11 ' A' ' 140' ' ' VAL . 33.5 mm-40 -102.39 21.59 14.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.55 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.422 HG13 ' O ' ' A' ' 180' ' ' GLN . 21.7 m -157.03 140.63 7.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.93 0.395 . . . . 0.0 111.13 179.698 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.1 m -117.03 146.27 21.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.146 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.647 ' HA ' HG12 ' A' ' 137' ' ' VAL . 3.4 tttm -83.3 128.2 34.3 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.869 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.247 -0.883 . . . . 0.0 111.113 179.97 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 48.4 mtt-85 . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.846 0.355 . . . . 0.0 110.854 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -57.51 155.42 9.54 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.742 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.42 ' HA2' HG22 ' A' ' 150' ' ' THR . . . 77.1 0.52 70.58 Favored Glycine 0 CA--C 1.519 0.343 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.78 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -66.0 153.49 42.03 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.838 0.352 . . . . 0.0 110.938 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 16.6 mt-30 -95.49 123.5 39.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.912 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.671 HG12 ' HA ' ' A' ' 183' ' ' LYS . 18.7 m -139.66 139.33 38.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.055 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.46 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -80.29 165.91 21.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.946 0.403 . . . . 0.0 110.808 179.837 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 147' ' ' PHE . 6.8 t -79.7 167.67 2.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.999 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.644 HG13 ' H ' ' A' ' 141' ' ' SER . 2.5 p -79.39 -63.18 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 N-CA-C 112.199 0.444 . . . . 0.0 112.199 -179.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.677 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.9 OUTLIER -160.28 -174.46 4.52 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.918 0.39 . . . . 0.0 111.321 -179.579 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 87.12 -167.19 37.55 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.397 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -59.53 -19.28 51.41 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.345 2.03 . . . . 0.0 111.965 179.541 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.539 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.3 m-85 -98.49 13.97 29.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.677 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -80.42 39.22 0.45 Allowed 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.275 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . 0.45 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 0.2 OUTLIER -160.78 31.57 0.15 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.901 0.381 . . . . 0.0 110.893 179.32 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.719 ' O ' HG23 ' A' ' 139' ' ' VAL . 22.4 m-85 -143.96 155.58 44.1 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.865 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.46 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 0.8 OUTLIER -110.7 159.56 17.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.224 179.423 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . 0.621 ' HA3' HG12 ' A' ' 163' ' ' VAL . . . -128.21 179.15 16.71 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.287 -0.958 . . . . 0.0 113.145 -179.504 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . 0.42 HG22 ' HA2' ' A' ' 134' ' ' GLY . 2.4 m -121.63 116.88 25.41 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.768 0.318 . . . . 0.0 110.729 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 37.2 t -67.49 145.53 13.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.984 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 20.4 p -137.55 -55.54 0.69 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.976 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . 0.529 ' O ' HG23 ' A' ' 154' ' ' ILE . 0.5 OUTLIER -115.91 159.68 21.24 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.912 -179.869 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . 0.563 HG22 HG12 ' A' ' 161' ' ' VAL . 1.9 pt -158.7 149.02 8.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.092 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 12.0 t30 -147.26 85.32 6.88 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.946 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.52 -22.34 27.54 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.523 2.149 . . . . 0.0 112.408 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -55.0 -69.48 0.13 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.124 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.87 -33.71 39.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.984 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 101.56 55.42 0.9 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.596 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 2.7 mtmp? -131.34 149.28 52.62 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.922 0.392 . . . . 0.0 110.807 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.906 HG22 ' HA ' ' A' ' 177' ' ' ASP . 27.9 m -142.58 136.76 27.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.128 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 17.8 tttp -100.31 141.33 33.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.94 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.624 HG23 HD13 ' A' ' 176' ' ' LEU . 12.0 t -152.08 137.06 10.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.986 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . 0.423 ' CG ' ' O ' ' A' ' 164' ' ' MET . 0.1 OUTLIER -97.49 106.48 18.81 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.982 0.42 . . . . 0.0 111.022 -179.9 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.448 HG12 ' N ' ' A' ' 166' ' ' THR . 5.5 t -103.4 159.88 4.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.176 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . 0.448 ' N ' HG12 ' A' ' 165' ' ' VAL . 15.8 p -95.14 145.52 24.95 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.85 179.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.816 HD13 ' O ' ' A' ' 167' ' ' ILE . 0.0 OUTLIER -114.6 -36.86 2.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.061 179.982 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -166.37 76.86 0.21 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 64.03 26.82 70.57 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.52 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.01 136.68 9.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.793 0.33 . . . . 0.0 110.879 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 7.2 pm0 -59.18 166.91 1.95 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.9 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 9.1 m -159.74 84.21 2.22 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.022 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.12 119.74 7.18 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.48 2.12 . . . . 0.0 112.138 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 15.6 m -142.13 151.2 18.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.255 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -83.63 142.51 30.75 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.575 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.624 HD13 HG23 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -152.56 -161.21 1.25 Allowed 'General case' 0 CA--C 1.518 -0.257 0 CA-C-O 121.301 0.572 . . . . 0.0 111.303 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.906 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.7 OUTLIER -151.17 154.04 36.13 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.208 178.453 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . 0.458 ' CE2' HG11 ' A' ' 161' ' ' VAL . 12.3 m-85 -48.17 -27.73 2.56 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.522 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 7.5 t -78.17 -1.94 35.17 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.679 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -124.27 13.0 8.89 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.659 0.266 . . . . 0.0 111.391 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 15.6 m -144.31 160.97 15.16 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.807 0.337 . . . . 0.0 111.15 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 28.6 m -141.6 148.22 21.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.054 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.671 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.1 OUTLIER -59.84 134.85 57.42 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.9 -179.938 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.215 -0.898 . . . . 0.0 111.169 179.963 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.839 0.352 . . . . 0.0 110.966 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -62.44 129.79 42.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.879 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 121.51 -22.62 7.77 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.604 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -56.8 163.82 1.76 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.841 0.353 . . . . 0.0 111.046 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -104.54 135.43 45.97 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.91 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.795 HG12 ' HA ' ' A' ' 183' ' ' LYS . 11.9 m -138.1 130.0 38.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.064 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.416 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.98 165.37 22.66 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.898 -179.927 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.694 HG23 ' O ' ' A' ' 147' ' ' PHE . 3.7 t -79.83 168.83 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.913 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.636 HG23 ' H ' ' A' ' 141' ' ' SER . 1.0 OUTLIER -79.52 -66.01 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.876 -179.55 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.684 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 52.1 p -160.22 -165.42 1.46 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.941 0.4 . . . . 0.0 110.954 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.73 -159.07 37.76 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.451 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.71 -12.31 35.06 Favored 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.578 2.186 . . . . 0.0 112.385 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.545 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.2 m-85 -108.57 20.91 17.98 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.164 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.684 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -80.53 38.44 0.43 Allowed 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -179.401 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -161.03 36.98 0.15 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.791 0.329 . . . . 0.0 110.915 179.309 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.694 ' O ' HG23 ' A' ' 139' ' ' VAL . 48.4 m-85 -147.91 161.06 42.07 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.951 -179.828 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.416 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 1.9 p -120.42 -176.79 3.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.66 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -149.39 151.44 23.56 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.602 -0.809 . . . . 0.0 112.724 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.1 m -96.56 99.18 10.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.788 0.328 . . . . 0.0 110.74 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.753 ' HA ' HG12 ' A' ' 163' ' ' VAL . 48.7 t -56.98 105.95 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.303 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 30.4 p -83.85 -38.96 20.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.535 179.683 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -143.81 160.31 40.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.701 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.8 mp -132.52 139.67 49.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.162 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -131.38 84.74 55.41 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.789 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -68.19 -27.68 34.93 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.511 2.14 . . . . 0.0 112.363 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -59.69 -58.4 8.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.882 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -87.54 -30.06 20.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.949 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 94.96 37.32 5.23 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.493 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 8.7 mtmt -114.08 154.06 28.39 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.8 0.333 . . . . 0.0 110.968 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.405 HG22 ' HA ' ' A' ' 177' ' ' ASP . 17.8 m -147.23 141.35 19.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.08 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 18.2 ttpt -115.47 122.85 47.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.943 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 1.038 HG22 HD11 ' A' ' 176' ' ' LEU . 33.4 m -136.63 146.49 28.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.285 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -93.32 106.32 18.29 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.486 179.692 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.523 HG22 ' O ' ' A' ' 172' ' ' THR . 30.4 m -88.18 171.75 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.372 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 82.6 p -148.26 103.85 3.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.673 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 2.9 mp -79.94 85.56 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.222 -179.849 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 59.1 31.5 21.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.958 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 105.6 35.39 3.07 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.56 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 9.3 mtt-85 -135.38 91.84 2.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.795 0.331 . . . . 0.0 110.882 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -58.64 136.72 57.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.91 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . 0.523 ' O ' HG22 ' A' ' 165' ' ' VAL . 19.7 m -159.53 104.48 1.49 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.994 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -69.43 105.79 1.49 Allowed 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.342 2.028 . . . . 0.0 112.105 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 22.0 t -122.5 135.32 62.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.247 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -87.41 139.55 30.43 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.653 179.666 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 1.038 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -144.52 -162.5 1.5 Allowed 'General case' 0 CA--C 1.516 -0.333 0 CA-C-O 121.415 0.626 . . . . 0.0 111.263 -179.665 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.405 ' HA ' HG22 ' A' ' 161' ' ' VAL . 10.0 m-20 -142.41 158.05 44.11 Favored 'General case' 0 N--CA 1.441 -0.896 0 CA-C-N 115.001 -1.0 . . . . 0.0 109.888 178.19 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -46.89 -33.47 4.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.424 -179.535 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -73.13 -8.75 57.14 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.534 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.58 ' C ' HG13 ' A' ' 140' ' ' VAL . 16.5 mm-40 -110.8 -12.97 14.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.712 0.292 . . . . 0.0 111.559 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.474 ' CG1' HD22 ' A' ' 176' ' ' LEU . 8.2 m -128.5 174.34 12.05 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.134 0 CA-C-O 120.865 0.364 . . . . 0.0 111.317 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.02 146.97 20.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.025 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.795 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -80.19 123.9 28.32 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.94 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.261 -0.876 . . . . 0.0 111.085 179.993 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 30.8 mtp180 . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.723 0.297 . . . . 0.0 110.972 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.72 131.49 50.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.918 179.869 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.38 -23.39 20.57 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.69 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -57.91 -176.08 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.869 0.366 . . . . 0.0 110.974 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -121.73 139.98 52.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.956 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.894 HG12 ' HA ' ' A' ' 183' ' ' LYS . 17.1 m -139.98 142.75 31.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.011 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.453 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -80.01 165.18 22.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.038 0.447 . . . . 0.0 110.837 -179.954 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.709 HG23 ' O ' ' A' ' 147' ' ' PHE . 4.6 t -79.86 168.03 2.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.92 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.654 HG13 ' H ' ' A' ' 141' ' ' SER . 3.2 p -79.37 -62.13 1.5 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.26 0 N-CA-C 112.011 0.375 . . . . 0.0 112.011 -179.263 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.658 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.7 OUTLIER -160.5 -163.5 1.1 Allowed 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.876 0.369 . . . . 0.0 111.124 -179.515 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 78.17 -165.39 51.95 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.465 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_endo -62.17 -17.11 54.9 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.506 2.137 . . . . 0.0 112.022 179.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.553 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.9 m-85 -100.26 16.38 24.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.207 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.658 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -79.53 37.68 0.35 Allowed 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -179.366 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . 0.438 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 11.2 p30 -160.91 32.05 0.15 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.971 0.415 . . . . 0.0 110.818 179.277 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.709 ' O ' HG23 ' A' ' 139' ' ' VAL . 24.8 m-85 -140.91 159.62 41.81 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.747 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 1.6 p -108.72 171.07 7.64 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.568 179.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -137.43 139.38 10.45 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.518 -0.849 . . . . 0.0 112.768 -179.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.9 m -91.2 105.66 17.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.751 0.31 . . . . 0.0 110.605 179.72 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.451 ' HA ' HG12 ' A' ' 163' ' ' VAL . 24.3 t -64.53 108.7 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.172 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 2.0 t -96.24 -30.54 13.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.955 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -140.63 164.98 28.71 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.979 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 9.5 tt -152.48 127.84 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.026 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 59.0 m-20 -103.22 93.87 5.09 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.951 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.67 -27.95 26.27 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.481 2.121 . . . . 0.0 112.293 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -90.35 26.8 1.83 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.394 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -159.86 -45.17 0.05 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.894 0.378 . . . . 0.0 110.901 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 101.56 36.55 3.75 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.486 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 19.4 mmmt -111.46 152.03 27.88 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.886 0.374 . . . . 0.0 110.849 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.758 HG22 ' HA ' ' A' ' 177' ' ' ASP . 12.3 m -140.27 125.99 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.032 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 22.4 tttt -103.88 119.66 39.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.844 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.736 HG22 ' CD1' ' A' ' 176' ' ' LEU . 33.7 m -132.15 152.65 37.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.116 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 11.9 ptp -100.55 121.07 40.98 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.045 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.423 HG12 ' N ' ' A' ' 166' ' ' THR . 7.1 t -101.93 158.29 4.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.016 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . 0.423 ' N ' HG12 ' A' ' 165' ' ' VAL . 7.3 m -115.12 110.16 19.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.961 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.751 HD13 ' HB2' ' A' ' 168' ' ' PHE . 0.0 OUTLIER -120.0 114.28 43.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.779 179.869 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . 0.751 ' HB2' HD13 ' A' ' 167' ' ' ILE . 0.1 OUTLIER 63.54 31.85 14.52 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.764 -179.617 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 72.4 36.4 59.36 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.478 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -142.96 109.03 5.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.799 0.333 . . . . 0.0 110.885 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -59.47 128.2 35.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.855 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 15.8 m -132.13 92.01 30.4 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.015 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -60.99 115.58 2.79 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.593 2.195 . . . . 0.0 112.046 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 11.3 p -121.74 147.56 25.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.295 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.3 pm0 -94.55 121.93 36.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.799 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.736 ' CD1' HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -137.54 -159.18 0.93 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.306 0.574 . . . . 0.0 111.113 -179.773 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.758 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.6 OUTLIER -143.25 155.2 44.44 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.101 178.182 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . 0.478 ' CE2' HG11 ' A' ' 161' ' ' VAL . 8.2 m-85 -46.68 -29.09 1.71 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.578 -179.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 6.4 p -70.67 -11.82 61.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.564 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -115.75 16.91 16.31 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.61 -0.268 . . . . 0.0 111.448 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 10.9 m -153.25 154.07 8.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-O 120.718 0.294 . . . . 0.0 111.234 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 28.9 m -127.21 146.41 33.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.177 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.894 ' HA ' HG12 ' A' ' 137' ' ' VAL . 17.7 tptm -71.31 139.54 49.95 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.205 -0.903 . . . . 0.0 111.121 -179.978 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 7.9 ttt85 . . . . . 0 C--O 1.233 0.192 0 CA-C-O 120.991 0.424 . . . . 0.0 110.912 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -56.01 155.84 5.96 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.776 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.99 9.36 59.75 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.869 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -80.78 162.18 24.18 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.775 0.321 . . . . 0.0 110.859 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 14.2 mt-30 -118.31 120.15 36.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.902 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.618 HG12 ' HA ' ' A' ' 183' ' ' LYS . 30.0 m -127.12 140.64 48.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.987 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.411 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.77 160.86 26.03 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.083 0.468 . . . . 0.0 110.883 -179.853 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.859 HG11 ' HB2' ' A' ' 144' ' ' PHE . 43.4 t -79.92 150.56 4.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.644 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.528 HG22 ' O ' ' A' ' 180' ' ' GLN . 35.5 m -91.97 -20.37 6.67 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 -179.418 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.733 ' H ' HG12 ' A' ' 139' ' ' VAL . 0.4 OUTLIER -79.15 153.25 30.22 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.893 0.377 . . . . 0.0 111.187 -178.937 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . 0.409 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -64.43 -63.2 4.46 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.946 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.409 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.2 Cg_endo -52.65 -22.86 18.22 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.666 2.244 . . . . 0.0 112.341 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.859 ' HB2' HG11 ' A' ' 139' ' ' VAL . 15.2 m-85 -112.8 2.48 15.99 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.505 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.674 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -69.82 46.93 0.08 Allowed 'General case' 0 CA--C 1.53 0.204 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -178.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . 0.406 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 11.4 p30 -160.71 32.19 0.15 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.023 0.44 . . . . 0.0 110.615 179.101 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.666 ' O ' HG23 ' A' ' 139' ' ' VAL . 69.0 m-85 -154.63 145.08 22.15 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.604 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.51 ' O ' HG12 ' A' ' 165' ' ' VAL . 68.7 p -102.03 172.81 6.7 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.709 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -128.14 132.67 7.45 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.47 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.8 m -95.93 104.45 16.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.745 0.307 . . . . 0.0 110.696 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.473 HG13 HG23 ' A' ' 161' ' ' VAL . 26.4 t -59.85 114.32 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.32 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -107.04 -40.13 5.54 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.64 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -135.2 153.48 51.93 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.685 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 2.0 mp -129.62 152.31 37.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.239 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 -130.16 79.09 73.48 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.762 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -69.07 -26.55 30.74 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.496 2.131 . . . . 0.0 112.427 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -61.93 -34.52 76.24 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.863 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 8.3 mtt180 -108.27 -43.69 4.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.921 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 112.82 48.45 0.62 Allowed Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.505 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -137.37 177.24 8.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.835 0.35 . . . . 0.0 110.996 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.473 HG23 HG13 ' A' ' 151' ' ' VAL . 1.3 p -152.06 159.73 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.125 0.488 . . . . 0.0 110.898 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . 0.472 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 7.1 tttm -119.43 124.35 46.31 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.867 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.419 HG12 ' HA ' ' A' ' 151' ' ' VAL . 29.7 m -136.4 146.33 29.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.252 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 8.5 ptm -92.71 130.38 38.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.878 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.51 HG12 ' O ' ' A' ' 148' ' ' THR . 27.7 m -131.5 144.49 37.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.184 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . 0.533 HG23 ' C ' ' A' ' 170' ' ' ARG . 0.6 OUTLIER -108.28 139.46 42.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.922 -179.952 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.8 mp -136.29 -66.83 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.182 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 16.3 m-85 -91.46 55.57 2.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.926 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 58.02 27.56 59.89 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.546 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . 0.533 ' C ' HG23 ' A' ' 166' ' ' THR . 0.5 OUTLIER -153.88 151.39 29.43 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.864 0.364 . . . . 0.0 110.938 -179.913 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -69.38 161.05 30.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.811 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . 0.553 HG22 ' CG2' ' A' ' 174' ' ' VAL . 16.4 m -153.52 96.49 2.81 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.876 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -66.77 83.37 0.31 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.389 2.059 . . . . 0.0 112.139 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.553 ' CG2' HG22 ' A' ' 172' ' ' THR . 26.8 t -104.93 135.66 41.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.981 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -79.97 145.04 32.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.59 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.905 HD13 HG13 ' A' ' 181' ' ' VAL . 5.7 mt -146.17 -169.31 3.22 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 121.336 0.588 . . . . 0.0 111.41 -179.55 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -140.27 153.53 46.53 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 115.092 -0.958 . . . . 0.0 110.285 178.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 10.0 m-85 -50.18 -31.94 15.01 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.269 -179.589 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.9 p -79.76 -1.21 37.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.385 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.72 ' HB3' HD22 ' A' ' 176' ' ' LEU . 1.3 mm-40 -116.0 3.01 13.57 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.714 0.292 . . . . 0.0 111.491 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.905 HG13 HD13 ' A' ' 176' ' ' LEU . 5.2 m -140.56 167.02 18.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-O 120.923 0.392 . . . . 0.0 111.074 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.4 m -135.07 146.36 30.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.124 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.618 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -59.99 139.15 57.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.886 -179.998 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.253 -0.88 . . . . 0.0 111.066 179.994 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 8.6 tpt180 . . . . . 0 C--O 1.23 0.068 0 CA-C-O 120.888 0.375 . . . . 0.0 110.86 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -66.07 132.24 48.08 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.795 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 106.45 -14.41 42.92 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.781 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -54.84 164.72 0.74 Allowed 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.912 0.387 . . . . 0.0 110.912 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . 0.456 ' O ' ' HB3' ' A' ' 184' ' ' ALA . 0.3 OUTLIER -112.15 115.87 29.56 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.07 -179.869 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 31.5 m -116.6 139.27 44.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.852 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.417 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.4 OUTLIER -79.97 155.02 27.86 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.025 0.441 . . . . 0.0 110.975 -179.924 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.588 HG12 ' N ' ' A' ' 140' ' ' VAL . 36.4 t -95.26 167.4 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.729 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.877 HG22 ' O ' ' A' ' 180' ' ' GLN . 14.1 m -133.9 -21.01 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.25 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -178.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.44 ' O ' ' CD2' ' A' ' 144' ' ' PHE . 2.7 m -79.49 149.65 31.45 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.112 0.482 . . . . 0.0 112.18 -178.249 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 39.64 -148.46 0.15 Allowed Glycine 0 C--N 1.334 0.424 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.678 179.46 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -73.62 4.43 4.03 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.774 2.316 . . . . 0.0 112.557 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.551 ' HB2' HG11 ' A' ' 139' ' ' VAL . 0.5 OUTLIER -79.55 -8.99 59.54 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.072 179.959 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.44 ' HA ' ' O ' ' A' ' 139' ' ' VAL . . . -67.82 39.49 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -178.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . 0.453 ' H ' ' C ' ' A' ' 144' ' ' PHE . 0.3 OUTLIER -160.89 31.23 0.15 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.103 0.478 . . . . 0.0 110.56 179.102 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.431 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 44.9 m-85 -148.88 154.51 39.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.772 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.417 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 67.6 p -108.69 134.88 50.82 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.872 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -94.2 160.75 24.02 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.579 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.0 m -102.34 103.74 14.2 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.772 0.32 . . . . 0.0 110.751 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.704 ' HA ' HG12 ' A' ' 163' ' ' VAL . 33.9 t -62.27 107.59 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.967 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -88.89 -49.34 6.86 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.843 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -135.48 171.06 14.99 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.698 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . 0.596 HD12 ' HD3' ' A' ' 156' ' ' PRO . 1.0 OUTLIER -137.64 158.82 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.168 -179.907 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -140.95 83.47 14.07 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.819 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . 0.596 ' HD3' HD12 ' A' ' 154' ' ' ILE . 56.5 Cg_endo -70.58 -27.04 23.04 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.515 2.143 . . . . 0.0 112.351 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -59.13 -42.4 90.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.885 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 4.6 mpt_? -103.8 -60.16 1.61 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.884 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 130.21 49.55 0.12 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.494 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 13.0 mttm -130.62 161.34 31.8 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.826 0.346 . . . . 0.0 110.928 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 17.3 m -147.33 124.48 3.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.193 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 9.3 tttt -87.38 123.92 32.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.888 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.704 HG12 ' HA ' ' A' ' 151' ' ' VAL . 15.4 m -142.34 135.92 28.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.033 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . 0.404 ' HE3' ' C ' ' A' ' 164' ' ' MET . 0.0 OUTLIER -80.49 130.44 35.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.728 -179.992 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.632 HG22 HG12 ' A' ' 174' ' ' VAL . 15.4 m -110.22 131.18 61.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.234 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -97.62 100.31 11.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.809 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.586 HG23 ' O ' ' A' ' 167' ' ' ILE . 8.0 tt -95.59 111.07 25.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.105 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER 60.61 43.58 12.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.907 -179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 65.55 52.18 41.56 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.465 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -154.16 119.22 5.03 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.911 0.386 . . . . 0.0 110.833 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -58.94 134.11 56.66 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.932 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -147.75 96.73 4.05 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.867 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.69 118.06 5.16 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.452 2.102 . . . . 0.0 112.184 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.632 HG12 HG22 ' A' ' 165' ' ' VAL . 9.9 p -145.93 144.12 21.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.092 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -79.99 134.35 36.24 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.724 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.814 HD12 ' HB3' ' A' ' 180' ' ' GLN . 2.1 mm? -121.68 -172.0 2.34 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-O 121.375 0.607 . . . . 0.0 111.341 -179.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.577 ' O ' HG22 ' A' ' 181' ' ' VAL . 2.5 m-20 -150.28 151.95 33.76 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.466 178.366 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 3.7 m-85 -45.12 -46.5 11.83 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.623 -179.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.12 -20.88 63.15 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.143 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.877 ' O ' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -92.93 -10.02 38.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.511 -179.786 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 177' ' ' ASP . 27.7 m -138.98 -176.63 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.803 0.335 . . . . 0.0 111.399 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . 0.4 HG23 ' HB2' ' A' ' 138' ' ' ARG . 14.4 m -150.32 157.37 6.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.032 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 10.9 tptt -71.69 138.07 48.3 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.888 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . 0.456 ' HB3' ' O ' ' A' ' 136' ' ' GLN . . . . . . . . 0 C--O 1.249 1.038 0 CA-C-O 118.199 -0.905 . . . . 0.0 111.195 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 1.8 tpt180 . . . . . 0 C--O 1.23 0.077 0 CA-C-O 120.853 0.358 . . . . 0.0 110.922 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -60.46 118.56 6.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.896 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.99 19.75 14.24 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.597 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -76.4 158.49 31.34 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.784 0.326 . . . . 0.0 110.847 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 -109.81 126.74 54.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.108 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.879 HG12 ' HA ' ' A' ' 183' ' ' LYS . 12.7 m -141.02 141.03 31.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.863 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.431 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 1.7 ttp180 -79.64 161.72 25.7 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.066 0.46 . . . . 0.0 110.833 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.855 HG11 ' HB2' ' A' ' 144' ' ' PHE . 27.6 t -79.98 151.37 4.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.607 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.552 HG13 ' O ' ' A' ' 180' ' ' GLN . 33.5 m -93.99 -19.44 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 -179.338 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.72 ' H ' HG12 ' A' ' 139' ' ' VAL . 4.2 m -79.14 153.4 30.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.767 0.318 . . . . 0.0 111.026 -179.079 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . -64.31 -63.87 4.02 Favored Glycine 0 CA--C 1.519 0.31 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.964 -179.497 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -53.36 -22.76 21.73 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.753 2.302 . . . . 0.0 112.474 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.855 ' HB2' HG11 ' A' ' 139' ' ' VAL . 6.4 m-85 -111.12 1.05 17.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.516 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.691 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -69.65 47.63 0.08 Allowed 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 112.61 0.596 . . . . 0.0 112.61 -178.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . 0.404 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 17.4 p-10 -160.79 32.34 0.15 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.157 0.503 . . . . 0.0 110.696 179.015 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.757 ' O ' HG23 ' A' ' 139' ' ' VAL . 35.0 m-85 -154.56 145.53 22.64 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.507 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.431 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 75.5 p -99.86 175.91 5.62 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.849 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -136.86 151.59 21.01 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.652 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.2 m -114.12 112.36 23.08 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.726 0.298 . . . . 0.0 110.978 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 21.8 t -66.36 107.87 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.071 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.33 -50.42 6.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.845 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -135.62 164.36 28.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.009 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.8 mt -126.88 151.78 34.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.092 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -113.88 86.78 11.53 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.91 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.63 -27.13 22.72 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.591 2.194 . . . . 0.0 112.337 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -60.09 -51.1 71.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.949 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 2.6 ttt85 -97.37 -67.21 0.86 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.895 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 141.24 52.89 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.417 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 14.3 mttp -131.14 178.76 6.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.831 0.348 . . . . 0.0 110.82 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.701 HG11 ' CE1' ' A' ' 178' ' ' PHE . 28.1 m -145.87 123.07 4.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.071 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 62.6 tttt -79.88 116.43 20.02 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.625 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.1 t -124.55 150.2 29.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.042 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 4.5 ptt? -103.65 116.49 32.43 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.023 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 3.2 m -113.17 138.15 43.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.051 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -97.69 133.79 41.74 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.852 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.612 HD13 ' HB2' ' A' ' 168' ' ' PHE . 0.0 OUTLIER -133.47 117.88 29.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.999 179.971 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . 0.612 ' HB2' HD13 ' A' ' 167' ' ' ILE . 0.2 OUTLIER 62.99 30.28 16.39 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.958 -179.7 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 77.0 45.01 12.31 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.494 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -157.85 128.56 6.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.827 0.346 . . . . 0.0 110.869 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -59.74 144.36 48.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . 0.701 ' O ' HG23 ' A' ' 174' ' ' VAL . 22.3 m -144.18 83.07 10.36 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.943 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_exo -56.23 90.16 0.04 OUTLIER 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.566 2.178 . . . . 0.0 112.312 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.701 HG23 ' O ' ' A' ' 172' ' ' THR . 24.7 t -109.0 132.69 56.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.086 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -79.92 125.84 30.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.278 179.602 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -134.43 -160.81 1.08 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.405 0.621 . . . . 0.0 111.459 -179.317 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.683 ' HA ' HG22 ' A' ' 161' ' ' VAL . 1.5 m-20 -151.44 156.53 40.84 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.936 178.299 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . 0.701 ' CE1' HG11 ' A' ' 161' ' ' VAL . 14.5 m-85 -46.77 -28.07 1.41 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.599 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -78.81 -0.26 29.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.708 -179.722 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.552 ' O ' HG13 ' A' ' 140' ' ' VAL . 79.1 mt-30 -118.74 0.14 11.4 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-O 120.481 0.182 . . . . 0.0 111.405 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 5.7 m -144.98 156.02 13.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 120.86 0.362 . . . . 0.0 111.099 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 30.3 m -126.41 146.43 32.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.167 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.879 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -64.85 128.8 37.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.003 179.97 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.059 0 CA-C-O 118.309 -0.853 . . . . 0.0 111.143 179.992 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 3.3 mtt180 . . . . . 0 C--O 1.231 0.126 0 CA-C-O 120.854 0.359 . . . . 0.0 110.936 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -60.34 120.69 10.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 108.67 11.3 23.38 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.674 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -90.04 169.4 11.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.756 0.313 . . . . 0.0 110.92 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.36 134.15 48.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.829 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.743 HG12 ' HA ' ' A' ' 183' ' ' LYS . 21.0 m -142.06 134.04 27.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.148 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.406 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.1 OUTLIER -80.99 163.13 23.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.94 0.4 . . . . 0.0 110.627 179.913 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.634 HG11 ' HB2' ' A' ' 144' ' ' PHE . 11.7 t -79.83 166.99 2.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.912 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.624 HG13 ' C ' ' A' ' 180' ' ' GLN . 2.1 m -79.31 -61.79 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -179.306 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.738 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 4.2 m -160.02 -166.4 1.7 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.811 0.338 . . . . 0.0 111.258 -179.466 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.59 -158.37 37.25 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.392 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -68.82 -10.96 30.6 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.586 2.191 . . . . 0.0 112.352 179.82 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.634 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.3 m-85 -107.31 14.18 26.33 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.468 -179.796 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.738 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -75.3 36.48 0.12 Allowed 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 112.403 0.519 . . . . 0.0 112.403 -179.342 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -161.16 34.13 0.14 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.913 0.387 . . . . 0.0 110.77 179.278 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.4 ' O ' HG23 ' A' ' 139' ' ' VAL . 23.1 m-85 -145.31 164.43 31.44 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.991 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.514 HG22 ' C ' ' A' ' 137' ' ' VAL . 0.6 OUTLIER -121.66 -173.94 2.75 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.43 179.586 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -154.6 161.83 30.4 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.449 -0.881 . . . . 0.0 112.844 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . 0.46 ' C ' HG13 ' A' ' 163' ' ' VAL . 88.9 m -110.49 101.6 10.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.833 0.349 . . . . 0.0 110.841 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 31.6 t -59.45 114.63 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.178 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -83.25 -61.07 1.95 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.866 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -134.23 168.98 17.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.895 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . 0.465 HG23 HG12 ' A' ' 161' ' ' VAL . 3.7 mt -126.96 135.51 63.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.069 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -107.12 84.48 1.67 Allowed Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.92 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.44 -28.12 22.36 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.607 2.204 . . . . 0.0 112.256 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -68.31 -34.15 75.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.968 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 25.0 mmt180 -101.53 -56.11 2.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.958 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 121.66 37.35 0.68 Allowed Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.495 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -126.98 175.09 8.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.758 0.314 . . . . 0.0 110.864 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.697 HG11 ' CE1' ' A' ' 178' ' ' PHE . 15.5 m -151.17 119.7 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.135 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 2.1 ttpm? -79.86 137.46 36.93 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.73 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.633 ' HB ' HD21 ' A' ' 176' ' ' LEU . 4.8 t -149.19 146.68 17.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.997 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.67 127.56 48.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.016 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.618 ' CG2' HD11 ' A' ' 167' ' ' ILE . 3.5 m -107.02 147.66 12.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.039 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 63.3 m -112.67 85.58 2.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.978 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.618 HD11 ' CG2' ' A' ' 165' ' ' VAL . 4.1 mp -98.09 126.81 51.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.031 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 61.57 31.33 18.84 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.902 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 69.5 38.38 79.32 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.554 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 72.5 mmt-85 -146.76 134.42 21.07 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.861 0.363 . . . . 0.0 110.924 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -72.29 147.99 45.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.882 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 1.8 m -157.14 88.41 2.62 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.804 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -50.8 115.54 2.06 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.608 2.205 . . . . 0.0 112.338 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.882 HG13 HD11 ' A' ' 176' ' ' LEU . 10.4 p -128.63 142.74 43.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.064 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . 0.872 ' C ' HD13 ' A' ' 176' ' ' LEU . 6.8 pt-20 -98.25 121.49 40.24 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.838 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.882 HD11 HG13 ' A' ' 174' ' ' VAL . 0.0 OUTLIER -126.94 -160.41 1.0 Allowed 'General case' 0 CA--C 1.518 -0.286 0 CA-C-O 121.353 0.597 . . . . 0.0 110.894 -179.939 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.427 ' HA ' HG22 ' A' ' 161' ' ' VAL . 4.8 m-20 -148.36 155.37 41.18 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.163 -0.926 . . . . 0.0 109.934 178.373 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . 0.697 ' CE1' HG11 ' A' ' 161' ' ' VAL . 11.7 m-85 -48.31 -33.83 9.53 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.482 -179.47 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 90.9 p -78.21 -2.55 38.3 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.643 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.624 ' C ' HG13 ' A' ' 140' ' ' VAL . 4.3 mt-30 -115.29 -2.81 12.58 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.545 0.212 . . . . 0.0 111.564 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 17.4 m -140.41 171.98 12.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-O 120.844 0.354 . . . . 0.0 111.393 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 27.5 m -136.72 146.43 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.219 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.743 ' HA ' HG12 ' A' ' 137' ' ' VAL . 5.2 mtmt -80.09 130.99 35.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.919 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.278 -0.867 . . . . 0.0 111.045 -179.972 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.23 0.065 0 CA-C-O 120.842 0.354 . . . . 0.0 110.921 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -59.62 123.73 17.84 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.48 5.72 27.76 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.834 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -67.61 162.57 23.23 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.739 0.304 . . . . 0.0 110.792 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -111.59 131.23 55.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.977 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.654 HG12 ' HA ' ' A' ' 183' ' ' LYS . 15.6 m -143.42 148.25 19.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.803 179.837 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.767 ' HD3' HG22 ' A' ' 148' ' ' THR . 0.2 OUTLIER -79.63 164.62 23.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.03 0.443 . . . . 0.0 111.033 -179.927 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.901 HG23 ' O ' ' A' ' 147' ' ' PHE . 22.3 t -79.88 151.06 4.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.674 -179.636 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 11.4 p -90.83 -24.17 5.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-N 116.044 -0.526 . . . . 0.0 112.076 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.684 ' H ' HG12 ' A' ' 139' ' ' VAL . 6.2 m -79.33 154.67 28.9 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.999 0.428 . . . . 0.0 111.412 -178.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . 0.439 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -67.26 -61.19 5.32 Favored Glycine 0 N--CA 1.451 -0.308 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.69 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.439 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.2 Cg_endo -51.43 -24.55 16.64 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.663 2.242 . . . . 0.0 112.205 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.865 ' HB2' HG11 ' A' ' 139' ' ' VAL . 21.3 m-85 -112.98 4.36 16.7 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.419 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.681 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -70.06 46.58 0.08 Allowed 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -179.097 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . 0.427 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 17.5 p-10 -160.56 30.82 0.16 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.204 0.526 . . . . 0.0 110.498 179.037 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.901 ' O ' HG23 ' A' ' 139' ' ' VAL . 24.2 m-85 -151.85 146.18 25.48 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.168 179.732 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.767 HG22 ' HD3' ' A' ' 138' ' ' ARG . 26.7 p -96.85 -177.36 3.86 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.737 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . 0.4 ' HA3' ' CG2' ' A' ' 163' ' ' VAL . . . -144.63 159.34 27.78 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.608 -179.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 2.2 m -117.09 111.55 19.67 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.798 0.332 . . . . 0.0 110.862 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 21.6 t -69.37 131.92 33.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.047 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.74 -68.92 0.79 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.026 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -123.71 172.92 8.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.948 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . 0.443 HG23 HG12 ' A' ' 161' ' ' VAL . 35.0 mt -139.35 128.93 30.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.074 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -100.81 99.51 10.48 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.897 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.41 -23.75 17.15 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.557 2.171 . . . . 0.0 112.417 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -90.27 23.2 2.99 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.301 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 16.4 mtp180 -158.6 -44.25 0.06 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.754 0.311 . . . . 0.0 110.765 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 97.4 57.39 1.06 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.472 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.55 162.95 34.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.765 0.317 . . . . 0.0 111.016 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.641 HG11 ' CE1' ' A' ' 178' ' ' PHE . 24.1 m -148.06 126.67 3.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.961 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 6.0 tttp -79.94 122.29 26.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.856 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.4 ' CG2' ' HA3' ' A' ' 149' ' ' GLY . 11.4 p -126.13 145.93 32.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.085 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.21 117.89 35.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.735 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.683 HG22 HG12 ' A' ' 174' ' ' VAL . 13.4 m -110.33 142.76 21.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.139 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . 0.484 HG23 ' C ' ' A' ' 170' ' ' ARG . 8.2 m -135.73 133.32 37.89 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.875 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.482 ' O ' HG22 ' A' ' 167' ' ' ILE . 4.1 mp -102.69 53.47 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.937 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER 65.67 96.49 0.05 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.974 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 65.81 33.55 86.17 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.679 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . 0.484 ' C ' HG23 ' A' ' 166' ' ' THR . 0.0 OUTLIER -154.44 86.07 1.14 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.849 0.357 . . . . 0.0 111.019 -179.884 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -68.79 141.95 55.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.706 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 63.4 m -160.0 93.3 1.68 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.167 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_exo -62.06 124.81 15.11 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.651 2.234 . . . . 0.0 112.057 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.683 HG12 HG22 ' A' ' 165' ' ' VAL . 11.2 p -137.91 132.33 43.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.32 -179.828 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -79.82 131.72 35.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.263 179.642 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.806 HD23 HG13 ' A' ' 181' ' ' VAL . 1.1 mp -133.07 -167.74 1.97 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.421 0.629 . . . . 0.0 111.608 -179.319 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.442 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.6 OUTLIER -144.66 154.11 42.45 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 114.961 -1.018 . . . . 0.0 110.199 178.152 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . 0.641 ' CE1' HG11 ' A' ' 161' ' ' VAL . 8.9 m-85 -44.73 -33.68 1.96 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.612 -179.548 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -82.32 14.65 2.83 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.679 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.427 ' N ' ' O ' ' A' ' 177' ' ' ASP . 21.6 mt-30 -127.85 4.91 6.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.576 0.227 . . . . 0.0 111.328 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.806 HG13 HD23 ' A' ' 176' ' ' LEU . 6.2 m -146.45 170.72 4.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.14 0 CA-C-O 120.874 0.369 . . . . 0.0 111.198 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 21.0 m -140.49 146.38 24.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.084 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.654 ' HA ' HG12 ' A' ' 137' ' ' VAL . 13.6 tttt -66.07 121.94 16.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.272 -0.871 . . . . 0.0 111.062 179.983 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 7.1 mmt180 . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.882 0.372 . . . . 0.0 111.059 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -64.22 122.83 17.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.792 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 96.23 18.26 31.8 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.617 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.49 176.51 9.33 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.798 0.333 . . . . 0.0 110.884 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 38.2 mt-30 -120.08 114.34 21.83 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.115 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.609 HG12 ' HA ' ' A' ' 183' ' ' LYS . 18.8 m -124.43 143.17 38.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.805 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -79.85 162.11 25.24 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.109 0.481 . . . . 0.0 111.054 -179.724 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.856 HG11 ' HB2' ' A' ' 144' ' ' PHE . 46.7 t -84.62 155.21 3.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.529 -179.423 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.553 HG13 ' O ' ' A' ' 180' ' ' GLN . 35.6 m -96.89 -24.65 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 N-CA-C 112.675 0.62 . . . . 0.0 112.675 -179.165 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.617 ' H ' HG12 ' A' ' 139' ' ' VAL . 0.2 OUTLIER -78.99 131.12 36.19 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.85 0.357 . . . . 0.0 111.32 -178.646 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . 0.476 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -44.19 -59.07 4.17 Favored Glycine 0 C--N 1.332 0.347 0 CA-C-N 115.823 -0.626 . . . . 0.0 113.597 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.476 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.7 Cg_endo -51.1 -22.74 11.3 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.669 2.246 . . . . 0.0 112.481 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.856 ' HB2' HG11 ' A' ' 139' ' ' VAL . 21.2 m-85 -120.13 4.83 10.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.466 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.522 ' N ' ' O ' ' A' ' 141' ' ' SER . . . -70.02 45.21 0.07 Allowed 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 112.55 0.574 . . . . 0.0 112.55 -178.653 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . 0.408 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 15.1 p-10 -160.69 31.74 0.15 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.13 0.491 . . . . 0.0 110.422 179.091 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.659 ' O ' HG23 ' A' ' 139' ' ' VAL . 46.3 m-85 -155.66 145.98 21.78 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.439 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 1.4 p -101.76 168.89 9.16 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.789 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -132.49 132.45 6.64 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.515 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.7 m -87.35 109.05 19.27 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.723 0.297 . . . . 0.0 110.802 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 19.2 t -64.38 123.8 17.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.093 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.2 p -100.97 -43.66 5.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.957 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 6.6 mt-10 -136.77 151.25 48.98 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . 0.488 HG23 HG12 ' A' ' 161' ' ' VAL . 7.8 mt -128.57 132.23 68.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.101 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -116.98 85.54 18.03 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.835 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -58.37 -30.05 90.06 Favored 'Trans proline' 0 C--N 1.343 0.278 0 C-N-CA 122.595 2.196 . . . . 0.0 112.321 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -60.38 -62.68 1.69 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.099 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 7.7 ttm180 -79.99 -30.89 39.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.029 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 93.53 27.15 13.54 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.58 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 2.9 mtmm -107.78 162.65 13.8 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.732 0.301 . . . . 0.0 110.754 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.759 HG11 ' CE1' ' A' ' 178' ' ' PHE . 15.7 m -153.71 123.19 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.163 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 29.4 tttt -85.66 146.97 26.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.816 179.806 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.781 HG21 HD11 ' A' ' 176' ' ' LEU . 25.0 m -144.96 170.1 7.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.276 -179.866 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -120.0 110.87 17.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.655 179.631 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.51 HG22 ' O ' ' A' ' 172' ' ' THR . 11.9 m -99.53 157.99 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.138 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 27.4 p -141.49 97.41 3.15 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.982 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.495 ' H ' HD12 ' A' ' 167' ' ' ILE . 3.9 mp -79.87 83.53 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.962 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 24.7 m-85 62.29 70.39 0.57 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.902 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 60.26 47.06 92.97 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.566 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 1.5 mtm180 -146.38 91.48 2.05 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.905 0.383 . . . . 0.0 110.977 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -58.17 140.39 53.03 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.984 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . 0.51 ' O ' HG22 ' A' ' 165' ' ' VAL . 2.8 m -160.09 97.8 1.49 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.933 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.86 123.76 10.38 Favored 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.405 2.07 . . . . 0.0 112.12 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.9 t -139.74 145.26 26.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.134 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . 0.89 ' O ' HD23 ' A' ' 176' ' ' LEU . 0.4 OUTLIER -88.92 142.47 27.62 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.859 179.997 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.89 HD23 ' O ' ' A' ' 175' ' ' GLU . 0.1 OUTLIER -147.68 -161.29 1.3 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.337 0.589 . . . . 0.0 111.088 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.583 ' HA ' HG22 ' A' ' 161' ' ' VAL . 1.0 OUTLIER -150.48 155.18 39.02 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.007 178.292 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . 0.759 ' CE1' HG11 ' A' ' 161' ' ' VAL . 25.6 m-85 -46.47 -30.4 2.18 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.536 -179.583 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 60.6 p -81.19 8.11 9.65 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.863 -179.799 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.553 ' O ' HG13 ' A' ' 140' ' ' VAL . 6.2 mt-30 -122.39 2.12 9.65 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-O 120.616 0.246 . . . . 0.0 111.286 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 4.8 m -143.24 172.31 7.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-O 120.88 0.371 . . . . 0.0 111.084 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 18.0 m -142.16 148.92 19.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.161 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.609 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -67.57 125.35 25.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.911 -179.968 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.174 -0.917 . . . . 0.0 111.106 179.92 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.931 0.396 . . . . 0.0 110.88 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -62.6 135.47 57.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.912 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 105.31 -23.94 28.99 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.637 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.8 t0 -58.2 158.23 7.34 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.825 0.345 . . . . 0.0 110.947 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 13.9 mm-40 -110.41 138.42 46.82 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.002 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.489 HG12 ' HA ' ' A' ' 183' ' ' LYS . 18.4 m -140.01 134.11 36.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.911 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.457 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 2.6 ttm180 -79.95 166.03 22.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.995 0.426 . . . . 0.0 110.839 179.877 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.673 HG23 ' O ' ' A' ' 147' ' ' PHE . 3.9 t -79.91 169.73 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.799 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.6 HG23 ' H ' ' A' ' 141' ' ' SER . 0.7 OUTLIER -79.49 -65.53 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 111.835 0.309 . . . . 0.0 111.835 -179.5 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.67 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.0 OUTLIER -160.18 -167.85 2.04 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.827 0.346 . . . . 0.0 111.059 -179.683 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 83.81 -162.27 39.09 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.417 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -64.28 -15.72 51.12 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.532 2.154 . . . . 0.0 112.241 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.655 ' HD1' HD13 ' A' ' 167' ' ' ILE . 2.8 m-85 -104.54 19.73 19.82 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.149 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.67 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -80.69 38.22 0.44 Allowed 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -179.259 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . 0.435 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 8.8 t70 -160.84 32.63 0.15 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.01 0.434 . . . . 0.0 110.977 179.234 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.673 ' O ' HG23 ' A' ' 139' ' ' VAL . 17.0 m-85 -140.3 161.11 38.47 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.7 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.457 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 25.1 p -116.42 -178.45 3.42 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.741 179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -145.43 137.42 7.04 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.664 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 14.5 m -92.83 108.64 20.15 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.78 0.324 . . . . 0.0 110.663 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.416 HG22 HG12 ' A' ' 163' ' ' VAL . 20.7 t -69.37 118.87 14.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.207 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -103.77 -34.82 8.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.854 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -151.25 159.72 44.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.859 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mp -139.83 140.52 35.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.136 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 24.3 m120 -103.71 92.2 4.05 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.863 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -69.4 -27.76 27.77 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.538 2.159 . . . . 0.0 112.25 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -70.25 -40.27 74.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.867 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 3.7 mmt180 -98.49 -62.42 1.24 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.855 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 125.47 55.42 0.16 Allowed Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.476 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -130.45 166.53 20.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.92 0.39 . . . . 0.0 110.921 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.659 HG22 ' HA ' ' A' ' 177' ' ' ASP . 3.4 m -147.94 116.93 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.059 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 26.1 ttpt -87.07 121.52 29.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.754 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.416 HG12 HG22 ' A' ' 151' ' ' VAL . 35.7 m -135.6 147.01 28.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.254 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 4.1 ptt? -102.17 118.73 37.51 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.043 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.432 HG12 ' N ' ' A' ' 166' ' ' THR . 7.4 t -106.2 158.45 6.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.12 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . 0.432 ' N ' HG12 ' A' ' 165' ' ' VAL . 0.6 OUTLIER -110.18 94.65 5.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.946 179.977 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.655 HD13 ' HD1' ' A' ' 144' ' ' PHE . 1.4 tp -112.16 136.74 47.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.965 179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER 61.31 30.1 18.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.921 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 67.74 39.97 90.03 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.633 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -159.88 140.21 11.86 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.787 0.327 . . . . 0.0 110.967 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.57 150.92 45.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.77 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . 0.403 ' O ' HG23 ' A' ' 174' ' ' VAL . 14.8 p -153.3 93.47 3.12 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.042 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.88 87.18 0.29 Allowed 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.444 2.096 . . . . 0.0 112.039 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 172' ' ' THR . 34.6 t -101.62 135.3 38.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.338 -179.746 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . 0.417 ' C ' HD23 ' A' ' 176' ' ' LEU . 10.9 pm0 -82.04 124.31 29.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.581 179.687 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.417 HD23 ' C ' ' A' ' 175' ' ' GLU . 0.2 OUTLIER -132.55 -160.9 1.09 Allowed 'General case' 0 CA--C 1.517 -0.308 0 CA-C-O 121.351 0.596 . . . . 0.0 111.254 -179.605 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.659 ' HA ' HG22 ' A' ' 161' ' ' VAL . 4.6 m-20 -149.88 155.2 39.62 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.169 178.377 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . 0.565 ' CE1' HG11 ' A' ' 161' ' ' VAL . 42.6 m-85 -46.34 -29.02 1.49 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.732 -179.502 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 8.2 m -74.52 -5.7 44.21 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.738 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.535 ' C ' HG13 ' A' ' 140' ' ' VAL . 11.9 mm-40 -120.76 -4.46 9.71 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 111.603 0.223 . . . . 0.0 111.603 -179.833 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.414 ' CG2' ' HA ' ' A' ' 178' ' ' PHE . 6.6 m -122.76 178.03 3.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.86 0.362 . . . . 0.0 111.223 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . 0.446 HG22 ' O ' ' A' ' 138' ' ' ARG . 27.2 m -152.06 146.78 15.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.135 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.489 ' HA ' HG12 ' A' ' 137' ' ' VAL . 3.8 ttmm -67.51 125.2 25.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.927 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.17 -0.919 . . . . 0.0 111.105 -179.985 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.818 0.342 . . . . 0.0 110.907 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -67.6 140.26 56.9 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.011 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 93.95 -21.51 41.37 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.58 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.43 176.28 0.65 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.851 0.358 . . . . 0.0 110.94 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -112.36 143.35 43.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.04 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.639 HG12 ' HA ' ' A' ' 183' ' ' LYS . 18.0 m -139.42 133.13 38.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.907 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.435 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 1.6 ttt180 -79.85 165.14 23.02 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.017 0.437 . . . . 0.0 110.94 -179.819 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 147' ' ' PHE . 4.4 t -80.03 169.08 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.904 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.619 HG23 ' H ' ' A' ' 141' ' ' SER . 0.8 OUTLIER -79.63 -65.97 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.805 -179.5 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.687 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 51.8 p -160.13 -165.52 1.49 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.823 0.344 . . . . 0.0 111.017 -179.78 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.61 -160.56 39.64 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.414 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.65 -13.42 39.82 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.613 2.209 . . . . 0.0 112.295 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.526 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.6 m-85 -106.97 20.49 18.97 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.164 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.687 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -81.13 38.91 0.49 Allowed 'General case' 0 C--N 1.331 -0.239 0 N-CA-C 112.3 0.481 . . . . 0.0 112.3 -179.377 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -160.97 36.49 0.15 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.88 0.371 . . . . 0.0 110.951 179.358 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.719 ' O ' HG23 ' A' ' 139' ' ' VAL . 48.0 m-85 -147.84 158.48 44.05 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.815 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.669 ' O ' HG12 ' A' ' 165' ' ' VAL . 58.2 p -118.93 169.2 10.08 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.792 179.869 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . 0.413 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -132.67 153.36 20.62 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.679 -179.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 2.7 m -101.81 107.72 18.99 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.819 0.343 . . . . 0.0 110.828 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 24.5 t -62.42 116.66 2.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.131 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 4.6 p -108.68 -57.2 2.17 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.859 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -113.23 155.99 24.08 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . 0.472 HG23 HG12 ' A' ' 161' ' ' VAL . 4.0 mp -142.31 141.72 28.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.172 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -123.65 101.29 36.88 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.812 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -69.23 -26.55 29.95 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.398 2.066 . . . . 0.0 112.438 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.57 -42.15 52.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.918 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 49.3 mtt-85 -87.43 -33.8 18.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.901 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 85.11 35.81 11.94 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.427 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . 0.533 ' O ' HG13 ' A' ' 161' ' ' VAL . 28.6 mttm -118.01 177.04 4.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.754 0.312 . . . . 0.0 110.857 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.576 HG11 ' CE1' ' A' ' 178' ' ' PHE . 6.1 m -158.94 121.49 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.166 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 80.5 tttt -84.87 132.75 34.35 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.822 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.413 ' HB ' ' HA3' ' A' ' 149' ' ' GLY . 33.8 m -139.67 138.67 39.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.144 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 12.6 ptm -90.67 113.84 26.0 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.669 HG12 ' O ' ' A' ' 148' ' ' THR . 27.4 m -115.46 156.91 16.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.171 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 16.7 p -105.98 142.52 35.54 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.719 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.811 HD13 ' O ' ' A' ' 167' ' ' ILE . 0.0 OUTLIER -103.77 -38.96 5.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.997 179.927 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -171.18 86.15 0.09 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.866 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 58.16 30.24 63.79 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.559 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -158.13 134.46 9.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.807 0.337 . . . . 0.0 110.925 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -67.96 155.89 38.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 3.4 m -159.96 93.71 1.66 Allowed Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.756 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -67.84 125.84 13.75 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.502 2.135 . . . . 0.0 112.294 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 7.4 m -139.38 139.02 39.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.3 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -79.87 126.49 31.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.344 179.524 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.904 HD13 HG13 ' A' ' 181' ' ' VAL . 6.8 mt -133.88 -170.99 2.62 Favored 'General case' 0 CA--C 1.516 -0.359 0 CA-C-O 121.388 0.613 . . . . 0.0 111.698 -179.345 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.453 ' O ' HG22 ' A' ' 181' ' ' VAL . 5.2 m-20 -144.36 155.7 43.91 Favored 'General case' 0 N--CA 1.442 -0.832 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.286 178.196 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . 0.576 ' CE1' HG11 ' A' ' 161' ' ' VAL . 10.7 m-85 -45.62 -41.74 10.51 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.577 -179.567 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 2.6 p -65.39 -15.88 63.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.373 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.779 ' CB ' HD22 ' A' ' 176' ' ' LEU . 4.0 mt-30 -103.78 -18.89 14.48 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.384 -179.689 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.904 HG13 HD13 ' A' ' 176' ' ' LEU . 11.0 m -120.75 173.05 6.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.922 0.392 . . . . 0.0 111.366 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 30.3 m -144.4 146.25 20.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.032 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.639 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -71.56 123.0 21.49 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.992 179.973 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.995 0 CA-C-O 118.324 -0.846 . . . . 0.0 111.061 179.977 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.769 0.318 . . . . 0.0 110.929 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -63.69 138.32 58.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.951 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 105.85 -22.4 31.9 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.613 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -57.41 156.16 8.26 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.818 0.342 . . . . 0.0 111.028 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 10.0 mt-30 -113.17 137.53 51.32 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.939 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.804 HG12 ' HA ' ' A' ' 183' ' ' LYS . 18.4 m -143.81 141.39 25.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.155 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.435 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 3.7 ttp180 -79.91 165.84 22.24 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.796 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.748 HG23 ' O ' ' A' ' 147' ' ' PHE . 7.6 t -80.1 167.22 2.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.116 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.624 HG13 ' H ' ' A' ' 141' ' ' SER . 2.6 p -79.35 -61.41 1.73 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.92 -179.395 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.677 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 2.6 m -160.35 -165.13 1.38 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.912 0.386 . . . . 0.0 111.138 -179.464 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.56 -165.85 50.32 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.334 179.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -62.15 -17.11 54.82 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.474 2.116 . . . . 0.0 112.02 179.659 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.587 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.7 m-85 -99.57 14.6 29.4 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.119 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.677 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -78.75 38.06 0.31 Allowed 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -179.234 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -160.89 36.6 0.15 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.88 0.371 . . . . 0.0 110.774 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.748 ' O ' HG23 ' A' ' 139' ' ' VAL . 16.2 m-85 -152.13 157.23 41.27 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.043 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.435 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 5.6 t -110.17 -176.02 2.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.636 179.823 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -154.89 140.41 7.38 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.539 -0.839 . . . . 0.0 112.779 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 12.2 m -94.16 110.19 21.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.754 0.311 . . . . 0.0 110.623 179.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.653 ' HA ' HG12 ' A' ' 163' ' ' VAL . 36.8 t -57.55 116.53 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.155 -179.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -111.45 -29.57 7.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.0 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -135.72 167.01 21.94 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.943 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 23.3 pt -145.59 133.27 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.167 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -117.19 81.18 12.78 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.803 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.44 -32.45 12.36 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.656 2.237 . . . . 0.0 112.224 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -59.74 -35.49 74.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.919 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -102.17 -33.98 9.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.927 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 99.16 43.87 2.5 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.45 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -139.76 156.12 46.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.934 0.397 . . . . 0.0 110.867 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.467 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.2 p -123.52 159.79 27.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.924 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . 0.467 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 13.0 ttpt -128.65 140.22 51.87 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.184 -179.753 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.928 HG22 HD11 ' A' ' 176' ' ' LEU . 34.6 m -139.84 -179.73 2.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.233 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -120.08 111.9 18.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.702 179.565 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.403 HG22 ' O ' ' A' ' 172' ' ' THR . 31.0 m -98.25 167.92 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.263 -179.773 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.16 79.56 1.7 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.821 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 30.9 mm -80.54 108.37 13.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.173 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 59.15 55.27 4.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.064 0.459 . . . . 0.0 110.928 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 57.53 41.48 93.48 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.571 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 6.1 ttt180 -137.51 106.32 5.92 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.803 0.335 . . . . 0.0 110.924 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -73.21 127.02 31.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.874 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . 0.403 ' O ' HG22 ' A' ' 165' ' ' VAL . 52.3 m -147.17 131.44 8.6 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.79 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -74.79 106.71 2.31 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.516 2.144 . . . . 0.0 112.415 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.443 HG13 ' O ' ' A' ' 174' ' ' VAL . 12.1 p -119.07 124.01 72.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.987 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 12.4 mt-10 -88.15 141.89 28.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.806 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.928 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -138.12 -162.55 1.32 Allowed 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 121.233 0.539 . . . . 0.0 111.151 -179.644 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.694 ' O ' HG22 ' A' ' 181' ' ' VAL . 0.3 OUTLIER -146.04 152.2 38.96 Favored 'General case' 0 N--CA 1.444 -0.762 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.207 178.404 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 -48.74 -37.04 17.72 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.432 -179.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 17.3 p -75.74 -9.54 58.68 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.56 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 23.5 mt-30 -118.58 21.14 12.72 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-O 120.603 0.239 . . . . 0.0 111.417 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.694 HG22 ' O ' ' A' ' 177' ' ' ASP . 17.6 m -152.92 146.5 14.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.891 0.377 . . . . 0.0 111.22 179.786 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 30.9 m -114.15 146.28 18.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.135 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.804 ' HA ' HG12 ' A' ' 137' ' ' VAL . 4.1 ttmt -80.92 137.28 36.13 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.955 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.065 0 CA-C-O 118.255 -0.879 . . . . 0.0 111.041 179.979 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.839 0.352 . . . . 0.0 110.843 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -69.21 141.25 54.54 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.835 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 89.29 -8.66 79.34 Favored Glycine 0 CA--C 1.519 0.339 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.724 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -56.87 164.14 1.67 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.826 0.346 . . . . 0.0 111.027 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -104.05 134.63 46.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.976 -179.867 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.735 HG12 ' HA ' ' A' ' 183' ' ' LYS . 21.0 m -141.66 131.54 24.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.886 179.839 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.414 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 3.4 ttp180 -79.78 164.28 23.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.013 0.435 . . . . 0.0 110.976 -180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.635 HG23 ' O ' ' A' ' 147' ' ' PHE . 3.7 t -79.96 168.55 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.86 -179.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.617 HG23 ' H ' ' A' ' 141' ' ' SER . 0.7 OUTLIER -79.6 -65.8 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.768 -179.518 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.716 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.3 OUTLIER -160.11 -164.57 1.31 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.768 0.318 . . . . 0.0 110.903 -179.835 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.36 -157.34 36.5 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.529 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -69.53 -10.23 28.2 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.558 2.172 . . . . 0.0 112.519 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.604 ' HB2' HG11 ' A' ' 139' ' ' VAL . 2.6 m-85 -110.46 19.54 18.67 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.201 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.716 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -78.86 37.85 0.31 Allowed 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -179.352 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . 0.406 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 1.5 p30 -161.08 36.0 0.14 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.893 0.378 . . . . 0.0 110.896 179.281 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.635 ' O ' HG23 ' A' ' 139' ' ' VAL . 44.0 m-85 -146.81 163.03 37.34 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.969 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.414 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 1.1 p -118.16 -177.07 3.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.771 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -147.47 142.95 10.68 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.526 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.7 m -99.7 103.71 15.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.779 0.324 . . . . 0.0 110.766 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.519 HG22 HG12 ' A' ' 163' ' ' VAL . 31.7 t -60.6 127.03 19.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.206 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.9 p -111.95 -33.98 6.12 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.858 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -136.01 157.7 46.21 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.874 179.883 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 25.9 pt -138.76 136.22 43.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.261 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -120.09 84.57 33.65 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.879 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -54.28 -26.44 43.19 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.535 2.157 . . . . 0.0 112.392 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -58.7 -73.3 0.08 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.907 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 7.2 mtt85 -80.01 -30.45 39.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.909 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 93.97 47.0 2.99 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.412 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -106.34 159.69 15.94 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.884 0.373 . . . . 0.0 110.872 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.504 HG11 ' HE1' ' A' ' 178' ' ' PHE . 5.2 m -143.16 116.94 3.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.15 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 19.1 tttp -90.78 111.23 22.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.826 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.614 HG22 ' CD1' ' A' ' 176' ' ' LEU . 33.8 m -119.24 148.71 22.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.163 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.5 ppp? -95.1 114.77 26.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.773 179.79 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.478 HG22 ' O ' ' A' ' 172' ' ' THR . 17.0 m -105.52 149.11 9.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.202 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 22.6 m -119.61 85.23 2.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.904 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.523 HG23 ' O ' ' A' ' 167' ' ' ILE . 1.7 tp -82.21 118.11 29.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.092 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 60.57 33.62 20.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.873 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 75.18 30.09 59.42 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.505 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.12 108.65 8.96 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.753 0.311 . . . . 0.0 110.981 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -59.95 139.91 57.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.807 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . 0.478 ' O ' HG22 ' A' ' 165' ' ' VAL . 53.8 m -154.12 109.56 2.46 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.913 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -67.45 100.67 0.58 Allowed 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.341 2.027 . . . . 0.0 112.157 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 11.9 p -108.45 129.01 63.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.286 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -90.63 123.39 34.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.614 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.614 ' CD1' HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -137.33 -159.52 0.96 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.43 0.633 . . . . 0.0 111.128 -179.712 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.456 ' HA ' HG22 ' A' ' 161' ' ' VAL . 7.5 m-20 -145.56 157.33 44.0 Favored 'General case' 0 N--CA 1.441 -0.875 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.055 178.21 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . 0.504 ' HE1' HG11 ' A' ' 161' ' ' VAL . 6.4 m-85 -44.24 -30.42 0.8 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.656 -179.631 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 35.5 t -67.25 -23.55 65.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.435 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.539 ' O ' HG13 ' A' ' 140' ' ' VAL . 22.6 mt-30 -101.83 -14.17 17.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.617 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 10.7 m -123.39 172.15 11.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-O 120.858 0.361 . . . . 0.0 111.461 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 32.9 m -146.39 146.2 19.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.164 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.735 ' HA ' HG12 ' A' ' 137' ' ' VAL . 9.9 mttt -66.0 125.74 26.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.943 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.273 -0.87 . . . . 0.0 111.075 179.994 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 2.0 ttm180 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.745 0.307 . . . . 0.0 110.98 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -59.66 120.16 8.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.939 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 121.71 -19.9 8.34 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.64 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -55.48 -178.85 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.824 0.345 . . . . 0.0 110.994 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 2.0 mt-30 -132.02 136.14 47.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.148 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.893 HG21 HG21 ' A' ' 181' ' ' VAL . 31.0 m -139.45 147.93 23.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.789 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -79.84 164.75 23.36 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.962 0.411 . . . . 0.0 111.022 -179.771 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.856 HG23 ' O ' ' A' ' 147' ' ' PHE . 39.7 t -79.8 149.35 5.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.433 -179.689 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 9.9 p -90.26 -20.36 6.99 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 115.991 -0.55 . . . . 0.0 112.181 -179.494 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.75 ' H ' HG12 ' A' ' 139' ' ' VAL . 0.4 OUTLIER -79.23 152.65 30.5 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.908 0.385 . . . . 0.0 111.145 -179.032 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . 0.407 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -65.5 -63.37 4.14 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.892 -179.793 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.407 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.6 Cg_endo -53.76 -22.7 24.07 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.7 2.266 . . . . 0.0 112.32 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.804 ' HB2' HG11 ' A' ' 139' ' ' VAL . 17.5 m-85 -110.36 1.99 18.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.365 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.651 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -70.31 49.68 0.11 Allowed 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -179.151 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -160.69 32.63 0.15 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.15 0.5 . . . . 0.0 110.465 179.093 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.856 ' O ' HG23 ' A' ' 139' ' ' VAL . 46.5 m-85 -157.23 145.77 19.58 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.533 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.444 ' O ' HG12 ' A' ' 165' ' ' VAL . 30.3 p -103.67 -179.26 3.9 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.865 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -144.71 141.98 10.52 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.619 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.4 m -93.38 107.41 19.24 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.714 0.293 . . . . 0.0 110.696 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.577 ' HA ' HG12 ' A' ' 163' ' ' VAL . 40.9 t -64.84 113.14 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.088 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 73.8 p -97.76 -46.4 5.98 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.763 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -124.69 167.48 14.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.848 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . 0.728 HG22 HG12 ' A' ' 161' ' ' VAL . 12.6 pt -146.49 160.14 10.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.203 -179.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 8.5 m-20 -132.24 89.71 36.55 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.923 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.15 -28.09 28.6 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.546 2.164 . . . . 0.0 112.289 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -62.49 -52.79 62.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.967 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.26 -49.43 5.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.905 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 115.44 52.23 0.41 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.574 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -125.88 170.15 11.94 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.864 0.364 . . . . 0.0 110.815 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.728 HG12 HG22 ' A' ' 154' ' ' ILE . 5.4 m -154.17 132.42 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.131 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 7.0 tttm -104.13 133.46 49.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.969 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.743 HG22 HD11 ' A' ' 176' ' ' LEU . 34.6 m -134.86 164.23 34.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.285 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 3.9 ptt? -106.7 120.55 42.27 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.808 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.444 HG12 ' O ' ' A' ' 148' ' ' THR . 16.9 m -117.51 157.56 18.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.13 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 23.6 m -142.37 105.81 4.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.974 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.1 mp -83.1 113.71 22.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.039 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 64.97 -77.71 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.971 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -154.47 44.23 0.57 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.448 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 5.2 ptt180 -148.24 115.27 6.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.883 0.373 . . . . 0.0 110.957 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -68.96 147.03 52.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.771 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 76.4 m -160.06 113.8 1.44 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.942 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -73.6 112.65 3.58 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.402 2.068 . . . . 0.0 112.141 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.5 t -119.41 124.4 72.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.225 -179.759 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -92.1 131.07 37.65 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.677 179.754 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.743 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -139.71 -161.65 1.22 Allowed 'General case' 0 CA--C 1.515 -0.385 0 CA-C-O 121.522 0.677 . . . . 0.0 111.259 -179.793 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.589 ' HA ' HG22 ' A' ' 161' ' ' VAL . 1.2 m-20 -138.06 161.29 37.14 Favored 'General case' 0 N--CA 1.439 -1.004 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.172 177.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . 0.48 ' HE1' HG11 ' A' ' 161' ' ' VAL . 3.4 m-85 -43.45 -38.51 2.85 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.693 -0.685 . . . . 0.0 112.554 -179.006 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.38 5.36 12.79 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.135 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.444 ' NE2' ' N ' ' A' ' 180' ' ' GLN . 1.2 mp0 -112.14 6.87 19.36 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.582 0.229 . . . . 0.0 111.407 -179.809 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.893 HG21 HG21 ' A' ' 137' ' ' VAL . 27.2 m -151.95 174.96 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 120.882 0.372 . . . . 0.0 111.289 -179.848 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 12.9 m -143.14 146.68 21.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.084 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.424 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.9 OUTLIER -60.82 123.27 17.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.926 -179.933 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.253 -0.88 . . . . 0.0 111.045 -179.96 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.894 0.378 . . . . 0.0 110.915 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.4 pp20? -59.56 122.25 13.58 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.926 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.68 15.97 25.49 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.709 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -69.66 157.25 37.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.761 0.315 . . . . 0.0 110.91 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -93.16 132.19 37.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.981 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.413 HG12 ' HA ' ' A' ' 183' ' ' LYS . 14.9 m -140.79 133.25 31.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.927 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.423 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.8 OUTLIER -79.82 166.38 21.77 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.912 0.387 . . . . 0.0 110.967 -179.907 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.655 HG23 ' O ' ' A' ' 147' ' ' PHE . 7.3 t -79.74 167.9 2.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.969 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.632 HG13 ' H ' ' A' ' 141' ' ' SER . 3.0 p -79.41 -61.47 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 -179.291 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.632 ' H ' HG13 ' A' ' 140' ' ' VAL . 39.6 p -160.45 -164.1 1.19 Allowed 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.766 0.317 . . . . 0.0 111.246 -179.675 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.86 -168.58 54.26 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.325 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -59.93 -18.56 50.54 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.541 2.161 . . . . 0.0 112.087 179.671 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.538 ' HB2' HG11 ' A' ' 139' ' ' VAL . 4.1 m-85 -97.04 16.8 18.55 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.094 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.539 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -80.58 39.44 0.47 Allowed 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 112.146 0.425 . . . . 0.0 112.146 -179.425 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . 0.416 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 8.3 t0 -160.74 34.69 0.15 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.979 0.419 . . . . 0.0 110.71 179.43 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.655 ' O ' HG23 ' A' ' 139' ' ' VAL . 24.3 m-85 -146.13 160.68 41.59 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.711 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.423 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 3.2 p -120.22 172.99 7.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.989 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -138.62 159.92 25.48 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.563 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.4 m -109.38 110.02 21.05 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.765 0.317 . . . . 0.0 110.796 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 31.6 t -60.2 99.84 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.113 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -90.95 -39.23 12.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.74 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -132.7 154.0 50.59 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.708 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . 0.995 HG22 HG12 ' A' ' 161' ' ' VAL . 32.9 pt -148.56 136.5 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.095 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -114.32 89.18 16.95 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.892 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.06 -26.26 37.14 Favored 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.545 2.164 . . . . 0.0 112.406 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -59.79 -32.31 70.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.851 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 27.4 mtt85 -113.87 -46.33 3.03 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.905 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 118.76 44.54 0.5 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.494 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . 0.436 ' O ' HG13 ' A' ' 161' ' ' VAL . 2.0 mmtt -119.26 166.13 13.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.769 0.318 . . . . 0.0 110.883 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.995 HG12 HG22 ' A' ' 154' ' ' ILE . 5.9 m -156.0 129.5 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.043 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -99.83 123.02 43.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.956 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 30.6 m -123.54 138.89 51.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.126 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -91.85 106.47 18.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.965 0.412 . . . . 0.0 110.796 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.505 ' CG2' HD11 ' A' ' 167' ' ' ILE . 13.5 m -90.14 167.0 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.096 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 3.4 m -130.16 92.76 3.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.911 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.505 HD11 ' CG2' ' A' ' 165' ' ' VAL . 4.1 mp -98.77 114.83 37.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.924 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 62.2 29.93 17.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 75.85 55.03 5.08 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.536 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -157.48 117.95 3.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.744 0.307 . . . . 0.0 111.0 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -65.94 121.18 14.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.819 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . 0.482 ' O ' HG22 ' A' ' 165' ' ' VAL . 23.5 m -130.64 89.78 42.56 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.962 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -68.17 101.35 0.7 Allowed 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.432 2.088 . . . . 0.0 112.231 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.738 ' CG2' HD21 ' A' ' 176' ' ' LEU . 28.3 m -110.32 138.74 36.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.155 -179.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . 0.433 ' O ' HD23 ' A' ' 176' ' ' LEU . 0.4 OUTLIER -80.02 117.96 21.32 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.559 179.615 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.738 HD21 ' CG2' ' A' ' 174' ' ' VAL . 0.3 OUTLIER -137.16 -159.76 0.99 Allowed 'General case' 0 CA--C 1.517 -0.323 0 CA-C-O 121.292 0.567 . . . . 0.0 111.15 -179.622 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.501 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.9 OUTLIER -150.71 154.88 38.22 Favored 'General case' 0 N--CA 1.442 -0.848 0 CA-C-N 115.232 -0.894 . . . . 0.0 110.151 178.399 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -46.61 -28.88 1.59 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.546 -179.731 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.9 p -67.6 -14.44 62.94 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.339 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.404 ' O ' HG13 ' A' ' 181' ' ' VAL . 5.3 mt-30 -116.88 10.15 14.04 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.515 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.438 HG12 ' HA ' ' A' ' 139' ' ' VAL . 31.4 m -156.99 150.39 9.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.807 0.337 . . . . 0.0 111.224 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . 0.489 HG12 ' H ' ' A' ' 183' ' ' LYS . 0.3 OUTLIER -121.29 173.72 6.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.898 179.958 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.489 ' H ' HG12 ' A' ' 182' ' ' VAL . 0.1 OUTLIER -75.85 150.3 37.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.956 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.995 0 CA-C-O 118.224 -0.893 . . . . 0.0 111.115 -179.998 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.063 0 CA-C-O 120.89 0.376 . . . . 0.0 110.824 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -65.07 135.42 55.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.846 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.82 -26.03 13.47 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.58 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -60.17 166.49 2.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.752 0.31 . . . . 0.0 110.912 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -112.7 130.38 56.08 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.989 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 19.5 m -134.27 141.94 42.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.946 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.9 166.19 21.9 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.967 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.563 HG12 ' H ' ' A' ' 140' ' ' VAL . 4.2 t -79.77 169.18 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.014 -179.861 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.665 HG13 ' H ' ' A' ' 141' ' ' SER . 2.1 p -79.18 -64.76 0.86 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 CA-C-N 116.566 -0.288 . . . . 0.0 111.773 -179.451 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.665 ' H ' HG13 ' A' ' 140' ' ' VAL . 0.2 OUTLIER -160.42 -163.55 1.11 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.811 0.339 . . . . 0.0 111.096 -179.642 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.37 -164.71 49.63 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.518 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -62.83 -16.39 53.29 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.495 2.13 . . . . 0.0 112.173 179.725 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.474 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.5 m-85 -102.59 20.17 17.65 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.083 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.649 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -82.49 39.85 0.62 Allowed 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 111.98 0.363 . . . . 0.0 111.98 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -160.81 35.97 0.15 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.927 0.394 . . . . 0.0 110.781 179.447 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.494 ' O ' HG23 ' A' ' 139' ' ' VAL . 19.2 m-85 -146.16 172.3 13.64 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.793 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.449 ' O ' HG12 ' A' ' 165' ' ' VAL . 33.8 p -122.55 -172.12 2.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.877 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -156.64 144.02 10.31 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.626 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.6 m -93.04 105.82 17.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.841 0.353 . . . . 0.0 110.845 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.586 ' HA ' HG12 ' A' ' 163' ' ' VAL . 25.1 t -61.9 137.74 23.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.403 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 65.4 p -119.88 -49.06 2.33 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.69 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -128.72 159.64 35.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.871 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mp -142.43 132.18 22.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.13 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -104.61 108.96 62.17 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.75 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -74.2 -44.05 0.48 Allowed 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.432 2.088 . . . . 0.0 112.409 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -65.4 -44.64 86.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.017 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 1.5 mtt180 -83.97 -41.08 17.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.894 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 89.49 36.72 7.31 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.336 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 24.6 mtpt -117.62 177.6 4.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.759 0.314 . . . . 0.0 110.941 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.554 HG23 HG13 ' A' ' 151' ' ' VAL . 1.3 p -159.91 159.57 2.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.09 0.471 . . . . 0.0 111.054 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . 0.469 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 20.3 tttm -127.53 133.3 49.83 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.799 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.825 HG22 HD11 ' A' ' 176' ' ' LEU . 18.3 m -139.17 160.16 29.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.177 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 12.5 ptp -102.29 116.22 32.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.603 179.706 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.449 HG12 ' O ' ' A' ' 148' ' ' THR . 15.5 m -107.62 160.26 6.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.362 -179.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 6.9 t -152.1 135.26 15.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.722 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.1 mp -91.8 -67.0 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.131 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -148.52 87.13 1.56 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.832 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 70.24 25.69 75.28 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.455 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 4.4 ttm180 -148.76 112.51 5.09 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.872 0.368 . . . . 0.0 110.889 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -89.46 157.39 18.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.836 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 65.1 m -160.11 112.39 1.42 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.969 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -71.72 121.18 7.43 Favored 'Trans proline' 0 C--N 1.347 0.46 0 C-N-CA 122.438 2.092 . . . . 0.0 112.117 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 27.4 m -128.08 142.79 42.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.362 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -93.28 127.85 39.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.672 179.791 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.825 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -137.45 -159.87 1.0 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.324 0.583 . . . . 0.0 111.203 -179.769 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.406 ' O ' ' N ' ' A' ' 180' ' ' GLN . 0.1 OUTLIER -149.47 154.11 38.31 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 115.103 -0.953 . . . . 0.0 110.269 178.447 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 31.0 m-85 -43.99 -28.57 0.48 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.862 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.09 8.12 7.81 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 111.865 0.32 . . . . 0.0 111.865 -179.791 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.406 ' N ' ' O ' ' A' ' 177' ' ' ASP . 9.9 mt-30 -131.05 9.25 4.84 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.601 0.238 . . . . 0.0 111.27 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 5.6 m -141.85 174.69 6.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 120.751 0.31 . . . . 0.0 111.089 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 17.3 m -147.55 154.49 11.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.132 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.25 134.02 44.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.899 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.267 -0.873 . . . . 0.0 111.092 -179.937 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.778 0.323 . . . . 0.0 110.872 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -62.48 139.42 58.58 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.833 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 97.34 -24.61 30.69 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.567 -179.987 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -58.0 -168.59 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.737 0.304 . . . . 0.0 111.009 -179.947 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 5.1 mm-40 -135.27 138.64 43.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.084 -179.907 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.513 ' HB ' ' O ' ' A' ' 182' ' ' VAL . 27.1 m -136.93 157.5 35.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.913 179.911 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.451 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 1.0 OUTLIER -90.49 165.93 13.52 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.944 0.402 . . . . 0.0 110.883 179.904 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.814 HG23 ' O ' ' A' ' 147' ' ' PHE . 5.2 t -79.95 168.31 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.046 -179.914 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.67 HG13 ' H ' ' A' ' 141' ' ' SER . 1.7 p -79.25 -65.41 0.78 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.778 -179.544 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.71 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 4.0 m -160.24 -164.43 1.27 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.849 0.357 . . . . 0.0 111.082 -179.552 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.53 -160.53 41.75 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.446 179.989 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -67.46 -11.6 32.73 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.421 2.08 . . . . 0.0 112.406 179.689 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.534 ' HB2' HG11 ' A' ' 139' ' ' VAL . 4.2 m-85 -107.92 19.67 19.74 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.105 -179.997 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.71 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -80.53 37.51 0.41 Allowed 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 112.197 0.443 . . . . 0.0 112.197 -179.467 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -161.08 35.6 0.14 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.996 0.427 . . . . 0.0 110.836 179.423 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.814 ' O ' HG23 ' A' ' 139' ' ' VAL . 8.6 m-85 -146.55 153.86 40.86 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.646 -179.892 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.624 ' O ' HG12 ' A' ' 165' ' ' VAL . 44.4 p -103.01 -179.91 4.09 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.816 -179.957 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -143.12 149.37 21.3 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.541 -0.838 . . . . 0.0 112.661 -179.818 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 16.2 m -95.73 102.69 14.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.831 0.348 . . . . 0.0 110.654 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.708 ' HA ' HG12 ' A' ' 163' ' ' VAL . 46.4 t -59.98 116.67 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.059 -179.917 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 3.3 p -97.02 -47.12 5.92 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.828 179.973 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -138.84 158.51 44.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.86 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 32.0 mt -131.08 141.57 45.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.198 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.4 m-20 -121.86 100.79 43.05 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.67 179.969 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -63.58 -55.62 0.67 Allowed 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.613 2.209 . . . . 0.0 112.43 -179.765 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -57.54 -43.75 84.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.414 -179.662 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 1.9 tpm_? -79.97 -26.2 40.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.154 -179.728 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 69.69 31.07 70.4 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.313 -179.902 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 20.0 mttt -111.7 165.17 12.27 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.78 0.324 . . . . 0.0 111.0 -179.902 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.627 HG22 ' HA ' ' A' ' 177' ' ' ASP . 6.9 m -147.3 126.34 4.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.006 179.907 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 3.5 ttmt -101.2 127.86 47.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.021 -179.899 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.708 HG12 ' HA ' ' A' ' 151' ' ' VAL . 18.8 m -141.74 149.47 19.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.218 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . 0.443 ' O ' ' HG3' ' A' ' 164' ' ' MET . 0.0 OUTLIER -98.52 120.66 39.33 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.843 179.687 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.624 HG12 ' O ' ' A' ' 148' ' ' THR . 31.2 m -107.05 153.99 8.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.347 -179.685 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . 0.411 HG22 ' HA ' ' A' ' 171' ' ' GLU . 0.7 OUTLIER -122.14 147.92 45.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.773 179.888 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 2.0 mp -102.85 -62.73 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.08 -179.973 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.3 59.51 1.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.881 -179.915 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 98.21 -20.76 49.22 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.575 -179.972 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 4.0 ttt180 -97.79 127.73 43.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.788 0.328 . . . . 0.0 110.975 -179.924 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . 0.411 ' HA ' HG22 ' A' ' 166' ' ' THR . 0.1 OUTLIER -84.24 155.13 22.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.856 179.968 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 42.1 m -157.79 101.11 1.81 Allowed Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.88 179.888 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -67.36 113.64 2.96 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.453 2.102 . . . . 0.0 112.192 -179.997 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.4 t -128.9 150.94 35.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.151 -179.931 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.99 157.34 26.84 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.754 179.949 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.849 HD22 HG13 ' A' ' 181' ' ' VAL . 1.0 OUTLIER -154.78 -171.06 3.71 Favored 'General case' 0 CA--C 1.516 -0.348 0 CA-C-O 121.26 0.552 . . . . 0.0 111.164 -179.963 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.627 ' HA ' HG22 ' A' ' 161' ' ' VAL . 3.5 m-20 -150.14 152.97 35.55 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.462 178.421 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -46.86 -45.19 20.14 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.388 -179.815 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 9.2 t -79.52 -1.53 38.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.531 -179.85 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.626 ' HB3' HD23 ' A' ' 176' ' ' LEU . 1.2 mt-30 -112.41 7.41 19.13 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.581 -0.281 . . . . 0.0 111.392 -179.84 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.849 HG13 HD22 ' A' ' 176' ' ' LEU . 23.2 m -136.23 178.58 4.86 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.927 0.394 . . . . 0.0 111.274 179.933 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . 0.513 ' O ' ' HB ' ' A' ' 137' ' ' VAL . 0.4 OUTLIER -133.34 -150.58 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.346 -179.965 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -122.52 138.86 54.43 Favored 'General case' 0 C--N 1.331 -0.197 0 O-C-N 122.176 -0.327 . . . . 0.0 111.0 -179.918 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.044 0 CA-C-O 118.166 -0.921 . . . . 0.0 111.098 179.864 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 44.4 mtm180 . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.934 0.397 . . . . 0.0 110.923 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -56.67 155.92 6.99 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.803 -179.939 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.55 8.21 59.49 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.86 -179.856 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.34 179.1 0.23 Allowed 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.801 0.334 . . . . 0.0 110.789 179.893 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 10.7 mt-30 -139.92 133.32 30.01 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.116 -179.859 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.587 HG12 ' HA ' ' A' ' 183' ' ' LYS . 23.1 m -142.49 146.18 22.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.774 179.88 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.464 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.5 OUTLIER -79.72 167.12 21.07 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 121.039 0.447 . . . . 0.0 111.172 -179.829 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.894 HG23 ' O ' ' A' ' 147' ' ' PHE . 20.3 t -79.75 152.27 4.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.366 -179.571 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 14.7 p -92.47 -24.42 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 CA-C-N 116.082 -0.508 . . . . 0.0 112.148 -179.326 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.669 ' O ' ' HB2' ' A' ' 145' ' ' ALA . 9.8 m -79.4 153.89 29.39 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.888 0.375 . . . . 0.0 111.274 -178.952 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . 0.435 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -66.13 -61.48 5.44 Favored Glycine 0 CA--C 1.519 0.312 0 C-N-CA 121.046 -0.597 . . . . 0.0 112.777 -179.86 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.435 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.6 Cg_endo -52.82 -23.85 21.99 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.581 2.188 . . . . 0.0 112.278 179.885 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.828 ' HB2' HG11 ' A' ' 139' ' ' VAL . 17.4 m-85 -111.6 2.64 17.43 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.281 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.669 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -70.22 50.02 0.11 Allowed 'General case' 0 C--O 1.233 0.218 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -179.163 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . 0.402 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 5.7 t70 -160.68 32.21 0.15 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.045 0.45 . . . . 0.0 110.399 179.134 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.894 ' O ' HG23 ' A' ' 139' ' ' VAL . 65.8 m-85 -155.24 146.2 22.52 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.376 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.765 ' O ' HG12 ' A' ' 165' ' ' VAL . 19.3 p -103.38 170.63 7.83 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.372 -0.377 . . . . 0.0 111.004 -179.853 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . 0.404 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -126.77 130.12 6.84 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.593 -179.969 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.3 m -92.22 106.21 18.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.759 0.314 . . . . 0.0 110.892 -179.99 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.452 HG22 HG12 ' A' ' 163' ' ' VAL . 20.2 t -63.79 106.79 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.936 179.928 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . 0.433 HG21 ' HE2' ' A' ' 162' ' ' LYS . 1.6 t -88.12 -30.67 19.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.878 -179.933 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -158.71 162.79 37.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.898 179.947 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.8 mt -126.12 130.46 72.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.126 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 70.6 m-20 -102.7 95.33 6.12 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.834 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.34 -34.93 11.78 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.409 2.073 . . . . 0.0 112.328 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -66.73 -31.44 72.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.942 -180.0 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -96.39 -43.6 7.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.898 -179.921 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 96.73 38.71 4.34 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.401 -179.889 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.4 mttm -135.1 175.61 9.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.888 0.375 . . . . 0.0 110.996 -179.974 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.665 HG11 ' CE1' ' A' ' 178' ' ' PHE . 5.2 m -136.59 127.78 42.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.002 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . 0.433 ' HE2' HG21 ' A' ' 152' ' ' THR . 18.0 tttt -87.3 111.75 21.37 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.847 -179.958 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.452 HG12 HG22 ' A' ' 151' ' ' VAL . 31.4 m -124.13 148.58 28.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.296 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 12.5 ptm -102.01 120.09 39.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.833 179.97 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.765 HG12 ' O ' ' A' ' 148' ' ' THR . 18.5 m -124.2 136.6 59.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.896 0.379 . . . . 0.0 111.213 -179.984 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 2.7 m -95.55 142.49 27.83 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.778 179.85 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.457 HG13 ' O ' ' A' ' 167' ' ' ILE . 3.8 tp -117.17 42.08 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.1 0.476 . . . . 0.0 110.95 -179.942 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER 63.99 99.18 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.847 179.877 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 125.8 -48.79 0.94 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.434 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 8.6 ptt180 -160.07 160.03 32.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.844 0.354 . . . . 0.0 110.894 179.948 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -66.67 166.23 13.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.82 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -154.65 90.03 3.15 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.967 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -68.42 102.54 0.84 Allowed 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.502 2.134 . . . . 0.0 112.255 179.938 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.502 HG22 HG22 ' A' ' 165' ' ' VAL . 34.8 m -119.1 137.97 51.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.114 -179.966 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -79.84 120.88 24.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.494 179.57 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.82 HD13 HG13 ' A' ' 181' ' ' VAL . 7.6 mt -124.31 -170.55 2.16 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.341 0.591 . . . . 0.0 111.504 -179.395 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.476 ' HA ' HG22 ' A' ' 161' ' ' VAL . 5.0 m-20 -143.08 155.5 44.62 Favored 'General case' 0 N--CA 1.442 -0.848 0 CA-C-N 114.996 -1.002 . . . . 0.0 110.197 178.129 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . 0.665 ' CE1' HG11 ' A' ' 161' ' ' VAL . 9.6 m-85 -48.54 -30.86 5.71 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.509 -179.606 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -79.86 -0.32 34.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.463 179.955 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.765 ' CB ' HD22 ' A' ' 176' ' ' LEU . 30.7 mt-30 -119.59 5.51 11.06 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.609 -0.268 . . . . 0.0 111.316 -179.964 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.82 HG13 HD13 ' A' ' 176' ' ' LEU . 5.3 m -143.46 179.69 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.879 0.371 . . . . 0.0 111.212 179.97 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 23.9 m -152.68 146.61 15.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.016 179.958 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.587 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.1 OUTLIER -63.42 125.93 25.78 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.908 -179.977 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.001 0 CA-C-O 118.201 -0.904 . . . . 0.0 111.002 -179.952 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 51.1 ttt-85 . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.732 0.301 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -59.85 117.82 5.47 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.923 179.978 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.615 ' HA2' HG22 ' A' ' 150' ' ' THR . . . 107.19 16.36 13.66 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.831 -0.7 . . . . 0.0 112.756 179.998 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -76.41 158.63 31.2 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.86 0.362 . . . . 0.0 110.81 179.948 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . 0.47 HE21 HG21 ' A' ' 148' ' ' THR . 0.9 OUTLIER -101.17 128.26 47.36 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.957 -179.992 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.934 HG12 ' HA ' ' A' ' 183' ' ' LYS . 11.3 m -141.61 135.87 30.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.814 179.965 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.426 ' CZ ' ' HB2' ' A' ' 138' ' ' ARG . 0.7 OUTLIER -79.79 162.95 24.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.943 0.402 . . . . 0.0 110.873 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.58 HG11 ' HB2' ' A' ' 144' ' ' PHE . 4.9 t -79.88 167.85 2.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.947 -179.84 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.638 HG13 ' H ' ' A' ' 141' ' ' SER . 2.4 p -79.35 -61.95 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.276 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.898 -179.264 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.686 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.1 OUTLIER -160.23 -164.57 1.29 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.734 0.302 . . . . 0.0 111.216 -179.581 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.46 -164.15 49.0 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.368 179.972 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -63.27 -16.08 52.26 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.383 2.056 . . . . 0.0 112.146 179.666 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.58 ' HB2' HG11 ' A' ' 139' ' ' VAL . 2.6 m-85 -101.31 15.73 27.85 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.185 179.956 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.686 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -78.48 37.26 0.27 Allowed 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 112.411 0.523 . . . . 0.0 112.411 -179.345 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . 0.414 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 1.9 t0 -161.11 32.8 0.14 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.033 0.444 . . . . 0.0 110.78 179.146 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.518 ' CE2' HG22 ' A' ' 167' ' ' ILE . 22.8 m-85 -140.77 170.06 16.47 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.616 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.47 HG21 HE21 ' A' ' 136' ' ' GLN . 3.1 p -118.05 -179.38 3.74 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.799 179.934 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -150.36 138.67 6.83 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.592 -179.978 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . 0.615 HG22 ' HA2' ' A' ' 134' ' ' GLY . 3.3 m -97.82 107.49 20.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.777 0.322 . . . . 0.0 110.851 179.833 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.624 ' HA ' HG12 ' A' ' 163' ' ' VAL . 23.5 t -55.52 115.7 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.236 -179.822 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.87 -33.19 8.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.877 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -144.56 157.82 44.04 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.839 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mp -141.1 129.45 23.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.15 179.993 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -100.5 98.58 8.25 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.779 -179.943 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.4 -43.26 2.22 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.527 2.152 . . . . 0.0 112.347 -179.984 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -78.39 -38.65 41.23 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.881 -179.901 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.0 -34.88 38.15 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.859 -179.901 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 80.59 67.31 1.56 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.48 -179.992 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 30.7 mttm -152.05 173.39 14.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.798 0.333 . . . . 0.0 110.933 -179.978 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.806 ' O ' HD12 ' A' ' 176' ' ' LEU . 4.1 m -149.34 122.3 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.02 179.943 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 36.0 ttmt -104.61 135.31 46.25 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.997 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 1.029 HG22 HD11 ' A' ' 176' ' ' LEU . 33.9 m -138.76 163.47 27.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.104 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -103.12 111.43 23.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.611 179.722 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.438 HG22 HG12 ' A' ' 174' ' ' VAL . 28.5 m -101.86 167.65 2.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.173 -179.803 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 1.5 m -131.11 125.11 32.25 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.872 -179.959 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.518 HG22 ' CE2' ' A' ' 147' ' ' PHE . 1.5 pp -149.09 138.76 15.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.124 179.879 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 62.41 30.29 17.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.774 -179.947 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 64.78 42.57 97.04 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.532 -179.926 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 66.4 mtp180 -157.17 137.96 13.28 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.809 0.338 . . . . 0.0 110.894 -179.984 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 15.5 mp0 -81.51 127.05 32.42 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.735 179.864 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.17 115.21 11.84 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.041 -179.866 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.37 113.19 3.53 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.483 2.122 . . . . 0.0 112.075 179.889 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.438 HG12 HG22 ' A' ' 165' ' ' VAL . 10.7 p -123.69 136.55 59.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.259 -179.834 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -80.49 146.86 31.15 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.68 179.742 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 1.029 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -137.78 -165.05 1.71 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.385 0.612 . . . . 0.0 111.313 -179.721 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.7 ' O ' HG22 ' A' ' 181' ' ' VAL . 5.4 m-20 -152.84 155.31 36.86 Favored 'General case' 0 N--CA 1.446 -0.643 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.923 178.392 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -47.63 -40.89 20.74 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.517 -179.668 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 18.2 p -78.82 -2.32 39.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.734 -179.799 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 79.5 mt-30 -120.23 9.25 11.02 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.574 0.226 . . . . 0.0 111.519 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.7 HG22 ' O ' ' A' ' 177' ' ' ASP . 22.7 m -146.02 165.01 9.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.85 0.357 . . . . 0.0 111.196 179.943 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.0 m -143.8 146.46 20.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.048 179.911 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.934 ' HA ' HG12 ' A' ' 137' ' ' VAL . 4.9 tttt -65.85 137.36 57.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.022 179.949 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.204 -0.903 . . . . 0.0 111.139 -179.981 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.927 0.394 . . . . 0.0 110.794 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -69.33 135.95 51.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.892 179.929 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 67.18 21.26 71.83 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.609 179.933 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -78.69 163.47 25.4 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.776 0.322 . . . . 0.0 110.801 179.979 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 35.1 mt-30 -103.16 125.21 49.75 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.052 -179.907 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.666 HG12 ' HA ' ' A' ' 183' ' ' LYS . 31.5 m -134.73 144.13 35.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.968 179.974 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.427 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.82 167.3 20.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.936 0.398 . . . . 0.0 110.887 179.978 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.781 HG23 ' O ' ' A' ' 147' ' ' PHE . 7.6 t -79.82 168.0 2.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.92 -179.932 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.659 HG13 ' H ' ' A' ' 141' ' ' SER . 2.7 p -79.54 -62.82 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 112.001 0.371 . . . . 0.0 112.001 -179.193 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.659 ' H ' HG13 ' A' ' 140' ' ' VAL . 0.3 OUTLIER -160.4 -164.15 1.21 Allowed 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.87 0.367 . . . . 0.0 111.105 -179.622 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 78.7 -167.1 52.66 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.94 -0.647 . . . . 0.0 112.456 179.89 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -61.93 -17.25 54.66 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.422 2.082 . . . . 0.0 112.094 179.699 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.49 ' HB2' HG11 ' A' ' 139' ' ' VAL . 4.3 m-85 -98.6 20.28 13.15 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.141 179.886 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.475 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -82.6 39.87 0.63 Allowed 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.496 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -160.77 36.22 0.15 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.998 0.428 . . . . 0.0 110.605 179.406 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.868 ' CZ ' HG22 ' A' ' 167' ' ' ILE . 26.4 m-85 -148.18 160.22 43.15 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.682 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.481 ' O ' HG12 ' A' ' 165' ' ' VAL . 7.3 p -109.47 -178.12 3.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.852 179.894 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . 0.422 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -147.85 140.07 8.19 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.609 -179.848 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.9 m -97.0 109.19 22.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.737 0.304 . . . . 0.0 110.957 179.99 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 17.5 t -64.47 101.96 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.259 -179.989 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.36 -33.74 15.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.799 179.854 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -139.83 150.12 44.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.979 179.965 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 16.5 mt -130.99 136.77 57.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.067 -179.969 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -127.83 86.16 58.94 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.759 179.963 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.61 -37.49 7.08 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.515 2.144 . . . . 0.0 112.374 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -59.84 -42.87 94.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.859 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.3 -38.52 16.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.824 179.947 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 97.32 43.37 3.0 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.621 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -139.1 159.12 42.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.859 0.362 . . . . 0.0 110.865 -179.961 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.447 ' CG2' ' CE1' ' A' ' 178' ' ' PHE . 6.1 t -131.05 157.62 43.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.001 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . 0.411 ' N ' HG12 ' A' ' 161' ' ' VAL . 22.2 tttm -122.07 108.29 13.19 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.943 -179.992 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.422 ' HB ' ' HA3' ' A' ' 149' ' ' GLY . 31.0 m -123.38 146.55 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.263 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 15.0 ptp -99.39 123.49 43.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.687 179.9 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.481 HG12 ' O ' ' A' ' 148' ' ' THR . 17.0 m -115.25 158.11 15.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.318 -179.893 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . 0.407 HG23 ' HA ' ' A' ' 171' ' ' GLU . 1.2 m -137.61 125.45 22.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.758 179.973 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.868 HG22 ' CZ ' ' A' ' 147' ' ' PHE . 1.8 pp -130.15 147.07 33.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.128 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 62.82 -79.91 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.973 -179.996 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -167.73 36.21 0.22 Allowed Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.446 -179.926 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 6.4 mmt85 -153.19 133.29 13.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.748 0.309 . . . . 0.0 110.936 179.972 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . 0.407 ' HA ' HG23 ' A' ' 166' ' ' THR . 1.1 tt0 -81.05 137.82 36.01 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.758 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 9.3 m -141.86 103.44 5.78 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.061 -179.88 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -72.09 114.44 3.98 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.475 2.117 . . . . 0.0 112.167 179.785 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.3 t -125.38 144.97 33.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.37 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -80.02 136.63 36.64 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.671 179.936 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.916 HD13 HG13 ' A' ' 181' ' ' VAL . 5.6 mt -133.05 -168.04 2.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.063 0.459 . . . . 0.0 111.329 -179.843 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -142.33 151.83 42.34 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.603 178.382 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . 0.447 ' CE1' ' CG2' ' A' ' 161' ' ' VAL . 20.7 m-85 -47.8 -38.2 15.25 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.502 -179.608 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.4 m -82.05 11.46 5.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.558 179.978 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.813 ' HB3' HD22 ' A' ' 176' ' ' LEU . 4.3 mp0 -120.74 3.49 10.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.668 -0.242 . . . . 0.0 111.28 179.922 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.916 HG13 HD13 ' A' ' 176' ' ' LEU . 2.9 m -144.08 177.69 2.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-O 120.858 0.361 . . . . 0.0 111.301 -179.957 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 27.8 m -143.32 146.42 21.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.116 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.666 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.6 OUTLIER -71.4 128.62 36.46 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.95 179.954 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.139 -0.934 . . . . 0.0 111.055 -179.991 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 8.2 mtt180 . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.775 0.322 . . . . 0.0 110.904 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -59.49 141.05 55.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.87 -179.976 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 90.96 -14.3 63.78 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.759 -179.852 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -61.34 174.0 0.79 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.825 0.345 . . . . 0.0 110.966 -179.962 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -112.76 143.09 44.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.895 -179.854 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.706 HG12 ' HA ' ' A' ' 183' ' ' LYS . 15.6 m -140.18 138.66 37.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.991 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.427 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.94 166.45 21.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.826 0.346 . . . . 0.0 110.945 179.973 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.568 HG12 ' H ' ' A' ' 140' ' ' VAL . 3.4 t -79.78 169.19 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.892 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.739 HG22 ' OG ' ' A' ' 141' ' ' SER . 2.1 p -79.48 -65.35 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.814 -179.413 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.739 ' OG ' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -160.44 -163.48 1.1 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.859 0.361 . . . . 0.0 111.102 -179.65 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.27 -165.28 50.28 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.419 179.908 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -61.7 -17.74 56.39 Favored 'Trans proline' 0 C--N 1.343 0.248 0 C-N-CA 122.481 2.12 . . . . 0.0 112.124 179.74 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.457 ' HB2' HG11 ' A' ' 139' ' ' VAL . 2.0 m-85 -102.15 22.04 13.88 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.978 179.947 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.625 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -83.29 38.95 0.63 Allowed 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.133 0.42 . . . . 0.0 112.133 -179.436 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -160.8 36.5 0.15 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.914 0.388 . . . . 0.0 110.771 179.4 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.418 ' O ' HG23 ' A' ' 139' ' ' VAL . 22.0 m-85 -141.35 172.99 11.93 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.645 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.429 ' O ' HG12 ' A' ' 165' ' ' VAL . 0.2 OUTLIER -125.0 171.01 10.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.99 179.986 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -137.12 136.2 8.15 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.504 -179.988 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 2.8 m -89.31 100.87 13.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.846 0.355 . . . . 0.0 110.81 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.619 ' HA ' HG12 ' A' ' 163' ' ' VAL . 21.5 t -58.9 115.04 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.267 -179.92 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 73.7 p -102.1 -32.28 10.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.842 179.954 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -151.91 160.2 43.59 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.942 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 6.5 pt -133.19 145.6 33.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.052 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -130.15 72.23 81.98 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.967 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -59.3 -29.04 89.23 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.614 2.209 . . . . 0.0 112.323 -179.939 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -57.98 -52.25 66.28 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.947 -179.928 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 3.2 tpm_? -90.82 -39.11 12.53 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.89 -179.966 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 105.9 41.81 1.77 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.432 179.975 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 30.7 mttp -131.29 158.71 39.92 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.768 0.318 . . . . 0.0 110.79 179.946 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.481 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.3 p -141.48 159.76 21.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 121.116 0.484 . . . . 0.0 110.91 -179.902 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . 0.481 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 25.6 ttmt -123.7 129.18 50.71 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.969 179.825 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.837 ' CG2' HD12 ' A' ' 176' ' ' LEU . 18.4 m -145.18 140.44 22.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.115 -179.933 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.09 133.68 33.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.795 179.857 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.429 HG12 ' O ' ' A' ' 148' ' ' THR . 15.5 m -124.91 167.85 18.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.174 -179.998 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -117.43 151.06 37.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.963 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.564 HD13 ' HB2' ' A' ' 168' ' ' PHE . 0.0 OUTLIER -157.18 119.16 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.947 -179.953 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . 0.564 ' HB2' HD13 ' A' ' 167' ' ' ILE . 0.3 OUTLIER 61.01 30.39 19.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.728 -179.867 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 77.6 31.68 49.26 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.47 179.961 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 17.9 mtm180 -142.25 144.39 33.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.895 0.378 . . . . 0.0 110.841 -179.897 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -80.9 148.95 29.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.831 179.867 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . 0.653 ' O ' HG23 ' A' ' 174' ' ' VAL . 68.5 m -154.82 91.9 2.93 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.064 179.973 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -58.74 104.27 0.18 Allowed 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.529 2.153 . . . . 0.0 112.157 179.998 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.653 HG23 ' O ' ' A' ' 172' ' ' THR . 21.5 t -122.18 142.23 39.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.162 -179.94 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -79.91 159.56 26.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.866 179.849 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.852 HD13 ' CG1' ' A' ' 181' ' ' VAL . 4.9 mt -147.5 -171.38 3.78 Favored 'General case' 0 CA--C 1.516 -0.347 0 CA-C-O 121.266 0.555 . . . . 0.0 111.223 -179.636 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.542 ' O ' HG22 ' A' ' 181' ' ' VAL . 1.5 m-20 -145.11 153.29 41.25 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.415 178.102 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 30.2 m-85 -48.38 -41.64 29.44 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.333 -179.708 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.7 m -78.51 -2.14 37.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.343 -179.959 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.404 ' HB3' ' CD2' ' A' ' 176' ' ' LEU . 4.8 mt-30 -116.84 6.58 13.16 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.594 -0.276 . . . . 0.0 111.345 -179.787 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.852 ' CG1' HD13 ' A' ' 176' ' ' LEU . 27.4 m -142.75 -179.44 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.959 0.409 . . . . 0.0 111.271 -179.91 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 12.6 m -155.34 146.5 12.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.977 179.956 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.706 ' HA ' HG12 ' A' ' 137' ' ' VAL . 4.0 tmtt? -72.38 138.26 47.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.968 -179.955 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.086 0 CA-C-O 118.256 -0.878 . . . . 0.0 111.151 179.997 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.877 0.37 . . . . 0.0 110.854 . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -60.13 128.6 37.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.981 179.906 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 121.97 -24.92 6.93 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.529 -179.962 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -59.31 169.81 1.1 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.816 0.341 . . . . 0.0 110.882 -179.887 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -124.94 136.21 53.54 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.059 -179.921 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.784 HG12 ' HA ' ' A' ' 183' ' ' LYS . 12.6 m -140.52 145.21 26.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.723 179.924 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.401 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.81 163.76 24.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.034 0.445 . . . . 0.0 111.125 -179.801 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.832 HG11 ' HB2' ' A' ' 144' ' ' PHE . 46.7 t -79.77 147.44 6.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.548 -179.672 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 12.5 p -86.27 -21.83 7.39 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 CA-C-N 116.02 -0.536 . . . . 0.0 112.35 -179.555 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.756 ' H ' HG12 ' A' ' 139' ' ' VAL . 1.7 m -79.18 152.83 30.47 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.939 0.4 . . . . 0.0 111.475 -178.783 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . 0.427 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -66.74 -61.79 5.03 Favored Glycine 0 C--N 1.332 0.34 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.699 -179.811 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.427 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.2 Cg_endo -53.41 -23.56 24.78 Favored 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.548 2.166 . . . . 0.0 112.083 179.853 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.832 ' HB2' HG11 ' A' ' 139' ' ' VAL . 9.2 m-85 -110.73 2.66 18.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.375 179.751 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.66 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -70.36 48.99 0.11 Allowed 'General case' 0 C--N 1.332 -0.193 0 N-CA-C 112.448 0.536 . . . . 0.0 112.448 -179.074 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . 0.464 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 16.4 p-10 -160.44 29.91 0.16 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.172 0.511 . . . . 0.0 110.49 179.116 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.682 ' O ' HG23 ' A' ' 139' ' ' VAL . 15.2 m-85 -150.44 147.97 28.18 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.183 179.741 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.401 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 69.6 p -102.25 168.58 9.26 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.798 0.333 . . . . 0.0 110.708 179.888 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -128.86 129.05 6.03 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.634 -0.793 . . . . 0.0 112.539 -179.865 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.7 m -86.76 105.83 17.25 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.739 0.305 . . . . 0.0 110.73 179.886 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.474 HG13 HG23 ' A' ' 161' ' ' VAL . 30.2 t -62.76 117.78 4.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.083 -179.862 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -93.04 -46.35 7.5 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.925 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -144.89 152.68 40.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.864 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mt -112.58 148.37 15.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.128 -179.951 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -119.24 84.01 26.77 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.85 -179.974 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -72.93 -37.88 3.31 Favored 'Trans proline' 0 C--N 1.343 0.27 0 C-N-CA 122.571 2.181 . . . . 0.0 112.303 179.969 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -60.13 -55.1 38.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.835 -179.93 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 12.6 ttt-85 -79.9 -67.11 0.79 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.004 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 129.92 59.49 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.498 -179.953 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 5.5 mtmm -155.64 -179.09 7.78 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.801 0.334 . . . . 0.0 110.84 -179.953 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.48 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.2 p -154.44 159.81 2.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.896 179.915 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . 0.48 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 10.8 tttt -124.15 127.75 48.24 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.932 -179.9 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.449 HG12 ' HA ' ' A' ' 151' ' ' VAL . 16.7 m -136.16 156.65 36.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.183 -179.991 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 16.4 ptm -106.54 120.02 40.83 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.004 179.93 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.752 ' O ' HG22 ' A' ' 172' ' ' THR . 2.6 t -117.62 153.83 19.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.102 -179.956 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . 0.408 HG23 ' C ' ' A' ' 170' ' ' ARG . 2.3 m -100.8 142.82 31.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.935 179.918 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.561 ' C ' HD13 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -159.78 -46.29 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.147 179.972 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . 0.5 ' N ' HG23 ' A' ' 167' ' ' ILE . 5.0 p90 -97.58 35.25 1.69 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.973 179.965 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 96.48 -30.98 7.94 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.448 -179.912 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . 0.408 ' C ' HG23 ' A' ' 166' ' ' THR . 0.0 OUTLIER -130.63 177.34 7.46 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.894 0.378 . . . . 0.0 110.691 179.953 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -69.51 168.26 15.0 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.881 -179.939 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . 0.752 HG22 ' O ' ' A' ' 165' ' ' VAL . 11.5 t -148.05 124.73 5.49 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.829 -179.914 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -71.77 97.36 0.81 Allowed 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.427 2.084 . . . . 0.0 112.331 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.522 HG23 HG23 ' A' ' 172' ' ' THR . 10.5 t -121.67 132.86 69.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.164 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -79.91 124.41 28.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.124 179.436 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.821 HD12 ' HB3' ' A' ' 180' ' ' GLN . 1.8 mm? -127.41 -170.08 2.16 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.322 0.582 . . . . 0.0 111.639 -179.164 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.428 ' HA ' HG12 ' A' ' 161' ' ' VAL . 0.4 OUTLIER -142.38 152.98 43.39 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.394 178.342 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -42.5 -58.42 2.26 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.607 -179.596 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 6.0 t -56.28 -23.0 33.64 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.241 179.998 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.821 ' HB3' HD12 ' A' ' 176' ' ' LEU . 5.4 mp0 -89.57 3.88 51.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.638 -179.837 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.42 HG22 ' O ' ' A' ' 177' ' ' ASP . 16.5 m -147.44 167.95 4.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.811 0.339 . . . . 0.0 111.166 179.967 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.4 m -145.08 146.19 20.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.1 179.872 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.784 ' HA ' HG12 ' A' ' 137' ' ' VAL . 1.5 tttp -61.68 136.68 58.09 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.825 -179.822 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.246 -0.883 . . . . 0.0 111.036 179.986 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 12.7 tpp180 . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.82 0.343 . . . . 0.0 110.876 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -61.54 144.76 53.79 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.861 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 96.71 -23.6 34.6 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.573 -179.988 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -57.34 163.79 2.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.906 0.384 . . . . 0.0 111.017 -179.994 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . 0.444 ' NE2' HG23 ' A' ' 150' ' ' THR . 33.0 mm-40 -121.06 139.14 53.72 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.969 -179.918 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.7 HG12 ' HA ' ' A' ' 183' ' ' LYS . 20.9 m -137.01 140.76 42.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.82 179.989 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.477 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.7 162.85 24.95 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.027 0.441 . . . . 0.0 111.002 -179.934 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.867 HG11 ' HB2' ' A' ' 144' ' ' PHE . 37.6 t -79.88 151.46 4.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.409 -179.627 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.512 HG13 ' C ' ' A' ' 180' ' ' GLN . 34.3 m -93.1 -21.29 6.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 112.4 0.518 . . . . 0.0 112.4 -179.216 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.697 ' H ' HG12 ' A' ' 139' ' ' VAL . 4.5 m -79.18 153.87 29.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.792 0.33 . . . . 0.0 111.315 -179.013 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . 0.423 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -65.12 -62.56 4.82 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 121.058 -0.591 . . . . 0.0 113.006 -179.664 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.423 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.4 Cg_endo -52.81 -23.17 19.84 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.685 2.257 . . . . 0.0 112.379 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.867 ' HB2' HG11 ' A' ' 139' ' ' VAL . 10.2 m-85 -112.62 2.65 16.27 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.471 179.982 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.689 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -70.11 48.39 0.1 Allowed 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -179.117 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -160.72 32.39 0.15 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.13 0.49 . . . . 0.0 110.631 179.109 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.733 ' O ' HG23 ' A' ' 139' ' ' VAL . 42.5 m-85 -154.87 145.59 22.38 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.469 179.946 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.718 ' O ' HG12 ' A' ' 165' ' ' VAL . 67.8 p -99.88 -177.58 3.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.908 -179.879 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -139.85 129.12 4.16 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.596 -179.838 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . 0.444 HG23 ' NE2' ' A' ' 136' ' ' GLN . 3.0 m -90.05 113.83 25.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.742 0.306 . . . . 0.0 110.68 179.754 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 21.7 t -70.71 120.83 19.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.305 -179.726 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -108.84 -31.75 7.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.713 179.643 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -153.95 161.35 42.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.705 179.824 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.6 mp -134.21 152.43 34.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.331 -179.966 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 -123.17 90.89 50.21 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.806 179.932 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.15 -34.04 13.99 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.613 2.209 . . . . 0.0 112.357 -179.893 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -90.14 18.14 6.25 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.338 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 31.2 ttt85 -138.07 -46.01 0.52 Allowed 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.808 0.337 . . . . 0.0 110.791 179.936 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 99.19 39.82 3.42 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.392 179.962 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 16.3 mtmt -146.18 170.5 16.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.815 0.34 . . . . 0.0 111.086 -179.979 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.475 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.0 OUTLIER -149.43 159.59 5.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.118 0.485 . . . . 0.0 110.795 179.918 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . 0.475 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 59.6 tttp -105.21 121.61 44.2 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.967 179.993 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 5.6 m -134.95 134.76 53.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.176 -179.982 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 7.6 ptm -93.55 135.43 34.82 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.841 179.954 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.718 HG12 ' O ' ' A' ' 148' ' ' THR . 27.6 m -134.25 149.76 30.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.217 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . 0.404 ' O ' ' CD2' ' A' ' 147' ' ' PHE . 3.8 m -113.26 110.57 20.59 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.809 -180.0 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.711 HD13 ' HB2' ' A' ' 168' ' ' PHE . 0.0 OUTLIER -97.32 113.83 32.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.075 179.985 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . 0.711 ' HB2' HD13 ' A' ' 167' ' ' ILE . 0.7 OUTLIER 59.52 43.26 16.33 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.894 -179.782 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 66.41 30.68 77.01 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.459 -179.922 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -129.86 124.55 33.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.743 0.306 . . . . 0.0 110.899 -179.905 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.85 126.08 26.18 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.725 179.957 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 2.0 m -150.66 89.68 4.37 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.127 -179.8 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -72.76 125.57 10.64 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.517 2.145 . . . . 0.0 112.104 179.81 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . 0.532 HG22 HG22 ' A' ' 165' ' ' VAL . 5.3 m -134.24 136.58 53.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.317 -179.866 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 3.3 pm0 -79.88 126.64 31.26 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.964 179.209 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.783 HD13 HG13 ' A' ' 181' ' ' VAL . 7.0 mt -127.62 -170.08 2.17 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.395 0.617 . . . . 0.0 111.772 -179.131 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.434 ' HA ' HG12 ' A' ' 161' ' ' VAL . 0.5 OUTLIER -141.33 154.59 45.77 Favored 'General case' 0 N--CA 1.442 -0.868 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.357 178.162 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -48.49 -31.14 5.97 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.366 -179.551 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.2 m -79.47 1.2 26.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.574 179.998 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.751 ' CB ' HD22 ' A' ' 176' ' ' LEU . 0.0 OUTLIER -122.12 10.7 10.08 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.652 0.263 . . . . 0.0 111.401 -179.798 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.783 HG13 HD13 ' A' ' 176' ' ' LEU . 14.4 m -149.35 159.14 5.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.944 0.402 . . . . 0.0 111.272 -179.989 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.0 m -123.27 146.48 28.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.048 179.985 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.7 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -71.79 120.46 17.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.864 -179.931 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.267 -0.873 . . . . 0.0 111.082 -179.942 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.789 0.328 . . . . 0.0 110.942 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -65.67 134.35 53.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.846 179.872 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 98.36 -2.83 59.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.845 -179.958 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -58.54 167.68 1.38 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.912 0.387 . . . . 0.0 110.897 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.27 116.93 29.78 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.028 179.999 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.714 HG12 ' HA ' ' A' ' 183' ' ' LYS . 30.1 m -123.17 138.76 52.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.833 179.932 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.4 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.99 161.9 25.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.956 0.408 . . . . 0.0 111.142 -179.899 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.579 HG12 ' N ' ' A' ' 140' ' ' VAL . 39.8 t -104.21 167.05 2.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.559 179.702 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.822 HG22 ' O ' ' A' ' 180' ' ' GLN . 16.2 m -138.04 -9.88 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 N-CA-C 113.001 0.741 . . . . 0.0 113.001 -178.874 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.461 ' O ' ' CD2' ' A' ' 144' ' ' PHE . 1.1 m -79.5 142.61 35.66 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.996 0.427 . . . . 0.0 111.761 -178.946 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 35.78 -139.83 0.24 Allowed Glycine 0 C--N 1.335 0.511 0 CA-C-N 115.67 -0.695 . . . . 0.0 113.656 179.523 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -74.3 3.86 4.87 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.691 2.261 . . . . 0.0 112.682 179.761 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.496 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 0.1 OUTLIER -79.57 -10.03 59.73 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.635 -0.257 . . . . 0.0 111.055 179.831 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.455 ' HA ' ' O ' ' A' ' 139' ' ' VAL . . . -68.52 41.84 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -178.996 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . 0.431 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 0.8 OUTLIER -160.95 32.78 0.15 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.056 0.455 . . . . 0.0 110.654 179.167 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.431 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 55.8 m-85 -151.7 164.41 37.01 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.582 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.609 ' O ' HG12 ' A' ' 165' ' ' VAL . 80.6 p -118.73 162.86 17.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.734 179.849 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -130.79 163.48 23.35 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.693 -179.847 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.6 m -103.24 103.35 13.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.766 0.317 . . . . 0.0 110.661 179.964 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.672 ' HA ' HG12 ' A' ' 163' ' ' VAL . 46.4 t -60.31 112.61 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.975 -179.935 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -101.81 -42.62 6.09 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.79 179.906 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -120.1 150.97 39.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.794 179.841 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 12.5 pt -143.31 124.14 10.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.154 179.984 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -117.3 86.61 21.99 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.896 -179.993 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -72.52 -20.22 23.89 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.555 2.17 . . . . 0.0 112.516 -179.938 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.38 25.65 2.18 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.389 -179.94 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 2.2 tpm_? -160.0 -45.06 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.772 0.32 . . . . 0.0 110.838 179.979 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 104.04 61.69 0.68 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.459 179.896 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 17.2 mtpt -154.18 149.6 27.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.813 0.34 . . . . 0.0 110.998 179.963 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.671 HG22 ' HA ' ' A' ' 177' ' ' ASP . 26.9 m -147.21 154.04 11.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.18 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 12.6 ttpt -127.13 129.61 48.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.907 -179.952 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.72 HG22 ' CD1' ' A' ' 176' ' ' LEU . 34.9 m -136.6 145.68 29.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.23 179.928 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -89.43 113.32 24.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.459 179.824 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.609 HG12 ' O ' ' A' ' 148' ' ' THR . 20.9 m -123.19 159.76 26.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.359 -179.696 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . 0.546 HG22 ' HA ' ' A' ' 171' ' ' GLU . 17.2 p -111.55 139.25 47.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.785 179.869 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.805 HD13 ' O ' ' A' ' 167' ' ' ILE . 0.0 OUTLIER -93.32 -36.38 7.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.04 -179.874 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 10.5 t80 -172.82 78.54 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.982 179.996 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 68.44 28.22 73.35 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.425 -179.93 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -156.72 124.28 5.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.728 0.299 . . . . 0.0 110.88 -179.995 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . 0.546 ' HA ' HG22 ' A' ' 166' ' ' THR . 67.8 mt-10 -61.08 154.61 22.44 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.788 179.905 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 25.4 m -160.08 89.84 1.82 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.146 -179.925 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -66.13 105.02 0.78 Allowed 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.615 2.21 . . . . 0.0 111.82 179.766 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 31.0 m -118.5 149.39 20.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.349 -179.716 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -89.14 135.91 33.31 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.731 179.759 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.72 ' CD1' HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -146.98 -161.12 1.26 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.397 0.617 . . . . 0.0 110.936 -179.709 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.686 ' O ' HG22 ' A' ' 181' ' ' VAL . 0.8 OUTLIER -151.85 153.2 33.73 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.379 178.474 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . 0.634 ' CE1' HG11 ' A' ' 161' ' ' VAL . 23.1 m-85 -42.36 -30.58 0.34 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.677 -179.654 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.4 m -69.57 -39.31 77.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.115 -179.963 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.822 ' O ' HG22 ' A' ' 140' ' ' VAL . 33.3 mt-30 -88.93 8.76 27.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.499 -179.724 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.686 HG22 ' O ' ' A' ' 177' ' ' ASP . 5.4 m -145.72 179.53 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.791 0.329 . . . . 0.0 111.165 179.903 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.6 m -145.09 147.07 19.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.167 179.975 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.714 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.1 OUTLIER -78.3 130.83 36.67 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.887 179.937 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.169 -0.919 . . . . 0.0 111.08 179.977 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.839 0.352 . . . . 0.0 111.028 . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -71.53 120.73 17.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.851 179.909 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 115.59 -14.96 17.49 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.671 -179.919 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -56.26 174.07 0.15 Allowed 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.795 0.331 . . . . 0.0 110.979 -179.921 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.73 140.67 51.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.95 -179.992 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.594 HG12 ' HA ' ' A' ' 183' ' ' LYS . 19.9 m -144.58 139.79 23.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.021 -179.959 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . 0.405 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.97 163.1 24.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.955 0.407 . . . . 0.0 110.945 179.865 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.918 HG11 ' HB2' ' A' ' 144' ' ' PHE . 21.7 t -79.83 156.08 4.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 115.848 -0.615 . . . . 0.0 111.576 -179.659 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.511 HG13 ' C ' ' A' ' 180' ' ' GLN . 33.7 m -96.64 -26.19 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 N-CA-C 112.424 0.528 . . . . 0.0 112.424 -179.135 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.688 ' O ' ' HB2' ' A' ' 145' ' ' ALA . 91.1 p -79.13 155.18 28.83 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.833 0.349 . . . . 0.0 111.401 -178.706 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . 0.454 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -64.82 -60.77 6.52 Favored Glycine 0 CA--C 1.52 0.346 0 CA-C-N 115.957 -0.565 . . . . 0.0 113.063 -179.581 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . 0.454 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 7.8 Cg_endo -50.11 -24.84 11.79 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.671 2.248 . . . . 0.0 112.507 -179.793 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.918 ' HB2' HG11 ' A' ' 139' ' ' VAL . 7.4 m-85 -115.77 4.52 14.0 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.468 -179.974 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.688 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -69.81 45.21 0.07 Allowed 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -178.809 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . 0.412 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 11.8 p-10 -160.69 32.19 0.15 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.032 0.444 . . . . 0.0 110.53 178.929 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.815 ' O ' HG23 ' A' ' 139' ' ' VAL . 64.6 m-85 -153.67 145.3 23.31 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.648 179.891 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.479 ' O ' HG12 ' A' ' 165' ' ' VAL . 1.8 p -102.39 175.73 5.42 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.744 179.863 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . 0.427 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -138.47 141.32 11.89 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.685 -179.9 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 4.6 m -93.56 109.84 21.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.837 0.351 . . . . 0.0 110.747 -179.999 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 16.4 t -68.65 96.84 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.054 179.902 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -81.39 -30.83 33.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.799 179.988 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -154.33 157.29 38.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.817 179.942 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.6 pt -128.62 172.98 14.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.196 179.987 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 -147.59 87.62 5.91 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.847 179.994 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.97 -33.63 15.43 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.584 2.19 . . . . 0.0 112.258 -179.974 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -68.92 -42.75 76.37 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.95 179.878 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 23.4 mmt180 -89.38 -61.87 1.6 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.913 179.982 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 120.54 57.12 0.24 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.488 179.954 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -145.0 173.01 12.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.804 0.335 . . . . 0.0 110.803 -179.973 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.614 HG22 ' HA ' ' A' ' 177' ' ' ASP . 31.1 m -153.98 118.36 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.056 179.892 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -79.85 113.87 18.34 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.712 -179.95 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.427 ' HB ' ' HA3' ' A' ' 149' ' ' GLY . 32.1 m -126.1 141.22 46.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.32 -179.756 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 5.1 ptm -101.68 117.16 34.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.925 179.934 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.479 HG12 ' O ' ' A' ' 148' ' ' THR . 15.8 m -108.56 -179.62 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.008 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.66 116.9 10.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.943 -179.837 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . 0.857 HD12 ' OG1' ' A' ' 172' ' ' THR . 2.4 mp -120.94 128.39 76.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.93 179.832 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . 0.442 ' CD1' HG22 ' A' ' 167' ' ' ILE . 4.6 m-85 61.3 34.46 18.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.966 179.887 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 65.7 51.44 46.99 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.598 179.947 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 2.5 ttt85 -160.06 128.09 4.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.837 0.351 . . . . 0.0 110.952 179.96 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -58.69 129.11 40.52 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.926 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . 0.857 ' OG1' HD12 ' A' ' 167' ' ' ILE . 0.2 OUTLIER -133.83 85.85 40.11 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.996 -179.932 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -68.67 109.42 2.08 Favored 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.488 2.125 . . . . 0.0 112.028 179.723 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.6 t -126.39 141.11 46.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.344 -179.741 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.93 118.67 21.9 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.181 179.434 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.598 HD23 ' HB3' ' A' ' 180' ' ' GLN . 1.2 mp -119.94 -170.39 1.95 Allowed 'General case' 0 CA--C 1.515 -0.376 0 CA-C-O 121.406 0.622 . . . . 0.0 111.63 -179.178 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.614 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.6 OUTLIER -142.89 155.37 44.73 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 114.911 -1.04 . . . . 0.0 110.004 178.016 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . 0.437 ' CE1' HG11 ' A' ' 161' ' ' VAL . 15.6 m-85 -47.14 -30.22 2.73 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.457 -179.533 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 83.6 p -80.08 2.65 23.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.686 -179.89 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.598 ' HB3' HD23 ' A' ' 176' ' ' LEU . 3.7 mt-30 -122.38 3.21 9.72 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-O 120.642 0.258 . . . . 0.0 111.361 180.0 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.528 HG13 ' CD2' ' A' ' 176' ' ' LEU . 11.3 m -139.97 169.63 16.09 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 120.765 0.317 . . . . 0.0 111.384 179.913 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 18.5 m -148.51 146.69 17.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.05 179.942 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.594 ' HA ' HG12 ' A' ' 137' ' ' VAL . 75.2 tttt -57.68 122.53 13.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.093 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.373 -0.822 . . . . 0.0 110.987 -179.962 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 6.2 ttt85 . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.843 0.354 . . . . 0.0 110.844 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -61.54 138.59 58.29 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.885 -179.951 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 108.74 -22.75 25.44 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.68 -179.9 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -57.08 165.03 1.42 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.827 0.346 . . . . 0.0 110.951 -179.974 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -107.85 143.69 36.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.877 -179.935 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.78 HG12 ' HA ' ' A' ' 183' ' ' LYS . 25.4 m -139.92 143.09 30.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.165 179.994 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.47 165.63 13.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.052 0.453 . . . . 0.0 110.955 179.939 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.898 HG23 ' O ' ' A' ' 147' ' ' PHE . 4.2 t -80.18 169.47 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.968 -179.921 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.603 HG23 ' H ' ' A' ' 141' ' ' SER . 0.1 OUTLIER -80.02 -71.49 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 116.525 -0.307 . . . . 0.0 111.393 -179.945 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.603 ' H ' HG23 ' A' ' 140' ' ' VAL . 0.1 OUTLIER -160.5 -163.52 1.1 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.96 -179.699 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.91 -160.54 41.01 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.457 179.842 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -57.94 -20.85 46.65 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.507 2.138 . . . . 0.0 111.976 179.786 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.545 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 1.5 m-85 -110.77 41.6 1.76 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.666 179.859 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.514 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -90.15 31.52 0.99 Allowed 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -179.424 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -161.26 38.69 0.14 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.284 179.492 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.898 ' O ' HG23 ' A' ' 139' ' ' VAL . 23.2 m-85 -134.72 154.18 51.68 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.002 0.429 . . . . 0.0 111.183 -179.758 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . 0.628 ' O ' HG12 ' A' ' 165' ' ' VAL . 31.4 p -118.23 171.86 7.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.446 179.722 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -144.66 155.89 26.6 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.362 -0.923 . . . . 0.0 112.905 -179.785 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 14.0 m -103.31 105.45 15.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.782 0.325 . . . . 0.0 110.781 179.743 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.734 ' HA ' HG12 ' A' ' 163' ' ' VAL . 48.8 t -58.48 118.13 2.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.108 -179.925 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 35.1 p -102.21 -46.67 4.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.852 179.977 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -125.98 157.87 36.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.912 179.985 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.9 mp -139.99 139.13 37.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.123 179.879 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -121.62 85.12 43.5 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.91 179.996 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.99 -28.35 13.13 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.531 2.154 . . . . 0.0 112.383 -179.917 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -69.84 -32.56 71.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.94 -179.953 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.75 -59.57 1.75 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.949 179.942 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 123.06 66.86 0.22 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.532 -179.994 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 43.7 mttp -148.46 163.48 37.03 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.804 0.335 . . . . 0.0 110.878 179.978 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.646 HG22 ' HA ' ' A' ' 177' ' ' ASP . 15.6 m -151.04 138.53 13.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.112 179.896 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 16.4 tttp -118.12 126.23 51.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.868 -179.985 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.842 HG22 HD11 ' A' ' 176' ' ' LEU . 33.5 m -135.94 149.01 27.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.275 -179.96 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . 0.4 ' O ' ' CG ' ' A' ' 164' ' ' MET . 10.5 ptt? -90.04 111.53 22.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.598 179.791 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.628 HG12 ' O ' ' A' ' 148' ' ' THR . 31.1 m -114.69 137.43 48.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.359 -179.851 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 5.5 t -92.22 136.94 32.78 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.575 179.774 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 18.5 tt -83.82 -29.26 7.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.069 -179.909 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -178.23 38.92 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.85 -179.976 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 124.13 -25.88 5.96 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.48 -179.973 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.14 122.68 45.82 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.865 0.364 . . . . 0.0 110.821 -179.967 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -63.1 121.01 12.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.99 179.933 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 53.9 m -117.57 100.4 52.59 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.824 -179.9 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -66.54 111.1 2.01 Favored 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 122.344 2.029 . . . . 0.0 112.215 -179.958 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 38.3 t -127.17 141.7 45.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.105 -179.773 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -86.63 138.11 31.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.626 179.736 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.842 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -148.15 -162.27 1.52 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.282 0.563 . . . . 0.0 111.298 -179.65 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.646 ' HA ' HG22 ' A' ' 161' ' ' VAL . 1.4 m-20 -146.15 157.02 43.82 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 115.067 -0.97 . . . . 0.0 109.896 178.213 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . 0.47 ' CE1' HG11 ' A' ' 161' ' ' VAL . 19.6 m-85 -47.0 -28.54 1.68 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.694 -179.503 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 40.7 t -75.76 -5.97 48.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.592 -179.902 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.513 ' O ' HG22 ' A' ' 140' ' ' VAL . 3.1 mm-40 -114.97 -6.95 12.57 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.599 -0.273 . . . . 0.0 111.449 -179.907 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.459 ' CG1' HD22 ' A' ' 176' ' ' LEU . 30.2 m -142.7 158.66 18.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 120.829 0.347 . . . . 0.0 111.331 -179.98 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 22.6 m -117.79 146.57 22.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.076 -179.984 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.78 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -86.19 129.58 34.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.921 -179.962 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.175 -0.917 . . . . 0.0 111.194 -179.991 . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 19.3 mtp180 . . . . . 0 C--O 1.232 0.163 0 CA-C-O 120.776 0.322 . . . . 4.75 110.931 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -59.53 118.69 6.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.302 -0.408 . . . . 2.4900000000000002 110.818 179.926 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 128.57 -21.2 5.41 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.823 -0.703 . . . . 0.84999999999999998 112.627 -179.921 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -55.37 164.74 0.9 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.821 0.343 . . . . 1.6899999999999999 110.929 -179.995 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 64.7 mt-30 -117.26 114.82 24.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.457 . . . . 2.5600000000000001 111.06 -179.977 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.647 HG12 ' HA ' ' A' ' 183' ' ' LYS . 16.9 m -118.61 141.95 35.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.57999999999999996 110.822 179.894 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -79.68 166.69 21.57 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.994 0.426 . . . . 2.7000000000000002 111.028 -179.773 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 139' ' ' VAL . . . . . 0.524 HG12 ' N ' ' A' ' 140' ' ' VAL . 8.7 t -79.52 167.39 2.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.935 -0.575 . . . . 0.79000000000000004 110.995 -179.901 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.636 HG13 ' H ' ' A' ' 141' ' ' SER . 2.8 p -78.87 -61.46 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.296 0 N-CA-C 112.052 0.39 . . . . 1.7 112.052 -179.289 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 141' ' ' SER . . . . . 0.636 ' H ' HG13 ' A' ' 140' ' ' VAL . 0.9 OUTLIER -160.83 -163.98 1.14 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.807 0.337 . . . . 3.04 111.29 -179.652 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.53 -169.35 54.75 Favored Glycine 0 C--N 1.331 0.284 0 C-N-CA 120.875 -0.679 . . . . 1.8300000000000001 112.357 179.958 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -59.14 -19.34 48.83 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.507 2.138 . . . . 1.6299999999999999 111.998 179.672 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.512 ' HB2' HG11 ' A' ' 139' ' ' VAL . 4.1 m-85 -95.98 18.37 13.5 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.16 -0.473 . . . . 1.6699999999999999 111.065 179.939 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.488 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -82.05 40.4 0.62 Allowed 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 112.058 0.392 . . . . 1.0900000000000001 112.058 -179.453 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . 0.403 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 0.5 OUTLIER -161.4 35.6 0.14 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.98 0.419 . . . . 2.4199999999999999 110.692 179.493 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 147' ' ' PHE . . . . . 0.518 ' O ' HG23 ' A' ' 139' ' ' VAL . 36.6 m-85 -146.82 169.76 18.44 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.929 -0.578 . . . . 1.5900000000000001 110.783 179.994 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 12.7 p -122.31 -178.43 3.88 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.264 -0.425 . . . . 0.88 110.874 179.943 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -145.49 134.74 5.62 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.648 -0.787 . . . . 0.62 112.549 -179.927 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.8 m -87.96 104.8 16.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.751 0.31 . . . . 0.75 110.817 179.893 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.695 ' HA ' HG12 ' A' ' 163' ' ' VAL . 43.6 t -64.21 121.18 12.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.239 -0.437 . . . . 0.66000000000000003 111.059 -179.967 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 14.9 p -107.37 -39.88 5.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.162 -0.472 . . . . 1.22 110.907 179.91 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -130.72 159.33 37.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.189 -0.459 . . . . 2.3199999999999998 110.855 179.922 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 26.9 mt -136.36 135.44 49.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.266 -0.425 . . . . 1.78 111.125 -179.968 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -115.83 86.31 15.98 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.108 -0.496 . . . . 1.8799999999999999 110.907 179.997 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.61 -30.43 18.35 Favored 'Trans proline' 0 C--N 1.345 0.343 0 C-N-CA 122.53 2.153 . . . . 1.8300000000000001 112.327 179.994 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -63.1 -42.67 99.63 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.191 -0.459 . . . . 3.6299999999999999 110.889 -179.996 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 3.6 mtt85 -96.09 -52.29 4.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.17 -0.468 . . . . 3.9199999999999999 110.845 -179.954 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 116.71 39.2 0.85 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.768 -0.729 . . . . 1.28 112.469 -179.948 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 15.0 mttt -120.65 168.98 10.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.818 0.342 . . . . 2.0299999999999998 110.959 179.97 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.71 HG11 ' CE1' ' A' ' 178' ' ' PHE . 19.4 m -150.72 125.47 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 1.28 111.065 179.983 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 68.6 tttt -94.83 130.07 41.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.126 -0.488 . . . . 1.8899999999999999 110.922 -179.989 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.695 HG12 ' HA ' ' A' ' 151' ' ' VAL . 17.2 m -140.48 163.23 23.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.457 . . . . 0.93000000000000005 111.087 -179.97 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 3.2 ptt? -109.51 116.93 32.69 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 1.8899999999999999 110.954 179.914 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 165' ' ' VAL . . . . . 0.567 HG22 ' O ' ' A' ' 172' ' ' THR . 6.9 m -96.45 163.95 2.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 1.1299999999999999 111.025 -179.997 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.13 106.25 9.13 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 1.6000000000000001 110.99 -179.964 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 5.2 mt -110.0 109.19 27.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.137 -0.483 . . . . 2.2400000000000002 110.97 179.94 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 62.38 47.28 5.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.194 -0.457 . . . . 4.3700000000000001 110.935 -179.958 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 61.01 50.8 63.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.727 -0.749 . . . . 1.51 112.551 179.986 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 12.2 ttt180 -153.72 129.34 10.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.819 0.343 . . . . 5.0 110.957 179.965 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 -71.15 145.62 49.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 2.5899999999999999 110.865 -179.924 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 172' ' ' THR . . . . . 0.567 ' O ' HG22 ' A' ' 165' ' ' VAL . 4.1 m -159.96 92.44 1.72 Allowed Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.116 -0.493 . . . . 1.28 110.828 179.951 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -67.42 119.62 6.64 Favored 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.451 2.101 . . . . 0.94999999999999996 112.326 -179.952 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.5 t -132.21 139.11 50.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 1.6299999999999999 111.047 179.969 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 175' ' ' GLU . . . . . 0.515 ' C ' HD23 ' A' ' 176' ' ' LEU . 4.6 pt-20 -80.76 119.88 23.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.446 . . . . 2.46 110.869 -179.976 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 176' ' ' LEU . . . . . 0.523 HD12 HG11 ' A' ' 181' ' ' VAL . 0.2 OUTLIER -125.02 -162.46 1.1 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.368 0.604 . . . . 1.6399999999999999 110.916 -179.979 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 177' ' ' ASP . . . . . 0.624 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.6 OUTLIER -152.73 152.75 32.03 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 115.168 -0.923 . . . . 1.49 110.221 178.405 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 178' ' ' PHE . . . . . 0.71 ' CE1' HG11 ' A' ' 161' ' ' VAL . 17.1 m-85 -44.99 -29.53 0.85 Allowed 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.925 -0.58 . . . . 1.8600000000000001 111.56 -179.726 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 60.1 m -72.25 -33.21 67.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.327 -0.397 . . . . 1.6799999999999999 111.096 -179.826 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 38.1 mt-30 -97.2 18.2 15.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.354 -0.384 . . . . 2.1600000000000001 111.337 -179.895 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 177' ' ' ASP . 32.4 m -151.79 164.51 2.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.843 0.354 . . . . 0.77000000000000002 111.113 179.891 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 23.1 m -139.83 149.96 22.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 0.88 111.123 179.907 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 183' ' ' LYS . . . . . 0.647 ' HA ' HG12 ' A' ' 137' ' ' VAL . 8.2 tttt -73.41 129.97 39.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 2.98 110.867 179.973 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.111 0 CA-C-O 118.292 -0.861 . . . . 1.6899999999999999 111.046 179.978 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.4 0 CA-C-O 120.796 0.332 . . . . 0.0 111.026 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 22.6 mm-40 -134.6 155.74 49.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.893 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.489 HG21 ' HG2' ' A' ' 132' ' ' ARG . 11.2 p -143.77 148.82 18.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.085 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -86.18 -44.45 12.19 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.127 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -151.43 157.48 42.43 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.943 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . 0.489 ' HG2' HG21 ' A' ' 129' ' ' VAL . 0.1 OUTLIER -150.51 134.1 16.53 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.97 179.946 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -58.23 147.8 29.29 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.952 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 79.54 6.52 88.96 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.967 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 12.9 m-20 -86.87 174.53 8.7 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.821 0.343 . . . . 0.0 110.99 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 36.3 mt-30 -113.96 132.61 55.9 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.836 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.438 HG12 ' HA ' ' A' ' 183' ' ' LYS . 31.0 m -131.9 136.2 57.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.081 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -80.03 166.26 21.73 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.703 179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.582 HG11 ' HB2' ' A' ' 144' ' ' PHE . 8.0 t -79.86 167.34 2.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.973 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.6 HG13 ' H ' ' A' ' 141' ' ' SER . 3.3 p -79.31 -60.3 2.36 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 112.138 0.421 . . . . 0.0 112.138 -179.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.657 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.1 OUTLIER -160.43 -164.18 1.21 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.822 0.344 . . . . 0.0 111.301 -179.542 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.37 -168.01 54.33 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.856 -0.687 . . . . 0.0 112.344 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -60.37 -19.02 56.44 Favored 'Trans proline' 0 C--N 1.343 0.277 0 C-N-CA 122.479 2.119 . . . . 0.0 111.95 179.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.582 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.9 m-85 -95.86 13.09 27.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.211 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.657 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -79.14 39.69 0.39 Allowed 'General case' 0 C--N 1.332 -0.179 0 N-CA-C 112.246 0.462 . . . . 0.0 112.246 -179.361 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . 0.409 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 1.0 OUTLIER -160.7 34.87 0.16 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.987 0.422 . . . . 0.0 110.675 179.336 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.494 ' O ' HG23 ' A' ' 139' ' ' VAL . 47.2 m-85 -148.0 167.13 25.7 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.91 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.669 ' O ' HG12 ' A' ' 165' ' ' VAL . 23.7 p -127.16 -173.98 3.04 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.672 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -150.43 164.81 29.86 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.657 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 5.6 m -103.99 108.47 19.83 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.779 0.323 . . . . 0.0 110.773 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.476 ' HA ' HG12 ' A' ' 163' ' ' VAL . 19.8 t -57.42 113.88 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.293 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 10.3 t -98.88 -33.92 10.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.778 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -153.48 158.48 41.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.894 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . 0.485 HG22 ' N ' ' A' ' 155' ' ' ASN . 2.7 mt -129.88 158.69 42.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.087 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.485 ' N ' HG22 ' A' ' 154' ' ' ILE . 0.8 OUTLIER -135.29 86.71 29.75 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.958 -179.997 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -71.69 -34.13 9.47 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.56 2.174 . . . . 0.0 112.385 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -58.98 -33.55 70.81 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.993 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.23 -61.23 1.69 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.94 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 127.04 42.73 0.27 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.489 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . 0.412 ' O ' HG13 ' A' ' 161' ' ' VAL . 11.8 mttt -115.59 170.34 8.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.772 0.32 . . . . 0.0 110.982 -179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.72 HG22 ' HA ' ' A' ' 177' ' ' ASP . 5.1 m -155.37 137.08 5.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.077 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 38.7 tttt -114.69 128.25 56.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.788 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.865 HG22 HD11 ' A' ' 176' ' ' LEU . 29.7 m -139.88 142.51 32.06 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.231 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . 0.4 ' CG ' ' O ' ' A' ' 164' ' ' MET . 0.4 OUTLIER -89.93 104.02 16.63 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.592 179.883 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.669 HG12 ' O ' ' A' ' 148' ' ' THR . 15.5 m -91.76 171.11 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.25 -179.791 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -132.41 115.34 15.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.796 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.406 HD12 ' CE2' ' A' ' 147' ' ' PHE . 1.6 tp -120.23 133.82 65.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.162 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 1.2 t80 61.74 30.42 18.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.878 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 70.28 45.26 56.25 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.555 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 2.2 tpm_? -159.98 138.86 10.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.789 0.328 . . . . 0.0 110.908 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -60.8 151.94 28.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.778 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 66.1 m -160.02 91.17 1.77 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.989 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -68.37 117.45 4.97 Favored 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 122.475 2.117 . . . . 0.0 112.155 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 29.7 m -132.84 154.98 40.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.256 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -98.8 138.1 36.43 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.639 179.741 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.865 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -144.33 -162.2 1.43 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.263 0.554 . . . . 0.0 111.229 -179.796 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.72 ' HA ' HG22 ' A' ' 161' ' ' VAL . 7.3 m-20 -153.11 156.71 39.18 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.079 178.424 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -45.86 -29.38 1.35 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.674 -179.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 7.3 m -76.01 -3.45 35.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.829 -179.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 15.1 mm100 -131.77 15.08 4.85 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.602 0.239 . . . . 0.0 111.437 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.474 HG22 ' O ' ' A' ' 177' ' ' ASP . 15.7 m -142.0 170.03 12.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.865 0.364 . . . . 0.0 111.221 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 22.4 m -142.41 146.71 21.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.037 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.438 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -83.36 131.33 35.06 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.946 -179.953 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.189 -0.91 . . . . 0.0 111.12 -179.997 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.309 0 CA-C-O 120.749 0.309 . . . . 0.0 111.022 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 60.51 158.81 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.909 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 11.3 m -138.05 35.27 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.024 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -77.78 138.04 38.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.141 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.605 ' CZ ' HG21 ' A' ' 151' ' ' VAL . 10.4 t80 -92.67 150.29 20.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.913 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 21.5 mtp180 -145.24 146.26 31.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.897 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -63.93 142.37 58.43 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.916 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 91.91 -14.05 65.27 Favored Glycine 0 CA--C 1.519 0.292 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.773 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 32.2 m-20 -54.54 165.01 0.63 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.766 0.317 . . . . 0.0 111.024 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -117.6 115.38 24.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.077 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.614 HG12 ' HA ' ' A' ' 183' ' ' LYS . 19.4 m -122.95 149.06 26.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.919 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.8 tpp180 -79.86 168.03 19.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.069 0.461 . . . . 0.0 110.854 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.574 HG23 ' O ' ' A' ' 147' ' ' PHE . 3.8 t -80.21 167.95 2.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.028 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.666 HG13 ' H ' ' A' ' 141' ' ' SER . 1.5 p -79.66 -66.85 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.55 -179.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.666 ' H ' HG13 ' A' ' 140' ' ' VAL . 0.2 OUTLIER -160.44 -164.69 1.29 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.876 0.37 . . . . 0.0 111.097 -179.91 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.94 -162.47 42.79 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.911 -0.661 . . . . 0.0 112.462 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -63.07 -18.42 65.06 Favored 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.458 2.106 . . . . 0.0 112.115 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.507 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.0 m-85 -102.14 29.24 5.22 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.957 179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -82.38 35.67 0.45 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.775 0.321 . . . . 0.0 111.853 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -160.96 35.63 0.15 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.506 179.354 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.574 ' O ' HG23 ' A' ' 139' ' ' VAL . 48.3 m-85 -135.15 175.7 9.34 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.888 -179.753 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.435 HG22 ' O ' ' A' ' 137' ' ' VAL . 0.3 OUTLIER -119.99 178.65 4.53 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.752 179.942 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -147.11 115.6 0.79 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.568 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.1 m -82.0 113.02 19.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.755 0.312 . . . . 0.0 110.782 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.605 HG21 ' CZ ' ' A' ' 131' ' ' PHE . 26.4 t -68.19 123.54 21.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.175 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -105.22 -60.47 1.61 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.846 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -121.58 165.83 15.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.91 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . 0.669 ' N ' HD13 ' A' ' 154' ' ' ILE . 0.1 OUTLIER -130.78 157.67 43.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.052 179.961 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 12.5 m-20 -121.58 89.27 47.28 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.902 -179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -73.25 -34.45 6.08 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.54 2.16 . . . . 0.0 112.298 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.33 27.67 1.62 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.386 -179.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 5.1 mtm180 -160.08 -50.1 0.05 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.856 0.36 . . . . 0.0 110.784 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 103.27 63.56 0.7 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.461 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.8 mttt -145.88 165.9 27.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.891 0.376 . . . . 0.0 111.028 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.535 HG11 ' CE1' ' A' ' 178' ' ' PHE . 3.7 m -150.04 120.99 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.903 179.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 3.7 ttmp? -86.75 131.68 34.06 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.096 -179.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.613 HG21 HD12 ' A' ' 176' ' ' LEU . 27.2 m -131.17 158.1 43.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.062 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 3.3 ptt? -116.27 126.58 53.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.029 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 2.5 t -106.99 153.88 8.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.847 179.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 2.1 p -122.98 103.32 8.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.063 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.512 HG22 ' CZ ' ' A' ' 168' ' ' PHE . 39.4 mm -80.0 67.52 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.625 179.71 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . 0.512 ' CZ ' HG22 ' A' ' 167' ' ' ILE . 1.1 p90 43.52 79.43 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.405 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 83.15 34.49 20.68 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.673 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -160.13 109.21 1.75 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.786 0.327 . . . . 0.0 111.077 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 11.7 mt-10 -89.84 134.41 34.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.717 179.731 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -145.26 105.57 4.4 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.126 -179.75 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.49 110.53 2.72 Favored 'Trans proline' 0 C--N 1.348 0.508 0 C-N-CA 122.46 2.107 . . . . 0.0 112.069 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 9.0 p -126.09 146.45 31.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.268 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -79.99 157.57 26.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.679 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.753 HD22 ' HB3' ' A' ' 180' ' ' GLN . 7.5 mt -159.99 -171.74 3.35 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-O 121.411 0.625 . . . . 0.0 111.408 -179.81 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.401 ' HA ' HG22 ' A' ' 161' ' ' VAL . 1.9 m-20 -146.55 153.61 40.57 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 115.021 -0.991 . . . . 0.0 110.205 178.074 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . 0.535 ' CE1' HG11 ' A' ' 161' ' ' VAL . 27.3 m-85 -46.06 -32.8 3.05 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.548 -179.573 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 6.2 m -81.74 11.47 4.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.709 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.753 ' HB3' HD22 ' A' ' 176' ' ' LEU . 7.4 mm-40 -125.46 3.19 7.68 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.596 0.236 . . . . 0.0 111.262 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.751 HG13 HD13 ' A' ' 176' ' ' LEU . 21.9 m -145.14 179.42 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-O 120.977 0.417 . . . . 0.0 111.113 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 15.7 m -150.64 148.14 15.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.145 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.614 ' HA ' HG12 ' A' ' 137' ' ' VAL . 7.1 tttt -63.89 131.94 49.27 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.94 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.146 0 CA-C-O 118.257 -0.878 . . . . 0.0 111.14 179.906 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.336 0 CA-C-O 120.846 0.355 . . . . 0.0 111.002 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 2.4 mt-30 -83.45 -40.32 19.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.902 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 11.3 p -119.09 -39.18 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.189 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -64.94 -31.17 72.28 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.21 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.492 ' CZ ' HG21 ' A' ' 151' ' ' VAL . 11.5 t80 -111.86 143.44 42.81 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.926 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 7.3 mtt-85 -133.38 135.35 44.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.887 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.7 mt-10 -63.24 152.92 36.26 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.693 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 65.71 11.75 54.73 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.982 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -89.57 165.42 14.27 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.799 0.3 . . . . 0.0 110.822 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -89.24 134.08 34.19 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.904 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.705 HG12 ' HA ' ' A' ' 183' ' ' LYS . 16.0 m -140.46 140.01 34.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.962 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.431 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.4 OUTLIER -80.79 164.83 22.43 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.999 0.428 . . . . 0.0 111.063 -179.912 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.625 HG11 ' HB2' ' A' ' 144' ' ' PHE . 5.2 t -81.9 167.3 2.09 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.042 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.608 HG13 ' H ' ' A' ' 141' ' ' SER . 2.3 p -79.47 -61.77 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.439 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.705 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 46.7 p -160.11 -165.14 1.41 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.87 0.367 . . . . 0.0 111.176 -179.47 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 80.15 -163.74 47.36 Favored Glycine 0 N--CA 1.45 -0.411 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.348 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -63.91 -14.76 45.12 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.394 2.062 . . . . 0.0 112.23 179.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.625 ' HB2' HG11 ' A' ' 139' ' ' VAL . 4.9 m-85 -102.52 14.64 31.44 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.253 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.705 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -77.48 36.87 0.2 Allowed 'General case' 0 C--N 1.332 -0.189 0 N-CA-C 112.462 0.541 . . . . 0.0 112.462 -179.289 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . 0.408 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 2.2 t0 -161.05 34.41 0.14 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 120.932 0.396 . . . . 0.0 110.805 179.223 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.573 ' O ' HG23 ' A' ' 139' ' ' VAL . 40.2 m-85 -146.1 165.98 27.49 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.745 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.431 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 0.7 OUTLIER -116.79 -176.18 2.92 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.792 179.939 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . 0.413 ' HA3' HG12 ' A' ' 163' ' ' VAL . . . -153.26 -176.4 25.7 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.572 -0.823 . . . . 0.0 112.57 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . 0.419 ' N ' HG13 ' A' ' 163' ' ' VAL . 40.9 m -125.3 113.14 17.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.808 0.337 . . . . 0.0 110.853 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.492 HG21 ' CZ ' ' A' ' 131' ' ' PHE . 32.9 t -63.91 106.24 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.101 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 5.8 p -83.99 -45.07 13.51 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.916 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 2.4 tp10 -152.68 171.69 17.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.812 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . 0.825 HG22 HG12 ' A' ' 161' ' ' VAL . 17.5 pt -145.33 151.43 15.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.096 179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 12.7 m-20 -117.68 86.76 24.5 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.915 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -62.04 -24.74 76.97 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.737 2.292 . . . . 0.0 112.326 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -90.21 29.12 1.28 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.407 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.07 -44.16 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.868 0.366 . . . . 0.0 111.015 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 104.55 39.5 2.38 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.291 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 4.5 mttt -127.87 161.4 29.13 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.921 0.391 . . . . 0.0 110.981 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.825 HG12 HG22 ' A' ' 154' ' ' ILE . 29.2 m -146.82 119.65 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.107 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 15.5 tttt -80.04 141.28 36.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.891 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.869 ' HB ' HD12 ' A' ' 176' ' ' LEU . 26.0 t -153.17 144.9 15.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.098 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -96.68 121.77 38.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.874 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.456 HG22 ' O ' ' A' ' 172' ' ' THR . 9.3 m -99.98 158.55 3.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.121 -179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . 0.668 HG22 ' HA ' ' A' ' 171' ' ' GLU . 31.4 p -145.31 146.35 31.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.815 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.8 mp -131.17 94.82 2.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.165 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 57.3 m-85 60.06 37.74 20.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.949 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 91.74 27.85 15.81 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.493 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.26 89.0 3.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.794 0.331 . . . . 0.0 110.913 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . 0.668 ' HA ' HG22 ' A' ' 166' ' ' THR . 1.8 mt-10 -59.24 144.61 45.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . 0.456 ' O ' HG22 ' A' ' 165' ' ' VAL . 0.2 OUTLIER -158.41 90.3 2.18 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.842 179.94 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_exo -60.49 125.78 18.27 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.573 2.182 . . . . 0.0 112.29 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 39.4 t -152.54 148.84 14.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.959 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -80.01 145.04 32.74 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.822 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.869 HD12 ' HB ' ' A' ' 163' ' ' VAL . 4.1 mt -125.63 -173.24 2.78 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.451 0.643 . . . . 0.0 111.324 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.813 ' O ' HG12 ' A' ' 181' ' ' VAL . 3.1 m-20 -152.91 153.76 33.67 Favored 'General case' 0 N--CA 1.446 -0.662 0 CA-C-N 115.023 -0.99 . . . . 0.0 109.99 178.147 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -42.79 -54.01 4.31 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.656 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 5.2 m -74.18 -9.61 58.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.418 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.55 ' HB3' HD23 ' A' ' 176' ' ' LEU . 0.0 OUTLIER -99.55 -14.03 19.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.504 -179.806 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.813 HG12 ' O ' ' A' ' 177' ' ' ASP . 1.3 p -132.59 160.32 42.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.033 0.444 . . . . 0.0 111.083 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . 0.478 ' N ' ' CG2' ' A' ' 181' ' ' VAL . 35.4 m -139.39 146.19 25.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.379 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.705 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -77.28 135.03 38.39 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.94 179.847 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.286 -0.864 . . . . 0.0 111.14 179.986 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.377 0 CA-C-O 120.807 0.337 . . . . 0.0 111.029 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 13.3 tt0 60.07 74.57 0.44 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.864 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 12.0 p -114.84 152.58 16.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.098 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -66.54 -48.55 69.33 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.095 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.752 ' CE2' HG21 ' A' ' 151' ' ' VAL . 6.2 t80 -125.21 149.04 48.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.959 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.01 145.07 15.06 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.887 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -59.81 135.11 57.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.869 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 105.97 -27.69 16.58 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.485 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -63.36 178.4 0.54 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.748 0.309 . . . . 0.0 110.977 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -128.19 130.34 47.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.015 0.436 . . . . 0.0 111.116 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.684 HG11 ' HE1' ' A' ' 131' ' ' PHE . 25.9 m -130.16 142.91 42.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.705 179.775 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.42 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.1 OUTLIER -79.7 164.49 23.7 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.025 0.44 . . . . 0.0 111.048 -179.843 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.817 HG11 ' HB2' ' A' ' 144' ' ' PHE . 48.8 t -79.74 147.22 6.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.647 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.549 HG11 ' HA ' ' A' ' 180' ' ' GLN . 12.4 p -85.87 -22.22 7.39 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.422 -179.47 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.747 ' H ' HG12 ' A' ' 139' ' ' VAL . 1.4 t -79.14 153.47 30.06 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.893 0.378 . . . . 0.0 111.429 -178.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . 0.415 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -66.89 -62.2 4.68 Favored Glycine 0 N--CA 1.452 -0.26 0 CA-C-N 115.893 -0.594 . . . . 0.0 112.733 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.415 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.2 Cg_endo -53.57 -23.2 24.51 Favored 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.583 2.189 . . . . 0.0 112.158 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.817 ' HB2' HG11 ' A' ' 139' ' ' VAL . 12.9 m-85 -109.81 0.61 18.86 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.387 179.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.658 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -69.63 50.71 0.1 Allowed 'General case' 0 N--CA 1.462 0.163 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -179.05 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -160.61 31.37 0.16 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.094 0.473 . . . . 0.0 110.527 179.029 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.696 ' O ' HG23 ' A' ' 139' ' ' VAL . 19.0 m-85 -155.4 146.41 22.5 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.389 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 9.0 p -104.56 169.05 8.69 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.952 -179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -129.01 133.41 7.57 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.59 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.8 m -86.55 110.47 19.82 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.823 0.344 . . . . 0.0 110.755 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.752 HG21 ' CE2' ' A' ' 131' ' ' PHE . 30.6 t -67.96 117.44 9.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.963 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.3 t -101.94 -30.37 11.27 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.899 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -147.21 165.78 29.02 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.83 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . 0.638 HD12 ' HD3' ' A' ' 156' ' ' PRO . 2.0 pp -152.41 141.42 14.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.152 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -120.94 92.87 48.66 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.871 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . 0.638 ' HD3' HD12 ' A' ' 154' ' ' ILE . 54.4 Cg_endo -69.54 -22.63 32.83 Favored 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.555 2.17 . . . . 0.0 112.425 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -90.21 26.36 1.92 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.372 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 1.4 mtp85 -159.96 -45.25 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.827 0.346 . . . . 0.0 110.825 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 102.45 55.19 0.86 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.425 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.3 mttt -137.66 147.56 45.01 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.801 0.334 . . . . 0.0 111.152 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.707 HG22 ' HA ' ' A' ' 177' ' ' ASP . 31.1 m -139.05 116.48 11.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.973 179.799 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 70.1 tttt -89.69 118.56 29.4 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.89 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.607 HG12 HG22 ' A' ' 151' ' ' VAL . 28.0 m -130.37 149.42 33.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.137 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . 0.425 ' O ' ' CG ' ' A' ' 164' ' ' MET . 3.7 ptt? -101.84 108.54 20.06 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.996 0.427 . . . . 0.0 110.81 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 27.1 m -98.31 143.08 13.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.126 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -91.9 90.55 7.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.938 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.794 HG22 ' OG1' ' A' ' 172' ' ' THR . 11.2 tt -89.55 129.67 40.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.82 179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . 0.418 ' CD2' HG12 ' A' ' 167' ' ' ILE . 31.2 m-85 65.86 -72.49 0.08 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.915 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -169.61 36.0 0.19 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.635 -0.793 . . . . 0.0 112.657 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 8.9 ptp180 -160.03 164.19 33.39 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.793 0.33 . . . . 0.0 111.063 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -66.89 158.37 30.81 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.906 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . 0.794 ' OG1' HG22 ' A' ' 167' ' ' ILE . 0.3 OUTLIER -159.99 81.3 2.38 Favored Pre-proline 0 C--N 1.33 -0.243 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.954 -179.985 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -68.57 102.65 0.87 Allowed 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.682 2.255 . . . . 0.0 112.229 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.823 ' CG2' HD21 ' A' ' 176' ' ' LEU . 21.4 m -114.46 136.04 52.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.137 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -80.16 108.89 14.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.669 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.823 HD21 ' CG2' ' A' ' 174' ' ' VAL . 0.3 OUTLIER -124.27 -158.96 0.84 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.322 0.582 . . . . 0.0 111.159 -179.605 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.707 ' HA ' HG22 ' A' ' 161' ' ' VAL . 4.7 m-20 -146.36 155.64 42.75 Favored 'General case' 0 N--CA 1.441 -0.875 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.167 178.161 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . 0.531 ' CE1' HG11 ' A' ' 161' ' ' VAL . 14.9 m-85 -42.97 -30.89 0.45 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.617 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.5 m -66.35 -30.14 70.48 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.313 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.549 ' HA ' HG11 ' A' ' 140' ' ' VAL . 33.5 mm-40 -102.39 21.59 14.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.49 -0.323 . . . . 0.0 111.55 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.422 HG13 ' O ' ' A' ' 180' ' ' GLN . 21.7 m -157.03 140.63 7.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.93 0.395 . . . . 0.0 111.13 179.698 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.1 m -117.03 146.27 21.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.146 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.647 ' HA ' HG12 ' A' ' 137' ' ' VAL . 3.4 tttm -83.3 128.2 34.3 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.869 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.247 -0.883 . . . . 0.0 111.113 179.97 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . 0.439 ' HB3' ' OE1' ' A' ' 128' ' ' GLN . . . . . . . . 0 N--CA 1.486 1.362 0 CA-C-O 120.834 0.35 . . . . 0.0 111.001 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . 0.439 ' OE1' ' HB3' ' A' ' 127' ' ' ALA . 10.6 mp0 -131.53 31.62 4.28 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.931 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.5 t -145.18 94.6 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.187 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -75.44 75.53 2.51 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.994 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.456 ' HZ ' HG21 ' A' ' 151' ' ' VAL . 22.3 t80 -96.94 145.14 26.19 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.959 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 48.4 mtt-85 -153.51 155.86 37.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.854 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -57.51 155.42 9.54 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.742 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.42 ' HA2' HG22 ' A' ' 150' ' ' THR . . . 77.1 0.52 70.58 Favored Glycine 0 CA--C 1.519 0.343 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.78 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -66.0 153.49 42.03 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.838 0.352 . . . . 0.0 110.938 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 16.6 mt-30 -95.49 123.5 39.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.912 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.671 HG12 ' HA ' ' A' ' 183' ' ' LYS . 18.7 m -139.66 139.33 38.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.055 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.46 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -80.29 165.91 21.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.946 0.403 . . . . 0.0 110.808 179.837 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 147' ' ' PHE . 6.8 t -79.7 167.67 2.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.999 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.644 HG13 ' H ' ' A' ' 141' ' ' SER . 2.5 p -79.39 -63.18 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 N-CA-C 112.199 0.444 . . . . 0.0 112.199 -179.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.677 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.9 OUTLIER -160.28 -174.46 4.52 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.918 0.39 . . . . 0.0 111.321 -179.579 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 87.12 -167.19 37.55 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.397 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -59.53 -19.28 51.41 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.345 2.03 . . . . 0.0 111.965 179.541 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.539 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.3 m-85 -98.49 13.97 29.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.677 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -80.42 39.22 0.45 Allowed 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.275 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . 0.45 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 0.2 OUTLIER -160.78 31.57 0.15 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.901 0.381 . . . . 0.0 110.893 179.32 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.719 ' O ' HG23 ' A' ' 139' ' ' VAL . 22.4 m-85 -143.96 155.58 44.1 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.865 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.46 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 0.8 OUTLIER -110.7 159.56 17.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.224 179.423 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . 0.621 ' HA3' HG12 ' A' ' 163' ' ' VAL . . . -128.21 179.15 16.71 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.287 -0.958 . . . . 0.0 113.145 -179.504 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . 0.42 HG22 ' HA2' ' A' ' 134' ' ' GLY . 2.4 m -121.63 116.88 25.41 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.768 0.318 . . . . 0.0 110.729 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.456 HG21 ' HZ ' ' A' ' 131' ' ' PHE . 37.2 t -67.49 145.53 13.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.984 179.823 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 20.4 p -137.55 -55.54 0.69 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.976 -179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . 0.529 ' O ' HG23 ' A' ' 154' ' ' ILE . 0.5 OUTLIER -115.91 159.68 21.24 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.912 -179.869 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . 0.563 HG22 HG12 ' A' ' 161' ' ' VAL . 1.9 pt -158.7 149.02 8.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.092 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 12.0 t30 -147.26 85.32 6.88 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.946 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.52 -22.34 27.54 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.523 2.149 . . . . 0.0 112.408 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -55.0 -69.48 0.13 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.124 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.87 -33.71 39.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.984 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 101.56 55.42 0.9 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.596 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 2.7 mtmp? -131.34 149.28 52.62 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.922 0.392 . . . . 0.0 110.807 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.906 HG22 ' HA ' ' A' ' 177' ' ' ASP . 27.9 m -142.58 136.76 27.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.092 -0.503 . . . . 0.0 111.128 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 17.8 tttp -100.31 141.33 33.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.94 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.624 HG23 HD13 ' A' ' 176' ' ' LEU . 12.0 t -152.08 137.06 10.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.986 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . 0.423 ' CG ' ' O ' ' A' ' 164' ' ' MET . 0.1 OUTLIER -97.49 106.48 18.81 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.982 0.42 . . . . 0.0 111.022 -179.9 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.448 HG12 ' N ' ' A' ' 166' ' ' THR . 5.5 t -103.4 159.88 4.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.176 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . 0.448 ' N ' HG12 ' A' ' 165' ' ' VAL . 15.8 p -95.14 145.52 24.95 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.85 179.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.816 HD13 ' O ' ' A' ' 167' ' ' ILE . 0.0 OUTLIER -114.6 -36.86 2.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.061 179.982 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -166.37 76.86 0.21 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 64.03 26.82 70.57 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.52 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.01 136.68 9.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.793 0.33 . . . . 0.0 110.879 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 7.2 pm0 -59.18 166.91 1.95 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.9 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 9.1 m -159.74 84.21 2.22 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.022 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -58.12 119.74 7.18 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.48 2.12 . . . . 0.0 112.138 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 15.6 m -142.13 151.2 18.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.255 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -83.63 142.51 30.75 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.575 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.624 HD13 HG23 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -152.56 -161.21 1.25 Allowed 'General case' 0 CA--C 1.518 -0.257 0 CA-C-O 121.301 0.572 . . . . 0.0 111.303 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.906 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.7 OUTLIER -151.17 154.04 36.13 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.208 178.453 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . 0.458 ' CE2' HG11 ' A' ' 161' ' ' VAL . 12.3 m-85 -48.17 -27.73 2.56 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.522 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 7.5 t -78.17 -1.94 35.17 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.679 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -124.27 13.0 8.89 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.659 0.266 . . . . 0.0 111.391 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 15.6 m -144.31 160.97 15.16 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.807 0.337 . . . . 0.0 111.15 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 28.6 m -141.6 148.22 21.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.054 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.671 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.1 OUTLIER -59.84 134.85 57.42 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.9 -179.938 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.215 -0.898 . . . . 0.0 111.169 179.963 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.332 0 CA-C-O 120.845 0.355 . . . . 0.0 111.037 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER 63.44 140.86 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.87 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.485 HG12 ' N ' ' A' ' 130' ' ' ALA . 20.8 t -130.78 159.58 42.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.164 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.485 ' N ' HG12 ' A' ' 129' ' ' VAL . . . -57.23 128.14 35.49 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.128 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 6.2 t80 -143.57 148.68 36.29 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.938 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -159.83 145.5 15.61 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.966 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -62.44 129.79 42.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.879 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 121.51 -22.62 7.77 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.604 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -56.8 163.82 1.76 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.841 0.353 . . . . 0.0 111.046 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -104.54 135.43 45.97 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.91 -179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.795 HG12 ' HA ' ' A' ' 183' ' ' LYS . 11.9 m -138.1 130.0 38.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.064 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.416 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.98 165.37 22.66 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.898 -179.927 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.694 HG23 ' O ' ' A' ' 147' ' ' PHE . 3.7 t -79.83 168.83 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.913 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.636 HG23 ' H ' ' A' ' 141' ' ' SER . 1.0 OUTLIER -79.52 -66.01 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.876 -179.55 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.684 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 52.1 p -160.22 -165.42 1.46 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.941 0.4 . . . . 0.0 110.954 -179.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.73 -159.07 37.76 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.451 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.71 -12.31 35.06 Favored 'Trans proline' 0 C--N 1.343 0.265 0 C-N-CA 122.578 2.186 . . . . 0.0 112.385 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.545 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.2 m-85 -108.57 20.91 17.98 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.164 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.684 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -80.53 38.44 0.43 Allowed 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -179.401 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -161.03 36.98 0.15 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.791 0.329 . . . . 0.0 110.915 179.309 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.694 ' O ' HG23 ' A' ' 139' ' ' VAL . 48.4 m-85 -147.91 161.06 42.07 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.951 -179.828 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.416 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 1.9 p -120.42 -176.79 3.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.66 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -149.39 151.44 23.56 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.602 -0.809 . . . . 0.0 112.724 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.1 m -96.56 99.18 10.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.788 0.328 . . . . 0.0 110.74 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.753 ' HA ' HG12 ' A' ' 163' ' ' VAL . 48.7 t -56.98 105.95 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.303 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 30.4 p -83.85 -38.96 20.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.535 179.683 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -143.81 160.31 40.99 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.701 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.8 mp -132.52 139.67 49.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.162 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -131.38 84.74 55.41 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.789 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -68.19 -27.68 34.93 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.511 2.14 . . . . 0.0 112.363 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -59.69 -58.4 8.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.882 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -87.54 -30.06 20.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.949 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 94.96 37.32 5.23 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.493 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 8.7 mtmt -114.08 154.06 28.39 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.8 0.333 . . . . 0.0 110.968 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.405 HG22 ' HA ' ' A' ' 177' ' ' ASP . 17.8 m -147.23 141.35 19.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.08 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 18.2 ttpt -115.47 122.85 47.0 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.943 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 1.038 HG22 HD11 ' A' ' 176' ' ' LEU . 33.4 m -136.63 146.49 28.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.285 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -93.32 106.32 18.29 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.486 179.692 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.523 HG22 ' O ' ' A' ' 172' ' ' THR . 30.4 m -88.18 171.75 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.372 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 82.6 p -148.26 103.85 3.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.673 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 2.9 mp -79.94 85.56 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.222 -179.849 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 59.1 31.5 21.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.958 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 105.6 35.39 3.07 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.56 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 9.3 mtt-85 -135.38 91.84 2.78 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.795 0.331 . . . . 0.0 110.882 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -58.64 136.72 57.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.91 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . 0.523 ' O ' HG22 ' A' ' 165' ' ' VAL . 19.7 m -159.53 104.48 1.49 Allowed Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.994 -179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -69.43 105.79 1.49 Allowed 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.342 2.028 . . . . 0.0 112.105 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 22.0 t -122.5 135.32 62.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.247 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -87.41 139.55 30.43 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.653 179.666 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 1.038 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -144.52 -162.5 1.5 Allowed 'General case' 0 CA--C 1.516 -0.333 0 CA-C-O 121.415 0.626 . . . . 0.0 111.263 -179.665 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.405 ' HA ' HG22 ' A' ' 161' ' ' VAL . 10.0 m-20 -142.41 158.05 44.11 Favored 'General case' 0 N--CA 1.441 -0.896 0 CA-C-N 115.001 -1.0 . . . . 0.0 109.888 178.19 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -46.89 -33.47 4.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.424 -179.535 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -73.13 -8.75 57.14 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.534 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.58 ' C ' HG13 ' A' ' 140' ' ' VAL . 16.5 mm-40 -110.8 -12.97 14.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.712 0.292 . . . . 0.0 111.559 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.474 ' CG1' HD22 ' A' ' 176' ' ' LEU . 8.2 m -128.5 174.34 12.05 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.134 0 CA-C-O 120.865 0.364 . . . . 0.0 111.317 -179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.02 146.97 20.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.025 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.795 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -80.19 123.9 28.32 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.921 179.94 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.261 -0.876 . . . . 0.0 111.085 179.993 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.379 0 CA-C-O 120.784 0.326 . . . . 0.0 111.033 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -135.11 125.47 26.46 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.918 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.593 ' O ' HG12 ' A' ' 129' ' ' VAL . 16.0 t -98.64 31.12 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.062 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -85.71 74.53 10.22 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.99 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.582 ' HZ ' HG21 ' A' ' 151' ' ' VAL . 42.5 t80 -131.98 150.47 52.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.859 -179.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 30.8 mtp180 -142.33 134.87 28.05 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.972 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -61.72 131.49 50.08 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.918 179.869 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.38 -23.39 20.57 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.69 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -57.91 -176.08 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.869 0.366 . . . . 0.0 110.974 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -121.73 139.98 52.89 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.956 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.894 HG12 ' HA ' ' A' ' 183' ' ' LYS . 17.1 m -139.98 142.75 31.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.011 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.453 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -80.01 165.18 22.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.038 0.447 . . . . 0.0 110.837 -179.954 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.709 HG23 ' O ' ' A' ' 147' ' ' PHE . 4.6 t -79.86 168.03 2.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.92 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.654 HG13 ' H ' ' A' ' 141' ' ' SER . 3.2 p -79.37 -62.13 1.5 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.26 0 N-CA-C 112.011 0.375 . . . . 0.0 112.011 -179.263 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.658 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.7 OUTLIER -160.5 -163.5 1.1 Allowed 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 120.876 0.369 . . . . 0.0 111.124 -179.515 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 78.17 -165.39 51.95 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.465 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_endo -62.17 -17.11 54.9 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.506 2.137 . . . . 0.0 112.022 179.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.553 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.9 m-85 -100.26 16.38 24.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.207 179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.658 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -79.53 37.68 0.35 Allowed 'General case' 0 C--N 1.331 -0.2 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -179.366 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . 0.438 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 11.2 p30 -160.91 32.05 0.15 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.971 0.415 . . . . 0.0 110.818 179.277 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.709 ' O ' HG23 ' A' ' 139' ' ' VAL . 24.8 m-85 -140.91 159.62 41.81 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.747 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 1.6 p -108.72 171.07 7.64 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.568 179.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -137.43 139.38 10.45 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.518 -0.849 . . . . 0.0 112.768 -179.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.9 m -91.2 105.66 17.96 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.751 0.31 . . . . 0.0 110.605 179.72 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.582 HG21 ' HZ ' ' A' ' 131' ' ' PHE . 24.3 t -64.53 108.7 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.172 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 2.0 t -96.24 -30.54 13.41 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.955 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -140.63 164.98 28.71 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.979 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 9.5 tt -152.48 127.84 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.026 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 59.0 m-20 -103.22 93.87 5.09 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.951 -179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.67 -27.95 26.27 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.481 2.121 . . . . 0.0 112.293 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -90.35 26.8 1.83 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.394 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -159.86 -45.17 0.05 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.894 0.378 . . . . 0.0 110.901 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 101.56 36.55 3.75 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.486 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 19.4 mmmt -111.46 152.03 27.88 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.886 0.374 . . . . 0.0 110.849 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.758 HG22 ' HA ' ' A' ' 177' ' ' ASP . 12.3 m -140.27 125.99 20.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.032 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 22.4 tttt -103.88 119.66 39.39 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.844 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.736 HG22 ' CD1' ' A' ' 176' ' ' LEU . 33.7 m -132.15 152.65 37.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.116 -179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 11.9 ptp -100.55 121.07 40.98 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.045 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.423 HG12 ' N ' ' A' ' 166' ' ' THR . 7.1 t -101.93 158.29 4.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.016 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . 0.423 ' N ' HG12 ' A' ' 165' ' ' VAL . 7.3 m -115.12 110.16 19.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.961 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.751 HD13 ' HB2' ' A' ' 168' ' ' PHE . 0.0 OUTLIER -120.0 114.28 43.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.779 179.869 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . 0.751 ' HB2' HD13 ' A' ' 167' ' ' ILE . 0.1 OUTLIER 63.54 31.85 14.52 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.764 -179.617 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 72.4 36.4 59.36 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.682 -0.77 . . . . 0.0 112.478 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -142.96 109.03 5.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.799 0.333 . . . . 0.0 110.885 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -59.47 128.2 35.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.855 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 15.8 m -132.13 92.01 30.4 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.015 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_exo -60.99 115.58 2.79 Favored 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.593 2.195 . . . . 0.0 112.046 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 11.3 p -121.74 147.56 25.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.295 -179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.3 pm0 -94.55 121.93 36.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.799 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.736 ' CD1' HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -137.54 -159.18 0.93 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.306 0.574 . . . . 0.0 111.113 -179.773 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.758 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.6 OUTLIER -143.25 155.2 44.44 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.101 178.182 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . 0.478 ' CE2' HG11 ' A' ' 161' ' ' VAL . 8.2 m-85 -46.68 -29.09 1.71 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.578 -179.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 6.4 p -70.67 -11.82 61.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.564 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 4.0 mt-30 -115.75 16.91 16.31 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.61 -0.268 . . . . 0.0 111.448 -179.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 10.9 m -153.25 154.07 8.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-O 120.718 0.294 . . . . 0.0 111.234 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 28.9 m -127.21 146.41 33.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.177 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.894 ' HA ' HG12 ' A' ' 137' ' ' VAL . 17.7 tptm -71.31 139.54 49.95 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.066 0 CA-C-O 118.205 -0.903 . . . . 0.0 111.121 -179.978 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.357 0 CA-C-O 120.894 0.378 . . . . 0.0 111.053 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -88.93 132.99 34.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.869 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.5 t -117.74 82.61 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.147 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.15 142.96 53.46 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.098 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.53 ' CZ ' HG21 ' A' ' 151' ' ' VAL . 18.6 t80 -153.63 158.33 40.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.832 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 7.9 ttt85 -159.23 146.4 17.13 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.991 0.424 . . . . 0.0 110.912 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -56.01 155.84 5.96 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.776 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.99 9.36 59.75 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.869 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -80.78 162.18 24.18 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.775 0.321 . . . . 0.0 110.859 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 14.2 mt-30 -118.31 120.15 36.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.902 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.618 HG12 ' HA ' ' A' ' 183' ' ' LYS . 30.0 m -127.12 140.64 48.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.987 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.411 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.77 160.86 26.03 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 121.083 0.468 . . . . 0.0 110.883 -179.853 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.859 HG11 ' HB2' ' A' ' 144' ' ' PHE . 43.4 t -79.92 150.56 4.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.644 -179.43 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.528 HG22 ' O ' ' A' ' 180' ' ' GLN . 35.5 m -91.97 -20.37 6.67 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 -179.418 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.733 ' H ' HG12 ' A' ' 139' ' ' VAL . 0.4 OUTLIER -79.15 153.25 30.22 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.893 0.377 . . . . 0.0 111.187 -178.937 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . 0.409 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -64.43 -63.2 4.46 Favored Glycine 0 CA--C 1.519 0.317 0 C-N-CA 121.153 -0.546 . . . . 0.0 112.946 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.409 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.2 Cg_endo -52.65 -22.86 18.22 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.666 2.244 . . . . 0.0 112.341 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.859 ' HB2' HG11 ' A' ' 139' ' ' VAL . 15.2 m-85 -112.8 2.48 15.99 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.417 -0.356 . . . . 0.0 111.505 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.674 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -69.82 46.93 0.08 Allowed 'General case' 0 CA--C 1.53 0.204 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -178.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . 0.406 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 11.4 p30 -160.71 32.19 0.15 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 121.023 0.44 . . . . 0.0 110.615 179.101 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.666 ' O ' HG23 ' A' ' 139' ' ' VAL . 69.0 m-85 -154.63 145.08 22.15 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.604 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.51 ' O ' HG12 ' A' ' 165' ' ' VAL . 68.7 p -102.03 172.81 6.7 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.709 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -128.14 132.67 7.45 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.47 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.8 m -95.93 104.45 16.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.745 0.307 . . . . 0.0 110.696 179.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.53 HG21 ' CZ ' ' A' ' 131' ' ' PHE . 26.4 t -59.85 114.32 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.32 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -107.04 -40.13 5.54 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.64 179.72 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -135.2 153.48 51.93 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.685 179.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 2.0 mp -129.62 152.31 37.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.239 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 -130.16 79.09 73.48 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.762 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -69.07 -26.55 30.74 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.496 2.131 . . . . 0.0 112.427 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.1 tt0 -61.93 -34.52 76.24 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.863 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 8.3 mtt180 -108.27 -43.69 4.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.921 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 112.82 48.45 0.62 Allowed Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.505 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -137.37 177.24 8.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.835 0.35 . . . . 0.0 110.996 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.473 HG23 HG13 ' A' ' 151' ' ' VAL . 1.3 p -152.06 159.73 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 121.125 0.488 . . . . 0.0 110.898 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.472 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 7.1 tttm -119.43 124.35 46.31 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.867 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.419 HG12 ' HA ' ' A' ' 151' ' ' VAL . 29.7 m -136.4 146.33 29.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.252 -179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 8.5 ptm -92.71 130.38 38.35 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.878 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.51 HG12 ' O ' ' A' ' 148' ' ' THR . 27.7 m -131.5 144.49 37.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.184 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . 0.533 HG23 ' C ' ' A' ' 170' ' ' ARG . 0.6 OUTLIER -108.28 139.46 42.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.922 -179.952 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.8 mp -136.29 -66.83 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.182 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 16.3 m-85 -91.46 55.57 2.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.926 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 58.02 27.56 59.89 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.546 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . 0.533 ' C ' HG23 ' A' ' 166' ' ' THR . 0.5 OUTLIER -153.88 151.39 29.43 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.864 0.364 . . . . 0.0 110.938 -179.913 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -69.38 161.05 30.18 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.811 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . 0.553 HG22 ' CG2' ' A' ' 174' ' ' VAL . 16.4 m -153.52 96.49 2.81 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.876 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -66.77 83.37 0.31 Allowed 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.389 2.059 . . . . 0.0 112.139 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.553 ' CG2' HG22 ' A' ' 172' ' ' THR . 26.8 t -104.93 135.66 41.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.981 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -79.97 145.04 32.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.59 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.905 HD13 HG13 ' A' ' 181' ' ' VAL . 5.7 mt -146.17 -169.31 3.22 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 121.336 0.588 . . . . 0.0 111.41 -179.55 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -140.27 153.53 46.53 Favored 'General case' 0 N--CA 1.442 -0.827 0 CA-C-N 115.092 -0.958 . . . . 0.0 110.285 178.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 10.0 m-85 -50.18 -31.94 15.01 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.269 -179.589 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.9 p -79.76 -1.21 37.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.385 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.72 ' HB3' HD22 ' A' ' 176' ' ' LEU . 1.3 mm-40 -116.0 3.01 13.57 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 120.714 0.292 . . . . 0.0 111.491 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.905 HG13 HD13 ' A' ' 176' ' ' LEU . 5.2 m -140.56 167.02 18.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-O 120.923 0.392 . . . . 0.0 111.074 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.4 m -135.07 146.36 30.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.124 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.618 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -59.99 139.15 57.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.886 -179.998 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.253 -0.88 . . . . 0.0 111.066 179.994 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 120.82 0.343 . . . . 0.0 111.024 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.42 -44.77 15.65 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.938 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 14.7 m -96.58 179.55 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.104 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -68.87 133.42 48.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.113 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 21.2 t80 -83.19 161.91 21.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.913 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 8.6 tpt180 -154.62 146.78 23.73 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.86 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -66.07 132.24 48.08 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.795 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 106.45 -14.41 42.92 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.781 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -54.84 164.72 0.74 Allowed 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.912 0.387 . . . . 0.0 110.912 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . 0.456 ' O ' ' HB3' ' A' ' 184' ' ' ALA . 0.3 OUTLIER -112.15 115.87 29.56 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.07 -179.869 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 31.5 m -116.6 139.27 44.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.852 179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.417 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.4 OUTLIER -79.97 155.02 27.86 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.025 0.441 . . . . 0.0 110.975 -179.924 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.588 HG12 ' N ' ' A' ' 140' ' ' VAL . 36.4 t -95.26 167.4 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.729 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.877 HG22 ' O ' ' A' ' 180' ' ' GLN . 14.1 m -133.9 -21.01 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.25 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -178.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.44 ' O ' ' CD2' ' A' ' 144' ' ' PHE . 2.7 m -79.49 149.65 31.45 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.112 0.482 . . . . 0.0 112.18 -178.249 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 39.64 -148.46 0.15 Allowed Glycine 0 C--N 1.334 0.424 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.678 179.46 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -73.62 4.43 4.03 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.774 2.316 . . . . 0.0 112.557 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.551 ' HB2' HG11 ' A' ' 139' ' ' VAL . 0.5 OUTLIER -79.55 -8.99 59.54 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.48 -0.327 . . . . 0.0 111.072 179.959 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.44 ' HA ' ' O ' ' A' ' 139' ' ' VAL . . . -67.82 39.49 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -178.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . 0.453 ' H ' ' C ' ' A' ' 144' ' ' PHE . 0.3 OUTLIER -160.89 31.23 0.15 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.103 0.478 . . . . 0.0 110.56 179.102 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.431 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 44.9 m-85 -148.88 154.51 39.57 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.772 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.417 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 67.6 p -108.69 134.88 50.82 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.872 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -94.2 160.75 24.02 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.579 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.0 m -102.34 103.74 14.2 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.772 0.32 . . . . 0.0 110.751 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.704 ' HA ' HG12 ' A' ' 163' ' ' VAL . 33.9 t -62.27 107.59 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.967 179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -88.89 -49.34 6.86 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.843 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -135.48 171.06 14.99 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.698 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . 0.596 HD12 ' HD3' ' A' ' 156' ' ' PRO . 1.0 OUTLIER -137.64 158.82 34.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.168 -179.907 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -140.95 83.47 14.07 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.819 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . 0.596 ' HD3' HD12 ' A' ' 154' ' ' ILE . 56.5 Cg_endo -70.58 -27.04 23.04 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.515 2.143 . . . . 0.0 112.351 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -59.13 -42.4 90.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.885 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 4.6 mpt_? -103.8 -60.16 1.61 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.884 179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 130.21 49.55 0.12 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.494 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 13.0 mttm -130.62 161.34 31.8 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.826 0.346 . . . . 0.0 110.928 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 17.3 m -147.33 124.48 3.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.193 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 9.3 tttt -87.38 123.92 32.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.888 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.704 HG12 ' HA ' ' A' ' 151' ' ' VAL . 15.4 m -142.34 135.92 28.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.033 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . 0.404 ' HE3' ' C ' ' A' ' 164' ' ' MET . 0.0 OUTLIER -80.49 130.44 35.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.728 -179.992 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.632 HG22 HG12 ' A' ' 174' ' ' VAL . 15.4 m -110.22 131.18 61.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.234 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -97.62 100.31 11.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.809 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.586 HG23 ' O ' ' A' ' 167' ' ' ILE . 8.0 tt -95.59 111.07 25.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.105 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER 60.61 43.58 12.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.907 -179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 65.55 52.18 41.56 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.465 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -154.16 119.22 5.03 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.911 0.386 . . . . 0.0 110.833 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 1.9 pt-20 -58.94 134.11 56.66 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.932 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -147.75 96.73 4.05 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.867 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.69 118.06 5.16 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.452 2.102 . . . . 0.0 112.184 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.632 HG12 HG22 ' A' ' 165' ' ' VAL . 9.9 p -145.93 144.12 21.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.092 -179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -79.99 134.35 36.24 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.724 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.814 HD12 ' HB3' ' A' ' 180' ' ' GLN . 2.1 mm? -121.68 -172.0 2.34 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-O 121.375 0.607 . . . . 0.0 111.341 -179.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.577 ' O ' HG22 ' A' ' 181' ' ' VAL . 2.5 m-20 -150.28 151.95 33.76 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.466 178.366 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 3.7 m-85 -45.12 -46.5 11.83 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.623 -179.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.12 -20.88 63.15 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.143 179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.877 ' O ' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -92.93 -10.02 38.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.511 -179.786 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 177' ' ' ASP . 27.7 m -138.98 -176.63 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.803 0.335 . . . . 0.0 111.399 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . 0.4 HG23 ' HB2' ' A' ' 138' ' ' ARG . 14.4 m -150.32 157.37 6.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.032 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 10.9 tptt -71.69 138.07 48.3 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.888 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . 0.456 ' HB3' ' O ' ' A' ' 136' ' ' GLN . . . . . . . . 0 C--O 1.249 1.038 0 CA-C-O 118.199 -0.905 . . . . 0.0 111.195 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.337 0 CA-C-O 120.844 0.354 . . . . 0.0 110.954 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -166.32 97.81 0.6 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.87 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.402 HG11 ' HD2' ' A' ' 183' ' ' LYS . 21.4 t -120.85 118.62 56.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.186 179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -70.64 157.23 38.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.166 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.475 ' CZ ' HG21 ' A' ' 151' ' ' VAL . 2.7 t80 -98.02 155.47 17.09 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.906 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 1.8 tpt180 -156.62 146.53 21.01 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.922 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -60.46 118.56 6.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.896 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.99 19.75 14.24 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.597 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -76.4 158.49 31.34 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.784 0.326 . . . . 0.0 110.847 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 -109.81 126.74 54.1 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.108 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.879 HG12 ' HA ' ' A' ' 183' ' ' LYS . 12.7 m -141.02 141.03 31.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.863 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.431 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 1.7 ttp180 -79.64 161.72 25.7 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.066 0.46 . . . . 0.0 110.833 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.855 HG11 ' HB2' ' A' ' 144' ' ' PHE . 27.6 t -79.98 151.37 4.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.784 -0.644 . . . . 0.0 111.607 -179.62 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.552 HG13 ' O ' ' A' ' 180' ' ' GLN . 33.5 m -93.99 -19.44 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 -179.338 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.72 ' H ' HG12 ' A' ' 139' ' ' VAL . 4.2 m -79.14 153.4 30.12 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.767 0.318 . . . . 0.0 111.026 -179.079 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . -64.31 -63.87 4.02 Favored Glycine 0 CA--C 1.519 0.31 0 C-N-CA 120.894 -0.669 . . . . 0.0 112.964 -179.497 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -53.36 -22.76 21.73 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.753 2.302 . . . . 0.0 112.474 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.855 ' HB2' HG11 ' A' ' 139' ' ' VAL . 6.4 m-85 -111.12 1.05 17.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.516 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.691 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -69.65 47.63 0.08 Allowed 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 112.61 0.596 . . . . 0.0 112.61 -178.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . 0.404 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 17.4 p-10 -160.79 32.34 0.15 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.157 0.503 . . . . 0.0 110.696 179.015 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.757 ' O ' HG23 ' A' ' 139' ' ' VAL . 35.0 m-85 -154.56 145.53 22.64 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.507 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.431 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 75.5 p -99.86 175.91 5.62 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.849 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -136.86 151.59 21.01 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.652 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.2 m -114.12 112.36 23.08 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.726 0.298 . . . . 0.0 110.978 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.475 HG21 ' CZ ' ' A' ' 131' ' ' PHE . 21.8 t -66.36 107.87 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.071 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -88.33 -50.42 6.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.845 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -135.62 164.36 28.03 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.009 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.8 mt -126.88 151.78 34.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.092 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -113.88 86.78 11.53 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.91 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.63 -27.13 22.72 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.591 2.194 . . . . 0.0 112.337 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -60.09 -51.1 71.05 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.949 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 2.6 ttt85 -97.37 -67.21 0.86 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.895 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 141.24 52.89 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.669 -0.776 . . . . 0.0 112.417 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 14.3 mttp -131.14 178.76 6.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.831 0.348 . . . . 0.0 110.82 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.701 HG11 ' CE1' ' A' ' 178' ' ' PHE . 28.1 m -145.87 123.07 4.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.071 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 62.6 tttt -79.88 116.43 20.02 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.625 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 3.1 t -124.55 150.2 29.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.042 -179.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 4.5 ptt? -103.65 116.49 32.43 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.023 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . . . . . . . . . 3.2 m -113.17 138.15 43.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.051 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -97.69 133.79 41.74 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.852 179.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.612 HD13 ' HB2' ' A' ' 168' ' ' PHE . 0.0 OUTLIER -133.47 117.88 29.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.999 179.971 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . 0.612 ' HB2' HD13 ' A' ' 167' ' ' ILE . 0.2 OUTLIER 62.99 30.28 16.39 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.958 -179.7 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 77.0 45.01 12.31 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.494 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -157.85 128.56 6.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.827 0.346 . . . . 0.0 110.869 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -59.74 144.36 48.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.831 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . 0.701 ' O ' HG23 ' A' ' 174' ' ' VAL . 22.3 m -144.18 83.07 10.36 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.943 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_exo -56.23 90.16 0.04 OUTLIER 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.566 2.178 . . . . 0.0 112.312 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.701 HG23 ' O ' ' A' ' 172' ' ' THR . 24.7 t -109.0 132.69 56.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.086 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -79.92 125.84 30.25 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.278 179.602 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -134.43 -160.81 1.08 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.405 0.621 . . . . 0.0 111.459 -179.317 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.683 ' HA ' HG22 ' A' ' 161' ' ' VAL . 1.5 m-20 -151.44 156.53 40.84 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.936 178.299 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . 0.701 ' CE1' HG11 ' A' ' 161' ' ' VAL . 14.5 m-85 -46.77 -28.07 1.41 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.599 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -78.81 -0.26 29.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.708 -179.722 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.552 ' O ' HG13 ' A' ' 140' ' ' VAL . 79.1 mt-30 -118.74 0.14 11.4 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-O 120.481 0.182 . . . . 0.0 111.405 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 5.7 m -144.98 156.02 13.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-O 120.86 0.362 . . . . 0.0 111.099 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 30.3 m -126.41 146.43 32.25 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.167 -179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.879 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -64.85 128.8 37.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.003 179.97 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.059 0 CA-C-O 118.309 -0.853 . . . . 0.0 111.143 179.992 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.312 0 CA-C-O 120.928 0.394 . . . . 0.0 111.102 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 13.9 tt0 -69.2 137.71 53.46 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.949 179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 5.1 m -119.85 113.2 39.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.177 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -89.88 -60.34 1.96 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.142 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.582 ' CZ ' HG21 ' A' ' 151' ' ' VAL . 3.2 t80 -83.96 151.83 24.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.942 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 3.3 mtt180 -147.36 131.74 17.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.936 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -60.34 120.69 10.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.847 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 108.67 11.3 23.38 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.674 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -90.04 169.4 11.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.756 0.313 . . . . 0.0 110.92 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.36 134.15 48.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.829 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.743 HG12 ' HA ' ' A' ' 183' ' ' LYS . 21.0 m -142.06 134.04 27.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.148 -179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.406 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.1 OUTLIER -80.99 163.13 23.5 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.94 0.4 . . . . 0.0 110.627 179.913 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.634 HG11 ' HB2' ' A' ' 144' ' ' PHE . 11.7 t -79.83 166.99 2.32 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.912 179.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.624 HG13 ' C ' ' A' ' 180' ' ' GLN . 2.1 m -79.31 -61.79 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -179.306 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.738 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 4.2 m -160.02 -166.4 1.7 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.811 0.338 . . . . 0.0 111.258 -179.466 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.59 -158.37 37.25 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.392 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -68.82 -10.96 30.6 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.586 2.191 . . . . 0.0 112.352 179.82 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.634 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.3 m-85 -107.31 14.18 26.33 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.468 -179.796 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.738 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -75.3 36.48 0.12 Allowed 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 112.403 0.519 . . . . 0.0 112.403 -179.342 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -161.16 34.13 0.14 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.913 0.387 . . . . 0.0 110.77 179.278 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.4 ' O ' HG23 ' A' ' 139' ' ' VAL . 23.1 m-85 -145.31 164.43 31.44 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.991 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.514 HG22 ' C ' ' A' ' 137' ' ' VAL . 0.6 OUTLIER -121.66 -173.94 2.75 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.43 179.586 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -154.6 161.83 30.4 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.449 -0.881 . . . . 0.0 112.844 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . 0.46 ' C ' HG13 ' A' ' 163' ' ' VAL . 88.9 m -110.49 101.6 10.28 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.833 0.349 . . . . 0.0 110.841 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.582 HG21 ' CZ ' ' A' ' 131' ' ' PHE . 31.6 t -59.45 114.63 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.178 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -83.25 -61.07 1.95 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.866 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -134.23 168.98 17.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.895 -179.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . 0.465 HG23 HG12 ' A' ' 161' ' ' VAL . 3.7 mt -126.96 135.51 63.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.069 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.2 m120 -107.12 84.48 1.67 Allowed Pre-proline 0 C--N 1.33 -0.275 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.92 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.44 -28.12 22.36 Favored 'Trans proline' 0 C--N 1.345 0.394 0 C-N-CA 122.607 2.204 . . . . 0.0 112.256 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -68.31 -34.15 75.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.968 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 25.0 mmt180 -101.53 -56.11 2.37 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.958 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 121.66 37.35 0.68 Allowed Glycine 0 N--CA 1.452 -0.244 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.495 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -126.98 175.09 8.34 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.758 0.314 . . . . 0.0 110.864 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.697 HG11 ' CE1' ' A' ' 178' ' ' PHE . 15.5 m -151.17 119.7 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.135 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 2.1 ttpm? -79.86 137.46 36.93 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.73 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.633 ' HB ' HD21 ' A' ' 176' ' ' LEU . 4.8 t -149.19 146.68 17.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.997 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.67 127.56 48.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.016 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.618 ' CG2' HD11 ' A' ' 167' ' ' ILE . 3.5 m -107.02 147.66 12.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.039 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 63.3 m -112.67 85.58 2.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.978 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.618 HD11 ' CG2' ' A' ' 165' ' ' VAL . 4.1 mp -98.09 126.81 51.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.031 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 61.57 31.33 18.84 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.902 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 69.5 38.38 79.32 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.554 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 72.5 mmt-85 -146.76 134.42 21.07 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.861 0.363 . . . . 0.0 110.924 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -72.29 147.99 45.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.882 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 1.8 m -157.14 88.41 2.62 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.804 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -50.8 115.54 2.06 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.608 2.205 . . . . 0.0 112.338 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.882 HG13 HD11 ' A' ' 176' ' ' LEU . 10.4 p -128.63 142.74 43.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.064 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . 0.872 ' C ' HD13 ' A' ' 176' ' ' LEU . 6.8 pt-20 -98.25 121.49 40.24 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.838 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.882 HD11 HG13 ' A' ' 174' ' ' VAL . 0.0 OUTLIER -126.94 -160.41 1.0 Allowed 'General case' 0 CA--C 1.518 -0.286 0 CA-C-O 121.353 0.597 . . . . 0.0 110.894 -179.939 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.427 ' HA ' HG22 ' A' ' 161' ' ' VAL . 4.8 m-20 -148.36 155.37 41.18 Favored 'General case' 0 N--CA 1.442 -0.83 0 CA-C-N 115.163 -0.926 . . . . 0.0 109.934 178.373 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . 0.697 ' CE1' HG11 ' A' ' 161' ' ' VAL . 11.7 m-85 -48.31 -33.83 9.53 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.482 -179.47 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 90.9 p -78.21 -2.55 38.3 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.643 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.624 ' C ' HG13 ' A' ' 140' ' ' VAL . 4.3 mt-30 -115.29 -2.81 12.58 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.545 0.212 . . . . 0.0 111.564 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 17.4 m -140.41 171.98 12.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.167 0 CA-C-O 120.844 0.354 . . . . 0.0 111.393 -179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 27.5 m -136.72 146.43 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.219 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.743 ' HA ' HG12 ' A' ' 137' ' ' VAL . 5.2 mtmt -80.09 130.99 35.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.919 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.278 -0.867 . . . . 0.0 111.045 -179.972 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.331 0 CA-C-O 120.876 0.369 . . . . 0.0 110.976 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 30.2 tt0 60.49 162.59 0.06 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.811 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 9.5 p -145.68 147.32 18.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.049 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -76.49 122.23 24.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.059 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 13.4 t80 -118.72 155.38 31.17 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.827 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -143.06 132.91 24.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.921 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -59.62 123.73 17.84 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.861 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.48 5.72 27.76 Favored Glycine 0 CA--C 1.519 0.286 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.834 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -67.61 162.57 23.23 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.739 0.304 . . . . 0.0 110.792 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -111.59 131.23 55.4 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.977 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.654 HG12 ' HA ' ' A' ' 183' ' ' LYS . 15.6 m -143.42 148.25 19.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.803 179.837 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.767 ' HD3' HG22 ' A' ' 148' ' ' THR . 0.2 OUTLIER -79.63 164.62 23.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.03 0.443 . . . . 0.0 111.033 -179.927 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.901 HG23 ' O ' ' A' ' 147' ' ' PHE . 22.3 t -79.88 151.06 4.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.674 -179.636 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 11.4 p -90.83 -24.17 5.75 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-N 116.044 -0.526 . . . . 0.0 112.076 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.684 ' H ' HG12 ' A' ' 139' ' ' VAL . 6.2 m -79.33 154.67 28.9 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.999 0.428 . . . . 0.0 111.412 -178.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . 0.439 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -67.26 -61.19 5.32 Favored Glycine 0 N--CA 1.451 -0.308 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.69 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.439 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.2 Cg_endo -51.43 -24.55 16.64 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 122.663 2.242 . . . . 0.0 112.205 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.865 ' HB2' HG11 ' A' ' 139' ' ' VAL . 21.3 m-85 -112.98 4.36 16.7 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.419 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.681 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -70.06 46.58 0.08 Allowed 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -179.097 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . 0.427 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 17.5 p-10 -160.56 30.82 0.16 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.204 0.526 . . . . 0.0 110.498 179.037 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.901 ' O ' HG23 ' A' ' 139' ' ' VAL . 24.2 m-85 -151.85 146.18 25.48 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.168 179.732 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.767 HG22 ' HD3' ' A' ' 138' ' ' ARG . 26.7 p -96.85 -177.36 3.86 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.737 -179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . 0.4 ' HA3' ' CG2' ' A' ' 163' ' ' VAL . . . -144.63 159.34 27.78 Favored Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.608 -179.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 2.2 m -117.09 111.55 19.67 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.798 0.332 . . . . 0.0 110.862 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 21.6 t -69.37 131.92 33.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.047 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -100.74 -68.92 0.79 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.026 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -123.71 172.92 8.46 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.948 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . 0.443 HG23 HG12 ' A' ' 161' ' ' VAL . 35.0 mt -139.35 128.93 30.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.074 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -100.81 99.51 10.48 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.897 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.41 -23.75 17.15 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.557 2.171 . . . . 0.0 112.417 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -90.27 23.2 2.99 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.301 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 16.4 mtp180 -158.6 -44.25 0.06 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.754 0.311 . . . . 0.0 110.765 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 97.4 57.39 1.06 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.472 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -142.55 162.95 34.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.765 0.317 . . . . 0.0 111.016 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.641 HG11 ' CE1' ' A' ' 178' ' ' PHE . 24.1 m -148.06 126.67 3.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.961 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 6.0 tttp -79.94 122.29 26.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.856 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.4 ' CG2' ' HA3' ' A' ' 149' ' ' GLY . 11.4 p -126.13 145.93 32.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.085 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -105.21 117.89 35.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.735 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.683 HG22 HG12 ' A' ' 174' ' ' VAL . 13.4 m -110.33 142.76 21.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.139 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . 0.484 HG23 ' C ' ' A' ' 170' ' ' ARG . 8.2 m -135.73 133.32 37.89 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.875 -179.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.482 ' O ' HG22 ' A' ' 167' ' ' ILE . 4.1 mp -102.69 53.47 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.937 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER 65.67 96.49 0.05 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.974 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 65.81 33.55 86.17 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.679 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . 0.484 ' C ' HG23 ' A' ' 166' ' ' THR . 0.0 OUTLIER -154.44 86.07 1.14 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.849 0.357 . . . . 0.0 111.019 -179.884 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -68.79 141.95 55.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.706 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 63.4 m -160.0 93.3 1.68 Allowed Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.167 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 26.6 Cg_exo -62.06 124.81 15.11 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.651 2.234 . . . . 0.0 112.057 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.683 HG12 HG22 ' A' ' 165' ' ' VAL . 11.2 p -137.91 132.33 43.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.32 -179.828 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -79.82 131.72 35.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.263 179.642 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.806 HD23 HG13 ' A' ' 181' ' ' VAL . 1.1 mp -133.07 -167.74 1.97 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.421 0.629 . . . . 0.0 111.608 -179.319 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.442 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.6 OUTLIER -144.66 154.11 42.45 Favored 'General case' 0 N--CA 1.442 -0.862 0 CA-C-N 114.961 -1.018 . . . . 0.0 110.199 178.152 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . 0.641 ' CE1' HG11 ' A' ' 161' ' ' VAL . 8.9 m-85 -44.73 -33.68 1.96 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.612 -179.548 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -82.32 14.65 2.83 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.679 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.427 ' N ' ' O ' ' A' ' 177' ' ' ASP . 21.6 mt-30 -127.85 4.91 6.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.576 0.227 . . . . 0.0 111.328 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.806 HG13 HD23 ' A' ' 176' ' ' LEU . 6.2 m -146.45 170.72 4.57 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.14 0 CA-C-O 120.874 0.369 . . . . 0.0 111.198 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 21.0 m -140.49 146.38 24.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.084 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.654 ' HA ' HG12 ' A' ' 137' ' ' VAL . 13.6 tttt -66.07 121.94 16.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.891 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.272 -0.871 . . . . 0.0 111.062 179.983 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.294 0 CA-C-O 120.7 0.286 . . . . 0.0 111.05 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 25.0 mt-30 -131.88 77.55 1.77 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.926 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 6.5 m -112.31 -32.69 2.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.15 179.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -82.56 113.89 20.59 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.116 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.535 ' CZ ' HG21 ' A' ' 151' ' ' VAL . 16.5 t80 -97.13 157.91 15.7 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.787 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 7.1 mmt180 -142.02 148.14 38.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.059 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -64.22 122.83 17.57 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.792 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 96.23 18.26 31.8 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.617 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.49 176.51 9.33 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.798 0.333 . . . . 0.0 110.884 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 38.2 mt-30 -120.08 114.34 21.83 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.115 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.609 HG12 ' HA ' ' A' ' 183' ' ' LYS . 18.8 m -124.43 143.17 38.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.805 179.701 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -79.85 162.11 25.24 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.109 0.481 . . . . 0.0 111.054 -179.724 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.856 HG11 ' HB2' ' A' ' 144' ' ' PHE . 46.7 t -84.62 155.21 3.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.529 -179.423 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.553 HG13 ' O ' ' A' ' 180' ' ' GLN . 35.6 m -96.89 -24.65 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 N-CA-C 112.675 0.62 . . . . 0.0 112.675 -179.165 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.617 ' H ' HG12 ' A' ' 139' ' ' VAL . 0.2 OUTLIER -78.99 131.12 36.19 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.85 0.357 . . . . 0.0 111.32 -178.646 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . 0.476 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -44.19 -59.07 4.17 Favored Glycine 0 C--N 1.332 0.347 0 CA-C-N 115.823 -0.626 . . . . 0.0 113.597 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.476 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.7 Cg_endo -51.1 -22.74 11.3 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.669 2.246 . . . . 0.0 112.481 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.856 ' HB2' HG11 ' A' ' 139' ' ' VAL . 21.2 m-85 -120.13 4.83 10.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.428 -0.351 . . . . 0.0 111.466 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.522 ' N ' ' O ' ' A' ' 141' ' ' SER . . . -70.02 45.21 0.07 Allowed 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 112.55 0.574 . . . . 0.0 112.55 -178.653 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . 0.408 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 15.1 p-10 -160.69 31.74 0.15 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.13 0.491 . . . . 0.0 110.422 179.091 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.659 ' O ' HG23 ' A' ' 139' ' ' VAL . 46.3 m-85 -155.66 145.98 21.78 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.439 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 1.4 p -101.76 168.89 9.16 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.789 -179.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -132.49 132.45 6.64 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.515 -179.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.7 m -87.35 109.05 19.27 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.723 0.297 . . . . 0.0 110.802 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.535 HG21 ' CZ ' ' A' ' 131' ' ' PHE . 19.2 t -64.38 123.8 17.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.093 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.2 p -100.97 -43.66 5.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.957 179.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 6.6 mt-10 -136.77 151.25 48.98 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.89 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . 0.488 HG23 HG12 ' A' ' 161' ' ' VAL . 7.8 mt -128.57 132.23 68.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.101 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -116.98 85.54 18.03 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.835 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -58.37 -30.05 90.06 Favored 'Trans proline' 0 C--N 1.343 0.278 0 C-N-CA 122.595 2.196 . . . . 0.0 112.321 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 28.0 tt0 -60.38 -62.68 1.69 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.099 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 7.7 ttm180 -79.99 -30.89 39.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.029 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 93.53 27.15 13.54 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.58 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 2.9 mtmm -107.78 162.65 13.8 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.732 0.301 . . . . 0.0 110.754 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.759 HG11 ' CE1' ' A' ' 178' ' ' PHE . 15.7 m -153.71 123.19 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.163 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 29.4 tttt -85.66 146.97 26.6 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.816 179.806 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.781 HG21 HD11 ' A' ' 176' ' ' LEU . 25.0 m -144.96 170.1 7.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.276 -179.866 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -120.0 110.87 17.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.655 179.631 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.51 HG22 ' O ' ' A' ' 172' ' ' THR . 11.9 m -99.53 157.99 3.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.138 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 27.4 p -141.49 97.41 3.15 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.982 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.495 ' H ' HD12 ' A' ' 167' ' ' ILE . 3.9 mp -79.87 83.53 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.962 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 24.7 m-85 62.29 70.39 0.57 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.902 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 60.26 47.06 92.97 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.566 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 1.5 mtm180 -146.38 91.48 2.05 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.905 0.383 . . . . 0.0 110.977 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -58.17 140.39 53.03 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.984 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . 0.51 ' O ' HG22 ' A' ' 165' ' ' VAL . 2.8 m -160.09 97.8 1.49 Allowed Pre-proline 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.933 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.86 123.76 10.38 Favored 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.405 2.07 . . . . 0.0 112.12 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.9 t -139.74 145.26 26.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.134 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . 0.89 ' O ' HD23 ' A' ' 176' ' ' LEU . 0.4 OUTLIER -88.92 142.47 27.62 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.859 179.997 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.89 HD23 ' O ' ' A' ' 175' ' ' GLU . 0.1 OUTLIER -147.68 -161.29 1.3 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.337 0.589 . . . . 0.0 111.088 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.583 ' HA ' HG22 ' A' ' 161' ' ' VAL . 1.0 OUTLIER -150.48 155.18 39.02 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.007 178.292 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . 0.759 ' CE1' HG11 ' A' ' 161' ' ' VAL . 25.6 m-85 -46.47 -30.4 2.18 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.536 -179.583 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 60.6 p -81.19 8.11 9.65 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.863 -179.799 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.553 ' O ' HG13 ' A' ' 140' ' ' VAL . 6.2 mt-30 -122.39 2.12 9.65 Favored 'General case' 0 C--O 1.233 0.227 0 CA-C-O 120.616 0.246 . . . . 0.0 111.286 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 4.8 m -143.24 172.31 7.59 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-O 120.88 0.371 . . . . 0.0 111.084 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 18.0 m -142.16 148.92 19.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.161 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.609 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -67.57 125.35 25.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.911 -179.968 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.174 -0.917 . . . . 0.0 111.106 179.92 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.308 0 CA-C-O 120.774 0.321 . . . . 0.0 111.006 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 1.5 mt-30 -98.91 30.71 3.25 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.919 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.4 t -136.63 148.16 27.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.197 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -59.96 -63.82 1.16 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.121 -179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.64 ' CE2' HG21 ' A' ' 151' ' ' VAL . 6.0 t80 -90.57 154.67 19.43 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.855 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -158.09 157.5 32.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.88 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -62.6 135.47 57.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.912 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 105.31 -23.94 28.99 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.637 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.8 t0 -58.2 158.23 7.34 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.825 0.345 . . . . 0.0 110.947 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 13.9 mm-40 -110.41 138.42 46.82 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.002 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.489 HG12 ' HA ' ' A' ' 183' ' ' LYS . 18.4 m -140.01 134.11 36.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.911 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.457 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 2.6 ttm180 -79.95 166.03 22.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.995 0.426 . . . . 0.0 110.839 179.877 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.673 HG23 ' O ' ' A' ' 147' ' ' PHE . 3.9 t -79.91 169.73 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.799 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.6 HG23 ' H ' ' A' ' 141' ' ' SER . 0.7 OUTLIER -79.49 -65.53 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 111.835 0.309 . . . . 0.0 111.835 -179.5 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.67 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.0 OUTLIER -160.18 -167.85 2.04 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.827 0.346 . . . . 0.0 111.059 -179.683 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 83.81 -162.27 39.09 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.417 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -64.28 -15.72 51.12 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.532 2.154 . . . . 0.0 112.241 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.655 ' HD1' HD13 ' A' ' 167' ' ' ILE . 2.8 m-85 -104.54 19.73 19.82 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.149 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.67 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -80.69 38.22 0.44 Allowed 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -179.259 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . 0.435 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 8.8 t70 -160.84 32.63 0.15 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.01 0.434 . . . . 0.0 110.977 179.234 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.673 ' O ' HG23 ' A' ' 139' ' ' VAL . 17.0 m-85 -140.3 161.11 38.47 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.7 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.457 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 25.1 p -116.42 -178.45 3.42 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.741 179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -145.43 137.42 7.04 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.664 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 14.5 m -92.83 108.64 20.15 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.78 0.324 . . . . 0.0 110.663 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.64 HG21 ' CE2' ' A' ' 131' ' ' PHE . 20.7 t -69.37 118.87 14.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.207 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -103.77 -34.82 8.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.854 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -151.25 159.72 44.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.859 179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mp -139.83 140.52 35.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.136 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 24.3 m120 -103.71 92.2 4.05 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.863 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -69.4 -27.76 27.77 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.538 2.159 . . . . 0.0 112.25 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -70.25 -40.27 74.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.867 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 3.7 mmt180 -98.49 -62.42 1.24 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.855 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 125.47 55.42 0.16 Allowed Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.476 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -130.45 166.53 20.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.92 0.39 . . . . 0.0 110.921 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.659 HG22 ' HA ' ' A' ' 177' ' ' ASP . 3.4 m -147.94 116.93 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.059 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 26.1 ttpt -87.07 121.52 29.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.754 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.416 HG12 HG22 ' A' ' 151' ' ' VAL . 35.7 m -135.6 147.01 28.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.254 -179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 4.1 ptt? -102.17 118.73 37.51 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.043 -179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.432 HG12 ' N ' ' A' ' 166' ' ' THR . 7.4 t -106.2 158.45 6.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.12 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . 0.432 ' N ' HG12 ' A' ' 165' ' ' VAL . 0.6 OUTLIER -110.18 94.65 5.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.946 179.977 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.655 HD13 ' HD1' ' A' ' 144' ' ' PHE . 1.4 tp -112.16 136.74 47.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.965 179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER 61.31 30.1 18.93 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.921 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 67.74 39.97 90.03 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.633 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -159.88 140.21 11.86 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.787 0.327 . . . . 0.0 110.967 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.57 150.92 45.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.77 -179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . 0.403 ' O ' HG23 ' A' ' 174' ' ' VAL . 14.8 p -153.3 93.47 3.12 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.042 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.88 87.18 0.29 Allowed 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.444 2.096 . . . . 0.0 112.039 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 172' ' ' THR . 34.6 t -101.62 135.3 38.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.338 -179.746 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . 0.417 ' C ' HD23 ' A' ' 176' ' ' LEU . 10.9 pm0 -82.04 124.31 29.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.581 179.687 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.417 HD23 ' C ' ' A' ' 175' ' ' GLU . 0.2 OUTLIER -132.55 -160.9 1.09 Allowed 'General case' 0 CA--C 1.517 -0.308 0 CA-C-O 121.351 0.596 . . . . 0.0 111.254 -179.605 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.659 ' HA ' HG22 ' A' ' 161' ' ' VAL . 4.6 m-20 -149.88 155.2 39.62 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.169 178.377 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . 0.565 ' CE1' HG11 ' A' ' 161' ' ' VAL . 42.6 m-85 -46.34 -29.02 1.49 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.732 -179.502 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 8.2 m -74.52 -5.7 44.21 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.574 -0.285 . . . . 0.0 111.738 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.535 ' C ' HG13 ' A' ' 140' ' ' VAL . 11.9 mm-40 -120.76 -4.46 9.71 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 111.603 0.223 . . . . 0.0 111.603 -179.833 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.414 ' CG2' ' HA ' ' A' ' 178' ' ' PHE . 6.6 m -122.76 178.03 3.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.86 0.362 . . . . 0.0 111.223 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . 0.446 HG22 ' O ' ' A' ' 138' ' ' ARG . 27.2 m -152.06 146.78 15.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.066 -0.516 . . . . 0.0 111.135 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.489 ' HA ' HG12 ' A' ' 137' ' ' VAL . 3.8 ttmm -67.51 125.2 25.4 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.927 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.17 -0.919 . . . . 0.0 111.105 -179.985 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.377 0 CA-C-O 120.81 0.338 . . . . 0.0 111.067 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -140.33 143.97 36.08 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.861 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.45 HG21 ' HG3' ' A' ' 132' ' ' ARG . 11.2 p -133.4 137.47 53.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.077 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -74.61 -44.52 50.22 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.155 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 6.7 t80 -145.06 145.83 31.61 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.859 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . 0.45 ' HG3' HG21 ' A' ' 129' ' ' VAL . 0.0 OUTLIER -149.94 152.03 34.34 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.907 180.0 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -67.6 140.26 56.9 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.011 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 93.95 -21.51 41.37 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.58 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.43 176.28 0.65 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.851 0.358 . . . . 0.0 110.94 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -112.36 143.35 43.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.04 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.639 HG12 ' HA ' ' A' ' 183' ' ' LYS . 18.0 m -139.42 133.13 38.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.907 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.435 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 1.6 ttt180 -79.85 165.14 23.02 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.017 0.437 . . . . 0.0 110.94 -179.819 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 147' ' ' PHE . 4.4 t -80.03 169.08 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.904 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.619 HG23 ' H ' ' A' ' 141' ' ' SER . 0.8 OUTLIER -79.63 -65.97 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.805 -179.5 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.687 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 51.8 p -160.13 -165.52 1.49 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.823 0.344 . . . . 0.0 111.017 -179.78 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.61 -160.56 39.64 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.414 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -66.65 -13.42 39.82 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.613 2.209 . . . . 0.0 112.295 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.526 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.6 m-85 -106.97 20.49 18.97 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.164 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.687 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -81.13 38.91 0.49 Allowed 'General case' 0 C--N 1.331 -0.239 0 N-CA-C 112.3 0.481 . . . . 0.0 112.3 -179.377 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -160.97 36.49 0.15 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.88 0.371 . . . . 0.0 110.951 179.358 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.719 ' O ' HG23 ' A' ' 139' ' ' VAL . 48.0 m-85 -147.84 158.48 44.05 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.815 -179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.669 ' O ' HG12 ' A' ' 165' ' ' VAL . 58.2 p -118.93 169.2 10.08 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.792 179.869 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . 0.413 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -132.67 153.36 20.62 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.641 -0.79 . . . . 0.0 112.679 -179.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 2.7 m -101.81 107.72 18.99 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.819 0.343 . . . . 0.0 110.828 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 24.5 t -62.42 116.66 2.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.131 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 4.6 p -108.68 -57.2 2.17 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.859 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -113.23 155.99 24.08 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.878 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . 0.472 HG23 HG12 ' A' ' 161' ' ' VAL . 4.0 mp -142.31 141.72 28.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.172 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -123.65 101.29 36.88 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.812 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -69.23 -26.55 29.95 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.398 2.066 . . . . 0.0 112.438 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.57 -42.15 52.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.918 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 49.3 mtt-85 -87.43 -33.8 18.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.901 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 85.11 35.81 11.94 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.427 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . 0.533 ' O ' HG13 ' A' ' 161' ' ' VAL . 28.6 mttm -118.01 177.04 4.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.754 0.312 . . . . 0.0 110.857 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.576 HG11 ' CE1' ' A' ' 178' ' ' PHE . 6.1 m -158.94 121.49 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.166 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 80.5 tttt -84.87 132.75 34.35 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.822 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.413 ' HB ' ' HA3' ' A' ' 149' ' ' GLY . 33.8 m -139.67 138.67 39.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.144 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 12.6 ptm -90.67 113.84 26.0 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.892 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.669 HG12 ' O ' ' A' ' 148' ' ' THR . 27.4 m -115.46 156.91 16.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.171 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 16.7 p -105.98 142.52 35.54 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.719 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.811 HD13 ' O ' ' A' ' 167' ' ' ILE . 0.0 OUTLIER -103.77 -38.96 5.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.997 179.927 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -171.18 86.15 0.09 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.866 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 58.16 30.24 63.79 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.559 -179.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -158.13 134.46 9.46 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.807 0.337 . . . . 0.0 110.925 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -67.96 155.89 38.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.899 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 3.4 m -159.96 93.71 1.66 Allowed Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.756 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -67.84 125.84 13.75 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.502 2.135 . . . . 0.0 112.294 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 7.4 m -139.38 139.02 39.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.3 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -79.87 126.49 31.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.344 179.524 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.904 HD13 HG13 ' A' ' 181' ' ' VAL . 6.8 mt -133.88 -170.99 2.62 Favored 'General case' 0 CA--C 1.516 -0.359 0 CA-C-O 121.388 0.613 . . . . 0.0 111.698 -179.345 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.453 ' O ' HG22 ' A' ' 181' ' ' VAL . 5.2 m-20 -144.36 155.7 43.91 Favored 'General case' 0 N--CA 1.442 -0.832 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.286 178.196 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . 0.576 ' CE1' HG11 ' A' ' 161' ' ' VAL . 10.7 m-85 -45.62 -41.74 10.51 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.577 -179.567 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 2.6 p -65.39 -15.88 63.05 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.373 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.779 ' CB ' HD22 ' A' ' 176' ' ' LEU . 4.0 mt-30 -103.78 -18.89 14.48 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.384 -179.689 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.904 HG13 HD13 ' A' ' 176' ' ' LEU . 11.0 m -120.75 173.05 6.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.922 0.392 . . . . 0.0 111.366 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 30.3 m -144.4 146.25 20.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.032 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.639 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -71.56 123.0 21.49 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.992 179.973 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.995 0 CA-C-O 118.324 -0.846 . . . . 0.0 111.061 179.977 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.372 0 CA-C-O 120.868 0.366 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . 0.49 ' O ' HG13 ' A' ' 129' ' ' VAL . 1.8 mm-40 -159.34 -57.92 0.06 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.829 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.49 HG13 ' O ' ' A' ' 128' ' ' GLN . 12.8 m -158.09 -43.58 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.287 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -55.93 -172.26 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.142 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.617 ' CZ ' HG21 ' A' ' 151' ' ' VAL . 7.4 t80 -95.21 147.53 23.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.877 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -147.43 142.31 26.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.929 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -63.69 138.32 58.44 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.951 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 105.85 -22.4 31.9 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.613 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.1 t0 -57.41 156.16 8.26 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.818 0.342 . . . . 0.0 111.028 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 10.0 mt-30 -113.17 137.53 51.32 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.939 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.804 HG12 ' HA ' ' A' ' 183' ' ' LYS . 18.4 m -143.81 141.39 25.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.155 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.435 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 3.7 ttp180 -79.91 165.84 22.24 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.796 179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.748 HG23 ' O ' ' A' ' 147' ' ' PHE . 7.6 t -80.1 167.22 2.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.116 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.624 HG13 ' H ' ' A' ' 141' ' ' SER . 2.6 p -79.35 -61.41 1.73 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.92 -179.395 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.677 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 2.6 m -160.35 -165.13 1.38 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.912 0.386 . . . . 0.0 111.138 -179.464 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.56 -165.85 50.32 Favored Glycine 0 C--N 1.332 0.334 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.334 179.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 27.0 Cg_endo -62.15 -17.11 54.82 Favored 'Trans proline' 0 C--N 1.344 0.306 0 C-N-CA 122.474 2.116 . . . . 0.0 112.02 179.659 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.587 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.7 m-85 -99.57 14.6 29.4 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.119 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.677 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -78.75 38.06 0.31 Allowed 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -179.234 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -160.89 36.6 0.15 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.88 0.371 . . . . 0.0 110.774 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.748 ' O ' HG23 ' A' ' 139' ' ' VAL . 16.2 m-85 -152.13 157.23 41.27 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.043 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.435 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 5.6 t -110.17 -176.02 2.88 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.636 179.823 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -154.89 140.41 7.38 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.539 -0.839 . . . . 0.0 112.779 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 12.2 m -94.16 110.19 21.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.754 0.311 . . . . 0.0 110.623 179.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.653 ' HA ' HG12 ' A' ' 163' ' ' VAL . 36.8 t -57.55 116.53 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.155 -179.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -111.45 -29.57 7.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.0 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -135.72 167.01 21.94 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.943 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 23.3 pt -145.59 133.27 15.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.167 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -117.19 81.18 12.78 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.803 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -71.44 -32.45 12.36 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 122.656 2.237 . . . . 0.0 112.224 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -59.74 -35.49 74.67 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.919 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -102.17 -33.98 9.44 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.927 -179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 99.16 43.87 2.5 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.45 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -139.76 156.12 46.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.934 0.397 . . . . 0.0 110.867 -179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.467 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.2 p -123.52 159.79 27.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.924 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.467 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 13.0 ttpt -128.65 140.22 51.87 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.184 -179.753 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.928 HG22 HD11 ' A' ' 176' ' ' LEU . 34.6 m -139.84 -179.73 2.3 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.233 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -120.08 111.9 18.45 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.702 179.565 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.403 HG22 ' O ' ' A' ' 172' ' ' THR . 31.0 m -98.25 167.92 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.263 -179.773 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.16 79.56 1.7 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.821 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 30.9 mm -80.54 108.37 13.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.173 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 59.15 55.27 4.44 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.064 0.459 . . . . 0.0 110.928 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 57.53 41.48 93.48 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.571 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 6.1 ttt180 -137.51 106.32 5.92 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.803 0.335 . . . . 0.0 110.924 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -73.21 127.02 31.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.874 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . 0.403 ' O ' HG22 ' A' ' 165' ' ' VAL . 52.3 m -147.17 131.44 8.6 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.79 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -74.79 106.71 2.31 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.516 2.144 . . . . 0.0 112.415 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.443 HG13 ' O ' ' A' ' 174' ' ' VAL . 12.1 p -119.07 124.01 72.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.987 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 12.4 mt-10 -88.15 141.89 28.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.806 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.928 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -138.12 -162.55 1.32 Allowed 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 121.233 0.539 . . . . 0.0 111.151 -179.644 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.694 ' O ' HG22 ' A' ' 181' ' ' VAL . 0.3 OUTLIER -146.04 152.2 38.96 Favored 'General case' 0 N--CA 1.444 -0.762 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.207 178.404 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 -48.74 -37.04 17.72 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.079 -0.51 . . . . 0.0 111.432 -179.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 17.3 p -75.74 -9.54 58.68 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.56 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 23.5 mt-30 -118.58 21.14 12.72 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-O 120.603 0.239 . . . . 0.0 111.417 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.694 HG22 ' O ' ' A' ' 177' ' ' ASP . 17.6 m -152.92 146.5 14.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.891 0.377 . . . . 0.0 111.22 179.786 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 30.9 m -114.15 146.28 18.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.135 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.804 ' HA ' HG12 ' A' ' 137' ' ' VAL . 4.1 ttmt -80.92 137.28 36.13 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.955 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.065 0 CA-C-O 118.255 -0.879 . . . . 0.0 111.041 179.979 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.868 0.366 . . . . 0.0 110.95 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -97.98 51.84 1.05 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.955 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.521 HG12 ' H ' ' A' ' 131' ' ' PHE . 19.1 t -132.19 132.5 60.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.195 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -90.3 25.52 2.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.536 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.521 ' H ' HG12 ' A' ' 129' ' ' VAL . 16.3 t80 -156.5 163.33 39.53 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.806 0.336 . . . . 0.0 110.991 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.24 136.63 50.35 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.843 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 -69.21 141.25 54.54 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.835 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 89.29 -8.66 79.34 Favored Glycine 0 CA--C 1.519 0.339 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.724 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -56.87 164.14 1.67 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.826 0.346 . . . . 0.0 111.027 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -104.05 134.63 46.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.976 -179.867 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.735 HG12 ' HA ' ' A' ' 183' ' ' LYS . 21.0 m -141.66 131.54 24.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.886 179.839 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.414 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 3.4 ttp180 -79.78 164.28 23.78 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.013 0.435 . . . . 0.0 110.976 -180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.635 HG23 ' O ' ' A' ' 147' ' ' PHE . 3.7 t -79.96 168.55 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.86 -179.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.617 HG23 ' H ' ' A' ' 141' ' ' SER . 0.7 OUTLIER -79.6 -65.8 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.202 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.768 -179.518 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.716 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.3 OUTLIER -160.11 -164.57 1.31 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.768 0.318 . . . . 0.0 110.903 -179.835 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 82.36 -157.34 36.5 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.529 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -69.53 -10.23 28.2 Favored 'Trans proline' 0 C--N 1.343 0.28 0 C-N-CA 122.558 2.172 . . . . 0.0 112.519 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.604 ' HB2' HG11 ' A' ' 139' ' ' VAL . 2.6 m-85 -110.46 19.54 18.67 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.511 -0.313 . . . . 0.0 111.201 -179.788 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.716 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -78.86 37.85 0.31 Allowed 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 112.248 0.462 . . . . 0.0 112.248 -179.352 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . 0.406 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 1.5 p30 -161.08 36.0 0.14 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.893 0.378 . . . . 0.0 110.896 179.281 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.635 ' O ' HG23 ' A' ' 139' ' ' VAL . 44.0 m-85 -146.81 163.03 37.34 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.969 -179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.414 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 1.1 p -118.16 -177.07 3.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.771 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -147.47 142.95 10.68 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.526 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.7 m -99.7 103.71 15.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.779 0.324 . . . . 0.0 110.766 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.519 HG22 HG12 ' A' ' 163' ' ' VAL . 31.7 t -60.6 127.03 19.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.206 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 1.9 p -111.95 -33.98 6.12 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.858 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -136.01 157.7 46.21 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.874 179.883 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 25.9 pt -138.76 136.22 43.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.261 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -120.09 84.57 33.65 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.879 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -54.28 -26.44 43.19 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.535 2.157 . . . . 0.0 112.392 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -58.7 -73.3 0.08 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.907 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 7.2 mtt85 -80.01 -30.45 39.6 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.909 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 93.97 47.0 2.99 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.412 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -106.34 159.69 15.94 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.884 0.373 . . . . 0.0 110.872 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.504 HG11 ' HE1' ' A' ' 178' ' ' PHE . 5.2 m -143.16 116.94 3.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.15 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 19.1 tttp -90.78 111.23 22.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.826 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.614 HG22 ' CD1' ' A' ' 176' ' ' LEU . 33.8 m -119.24 148.71 22.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.163 -179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 1.5 ppp? -95.1 114.77 26.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.773 179.79 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.478 HG22 ' O ' ' A' ' 172' ' ' THR . 17.0 m -105.52 149.11 9.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.202 -179.9 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 22.6 m -119.61 85.23 2.34 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.904 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.523 HG23 ' O ' ' A' ' 167' ' ' ILE . 1.7 tp -82.21 118.11 29.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.092 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 60.57 33.62 20.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.873 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 75.18 30.09 59.42 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.789 -0.719 . . . . 0.0 112.505 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.12 108.65 8.96 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.753 0.311 . . . . 0.0 110.981 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -59.95 139.91 57.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.807 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . 0.478 ' O ' HG22 ' A' ' 165' ' ' VAL . 53.8 m -154.12 109.56 2.46 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.913 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -67.45 100.67 0.58 Allowed 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.341 2.027 . . . . 0.0 112.157 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 11.9 p -108.45 129.01 63.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.286 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -90.63 123.39 34.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.614 179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.614 ' CD1' HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -137.33 -159.52 0.96 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.43 0.633 . . . . 0.0 111.128 -179.712 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.456 ' HA ' HG22 ' A' ' 161' ' ' VAL . 7.5 m-20 -145.56 157.33 44.0 Favored 'General case' 0 N--CA 1.441 -0.875 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.055 178.21 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . 0.504 ' HE1' HG11 ' A' ' 161' ' ' VAL . 6.4 m-85 -44.24 -30.42 0.8 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.015 -0.538 . . . . 0.0 111.656 -179.631 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 35.5 t -67.25 -23.55 65.71 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.435 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.539 ' O ' HG13 ' A' ' 140' ' ' VAL . 22.6 mt-30 -101.83 -14.17 17.38 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.617 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 10.7 m -123.39 172.15 11.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-O 120.858 0.361 . . . . 0.0 111.461 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 32.9 m -146.39 146.2 19.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.164 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.735 ' HA ' HG12 ' A' ' 137' ' ' VAL . 9.9 mttt -66.0 125.74 26.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.943 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.273 -0.87 . . . . 0.0 111.075 179.994 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.353 0 CA-C-O 120.788 0.328 . . . . 0.0 111.028 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . 0.521 ' OE1' ' HB3' ' A' ' 130' ' ' ALA . 0.0 OUTLIER 60.65 172.23 0.1 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.85 179.94 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 15.3 m -111.16 -32.29 2.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.137 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . 0.521 ' HB3' ' OE1' ' A' ' 128' ' ' GLN . . . -87.8 -176.57 5.55 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.103 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 11.0 p90 -93.36 179.23 5.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.827 -179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 2.0 ttm180 -112.69 167.22 10.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.98 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -59.66 120.16 8.95 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.939 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 121.71 -19.9 8.34 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.64 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -55.48 -178.85 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.824 0.345 . . . . 0.0 110.994 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 2.0 mt-30 -132.02 136.14 47.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.148 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.893 HG21 HG21 ' A' ' 181' ' ' VAL . 31.0 m -139.45 147.93 23.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.789 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -79.84 164.75 23.36 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.962 0.411 . . . . 0.0 111.022 -179.771 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.856 HG23 ' O ' ' A' ' 147' ' ' PHE . 39.7 t -79.8 149.35 5.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.433 -179.689 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 9.9 p -90.26 -20.36 6.99 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.193 0 CA-C-N 115.991 -0.55 . . . . 0.0 112.181 -179.494 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.75 ' H ' HG12 ' A' ' 139' ' ' VAL . 0.4 OUTLIER -79.23 152.65 30.5 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.908 0.385 . . . . 0.0 111.145 -179.032 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . 0.407 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -65.5 -63.37 4.14 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.892 -179.793 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.407 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.6 Cg_endo -53.76 -22.7 24.07 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.7 2.266 . . . . 0.0 112.32 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.804 ' HB2' HG11 ' A' ' 139' ' ' VAL . 17.5 m-85 -110.36 1.99 18.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.365 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.651 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -70.31 49.68 0.11 Allowed 'General case' 0 C--N 1.332 -0.183 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -179.151 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -160.69 32.63 0.15 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.15 0.5 . . . . 0.0 110.465 179.093 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.856 ' O ' HG23 ' A' ' 139' ' ' VAL . 46.5 m-85 -157.23 145.77 19.58 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.533 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.444 ' O ' HG12 ' A' ' 165' ' ' VAL . 30.3 p -103.67 -179.26 3.9 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.865 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -144.71 141.98 10.52 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.619 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 7.4 m -93.38 107.41 19.24 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.714 0.293 . . . . 0.0 110.696 179.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.577 ' HA ' HG12 ' A' ' 163' ' ' VAL . 40.9 t -64.84 113.14 1.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.088 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 73.8 p -97.76 -46.4 5.98 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.763 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -124.69 167.48 14.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.848 179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . 0.728 HG22 HG12 ' A' ' 161' ' ' VAL . 12.6 pt -146.49 160.14 10.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.203 -179.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 8.5 m-20 -132.24 89.71 36.55 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.923 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.15 -28.09 28.6 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.546 2.164 . . . . 0.0 112.289 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -62.49 -52.79 62.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.967 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.26 -49.43 5.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.905 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 115.44 52.23 0.41 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.574 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 6.0 tttt -125.88 170.15 11.94 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.864 0.364 . . . . 0.0 110.815 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.728 HG12 HG22 ' A' ' 154' ' ' ILE . 5.4 m -154.17 132.42 2.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.131 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 7.0 tttm -104.13 133.46 49.02 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.969 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.743 HG22 HD11 ' A' ' 176' ' ' LEU . 34.6 m -134.86 164.23 34.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.285 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 3.9 ptt? -106.7 120.55 42.27 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.808 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.444 HG12 ' O ' ' A' ' 148' ' ' THR . 16.9 m -117.51 157.56 18.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.13 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 23.6 m -142.37 105.81 4.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.974 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.1 mp -83.1 113.71 22.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.039 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 64.97 -77.71 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.971 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -154.47 44.23 0.57 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.448 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 5.2 ptt180 -148.24 115.27 6.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.883 0.373 . . . . 0.0 110.957 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -68.96 147.03 52.23 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.771 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 76.4 m -160.06 113.8 1.44 Allowed Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.942 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 64.9 Cg_endo -73.6 112.65 3.58 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.402 2.068 . . . . 0.0 112.141 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.5 t -119.41 124.4 72.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.225 -179.759 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -92.1 131.07 37.65 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.677 179.754 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.743 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -139.71 -161.65 1.22 Allowed 'General case' 0 CA--C 1.515 -0.385 0 CA-C-O 121.522 0.677 . . . . 0.0 111.259 -179.793 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.589 ' HA ' HG22 ' A' ' 161' ' ' VAL . 1.2 m-20 -138.06 161.29 37.14 Favored 'General case' 0 N--CA 1.439 -1.004 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.172 177.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . 0.48 ' HE1' HG11 ' A' ' 161' ' ' VAL . 3.4 m-85 -43.45 -38.51 2.85 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.693 -0.685 . . . . 0.0 112.554 -179.006 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -79.38 5.36 12.79 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.135 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.444 ' NE2' ' N ' ' A' ' 180' ' ' GLN . 1.2 mp0 -112.14 6.87 19.36 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.582 0.229 . . . . 0.0 111.407 -179.809 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.893 HG21 HG21 ' A' ' 137' ' ' VAL . 27.2 m -151.95 174.96 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 120.882 0.372 . . . . 0.0 111.289 -179.848 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 12.9 m -143.14 146.68 21.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.084 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.424 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.9 OUTLIER -60.82 123.27 17.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.926 -179.933 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.253 -0.88 . . . . 0.0 111.045 -179.96 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.335 0 CA-C-O 120.808 0.337 . . . . 0.0 111.034 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 7.0 mm-40 -119.27 -176.04 3.05 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.747 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.403 HG22 ' H ' ' A' ' 129' ' ' VAL . 8.7 m -79.92 122.08 34.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.051 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -60.39 179.21 0.16 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.278 -179.831 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 67.9 t80 -157.66 155.22 29.64 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.806 179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -148.23 150.61 34.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.915 -179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.4 pp20? -59.56 122.25 13.58 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.926 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.68 15.97 25.49 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.709 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -69.66 157.25 37.62 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.761 0.315 . . . . 0.0 110.91 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -93.16 132.19 37.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.981 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.413 HG12 ' HA ' ' A' ' 183' ' ' LYS . 14.9 m -140.79 133.25 31.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.927 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.423 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.8 OUTLIER -79.82 166.38 21.77 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.912 0.387 . . . . 0.0 110.967 -179.907 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.655 HG23 ' O ' ' A' ' 147' ' ' PHE . 7.3 t -79.74 167.9 2.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.969 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.632 HG13 ' H ' ' A' ' 141' ' ' SER . 3.0 p -79.41 -61.47 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 -179.291 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.632 ' H ' HG13 ' A' ' 140' ' ' VAL . 39.6 p -160.45 -164.1 1.19 Allowed 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.766 0.317 . . . . 0.0 111.246 -179.675 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.86 -168.58 54.26 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.325 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -59.93 -18.56 50.54 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.541 2.161 . . . . 0.0 112.087 179.671 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.538 ' HB2' HG11 ' A' ' 139' ' ' VAL . 4.1 m-85 -97.04 16.8 18.55 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.094 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.539 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -80.58 39.44 0.47 Allowed 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 112.146 0.425 . . . . 0.0 112.146 -179.425 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . 0.416 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 8.3 t0 -160.74 34.69 0.15 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.979 0.419 . . . . 0.0 110.71 179.43 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.655 ' O ' HG23 ' A' ' 139' ' ' VAL . 24.3 m-85 -146.13 160.68 41.59 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.711 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.423 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 3.2 p -120.22 172.99 7.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.989 -179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -138.62 159.92 25.48 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.563 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 3.4 m -109.38 110.02 21.05 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.765 0.317 . . . . 0.0 110.796 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 31.6 t -60.2 99.84 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.113 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -90.95 -39.23 12.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.74 179.861 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -132.7 154.0 50.59 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.708 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . 0.995 HG22 HG12 ' A' ' 161' ' ' VAL . 32.9 pt -148.56 136.5 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.095 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -114.32 89.18 16.95 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.892 179.909 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.06 -26.26 37.14 Favored 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.545 2.164 . . . . 0.0 112.406 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -59.79 -32.31 70.49 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.851 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 27.4 mtt85 -113.87 -46.33 3.03 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.905 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 118.76 44.54 0.5 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.494 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . 0.436 ' O ' HG13 ' A' ' 161' ' ' VAL . 2.0 mmtt -119.26 166.13 13.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.769 0.318 . . . . 0.0 110.883 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.995 HG12 HG22 ' A' ' 154' ' ' ILE . 5.9 m -156.0 129.5 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.301 -0.409 . . . . 0.0 111.043 180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 1.9 ttmp? -99.83 123.02 43.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.956 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 30.6 m -123.54 138.89 51.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.126 -179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -91.85 106.47 18.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.965 0.412 . . . . 0.0 110.796 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.505 ' CG2' HD11 ' A' ' 167' ' ' ILE . 13.5 m -90.14 167.0 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.096 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 3.4 m -130.16 92.76 3.34 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.911 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.505 HD11 ' CG2' ' A' ' 165' ' ' VAL . 4.1 mp -98.77 114.83 37.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.924 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 62.2 29.93 17.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 75.85 55.03 5.08 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.536 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -157.48 117.95 3.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.744 0.307 . . . . 0.0 111.0 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 4.2 mp0 -65.94 121.18 14.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.819 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . 0.482 ' O ' HG22 ' A' ' 165' ' ' VAL . 23.5 m -130.64 89.78 42.56 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.962 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -68.17 101.35 0.7 Allowed 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.432 2.088 . . . . 0.0 112.231 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.738 ' CG2' HD21 ' A' ' 176' ' ' LEU . 28.3 m -110.32 138.74 36.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.155 -179.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . 0.433 ' O ' HD23 ' A' ' 176' ' ' LEU . 0.4 OUTLIER -80.02 117.96 21.32 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.559 179.615 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.738 HD21 ' CG2' ' A' ' 174' ' ' VAL . 0.3 OUTLIER -137.16 -159.76 0.99 Allowed 'General case' 0 CA--C 1.517 -0.323 0 CA-C-O 121.292 0.567 . . . . 0.0 111.15 -179.622 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.501 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.9 OUTLIER -150.71 154.88 38.22 Favored 'General case' 0 N--CA 1.442 -0.848 0 CA-C-N 115.232 -0.894 . . . . 0.0 110.151 178.399 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -46.61 -28.88 1.59 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.546 -179.731 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.9 p -67.6 -14.44 62.94 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.339 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.404 ' O ' HG13 ' A' ' 181' ' ' VAL . 5.3 mt-30 -116.88 10.15 14.04 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.515 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.438 HG12 ' HA ' ' A' ' 139' ' ' VAL . 31.4 m -156.99 150.39 9.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.177 0 CA-C-O 120.807 0.337 . . . . 0.0 111.224 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . 0.489 HG12 ' H ' ' A' ' 183' ' ' LYS . 0.3 OUTLIER -121.29 173.72 6.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.898 179.958 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.489 ' H ' HG12 ' A' ' 182' ' ' VAL . 0.1 OUTLIER -75.85 150.3 37.67 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.956 -179.976 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.995 0 CA-C-O 118.224 -0.893 . . . . 0.0 111.115 -179.998 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.279 0 CA-C-O 120.806 0.336 . . . . 0.0 110.995 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -169.54 95.18 0.3 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.926 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 31.5 m -113.92 31.12 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.077 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -82.4 164.09 21.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.132 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.581 ' CZ ' HG21 ' A' ' 151' ' ' VAL . 11.1 t80 -109.67 162.38 14.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.924 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -159.36 145.44 16.31 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.824 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -65.07 135.42 55.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.846 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.82 -26.03 13.47 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.58 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -60.17 166.49 2.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.752 0.31 . . . . 0.0 110.912 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -112.7 130.38 56.08 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.989 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . . . . . . . . . 19.5 m -134.27 141.94 42.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.946 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.9 166.19 21.9 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.967 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.563 HG12 ' H ' ' A' ' 140' ' ' VAL . 4.2 t -79.77 169.18 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.014 -179.861 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.665 HG13 ' H ' ' A' ' 141' ' ' SER . 2.1 p -79.18 -64.76 0.86 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 CA-C-N 116.566 -0.288 . . . . 0.0 111.773 -179.451 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.665 ' H ' HG13 ' A' ' 140' ' ' VAL . 0.2 OUTLIER -160.42 -163.55 1.11 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.811 0.339 . . . . 0.0 111.096 -179.642 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.37 -164.71 49.63 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.518 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -62.83 -16.39 53.29 Favored 'Trans proline' 0 C--N 1.342 0.233 0 C-N-CA 122.495 2.13 . . . . 0.0 112.173 179.725 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.474 ' HB2' HG11 ' A' ' 139' ' ' VAL . 3.5 m-85 -102.59 20.17 17.65 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.083 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.649 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -82.49 39.85 0.62 Allowed 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 111.98 0.363 . . . . 0.0 111.98 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -160.81 35.97 0.15 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.927 0.394 . . . . 0.0 110.781 179.447 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.494 ' O ' HG23 ' A' ' 139' ' ' VAL . 19.2 m-85 -146.16 172.3 13.64 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.793 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.449 ' O ' HG12 ' A' ' 165' ' ' VAL . 33.8 p -122.55 -172.12 2.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.877 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -156.64 144.02 10.31 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.626 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.6 m -93.04 105.82 17.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.841 0.353 . . . . 0.0 110.845 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.586 ' HA ' HG12 ' A' ' 163' ' ' VAL . 25.1 t -61.9 137.74 23.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.403 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 65.4 p -119.88 -49.06 2.33 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.69 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -128.72 159.64 35.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.871 179.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mp -142.43 132.18 22.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.13 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -104.61 108.96 62.17 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.75 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -74.2 -44.05 0.48 Allowed 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.432 2.088 . . . . 0.0 112.409 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 13.8 mt-10 -65.4 -44.64 86.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.017 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 1.5 mtt180 -83.97 -41.08 17.7 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.894 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 89.49 36.72 7.31 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.336 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 24.6 mtpt -117.62 177.6 4.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.759 0.314 . . . . 0.0 110.941 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.554 HG23 HG13 ' A' ' 151' ' ' VAL . 1.3 p -159.91 159.57 2.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.09 0.471 . . . . 0.0 111.054 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.469 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 20.3 tttm -127.53 133.3 49.83 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.799 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.825 HG22 HD11 ' A' ' 176' ' ' LEU . 18.3 m -139.17 160.16 29.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.177 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 12.5 ptp -102.29 116.22 32.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.603 179.706 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.449 HG12 ' O ' ' A' ' 148' ' ' THR . 15.5 m -107.62 160.26 6.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.362 -179.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 6.9 t -152.1 135.26 15.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.722 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 3.1 mp -91.8 -67.0 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.131 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -148.52 87.13 1.56 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.832 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 70.24 25.69 75.28 Favored Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.455 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 4.4 ttm180 -148.76 112.51 5.09 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.872 0.368 . . . . 0.0 110.889 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -89.46 157.39 18.14 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.836 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 65.1 m -160.11 112.39 1.42 Allowed Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.969 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -71.72 121.18 7.43 Favored 'Trans proline' 0 C--N 1.347 0.46 0 C-N-CA 122.438 2.092 . . . . 0.0 112.117 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 27.4 m -128.08 142.79 42.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.362 -179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -93.28 127.85 39.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.672 179.791 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.825 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -137.45 -159.87 1.0 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.324 0.583 . . . . 0.0 111.203 -179.769 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.406 ' O ' ' N ' ' A' ' 180' ' ' GLN . 0.1 OUTLIER -149.47 154.11 38.31 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 115.103 -0.953 . . . . 0.0 110.269 178.447 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 31.0 m-85 -43.99 -28.57 0.48 Allowed 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.862 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.09 8.12 7.81 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 111.865 0.32 . . . . 0.0 111.865 -179.791 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.406 ' N ' ' O ' ' A' ' 177' ' ' ASP . 9.9 mt-30 -131.05 9.25 4.84 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.601 0.238 . . . . 0.0 111.27 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 5.6 m -141.85 174.69 6.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-O 120.751 0.31 . . . . 0.0 111.089 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 17.3 m -147.55 154.49 11.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.132 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.25 134.02 44.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.899 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.267 -0.873 . . . . 0.0 111.092 -179.937 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 120.79 0.329 . . . . 0.0 111.096 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 21.1 mt-30 -107.41 149.63 27.67 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.945 179.899 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.5 t -89.13 108.77 19.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.168 -179.963 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -74.78 -30.77 61.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.007 179.996 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.497 ' CZ ' HG21 ' A' ' 151' ' ' VAL . 30.8 t80 -80.01 155.83 27.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.905 -179.975 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.04 146.57 15.94 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.872 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -62.48 139.42 58.58 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.833 179.962 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 97.34 -24.61 30.69 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.567 -179.987 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.2 t0 -58.0 -168.59 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.737 0.304 . . . . 0.0 111.009 -179.947 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 5.1 mm-40 -135.27 138.64 43.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.084 -179.907 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.513 ' HB ' ' O ' ' A' ' 182' ' ' VAL . 27.1 m -136.93 157.5 35.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.913 179.911 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.451 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 1.0 OUTLIER -90.49 165.93 13.52 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.944 0.402 . . . . 0.0 110.883 179.904 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.814 HG23 ' O ' ' A' ' 147' ' ' PHE . 5.2 t -79.95 168.31 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.046 -179.914 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.67 HG13 ' H ' ' A' ' 141' ' ' SER . 1.7 p -79.25 -65.41 0.78 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.778 -179.544 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.71 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 4.0 m -160.24 -164.43 1.27 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.849 0.357 . . . . 0.0 111.082 -179.552 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.53 -160.53 41.75 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.446 179.989 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -67.46 -11.6 32.73 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.421 2.08 . . . . 0.0 112.406 179.689 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.534 ' HB2' HG11 ' A' ' 139' ' ' VAL . 4.2 m-85 -107.92 19.67 19.74 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.105 -179.997 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.71 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -80.53 37.51 0.41 Allowed 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 112.197 0.443 . . . . 0.0 112.197 -179.467 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -161.08 35.6 0.14 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.996 0.427 . . . . 0.0 110.836 179.423 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.814 ' O ' HG23 ' A' ' 139' ' ' VAL . 8.6 m-85 -146.55 153.86 40.86 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.646 -179.892 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.624 ' O ' HG12 ' A' ' 165' ' ' VAL . 44.4 p -103.01 -179.91 4.09 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.816 -179.957 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -143.12 149.37 21.3 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.541 -0.838 . . . . 0.0 112.661 -179.818 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 16.2 m -95.73 102.69 14.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.831 0.348 . . . . 0.0 110.654 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.708 ' HA ' HG12 ' A' ' 163' ' ' VAL . 46.4 t -59.98 116.67 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.35 -0.387 . . . . 0.0 111.059 -179.917 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 3.3 p -97.02 -47.12 5.92 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.828 179.973 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -138.84 158.51 44.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.86 -179.998 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 32.0 mt -131.08 141.57 45.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.198 179.943 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.4 m-20 -121.86 100.79 43.05 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.67 179.969 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -63.58 -55.62 0.67 Allowed 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.613 2.209 . . . . 0.0 112.43 -179.765 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -57.54 -43.75 84.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.414 -179.662 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 1.9 tpm_? -79.97 -26.2 40.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.154 -179.728 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 69.69 31.07 70.4 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.313 -179.902 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 20.0 mttt -111.7 165.17 12.27 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.78 0.324 . . . . 0.0 111.0 -179.902 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.627 HG22 ' HA ' ' A' ' 177' ' ' ASP . 6.9 m -147.3 126.34 4.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.006 179.907 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 3.5 ttmt -101.2 127.86 47.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.021 -179.899 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.708 HG12 ' HA ' ' A' ' 151' ' ' VAL . 18.8 m -141.74 149.47 19.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.218 179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . 0.443 ' O ' ' HG3' ' A' ' 164' ' ' MET . 0.0 OUTLIER -98.52 120.66 39.33 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.843 179.687 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.624 HG12 ' O ' ' A' ' 148' ' ' THR . 31.2 m -107.05 153.99 8.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.347 -179.685 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . 0.411 HG22 ' HA ' ' A' ' 171' ' ' GLU . 0.7 OUTLIER -122.14 147.92 45.55 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.773 179.888 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 2.0 mp -102.85 -62.73 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.08 -179.973 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -146.3 59.51 1.22 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.881 -179.915 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 98.21 -20.76 49.22 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.575 -179.972 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 4.0 ttt180 -97.79 127.73 43.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.788 0.328 . . . . 0.0 110.975 -179.924 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . 0.411 ' HA ' HG22 ' A' ' 166' ' ' THR . 0.1 OUTLIER -84.24 155.13 22.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.856 179.968 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 42.1 m -157.79 101.11 1.81 Allowed Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.88 179.888 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -67.36 113.64 2.96 Favored 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.453 2.102 . . . . 0.0 112.192 -179.997 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.4 t -128.9 150.94 35.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.151 -179.931 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -79.99 157.34 26.84 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.754 179.949 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.849 HD22 HG13 ' A' ' 181' ' ' VAL . 1.0 OUTLIER -154.78 -171.06 3.71 Favored 'General case' 0 CA--C 1.516 -0.348 0 CA-C-O 121.26 0.552 . . . . 0.0 111.164 -179.963 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.627 ' HA ' HG22 ' A' ' 161' ' ' VAL . 3.5 m-20 -150.14 152.97 35.55 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.462 178.421 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -46.86 -45.19 20.14 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.388 -179.815 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 9.2 t -79.52 -1.53 38.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.531 -179.85 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.626 ' HB3' HD23 ' A' ' 176' ' ' LEU . 1.2 mt-30 -112.41 7.41 19.13 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.581 -0.281 . . . . 0.0 111.392 -179.84 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.849 HG13 HD22 ' A' ' 176' ' ' LEU . 23.2 m -136.23 178.58 4.86 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.927 0.394 . . . . 0.0 111.274 179.933 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . 0.513 ' O ' ' HB ' ' A' ' 137' ' ' VAL . 0.4 OUTLIER -133.34 -150.58 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.346 -179.965 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -122.52 138.86 54.43 Favored 'General case' 0 C--N 1.331 -0.197 0 O-C-N 122.176 -0.327 . . . . 0.0 111.0 -179.918 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.044 0 CA-C-O 118.166 -0.921 . . . . 0.0 111.098 179.864 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 120.728 0.299 . . . . 0.0 110.991 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -59.43 163.75 3.83 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.861 -179.979 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 11.0 p -108.82 143.73 18.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.139 179.997 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -89.53 104.42 16.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.115 179.923 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.702 ' HZ ' HG21 ' A' ' 151' ' ' VAL . 16.9 t80 -95.18 163.94 13.07 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.873 -179.906 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 44.4 mtm180 -154.49 139.91 17.74 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.923 179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -56.67 155.92 6.99 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.803 -179.939 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.55 8.21 59.49 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.86 -179.856 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.34 179.1 0.23 Allowed 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.801 0.334 . . . . 0.0 110.789 179.893 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 10.7 mt-30 -139.92 133.32 30.01 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.116 -179.859 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.587 HG12 ' HA ' ' A' ' 183' ' ' LYS . 23.1 m -142.49 146.18 22.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.774 179.88 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.464 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.5 OUTLIER -79.72 167.12 21.07 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 121.039 0.447 . . . . 0.0 111.172 -179.829 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.894 HG23 ' O ' ' A' ' 147' ' ' PHE . 20.3 t -79.75 152.27 4.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.366 -179.571 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 14.7 p -92.47 -24.42 5.34 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.169 0 CA-C-N 116.082 -0.508 . . . . 0.0 112.148 -179.326 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.669 ' O ' ' HB2' ' A' ' 145' ' ' ALA . 9.8 m -79.4 153.89 29.39 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.888 0.375 . . . . 0.0 111.274 -178.952 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . 0.435 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -66.13 -61.48 5.44 Favored Glycine 0 CA--C 1.519 0.312 0 C-N-CA 121.046 -0.597 . . . . 0.0 112.777 -179.86 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.435 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.6 Cg_endo -52.82 -23.85 21.99 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.581 2.188 . . . . 0.0 112.278 179.885 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.828 ' HB2' HG11 ' A' ' 139' ' ' VAL . 17.4 m-85 -111.6 2.64 17.43 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.281 179.988 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.669 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -70.22 50.02 0.11 Allowed 'General case' 0 C--O 1.233 0.218 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -179.163 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . 0.402 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 5.7 t70 -160.68 32.21 0.15 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.045 0.45 . . . . 0.0 110.399 179.134 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.894 ' O ' HG23 ' A' ' 139' ' ' VAL . 65.8 m-85 -155.24 146.2 22.52 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.376 179.965 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.765 ' O ' HG12 ' A' ' 165' ' ' VAL . 19.3 p -103.38 170.63 7.83 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.372 -0.377 . . . . 0.0 111.004 -179.853 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . 0.404 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -126.77 130.12 6.84 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.593 -179.969 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.3 m -92.22 106.21 18.26 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.759 0.314 . . . . 0.0 110.892 -179.99 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.702 HG21 ' HZ ' ' A' ' 131' ' ' PHE . 20.2 t -63.79 106.79 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.936 179.928 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . 0.433 HG21 ' HE2' ' A' ' 162' ' ' LYS . 1.6 t -88.12 -30.67 19.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.878 -179.933 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -158.71 162.79 37.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.898 179.947 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.8 mt -126.12 130.46 72.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.126 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 70.6 m-20 -102.7 95.33 6.12 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.834 179.986 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -70.34 -34.93 11.78 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.409 2.073 . . . . 0.0 112.328 -179.969 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -66.73 -31.44 72.1 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.942 -180.0 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -96.39 -43.6 7.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.898 -179.921 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 96.73 38.71 4.34 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.401 -179.889 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 3.4 mttm -135.1 175.61 9.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.888 0.375 . . . . 0.0 110.996 -179.974 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.665 HG11 ' CE1' ' A' ' 178' ' ' PHE . 5.2 m -136.59 127.78 42.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.002 179.943 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.433 ' HE2' HG21 ' A' ' 152' ' ' THR . 18.0 tttt -87.3 111.75 21.37 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.847 -179.958 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.452 HG12 HG22 ' A' ' 151' ' ' VAL . 31.4 m -124.13 148.58 28.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.296 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 12.5 ptm -102.01 120.09 39.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.833 179.97 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.765 HG12 ' O ' ' A' ' 148' ' ' THR . 18.5 m -124.2 136.6 59.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.896 0.379 . . . . 0.0 111.213 -179.984 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 2.7 m -95.55 142.49 27.83 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.778 179.85 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.457 HG13 ' O ' ' A' ' 167' ' ' ILE . 3.8 tp -117.17 42.08 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.1 0.476 . . . . 0.0 110.95 -179.942 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER 63.99 99.18 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.847 179.877 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 125.8 -48.79 0.94 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.434 -179.981 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 8.6 ptt180 -160.07 160.03 32.62 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.844 0.354 . . . . 0.0 110.894 179.948 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -66.67 166.23 13.35 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.82 -179.978 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -154.65 90.03 3.15 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.967 179.998 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -68.42 102.54 0.84 Allowed 'Trans proline' 0 C--N 1.345 0.348 0 C-N-CA 122.502 2.134 . . . . 0.0 112.255 179.938 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.502 HG22 HG22 ' A' ' 165' ' ' VAL . 34.8 m -119.1 137.97 51.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.114 -179.966 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -79.84 120.88 24.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.494 179.57 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.82 HD13 HG13 ' A' ' 181' ' ' VAL . 7.6 mt -124.31 -170.55 2.16 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.341 0.591 . . . . 0.0 111.504 -179.395 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.476 ' HA ' HG22 ' A' ' 161' ' ' VAL . 5.0 m-20 -143.08 155.5 44.62 Favored 'General case' 0 N--CA 1.442 -0.848 0 CA-C-N 114.996 -1.002 . . . . 0.0 110.197 178.129 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . 0.665 ' CE1' HG11 ' A' ' 161' ' ' VAL . 9.6 m-85 -48.54 -30.86 5.71 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.509 -179.606 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -79.86 -0.32 34.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.463 179.955 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.765 ' CB ' HD22 ' A' ' 176' ' ' LEU . 30.7 mt-30 -119.59 5.51 11.06 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.609 -0.268 . . . . 0.0 111.316 -179.964 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.82 HG13 HD13 ' A' ' 176' ' ' LEU . 5.3 m -143.46 179.69 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.879 0.371 . . . . 0.0 111.212 179.97 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 23.9 m -152.68 146.61 15.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.016 179.958 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.587 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.1 OUTLIER -63.42 125.93 25.78 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.908 -179.977 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.001 0 CA-C-O 118.201 -0.904 . . . . 0.0 111.002 -179.952 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.35 0 CA-C-O 120.837 0.351 . . . . 0.0 111.025 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -162.57 37.13 0.11 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.793 179.907 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 12.4 p -106.31 133.22 51.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.131 -179.953 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -67.33 -54.79 17.49 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.114 179.954 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -96.16 138.89 33.13 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.89 179.975 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 51.1 ttt-85 -147.47 143.85 28.17 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.906 -179.961 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -59.85 117.82 5.47 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.923 179.978 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.615 ' HA2' HG22 ' A' ' 150' ' ' THR . . . 107.19 16.36 13.66 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.831 -0.7 . . . . 0.0 112.756 179.998 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -76.41 158.63 31.2 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.86 0.362 . . . . 0.0 110.81 179.948 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . 0.47 HE21 HG21 ' A' ' 148' ' ' THR . 0.9 OUTLIER -101.17 128.26 47.36 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.957 -179.992 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.934 HG12 ' HA ' ' A' ' 183' ' ' LYS . 11.3 m -141.61 135.87 30.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.814 179.965 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.426 ' CZ ' ' HB2' ' A' ' 138' ' ' ARG . 0.7 OUTLIER -79.79 162.95 24.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.943 0.402 . . . . 0.0 110.873 -179.952 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.58 HG11 ' HB2' ' A' ' 144' ' ' PHE . 4.9 t -79.88 167.85 2.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.947 -179.84 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.638 HG13 ' H ' ' A' ' 141' ' ' SER . 2.4 p -79.35 -61.95 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.276 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.898 -179.264 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.686 ' HA ' ' HB2' ' A' ' 145' ' ' ALA . 0.1 OUTLIER -160.23 -164.57 1.29 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.734 0.302 . . . . 0.0 111.216 -179.581 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.46 -164.15 49.0 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.368 179.972 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -63.27 -16.08 52.26 Favored 'Trans proline' 0 C--N 1.343 0.287 0 C-N-CA 122.383 2.056 . . . . 0.0 112.146 179.666 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.58 ' HB2' HG11 ' A' ' 139' ' ' VAL . 2.6 m-85 -101.31 15.73 27.85 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.185 179.956 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.686 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -78.48 37.26 0.27 Allowed 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 112.411 0.523 . . . . 0.0 112.411 -179.345 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . 0.414 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 1.9 t0 -161.11 32.8 0.14 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.033 0.444 . . . . 0.0 110.78 179.146 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.518 ' CE2' HG22 ' A' ' 167' ' ' ILE . 22.8 m-85 -140.77 170.06 16.47 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.616 179.995 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.47 HG21 HE21 ' A' ' 136' ' ' GLN . 3.1 p -118.05 -179.38 3.74 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.799 179.934 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -150.36 138.67 6.83 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.592 -179.978 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . 0.615 HG22 ' HA2' ' A' ' 134' ' ' GLY . 3.3 m -97.82 107.49 20.0 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.777 0.322 . . . . 0.0 110.851 179.833 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.624 ' HA ' HG12 ' A' ' 163' ' ' VAL . 23.5 t -55.52 115.7 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.236 -179.822 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.87 -33.19 8.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.877 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -144.56 157.82 44.04 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.839 -179.972 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mp -141.1 129.45 23.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.15 179.993 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -100.5 98.58 8.25 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.779 -179.943 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.4 -43.26 2.22 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.527 2.152 . . . . 0.0 112.347 -179.984 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -78.39 -38.65 41.23 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.881 -179.901 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.0 -34.88 38.15 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.859 -179.901 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 80.59 67.31 1.56 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.48 -179.992 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 30.7 mttm -152.05 173.39 14.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.798 0.333 . . . . 0.0 110.933 -179.978 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.806 ' O ' HD12 ' A' ' 176' ' ' LEU . 4.1 m -149.34 122.3 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.02 179.943 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 36.0 ttmt -104.61 135.31 46.25 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.997 179.996 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 1.029 HG22 HD11 ' A' ' 176' ' ' LEU . 33.9 m -138.76 163.47 27.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.104 -179.99 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -103.12 111.43 23.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.611 179.722 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.438 HG22 HG12 ' A' ' 174' ' ' VAL . 28.5 m -101.86 167.65 2.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.173 -179.803 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 1.5 m -131.11 125.11 32.25 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.872 -179.959 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.518 HG22 ' CE2' ' A' ' 147' ' ' PHE . 1.5 pp -149.09 138.76 15.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.124 179.879 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 62.41 30.29 17.3 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.774 -179.947 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 64.78 42.57 97.04 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.532 -179.926 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 66.4 mtp180 -157.17 137.96 13.28 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 120.809 0.338 . . . . 0.0 110.894 -179.984 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 15.5 mp0 -81.51 127.05 32.42 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.735 179.864 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -135.17 115.21 11.84 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.041 -179.866 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.37 113.19 3.53 Favored 'Trans proline' 0 C--N 1.346 0.416 0 C-N-CA 122.483 2.122 . . . . 0.0 112.075 179.889 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.438 HG12 HG22 ' A' ' 165' ' ' VAL . 10.7 p -123.69 136.55 59.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.259 -179.834 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -80.49 146.86 31.15 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.68 179.742 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 1.029 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -137.78 -165.05 1.71 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.385 0.612 . . . . 0.0 111.313 -179.721 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.7 ' O ' HG22 ' A' ' 181' ' ' VAL . 5.4 m-20 -152.84 155.31 36.86 Favored 'General case' 0 N--CA 1.446 -0.643 0 CA-C-N 114.894 -1.048 . . . . 0.0 109.923 178.392 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 8.4 m-85 -47.63 -40.89 20.74 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.517 -179.668 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 18.2 p -78.82 -2.32 39.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.734 -179.799 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 79.5 mt-30 -120.23 9.25 11.02 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.574 0.226 . . . . 0.0 111.519 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.7 HG22 ' O ' ' A' ' 177' ' ' ASP . 22.7 m -146.02 165.01 9.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.85 0.357 . . . . 0.0 111.196 179.943 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.0 m -143.8 146.46 20.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.048 179.911 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.934 ' HA ' HG12 ' A' ' 137' ' ' VAL . 4.9 tttt -65.85 137.36 57.15 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.022 179.949 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.089 0 CA-C-O 118.204 -0.903 . . . . 0.0 111.139 -179.981 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.338 0 CA-C-O 120.851 0.358 . . . . 0.0 111.027 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 -111.34 -30.77 7.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.061 -179.997 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 11.4 p -93.72 -29.27 4.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.137 -179.932 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -62.04 -70.65 0.18 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.117 -179.949 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.577 ' CZ ' HG21 ' A' ' 151' ' ' VAL . 21.0 t80 -115.81 166.81 11.53 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.984 179.981 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -129.68 140.29 51.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.794 179.969 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -69.33 135.95 51.12 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.892 179.929 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 67.18 21.26 71.83 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.609 179.933 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -78.69 163.47 25.4 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.776 0.322 . . . . 0.0 110.801 179.979 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 35.1 mt-30 -103.16 125.21 49.75 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.052 -179.907 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.666 HG12 ' HA ' ' A' ' 183' ' ' LYS . 31.5 m -134.73 144.13 35.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.968 179.974 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.427 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.82 167.3 20.75 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.936 0.398 . . . . 0.0 110.887 179.978 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.781 HG23 ' O ' ' A' ' 147' ' ' PHE . 7.6 t -79.82 168.0 2.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.92 -179.932 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.659 HG13 ' H ' ' A' ' 141' ' ' SER . 2.7 p -79.54 -62.82 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 112.001 0.371 . . . . 0.0 112.001 -179.193 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.659 ' H ' HG13 ' A' ' 140' ' ' VAL . 0.3 OUTLIER -160.4 -164.15 1.21 Allowed 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.87 0.367 . . . . 0.0 111.105 -179.622 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 78.7 -167.1 52.66 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.94 -0.647 . . . . 0.0 112.456 179.89 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -61.93 -17.25 54.66 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 122.422 2.082 . . . . 0.0 112.094 179.699 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.49 ' HB2' HG11 ' A' ' 139' ' ' VAL . 4.3 m-85 -98.6 20.28 13.15 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.141 179.886 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.475 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -82.6 39.87 0.63 Allowed 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.496 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -160.77 36.22 0.15 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.998 0.428 . . . . 0.0 110.605 179.406 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.868 ' CZ ' HG22 ' A' ' 167' ' ' ILE . 26.4 m-85 -148.18 160.22 43.15 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.682 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.481 ' O ' HG12 ' A' ' 165' ' ' VAL . 7.3 p -109.47 -178.12 3.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.852 179.894 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . 0.422 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -147.85 140.07 8.19 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.609 -179.848 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.9 m -97.0 109.19 22.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.737 0.304 . . . . 0.0 110.957 179.99 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.577 HG21 ' CZ ' ' A' ' 131' ' ' PHE . 17.5 t -64.47 101.96 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.259 -179.989 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.36 -33.74 15.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.799 179.854 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -139.83 150.12 44.3 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.979 179.965 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 16.5 mt -130.99 136.77 57.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.067 -179.969 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -127.83 86.16 58.94 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.759 179.963 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.61 -37.49 7.08 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.515 2.144 . . . . 0.0 112.374 -179.991 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -59.84 -42.87 94.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.859 -179.982 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.3 -38.52 16.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.824 179.947 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 97.32 43.37 3.0 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.621 -179.987 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -139.1 159.12 42.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.859 0.362 . . . . 0.0 110.865 -179.961 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.447 ' CG2' ' CE1' ' A' ' 178' ' ' PHE . 6.1 t -131.05 157.62 43.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.001 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.411 ' N ' HG12 ' A' ' 161' ' ' VAL . 22.2 tttm -122.07 108.29 13.19 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.943 -179.992 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.422 ' HB ' ' HA3' ' A' ' 149' ' ' GLY . 31.0 m -123.38 146.55 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.263 179.985 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 15.0 ptp -99.39 123.49 43.71 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.687 179.9 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.481 HG12 ' O ' ' A' ' 148' ' ' THR . 17.0 m -115.25 158.11 15.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.318 -179.893 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . 0.407 HG23 ' HA ' ' A' ' 171' ' ' GLU . 1.2 m -137.61 125.45 22.55 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.758 179.973 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.868 HG22 ' CZ ' ' A' ' 147' ' ' PHE . 1.8 pp -130.15 147.07 33.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.128 -179.984 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 62.82 -79.91 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.973 -179.996 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . -167.73 36.21 0.22 Allowed Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.446 -179.926 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 6.4 mmt85 -153.19 133.29 13.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.748 0.309 . . . . 0.0 110.936 179.972 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . 0.407 ' HA ' HG23 ' A' ' 166' ' ' THR . 1.1 tt0 -81.05 137.82 36.01 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.758 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 9.3 m -141.86 103.44 5.78 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.061 -179.88 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -72.09 114.44 3.98 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 122.475 2.117 . . . . 0.0 112.167 179.785 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.3 t -125.38 144.97 33.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.37 -179.895 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -80.02 136.63 36.64 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.671 179.936 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.916 HD13 HG13 ' A' ' 181' ' ' VAL . 5.6 mt -133.05 -168.04 2.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.063 0.459 . . . . 0.0 111.329 -179.843 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -142.33 151.83 42.34 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.603 178.382 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . 0.447 ' CE1' ' CG2' ' A' ' 161' ' ' VAL . 20.7 m-85 -47.8 -38.2 15.25 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.502 -179.608 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.4 m -82.05 11.46 5.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.558 179.978 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.813 ' HB3' HD22 ' A' ' 176' ' ' LEU . 4.3 mp0 -120.74 3.49 10.62 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.668 -0.242 . . . . 0.0 111.28 179.922 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.916 HG13 HD13 ' A' ' 176' ' ' LEU . 2.9 m -144.08 177.69 2.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-O 120.858 0.361 . . . . 0.0 111.301 -179.957 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 27.8 m -143.32 146.42 21.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.116 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.666 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.6 OUTLIER -71.4 128.62 36.46 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.95 179.954 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.139 -0.934 . . . . 0.0 111.055 -179.991 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.355 0 CA-C-O 120.76 0.314 . . . . 0.0 111.001 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 39.1 mt-30 -145.51 157.07 44.06 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.894 179.968 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 6.4 m -133.52 23.81 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.266 -179.948 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -89.92 -54.24 4.13 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.912 0.387 . . . . 0.0 111.098 179.873 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -151.1 -178.51 6.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.891 -179.892 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 8.2 mtt180 -110.91 146.34 36.72 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.904 -179.984 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -59.49 141.05 55.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.87 -179.976 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 90.96 -14.3 63.78 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.759 -179.852 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -61.34 174.0 0.79 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.825 0.345 . . . . 0.0 110.966 -179.962 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -112.76 143.09 44.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.895 -179.854 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.706 HG12 ' HA ' ' A' ' 183' ' ' LYS . 15.6 m -140.18 138.66 37.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.991 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.427 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.94 166.45 21.62 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.826 0.346 . . . . 0.0 110.945 179.973 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.568 HG12 ' H ' ' A' ' 140' ' ' VAL . 3.4 t -79.78 169.19 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.892 -179.984 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.739 HG22 ' OG ' ' A' ' 141' ' ' SER . 2.1 p -79.48 -65.35 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.814 -179.413 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.739 ' OG ' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -160.44 -163.48 1.1 Allowed 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.859 0.361 . . . . 0.0 111.102 -179.65 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 79.27 -165.28 50.28 Favored Glycine 0 C--N 1.333 0.369 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.419 179.908 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -61.7 -17.74 56.39 Favored 'Trans proline' 0 C--N 1.343 0.248 0 C-N-CA 122.481 2.12 . . . . 0.0 112.124 179.74 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.457 ' HB2' HG11 ' A' ' 139' ' ' VAL . 2.0 m-85 -102.15 22.04 13.88 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.978 179.947 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.625 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -83.29 38.95 0.63 Allowed 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.133 0.42 . . . . 0.0 112.133 -179.436 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -160.8 36.5 0.15 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 120.914 0.388 . . . . 0.0 110.771 179.4 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.418 ' O ' HG23 ' A' ' 139' ' ' VAL . 22.0 m-85 -141.35 172.99 11.93 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.645 -179.975 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.429 ' O ' HG12 ' A' ' 165' ' ' VAL . 0.2 OUTLIER -125.0 171.01 10.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.99 179.986 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -137.12 136.2 8.15 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.504 -179.988 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 2.8 m -89.31 100.87 13.57 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.846 0.355 . . . . 0.0 110.81 179.977 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.619 ' HA ' HG12 ' A' ' 163' ' ' VAL . 21.5 t -58.9 115.04 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.267 -179.92 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 73.7 p -102.1 -32.28 10.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.842 179.954 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 17.3 mt-10 -151.91 160.2 43.59 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.942 179.965 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 6.5 pt -133.19 145.6 33.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.052 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -130.15 72.23 81.98 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.967 -179.985 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -59.3 -29.04 89.23 Favored 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.614 2.209 . . . . 0.0 112.323 -179.939 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -57.98 -52.25 66.28 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.947 -179.928 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 3.2 tpm_? -90.82 -39.11 12.53 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.89 -179.966 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 105.9 41.81 1.77 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.432 179.975 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 30.7 mttp -131.29 158.71 39.92 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.768 0.318 . . . . 0.0 110.79 179.946 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.481 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.3 p -141.48 159.76 21.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 121.116 0.484 . . . . 0.0 110.91 -179.902 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.481 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 25.6 ttmt -123.7 129.18 50.71 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.969 179.825 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.837 ' CG2' HD12 ' A' ' 176' ' ' LEU . 18.4 m -145.18 140.44 22.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.115 -179.933 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.09 133.68 33.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.795 179.857 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.429 HG12 ' O ' ' A' ' 148' ' ' THR . 15.5 m -124.91 167.85 18.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.174 -179.998 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -117.43 151.06 37.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.963 179.999 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.564 HD13 ' HB2' ' A' ' 168' ' ' PHE . 0.0 OUTLIER -157.18 119.16 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.947 -179.953 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . 0.564 ' HB2' HD13 ' A' ' 167' ' ' ILE . 0.3 OUTLIER 61.01 30.39 19.55 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.728 -179.867 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 77.6 31.68 49.26 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.47 179.961 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 17.9 mtm180 -142.25 144.39 33.3 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.895 0.378 . . . . 0.0 110.841 -179.897 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 18.0 tt0 -80.9 148.95 29.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.831 179.867 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . 0.653 ' O ' HG23 ' A' ' 174' ' ' VAL . 68.5 m -154.82 91.9 2.93 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.064 179.973 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -58.74 104.27 0.18 Allowed 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.529 2.153 . . . . 0.0 112.157 179.998 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.653 HG23 ' O ' ' A' ' 172' ' ' THR . 21.5 t -122.18 142.23 39.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.162 -179.94 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 1.8 pt-20 -79.91 159.56 26.32 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.866 179.849 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.852 HD13 ' CG1' ' A' ' 181' ' ' VAL . 4.9 mt -147.5 -171.38 3.78 Favored 'General case' 0 CA--C 1.516 -0.347 0 CA-C-O 121.266 0.555 . . . . 0.0 111.223 -179.636 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.542 ' O ' HG22 ' A' ' 181' ' ' VAL . 1.5 m-20 -145.11 153.29 41.25 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.415 178.102 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 30.2 m-85 -48.38 -41.64 29.44 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.839 -0.619 . . . . 0.0 111.333 -179.708 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.7 m -78.51 -2.14 37.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.343 -179.959 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.404 ' HB3' ' CD2' ' A' ' 176' ' ' LEU . 4.8 mt-30 -116.84 6.58 13.16 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.594 -0.276 . . . . 0.0 111.345 -179.787 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.852 ' CG1' HD13 ' A' ' 176' ' ' LEU . 27.4 m -142.75 -179.44 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.959 0.409 . . . . 0.0 111.271 -179.91 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 12.6 m -155.34 146.5 12.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.977 179.956 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.706 ' HA ' HG12 ' A' ' 137' ' ' VAL . 4.0 tmtt? -72.38 138.26 47.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.968 -179.955 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.086 0 CA-C-O 118.256 -0.878 . . . . 0.0 111.151 179.997 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.318 0 CA-C-O 120.888 0.375 . . . . 0.0 111.045 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 2.8 mm-40 60.04 31.16 20.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.031 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 9.7 p -102.67 146.26 10.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.122 -179.993 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -86.78 166.62 15.1 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.109 -179.926 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.486 ' CE1' HG21 ' A' ' 151' ' ' VAL . 6.0 p90 -124.48 -178.67 4.2 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.82 -179.91 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -107.99 159.46 16.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.854 179.95 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -60.13 128.6 37.61 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.981 179.906 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 121.97 -24.92 6.93 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.529 -179.962 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -59.31 169.81 1.1 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.816 0.341 . . . . 0.0 110.882 -179.887 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -124.94 136.21 53.54 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.059 -179.921 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.784 HG12 ' HA ' ' A' ' 183' ' ' LYS . 12.6 m -140.52 145.21 26.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.723 179.924 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.401 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.81 163.76 24.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.034 0.445 . . . . 0.0 111.125 -179.801 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.832 HG11 ' HB2' ' A' ' 144' ' ' PHE . 46.7 t -79.77 147.44 6.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.548 -179.672 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . . . . . . . . . 12.5 p -86.27 -21.83 7.39 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 CA-C-N 116.02 -0.536 . . . . 0.0 112.35 -179.555 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.756 ' H ' HG12 ' A' ' 139' ' ' VAL . 1.7 m -79.18 152.83 30.47 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.939 0.4 . . . . 0.0 111.475 -178.783 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . 0.427 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -66.74 -61.79 5.03 Favored Glycine 0 C--N 1.332 0.34 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.699 -179.811 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.427 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 10.2 Cg_endo -53.41 -23.56 24.78 Favored 'Trans proline' 0 C--N 1.345 0.351 0 C-N-CA 122.548 2.166 . . . . 0.0 112.083 179.853 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.832 ' HB2' HG11 ' A' ' 139' ' ' VAL . 9.2 m-85 -110.73 2.66 18.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.375 179.751 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.66 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -70.36 48.99 0.11 Allowed 'General case' 0 C--N 1.332 -0.193 0 N-CA-C 112.448 0.536 . . . . 0.0 112.448 -179.074 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . 0.464 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 16.4 p-10 -160.44 29.91 0.16 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.172 0.511 . . . . 0.0 110.49 179.116 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.682 ' O ' HG23 ' A' ' 139' ' ' VAL . 15.2 m-85 -150.44 147.97 28.18 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.183 179.741 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.401 ' HA ' ' HA ' ' A' ' 138' ' ' ARG . 69.6 p -102.25 168.58 9.26 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.798 0.333 . . . . 0.0 110.708 179.888 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -128.86 129.05 6.03 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.634 -0.793 . . . . 0.0 112.539 -179.865 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.7 m -86.76 105.83 17.25 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.739 0.305 . . . . 0.0 110.73 179.886 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.486 HG21 ' CE1' ' A' ' 131' ' ' PHE . 30.2 t -62.76 117.78 4.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.083 -179.862 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -93.04 -46.35 7.5 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.925 179.989 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -144.89 152.68 40.62 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.864 179.992 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.0 mt -112.58 148.37 15.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.128 -179.951 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -119.24 84.01 26.77 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.85 -179.974 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -72.93 -37.88 3.31 Favored 'Trans proline' 0 C--N 1.343 0.27 0 C-N-CA 122.571 2.181 . . . . 0.0 112.303 179.969 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -60.13 -55.1 38.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.835 -179.93 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 12.6 ttt-85 -79.9 -67.11 0.79 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.004 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 129.92 59.49 0.1 OUTLIER Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.498 -179.953 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 5.5 mtmm -155.64 -179.09 7.78 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.801 0.334 . . . . 0.0 110.84 -179.953 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.48 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.2 p -154.44 159.81 2.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.896 179.915 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.48 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 10.8 tttt -124.15 127.75 48.24 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.932 -179.9 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.449 HG12 ' HA ' ' A' ' 151' ' ' VAL . 16.7 m -136.16 156.65 36.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.183 -179.991 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 16.4 ptm -106.54 120.02 40.83 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.004 179.93 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.752 ' O ' HG22 ' A' ' 172' ' ' THR . 2.6 t -117.62 153.83 19.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.102 -179.956 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . 0.408 HG23 ' C ' ' A' ' 170' ' ' ARG . 2.3 m -100.8 142.82 31.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.935 179.918 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.561 ' C ' HD13 ' A' ' 167' ' ' ILE . 0.0 OUTLIER -159.78 -46.29 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.147 179.972 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . 0.5 ' N ' HG23 ' A' ' 167' ' ' ILE . 5.0 p90 -97.58 35.25 1.69 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.973 179.965 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 96.48 -30.98 7.94 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.448 -179.912 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . 0.408 ' C ' HG23 ' A' ' 166' ' ' THR . 0.0 OUTLIER -130.63 177.34 7.46 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.894 0.378 . . . . 0.0 110.691 179.953 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -69.51 168.26 15.0 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.881 -179.939 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . 0.752 HG22 ' O ' ' A' ' 165' ' ' VAL . 11.5 t -148.05 124.73 5.49 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.829 -179.914 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -71.77 97.36 0.81 Allowed 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.427 2.084 . . . . 0.0 112.331 179.986 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.522 HG23 HG23 ' A' ' 172' ' ' THR . 10.5 t -121.67 132.86 69.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.164 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -79.91 124.41 28.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.124 179.436 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.821 HD12 ' HB3' ' A' ' 180' ' ' GLN . 1.8 mm? -127.41 -170.08 2.16 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.322 0.582 . . . . 0.0 111.639 -179.164 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.428 ' HA ' HG12 ' A' ' 161' ' ' VAL . 0.4 OUTLIER -142.38 152.98 43.39 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.394 178.342 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -42.5 -58.42 2.26 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.607 -179.596 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 6.0 t -56.28 -23.0 33.64 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.241 179.998 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.821 ' HB3' HD12 ' A' ' 176' ' ' LEU . 5.4 mp0 -89.57 3.88 51.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.384 -0.371 . . . . 0.0 111.638 -179.837 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.42 HG22 ' O ' ' A' ' 177' ' ' ASP . 16.5 m -147.44 167.95 4.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-O 120.811 0.339 . . . . 0.0 111.166 179.967 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.4 m -145.08 146.19 20.1 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.1 179.872 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.784 ' HA ' HG12 ' A' ' 137' ' ' VAL . 1.5 tttp -61.68 136.68 58.09 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.825 -179.822 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.063 0 CA-C-O 118.246 -0.883 . . . . 0.0 111.036 179.986 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.41 0 CA-C-O 120.894 0.378 . . . . 0.0 111.062 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -60.26 125.51 23.96 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.941 -179.949 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.573 HG23 ' O ' ' A' ' 129' ' ' VAL . 17.8 m -134.5 86.04 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.135 179.991 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -89.68 150.44 22.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.062 -179.959 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -118.43 150.09 40.15 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.906 179.961 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 12.7 tpp180 -153.52 147.56 25.58 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.876 179.966 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -61.54 144.76 53.79 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.861 179.999 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 96.71 -23.6 34.6 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.573 -179.988 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -57.34 163.79 2.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.906 0.384 . . . . 0.0 111.017 -179.994 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . 0.444 ' NE2' HG23 ' A' ' 150' ' ' THR . 33.0 mm-40 -121.06 139.14 53.72 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.969 -179.918 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.7 HG12 ' HA ' ' A' ' 183' ' ' LYS . 20.9 m -137.01 140.76 42.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.82 179.989 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.477 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.7 162.85 24.95 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.027 0.441 . . . . 0.0 111.002 -179.934 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.867 HG11 ' HB2' ' A' ' 144' ' ' PHE . 37.6 t -79.88 151.46 4.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.409 -179.627 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.512 HG13 ' C ' ' A' ' 180' ' ' GLN . 34.3 m -93.1 -21.29 6.15 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 112.4 0.518 . . . . 0.0 112.4 -179.216 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.697 ' H ' HG12 ' A' ' 139' ' ' VAL . 4.5 m -79.18 153.87 29.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.792 0.33 . . . . 0.0 111.315 -179.013 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . 0.423 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -65.12 -62.56 4.82 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 121.058 -0.591 . . . . 0.0 113.006 -179.664 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.423 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 9.4 Cg_endo -52.81 -23.17 19.84 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.685 2.257 . . . . 0.0 112.379 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.867 ' HB2' HG11 ' A' ' 139' ' ' VAL . 10.2 m-85 -112.62 2.65 16.27 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.471 179.982 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.689 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -70.11 48.39 0.1 Allowed 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -179.117 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -160.72 32.39 0.15 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.13 0.49 . . . . 0.0 110.631 179.109 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.733 ' O ' HG23 ' A' ' 139' ' ' VAL . 42.5 m-85 -154.87 145.59 22.38 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.469 179.946 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.718 ' O ' HG12 ' A' ' 165' ' ' VAL . 67.8 p -99.88 -177.58 3.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.908 -179.879 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -139.85 129.12 4.16 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.596 -179.838 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . 0.444 HG23 ' NE2' ' A' ' 136' ' ' GLN . 3.0 m -90.05 113.83 25.61 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.742 0.306 . . . . 0.0 110.68 179.754 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 21.7 t -70.71 120.83 19.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.305 -179.726 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -108.84 -31.75 7.56 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.713 179.643 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -153.95 161.35 42.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.705 179.824 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.6 mp -134.21 152.43 34.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.331 -179.966 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 -123.17 90.89 50.21 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.806 179.932 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.15 -34.04 13.99 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.613 2.209 . . . . 0.0 112.357 -179.893 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -90.14 18.14 6.25 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.338 179.951 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 31.2 ttt85 -138.07 -46.01 0.52 Allowed 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.808 0.337 . . . . 0.0 110.791 179.936 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 99.19 39.82 3.42 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.392 179.962 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 16.3 mtmt -146.18 170.5 16.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.815 0.34 . . . . 0.0 111.086 -179.979 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.475 ' CG2' ' N ' ' A' ' 162' ' ' LYS . 1.0 OUTLIER -149.43 159.59 5.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 121.118 0.485 . . . . 0.0 110.795 179.918 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.475 ' N ' ' CG2' ' A' ' 161' ' ' VAL . 59.6 tttp -105.21 121.61 44.2 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.967 179.993 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 5.6 m -134.95 134.76 53.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.176 -179.982 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 7.6 ptm -93.55 135.43 34.82 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.841 179.954 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.718 HG12 ' O ' ' A' ' 148' ' ' THR . 27.6 m -134.25 149.76 30.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.217 179.915 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . 0.404 ' O ' ' CD2' ' A' ' 147' ' ' PHE . 3.8 m -113.26 110.57 20.59 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.809 -180.0 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.711 HD13 ' HB2' ' A' ' 168' ' ' PHE . 0.0 OUTLIER -97.32 113.83 32.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.075 179.985 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . 0.711 ' HB2' HD13 ' A' ' 167' ' ' ILE . 0.7 OUTLIER 59.52 43.26 16.33 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.894 -179.782 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 66.41 30.68 77.01 Favored Glycine 0 N--CA 1.452 -0.241 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.459 -179.922 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -129.86 124.55 33.5 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.743 0.306 . . . . 0.0 110.899 -179.905 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -58.85 126.08 26.18 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.725 179.957 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 2.0 m -150.66 89.68 4.37 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.127 -179.8 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -72.76 125.57 10.64 Favored 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.517 2.145 . . . . 0.0 112.104 179.81 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . 0.532 HG22 HG22 ' A' ' 165' ' ' VAL . 5.3 m -134.24 136.58 53.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.317 -179.866 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 3.3 pm0 -79.88 126.64 31.26 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.964 179.209 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.783 HD13 HG13 ' A' ' 181' ' ' VAL . 7.0 mt -127.62 -170.08 2.17 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.395 0.617 . . . . 0.0 111.772 -179.131 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.434 ' HA ' HG12 ' A' ' 161' ' ' VAL . 0.5 OUTLIER -141.33 154.59 45.77 Favored 'General case' 0 N--CA 1.442 -0.868 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.357 178.162 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -48.49 -31.14 5.97 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.366 -179.551 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.2 m -79.47 1.2 26.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.466 -0.334 . . . . 0.0 111.574 179.998 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.751 ' CB ' HD22 ' A' ' 176' ' ' LEU . 0.0 OUTLIER -122.12 10.7 10.08 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.652 0.263 . . . . 0.0 111.401 -179.798 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.783 HG13 HD13 ' A' ' 176' ' ' LEU . 14.4 m -149.35 159.14 5.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 120.944 0.402 . . . . 0.0 111.272 -179.989 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.0 m -123.27 146.48 28.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.048 179.985 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.7 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -71.79 120.46 17.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.864 -179.931 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.267 -0.873 . . . . 0.0 111.082 -179.942 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.317 0 CA-C-O 120.833 0.349 . . . . 0.0 111.015 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 23.6 mt-30 -147.41 170.32 17.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.841 -179.995 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.42 HG23 ' O ' ' A' ' 129' ' ' VAL . 5.0 m -132.33 103.63 6.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.116 179.992 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -61.96 -172.55 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.04 179.919 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . 0.439 ' HZ ' HG11 ' A' ' 151' ' ' VAL . 77.1 t80 -143.5 162.39 35.95 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.751 179.976 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -153.73 149.55 27.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.942 -179.951 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -65.67 134.35 53.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.846 179.872 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 98.36 -2.83 59.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.845 -179.958 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -58.54 167.68 1.38 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.912 0.387 . . . . 0.0 110.897 179.948 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.27 116.93 29.78 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.028 179.999 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.714 HG12 ' HA ' ' A' ' 183' ' ' LYS . 30.1 m -123.17 138.76 52.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.833 179.932 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.4 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.99 161.9 25.2 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.956 0.408 . . . . 0.0 111.142 -179.899 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.579 HG12 ' N ' ' A' ' 140' ' ' VAL . 39.8 t -104.21 167.05 2.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.559 179.702 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.822 HG22 ' O ' ' A' ' 180' ' ' GLN . 16.2 m -138.04 -9.88 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 N-CA-C 113.001 0.741 . . . . 0.0 113.001 -178.874 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.461 ' O ' ' CD2' ' A' ' 144' ' ' PHE . 1.1 m -79.5 142.61 35.66 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.996 0.427 . . . . 0.0 111.761 -178.946 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 35.78 -139.83 0.24 Allowed Glycine 0 C--N 1.335 0.511 0 CA-C-N 115.67 -0.695 . . . . 0.0 113.656 179.523 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -74.3 3.86 4.87 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.691 2.261 . . . . 0.0 112.682 179.761 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.496 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 0.1 OUTLIER -79.57 -10.03 59.73 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.635 -0.257 . . . . 0.0 111.055 179.831 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.455 ' HA ' ' O ' ' A' ' 139' ' ' VAL . . . -68.52 41.84 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -178.996 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . 0.431 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 0.8 OUTLIER -160.95 32.78 0.15 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.056 0.455 . . . . 0.0 110.654 179.167 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.431 ' CD1' ' O ' ' A' ' 146' ' ' ASP . 55.8 m-85 -151.7 164.41 37.01 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.582 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.609 ' O ' HG12 ' A' ' 165' ' ' VAL . 80.6 p -118.73 162.86 17.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.734 179.849 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -130.79 163.48 23.35 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.596 -0.811 . . . . 0.0 112.693 -179.847 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 17.6 m -103.24 103.35 13.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.766 0.317 . . . . 0.0 110.661 179.964 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.672 ' HA ' HG12 ' A' ' 163' ' ' VAL . 46.4 t -60.31 112.61 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.975 -179.935 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -101.81 -42.62 6.09 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.79 179.906 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -120.1 150.97 39.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.794 179.841 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 12.5 pt -143.31 124.14 10.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.154 179.984 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -117.3 86.61 21.99 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.896 -179.993 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -72.52 -20.22 23.89 Favored 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.555 2.17 . . . . 0.0 112.516 -179.938 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.38 25.65 2.18 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.389 -179.94 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 2.2 tpm_? -160.0 -45.06 0.05 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.772 0.32 . . . . 0.0 110.838 179.979 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 104.04 61.69 0.68 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.459 179.896 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 17.2 mtpt -154.18 149.6 27.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.813 0.34 . . . . 0.0 110.998 179.963 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.671 HG22 ' HA ' ' A' ' 177' ' ' ASP . 26.9 m -147.21 154.04 11.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.18 179.933 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 12.6 ttpt -127.13 129.61 48.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.907 -179.952 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.72 HG22 ' CD1' ' A' ' 176' ' ' LEU . 34.9 m -136.6 145.68 29.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.23 179.928 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -89.43 113.32 24.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.459 179.824 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.609 HG12 ' O ' ' A' ' 148' ' ' THR . 20.9 m -123.19 159.76 26.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.359 -179.696 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . 0.546 HG22 ' HA ' ' A' ' 171' ' ' GLU . 17.2 p -111.55 139.25 47.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.785 179.869 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.805 HD13 ' O ' ' A' ' 167' ' ' ILE . 0.0 OUTLIER -93.32 -36.38 7.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.04 -179.874 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 10.5 t80 -172.82 78.54 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.982 179.996 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 68.44 28.22 73.35 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.425 -179.93 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -156.72 124.28 5.41 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.728 0.299 . . . . 0.0 110.88 -179.995 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . 0.546 ' HA ' HG22 ' A' ' 166' ' ' THR . 67.8 mt-10 -61.08 154.61 22.44 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.788 179.905 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 25.4 m -160.08 89.84 1.82 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.146 -179.925 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -66.13 105.02 0.78 Allowed 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.615 2.21 . . . . 0.0 111.82 179.766 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 31.0 m -118.5 149.39 20.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.349 -179.716 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -89.14 135.91 33.31 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.731 179.759 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.72 ' CD1' HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -146.98 -161.12 1.26 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.397 0.617 . . . . 0.0 110.936 -179.709 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.686 ' O ' HG22 ' A' ' 181' ' ' VAL . 0.8 OUTLIER -151.85 153.2 33.73 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.379 178.474 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . 0.634 ' CE1' HG11 ' A' ' 161' ' ' VAL . 23.1 m-85 -42.36 -30.58 0.34 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.677 -179.654 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 1.4 m -69.57 -39.31 77.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.115 -179.963 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.822 ' O ' HG22 ' A' ' 140' ' ' VAL . 33.3 mt-30 -88.93 8.76 27.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.499 -179.724 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.686 HG22 ' O ' ' A' ' 177' ' ' ASP . 5.4 m -145.72 179.53 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.791 0.329 . . . . 0.0 111.165 179.903 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 31.6 m -145.09 147.07 19.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.167 179.975 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.714 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.1 OUTLIER -78.3 130.83 36.67 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.887 179.937 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.057 0 CA-C-O 118.169 -0.919 . . . . 0.0 111.08 179.977 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.403 0 CA-C-O 120.935 0.398 . . . . 0.0 111.015 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -94.22 166.78 11.94 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.916 179.975 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.5 t -108.76 105.79 19.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.103 179.91 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -76.26 -32.28 58.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.175 -179.958 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 9.8 t80 -146.99 150.47 35.2 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.912 180.0 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -134.87 154.36 51.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.028 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -71.53 120.73 17.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.851 179.909 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 115.59 -14.96 17.49 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.671 -179.919 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -56.26 174.07 0.15 Allowed 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.795 0.331 . . . . 0.0 110.979 -179.921 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.73 140.67 51.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.95 -179.992 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.594 HG12 ' HA ' ' A' ' 183' ' ' LYS . 19.9 m -144.58 139.79 23.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.021 -179.959 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.405 ' HA ' ' HA ' ' A' ' 148' ' ' THR . 0.0 OUTLIER -79.97 163.1 24.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.955 0.407 . . . . 0.0 110.945 179.865 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.918 HG11 ' HB2' ' A' ' 144' ' ' PHE . 21.7 t -79.83 156.08 4.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 115.848 -0.615 . . . . 0.0 111.576 -179.659 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.511 HG13 ' C ' ' A' ' 180' ' ' GLN . 33.7 m -96.64 -26.19 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 N-CA-C 112.424 0.528 . . . . 0.0 112.424 -179.135 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.688 ' O ' ' HB2' ' A' ' 145' ' ' ALA . 91.1 p -79.13 155.18 28.83 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.833 0.349 . . . . 0.0 111.401 -178.706 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . 0.454 ' N ' ' HD2' ' A' ' 143' ' ' PRO . . . -64.82 -60.77 6.52 Favored Glycine 0 CA--C 1.52 0.346 0 CA-C-N 115.957 -0.565 . . . . 0.0 113.063 -179.581 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . 0.454 ' HD2' ' N ' ' A' ' 142' ' ' GLY . 7.8 Cg_endo -50.11 -24.84 11.79 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.671 2.248 . . . . 0.0 112.507 -179.793 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.918 ' HB2' HG11 ' A' ' 139' ' ' VAL . 7.4 m-85 -115.77 4.52 14.0 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.468 -179.974 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.688 ' HB2' ' O ' ' A' ' 141' ' ' SER . . . -69.81 45.21 0.07 Allowed 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -178.809 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . 0.412 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 11.8 p-10 -160.69 32.19 0.15 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.032 0.444 . . . . 0.0 110.53 178.929 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.815 ' O ' HG23 ' A' ' 139' ' ' VAL . 64.6 m-85 -153.67 145.3 23.31 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.648 179.891 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.479 ' O ' HG12 ' A' ' 165' ' ' VAL . 1.8 p -102.39 175.73 5.42 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.744 179.863 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . 0.427 ' HA3' ' HB ' ' A' ' 163' ' ' VAL . . . -138.47 141.32 11.89 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.685 -179.9 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 4.6 m -93.56 109.84 21.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.837 0.351 . . . . 0.0 110.747 -179.999 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 16.4 t -68.65 96.84 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.054 179.902 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -81.39 -30.83 33.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.799 179.988 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -154.33 157.29 38.39 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.817 179.942 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 4.6 pt -128.62 172.98 14.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.196 179.987 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 -147.59 87.62 5.91 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.847 179.994 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.97 -33.63 15.43 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.584 2.19 . . . . 0.0 112.258 -179.974 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -68.92 -42.75 76.37 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.95 179.878 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 23.4 mmt180 -89.38 -61.87 1.6 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.913 179.982 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 120.54 57.12 0.24 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.488 179.954 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -145.0 173.01 12.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.804 0.335 . . . . 0.0 110.803 -179.973 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.614 HG22 ' HA ' ' A' ' 177' ' ' ASP . 31.1 m -153.98 118.36 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.056 179.892 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 34.1 tttm -79.85 113.87 18.34 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.712 -179.95 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.427 ' HB ' ' HA3' ' A' ' 149' ' ' GLY . 32.1 m -126.1 141.22 46.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.32 -179.756 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 5.1 ptm -101.68 117.16 34.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.925 179.934 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.479 HG12 ' O ' ' A' ' 148' ' ' THR . 15.8 m -108.56 -179.62 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.008 179.902 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.66 116.9 10.62 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.943 -179.837 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . 0.857 HD12 ' OG1' ' A' ' 172' ' ' THR . 2.4 mp -120.94 128.39 76.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.93 179.832 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . 0.442 ' CD1' HG22 ' A' ' 167' ' ' ILE . 4.6 m-85 61.3 34.46 18.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.966 179.887 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 65.7 51.44 46.99 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.598 179.947 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 2.5 ttt85 -160.06 128.09 4.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.837 0.351 . . . . 0.0 110.952 179.96 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -58.69 129.11 40.52 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 179.926 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . 0.857 ' OG1' HD12 ' A' ' 167' ' ' ILE . 0.2 OUTLIER -133.83 85.85 40.11 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.996 -179.932 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -68.67 109.42 2.08 Favored 'Trans proline' 0 C--N 1.345 0.383 0 C-N-CA 122.488 2.125 . . . . 0.0 112.028 179.723 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.6 t -126.39 141.11 46.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.344 -179.741 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.93 118.67 21.9 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.181 179.434 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.598 HD23 ' HB3' ' A' ' 180' ' ' GLN . 1.2 mp -119.94 -170.39 1.95 Allowed 'General case' 0 CA--C 1.515 -0.376 0 CA-C-O 121.406 0.622 . . . . 0.0 111.63 -179.178 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.614 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.6 OUTLIER -142.89 155.37 44.73 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 114.911 -1.04 . . . . 0.0 110.004 178.016 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . 0.437 ' CE1' HG11 ' A' ' 161' ' ' VAL . 15.6 m-85 -47.14 -30.22 2.73 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.457 -179.533 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 83.6 p -80.08 2.65 23.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.686 -179.89 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.598 ' HB3' HD23 ' A' ' 176' ' ' LEU . 3.7 mt-30 -122.38 3.21 9.72 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-O 120.642 0.258 . . . . 0.0 111.361 180.0 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.528 HG13 ' CD2' ' A' ' 176' ' ' LEU . 11.3 m -139.97 169.63 16.09 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-O 120.765 0.317 . . . . 0.0 111.384 179.913 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 18.5 m -148.51 146.69 17.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.05 179.942 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.594 ' HA ' HG12 ' A' ' 137' ' ' VAL . 75.2 tttt -57.68 122.53 13.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.093 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.028 0 CA-C-O 118.373 -0.822 . . . . 0.0 110.987 -179.962 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 120.797 0.332 . . . . 0.0 111.02 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 60.99 101.26 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.792 179.87 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 129' ' ' VAL . 10.5 m -79.93 91.39 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.196 179.922 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -61.61 -42.23 98.58 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.133 179.914 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -124.19 155.3 38.77 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.908 -179.966 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 6.2 ttt85 -155.34 148.93 25.2 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.844 179.988 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -61.54 138.59 58.29 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.885 -179.951 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 108.74 -22.75 25.44 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.68 -179.9 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -57.08 165.03 1.42 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.827 0.346 . . . . 0.0 110.951 -179.974 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -107.85 143.69 36.1 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.877 -179.935 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.78 HG12 ' HA ' ' A' ' 183' ' ' LYS . 25.4 m -139.92 143.09 30.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.165 179.994 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.47 165.63 13.7 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.052 0.453 . . . . 0.0 110.955 179.939 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.898 HG23 ' O ' ' A' ' 147' ' ' PHE . 4.2 t -80.18 169.47 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.968 -179.921 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.603 HG23 ' H ' ' A' ' 141' ' ' SER . 0.1 OUTLIER -80.02 -71.49 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.175 0 CA-C-N 116.525 -0.307 . . . . 0.0 111.393 -179.945 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.603 ' H ' HG23 ' A' ' 140' ' ' VAL . 0.1 OUTLIER -160.5 -163.52 1.1 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.96 -179.699 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 81.91 -160.54 41.01 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.457 179.842 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -57.94 -20.85 46.65 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.507 2.138 . . . . 0.0 111.976 179.786 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.545 ' O ' ' HB ' ' A' ' 139' ' ' VAL . 1.5 m-85 -110.77 41.6 1.76 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.666 179.859 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.514 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -90.15 31.52 0.99 Allowed 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -179.424 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 2.3 t0 -161.26 38.69 0.14 Allowed 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.284 179.492 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.898 ' O ' HG23 ' A' ' 139' ' ' VAL . 23.2 m-85 -134.72 154.18 51.68 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 121.002 0.429 . . . . 0.0 111.183 -179.758 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . 0.628 ' O ' HG12 ' A' ' 165' ' ' VAL . 31.4 p -118.23 171.86 7.83 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.446 179.722 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -144.66 155.89 26.6 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.362 -0.923 . . . . 0.0 112.905 -179.785 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 14.0 m -103.31 105.45 15.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.782 0.325 . . . . 0.0 110.781 179.743 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.734 ' HA ' HG12 ' A' ' 163' ' ' VAL . 48.8 t -58.48 118.13 2.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.108 -179.925 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 35.1 p -102.21 -46.67 4.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.852 179.977 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -125.98 157.87 36.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.912 179.985 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 3.9 mp -139.99 139.13 37.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.123 179.879 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -121.62 85.12 43.5 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.91 179.996 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -72.99 -28.35 13.13 Favored 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.531 2.154 . . . . 0.0 112.383 -179.917 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 2.7 pt-20 -69.84 -32.56 71.03 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.94 -179.953 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.75 -59.57 1.75 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.949 179.942 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 123.06 66.86 0.22 Allowed Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.532 -179.994 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 43.7 mttp -148.46 163.48 37.03 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.804 0.335 . . . . 0.0 110.878 179.978 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.646 HG22 ' HA ' ' A' ' 177' ' ' ASP . 15.6 m -151.04 138.53 13.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.112 179.896 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 16.4 tttp -118.12 126.23 51.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.868 -179.985 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.842 HG22 HD11 ' A' ' 176' ' ' LEU . 33.5 m -135.94 149.01 27.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.275 -179.96 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . 0.4 ' O ' ' CG ' ' A' ' 164' ' ' MET . 10.5 ptt? -90.04 111.53 22.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.598 179.791 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.628 HG12 ' O ' ' A' ' 148' ' ' THR . 31.1 m -114.69 137.43 48.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.359 -179.851 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 5.5 t -92.22 136.94 32.78 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.575 179.774 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 18.5 tt -83.82 -29.26 7.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.069 -179.909 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -178.23 38.92 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.85 -179.976 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 124.13 -25.88 5.96 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.48 -179.973 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -104.14 122.68 45.82 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.865 0.364 . . . . 0.0 110.821 -179.967 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -63.1 121.01 12.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.99 179.933 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . . . . . . . . . 53.9 m -117.57 100.4 52.59 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.824 -179.9 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -66.54 111.1 2.01 Favored 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 122.344 2.029 . . . . 0.0 112.215 -179.958 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 38.3 t -127.17 141.7 45.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.105 -179.773 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -86.63 138.11 31.94 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.626 179.736 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.842 HD11 HG22 ' A' ' 163' ' ' VAL . 0.0 OUTLIER -148.15 -162.27 1.52 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.282 0.563 . . . . 0.0 111.298 -179.65 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.646 ' HA ' HG22 ' A' ' 161' ' ' VAL . 1.4 m-20 -146.15 157.02 43.82 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-N 115.067 -0.97 . . . . 0.0 109.896 178.213 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . 0.47 ' CE1' HG11 ' A' ' 161' ' ' VAL . 19.6 m-85 -47.0 -28.54 1.68 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.694 -179.503 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 40.7 t -75.76 -5.97 48.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.499 -0.319 . . . . 0.0 111.592 -179.902 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.513 ' O ' HG22 ' A' ' 140' ' ' VAL . 3.1 mm-40 -114.97 -6.95 12.57 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.599 -0.273 . . . . 0.0 111.449 -179.907 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.459 ' CG1' HD22 ' A' ' 176' ' ' LEU . 30.2 m -142.7 158.66 18.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 120.829 0.347 . . . . 0.0 111.331 -179.98 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 22.6 m -117.79 146.57 22.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.076 -179.984 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.78 ' HA ' HG12 ' A' ' 137' ' ' VAL . 0.0 OUTLIER -86.19 129.58 34.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.921 -179.962 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.175 -0.917 . . . . 0.0 111.194 -179.991 . . . . . . . . 0 0 . 1 . 031 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.309 0 CA-C-O 120.801 0.334 . . . . 8.4900000000000002 111.087 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild full ' A' A ' 128' ' ' GLN . . . . . . . . . . . . . 8.7 mt-30 61.62 116.95 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.194 -0.457 . . . . 7.7300000000000004 111.021 -179.929 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . . . . . . . . . 21.5 t -79.96 78.61 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.272 -0.422 . . . . 5.1299999999999999 111.131 179.926 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 130' ' ' ALA . . . . . . . . . . . . . . . -61.15 121.77 13.34 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.111 -0.495 . . . . 2.79 111.171 179.99 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 131' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -97.17 139.98 32.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.188 -0.46 . . . . 1.6299999999999999 110.888 179.972 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 19.3 mtp180 -132.87 135.23 45.48 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.219 -0.446 . . . . 4.75 110.931 179.975 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -59.53 118.69 6.35 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.302 -0.408 . . . . 2.4900000000000002 110.818 179.926 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 128.57 -21.2 5.41 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.823 -0.703 . . . . 0.84999999999999998 112.627 -179.921 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -55.37 164.74 0.9 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.821 0.343 . . . . 1.6899999999999999 110.929 -179.995 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 136' ' ' GLN . . . . . . . . . . . . . 64.7 mt-30 -117.26 114.82 24.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.457 . . . . 2.5600000000000001 111.06 -179.977 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.647 HG12 ' HA ' ' A' ' 183' ' ' LYS . 16.9 m -118.61 141.95 35.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.57999999999999996 110.822 179.894 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -79.68 166.69 21.57 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.994 0.426 . . . . 2.7000000000000002 111.028 -179.773 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 139' ' ' VAL . . . . . 0.524 HG12 ' N ' ' A' ' 140' ' ' VAL . 8.7 t -79.52 167.39 2.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.935 -0.575 . . . . 0.79000000000000004 110.995 -179.901 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.636 HG13 ' H ' ' A' ' 141' ' ' SER . 2.8 p -78.87 -61.46 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.296 0 N-CA-C 112.052 0.39 . . . . 1.7 112.052 -179.289 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 141' ' ' SER . . . . . 0.636 ' H ' HG13 ' A' ' 140' ' ' VAL . 0.9 OUTLIER -160.83 -163.98 1.14 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.807 0.337 . . . . 3.04 111.29 -179.652 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 77.53 -169.35 54.75 Favored Glycine 0 C--N 1.331 0.284 0 C-N-CA 120.875 -0.679 . . . . 1.8300000000000001 112.357 179.958 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 143' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -59.14 -19.34 48.83 Favored 'Trans proline' 0 C--N 1.344 0.3 0 C-N-CA 122.507 2.138 . . . . 1.6299999999999999 111.998 179.672 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.512 ' HB2' HG11 ' A' ' 139' ' ' VAL . 4.1 m-85 -95.98 18.37 13.5 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.16 -0.473 . . . . 1.6699999999999999 111.065 179.939 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.488 ' HB2' ' HA ' ' A' ' 141' ' ' SER . . . -82.05 40.4 0.62 Allowed 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 112.058 0.392 . . . . 1.0900000000000001 112.058 -179.453 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . 0.403 ' O ' ' CD1' ' A' ' 147' ' ' PHE . 0.5 OUTLIER -161.4 35.6 0.14 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.98 0.419 . . . . 2.4199999999999999 110.692 179.493 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 147' ' ' PHE . . . . . 0.518 ' O ' HG23 ' A' ' 139' ' ' VAL . 36.6 m-85 -146.82 169.76 18.44 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.929 -0.578 . . . . 1.5900000000000001 110.783 179.994 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 148' ' ' THR . . . . . . . . . . . . . 12.7 p -122.31 -178.43 3.88 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.264 -0.425 . . . . 0.88 110.874 179.943 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 149' ' ' GLY . . . . . . . . . . . . . . . -145.49 134.74 5.62 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.648 -0.787 . . . . 0.62 112.549 -179.927 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 150' ' ' THR . . . . . . . . . . . . . 1.8 m -87.96 104.8 16.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.751 0.31 . . . . 0.75 110.817 179.893 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.695 ' HA ' HG12 ' A' ' 163' ' ' VAL . 43.6 t -64.21 121.18 12.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.239 -0.437 . . . . 0.66000000000000003 111.059 -179.967 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 152' ' ' THR . . . . . . . . . . . . . 14.9 p -107.37 -39.88 5.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.162 -0.472 . . . . 1.22 110.907 179.91 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -130.72 159.33 37.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.189 -0.459 . . . . 2.3199999999999998 110.855 179.922 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 154' ' ' ILE . . . . . . . . . . . . . 26.9 mt -136.36 135.44 49.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.266 -0.425 . . . . 1.78 111.125 -179.968 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -115.83 86.31 15.98 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.108 -0.496 . . . . 1.8799999999999999 110.907 179.997 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.61 -30.43 18.35 Favored 'Trans proline' 0 C--N 1.345 0.343 0 C-N-CA 122.53 2.153 . . . . 1.8300000000000001 112.327 179.994 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 157' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -63.1 -42.67 99.63 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.191 -0.459 . . . . 3.6299999999999999 110.889 -179.996 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 158' ' ' ARG . . . . . . . . . . . . . 3.6 mtt85 -96.09 -52.29 4.09 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.17 -0.468 . . . . 3.9199999999999999 110.845 -179.954 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 116.71 39.2 0.85 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.768 -0.729 . . . . 1.28 112.469 -179.948 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 15.0 mttt -120.65 168.98 10.82 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.818 0.342 . . . . 2.0299999999999998 110.959 179.97 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.71 HG11 ' CE1' ' A' ' 178' ' ' PHE . 19.4 m -150.72 125.47 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 1.28 111.065 179.983 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 68.6 tttt -94.83 130.07 41.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.126 -0.488 . . . . 1.8899999999999999 110.922 -179.989 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.695 HG12 ' HA ' ' A' ' 151' ' ' VAL . 17.2 m -140.48 163.23 23.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.196 -0.457 . . . . 0.93000000000000005 111.087 -179.97 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 164' ' ' MET . . . . . . . . . . . . . 3.2 ptt? -109.51 116.93 32.69 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.19 -0.459 . . . . 1.8899999999999999 110.954 179.914 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 165' ' ' VAL . . . . . 0.567 HG22 ' O ' ' A' ' 172' ' ' THR . 6.9 m -96.45 163.95 2.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.194 -0.457 . . . . 1.1299999999999999 111.025 -179.997 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 166' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.13 106.25 9.13 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 1.6000000000000001 110.99 -179.964 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 167' ' ' ILE . . . . . . . . . . . . . 5.2 mt -110.0 109.19 27.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.137 -0.483 . . . . 2.2400000000000002 110.97 179.94 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 62.38 47.28 5.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.194 -0.457 . . . . 4.3700000000000001 110.935 -179.958 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 169' ' ' GLY . . . . . . . . . . . . . . . 61.01 50.8 63.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.727 -0.749 . . . . 1.51 112.551 179.986 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 170' ' ' ARG . . . . . . . . . . . . . 12.2 ttt180 -153.72 129.34 10.01 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.819 0.343 . . . . 5.0 110.957 179.965 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 171' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 -71.15 145.62 49.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 2.5899999999999999 110.865 -179.924 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 172' ' ' THR . . . . . 0.567 ' O ' HG22 ' A' ' 165' ' ' VAL . 4.1 m -159.96 92.44 1.72 Allowed Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.116 -0.493 . . . . 1.28 110.828 179.951 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 173' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_endo -67.42 119.62 6.64 Favored 'Trans proline' 0 C--N 1.345 0.369 0 C-N-CA 122.451 2.101 . . . . 0.94999999999999996 112.326 -179.952 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 174' ' ' VAL . . . . . . . . . . . . . 21.5 t -132.21 139.11 50.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 1.6299999999999999 111.047 179.969 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 175' ' ' GLU . . . . . 0.515 ' C ' HD23 ' A' ' 176' ' ' LEU . 4.6 pt-20 -80.76 119.88 23.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.446 . . . . 2.46 110.869 -179.976 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 176' ' ' LEU . . . . . 0.523 HD12 HG11 ' A' ' 181' ' ' VAL . 0.2 OUTLIER -125.02 -162.46 1.1 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.368 0.604 . . . . 1.6399999999999999 110.916 -179.979 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 177' ' ' ASP . . . . . 0.624 ' HA ' HG22 ' A' ' 161' ' ' VAL . 0.6 OUTLIER -152.73 152.75 32.03 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-N 115.168 -0.923 . . . . 1.49 110.221 178.405 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 178' ' ' PHE . . . . . 0.71 ' CE1' HG11 ' A' ' 161' ' ' VAL . 17.1 m-85 -44.99 -29.53 0.85 Allowed 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.925 -0.58 . . . . 1.8600000000000001 111.56 -179.726 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 179' ' ' SER . . . . . . . . . . . . . 60.1 m -72.25 -33.21 67.34 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.327 -0.397 . . . . 1.6799999999999999 111.096 -179.826 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 38.1 mt-30 -97.2 18.2 15.53 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.354 -0.384 . . . . 2.1600000000000001 111.337 -179.895 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 177' ' ' ASP . 32.4 m -151.79 164.51 2.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.843 0.354 . . . . 0.77000000000000002 111.113 179.891 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 182' ' ' VAL . . . . . . . . . . . . . 23.1 m -139.83 149.96 22.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 0.88 111.123 179.907 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.647 ' HA ' HG12 ' A' ' 137' ' ' VAL . 8.2 tttt -73.41 129.97 39.13 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.196 -0.456 . . . . 2.98 110.867 179.973 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 184' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.111 0 CA-C-O 118.292 -0.861 . . . . 1.6899999999999999 111.046 179.978 . . . . . . . . 0 0 . 1 stop_ save_